The	O
Cdc6	B-GGP
protein	O
is	O
ubiquitinated	O
in	O
vivo	O
for	O
proteolysis	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
Cdc6	B-GGP
protein	O
is	O
necessary	O
for	O
the	O
formation	O
of	O
pre	B-COM
-	I-COM
replicative	I-COM
complexes	I-COM
that	O
are	O
required	O
for	O
firing	O
DNA	O
replication	O
at	O
origins	O
at	O
the	O
beginning	O
of	O
S	O
phase	O
.	O

Cdc6p	B-GGP
protein	O
levels	O
oscillate	O
during	O
the	O
cell	O
cycle	O
.	O

In	O
a	O
normal	O
cell	O
cycle	O
the	O
presence	O
of	O
this	O
protein	O
is	O
restricted	O
to	O
G1	O
,	O
partly	O
because	O
the	O
CDC6	B-GGP
gene	O
is	O
transcribed	O
only	O
during	O
G1	O
and	O
partly	O
because	O
the	O
Cdc6p	B-GGP
protein	O
is	O
rapidly	O
degraded	O
at	O
late	O
G1	O
/	O
early	O
S	O
phase	O
.	O

We	O
report	O
here	O
that	O
the	O
Cdc6p	B-GGP
protein	O
is	O
degraded	O
in	O
a	O
Cdc4	B-GGP
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
phosphorylated	O
Cdc6	B-GGP
is	O
specifically	O
recognized	O
by	O
the	O
ubiquitin	B-GGP
-	O
mediated	O
proteolysis	O
machinery	O
.	O

Indeed	O
,	O
we	O
have	O
found	O
that	O
Cdc6	B-GGP
is	O
ubiquitinated	O
in	O
vivo	O
and	O
degraded	O
by	O
a	O
Cdc4	B-GGP
-	O
dependent	O
mechanism	O
.	O

Our	O
data	O
,	O
together	O
with	O
previous	O
observations	O
regarding	O
Cdc6	B-GGP
stability	O
,	O
suggest	O
that	O
under	O
physiological	O
conditions	O
budding	O
yeast	O
cells	O
degrade	O
ubiquitinated	O
Cdc6	B-GGP
every	O
cell	O
cycle	O
at	O
the	O
beginning	O
of	O
S	O
phase	O
.	O

Regulation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
RelA	B-GGP
phosphorylation	O
and	O
transcriptional	O
activity	O
by	O
p21	B-GGP
(	O
ras	B-GGP
)	O
and	O
protein	B-GGP
kinase	I-GGP
Czeta	I-GGP
in	O
primary	O
endothelial	O
cells	O
.	O

The	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
is	O
thought	O
to	O
be	O
regulated	O
mainly	O
through	O
cytoplasmic	B-CC
retention	O
by	O
IkappaB	B-GGP
molecules	O
.	O

Here	O
we	O
present	O
evidence	O
of	O
a	O
second	O
mechanism	O
of	O
regulation	O
acting	O
on	O
NF	B-COM
-	I-COM
kappaB	I-COM
after	O
release	O
from	O
IkappaB	B-GGP
.	O

In	O
endothelial	O
cells	O
this	O
mechanism	O
involves	O
phosphorylation	O
of	O
the	O
RelA	B-GGP
subunit	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
through	O
a	O
pathway	O
involving	O
activation	O
of	O
protein	B-GGP
kinase	I-GGP
Czeta	I-GGP
(	O
PKCzeta	B-GGP
)	O
and	O
p21	B-GGP
(	O
ras	B-GGP
)	O
.	O

We	O
show	O
that	O
transcriptional	O
activity	O
of	O
RelA	B-GGP
is	O
dependent	O
on	O
phosphorylation	O
of	O
the	O
N	O
-	O
terminal	O
Rel	B-GGP
homology	O
domain	O
but	O
not	O
the	O
C	O
-	O
terminal	O
transactivation	O
domain	O
.	O

Inhibition	O
of	O
phosphorylation	O
by	O
dominant	O
negative	O
mutants	O
of	O
PKCzeta	B-GGP
or	O
p21	B-GGP
(	O
ras	B-GGP
)	O
results	O
in	O
loss	O
of	O
RelA	B-GGP
transcriptional	O
activity	O
without	O
interfering	O
with	O
DNA	O
binding	O
.	O

Raf	B-GGP
/	O
MEK	B-GGP
,	O
small	O
GTPases	O
,	O
phosphatidylinositol	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
,	O
and	O
stress	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
pathways	O
are	O
not	O
involved	O
in	O
this	O
mechanism	O
of	O
regulation	O
.	O

Cloning	O
and	O
characterization	O
of	O
retinol	B-GGP
dehydrogenase	I-GGP
transcripts	O
expressed	O
in	O
human	O
epidermal	O
keratinocytes	O
.	O

The	O
normal	O
growth	O
and	O
differentiation	O
of	O
the	O
epidermis	O
require	O
an	O
adequate	O
supply	O
of	O
vitamin	B-MED
A	I-MED
.	O

The	O
active	O
form	O
of	O
vitamin	B-MED
A	I-MED
for	O
normal	O
epidermal	O
homeostasis	O
is	O
retinoic	B-MED
acid	I-MED
(	O
RA	B-MED
)	O
.	O

Retinoic	B-MED
acid	I-MED
controls	O
the	O
expression	O
of	O
retinoid	B-MED
-	O
responsive	O
genes	O
via	O
interactions	O
of	O
the	O
retinoic	B-COM
acid	I-COM
/	I-COM
nuclear	I-COM
receptor	I-COM
complexes	O
at	O
specific	O
DNA	O
sequences	O
in	O
their	O
control	O
regions	O
.	O

The	O
message	O
conveyed	O
by	O
RA	B-MED
is	O
likely	O
modulated	O
by	O
the	O
concentration	O
of	O
the	O
ligand	O
available	O
for	O
binding	O
to	O
the	O
receptors	O
.	O

Following	O
the	O
uptake	O
of	O
plasma	O
retinol	B-MED
,	O
epidermal	O
keratinocytes	O
synthesize	O
retinoic	B-MED
acid	I-MED
via	O
two	O
sequential	O
reactions	O
with	O
retinaldehyde	B-MED
as	O
an	O
intermediate	O
.	O

Several	O
retinol	B-GGP
dehydrogenase	I-GGP
(	O
RDH	B-GGP
)	O
enzymes	O
,	O
members	O
of	O
the	O
short	B-GGP
-	I-GGP
chain	I-GGP
dehydrogenase	I-GGP
/	I-GGP
reductase	I-GGP
(	O
SDR	B-GGP
)	O
gene	O
superfamily	O
,	O
catalyze	O
the	O
first	O
and	O
rate	O
-	O
limiting	O
step	O
that	O
generates	O
retinaldehyde	B-MED
from	O
retinol	B-MED
bound	O
to	O
cellular	B-GGP
retinol	I-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
(	O
holo	O
-	O
CRBP	B-GGP
)	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
these	O
enzymes	O
and	O
their	O
genes	O
in	O
the	O
epidermal	O
cells	O
.	O

Our	O
work	O
describes	O
the	O
first	O
member	O
of	O
the	O
RDH	B-GGP
family	O
found	O
in	O
epidermis	O
.	O

We	O
show	O
that	O
this	O
gene	O
is	O
expressed	O
predominantly	O
in	O
the	O
differentiating	O
spinous	O
layers	O
and	O
that	O
it	O
is	O
under	O
positive	O
,	O
feed	O
-	O
forward	O
regulation	O
by	O
retinoic	B-MED
acid	I-MED
.	O

It	O
encodes	O
a	O
protein	O
that	O
,	O
using	O
NAD	B-MED
+	I-MED
as	O
a	O
preferred	O
cofactor	O
,	O
utilizes	O
free	O
and	O
CRBP	B-GGP
-	O
bound	O
all	B-MED
-	I-MED
trans	I-MED
-	I-MED
retinol	I-MED
and	O
steroids	O
as	O
substrates	O
.	O

Signaling	O
by	O
proinflammatory	O
cytokines	O
:	O
oligomerization	O
of	O
TRAF2	B-GGP
and	O
TRAF6	B-GGP
is	O
sufficient	O
for	O
JNK	B-GGP
and	O
IKK	B-COM
activation	O
and	O
target	O
gene	O
induction	O
via	O
an	O
amino	O
-	O
terminal	O
effector	O
domain	O
.	O

Interleukin	B-GGP
-	I-GGP
1	I-GGP
(	O
IL	B-GGP
-	I-GGP
1	I-GGP
)	O
and	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
(	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
)	O
stimulate	O
transcription	O
factors	O
AP	B-GGP
-	I-GGP
1	I-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
through	O
activation	O
of	O
the	O
MAP	B-GGP
kinases	I-GGP
JNK	B-GGP
and	O
p38	B-GGP
and	O
the	O
IkappaB	B-COM
kinase	I-COM
(	O
IKK	B-COM
)	O
,	O
respectively	O
.	O

The	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
and	O
IL	B-GGP
-	I-GGP
1	I-GGP
signals	O
are	O
transduced	O
through	O
TRAF2	B-GGP
and	O
TRAF6	B-GGP
,	O
respectively	O
.	O

Overexpressed	O
TRAF2	B-GGP
or	O
TRAF6	B-GGP
activate	O
JNK	B-GGP
,	O
p38	B-GGP
,	O
or	O
IKK	B-COM
in	O
the	O
absence	O
of	O
extracellular	B-CC
stimulation	O
.	O

By	O
replacing	O
the	O
carboxy	O
-	O
terminal	O
TRAF	B-GGP
domain	O
of	O
TRAF2	B-GGP
and	O
TRAF6	B-GGP
with	O
repeats	O
of	O
the	O
immunophilin	O
FKBP12	B-GGP
,	O
we	O
demonstrate	O
that	O
their	O
effector	O
domains	O
are	O
composed	O
of	O
their	O
amino	O
-	O
terminal	O
Zn	B-MED
and	O
RING	O
fingers	O
.	O

Oligomerization	O
of	O
the	O
TRAF2	B-GGP
effector	O
domain	O
results	O
in	O
specific	O
binding	O
to	O
MEKK1	B-GGP
,	O
a	O
protein	O
kinase	O
capable	O
of	O
JNK	B-GGP
,	O
p38	B-GGP
,	O
and	O
IKK	B-COM
activation	O
,	O
and	O
induction	O
of	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
and	O
IL	B-GGP
-	I-GGP
1	I-GGP
responsive	O
genes	O
.	O

TNF	B-GGP
-	I-GGP
alpha	I-GGP
also	O
enhances	O
the	O
binding	O
of	O
native	O
TRAF2	B-GGP
to	O
MEKK1	B-GGP
and	O
stimulates	O
the	O
kinase	O
activity	O
of	O
the	O
latter	O
.	O

Thus	O
,	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
and	O
IL	B-GGP
-	I-GGP
1	I-GGP
signaling	O
is	O
based	O
on	O
oligomerization	O
of	O
TRAF2	B-GGP
and	O
TRAF6	B-GGP
leading	O
to	O
activation	O
of	O
effector	O
kinases	O
.	O

Peptidoglycan	B-MED
-	O
and	O
lipoteichoic	B-MED
acid	I-MED
-	O
induced	O
cell	O
activation	O
is	O
mediated	O
by	O
toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
2	I-GGP
.	O

The	O
life	O
-	O
threatening	O
complications	O
of	O
sepsis	O
in	O
humans	O
are	O
elicited	O
by	O
infection	O
with	O
Gram	O
-	O
negative	O
as	O
well	O
as	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Recently	O
,	O
lipopolysaccharide	B-MED
(	O
LPS	B-MED
)	O
,	O
a	O
major	O
biologically	O
active	O
agent	O
of	O
Gram	O
-	O
negative	O
bacteria	O
,	O
was	O
shown	O
to	O
mediate	O
cellular	O
activation	O
by	O
a	O
member	O
of	O
the	O
human	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
family	O
,	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	I-GGP
TLR	I-GGP
)	I-GGP
2	I-GGP
.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
of	O
cellular	O
activation	O
by	O
soluble	O
peptidoglycan	B-MED
(	O
sPGN	B-MED
)	O
and	O
lipoteichoic	B-MED
acid	I-MED
(	O
LTA	B-MED
)	O
,	O
main	O
stimulatory	O
components	O
of	O
Gram	O
-	O
positive	O
bacteria	O
.	O

Like	O
LPS	B-MED
,	O
sPGN	B-MED
and	O
LTA	B-MED
bind	O
to	O
the	O
glycosylphosphatidylinositol	B-MED
-	O
anchored	O
membrane	B-CC
protein	O
CD14	B-GGP
and	O
induce	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
host	O
cells	O
like	O
macrophages	O
.	O

We	O
show	O
that	O
whole	O
Gram	O
-	O
positive	O
bacteria	O
,	O
sPGN	B-MED
and	O
LTA	B-MED
induce	O
the	O
activation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
HEK293	O
cells	O
expressing	O
TLR2	B-GGP
but	O
not	O
in	O
cells	O
expressing	O
TLR1	B-GGP
or	O
TLR4	B-GGP
.	O

The	O
sPGN	B-MED
-	O
and	O
LTA	B-MED
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
was	O
not	O
inhibited	O
by	O
polymyxin	B-MED
B	I-MED
,	O
an	O
antibiotic	O
that	O
binds	O
and	O
neutralizes	O
LPS	B-MED
.	O

Coexpression	O
together	O
with	O
membrane	B-CC
CD14	B-GGP
enhances	O
sPGN	B-MED
signal	O
transmission	O
through	O
TLR2	B-GGP
.	O

In	O
contrast	O
to	O
LPS	B-MED
signaling	O
,	O
activation	O
of	O
TLR2	B-GGP
by	O
sPGN	B-MED
and	O
LTA	B-MED
does	O
not	O
require	O
serum	O
.	O

These	O
findings	O
identify	O
TLR2	B-GGP
as	O
a	O
signal	O
transducer	O
for	O
sPGN	B-MED
and	O
LTA	B-MED
in	O
addition	O
to	O
LPS	B-MED
.	O

Glycoprotein	O
reglucosylation	O
and	O
nucleotide	O
sugar	O
utilization	O
in	O
the	O
secretory	O
pathway	O
:	O
identification	O
of	O
a	O
nucleoside	B-GGP
diphosphatase	I-GGP
in	O
the	O
endoplasmic	B-CC
reticulum	I-CC
.	O

UDP	B-MED
is	O
generated	O
in	O
the	O
lumen	B-CC
of	O
the	O
endoplasmic	B-CC
reticulum	I-CC
(	O
ER	B-CC
)	O
as	O
a	O
product	O
of	O
the	O
UDP	B-MED
-	I-MED
glucose	I-MED
-	O
dependent	O
glycoprotein	O
reglucosylation	O
in	O
the	O
calnexin	B-GGP
/	O
calreticulin	B-GGP
cycle	O
.	O

We	O
describe	O
here	O
the	O
identification	O
,	O
purification	O
and	O
characterization	O
of	O
an	O
ER	B-CC
enzyme	O
that	O
hydrolyzes	O
UDP	B-MED
to	O
UMP	B-MED
.	O

This	O
nucleoside	B-GGP
diphosphatase	I-GGP
is	O
a	O
ubiquitously	O
expressed	O
,	O
soluble	O
45	O
kDa	O
glycoprotein	O
devoid	O
of	O
transmembrane	O
domains	O
and	O
KDEL	B-GGP
-	O
related	O
ER	B-CC
localization	O
sequences	O
.	O

It	O
requires	O
divalent	B-MED
cations	I-MED
for	O
activity	O
and	O
hydrolyzes	O
UDP	B-MED
,	O
GDP	B-MED
and	O
IDP	B-MED
but	O
not	O
any	O
other	O
nucleoside	B-MED
di	I-MED
-	I-MED
,	O
mono	B-MED
-	I-MED
or	O
triphosphates	B-MED
,	O
nor	O
thiamine	B-MED
pyrophosphate	I-MED
.	O

By	O
eliminating	O
UDP	B-MED
,	O
which	O
is	O
an	O
inhibitory	O
product	O
of	O
the	O
UDP	B-MED
-	I-MED
Glc	I-MED
:	O
glycoprotein	B-GGP
glucosyltransferase	I-GGP
,	O
it	O
is	O
likely	O
to	O
promote	O
reglucosylation	O
reactions	O
involved	O
in	O
glycoprotein	O
folding	O
and	O
quality	O
control	O
in	O
the	O
ER	B-CC
.	O

Overproduction	O
of	O
human	O
Myt1	B-GGP
kinase	O
induces	O
a	O
G2	O
cell	O
cycle	O
delay	O
by	O
interfering	O
with	O
the	O
intracellular	B-CC
trafficking	O
of	O
Cdc2	B-COM
-	I-COM
cyclin	I-COM
B1	I-COM
complexes	O
.	O

The	O
Myt1	B-GGP
protein	O
kinase	O
functions	O
to	O
negatively	O
regulate	O
Cdc2	B-COM
-	I-COM
cyclin	I-COM
B	I-COM
complexes	O
by	O
phosphorylating	O
Cdc2	B-GGP
on	O
threonine	B-MED
14	I-MED
and	O
tyrosine	B-MED
15	I-MED
.	O

Throughout	O
interphase	O
,	O
human	O
Myt1	B-GGP
localizes	O
to	O
the	O
endoplasmic	B-CC
reticulum	I-CC
and	O
Golgi	B-CC
complex	I-CC
,	O
whereas	O
Cdc2	B-COM
-	I-COM
cyclin	I-COM
B1	I-COM
complexes	O
shuttle	O
between	O
the	O
nucleus	B-CC
and	O
the	O
cytoplasm	B-CC
.	O

Here	O
we	O
report	O
that	O
overproduction	O
of	O
either	O
kinase	O
-	O
active	O
or	O
kinase	O
-	O
inactive	O
forms	O
of	O
Myt1	B-GGP
blocked	O
the	O
nuclear	B-CC
-	O
cytoplasmic	B-CC
shuttling	O
of	O
cyclin	B-GGP
B1	I-GGP
and	O
caused	O
cells	O
to	O
delay	O
in	O
the	O
G2	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

The	O
COOH	O
-	O
terminal	O
63	O
amino	O
acids	O
of	O
Myt1	B-GGP
were	O
identified	O
as	O
a	O
Cdc2	B-COM
-	I-COM
cyclin	I-COM
B1	I-COM
interaction	O
domain	O
.	O

Myt1	B-GGP
mutants	O
lacking	O
this	O
domain	O
no	O
longer	O
bound	O
cyclin	B-GGP
B1	I-GGP
and	O
did	O
not	O
efficiently	O
phosphorylate	O
Cdc2	B-COM
-	I-COM
cyclin	I-COM
B1	I-COM
complexes	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
cells	O
overproducing	O
mutant	O
forms	O
of	O
Myt1	B-GGP
lacking	O
the	O
interaction	O
domain	O
exhibited	O
normal	O
trafficking	O
of	O
cyclin	B-GGP
B1	I-GGP
and	O
unperturbed	O
cell	O
cycle	O
progression	O
.	O

These	O
results	O
suggest	O
that	O
the	O
docking	O
of	O
Cdc2	B-COM
-	I-COM
cyclin	I-COM
B1	I-COM
complexes	O
to	O
the	O
COOH	O
terminus	O
of	O
Myt1	B-GGP
facilitates	O
the	O
phosphorylation	O
of	O
Cdc2	B-GGP
by	O
Myt1	B-GGP
and	O
that	O
overproduction	O
of	O
Myt1	B-GGP
perturbs	O
cell	O
cycle	O
progression	O
by	O
sequestering	O
Cdc2	B-COM
-	I-COM
cyclin	I-COM
B1	I-COM
complexes	O
in	O
the	O
cytoplasm	B-CC
.	O

IRAK	B-GGP
-	I-GGP
M	I-GGP
is	O
a	O
novel	O
member	O
of	O
the	O
Pelle	B-GGP
/	O
interleukin	B-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
-	I-GGP
associated	I-GGP
kinase	I-GGP
(	O
IRAK	B-GGP
)	O
family	O
.	O

The	O
interleukin	B-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
-	I-GGP
associated	I-GGP
kinase	I-GGP
(	O
IRAK	B-GGP
)	O
was	O
first	O
described	O
as	O
a	O
signal	O
transducer	O
for	O
interleukin	B-GGP
-	I-GGP
1	I-GGP
(	O
IL	B-GGP
-	I-GGP
1	I-GGP
)	O
and	O
has	O
later	O
been	O
implicated	O
in	O
signal	O
transduction	O
of	O
other	O
members	O
of	O
the	O
Toll	B-GGP
/	I-GGP
IL	I-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
family	O
.	O

We	O
now	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
novel	O
IRAK	B-GGP
-	O
like	O
molecule	O
.	O

In	O
contrast	O
to	O
the	O
ubiquitously	O
expressed	O
IRAK	B-GGP
and	O
IRAK	B-GGP
-	I-GGP
2	I-GGP
,	O
this	O
new	O
IRAK	B-GGP
-	O
like	O
molecule	O
is	O
found	O
mainly	O
in	O
cells	O
of	O
monomyeloic	O
origin	O
and	O
is	O
,	O
therefore	O
,	O
designated	O
IRAK	B-GGP
-	I-GGP
M	I-GGP
.	O

Although	O
IRAK	B-GGP
-	I-GGP
M	I-GGP
and	O
IRAK	B-GGP
-	I-GGP
2	I-GGP
exhibit	O
only	O
a	O
negligible	O
autophosphorylation	O
activity	O
,	O
they	O
can	O
reconstitute	O
the	O
IL	B-GGP
-	I-GGP
1	I-GGP
response	O
in	O
a	O
293	O
mutant	O
cell	O
line	O
lacking	O
IRAK	B-GGP
.	O

In	O
addition	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
members	O
of	O
the	O
IRAK	B-GGP
family	O
are	O
indispensable	O
elements	O
of	O
lipopolysaccharide	B-MED
signal	O
transduction	O
.	O

The	O
discovery	O
of	O
IRAK	B-GGP
-	I-GGP
M	I-GGP
adds	O
another	O
level	O
of	O
complexity	O
to	O
our	O
understanding	O
of	O
signaling	O
by	O
members	O
of	O
the	O
Toll	B-GGP
/	I-GGP
IL	I-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
family	O
.	O

The	O
zinc	B-MED
finger	O
protein	O
A20	B-GGP
inhibits	O
TNF	B-GGP
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
dependent	O
gene	O
expression	O
by	O
interfering	O
with	O
an	O
RIP	B-GGP
-	O
or	O
TRAF2	B-GGP
-	O
mediated	O
transactivation	O
signal	O
and	O
directly	O
binds	O
to	O
a	O
novel	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
inhibiting	O
protein	O
ABIN	B-GGP
.	O

The	O
zinc	B-MED
finger	O
protein	O
A20	B-GGP
is	O
a	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
(	O
TNF	B-GGP
)	O
-	O
and	O
interleukin	B-GGP
1	I-GGP
(	O
IL	B-GGP
-	I-GGP
1	I-GGP
)	O
-	O
inducible	O
protein	O
that	O
negatively	O
regulates	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappa	I-COM
B	I-COM
(	O
NF	B-COM
-	I-COM
kappaB	I-COM
)	O
-	O
dependent	O
gene	O
expression	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
by	O
which	O
A20	B-GGP
exerts	O
this	O
effect	O
is	O
still	O
unclear	O
.	O

We	O
show	O
that	O
A20	B-GGP
does	O
not	O
inhibit	O
TNF	B-GGP
-	O
induced	O
nuclear	B-CC
translocation	O
and	O
DNA	O
binding	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
although	O
it	O
completely	O
prevents	O
the	O
TNF	B-GGP
-	O
induced	O
activation	O
of	O
an	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
dependent	O
reporter	O
gene	O
,	O
as	O
well	O
as	O
TNF	B-GGP
-	O
induced	O
IL	B-GGP
-	I-GGP
6	I-GGP
and	O
granulocyte	B-GGP
macrophage	I-GGP
-	I-GGP
colony	I-GGP
stimulating	I-GGP
factor	I-GGP
gene	O
expression	O
.	O

Moreover	O
,	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
induced	O
by	O
overexpression	O
of	O
the	O
TNF	B-GGP
receptor	I-GGP
-	O
associated	O
proteins	O
TNF	B-GGP
receptor	I-GGP
-	I-GGP
associated	I-GGP
death	I-GGP
domain	I-GGP
protein	I-GGP
(	O
TRADD	B-GGP
)	O
,	O
receptor	B-GGP
interacting	I-GGP
protein	I-GGP
(	O
RIP	B-GGP
)	O
,	O
and	O
TNF	B-GGP
recep	I-GGP
-	I-GGP
tor	I-GGP
-	I-GGP
associated	I-GGP
factor	I-GGP
2	I-GGP
(	O
TRAF2	B-GGP
)	O
was	O
also	O
inhibited	O
by	O
expression	O
of	O
A20	B-GGP
,	O
whereas	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
induced	O
by	O
overexpression	O
of	O
NF	B-GGP
-	I-GGP
kappaB	I-GGP
-	I-GGP
inducing	I-GGP
kinase	I-GGP
(	O
NIK	B-GGP
)	O
or	O
the	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
Tax	B-GGP
was	O
unaffected	O
.	O

These	O
results	O
demonstrate	O
that	O
A20	B-GGP
inhibits	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
dependent	O
gene	O
expression	O
by	O
interfering	O
with	O
a	O
novel	O
TNF	B-GGP
-	O
induced	O
and	O
RIP	B-GGP
-	O
or	O
TRAF2	B-GGP
-	O
mediated	O
pathway	O
that	O
is	O
different	O
from	O
the	O
NIK	B-GGP
-	O
IkappaB	B-COM
kinase	I-COM
pathway	O
and	O
that	O
is	O
specifically	O
involved	O
in	O
the	O
transactivation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

Via	O
yeast	O
two	O
-	O
hybrid	O
screening	O
,	O
we	O
found	O
that	O
A20	B-GGP
binds	O
to	O
a	O
novel	O
protein	O
,	O
ABIN	B-GGP
,	O
which	O
mimics	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibiting	O
effects	O
of	O
A20	B-GGP
upon	O
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
of	O
A20	B-GGP
is	O
mediated	O
by	O
its	O
interaction	O
with	O
this	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibiting	O
protein	O
,	O
ABIN	B-GGP
.	O

Role	O
of	O
MAO	B-GGP
A	I-GGP
and	O
B	B-GGP
in	O
neurotransmitter	O
metabolism	O
and	O
behavior	O
.	O

MAO	B-GGP
(	I-GGP
monoamine	I-GGP
oxidase	I-GGP
)	I-GGP
A	I-GGP
and	O
B	B-GGP
are	O
key	O
isoenzymes	O
that	O
degrade	O
biogenic	O
and	O
dietary	O
amines	B-MED
.	O

MAO	B-GGP
A	I-GGP
preferentially	O
oxidizes	O
serotonin	B-MED
(	O
5	B-MED
-	I-MED
hydroxytryptamine	I-MED
,	O
5	B-MED
-	I-MED
HT	I-MED
)	O
and	O
norepinephrine	B-MED
(	O
NE	B-MED
)	O
,	O
whereas	O
MAO	B-GGP
B	I-GGP
preferentially	O
oxidizes	O
phenylethylamine	B-MED
(	O
PEA	B-MED
)	O
.	O

Both	O
forms	O
can	O
oxidize	O
dopamine	B-MED
(	O
DA	B-MED
)	O
.	O

However	O
,	O
the	O
substrate	O
specificity	O
overlap	O
and	O
the	O
in	O
vivo	O
function	O
of	O
these	O
two	O
isoenzymes	O
is	O
not	O
clear	O
.	O

Recently	O
,	O
we	O
have	O
shown	O
that	O
MAO	B-GGP
A	I-GGP
and	O
B	B-GGP
knock	O
-	O
out	O
(	O
KO	O
)	O
mice	O
exhibit	O
distinct	O
differences	O
in	O
neurotransmitter	O
metabolism	O
and	O
behavior	O
.	O

MAO	B-GGP
A	I-GGP
KO	O
mice	O
have	O
elevated	O
brain	O
levels	O
of	O
5	B-MED
-	I-MED
HT	I-MED
,	O
NE	B-MED
and	O
DA	B-MED
and	O
manifest	O
aggressive	O
behavior	O
similar	O
to	O
men	O
with	O
a	O
deletion	O
of	O
MAO	B-GGP
A	I-GGP
.	O

In	O
contrast	O
,	O
MAO	B-GGP
B	I-GGP
KO	O
mice	O
do	O
not	O
exhibit	O
aggression	O
and	O
only	O
levels	O
of	O
PEA	B-MED
are	O
increased	O
.	O

Both	O
MAO	B-GGP
A	I-GGP
and	O
B	B-GGP
KO	O
mice	O
show	O
increased	O
reactivity	O
to	O
stress	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
MAO	B-GGP
A	I-GGP
and	O
B	B-GGP
have	O
distinctly	O
different	O
roles	O
in	O
monoamine	B-MED
metabolism	O
.	O

Further	O
,	O
these	O
mice	O
are	O
valuable	O
models	O
for	O
investigating	O
the	O
role	O
of	O
monoamines	O
in	O
psychoses	O
and	O
neurodegenerative	O
and	O
stress	O
-	O
related	O
disorders	O
.	O

The	O
TAK1	B-GGP
-	O
NLK	B-GGP
-	O
MAPK	B-GGP
-	O
related	O
pathway	O
antagonizes	O
signalling	O
between	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
and	O
transcription	O
factor	O
TCF	B-GGP
.	O

The	O
Wnt	B-GGP
signalling	O
pathway	O
regulates	O
many	O
developmental	O
processes	O
through	O
a	O
complex	O
of	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
and	O
the	O
T	B-GGP
-	I-GGP
cell	I-GGP
factor	I-GGP
/	O
lymphoid	B-GGP
enhancer	I-GGP
factor	I-GGP
(	O
TCF	B-GGP
/	O
LEF	B-GGP
)	O
family	O
of	O
high	O
-	O
mobility	O
-	O
group	O
transcription	O
factors	O
.	O

Wnt	B-GGP
stabilizes	O
cytosolic	B-CC
beta	B-GGP
-	I-GGP
catenin	I-GGP
,	O
which	O
then	O
binds	O
to	O
TCF	B-GGP
and	O
activates	O
gene	O
transcription	O
.	O

This	O
signalling	O
cascade	O
is	O
conserved	O
in	O
vertebrates	O
,	O
Drosophila	O
and	O
Caenorhabditis	O
elegans	O
.	O

In	O
C	O
.	O
elegans	O
,	O
the	O
proteins	O
MOM	B-GGP
-	I-GGP
4	I-GGP
and	O
LIT	B-GGP
-	I-GGP
1	I-GGP
regulate	O
Wnt	B-GGP
signalling	O
to	O
polarize	O
responding	O
cells	O
during	O
embryogenesis	O
.	O

MOM	B-GGP
-	I-GGP
4	I-GGP
and	O
LIT	B-GGP
-	I-GGP
1	I-GGP
are	O
homologous	O
to	O
TAK1	B-GGP
(	O
a	O
kinase	O
activated	O
by	O
transforming	B-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
beta	I-GGP
)	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
-	I-GGP
kinase	I-GGP
-	I-GGP
kinase	I-GGP
kinase	I-GGP
(	O
MAP3K	B-GGP
)	O
and	O
MAP	B-GGP
kinase	I-GGP
(	O
MAPK	B-GGP
)	O
-	O
related	O
NEMO	B-GGP
-	I-GGP
like	I-GGP
kinase	I-GGP
(	O
NLK	B-GGP
)	O
,	O
respectively	O
,	O
in	O
mammalian	O
cells	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
TAK1	B-GGP
and	O
NLK	B-GGP
are	O
also	O
involved	O
in	O
Wnt	B-GGP
signalling	O
in	O
mammalian	O
cells	O
.	O

Here	O
we	O
show	O
that	O
TAK1	B-GGP
activation	O
stimulates	O
NLK	B-GGP
activity	O
and	O
downregulates	O
transcriptional	O
activation	O
mediated	O
by	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
and	O
TCF	B-GGP
.	O

Injection	O
of	O
NLK	B-GGP
suppresses	O
the	O
induction	O
of	O
axis	O
duplication	O
by	O
microinjected	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
in	O
Xenopus	O
embryos	O
.	O

NLK	B-GGP
phosphorylates	O
TCF	B-GGP
/	O
LEF	B-GGP
factors	I-GGP
and	O
inhibits	O
the	O
interaction	O
of	O
the	O
beta	B-COM
-	I-COM
catenin	I-COM
-	I-COM
TCF	I-COM
complex	O
with	O
DNA	O
.	O

Thus	O
,	O
the	O
TAK1	B-GGP
-	O
NLK	B-GGP
-	O
MAPK	B-GGP
-	O
like	O
pathway	O
negatively	O
regulates	O
the	O
Wnt	B-GGP
signalling	O
pathway	O
.	O

Wnt	B-GGP
-	O
induced	O
dephosphorylation	O
of	O
axin	B-GGP
releases	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
from	O
the	O
axin	B-COM
complex	I-COM
.	O

The	O
stabilization	O
of	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
is	O
a	O
key	O
regulatory	O
step	O
during	O
cell	O
fate	O
changes	O
and	O
transformations	O
to	O
tumor	O
cells	O
.	O

Several	O
interacting	O
proteins	O
,	O
including	O
Axin	B-GGP
,	O
APC	B-GGP
,	O
and	O
the	O
protein	O
kinase	O
GSK	B-GGP
-	I-GGP
3beta	I-GGP
are	O
implicated	O
in	O
regulating	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
phosphorylation	O
and	O
its	O
subsequent	O
degradation	O
.	O

Wnt	B-GGP
signaling	O
stabilizes	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
,	O
but	O
it	O
was	O
not	O
clear	O
whether	O
and	O
how	O
Wnt	B-GGP
signaling	O
regulates	O
the	O
beta	B-COM
-	I-COM
catenin	I-COM
complex	I-COM
.	O

Here	O
we	O
show	O
that	O
Axin	B-GGP
is	O
dephosphorylated	O
in	O
response	O
to	O
Wnt	B-GGP
signaling	O
.	O

The	O
dephosphorylated	O
Axin	B-GGP
binds	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
less	O
efficiently	O
than	O
the	O
phosphorylated	O
form	O
.	O

Thus	O
,	O
Wnt	B-GGP
signaling	O
lowers	O
Axin	B-GGP
'	O
s	O
affinity	O
for	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
,	O
thereby	O
disengaging	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
from	O
the	O
degradation	O
machinery	O
.	O

Phosphorylation	O
of	O
Ser	B-MED
-	I-MED
241	I-MED
is	O
essential	O
for	O
the	O
activity	O
of	O
3	B-GGP
-	I-GGP
phosphoinositide	I-GGP
-	I-GGP
dependent	I-GGP
protein	I-GGP
kinase	I-GGP
-	I-GGP
1	I-GGP
:	O
identification	O
of	O
five	O
sites	O
of	O
phosphorylation	O
in	O
vivo	O
.	O

3	B-GGP
-	I-GGP
phosphoinositide	I-GGP
-	I-GGP
dependent	I-GGP
protein	I-GGP
kinase	I-GGP
-	I-GGP
1	I-GGP
(	O
PDK1	B-GGP
)	O
expressed	O
in	O
unstimulated	O
293	O
cells	O
was	O
phosphorylated	O
at	O
Ser	B-MED
-	I-MED
25	I-MED
,	O
Ser	B-MED
-	I-MED
241	I-MED
,	O
Ser	B-MED
-	I-MED
393	I-MED
,	O
Ser	B-MED
-	I-MED
396	I-MED
and	O
Ser	B-MED
-	I-MED
410	I-MED
and	O
the	O
level	O
of	O
phosphorylation	O
of	O
each	O
site	O
was	O
unaffected	O
by	O
stimulation	O
with	O
insulin	B-GGP
-	I-GGP
like	I-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
1	I-GGP
.	O

Mutation	O
of	O
Ser	B-MED
-	I-MED
241	I-MED
to	O
Ala	B-MED
abolished	O
PDK1	B-GGP
activity	O
,	O
whereas	O
mutation	O
of	O
the	O
other	O
phosphorylation	O
sites	O
individually	O
to	O
Ala	B-MED
did	O
not	O
affect	O
PDK1	B-GGP
activity	O
.	O

Ser	B-MED
-	I-MED
241	I-MED
,	O
unlike	O
the	O
other	O
phosphorylation	O
sites	O
on	O
PDK1	B-GGP
,	O
was	O
resistant	O
to	O
dephosphorylation	O
by	O
protein	B-GGP
phosphatase	I-GGP
2A	I-GGP
(	I-GGP
1	I-GGP
)	I-GGP
.	O

Ser	B-MED
-	I-MED
241	I-MED
lies	O
in	O
the	O
activation	O
loop	O
of	O
the	O
PDK1	B-GGP
kinase	O
domain	O
between	O
subdomains	O
VII	O
and	O
VIII	O
in	O
the	O
equivalent	O
position	O
to	O
the	O
site	O
that	O
PDK1	B-GGP
phosphorylates	O
on	O
its	O
protein	O
kinase	O
substrates	O
.	O

PDK1	B-GGP
expressed	O
in	O
bacteria	O
was	O
active	O
and	O
phosphorylated	O
at	O
Ser	B-MED
-	I-MED
241	I-MED
,	O
suggesting	O
that	O
PDK1	B-GGP
can	O
phosphorylate	O
itself	O
at	O
this	O
site	O
,	O
leading	O
to	O
its	O
own	O
activation	O
.	O

NuA4	B-COM
,	O
an	O
essential	O
transcription	B-GGP
adaptor	I-GGP
/	O
histone	B-GGP
H4	I-GGP
acetyltransferase	I-GGP
complex	O
containing	O
Esa1p	B-GGP
and	O
the	O
ATM	B-GGP
-	O
related	O
cofactor	O
Tra1p	B-GGP
.	O

Post	O
-	O
translational	O
acetylation	O
of	O
histone	B-GGP
H4	I-GGP
N	O
-	O
terminal	O
tail	O
in	O
chromatin	B-CC
has	O
been	O
associated	O
with	O
several	O
nuclear	B-CC
processes	O
including	O
transcription	O
.	O

We	O
report	O
the	O
purification	O
and	O
characterization	O
of	O
a	O
native	O
multisubunit	O
complex	O
(	O
NuA4	B-COM
)	O
from	O
yeast	O
that	O
acetylates	O
nucleosomal	B-CC
histone	B-GGP
H4	I-GGP
.	O

NuA4	B-COM
has	O
an	O
apparent	O
molecular	O
mass	O
of	O
1	O
.	O
3	O
MDa	O
.	O

All	O
four	O
conserved	O
lysines	B-MED
of	O
histone	B-GGP
H4	I-GGP
can	O
be	O
acetylated	O
by	O
NuA4	B-COM
.	O

We	O
have	O
identified	O
the	O
catalytic	O
subunit	O
of	O
the	O
complex	O
as	O
the	O
product	O
of	O
ESA1	B-GGP
,	O
an	O
essential	O
gene	O
required	O
for	O
cell	O
cycle	O
progression	O
in	O
yeast	O
.	O

Antibodies	O
against	O
Esa1p	B-GGP
specifically	O
immunoprecipitate	O
NuA4	B-COM
activity	O
whereas	O
the	O
complex	O
purified	O
from	O
a	O
temperature	O
-	O
sensitive	O
esa1	B-GGP
mutant	O
loses	O
its	O
acetyltransferase	O
activity	O
at	O
the	O
restrictive	O
temperature	O
.	O

Additionally	O
,	O
we	O
have	O
identified	O
another	O
subunit	O
of	O
the	O
complex	O
as	O
the	O
product	O
of	O
TRA1	B-GGP
,	O
an	O
ATM	B-GGP
-	O
related	O
essential	O
gene	O
homologous	O
to	O
human	O
TRRAP	B-GGP
,	O
an	O
essential	O
cofactor	O
for	O
c	B-GGP
-	I-GGP
Myc	I-GGP
-	O
and	O
E2F	B-GGP
-	O
mediated	O
oncogenic	O
transformation	O
.	O

Finally	O
,	O
the	O
ability	O
of	O
NuA4	B-COM
to	O
stimulate	O
GAL4	B-GGP
-	I-GGP
VP16	I-GGP
-	O
driven	O
transcription	O
from	O
chromatin	B-CC
templates	O
in	O
vitro	O
is	O
also	O
lost	O
in	O
the	O
temperature	O
-	O
sensitive	O
esa1	B-GGP
mutant	O
.	O

The	O
function	O
of	O
the	O
essential	O
Esa1	B-GGP
protein	O
as	O
the	O
HAT	B-GGP
subunit	O
of	O
NuA4	B-COM
and	O
the	O
presence	O
of	O
Tra1p	B-GGP
,	O
a	O
putative	O
transcription	O
activator	O
-	O
interacting	O
subunit	O
,	O
supports	O
an	O
essential	O
link	O
between	O
nuclear	B-CC
H4	B-GGP
acetylation	O
,	O
transcriptional	O
regulation	O
and	O
cell	O
cycle	O
control	O
.	O

Two	O
co	O
-	O
existing	O
mechanisms	O
for	O
nuclear	B-CC
import	O
of	O
MAP	B-GGP
kinase	I-GGP
:	O
passive	O
diffusion	O
of	O
a	O
monomer	O
and	O
active	O
transport	O
of	O
a	O
dimer	O
.	O

In	O
response	O
to	O
extracellular	O
stimuli	O
,	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
(	O
MAPK	B-GGP
,	O
also	O
known	O
as	O
ERK	B-GGP
)	O
translocates	O
from	O
the	O
cytoplasm	B-CC
to	O
the	O
nucleus	B-CC
.	O

MAP	B-GGP
kinase	I-GGP
kinase	I-GGP
(	O
MAPKK	B-GGP
,	O
also	O
know	O
as	O
MEK	B-GGP
)	O
,	O
which	O
possesses	O
a	O
nuclear	B-CC
export	O
signal	O
(	O
NES	O
)	O
,	O
acts	O
as	O
a	O
cytoplasmic	B-CC
anchor	O
of	O
MAPK	B-GGP
.	O

Here	O
we	O
show	O
evidence	O
that	O
tyrosine	B-MED
(	O
Tyr190	B-MED
in	O
Xenopus	O
MPK1	B-GGP
/	O
ERK2	B-GGP
)	O
phosphorylation	O
of	O
MAPK	B-GGP
by	O
MAPKK	B-GGP
is	O
necessary	O
and	O
sufficient	O
for	O
the	O
dissociation	O
of	O
the	O
MAPKK	B-COM
-	I-COM
MAPK	I-COM
complex	O
,	O
and	O
that	O
the	O
dissociation	O
of	O
the	O
complex	O
is	O
required	O
for	O
the	O
nuclear	B-CC
translocation	O
of	O
MAPK	B-GGP
.	O

We	O
then	O
show	O
that	O
nuclear	B-CC
entry	O
of	O
MAPK	B-GGP
through	O
a	O
nuclear	B-CC
pore	I-CC
occurs	O
via	O
two	O
distinct	O
mechanisms	O
.	O

Nuclear	B-CC
import	O
of	O
wild	O
-	O
type	O
MAPK	B-GGP
(	O
mol	O
.	O
wt	O
42	O
kDa	O
)	O
was	O
induced	O
by	O
activation	O
of	O
the	O
MAPK	B-GGP
pathway	O
even	O
in	O
the	O
presence	O
of	O
wheat	O
germ	O
agglutinin	B-GGP
or	O
dominant	O
-	O
negative	O
Ran	B-GGP
,	O
whereas	O
nuclear	B-CC
import	O
of	O
beta	B-GGP
-	I-GGP
galactosidase	I-GGP
(	O
beta	B-GGP
-	I-GGP
gal	I-GGP
)	O
-	O
fused	O
MAPK	B-GGP
(	O
mol	O
.	O
wt	O
160	O
kDa	O
)	O
,	O
which	O
occurred	O
in	O
response	O
to	O
stimuli	O
,	O
was	O
completely	O
blocked	O
by	O
these	O
inhibitors	O
.	O

Moreover	O
,	O
while	O
a	O
dimerization	O
-	O
deficient	O
mutant	O
of	O
MAPK	B-GGP
was	O
able	O
to	O
translocate	O
to	O
the	O
nucleus	B-CC
upon	O
stimulation	O
,	O
this	O
mutant	O
MAPK	B-GGP
,	O
when	O
fused	O
to	O
beta	B-GGP
-	I-GGP
gal	I-GGP
,	O
became	O
unable	O
to	O
enter	O
the	O
nucleus	B-CC
.	O

These	O
results	O
suggest	O
that	O
monomeric	O
and	O
dimeric	O
forms	O
of	O
MAPK	B-GGP
enter	O
the	O
nucleus	B-CC
by	O
passive	O
diffusion	O
and	O
active	O
transport	O
mechanisms	O
,	O
respectively	O
.	O

The	O
structure	O
of	O
phosphorylated	O
p38gamma	B-GGP
is	O
monomeric	O
and	O
reveals	O
a	O
conserved	O
activation	O
-	O
loop	O
conformation	O
.	O

BACKGROUND	O
:	O
Mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
(	I-GGP
MAP	I-GGP
)	I-GGP
kinases	I-GGP
mediate	O
the	O
cellular	O
response	O
to	O
stimuli	O
such	O
as	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
environmental	O
stress	O
.	O

P38gamma	B-GGP
is	O
a	O
new	O
member	O
of	O
the	O
MAP	B-GGP
kinase	I-GGP
family	O
,	O
and	O
is	O
expressed	O
at	O
its	O
highest	O
levels	O
in	O
skeletal	O
muscle	O
.	O

P38gamma	B-GGP
is	O
63	O
%	O
identical	O
in	O
sequence	O
to	O
P38alpha	B-GGP
.	O

The	O
structure	O
of	O
P38alpha	B-GGP
MAP	I-GGP
kinase	I-GGP
has	O
been	O
determined	O
in	O
the	O
apo	O
,	O
unphosphorylated	O
,	O
inactive	O
form	O
.	O

The	O
structures	O
of	O
apo	O
unphosphorylated	O
ERK2	B-GGP
,	O
a	O
related	O
MAP	B-GGP
kinase	I-GGP
,	O
and	O
apo	O
phosphorylated	O
ERK2	B-GGP
have	O
also	O
been	O
determined	O
.	O

RESULTS	O
:	O
We	O
have	O
determined	O
the	O
structure	O
of	O
doubly	O
phosphorylated	O
P38gamma	B-GGP
in	O
complex	O
with	O
an	O
ATP	B-MED
analog	O
by	O
X	O
-	O
ray	O
crystallography	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
structure	O
of	O
an	O
activated	O
kinase	O
in	O
the	O
P38	B-GGP
subfamily	O
,	O
and	O
the	O
first	O
bound	O
to	O
a	O
nucleotide	O
.	O

P38gamma	B-GGP
residue	O
phosphoryl	O
-	O
Thr183	B-MED
forms	O
hydrogen	B-MED
bonds	O
with	O
five	O
basic	O
amino	O
acids	O
,	O
and	O
these	O
interactions	O
induce	O
an	O
interdomain	O
rotation	O
.	O

The	O
conformation	O
of	O
the	O
activation	O
loop	O
of	O
P38gamma	B-GGP
is	O
almost	O
identical	O
to	O
that	O
observed	O
in	O
the	O
structure	O
of	O
activated	O
ERK2	B-GGP
.	O

However	O
,	O
unlike	O
ERK2	B-GGP
,	O
the	O
crystal	O
structure	O
and	O
solution	O
studies	O
indicate	O
that	O
activated	O
P38gamma	B-GGP
exists	O
as	O
a	O
monomer	O
.	O

CONCLUSIONS	O
:	O
Interactions	O
mediated	O
by	O
phosphoryl	O
-	O
Thr183	B-MED
induce	O
structural	O
changes	O
that	O
direct	O
the	O
domains	O
and	O
active	O
-	O
site	O
residues	O
of	O
P38gamma	B-GGP
into	O
a	O
conformation	O
consistent	O
with	O
catalytic	O
activity	O
.	O

The	O
conformation	O
of	O
the	O
phosphorylation	O
loop	O
is	O
likely	O
to	O
be	O
similar	O
in	O
all	O
activated	O
MAP	B-GGP
kinases	I-GGP
,	O
but	O
not	O
all	O
activated	O
MAP	B-GGP
kinases	I-GGP
form	O
dimers	O
.	O

Regulated	O
nuclear	B-CC
localisation	O
of	O
the	O
yeast	O
transcription	O
factor	O
Ace2p	B-GGP
controls	O
expression	O
of	O
chitinase	B-GGP
(	O
CTS1	B-GGP
)	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
yeast	O
transcription	O
factor	O
Ace2p	B-GGP
regulates	O
expression	O
of	O
the	O
chitinase	B-GGP
gene	O
CTS1	B-GGP
in	O
a	O
cell	O
cycle	O
-	O
dependent	O
manner	O
.	O

Nuclear	B-CC
localisation	O
of	O
Ace2p	B-GGP
is	O
restricted	O
to	O
late	O
M	O
and	O
early	O
G	O
phases	O
of	O
the	O
mitotic	O
cell	O
cycle	O
.	O

We	O
show	O
here	O
that	O
this	O
nuclear	B-CC
localisation	O
is	O
directly	O
associated	O
with	O
regulation	O
of	O
CTS1	B-GGP
expression	O
.	O

Using	O
a	O
version	O
of	O
Ace2p	B-GGP
tagged	O
with	O
a	O
c	B-GGP
-	I-GGP
myc	I-GGP
epitope	O
,	O
we	O
show	O
that	O
the	O
protein	O
is	O
excluded	O
from	O
the	O
nucleus	B-CC
of	O
cells	O
during	O
most	O
phases	O
of	O
the	O
mitotic	O
cell	O
cycle	O
.	O

A	O
mutant	O
derivative	O
in	O
which	O
one	O
threonine	B-MED
and	O
two	O
serine	B-MED
residues	O
,	O
which	O
are	O
candidate	O
phosphorylation	O
sites	O
,	O
were	O
replaced	O
by	O
alanine	B-MED
(	O
to	O
mimic	O
constitutive	O
dephosphorylation	O
)	O
is	O
localised	O
in	O
the	O
nucleus	B-CC
throughout	O
the	O
cell	O
cycle	O
.	O

The	O
mechanism	O
of	O
localisation	O
of	O
Ace2p	B-GGP
therefore	O
involves	O
regulation	O
of	O
its	O
phosphorylation	O
state	O
,	O
and	O
closely	O
resembles	O
that	O
used	O
by	O
the	O
homologous	O
transcription	O
factor	O
Swi5p	B-GGP
.	O

The	O
wild	O
-	O
type	O
Ace2	B-GGP
protein	O
associates	O
with	O
Cdc28p	B-GGP
in	O
vivo	O
,	O
suggesting	O
this	O
may	O
be	O
the	O
kinase	O
that	O
mediates	O
the	O
phosphorylation	O
event	O
.	O

The	O
stability	O
of	O
the	O
protein	O
is	O
greatly	O
reduced	O
in	O
a	O
mutant	O
that	O
is	O
constitutively	O
localised	O
to	O
the	O
nucleus	B-CC
,	O
but	O
is	O
restored	O
in	O
a	O
deletion	O
derivative	O
which	O
remains	O
in	O
the	O
cytoplasm	B-CC
.	O

Ace2p	B-GGP
is	O
therefore	O
controlled	O
throughout	O
the	O
cell	O
cycle	O
at	O
three	O
levels	O
:	O
transcription	O
,	O
nuclear	B-CC
localisation	O
,	O
and	O
proteolysis	O
.	O

Role	O
of	O
two	O
upstream	O
open	O
reading	O
frames	O
in	O
the	O
translational	O
control	O
of	O
oncogene	O
mdm2	B-GGP
.	O

Overexpression	O
of	O
oncoprotein	O
MDM2	B-GGP
has	O
been	O
found	O
in	O
a	O
significant	O
number	O
of	O
human	O
soft	O
tissue	O
tumors	O
.	O

In	O
a	O
subset	O
of	O
these	O
tumors	O
,	O
overexpression	O
is	O
a	O
result	O
of	O
enhanced	O
translation	O
of	O
mdm2	B-GGP
mRNA	O
.	O

There	O
are	O
two	O
transcripts	O
from	O
the	O
mdm2	B-GGP
gene	O
that	O
differ	O
only	O
in	O
their	O
5	O
'	O
leaders	O
:	O
a	O
long	O
form	O
(	O
L	B-GGP
-	I-GGP
mdm2	I-GGP
)	O
and	O
a	O
short	O
form	O
(	O
S	B-GGP
-	I-GGP
mdm2	I-GGP
)	O
that	O
arise	O
from	O
the	O
use	O
of	O
different	O
promoters	O
.	O

L	B-GGP
-	I-GGP
mdm2	I-GGP
mRNA	O
contains	O
two	O
upstream	O
open	O
reading	O
frames	O
(	O
uORFs	O
)	O
and	O
this	O
mRNA	O
was	O
loaded	O
with	O
ribosomes	O
inefficiently	O
in	O
comparison	O
with	O
S	B-GGP
-	I-GGP
mdm2	I-GGP
.	O

The	O
5	O
'	O
leader	O
of	O
L	B-GGP
-	I-GGP
mdm2	I-GGP
was	O
sufficient	O
to	O
transfer	O
translational	O
repression	O
to	O
a	O
reporter	O
gene	O
and	O
the	O
two	O
uORFs	O
acted	O
synergistically	O
to	O
achieve	O
full	O
suppression	O
.	O

In	O
contrast	O
,	O
the	O
5	O
'	O
leader	O
of	O
S	B-GGP
-	I-GGP
mdm2	I-GGP
allowed	O
efficient	O
translation	O
of	O
an	O
attached	O
reporter	O
gene	O
in	O
the	O
tumor	O
cells	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
overexpression	O
of	O
MDM2	B-GGP
in	O
certain	O
tumors	O
results	O
from	O
a	O
change	O
in	O
mRNA	O
structure	O
due	O
to	O
a	O
switch	O
in	O
promoter	O
usage	O
.	O

Interleukin	B-GGP
-	I-GGP
10	I-GGP
signaling	O
blocks	O
inhibitor	B-COM
of	I-COM
kappaB	I-COM
kinase	I-COM
activity	O
and	O
nuclear	B-COM
factor	I-COM
kappaB	I-COM
DNA	O
binding	O
.	O

The	O
transcription	O
factor	O
nuclear	B-COM
factor	I-COM
kappaB	I-COM
(	O
NF	B-COM
-	I-COM
kappaB	I-COM
)	O
coordinates	O
the	O
activation	O
of	O
numerous	O
genes	O
in	O
response	O
to	O
pathogens	O
and	O
proinflammatory	O
cytokines	O
and	O
is	O
,	O
therefore	O
,	O
pivotal	O
in	O
the	O
development	O
of	O
acute	O
and	O
chronic	O
inflammatory	O
diseases	O
.	O

In	O
its	O
inactive	O
state	O
,	O
NF	B-COM
-	I-COM
kappaB	I-COM
is	O
constitutively	O
present	O
in	O
the	O
cytoplasm	B-CC
as	O
a	O
p50	B-COM
-	I-COM
p65	I-COM
heterodimer	O
bound	O
to	O
its	O
inhibitory	O
protein	O
IkappaB	B-GGP
.	O

Proinflammatory	O
cytokines	O
,	O
such	O
as	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
(	O
TNF	B-GGP
)	O
,	O
activate	O
NF	B-COM
-	I-COM
kappaB	I-COM
by	O
stimulating	O
the	O
activity	O
of	O
the	O
IkappaB	B-COM
kinases	I-COM
(	O
IKKs	B-COM
)	O
which	O
phosphorylate	O
IkappaBalpha	B-GGP
on	O
serine	B-MED
residues	I-MED
32	I-MED
and	O
36	B-MED
,	O
targeting	O
it	O
for	O
rapid	O
degradation	O
by	O
the	O
26	B-CC
S	I-CC
proteasome	I-CC
.	O

This	O
enables	O
the	O
release	O
and	O
nuclear	B-CC
translocation	O
of	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
complex	O
and	O
activation	O
of	O
gene	O
transcription	O
.	O

Interleukin	B-GGP
-	I-GGP
10	I-GGP
(	O
IL	B-GGP
-	I-GGP
10	I-GGP
)	O
is	O
a	O
pleiotropic	O
cytokine	O
that	O
controls	O
inflammatory	O
processes	O
by	O
suppressing	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
which	O
are	O
known	O
to	O
be	O
transcriptionally	O
controlled	O
by	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

Conflicting	O
data	O
exists	O
on	O
the	O
effects	O
of	O
IL	B-GGP
-	I-GGP
10	I-GGP
on	O
TNF	B-GGP
-	O
and	O
LPS	B-MED
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
activity	O
in	O
human	O
monocytes	O
and	O
the	O
molecular	O
mechanisms	O
involved	O
have	O
not	O
been	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
IL	B-GGP
-	I-GGP
10	I-GGP
functions	O
to	O
block	O
NF	B-COM
-	I-COM
kappaB	I-COM
activity	O
at	O
two	O
levels	O
:	O
1	O
)	O
through	O
the	O
suppression	O
of	O
IKK	B-COM
activity	O
and	O
2	O
)	O
through	O
the	O
inhibition	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
DNA	O
binding	O
activity	O
.	O

This	O
is	O
the	O
first	O
evidence	O
of	O
an	O
anti	O
-	O
inflammatory	O
protein	O
inhibiting	O
IKK	B-COM
activity	O
and	O
demonstrates	O
that	O
IKK	B-COM
is	O
a	O
logical	O
target	O
for	O
blocking	O
inflammatory	O
diseases	O
.	O

Cloning	O
and	O
functional	O
characterization	O
of	O
the	O
human	O
sodium	B-MED
-	O
dependent	O
vitamin	B-MED
C	I-MED
transporters	O
hSVCT1	B-GGP
and	O
hSVCT2	B-GGP
.	O

Two	O
sodium	B-MED
-	O
dependent	O
vitamin	B-MED
C	I-MED
transporters	O
,	O
hSVCT1	B-GGP
and	O
hSVCT2	B-GGP
,	O
were	O
cloned	O
from	O
a	O
human	O
kidney	O
cDNA	O
library	O
.	O

hSVCT1	B-GGP
had	O
a	O
1797	O
bp	O
open	O
reading	O
frame	O
encoding	O
a	O
598	O
amino	O
acid	O
polypeptide	O
.	O

The	O
1953	O
bp	O
open	O
reading	O
frame	O
of	O
hSVCT2	B-GGP
encoded	O
a	O
650	O
amino	O
acid	O
polypeptide	O
.	O

Using	O
a	O
Xenopus	O
laevis	O
oocyte	O
expression	O
system	O
,	O
both	O
transporters	O
were	O
functionally	O
expressed	O
.	O

By	O
Eadie	O
-	O
Hofstee	O
transformation	O
the	O
apparent	O
K	O
(	O
m	O
)	O
of	O
hSVCT1	B-GGP
for	O
ascorbate	B-MED
was	O
252	O
.	O
0	O
microM	O
and	O
of	O
hSVCT2	B-GGP
for	O
ascorbate	B-MED
was	O
21	O
.	O
3	O
microM	O
.	O

Both	O
transporters	O
were	O
sodium	B-MED
-	O
dependent	O
and	O
did	O
not	O
transport	O
dehydroascorbic	B-MED
acid	I-MED
.	O

Incubation	O
of	O
oocytes	O
expressing	O
either	O
transporter	O
with	O
phorbol	B-MED
12	I-MED
-	I-MED
myristate	I-MED
13	I-MED
-	I-MED
acetate	I-MED
(	O
PMA	B-MED
)	O
inhibited	O
ascorbate	B-MED
transport	O
activity	O
.	O

Availability	O
of	O
the	O
human	O
transporter	O
clones	O
may	O
facilitate	O
new	O
strategies	O
for	O
determining	O
vitamin	B-MED
C	I-MED
intake	O
.	O

PDK1	B-GGP
homologs	O
activate	O
the	O
Pkc1	B-GGP
-	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
pathway	O
in	O
yeast	O
.	O

PDK1	B-GGP
(	O
phosphoinositide	B-GGP
-	I-GGP
dependent	I-GGP
kinase	I-GGP
1	I-GGP
)	O
is	O
a	O
mammalian	O
growth	O
factor	O
-	O
regulated	O
serine	B-MED
/	O
threonine	B-MED
kinase	O
.	O

Using	O
a	O
genetic	O
selection	O
based	O
on	O
a	O
mutant	O
form	O
of	O
the	O
yeast	O
MAP	B-GGP
kinase	I-GGP
kinase	I-GGP
Ste7	B-GGP
,	O
we	O
isolated	O
a	O
gene	O
,	O
PKH2	B-GGP
,	O
encoding	O
a	O
structurally	O
and	O
functionally	O
conserved	O
yeast	O
homolog	O
of	O
PDK1	B-GGP
.	O

Yeast	O
cells	O
lacking	O
both	O
PKH2	B-GGP
and	O
PKH1	B-GGP
,	O
encoding	O
another	O
PDK1	B-GGP
homolog	O
,	O
were	O
nonviable	O
,	O
indicating	O
that	O
Pkh1	B-GGP
and	O
Pkh2	B-GGP
share	O
an	O
essential	O
function	O
.	O

A	O
temperature	O
-	O
sensitive	O
mutant	O
,	O
pkh1	B-GGP
(	O
D398G	O
)	O
pkh2	B-GGP
,	O
was	O
phenotypically	O
similar	O
to	O
mutants	O
defective	O
in	O
the	O
Pkc1	B-GGP
-	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
(	O
MAPK	B-GGP
)	O
pathway	O
.	O

Genetic	O
epistasis	O
analyses	O
,	O
the	O
phosphorylation	O
of	O
Pkc1	B-GGP
by	O
Pkh2	B-GGP
in	O
vitro	O
,	O
and	O
reduced	O
Pkc1	B-GGP
activity	O
in	O
the	O
pkh1	B-GGP
(	O
D398G	O
)	O
pkh2	B-GGP
mutant	O
indicate	O
that	O
Pkh	B-GGP
functions	O
upstream	O
of	O
Pkc1	B-GGP
.	O

The	O
Pkh2	B-GGP
phosphorylation	O
site	O
in	O
Pkc1	B-GGP
(	O
Thr	B-MED
-	I-MED
983	I-MED
)	O
is	O
part	O
of	O
a	O
conserved	O
PDK1	B-GGP
target	O
motif	O
and	O
essential	O
for	O
Pkc1	B-GGP
function	O
.	O

Thus	O
,	O
the	O
yeast	O
PDK1	B-GGP
homologs	O
activate	O
Pkc1	B-GGP
and	O
the	O
Pkc1	B-GGP
-	O
effector	O
MAPK	B-GGP
pathway	O
.	O

Pig	B-GGP
-	I-GGP
n	I-GGP
,	O
a	O
mammalian	O
homologue	O
of	O
yeast	O
Mcd4p	B-GGP
,	O
is	O
involved	O
in	O
transferring	O
phosphoethanolamine	B-MED
to	O
the	O
first	O
mannose	B-MED
of	O
the	O
glycosylphosphatidylinositol	B-MED
.	O

Many	O
cell	B-CC
surface	I-CC
proteins	O
are	O
anchored	O
to	O
the	O
membrane	B-CC
via	O
a	O
glycosylphosphatidylinositol	B-MED
(	O
GPI	B-MED
)	O
moiety	O
,	O
which	O
is	O
attached	O
to	O
the	O
C	O
terminus	O
of	O
the	O
proteins	O
.	O

The	O
core	O
of	O
the	O
GPI	B-MED
anchor	I-MED
is	O
conserved	O
in	O
all	O
eukaryotes	O
but	O
is	O
modified	O
by	O
various	O
side	O
chains	O
.	O

We	O
cloned	O
a	O
mouse	O
phosphatidylinositol	B-GGP
glycan	I-GGP
-	I-GGP
class	I-GGP
N	I-GGP
(	O
Pig	B-GGP
-	I-GGP
n	I-GGP
)	O
gene	O
that	O
encodes	O
a	O
931amino	O
acid	O
protein	O
expressed	O
in	O
the	O
endoplasmic	B-CC
reticulum	I-CC
,	O
which	O
is	O
homologous	O
to	O
yeast	O
Mcd4p	B-GGP
.	O

We	O
disrupted	O
the	O
gene	O
in	O
F9	O
embryonal	O
carcinoma	O
cells	O
.	O

In	O
the	O
Pig	B-GGP
-	I-GGP
n	I-GGP
knockout	O
cells	O
,	O
the	O
first	O
mannose	B-MED
in	O
the	O
GPI	B-MED
precursors	O
was	O
not	O
modified	O
by	O
phosphoethanolamine	B-MED
.	O

Nevertheless	O
,	O
further	O
biosynthetic	O
steps	O
continued	O
with	O
the	O
addition	O
of	O
the	O
third	O
mannose	B-MED
and	O
the	O
terminal	O
phosphoethanolamine	B-MED
.	O

The	O
surface	B-CC
expression	O
of	O
Thy	B-GGP
-	I-GGP
1	I-GGP
was	O
only	O
partially	O
affected	O
,	O
indicating	O
that	O
modification	O
of	O
the	O
first	O
mannose	B-MED
by	O
phosphoethanolamine	B-MED
is	O
not	O
essential	O
for	O
attachment	O
of	O
GPI	B-MED
anchors	I-MED
in	O
mammalian	O
cells	O
.	O

An	O
inhibitor	O
of	O
GPI	B-MED
biosynthesis	O
,	O
YW3548	B-MED
/	O
BE49385A	B-MED
,	O
inhibited	O
transfer	O
of	O
phosphoethanolamine	B-MED
to	O
the	O
first	O
mannose	B-MED
in	O
mammalian	O
cells	O
but	O
only	O
slightly	O
affected	O
the	O
surface	B-CC
expression	O
of	O
GPI	B-MED
-	O
anchored	O
proteins	O
.	O

Biosynthesis	O
of	O
GPI	B-MED
in	O
the	O
Pig	B-GGP
-	I-GGP
n	I-GGP
knockout	O
cells	O
was	O
not	O
affected	O
by	O
YW3548	B-MED
/	O
BE49385A	B-MED
,	O
and	O
yeast	O
overexpressing	O
MCD4	B-GGP
was	O
highly	O
resistant	O
to	O
YW3548	B-MED
/	O
BE49385A	B-MED
,	O
suggesting	O
that	O
Pig	B-GGP
-	I-GGP
n	I-GGP
and	O
Mcd4p	B-GGP
are	O
targets	O
of	O
this	O
drug	O
.	O

Heparan	B-GGP
sulfate	I-GGP
D	I-GGP
-	I-GGP
glucosaminyl	I-GGP
3	I-GGP
-	I-GGP
O	I-GGP
-	I-GGP
sulfotransferase	I-GGP
-	I-GGP
3A	I-GGP
sulfates	O
N	O
-	O
unsubstituted	O
glucosamine	B-MED
residues	O
.	O

3	O
-	O
O	O
-	O
Sulfation	O
of	O
glucosamine	B-MED
by	O
heparan	B-GGP
sulfate	I-GGP
D	I-GGP
-	I-GGP
glucosaminyl	I-GGP
3	I-GGP
-	I-GGP
O	I-GGP
-	I-GGP
sulfotransferase	I-GGP
(	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
1	I-GGP
)	O
is	O
the	O
key	O
modification	O
in	O
anticoagulant	O
heparan	B-MED
sulfate	I-MED
synthesis	O
.	O

However	O
,	O
the	O
heparan	B-MED
sulfates	I-MED
modified	O
by	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
2	I-GGP
and	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
,	O
isoforms	O
of	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
1	I-GGP
,	O
do	O
not	O
have	O
anticoagulant	O
activity	O
,	O
although	O
these	O
isoforms	O
transfer	O
sulfate	B-MED
to	O
the	O
3	B-MED
-	I-MED
OH	I-MED
position	O
of	O
glucosamine	B-MED
residues	O
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
the	O
substrate	O
specificity	O
of	O
purified	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
at	O
the	O
tetrasaccharide	B-MED
level	O
.	O

The	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
enzyme	O
was	O
purified	O
from	O
Sf9	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
containing	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
cDNA	O
.	O

Two	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
-	O
modified	O
tetrasaccharides	B-MED
were	O
purified	O
from	O
the	O
3	O
-	O
O	O
-	O
(	O
35	O
)	O
S	O
-	O
sulfated	O
heparan	B-MED
sulfate	I-MED
that	O
was	O
digested	O
by	O
heparin	B-GGP
lyases	I-GGP
.	O

These	O
tetrasaccharides	B-MED
were	O
analyzed	O
using	O
nitrous	B-MED
acid	I-MED
and	O
enzymatic	O
degradation	O
combined	O
with	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
-	O
mass	O
spectrometry	O
.	O

Two	O
novel	O
tetrasaccharides	B-MED
were	O
discovered	O
with	O
proposed	O
structures	O
of	O
DeltaUA2S	B-MED
-	I-MED
GlcNS	I-MED
-	I-MED
IdoUA2S	I-MED
-	I-MED
[	I-MED
(	I-MED
35	I-MED
)	I-MED
S	I-MED
]	I-MED
GlcNH	I-MED
(	I-MED
2	I-MED
)	I-MED
3S	I-MED
and	O
DeltaUA2S	B-MED
-	I-MED
GlcNS	I-MED
-	I-MED
IdoUA2S	I-MED
-	I-MED
[	I-MED
3	I-MED
-	I-MED
(	I-MED
35	I-MED
)	I-MED
S	I-MED
]	I-MED
GlcNH	I-MED
(	I-MED
2	I-MED
)	I-MED
3S6S	I-MED
.	O

The	O
results	O
demonstrate	O
that	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
sulfates	O
N	O
-	O
unsubstituted	O
glucosamine	B-MED
residues	O
,	O
and	O
the	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
modification	O
sites	O
are	O
probably	O
located	O
in	O
defined	O
oligosaccharide	B-MED
sequences	O
.	O

Our	O
study	O
suggests	O
that	O
oligosaccharides	B-MED
with	O
N	O
-	O
unsubstituted	O
glucosamine	B-MED
are	O
precursors	O
for	O
sulfation	O
by	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
.	O

The	O
intriguing	O
linkage	O
between	O
N	O
-	O
unsubstituted	O
glucosamine	B-MED
and	O
the	O
3	O
-	O
O	O
-	O
sulfation	O
by	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
may	O
provide	O
a	O
clue	O
to	O
the	O
potential	O
biological	O
functions	O
of	O
3	B-GGP
-	I-GGP
OST	I-GGP
-	I-GGP
3A	I-GGP
-	O
modified	O
heparan	B-MED
sulfate	I-MED
.	O

The	O
putative	O
tumor	O
suppressors	O
EXT1	B-GGP
and	O
EXT2	B-GGP
form	O
a	O
stable	O
complex	O
that	O
accumulates	O
in	O
the	O
Golgi	B-CC
apparatus	I-CC
and	O
catalyzes	O
the	O
synthesis	O
of	O
heparan	B-MED
sulfate	I-MED
.	O

Hereditary	O
multiple	O
exostoses	O
,	O
a	O
dominantly	O
inherited	O
genetic	O
disorder	O
characterized	O
by	O
multiple	O
cartilaginous	O
tumors	O
,	O
is	O
caused	O
by	O
mutations	O
in	O
members	O
of	O
the	O
EXT	B-GGP
gene	O
family	O
,	O
EXT1	B-GGP
or	O
EXT2	B-GGP
.	O

The	O
proteins	O
encoded	O
by	O
these	O
genes	O
,	O
EXT1	B-GGP
and	O
EXT2	B-GGP
,	O
are	O
endoplasmic	B-CC
reticulum	I-CC
-	O
localized	O
type	B-GGP
II	I-GGP
transmembrane	I-GGP
glycoproteins	I-GGP
that	O
possess	O
or	O
are	O
tightly	O
associated	O
with	O
glycosyltransferase	O
activities	O
involved	O
in	O
the	O
polymerization	O
of	O
heparan	B-MED
sulfate	I-MED
.	O

Here	O
,	O
by	O
testing	O
a	O
cell	O
line	O
with	O
a	O
specific	O
defect	O
in	O
EXT1	B-GGP
in	O
in	O
vivo	O
and	O
in	O
vitro	O
assays	O
,	O
we	O
show	O
that	O
EXT2	B-GGP
does	O
not	O
harbor	O
significant	O
glycosyltransferase	O
activity	O
in	O
the	O
absence	O
of	O
EXT1	B-GGP
.	O

Instead	O
,	O
it	O
appears	O
that	O
EXT1	B-GGP
and	O
EXT2	B-GGP
form	O
a	O
hetero	O
-	O
oligomeric	O
complex	O
in	O
vivo	O
that	O
leads	O
to	O
the	O
accumulation	O
of	O
both	O
proteins	O
in	O
the	O
Golgi	B-CC
apparatus	I-CC
.	O

Remarkably	O
,	O
the	O
Golgi	B-CC
-	O
localized	O
EXT1	B-GGP
/	O
EXT2	B-GGP
complex	O
possesses	O
substantially	O
higher	O
glycosyltransferase	O
activity	O
than	O
EXT1	B-GGP
or	O
EXT2	B-GGP
alone	O
,	O
which	O
suggests	O
that	O
the	O
complex	O
represents	O
the	O
biologically	O
relevant	O
form	O
of	O
the	O
enzyme	O
(	O
s	O
)	O
.	O

These	O
findings	O
provide	O
a	O
rationale	O
to	O
explain	O
how	O
inherited	O
mutations	O
in	O
either	O
of	O
the	O
two	O
EXT	B-GGP
genes	O
can	O
cause	O
loss	O
of	O
activity	O
,	O
resulting	O
in	O
hereditary	O
multiple	O
exostoses	O
.	O

Rad6	B-GGP
-	O
dependent	O
ubiquitination	O
of	O
histone	B-GGP
H2B	I-GGP
in	O
yeast	O
.	O

Although	O
ubiquitinated	O
histones	B-GGP
are	O
present	O
in	O
substantial	O
levels	O
in	O
vertebrate	O
cells	O
,	O
the	O
roles	O
they	O
play	O
in	O
specific	O
biological	O
processes	O
and	O
the	O
cellular	O
factors	O
that	O
regulate	O
this	O
modification	O
are	O
not	O
well	O
characterized	O
.	O

Ubiquitinated	O
H2B	B-GGP
(	O
uH2B	B-GGP
)	O
has	O
been	O
identified	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
and	O
mutation	O
of	O
the	O
conserved	O
ubiquitination	O
site	O
is	O
shown	O
to	O
confer	O
defects	O
in	O
mitotic	O
cell	O
growth	O
and	O
meiosis	O
.	O

uH2B	B-GGP
was	O
not	O
detected	O
in	O
rad6	B-GGP
mutants	O
,	O
which	O
are	O
defective	O
for	O
the	O
ubiquitin	B-GGP
-	O
conjugating	O
enzyme	O
Ubc2	B-GGP
,	O
thus	O
identifying	O
Rad6	B-GGP
as	O
the	O
major	O
cellular	O
activity	O
that	O
ubiquitinates	O
H2B	B-GGP
in	O
yeast	O
.	O

Nuclear	B-CC
sequestration	O
of	O
the	O
exchange	O
factor	O
Cdc24	B-GGP
by	O
Far1	B-GGP
regulates	O
cell	O
polarity	O
during	O
yeast	O
mating	O
.	O

Cytoskeletal	B-CC
rearrangements	O
during	O
the	O
cell	O
cycle	O
and	O
in	O
response	O
to	O
signals	O
are	O
regulated	O
by	O
small	O
Rho	B-GGP
-	O
type	O
GTPases	O
,	O
but	O
it	O
is	O
not	O
known	O
how	O
these	O
GTPases	O
are	O
activated	O
in	O
a	O
spatial	O
and	O
temporal	O
manner	O
.	O

Here	O
we	O
show	O
that	O
Cdc24	B-GGP
,	O
the	O
guanine	B-MED
-	O
nucleotide	O
exchange	O
factor	O
for	O
the	O
yeast	O
GTPase	O
Cdc42	B-GGP
,	O
is	O
sequestered	O
in	O
the	O
cell	B-CC
nucleus	I-CC
by	O
Far1	B-GGP
.	O

Export	O
of	O
Cdc24	B-GGP
to	O
a	O
site	O
of	O
cell	O
polarization	O
is	O
mediated	O
by	O
two	O
mechanisms	O
.	O

At	O
bud	O
emergence	O
,	O
activation	O
of	O
the	O
G1	O
cyclin	B-GGP
-	I-GGP
dependent	I-GGP
kinase	I-GGP
Cdc28	B-COM
-	I-COM
Cln	I-COM
triggers	O
degradation	O
of	O
Far1	B-GGP
and	O
,	O
as	O
a	O
result	O
,	O
relocation	O
of	O
Cdc24	B-GGP
to	O
the	O
cytoplasm	B-CC
.	O

Cells	O
overexpressing	O
a	O
non	O
-	O
degradable	O
Far1	B-GGP
were	O
unable	O
to	O
polarize	O
their	O
actin	B-GGP
cytoskeleton	B-CC
because	O
they	O
failed	O
to	O
relocate	O
Cdc24	B-GGP
to	O
the	O
incipient	O
bud	B-CC
site	I-CC
.	O

In	O
contrast	O
,	O
in	O
response	O
to	O
mating	O
pheromones	O
,	O
the	O
Far1	B-COM
-	I-COM
Cdc24	I-COM
complex	O
is	O
exported	O
from	O
the	O
nucleus	B-CC
by	O
Msn5	B-GGP
.	O

This	O
mechanism	O
ensures	O
that	O
Cdc24	B-GGP
is	O
targeted	O
to	O
the	O
site	O
of	O
receptor	O
-	O
associated	O
heterotrimeric	O
G	O
-	O
protein	O
activation	O
at	O
the	O
plasma	B-CC
membrane	I-CC
,	O
thereby	O
allowing	O
polarization	O
of	O
the	O
actin	B-GGP
cytoskeleton	B-CC
along	O
the	O
morphogenetic	O
gradient	O
of	O
pheromone	O
.	O

Either	O
degradation	O
of	O
Far1	B-GGP
or	O
its	O
nuclear	B-CC
export	O
by	O
Msn5	B-GGP
was	O
sufficient	O
for	O
cell	O
growth	O
,	O
suggesting	O
that	O
the	O
two	O
mechanisms	O
are	O
redundant	O
for	O
cell	O
viability	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
Far1	B-GGP
functions	O
as	O
a	O
nuclear	B-CC
anchor	O
for	O
Cdc24	B-GGP
.	O

This	O
sequestration	O
regulates	O
cell	O
polarity	O
in	O
response	O
to	O
pheromones	O
by	O
restricting	O
activation	O
of	O
Cdc42	B-GGP
to	O
the	O
site	O
of	O
pheromone	O
receptor	O
activation	O
.	O

Molecular	O
cloning	O
of	O
globotriaosylceramide	B-GGP
/	I-GGP
CD77	I-GGP
synthase	I-GGP
,	O
a	O
glycosyltransferase	O
that	O
initiates	O
the	O
synthesis	O
of	O
globo	O
series	O
glycosphingolipids	B-MED
.	O

The	O
expression	O
cloning	O
of	O
a	O
cDNA	O
for	O
globotriaosylceramide	B-GGP
(	I-GGP
Gb3	I-GGP
)	I-GGP
/	I-GGP
CD77	I-GGP
synthase	I-GGP
(	O
alpha1	B-GGP
,	I-GGP
4	I-GGP
-	I-GGP
galactosyltransferase	I-GGP
)	O
was	O
achieved	O
using	O
an	O
anti	O
-	O
Gb3	B-MED
antibody	O
and	O
mouse	O
L	O
cells	O
as	O
a	O
recipient	O
cell	O
line	O
for	O
the	O
transfection	O
.	O

The	O
isolated	O
cDNA	O
clone	O
designated	O
pVTR1	B-GGP
predicted	O
a	O
type	O
II	O
membrane	B-CC
protein	O
with	O
19	O
amino	O
acids	O
of	O
cytoplasmic	B-CC
domain	O
,	O
26	O
amino	O
acids	O
of	O
transmembrane	B-CC
region	O
,	O
and	O
a	O
catalytic	O
domain	O
with	O
308	O
amino	O
acids	O
.	O

Introduction	O
of	O
the	O
cDNA	O
clone	O
into	O
L	O
cells	O
resulted	O
in	O
the	O
neosynthesis	O
of	O
Gb3	B-MED
/	O
CD77	B-MED
,	O
and	O
the	O
extracts	O
of	O
the	O
transfectant	O
cells	O
showed	O
alpha1	B-GGP
,	I-GGP
4	I-GGP
-	I-GGP
galactosyltransferase	I-GGP
activity	O
only	O
on	O
lactosylceramide	B-MED
and	O
galactosylceramide	B-MED
.	O

In	O
Northern	O
blotting	O
,	O
a	O
2	O
.	O
3	O
-	O
kilobase	O
mRNA	O
was	O
strongly	O
expressed	O
in	O
heart	O
,	O
kidney	O
,	O
spleen	O
,	O
and	O
placenta	O
and	O
weakly	O
in	O
colon	O
,	O
small	O
intestine	O
,	O
and	O
brain	O
.	O

Transfection	O
of	O
the	O
cDNA	O
into	O
L	O
cells	O
resulted	O
in	O
the	O
constitution	O
of	O
sensitivity	O
to	O
the	O
apoptosis	O
with	O
Shiga	B-GGP
-	I-GGP
like	I-GGP
toxins	I-GGP
(	O
verotoxins	B-GGP
)	O
.	O

Since	O
Gb3	B-GGP
/	I-GGP
CD77	I-GGP
synthase	I-GGP
initiates	O
the	O
synthesis	O
of	O
globo	O
series	O
glycolipids	B-MED
,	O
the	O
isolation	O
of	O
this	O
cDNA	O
will	O
make	O
possible	O
further	O
investigations	O
into	O
the	O
function	O
of	O
its	O
important	O
series	O
of	O
glycolipids	B-MED
.	O

E2F	B-GGP
family	O
members	O
are	O
differentially	O
regulated	O
by	O
reversible	O
acetylation	O
.	O

The	O
six	O
members	O
of	O
the	O
E2F	B-GGP
family	O
of	O
transcription	O
factors	O
play	O
a	O
key	O
role	O
in	O
the	O
control	O
of	O
cell	O
cycle	O
progression	O
by	O
regulating	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
DNA	O
replication	O
and	O
cell	O
proliferation	O
.	O

E2F	B-GGP
-	I-GGP
1	I-GGP
,	O
-	B-GGP
2	I-GGP
,	O
and	O
-	B-GGP
3	I-GGP
belong	O
to	O
a	O
structural	O
and	O
functional	O
subfamily	O
distinct	O
from	O
those	O
of	O
the	O
other	O
E2F	B-GGP
family	O
members	O
.	O

Here	O
we	O
report	O
that	O
E2F	B-GGP
-	I-GGP
1	I-GGP
,	O
-	B-GGP
2	I-GGP
,	O
and	O
-	B-GGP
3	I-GGP
,	O
but	O
not	O
E2F	B-GGP
-	I-GGP
4	I-GGP
,	O
-	B-GGP
5	I-GGP
,	O
and	O
-	B-GGP
6	I-GGP
,	O
associate	O
with	O
and	O
are	O
acetylated	O
by	O
p300	B-GGP
and	O
cAMP	B-GGP
-	I-GGP
response	I-GGP
element	I-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
acetyltransferases	O
.	O

Acetylation	O
occurs	O
at	O
three	O
conserved	O
lysine	B-MED
residues	O
located	O
at	O
the	O
N	O
-	O
terminal	O
boundary	O
of	O
their	O
DNA	O
binding	O
domains	O
.	O

Acetylation	O
of	O
E2F	B-GGP
-	I-GGP
1	I-GGP
in	O
vitro	O
and	O
in	O
vivo	O
markedly	O
increases	O
its	O
binding	O
affinity	O
for	O
a	O
consensus	O
E2F	B-GGP
DNA	O
-	O
binding	O
site	O
,	O
which	O
is	O
paralleled	O
by	O
enhanced	O
transactivation	O
of	O
an	O
E2F	B-GGP
-	O
responsive	O
promoter	O
.	O

Acetylation	O
of	O
E2F	B-GGP
-	I-GGP
1	I-GGP
can	O
be	O
reversed	O
by	O
histone	B-GGP
deacetylase	I-GGP
-	I-GGP
1	I-GGP
,	O
indicating	O
that	O
reversible	O
acetylation	O
is	O
a	O
mechanism	O
for	O
regulation	O
also	O
of	O
non	O
-	O
histone	B-GGP
proteins	O
.	O

Mechanism	O
of	O
reaction	O
of	O
myeloperoxidase	B-GGP
with	O
nitrite	B-MED
.	O

Myeloperoxidase	B-GGP
(	O
MPO	B-GGP
)	O
is	O
a	O
major	O
neutrophil	O
protein	O
and	O
may	O
be	O
involved	O
in	O
the	O
nitration	O
of	O
tyrosine	O
residues	O
observed	O
in	O
a	O
wide	O
range	O
of	O
inflammatory	O
diseases	O
that	O
involve	O
neutrophils	O
and	O
macrophage	O
activation	O
.	O

In	O
order	O
to	O
clarify	O
if	O
nitrite	B-MED
could	O
be	O
a	O
physiological	O
substrate	O
of	O
myeloperoxidase	B-GGP
,	O
we	O
investigated	O
the	O
reactions	O
of	O
the	O
ferric	O
enzyme	O
and	O
its	O
redox	O
intermediates	O
,	O
compound	B-GGP
I	I-GGP
and	O
compound	B-GGP
II	I-GGP
,	O
with	O
nitrite	B-MED
under	O
pre	O
-	O
steady	O
state	O
conditions	O
by	O
using	O
sequential	O
mixing	O
stopped	O
-	O
flow	O
analysis	O
in	O
the	O
pH	O
range	O
4	O
-	O
8	O
.	O

At	O
15	O
degrees	O
C	O
the	O
rate	O
of	O
formation	O
of	O
the	O
low	O
spin	O
MPO	B-GGP
-	O
nitrite	B-MED
complex	O
is	O
(	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
2	O
)	O
x	O
10	O
(	O
4	O
)	O
m	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
at	O
pH	O
7	O
and	O
(	O
2	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
x	O
10	O
(	O
6	O
)	O
m	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
at	O
pH	O
5	O
.	O

The	O
dissociation	O
constant	O
of	O
nitrite	B-MED
bound	O
to	O
the	O
native	O
enzyme	O
is	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
at	O
pH	O
7	O
and	O
31	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
5	O
micrometer	O
at	O
pH	O
5	O
.	O

Nitrite	B-MED
is	O
oxidized	O
by	O
two	O
one	O
-	O
electron	O
steps	O
in	O
the	O
MPO	B-GGP
peroxidase	O
cycle	O
.	O

The	O
second	O
-	O
order	O
rate	O
constant	O
of	O
reduction	O
of	O
compound	B-GGP
I	I-GGP
to	O
compound	B-GGP
II	I-GGP
at	O
15	O
degrees	O
C	O
is	O
(	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
)	O
x	O
10	O
(	O
6	O
)	O
m	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
at	O
pH	O
7	O
and	O
(	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
2	O
)	O
x	O
10	O
(	O
7	O
)	O
m	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
at	O
pH	O
5	O
.	O

The	O
rate	O
constant	O
of	O
reduction	O
of	O
compound	B-GGP
II	I-GGP
to	O
the	O
ferric	O
native	O
enzyme	O
at	O
15	O
degrees	O
C	O
is	O
(	O
5	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
)	O
x	O
10	O
(	O
2	O
)	O
m	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
at	O
pH	O
7	O
and	O
(	O
8	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
6	O
)	O
x	O
10	O
(	O
4	O
)	O
m	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
at	O
pH	O
5	O
.	O

pH	O
dependence	O
studies	O
suggest	O
that	O
both	O
complex	O
formation	O
between	O
the	O
ferric	O
enzyme	O
and	O
nitrite	B-MED
and	O
nitrite	B-MED
oxidation	O
by	O
compounds	B-GGP
I	I-GGP
and	O
II	B-GGP
are	O
controlled	O
by	O
a	O
residue	O
with	O
a	O
pK	O
(	O
a	O
)	O
of	O
(	O
4	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
)	O
.	O

Protonation	O
of	O
this	O
group	O
(	O
which	O
is	O
most	O
likely	O
the	O
distal	O
histidine	B-MED
)	O
is	O
necessary	O
for	O
optimum	O
nitrite	B-MED
binding	O
and	O
oxidation	O
.	O

Bruton	B-GGP
'	I-GGP
s	I-GGP
tyrosine	I-GGP
kinase	I-GGP
is	O
required	O
for	O
activation	O
of	O
IkappaB	B-COM
kinase	I-COM
and	O
nuclear	B-COM
factor	I-COM
kappaB	I-COM
in	O
response	O
to	O
B	O
cell	O
receptor	O
engagement	O
.	O

Mutations	O
in	O
the	O
gene	O
encoding	O
Bruton	B-GGP
'	I-GGP
s	I-GGP
tyrosine	I-GGP
kinase	I-GGP
(	O
btk	B-GGP
)	O
cause	O
the	O
B	O
cell	O
deficiency	O
diseases	O
X	O
-	O
linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
in	O
humans	O
and	O
X	O
-	O
linked	O
immunodeficiency	O
(	O
xid	O
)	O
in	O
mice	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
studies	O
indicate	O
that	O
the	O
BTK	B-GGP
protein	O
is	O
essential	O
for	O
B	O
cell	O
survival	O
,	O
cell	O
cycle	O
progression	O
,	O
and	O
proliferation	O
in	O
response	O
to	O
B	B-COM
cell	I-COM
antigen	I-COM
receptor	I-COM
(	O
BCR	B-COM
)	O
stimulation	O
.	O

BCR	B-COM
stimulation	O
leads	O
to	O
the	O
activation	O
of	O
transcription	O
factor	O
nuclear	B-COM
factor	I-COM
(	I-COM
NF	I-COM
)	I-COM
-	I-COM
kappaB	I-COM
,	O
which	O
in	O
turn	O
regulates	O
genes	O
controlling	O
B	O
cell	O
growth	O
.	O

We	O
now	O
demonstrate	O
that	O
a	O
null	O
mutation	O
in	O
btk	B-GGP
known	O
to	O
cause	O
the	O
xid	O
phenotype	O
prevents	O
BCR	B-COM
-	O
induced	O
activation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

This	O
defect	O
can	O
be	O
rescued	O
by	O
reconstitution	O
with	O
wild	O
-	O
type	O
BTK	B-GGP
.	O

This	O
mutation	O
also	O
interferes	O
with	O
BCR	B-COM
-	O
directed	O
activation	O
of	O
IkappaB	B-COM
kinase	I-COM
(	O
IKK	B-COM
)	O
,	O
which	O
normally	O
targets	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitor	O
IkappaBalpha	B-GGP
for	O
degradation	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
BTK	B-GGP
couples	O
IKK	B-COM
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
to	O
the	O
BCR	B-COM
.	O

Interference	O
with	O
this	O
coupling	O
mechanism	O
may	O
contribute	O
to	O
the	O
B	O
cell	O
deficiencies	O
observed	O
in	O
XLA	O
and	O
xid	O
.	O

Phosphorylation	O
meets	O
ubiquitination	O
:	O
the	O
control	O
of	O
NF	B-COM
-	I-COM
[	I-COM
kappa	I-COM
]	I-COM
B	I-COM
activity	O
.	O

NF	B-COM
-	I-COM
kappaB	I-COM
(	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
)	O
is	O
a	O
collective	O
name	O
for	O
inducible	O
dimeric	O
transcription	O
factors	O
composed	O
of	O
members	O
of	O
the	O
Rel	B-GGP
family	O
of	O
DNA	O
-	O
binding	O
proteins	O
that	O
recognize	O
a	O
common	O
sequence	O
motif	O
.	O

NF	B-COM
-	I-COM
kappaB	I-COM
is	O
found	O
in	O
essentially	O
all	O
cell	O
types	O
and	O
is	O
involved	O
in	O
activation	O
of	O
an	O
exceptionally	O
large	O
number	O
of	O
genes	O
in	O
response	O
to	O
infections	O
,	O
inflammation	O
,	O
and	O
other	O
stressful	O
situations	O
requiring	O
rapid	O
reprogramming	O
of	O
gene	O
expression	O
.	O

NF	B-COM
-	I-COM
kappaB	I-COM
is	O
normally	O
sequestered	O
in	O
the	O
cytoplasm	B-CC
of	O
nonstimulated	O
cells	O
and	O
consequently	O
must	O
be	O
translocated	O
into	O
the	O
nucleus	B-CC
to	O
function	O
.	O

The	O
subcellular	O
location	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
is	O
controlled	O
by	O
a	O
family	O
of	O
inhibitory	O
proteins	O
,	O
IkappaBs	B-GGP
,	O
which	O
bind	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
mask	O
its	O
nuclear	B-CC
localization	O
signal	O
,	O
thereby	O
preventing	O
nuclear	B-CC
uptake	O
.	O

Exposure	O
of	O
cells	O
to	O
a	O
variety	O
of	O
extracellular	B-CC
stimuli	O
leads	O
to	O
the	O
rapid	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
ultimately	O
proteolytic	O
degradation	O
of	O
IkappaB	B-GGP
,	O
which	O
frees	O
NF	B-COM
-	I-COM
kappaB	I-COM
to	O
translocate	O
to	O
the	O
nucleus	B-CC
where	O
it	O
regulates	O
gene	O
transcription	O
.	O

NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
represents	O
a	O
paradigm	O
for	O
controlling	O
the	O
function	O
of	O
a	O
regulatory	O
protein	O
via	O
ubiquitination	O
-	O
dependent	O
proteolysis	O
,	O
as	O
an	O
integral	O
part	O
of	O
a	O
phosphorylationbased	O
signaling	O
cascade	O
.	O

Recently	O
,	O
considerable	O
progress	O
has	O
been	O
made	O
in	O
understanding	O
the	O
details	O
of	O
the	O
signaling	O
pathways	O
that	O
regulate	O
NF	B-COM
-	I-COM
kappaB	I-COM
activity	O
,	O
particularly	O
those	O
responding	O
to	O
the	O
proinflammatory	O
cytokines	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
-	I-GGP
alpha	I-GGP
and	O
interleukin	B-GGP
-	I-GGP
1	I-GGP
.	O

The	O
multisubunit	O
IkappaB	B-COM
kinase	I-COM
(	O
IKK	B-COM
)	O
responsible	O
for	O
inducible	O
IkappaB	B-GGP
phosphorylation	O
is	O
the	O
point	O
of	O
convergence	O
for	O
most	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
activating	O
stimuli	O
.	O

IKK	B-COM
contains	O
two	O
catalytic	O
subunits	O
,	O
IKKalpha	B-GGP
and	O
IKKbeta	B-GGP
,	O
both	O
of	O
which	O
are	O
able	O
to	O
correctly	O
phosphorylate	O
IkappaB	B-GGP
.	O

Gene	O
knockout	O
studies	O
have	O
shed	O
light	O
on	O
the	O
very	O
different	O
physiological	O
functions	O
of	O
IKKalpha	B-GGP
and	O
IKKbeta	B-GGP
.	O

After	O
phosphorylation	O
,	O
the	O
IKK	B-COM
phosphoacceptor	O
sites	O
on	O
IkappaB	B-GGP
serve	O
as	O
an	O
essential	O
part	O
of	O
a	O
specific	O
recognition	O
site	O
for	O
E3RS	B-GGP
(	O
IkappaB	B-GGP
/	O
beta	B-GGP
-	I-GGP
TrCP	I-GGP
)	O
,	O
an	O
SCF	O
-	O
type	O
E3	O
ubiquitin	B-GGP
ligase	O
,	O
thereby	O
explaining	O
how	O
IKK	B-COM
controls	O
IkappaB	B-GGP
ubiquitination	O
and	O
degradation	O
.	O

A	O
variety	O
of	O
other	O
signaling	O
events	O
,	O
including	O
phosphorylation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
hyperphosphorylation	O
of	O
IKK	B-COM
,	O
induction	O
of	O
IkappaB	B-GGP
synthesis	O
,	O
and	O
the	O
processing	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
precursors	O
,	O
provide	O
additional	O
mechanisms	O
that	O
modulate	O
the	O
level	O
and	O
duration	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
activity	O
.	O

p63	B-GGP
and	O
p73	B-GGP
transactivate	O
differentiation	O
gene	O
promoters	O
in	O
human	O
keratinocytes	O
.	O

p53	B-GGP
and	O
its	O
two	O
homologues	O
,	O
p73	B-GGP
and	O
p63	B-GGP
,	O
share	O
considerable	O
structural	O
similarities	O
,	O
an	O
ability	O
to	O
interact	O
between	O
themselves	O
and	O
to	O
transactivate	O
the	O
same	O
promoters	O
,	O
including	O
for	O
example	O
p21	B-GGP
.	O

Furthermore	O
,	O
p73	B-GGP
can	O
induce	O
cell	O
death	O
via	O
its	O
interaction	O
with	O
c	B-GGP
-	I-GGP
Abl	I-GGP
.	O

In	O
contrast	O
,	O
p63	B-GGP
has	O
been	O
demonstrated	O
to	O
be	O
essential	O
for	O
limb	O
and	O
skin	O
formation	O
.	O

We	O
evaluated	O
the	O
expression	O
of	O
p63	B-GGP
and	O
p73	B-GGP
in	O
differentiating	O
human	O
keratinocytes	O
in	O
vitro	O
.	O

Skin	O
biopsy	O
and	O
primary	O
cultures	O
of	O
normal	O
human	O
epidermal	O
keratinocytes	O
(	O
NHEK	O
)	O
express	O
both	O
p73	B-GGP
and	O
p63	B-GGP
.	O

NHEK	O
induced	O
to	O
differentiate	O
in	O
vitro	O
by	O
high	O
calcium	B-MED
exposure	O
show	O
induction	O
of	O
p73	B-GGP
delta	I-GGP
and	O
downregulation	O
of	O
all	O
isoforms	O
of	O
p63	B-GGP
.	O

This	O
latter	O
gene	O
is	O
predominantly	O
expressed	O
in	O
its	O
transcriptionally	O
inactive	O
form	O
,	O
DeltaNp63	B-GGP
.	O

We	O
further	O
evaluated	O
the	O
effect	O
of	O
either	O
p73s	B-GGP
or	O
p63	B-GGP
transfected	O
in	O
either	O
NHEK	O
or	O
transformed	O
human	O
keratinocytes	O
(	O
HaCat	O
cells	O
)	O
.	O

p73	B-GGP
gamma	I-GGP
,	O
delta	B-GGP
,	O
and	O
p63	B-GGP
were	O
able	O
to	O
transactivate	O
the	O
promoters	O
of	O
loricrin	B-GGP
and	O
involucrin	B-GGP
in	O
both	O
NHEK	O
and	O
HaCat	O
cells	O
.	O

These	O
results	O
suggest	O
the	O
involvement	O
of	O
both	O
p73	B-GGP
and	O
p63	B-GGP
genes	O
in	O
keratinocyte	O
terminal	O
differentiation	O
.	O

Translocation	O
of	O
Akt	B-GGP
/	O
PKB	B-GGP
to	O
the	O
nucleus	B-CC
of	O
osteoblast	O
-	O
like	O
MC3T3	O
-	O
E1	O
cells	O
exposed	O
to	O
proliferative	O
growth	O
factors	O
.	O

An	O
active	O
phosphatidylinositol	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
(	O
PI3K	B-GGP
)	O
has	O
been	O
shown	O
in	O
nuclei	B-CC
of	O
different	O
cell	O
types	O
.	O

The	O
products	O
of	O
this	O
enzyme	O
,	O
i	O
.	O
e	O
.	O
inositides	B-MED
phosphorylated	O
in	O
the	O
D3	O
position	O
of	O
the	O
inositol	B-MED
ring	O
,	O
may	O
act	O
as	O
second	O
messengers	O
themselves	O
.	O

Nuclear	B-CC
PI3K	B-GGP
translocation	O
has	O
been	O
demonstrated	O
to	O
be	O
related	O
to	O
an	O
analogous	O
translocation	O
of	O
a	O
PtdIns	B-MED
(	I-MED
3	I-MED
,	I-MED
4	I-MED
,	I-MED
5	I-MED
)	I-MED
P	I-MED
(	I-MED
3	I-MED
)	I-MED
activated	O
PKC	B-GGP
,	O
the	O
zeta	O
isozyme	O
.	O

We	O
have	O
examined	O
the	O
issue	O
of	O
whether	O
or	O
not	O
in	O
the	O
osteoblast	O
-	O
like	O
clonal	O
cell	O
line	O
MC3T3	O
-	O
E1	O
there	O
may	O
be	O
observed	O
an	O
insulin	B-GGP
-	I-GGP
like	I-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
I	I-GGP
-	O
(	O
IGF	B-GGP
-	I-GGP
I	I-GGP
)	O
and	O
platelet	B-GGP
-	I-GGP
derived	I-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
(	O
PDGF	B-GGP
)	O
dependent	O
nuclear	B-CC
translocation	O
of	O
an	O
active	O
Akt	B-GGP
/	O
PKB	B-GGP
.	O

Western	O
blot	O
analysis	O
showed	O
a	O
maximal	O
nuclear	B-CC
translocation	O
after	O
20	O
min	O
of	O
IGF	B-GGP
-	I-GGP
I	I-GGP
stimulation	O
or	O
after	O
30	O
min	O
of	O
PDGF	B-GGP
treatment	O
.	O

Both	O
growth	O
factors	O
increased	O
rapidly	O
and	O
transiently	O
the	O
enzyme	O
activity	O
of	O
immunoprecipitable	O
nuclear	B-CC
Akt	B-GGP
/	O
PKB	B-GGP
on	O
a	O
similar	O
time	O
scale	O
and	O
after	O
60	O
min	O
the	O
values	O
were	O
slightly	O
higher	O
than	O
the	O
basal	O
levels	O
.	O

Enzyme	O
translocation	O
was	O
blocked	O
by	O
the	O
specific	O
PI3K	B-GGP
inhibitor	O
,	O
LY294002	B-MED
,	O
as	O
well	O
as	O
cell	O
entry	O
into	O
S	O
-	O
phase	O
.	O

Confocal	O
microscopy	O
showed	O
an	O
evident	O
increase	O
in	O
immunostaining	O
intensity	O
in	O
the	O
nuclear	B-CC
interior	I-CC
after	O
growth	O
factor	O
treatment	O
but	O
no	O
changes	O
in	O
the	O
subcellular	B-CC
distribution	O
of	O
Akt	B-GGP
/	O
PKB	B-GGP
when	O
a	O
LY294002	B-MED
pre	O
-	O
treatment	O
was	O
administered	O
to	O
the	O
cells	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
intranuclear	B-CC
translocation	O
of	O
Akt	B-GGP
/	O
PKB	B-GGP
is	O
an	O
important	O
step	O
in	O
signalling	O
pathways	O
that	O
mediate	O
cell	O
proliferation	O
.	O

Characterization	O
of	O
a	O
cDNA	O
encoding	O
a	O
novel	O
human	O
Golgi	B-CC
alpha	B-GGP
1	I-GGP
,	I-GGP
2	I-GGP
-	I-GGP
mannosidase	I-GGP
(	O
IC	B-GGP
)	O
involved	O
in	O
N	B-MED
-	I-MED
glycan	I-MED
biosynthesis	O
.	O

A	O
human	O
cDNA	O
encoding	O
a	O
70	O
.	O
9	O
-	O
kDa	O
type	O
II	O
membrane	B-CC
protein	O
with	O
sequence	O
similarity	O
to	O
class	B-GGP
I	I-GGP
alpha1	I-GGP
,	I-GGP
2	I-GGP
-	I-GGP
mannosidases	I-GGP
was	O
isolated	O
.	O

The	O
enzymatic	O
properties	O
of	O
the	O
novel	O
alpha1	B-GGP
,	I-GGP
2	I-GGP
-	I-GGP
mannosidase	I-GGP
IC	I-GGP
were	O
studied	O
by	O
expressing	O
its	O
catalytic	O
domain	O
in	O
Pichia	O
pastoris	O
as	O
a	O
secreted	O
glycoprotein	O
.	O

alpha1	B-GGP
,	I-GGP
2	I-GGP
-	I-GGP
Mannosidase	I-GGP
IC	I-GGP
sequentially	O
hydrolyzes	O
the	O
alpha1	O
,	O
2	O
-	O
linked	O
mannose	B-MED
residues	O
of	O
[	B-MED
(	I-MED
3	I-MED
)	I-MED
H	I-MED
]	I-MED
mannose	I-MED
-	O
labeled	O
Man	B-MED
(	I-MED
9	I-MED
)	I-MED
GlcNAc	I-MED
to	O
form	O
[	B-MED
(	I-MED
3	I-MED
)	I-MED
H	I-MED
]	I-MED
Man	I-MED
(	I-MED
6	I-MED
)	I-MED
GlcNAc	I-MED
and	O
a	O
small	O
amount	O
of	O
[	B-MED
(	I-MED
3	I-MED
)	I-MED
H	I-MED
]	I-MED
Man	I-MED
(	I-MED
5	I-MED
)	I-MED
GlcNAc	I-MED
.	O

The	O
enzyme	O
requires	O
calcium	B-MED
for	O
activity	O
and	O
is	O
inhibited	O
by	O
both	O
1	B-MED
-	I-MED
deoxymannojirimycin	I-MED
and	O
kifunensine	B-MED
.	O

The	O
order	O
of	O
mannose	B-MED
removal	O
was	O
determined	O
by	O
separating	O
oligosaccharide	O
isomers	O
formed	O
from	O
pyridylaminated	O
Man	B-MED
(	I-MED
9	I-MED
)	I-MED
GlcNAc	I-MED
(	I-MED
2	I-MED
)	I-MED
by	O
high	O
performance	O
liquid	O
chromatography	O
.	O

The	O
terminal	O
alpha1	O
,	O
2	O
-	O
linked	O
mannose	B-MED
residue	O
from	O
the	O
middle	O
branch	O
is	O
the	O
last	O
mannose	B-MED
removed	O
by	O
the	O
enzyme	O
.	O

This	O
residue	O
is	O
the	O
mannose	B-MED
cleaved	O
from	O
Man	B-MED
(	I-MED
9	I-MED
)	I-MED
GlcNAc	I-MED
(	I-MED
2	I-MED
)	I-MED
by	O
the	O
endoplasmic	B-CC
reticulum	I-CC
alpha1	B-GGP
,	I-GGP
2	I-GGP
-	I-GGP
mannosidase	I-GGP
I	I-GGP
to	O
form	O
Man	B-MED
(	I-MED
8	I-MED
)	I-MED
GlcNAc	I-MED
(	I-MED
2	I-MED
)	I-MED
isomer	I-MED
B	I-MED
.	O

The	O
order	O
of	O
mannose	B-MED
hydrolysis	O
from	O
either	O
pyridylaminated	O
Man	B-MED
(	I-MED
9	I-MED
)	I-MED
GlcNAc	I-MED
(	I-MED
2	I-MED
)	I-MED
or	O
Man	B-MED
(	I-MED
8	I-MED
)	I-MED
GlcNAc	I-MED
(	I-MED
2	I-MED
)	I-MED
isomer	I-MED
B	I-MED
differs	O
from	O
that	O
previously	O
reported	O
for	O
mammalian	O
Golgi	B-CC
alpha1	B-GGP
,	I-GGP
2	I-GGP
-	I-GGP
mannosidases	I-GGP
IA	I-GGP
and	O
IB	B-GGP
.	O

The	O
full	O
-	O
length	O
alpha1	B-GGP
,	I-GGP
2	I-GGP
-	I-GGP
mannosidase	I-GGP
IC	I-GGP
was	O
localized	O
to	O
the	O
Golgi	B-CC
of	O
MDBK	O
and	O
MDCK	O
cells	O
by	O
indirect	O
immunofluorescence	O
.	O

Northern	O
blot	O
analysis	O
showed	O
tissue	O
-	O
specific	O
expression	O
of	O
a	O
major	O
transcript	O
of	O
3	O
.	O
8	O
kilobase	O
pairs	O
.	O

The	O
expression	O
pattern	O
is	O
different	O
from	O
that	O
of	O
human	O
Golgi	B-CC
alpha1	B-GGP
,	I-GGP
2	I-GGP
-	I-GGP
mannosidases	I-GGP
IA	I-GGP
and	O
IB	B-GGP
.	O

Therefore	O
,	O
the	O
human	O
genome	O
contains	O
at	O
least	O
three	O
differentially	O
regulated	O
Golgi	B-CC
alpha1	B-GGP
,	I-GGP
2	I-GGP
-	I-GGP
mannosidase	I-GGP
genes	O
encoding	O
enzymes	O
with	O
similar	O
,	O
but	O
not	O
identical	O
specificities	O
.	O

SCF	B-COM
(	I-COM
beta	I-COM
-	I-COM
TRCP	I-COM
)	I-COM
and	O
phosphorylation	O
dependent	O
ubiquitinationof	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
catalyzed	O
by	O
Ubc3	B-GGP
and	O
Ubc4	B-GGP
.	O

NF	B-COM
kappa	I-COM
B	I-COM
is	O
an	O
important	O
transcriptional	O
regulator	O
of	O
multiple	O
pro	O
-	O
inflammatory	O
genes	O
.	O

In	O
non	O
-	O
stimulated	O
cells	O
NF	B-COM
kappa	I-COM
B	I-COM
is	O
anchored	O
in	O
the	O
cytoplasm	B-CC
via	O
the	O
inhibitory	O
protein	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
.	O

Following	O
exposure	O
to	O
diverse	O
pro	O
-	O
inflammatory	O
signals	O
(	O
e	O
.	O
g	O
.	O
TNF	B-GGP
alpha	I-GGP
,	O
IL1	B-GGP
,	O
LPS	B-MED
)	O
various	O
signal	O
transduction	O
cascades	O
are	O
initiated	O
converging	O
on	O
the	O
I	B-COM
kappa	I-COM
B	I-COM
kinase	I-COM
(	O
IKK	B-COM
)	O
.	O

IKK	B-COM
phosphorylates	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
on	O
serines	B-MED
32	I-MED
and	O
36	B-MED
signaling	O
the	O
inhibitory	O
protein	O
for	O
ubiquitin	B-GGP
-	O
mediated	O
degradation	O
.	O

The	O
SCF	B-COM
beta	I-COM
-	I-COM
TRCP	I-COM
complex	O
is	O
the	O
ubiquitin	B-GGP
ligase	O
responsible	O
for	O
mediating	O
phosphorylation	O
dependent	O
ubiquitination	O
of	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
.	O

Here	O
we	O
reconstitute	O
phosphorylation	O
dependent	O
ubiquitination	O
of	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
using	O
recombinant	O
components	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
cullin	B-GGP
specificity	O
of	O
the	O
SCF	B-COM
complex	I-COM
may	O
reflect	O
its	O
ability	O
to	O
associate	O
with	O
Rbx1	B-GGP
.	O

We	O
demonstrate	O
specific	O
ubiquitination	O
of	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
by	O
Ubc3	B-GGP
and	O
Ubc4	B-GGP
in	O
a	O
phosphorylation	O
and	O
SCF	B-COM
beta	I-COM
-	I-COM
TRCP	I-COM
dependent	O
manner	O
and	O
that	O
both	O
are	O
capable	O
of	O
associating	O
with	O
the	O
SCF	B-COM
beta	I-COM
-	I-COM
TRCP	I-COM
complex	O
isolated	O
from	O
human	O
cells	O
.	O

Finally	O
,	O
we	O
show	O
that	O
Ubc4	B-GGP
is	O
in	O
excess	O
to	O
Ubc3	B-GGP
in	O
THP	O
.	O
1	O
cells	O
and	O
19	O
times	O
more	O
efficient	O
in	O
catalyzing	O
the	O
reaction	O
,	O
suggesting	O
that	O
Ubc4	B-GGP
is	O
the	O
preferentially	O
used	O
Ubc	B-GGP
in	O
this	O
reaction	O
in	O
vivo	O
.	O

Our	O
results	O
also	O
suggest	O
that	O
ubiquitin	B-GGP
is	O
transferred	O
directly	O
from	O
the	O
Ubc	B-GGP
to	O
phospho	O
-	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
in	O
a	O
SCF	B-COM
beta	I-COM
-	I-COM
TRCP	I-COM
dependent	O
reaction	O
.	O

Oncogene	O
(	O
2000	O
)	O
19	O
,	O
3529	O
-	O
3536	O

Regulation	O
of	O
transcription	O
by	O
ubiquitination	O
without	O
proteolysis	O
:	O
Cdc34	B-COM
/	I-COM
SCF	I-COM
(	I-COM
Met30	I-COM
)	I-COM
-	O
mediated	O
inactivation	O
of	O
the	O
transcription	O
factor	O
Met4	B-GGP
.	O

Polyubiquitination	O
of	O
proteins	O
by	O
Cdc34	B-COM
/	I-COM
SCF	I-COM
complexes	O
targets	O
them	O
for	O
degradation	O
by	O
the	O
26S	B-CC
proteasome	I-CC
.	O

The	O
essential	O
F	O
-	O
box	O
protein	O
Met30	B-GGP
is	O
the	O
substrate	O
recognition	O
subunit	O
of	O
the	O
ubiquitin	B-GGP
ligase	O
SCF	B-COM
(	I-COM
Met30	I-COM
)	I-COM
.	O

The	O
critical	O
target	O
of	O
SCF	B-COM
(	I-COM
Met30	I-COM
)	I-COM
is	O
the	O
transcription	O
factor	O
Met4	B-GGP
,	O
as	O
deletion	O
of	O
MET4	B-GGP
suppresses	O
the	O
lethality	O
of	O
met30	B-GGP
mutants	O
.	O

Surprisingly	O
,	O
Met4	B-GGP
is	O
a	O
relatively	O
stable	O
protein	O
and	O
its	O
abundance	O
is	O
not	O
influenced	O
by	O
Met30	B-GGP
.	O

However	O
,	O
transcriptional	O
repression	O
of	O
Met4	B-GGP
target	O
genes	O
correlates	O
with	O
Cdc34	B-COM
/	I-COM
SCF	I-COM
(	I-COM
Met30	I-COM
)	I-COM
-	O
dependent	O
ubiquitination	O
of	O
Met4	B-GGP
.	O

Functionally	O
,	O
ubiquitinated	O
Met4	B-GGP
associates	O
with	O
target	O
promoters	O
but	O
fails	O
to	O
form	O
functional	O
transcription	O
complexes	O
.	O

Our	O
data	O
reveal	O
a	O
novel	O
proteolysis	O
-	O
independent	O
function	O
for	O
Cdc34	B-COM
/	I-COM
SCF	I-COM
and	O
indicate	O
that	O
ubiquitination	O
of	O
transcription	O
factors	O
can	O
be	O
utilized	O
to	O
directly	O
regulate	O
their	O
activities	O
.	O

Nud1p	B-GGP
links	O
astral	B-CC
microtubule	I-CC
organization	O
and	O
the	O
control	O
of	O
exit	O
from	O
mitosis	O
.	O

The	O
budding	O
yeast	O
spindle	B-CC
pole	I-CC
body	I-CC
(	O
SPB	B-CC
)	O
not	O
only	O
organizes	O
the	O
astral	B-CC
and	O
nuclear	B-CC
microtubules	I-CC
but	O
is	O
also	O
associated	O
with	O
a	O
number	O
of	O
cell	O
-	O
cycle	O
regulators	O
that	O
control	O
mitotic	O
exit	O
.	O

Here	O
,	O
we	O
describe	O
that	O
the	O
core	O
SPB	B-CC
component	O
Nud1p	B-GGP
is	O
a	O
key	O
protein	O
that	O
functions	O
in	O
both	O
processes	O
.	O

The	O
astral	B-CC
microtubule	I-CC
organizing	O
function	O
of	O
Nud1p	B-GGP
is	O
mediated	O
by	O
its	O
interaction	O
with	O
the	O
gamma	B-COM
-	I-COM
tubulin	I-COM
complex	O
binding	O
protein	O
Spc72p	B-GGP
.	O

This	O
function	O
of	O
Nud1p	B-GGP
is	O
distinct	O
from	O
its	O
role	O
in	O
cell	O
-	O
cycle	O
control	O
:	O
Nud1p	B-GGP
binds	O
the	O
spindle	B-CC
checkpoint	O
control	O
proteins	O
Bfa1p	B-GGP
and	O
Bub2p	B-GGP
to	O
the	O
SPB	B-CC
,	O
and	O
is	O
part	O
of	O
the	O
mitotic	O
exit	O
network	O
(	O
MEN	O
)	O
in	O
which	O
it	O
functions	O
upstream	O
of	O
CDC15	B-GGP
but	O
downstream	O
of	O
LTE1	B-GGP
.	O

In	O
conditional	O
lethal	O
nud1	B-GGP
-	I-GGP
2	I-GGP
cells	O
,	O
the	O
MEN	O
component	O
Tem1p	B-GGP
,	O
a	O
GTPase	O
,	O
is	O
mislocalized	O
,	O
whereas	O
the	O
kinase	O
Cdc15p	B-GGP
is	O
still	O
associated	O
with	O
the	O
SPB	B-CC
.	O

Thus	O
,	O
in	O
nud1	B-GGP
-	I-GGP
2	I-GGP
cells	O
the	O
failure	O
of	O
Tem1p	B-GGP
to	O
interact	O
with	O
Cdc15p	B-GGP
at	O
the	O
SPB	B-CC
probably	O
prevents	O
mitotic	O
exit	O
.	O

Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
2	I-GGP
-	O
mediated	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
activation	O
requires	O
a	O
Rac1	B-GGP
-	O
dependent	O
pathway	O
.	O

Mammalian	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptors	I-GGP
(	O
TLRs	B-GGP
)	O
are	O
expressed	O
on	O
innate	O
immune	O
cells	O
and	O
respond	O
to	O
the	O
membrane	B-CC
components	I-CC
of	O
Gram	O
-	O
positive	O
or	O
Gram	O
-	O
negative	O
bacteria	O
.	O

When	O
activated	O
,	O
they	O
convey	O
signals	O
to	O
transcription	O
factors	O
that	O
orchestrate	O
the	O
inflammatory	O
response	O
.	O

However	O
,	O
the	O
intracellular	B-CC
signaling	O
events	O
following	O
TLR	B-GGP
activation	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
TLR2	B-GGP
stimulation	O
by	O
Staphylococcus	O
aureus	O
induces	O
a	O
fast	O
and	O
transient	O
activation	O
of	O
the	O
Rho	B-GGP
GTPases	O
Rac1	B-GGP
and	O
Cdc42	B-GGP
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
and	O
in	O
293	O
cells	O
expressing	O
TLR2	B-GGP
.	O

Dominant	O
-	O
negative	O
Rac1N17	B-GGP
,	O
but	O
not	O
dominant	O
-	O
negative	O
Cdc42N17	B-GGP
,	O
block	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappa	I-COM
B	I-COM
(	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
)	O
transactivation	O
.	O

S	O
.	O
aureus	O
stimulation	O
causes	O
the	O
recruitment	O
of	O
active	O
Rac1	B-GGP
and	O
phosphatidylinositol	B-GGP
-	I-GGP
3	I-GGP
kinase	I-GGP
(	O
PI3K	B-GGP
)	O
to	O
the	O
TLR2	B-GGP
cytosolic	B-CC
domain	O
.	O

Tyrosine	B-MED
phosphorylation	O
of	O
TLR2	B-GGP
is	O
required	O
for	O
assembly	O
of	O
a	O
multiprotein	O
complex	O
that	O
is	O
necessary	O
for	O
subsequent	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
transcriptional	O
activity	O
.	O

A	O
signaling	O
cascade	O
composed	O
of	O
Rac1	B-GGP
,	O
PI3K	B-GGP
and	O
Akt	B-GGP
targets	O
nuclear	B-CC
p65	B-GGP
transactivation	O
independently	O
of	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
degradation	O
.	O

Thus	O
Rac1	B-GGP
controls	O
a	O
second	O
,	O
I	B-GGP
kappa	I-GGP
B	I-GGP
-	O
independent	O
,	O
pathway	O
to	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
activation	O
and	O
is	O
essential	O
in	O
innate	O
immune	O
cell	O
signaling	O
via	O
TLR2	B-GGP
.	O

p53	B-GGP
-	O
independent	O
upregulation	O
of	O
KILLER	B-GGP
/	O
DR5	B-GGP
TRAIL	B-GGP
receptor	O
expression	O
by	O
glucocorticoids	B-MED
and	O
interferon	B-GGP
-	I-GGP
gamma	I-GGP
.	O

KILLER	B-GGP
/	O
DR5	B-GGP
is	O
a	O
death	O
-	O
domain	O
-	O
containing	O
proapoptotic	B-GGP
receptor	O
that	O
binds	O
to	O
the	O
cytotoxic	O
ligand	O
TRAIL	B-GGP
.	O

It	O
was	O
originally	O
reported	O
that	O
induction	O
of	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
following	O
DNA	O
damage	O
was	O
p53	B-GGP
-	O
dependent	O
,	O
but	O
some	O
drugs	O
that	O
induce	O
apoptosis	O
can	O
upregulate	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
expression	O
in	O
cell	O
lines	O
with	O
mutated	O
p53	B-GGP
.	O

We	O
further	O
extend	O
those	O
findings	O
by	O
classifying	O
the	O
capability	O
of	O
various	O
apoptosis	O
-	O
inducing	O
drugs	O
to	O
increase	O
the	O
expression	O
of	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
in	O
a	O
p53	B-GGP
-	O
independent	O
manner	O
.	O

beta	B-GGP
-	I-GGP
Lapachone	I-GGP
,	O
a	O
topoisomerase	O
inhibitor	O
,	O
increased	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
in	O
colon	O
cancer	O
cell	O
lines	O
with	O
wild	O
-	O
type	O
p53	B-GGP
but	O
not	O
with	O
mutant	O
p53	B-GGP
.	O

In	O
contrast	O
,	O
betulinic	B-MED
acid	I-MED
,	O
a	O
novel	O
chemotherapeutic	O
compound	O
,	O
induced	O
apoptosis	O
and	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
in	O
melanoma	O
and	O
glioblastoma	O
cells	O
through	O
a	O
p53	B-GGP
-	O
independent	O
mechanism	O
.	O

The	O
synthetic	O
glucocorticoid	B-MED
dexamethasone	B-MED
elevated	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
in	O
glioblastoma	O
,	O
ovarian	O
cancer	O
,	O
and	O
colon	O
cancer	O
cell	O
lines	O
with	O
mutant	O
p53	B-GGP
undergoing	O
apoptosis	O
,	O
and	O
this	O
induction	O
was	O
inhibited	O
by	O
the	O
transcriptional	O
inhibitor	O
actinomycin	B-GGP
D	I-GGP
.	O

Although	O
another	O
glucocorticoid	B-MED
,	O
prednisolone	B-MED
,	O
also	O
induced	O
apoptosis	O
,	O
it	O
did	O
not	O
increase	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
.	O

Finally	O
,	O
the	O
cytokine	O
interferon	B-GGP
-	I-GGP
gamma	I-GGP
(	O
IFN	B-GGP
-	I-GGP
gamma	I-GGP
)	O
induced	O
apoptosis	O
and	O
KILLER	B-GGP
/	O
DR5	B-GGP
in	O
cell	O
lines	O
with	O
mutant	O
p53	B-GGP
,	O
and	O
the	O
induction	O
of	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
by	O
IFN	B-GGP
-	I-GGP
gamma	I-GGP
was	O
delayed	O
in	O
cells	O
lacking	O
wild	O
-	O
type	O
STAT1	B-GGP
,	O
a	O
transcription	O
factor	O
implicated	O
in	O
IFN	B-GGP
-	I-GGP
gamma	I-GGP
signaling	O
.	O

Similarly	O
,	O
the	O
induction	O
of	O
KILLER	B-GGP
/	O
DR5	B-GGP
mRNA	O
by	O
the	O
cytokine	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
was	O
also	O
delayed	O
in	O
cell	O
lines	O
with	O
mutated	O
STAT1	B-GGP
.	O

These	O
findings	O
suggest	O
that	O
KILLER	B-GGP
/	O
DR5	B-GGP
may	O
play	O
a	O
role	O
in	O
p53	B-GGP
-	O
independent	O
apoptosis	O
induced	O
by	O
specific	O
drugs	O
and	O
warrants	O
further	O
investigation	O
as	O
a	O
novel	O
target	O
for	O
chemotherapy	O
of	O
tumors	O
lacking	O
wild	O
-	O
type	O
p53	B-GGP
.	O

Phosphorylation	O
of	O
elongation	B-GGP
factor	I-GGP
-	I-GGP
2	I-GGP
kinase	I-GGP
on	O
serine	B-MED
499	I-MED
by	O
cAMP	B-COM
-	I-COM
dependent	I-COM
protein	I-COM
kinase	I-COM
induces	O
Ca2	B-MED
+	I-MED
/	O
calmodulin	B-GGP
-	O
independent	O
activity	O
.	O

Elongation	B-GGP
factor	I-GGP
-	I-GGP
2	I-GGP
kinase	I-GGP
(	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
)	O
negatively	O
regulates	O
mRNA	O
translation	O
via	O
the	O
phosphorylation	O
and	O
inactivation	O
of	O
elongation	B-GGP
factor	I-GGP
-	I-GGP
2	I-GGP
(	O
eEF	B-GGP
-	I-GGP
2	I-GGP
)	O
.	O

We	O
have	O
shown	O
previously	O
that	O
purified	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
can	O
be	O
phosphorylated	O
in	O
vitro	O
by	O
cAMP	B-COM
-	I-COM
dependent	I-COM
protein	I-COM
kinase	I-COM
(	O
PKA	B-COM
)	O
and	O
that	O
this	O
induces	O
significant	O
Ca	B-MED
(	I-MED
2	I-MED
+	I-MED
)	I-MED
/	O
calmodulin	B-GGP
(	O
CaM	B-GGP
)	O
-	O
independent	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
activity	O
[	O
Redpath	O
and	O
Proud	O
(	O
1993	O
)	O
Biochem	O
.	O
J	O
.	O
293	O
,	O
31	O
-	O
34	O
]	O
.	O

Furthermore	O
,	O
elevation	O
of	O
cAMP	B-MED
levels	O
in	O
adipocytes	O
also	O
increases	O
the	O
level	O
of	O
Ca	B-MED
(	I-MED
2	I-MED
+	I-MED
)	I-MED
/	O
CaM	B-GGP
-	O
independent	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
activity	O
to	O
a	O
similar	O
extent	O
,	O
providing	O
a	O
mechanistic	O
link	O
between	O
elevated	O
cAMP	B-MED
and	O
the	O
inhibition	O
of	O
protein	O
synthesis	O
[	O
Diggle	O
,	O
Redpath	O
,	O
Heesom	O
and	O
Denton	O
(	O
1998	O
)	O
Biochem	O
.	O
J	O
.	O
336	O
,	O
525	O
-	O
529	O
]	O
.	O

Here	O
we	O
describe	O
the	O
expression	O
of	O
glutathione	B-GGP
S	I-GGP
-	I-GGP
transferase	I-GGP
(	I-GGP
GST	I-GGP
)	I-GGP
-	I-GGP
eEF	I-GGP
-	I-GGP
2K	I-GGP
fusion	O
protein	O
and	O
the	O
identification	O
of	O
two	O
serine	B-MED
residues	O
that	O
are	O
phosphorylated	O
by	O
PKA	B-COM
in	O
vitro	O
.	O

Endoproteinase	O
Arg	B-GGP
-	I-GGP
C	I-GGP
digestion	O
of	O
GST	B-GGP
-	I-GGP
eEF	I-GGP
-	I-GGP
2K	I-GGP
produced	O
two	O
phosphopeptides	O
that	O
were	O
separated	O
by	O
HPLC	O
and	O
sequenced	O
.	O

(	O
32	O
)	O
P	O
Radioactivity	O
release	O
from	O
these	O
peptides	O
indicated	O
that	O
the	O
sites	O
of	O
phosphorylation	O
were	O
Ser	B-MED
-	I-MED
365	I-MED
and	O
Ser	B-MED
-	I-MED
499	I-MED
,	O
both	O
of	O
which	O
lie	O
C	O
-	O
terminal	O
to	O
the	O
catalytic	O
domain	O
.	O

Mutation	O
of	O
these	O
sites	O
to	O
non	O
-	O
phosphorylatable	O
residues	O
indicated	O
that	O
both	O
sites	O
need	O
to	O
be	O
phosphorylated	O
to	O
induce	O
Ca	B-MED
(	I-MED
2	I-MED
+	I-MED
)	I-MED
/	O
CaM	B-GGP
-	O
independent	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
activity	O
in	O
vitro	O
.	O

However	O
,	O
expression	O
of	O
Myc	B-GGP
-	O
tagged	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
in	O
HEK	O
293	O
cells	O
,	O
followed	O
by	O
treatment	O
with	O
chlorophenylthio	B-MED
-	I-MED
cAMP	I-MED
(	O
CPT	B-MED
-	I-MED
cAMP	I-MED
)	O
,	O
showed	O
that	O
Ser	B-MED
-	I-MED
499	I-MED
phosphorylation	O
alone	O
induced	O
Ca	B-MED
(	I-MED
2	I-MED
+	I-MED
)	I-MED
/	O
CaM	B-GGP
-	O
independent	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
activity	O
in	O
cells	O
.	O

Co	O
-	O
expression	O
of	O
wild	O
-	O
type	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
with	O
luciferase	B-GGP
resulted	O
in	O
a	O
2	O
-	O
3	O
-	O
fold	O
reduction	O
in	O
luciferase	B-GGP
expression	O
.	O

Expression	O
of	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
S499D	I-GGP
resulted	O
in	O
a	O
10	O
-	O
fold	O
reduction	O
in	O
luciferase	B-GGP
expression	O
despite	O
the	O
fact	O
that	O
this	O
mutant	O
was	O
expressed	O
at	O
very	O
low	O
levels	O
.	O

This	O
indicates	O
that	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
S499D	I-GGP
is	O
constitutively	O
active	O
when	O
expressed	O
in	O
cells	O
,	O
thus	O
leading	O
to	O
the	O
suppression	O
of	O
its	O
own	O
expression	O
.	O

Our	O
data	O
demonstrate	O
an	O
important	O
role	O
for	O
the	O
phosphorylation	O
of	O
Ser	B-MED
-	I-MED
499	I-MED
in	O
the	O
activation	O
of	O
eEF	B-GGP
-	I-GGP
2K	I-GGP
by	O
PKA	B-COM
and	O
the	O
inhibition	O
of	O
protein	O
synthesis	O
.	O

Yeast	O
Mps1p	B-GGP
phosphorylates	O
the	O
spindle	B-CC
pole	I-CC
component	O
Spc110p	B-GGP
in	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

The	O
yeast	O
spindle	B-CC
pole	I-CC
body	I-CC
(	O
SPB	B-CC
)	O
component	O
Spc110p	B-GGP
(	O
Nuf1p	B-GGP
)	O
undergoes	O
specific	O
serine	B-MED
/	O
threonine	B-MED
phosphorylation	O
as	O
the	O
mitotic	O
spindle	B-CC
apparatus	I-CC
forms	O
,	O
and	O
this	O
phosphorylation	O
persists	O
until	O
cells	O
enter	O
anaphase	O
.	O

We	O
demonstrate	O
that	O
the	O
dual	O
-	O
specificity	O
kinase	O
Mps1p	B-GGP
is	O
essential	O
for	O
the	O
mitosis	O
-	O
specific	O
phosphorylation	O
of	O
Spc110p	B-GGP
in	O
vivo	O
and	O
that	O
Mps1p	B-GGP
phosphorylates	O
Spc110p	B-GGP
in	O
vitro	O
.	O

Phosphopeptides	O
generated	O
by	O
proteolytic	O
cleavage	O
were	O
identified	O
and	O
sequenced	O
by	O
mass	O
spectrometry	O
.	O

Ser	B-MED
(	I-MED
60	I-MED
)	I-MED
,	O
Thr	B-MED
(	I-MED
64	I-MED
)	I-MED
,	O
and	O
Thr	B-MED
(	I-MED
68	I-MED
)	I-MED
are	O
the	O
major	O
sites	O
in	O
Spc110p	B-GGP
phosphorylated	O
by	O
Mps1p	B-GGP
in	O
vitro	O
,	O
and	O
alanine	B-MED
substitution	O
at	O
these	O
sites	O
abolishes	O
the	O
mitosis	O
-	O
specific	O
isoform	O
in	O
vivo	O
.	O

This	O
is	O
the	O
first	O
time	O
that	O
phosphorylation	O
sites	O
of	O
an	O
SPB	B-CC
component	O
have	O
been	O
determined	O
,	O
and	O
these	O
are	O
the	O
first	O
sites	O
of	O
Mps1p	B-GGP
phosphorylation	O
identified	O
.	O

Alanine	B-MED
substitution	O
for	O
any	O
one	O
of	O
these	O
phosphorylated	O
residues	O
,	O
in	O
conjunction	O
with	O
an	O
alanine	B-MED
substitution	O
at	O
residue	O
Ser	B-MED
(	I-MED
36	I-MED
)	I-MED
,	O
is	O
lethal	O
in	O
combination	O
with	O
alleles	O
of	O
SPC97	B-GGP
,	O
which	O
encodes	O
a	O
component	O
of	O
the	O
Tub4p	B-COM
complex	O
.	O

Consistent	O
with	O
a	O
specific	O
dysfunction	O
for	O
the	O
alanine	B-MED
substitution	O
mutations	O
,	O
simultaneous	O
mutation	O
of	O
all	O
four	O
serine	B-MED
/	O
threonine	B-MED
residues	O
to	O
aspartate	B-MED
does	O
not	O
confer	O
any	O
defect	O
.	O

Sites	O
of	O
Mps1p	B-GGP
phosphorylation	O
and	O
Ser	B-MED
(	I-MED
36	I-MED
)	I-MED
are	O
located	O
within	O
the	O
N	O
-	O
terminal	O
globular	O
domain	O
of	O
Spc110p	B-GGP
,	O
which	O
resides	O
at	O
the	O
inner	B-CC
plaque	I-CC
of	O
the	O
SPB	B-CC
and	O
binds	O
the	O
Tub4p	B-COM
complex	O
.	O

Localization	O
of	O
human	O
Cdc25C	B-GGP
is	O
regulated	O
both	O
by	O
nuclear	B-CC
export	O
and	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
protein	O
binding	O
.	O

Entry	O
into	O
mitosis	O
requires	O
activation	O
of	O
the	O
Cdc2	B-GGP
protein	O
kinase	O
by	O
the	O
Cdc25C	B-GGP
protein	O
phosphatase	O
.	O

The	O
interactions	O
between	O
Cdc2	B-GGP
and	O
Cdc25C	B-GGP
are	O
negatively	O
regulated	O
throughout	O
interphase	O
and	O
in	O
response	O
to	O
G2	O
checkpoint	O
activation	O
.	O

This	O
is	O
accomplished	O
in	O
part	O
by	O
maintaining	O
the	O
Cdc25	B-GGP
phosphatase	O
in	O
a	O
phosphorylated	O
form	O
that	O
binds	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
proteins	O
.	O

Here	O
we	O
report	O
that	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
binding	O
regulates	O
the	O
intracellular	B-CC
trafficking	O
of	O
Cdc25C	B-GGP
.	O

Although	O
primarily	O
cytoplasmic	B-CC
,	O
Cdc25C	B-GGP
accumulated	O
in	O
the	O
nuclei	B-CC
of	O
leptomycin	B-MED
B	I-MED
(	O
LMB	B-MED
)	O
-	O
treated	O
cells	O
,	O
indicating	O
that	O
Cdc25C	B-GGP
is	O
actively	O
exported	O
out	O
of	O
the	O
nucleus	B-CC
.	O

A	O
mutant	O
of	O
Cdc25C	B-GGP
that	O
is	O
unable	O
to	O
bind	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
was	O
partially	O
nuclear	B-CC
in	O
the	O
absence	O
of	O
LMB	B-MED
and	O
its	O
nuclear	B-CC
accumulation	O
was	O
greatly	O
enhanced	O
by	O
LMB	B-MED
-	O
treatment	O
.	O

A	O
nuclear	B-CC
export	O
signal	O
(	O
NES	O
)	O
was	O
identified	O
within	O
the	O
amino	O
terminus	O
of	O
Cdc25C	B-GGP
.	O

Although	O
mutation	O
of	O
the	O
NES	O
did	O
not	O
effect	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
binding	O
,	O
it	O
did	O
cause	O
nuclear	B-CC
accumulation	O
of	O
Cdc25C	B-GGP
.	O

These	O
results	O
demonstrate	O
that	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
binding	O
is	O
dispensable	O
for	O
the	O
nuclear	B-CC
export	O
of	O
Cdc25C	B-GGP
.	O

However	O
,	O
complete	O
nuclear	B-CC
accumulation	O
of	O
Cdc25C	B-GGP
required	O
loss	O
of	O
both	O
NES	O
function	O
and	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
binding	O
and	O
this	O
was	O
accomplished	O
both	O
pharmacologically	O
and	O
by	O
mutation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
nuclear	B-CC
export	O
of	O
Cdc25C	B-GGP
is	O
mediated	O
by	O
an	O
intrinsic	O
NES	O
and	O
that	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
binding	O
negatively	O
regulates	O
nuclear	B-CC
import	O
.	O

Regulation	O
of	O
the	O
Cdc25A	B-GGP
gene	O
by	O
the	O
human	O
papillomavirus	O
Type	O
16	O
E7	B-GGP
oncogene	O
.	O

Cdc25A	B-GGP
is	O
a	O
tyrosine	B-MED
phosphatase	O
that	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
G1	O
/	O
S	O
phase	O
transition	O
by	O
activating	O
cyclin	B-COM
E	I-COM
/	I-COM
Cdk2	I-COM
and	O
cyclin	B-COM
A	I-COM
/	I-COM
Cdk2	I-COM
complexes	O
through	O
removal	O
of	O
inhibitory	O
phosphorylations	O
.	O

The	O
E6	B-GGP
and	O
E7	B-GGP
oncoproteins	O
of	O
the	O
high	O
-	O
risk	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
interact	O
with	O
and	O
functionally	O
abrogate	O
the	O
p53	B-GGP
and	O
pRB	B-GGP
proteins	O
,	O
respectively	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
investigated	O
the	O
regulation	O
of	O
the	O
Cdc25A	B-GGP
promoter	O
during	O
G1	O
and	O
S	O
-	O
phases	O
of	O
the	O
cell	O
cycle	O
and	O
by	O
the	O
HPV	O
-	O
16	O
E7	B-GGP
oncoprotein	O
.	O

Serum	O
induction	O
leads	O
to	O
a	O
derepression	O
of	O
the	O
Cdc25A	B-GGP
promoter	O
and	O
can	O
be	O
mediated	O
through	O
two	O
E2F	B-GGP
binding	O
sites	O
,	O
E2F	O
-	O
A	O
and	O
E2F	O
-	O
C	O
.	O

While	O
E2F	O
-	O
A	O
is	O
by	O
both	O
E2F1	B-GGP
and	O
E2F4	B-GGP
,	O
E2F	O
-	O
C	O
is	O
regulated	O
only	O
by	O
E2F1	B-GGP
.	O

The	O
Cdc25A	B-GGP
promoter	O
is	O
transactivated	O
by	O
the	O
E7	B-GGP
oncogene	O
of	O
HPV	O
-	O
16	O
.	O

Furthermore	O
,	O
Cdc25A	B-GGP
levels	O
are	O
highly	O
increased	O
in	O
E7	B-GGP
-	O
expressing	O
cell	O
lines	O
.	O

Inducible	O
expression	O
of	O
E7	B-GGP
leads	O
to	O
an	O
immediate	O
increase	O
in	O
Cdc25A	B-GGP
protein	O
levels	O
.	O

These	O
data	O
suggest	O
that	O
Cdc25A	B-GGP
may	O
be	O
a	O
critical	O
target	O
of	O
HPV	O
-	O
16	O
E7	B-GGP
in	O
the	O
disruption	O
of	O
the	O
G1	O
/	O
S	O
phase	O
transition	O
.	O

[	O
Molecular	O
mechanisms	O
controlling	O
the	O
cell	O
cycle	O
:	O
fundamental	O
aspects	O
and	O
implications	O
for	O
oncology	O
]	O
.	O

INTRODUCTION	O
:	O
Comprehension	O
of	O
cell	O
cycle	O
regulation	O
mechanisms	O
has	O
progressed	O
very	O
quickly	O
these	O
past	O
few	O
years	O
and	O
regulators	O
of	O
the	O
cell	O
cycle	O
have	O
gained	O
widespread	O
importance	O
in	O
cancer	O
.	O

This	O
review	O
first	O
summarizes	O
major	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
control	O
of	O
cell	O
cycle	O
mechanisms	O
.	O

Examples	O
of	O
how	O
this	O
control	O
is	O
altered	O
in	O
tumoral	O
cells	O
are	O
then	O
described	O
.	O

CURRENT	O
KNOWLEDGE	O
AND	O
KEY	O
POINTS	O
:	O
The	O
typical	O
mammalian	O
cell	O
cycle	O
consists	O
of	O
four	O
distinct	O
phases	O
occurring	O
in	O
a	O
well	O
-	O
defined	O
order	O
,	O
each	O
of	O
which	O
should	O
be	O
completed	O
successfully	O
before	O
the	O
next	O
begins	O
.	O

Progression	O
of	O
eukaryotic	O
cells	O
through	O
major	O
cell	O
cycle	O
transitions	O
is	O
mediated	O
by	O
sequential	O
assembly	O
and	O
activation	O
of	O
a	O
family	O
of	O
serine	B-MED
-	O
threonine	B-MED
protein	O
kinases	O
,	O
the	O
cyclin	B-GGP
dependent	I-GGP
kinases	I-GGP
(	O
CDK	B-GGP
)	O
.	O

The	O
timing	O
of	O
their	O
activation	O
is	O
determined	O
by	O
their	O
post	O
-	O
translational	O
modifications	O
(	O
phosphorylations	O
/	O
dephosphorylations	O
)	O
,	O
and	O
by	O
the	O
association	O
of	O
a	O
protein	O
called	O
cyclin	B-GGP
,	O
which	O
is	O
the	O
regulatory	O
subunit	O
of	O
the	O
kinase	O
complex	O
.	O

The	O
cyclin	B-GGP
family	O
is	O
divided	O
into	O
two	O
main	O
classes	O
.	O

The	O
'	O
G1	B-GGP
cyclins	I-GGP
'	O
include	O
cyclins	B-GGP
C	I-GGP
,	O
D1	B-GGP
-	O
3	B-GGP
,	O
and	O
E	B-GGP
,	O
and	O
their	O
accumulation	O
is	O
rate	O
-	O
limiting	O
for	O
progression	O
from	O
the	O
G1	O
to	O
S	O
phase	O
.	O

The	O
'	O
mitotic	B-GGP
or	O
G2	B-GGP
cyclins	I-GGP
'	O
,	O
which	O
include	O
cyclin	B-GGP
A	I-GGP
and	O
cyclin	B-GGP
B	I-GGP
,	O
are	O
involved	O
in	O
the	O
control	O
of	O
G2	O
/	O
M	O
transition	O
and	O
mitosis	O
.	O

The	O
cyclins	B-GGP
bind	O
to	O
and	O
activate	O
the	O
CDK	B-GGP
,	O
which	O
leads	O
to	O
phosphorylation	O
(	O
and	O
then	O
inhibition	O
)	O
of	O
the	O
tumor	O
suppressor	O
protein	O
,	O
pRb	B-GGP
.	O

pRb	B-GGP
controls	O
commitment	O
to	O
progress	O
from	O
the	O
G1	O
to	O
S	O
phase	O
,	O
at	O
least	O
in	O
part	O
by	O
repressing	O
the	O
activity	O
of	O
the	O
E2F	B-GGP
transcription	O
factors	O
known	O
to	O
promote	O
cell	O
proliferation	O
.	O

Both	O
the	O
D	B-GGP
-	I-GGP
type	I-GGP
cyclins	I-GGP
and	O
their	O
partner	O
kinases	O
CDK4	B-GGP
/	O
6	B-GGP
have	O
proto	O
-	O
oncogenic	O
properties	O
,	O
and	O
their	O
activity	O
is	O
carefully	O
regulated	O
at	O
multiple	O
levels	O
including	O
negative	O
control	O
by	O
two	O
families	O
of	O
CDK	B-GGP
inhibitors	O
.	O

While	O
members	O
of	O
the	O
INK4	B-GGP
family	O
(	O
p16INK4A	B-GGP
,	O
p15INK4B	B-GGP
,	O
p18INK4C	B-GGP
,	O
p19INK4D	B-GGP
)	O
interact	O
specifically	O
with	O
CDK4	B-GGP
and	O
CDK6	B-GGP
,	O
the	O
CIP	B-GGP
/	I-GGP
KIP	I-GGP
inhibitors	O
p21CIP1	B-GGP
/	O
WAF1	B-GGP
,	O
p27KIP1	B-GGP
and	O
p57KIP2	B-GGP
inhibit	O
a	O
broader	O
spectrum	O
of	O
CDK	B-GGP
.	O

The	O
interplay	O
between	O
p16INK4A	B-GGP
,	O
cyclin	B-GGP
D	I-GGP
/	O
CDK	B-GGP
,	O
and	O
pRb	B-GGP
/	O
E2F	B-GGP
together	O
constitute	O
a	O
functional	O
unit	O
collectively	O
known	O
as	O
the	O
'	O
pRb	B-GGP
pathway	O
'	O
.	O

Each	O
of	O
the	O
major	O
components	O
of	O
this	O
mechanism	O
may	O
become	O
deregulated	O
in	O
cancer	O
,	O
and	O
accumulating	O
evidence	O
points	O
to	O
the	O
'	O
pRb	B-GGP
pathway	O
'	O
as	O
a	O
candidate	O
obligatory	O
target	O
in	O
multistep	O
oncogenesis	O
of	O
possibly	O
all	O
human	O
tumor	O
types	O
.	O

FUTURE	O
PROSPECTS	O
AND	O
PROJECTS	O
:	O
Major	O
advances	O
in	O
the	O
understanding	O
of	O
cell	O
cycle	O
regulation	O
mechanisms	O
provided	O
a	O
better	O
knowledge	O
of	O
the	O
molecular	O
interactions	O
involved	O
in	O
human	O
cancer	O
.	O

This	O
progress	O
has	O
led	O
to	O
the	O
promotion	O
of	O
new	O
therapeutic	O
agents	O
presently	O
in	O
clinical	O
trials	O
or	O
under	O
development	O
.	O

Moreover	O
,	O
the	O
components	O
of	O
the	O
cell	O
cycle	O
are	O
probably	O
involved	O
in	O
other	O
non	O
-	O
cancerous	O
diseases	O
and	O
their	O
role	O
must	O
be	O
defined	O
.	O

The	O
Rb	B-GGP
/	O
chromatin	B-CC
connection	O
and	O
epigenetic	O
control	O
:	O
opinion	O
.	O

The	O
balance	O
between	O
cell	O
differentiation	O
and	O
proliferation	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

In	O
the	O
cell	O
cycle	O
,	O
the	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
(	O
G1	O
/	O
S	O
transition	O
)	O
is	O
of	O
paramount	O
importance	O
in	O
this	O
regard	O
.	O

Indeed	O
,	O
it	O
is	O
only	O
before	O
this	O
point	O
that	O
cells	O
can	O
be	O
oriented	O
toward	O
the	O
differentiation	O
pathway	O
:	O
beyond	O
,	O
cells	O
progress	O
into	O
the	O
cycle	O
in	O
an	O
autonomous	O
manner	O
.	O

The	O
G1	O
/	O
S	O
transition	O
is	O
orchestrated	O
by	O
the	O
transcription	O
factor	O
E2F	B-GGP
.	O

E2F	B-GGP
controls	O
the	O
expression	O
of	O
a	O
group	O
of	O
checkpoint	O
genes	O
whose	O
products	O
are	O
required	O
either	O
for	O
the	O
G1	O
-	O
to	O
-	O
S	O
transition	O
itself	O
or	O
for	O
DNA	O
replication	O
(	O
e	O
.	O
g	O
.	O
DNA	B-COM
polymerase	I-COM
alpha	I-COM
)	O
.	O

E2F	B-GGP
activity	O
is	O
repressed	O
in	O
growth	O
-	O
arrested	O
cells	O
and	O
in	O
early	O
G1	O
,	O
and	O
is	O
activated	O
at	O
mid	O
-	O
to	O
-	O
late	O
G1	O
.	O

E2F	B-GGP
is	O
controlled	O
by	O
the	O
retinoblastoma	O
tumor	O
suppressor	O
protein	O
Rb	B-GGP
.	O

Rb	B-GGP
represses	O
E2F	B-GGP
mainly	O
by	O
recruiting	O
chromatin	B-CC
remodeling	O
factors	O
(	O
histone	B-GGP
deacetylases	I-GGP
and	O
SWI	B-COM
/	I-COM
SNF	I-COM
complexes	O
)	O
,	O
the	O
DNA	B-GGP
methyltransferase	I-GGP
DNMT1	B-GGP
,	O
and	O
a	O
histone	B-GGP
methyltransferase	I-GGP
.	O

This	O
review	O
will	O
focus	O
on	O
the	O
molecular	O
mechanisms	O
of	O
E2F	B-GGP
repression	O
by	O
Rb	B-GGP
during	O
the	O
cell	O
cycle	O
and	O
during	O
cell	O
-	O
cycle	O
exit	O
by	O
differentiating	O
cells	O
.	O

A	O
model	O
in	O
which	O
Rb	B-GGP
irreversibly	O
represses	O
E2F	B-GGP
-	O
regulated	O
genes	O
in	O
differentiated	O
cells	O
by	O
an	O
epigenetic	O
mechanism	O
linked	O
to	O
heterochromatin	B-CC
,	O
and	O
involving	O
histone	B-GGP
H3	I-GGP
and	O
promoter	O
DNA	O
methylation	O
,	O
is	O
discussed	O
.	O

Activation	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
by	O
nontypeable	O
Hemophilus	O
influenzae	O
is	O
mediated	O
by	O
toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
2	I-GGP
-	O
TAK1	B-GGP
-	O
dependent	O
NIK	B-COM
-	I-COM
IKK	I-COM
alpha	I-COM
/	I-COM
beta	I-COM
-	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
and	O
MKK3	B-GGP
/	I-GGP
6	I-GGP
-	O
p38	B-GGP
MAP	I-GGP
kinase	I-GGP
signaling	O
pathways	O
in	O
epithelial	O
cells	O
.	O

Nontypeable	O
Hemophilus	O
influenzae	O
(	O
NTHi	O
)	O
is	O
an	O
important	O
human	O
pathogen	O
in	O
both	O
children	O
and	O
adults	O
.	O

In	O
children	O
,	O
it	O
causes	O
otitis	O
media	O
,	O
the	O
most	O
common	O
childhood	O
infection	O
and	O
the	O
leading	O
cause	O
of	O
conductive	O
hearing	O
loss	O
in	O
the	O
United	O
States	O
.	O

In	O
adults	O
,	O
it	O
causes	O
lower	O
respiratory	O
tract	O
infections	O
in	O
the	O
setting	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
the	O
fourth	O
leading	O
cause	O
of	O
death	O
in	O
the	O
United	O
States	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
pathogenesis	O
of	O
NTHi	O
-	O
induced	O
infections	O
remain	O
undefined	O
,	O
but	O
they	O
may	O
involve	O
activation	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
,	O
a	O
transcriptional	O
activator	O
of	O
multiple	O
host	O
defense	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Here	O
,	O
we	O
show	O
that	O
NTHi	O
strongly	O
activates	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
in	O
human	O
epithelial	O
cells	O
via	O
two	O
distinct	O
signaling	O
pathways	O
,	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
translocation	O
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
.	O

The	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
translocation	O
-	O
dependent	O
pathway	O
involves	O
activation	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
inducing	I-COM
kinase	I-COM
(	I-COM
NIK	I-COM
)	I-COM
-	I-COM
-	I-COM
IKK	I-COM
alpha	I-COM
/	I-COM
beta	I-COM
complex	O
leading	O
to	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
phosphorylation	O
and	O
degradation	O
,	O
whereas	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
translocation	O
-	O
independent	O
pathway	O
involves	O
activation	O
of	O
MKK3	B-GGP
/	I-GGP
6	I-GGP
-	O
-	O
p38	B-GGP
mitogen	I-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
(	I-GGP
MAP	I-GGP
)	I-GGP
kinase	I-GGP
pathway	O
.	O

Bifurcation	O
of	O
NTHi	O
-	O
induced	O
NIK	B-COM
-	I-COM
IKK	I-COM
alpha	I-COM
/	I-COM
beta	I-COM
-	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
and	O
MKK3	B-GGP
/	I-GGP
6	I-GGP
-	O
-	O
p38	B-GGP
MAP	I-GGP
kinase	I-GGP
pathways	O
may	O
occur	O
at	O
transforming	B-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
beta	I-GGP
activated	I-GGP
kinase	I-GGP
1	I-GGP
(	O
TAK1	B-GGP
)	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
2	I-GGP
(	O
TLR2	B-GGP
)	O
is	O
required	O
for	O
NTHi	O
-	O
induced	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
activation	O
.	O

In	O
addition	O
,	O
several	O
key	O
inflammatory	O
mediators	O
including	O
IL	B-GGP
-	I-GGP
1	I-GGP
beta	I-GGP
,	O
IL	B-GGP
-	I-GGP
8	I-GGP
,	O
and	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
-	I-GGP
alpha	I-GGP
are	O
up	O
-	O
regulated	O
by	O
NTHi	O
.	O

Finally	O
,	O
P6	O
,	O
a	O
16	O
-	O
kDa	O
lipoprotein	O
highly	O
conserved	O
in	O
the	O
outer	B-CC
membrane	I-CC
of	O
all	O
NTHi	O
and	O
H	O
.	O
influenzae	O
type	O
b	O
strains	O
,	O
appears	O
to	O
also	O
activate	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
via	O
similar	O
signaling	O
pathways	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
NTHi	O
activates	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
via	O
TLR2	B-GGP
-	O
TAK1	B-GGP
-	O
dependent	O
NIK	B-COM
-	I-COM
-	I-COM
IKK	I-COM
alpha	I-COM
/	I-COM
beta	I-COM
-	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
and	O
MKK3	B-GGP
/	I-GGP
6	I-GGP
-	O
-	O
p38	B-GGP
MAP	I-GGP
kinase	I-GGP
signaling	O
pathways	O
.	O

These	O
studies	O
may	O
bring	O
new	O
insights	O
into	O
molecular	O
pathogenesis	O
of	O
NTHi	O
-	O
induced	O
infections	O
and	O
open	O
up	O
new	O
therapeutic	O
targets	O
for	O
these	O
diseases	O
.	O

Cooperation	O
of	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
2	I-GGP
and	O
6	B-GGP
for	O
cellular	O
activation	O
by	O
soluble	B-GGP
tuberculosis	I-GGP
factor	I-GGP
and	O
Borrelia	O
burgdorferi	O
outer	B-GGP
surface	I-GGP
protein	I-GGP
A	I-GGP
lipoprotein	I-GGP
:	O
role	O
of	O
Toll	B-GGP
-	I-GGP
interacting	I-GGP
protein	I-GGP
and	O
IL	B-GGP
-	I-GGP
1	I-GGP
receptor	O
signaling	O
molecules	O
in	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
2	I-GGP
signaling	O
.	O

Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
2	I-GGP
(	O
TLR2	B-GGP
)	O
and	O
TLR4	B-GGP
play	O
important	O
roles	O
in	O
innate	O
immune	O
responses	O
to	O
various	O
microbial	O
agents	O
.	O

We	O
have	O
previously	O
shown	O
that	O
human	O
dermal	O
endothelial	O
cells	O
(	O
HMEC	O
)	O
express	O
TLR4	B-GGP
,	O
but	O
very	O
little	O
TLR2	B-GGP
,	O
and	O
respond	O
to	O
LPS	B-MED
,	O
but	O
not	O
to	O
Mycobacterium	O
tuberculosis	O
19	O
-	O
kDa	O
lipoprotein	O
,	O
unless	O
transfected	O
with	O
TLR2	B-GGP
.	O

Here	O
we	O
report	O
that	O
HMEC	O
are	O
unresponsive	O
to	O
several	O
additional	O
biologically	O
relevant	O
TLR2	B-GGP
ligands	O
,	O
including	O
,	O
phenol	B-COM
-	I-COM
soluble	I-COM
modulin	I-COM
(	O
PSM	B-COM
)	O
,	O
a	O
complex	O
of	O
three	O
small	O
secreted	O
polypeptides	O
from	O
the	O
skin	O
commensal	O
Staphylococcus	O
epidermidis	O
,	O
soluble	B-GGP
tuberculosis	I-GGP
factor	I-GGP
(	O
STF	B-GGP
)	O
,	O
and	O
Borrelia	O
burgdorferi	O
outer	B-GGP
surface	I-GGP
protein	I-GGP
A	I-GGP
lipoprotein	I-GGP
(	O
OspA	B-GGP
-	I-GGP
L	I-GGP
)	O
.	O

Expression	O
of	O
TLR2	B-GGP
renders	O
HMEC	O
responsive	O
to	O
all	O
these	O
ligands	O
.	O

We	O
further	O
characterized	O
the	O
signaling	O
pathway	O
in	O
response	O
to	O
STF	B-GGP
,	O
OspA	B-GGP
-	I-GGP
L	I-GGP
,	O
and	O
PSM	B-COM
in	O
TLR2	B-GGP
-	O
transfected	O
HMEC	O
.	O

The	O
TLR2	B-GGP
signaling	O
pathway	O
for	O
NF	B-COM
-	I-COM
kappaB	I-COM
trans	O
-	O
activation	O
shares	O
the	O
IL	B-GGP
-	I-GGP
1R	I-GGP
signaling	O
molecules	O
.	O

Dominant	O
negative	O
constructs	O
of	O
TLR2	B-GGP
or	O
TLR6	B-GGP
inhibit	O
the	O
responses	O
of	O
STF	B-GGP
and	O
OspA	B-GGP
-	I-GGP
L	I-GGP
as	O
well	O
as	O
PSM	B-COM
in	O
TLR2	B-GGP
-	O
transfected	O
HMEC	O
,	O
supporting	O
the	O
concept	O
of	O
functional	O
cooperation	O
between	O
TLR2	B-GGP
and	O
TLR6	B-GGP
for	O
all	O
these	O
TLR2	B-GGP
ligands	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
Toll	B-GGP
-	I-GGP
interacting	I-GGP
protein	I-GGP
(	O
Tollip	B-GGP
)	O
coimmunoprecipitates	O
with	O
TLR2	B-GGP
and	O
TLR4	B-GGP
using	O
HEK	O
293	O
cells	O
,	O
and	O
overexpression	O
of	O
Tollip	B-GGP
inhibits	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
in	O
response	O
to	O
TLR2	B-GGP
and	O
TLR4	B-GGP
signaling	O
.	O

Collectively	O
,	O
these	O
findings	O
suggest	O
that	O
there	O
is	O
functional	O
interaction	O
between	O
TLR2	B-GGP
and	O
TLR6	B-GGP
in	O
the	O
cellular	O
response	O
to	O
STF	B-GGP
and	O
OspA	B-GGP
-	I-GGP
L	I-GGP
in	O
addition	O
to	O
S	O
.	O
epidermidis	O
(	O
PSM	B-COM
)	O
Ags	O
,	O
and	O
that	O
engagement	O
of	O
TLR2	B-GGP
triggers	O
a	O
signaling	O
cascade	O
,	O
which	O
shares	O
the	O
IL	B-GGP
-	I-GGP
1R	I-GGP
signaling	O
molecules	O
,	O
similar	O
to	O
the	O
TLR4	B-GGP
-	O
LPS	B-MED
signaling	O
cascade	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
Tollip	B-GGP
may	O
be	O
an	O
important	O
constituent	O
of	O
both	O
the	O
TLR2	B-GGP
and	O
TLR4	B-GGP
signaling	O
pathways	O
.	O

Inhibition	O
of	O
promyelocytic	B-GGP
leukemia	I-GGP
(	O
PML	B-GGP
)	O
/	O
retinoic	B-GGP
acid	I-GGP
receptor	I-GGP
-	I-GGP
alpha	I-GGP
and	O
PML	B-GGP
expression	O
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
by	O
anti	O
-	O
PML	B-GGP
peptide	B-MED
nucleic	I-MED
acid	I-MED
.	O

The	O
fusion	O
protein	O
promyelocytic	B-GGP
leukemia	I-GGP
(	O
PML	B-GGP
)	O
/	O
retinoic	B-GGP
acid	I-GGP
receptor	I-GGP
(	I-GGP
RAR	I-GGP
)	I-GGP
alpha	I-GGP
is	O
tightly	O
linked	O
to	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
hence	O
,	O
it	O
represents	O
a	O
tumor	O
-	O
associated	O
,	O
transformation	O
-	O
related	O
molecule	O
.	O

In	O
this	O
study	O
,	O
three	O
anti	O
-	O
PML	B-GGP
adamantyl	B-MED
-	O
conjugated	O
peptide	B-MED
nucleic	I-MED
acid	I-MED
(	O
PNA	B-MED
)	O
oligomers	O
previously	O
described	O
as	O
in	O
vitro	O
inhibitors	O
of	O
PML	B-GGP
/	O
RARalpha	B-GGP
translation	O
were	O
combined	O
and	O
used	O
to	O
block	O
PML	B-GGP
/	O
RARalpha	B-GGP
synthesis	O
in	O
NB4	O
cells	O
.	O

Cationic	O
liposomes	O
were	O
used	O
to	O
achieve	O
sufficient	O
delivery	O
of	O
PNAs	O
into	O
the	O
cells	O
.	O

Upon	O
treatment	O
of	O
cells	O
with	O
the	O
liposome	O
/	O
PNA	B-MED
mixture	O
,	O
enhanced	O
cellular	O
uptake	O
of	O
PNA	B-MED
(	O
approximately	O
5	O
-	O
fold	O
compared	O
with	O
control	O
)	O
was	O
obtained	O
.	O

Concomitantly	O
,	O
a	O
substantial	O
reduction	O
(	O
>	O
90	O
%	O
)	O
of	O
the	O
expression	O
of	O
PML	B-GGP
/	O
RARalpha	B-GGP
was	O
observed	O
when	O
all	O
of	O
the	O
three	O
PNAs	B-MED
were	O
used	O
together	O
.	O

This	O
resulted	O
in	O
a	O
dramatic	O
effect	O
on	O
the	O
number	O
and	O
viability	O
of	O
NB4	O
cells	O
in	O
culture	O
after	O
48	O
h	O
of	O
treatment	O
.	O

This	O
phenomenon	O
was	O
preceded	O
by	O
induction	O
of	O
apoptosis	O
that	O
could	O
be	O
observed	O
24	O
h	O
after	O
treatment	O
.	O

No	O
sign	O
of	O
granulocytic	O
differentiation	O
was	O
observed	O
after	O
treatment	O
.	O

These	O
effects	O
were	O
also	O
noted	O
on	O
other	O
leukemic	O
cell	O
lines	O
that	O
express	O
PML	B-GGP
but	O
not	O
the	O
fusion	O
transcript	O
.	O

These	O
results	O
show	O
that	O
it	O
is	O
possible	O
to	O
deliver	O
PNA	B-MED
into	O
hematopoietic	O
cells	O
and	O
obtain	O
specific	O
gene	O
inhibition	O
,	O
and	O
they	O
suggest	O
that	O
a	O
growth	O
inhibitory	O
effect	O
on	O
acute	O
promyelocytic	O
leukemia	O
cells	O
can	O
be	O
obtained	O
through	O
the	O
block	O
of	O
PML	B-GGP
/	O
RARalpha	B-GGP
and	O
PML	B-GGP
expression	O
.	O

Molecular	O
identification	O
and	O
characterization	O
of	O
two	O
medium	B-GGP
-	I-GGP
chain	I-GGP
acyl	I-GGP
-	I-GGP
CoA	I-GGP
synthetases	I-GGP
,	O
MACS1	B-GGP
and	O
the	O
Sa	B-GGP
gene	O
product	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
and	O
characterized	O
two	O
murine	O
cDNAs	O
encoding	O
medium	B-GGP
-	I-GGP
chain	I-GGP
acyl	I-GGP
-	I-GGP
CoA	I-GGP
synthetase	I-GGP
(	O
MACS	B-GGP
)	O
.	O

One	O
,	O
designated	O
MACS1	B-GGP
,	O
is	O
a	O
novel	O
protein	O
and	O
the	O
other	O
the	O
product	O
of	O
the	O
Sa	B-GGP
gene	O
(	O
Sa	B-GGP
protein	O
)	O
,	O
which	O
is	O
preferentially	O
expressed	O
in	O
spontaneously	O
hypertensive	O
rats	O
.	O

Based	O
on	O
the	O
murine	O
MACS1	B-GGP
sequence	O
,	O
we	O
also	O
identified	O
the	O
location	O
and	O
organization	O
of	O
the	O
human	O
MACS1	B-GGP
gene	O
,	O
showing	O
that	O
the	O
human	O
MACS1	B-GGP
and	O
Sa	B-GGP
genes	O
are	O
located	O
in	O
the	O
opposite	O
transcriptional	O
direction	O
within	O
a	O
150	O
-	O
kilobase	O
region	O
on	O
chromosome	B-CC
16p13	I-CC
.	O
1	O
.	O

Murine	O
MACS1	B-GGP
and	O
Sa	B-GGP
protein	O
were	O
overexpressed	O
in	O
COS	O
cells	O
,	O
purified	O
to	O
homogeneity	O
,	O
and	O
characterized	O
.	O

Among	O
C4	B-MED
-	I-MED
C16	I-MED
fatty	I-MED
acids	I-MED
,	O
MACS1	B-GGP
preferentially	O
utilizes	O
octanoate	B-MED
,	O
whereas	O
isobutyrate	B-MED
is	O
the	O
most	O
preferred	O
fatty	B-MED
acid	I-MED
among	O
C2	B-MED
-	I-MED
C6	I-MED
fatty	I-MED
acids	I-MED
for	O
Sa	B-GGP
protein	O
.	O

Like	O
Sa	B-GGP
gene	O
transcript	O
,	O
MACS1	B-GGP
mRNA	O
was	O
detected	O
mainly	O
in	O
the	O
liver	O
and	O
kidney	O
.	O

Subcellular	B-CC
fractionation	O
revealed	O
that	O
both	O
MACS1	B-GGP
and	O
Sa	B-GGP
protein	O
are	O
localized	O
in	O
the	O
mitochondrial	B-CC
matrix	I-CC
.	O

(	B-MED
14	I-MED
)	I-MED
C	I-MED
-	I-MED
Fatty	I-MED
acid	I-MED
incorporation	O
studies	O
indicated	O
that	O
acyl	B-MED
-	I-MED
CoAs	I-MED
produced	O
by	O
MACS1	B-GGP
and	O
Sa	B-GGP
protein	O
are	O
utilized	O
mainly	O
for	O
oxidation	O
.	O

PIG	B-GGP
-	I-GGP
S	I-GGP
and	O
PIG	B-GGP
-	I-GGP
T	I-GGP
,	O
essential	O
for	O
GPI	B-MED
anchor	O
attachment	O
to	O
proteins	O
,	O
form	O
a	O
complex	O
with	O
GAA1	B-GGP
and	O
GPI8	B-GGP
.	O

Many	O
eukaryotic	O
cell	B-CC
surface	I-CC
proteins	O
are	O
anchored	O
to	O
the	O
plasma	B-CC
membrane	I-CC
via	O
glycosylphosphatidylinositol	B-MED
(	O
GPI	B-MED
)	O
.	O

The	O
GPI	B-COM
transamidase	I-COM
mediates	O
GPI	B-MED
anchoring	O
in	O
the	O
endoplasmic	B-CC
reticulum	I-CC
,	O
by	O
replacing	O
a	O
protein	O
'	O
s	O
C	O
-	O
terminal	O
GPI	B-MED
attachment	O
signal	O
peptide	O
with	O
a	O
pre	O
-	O
assembled	O
GPI	B-MED
.	O

During	O
this	O
transamidation	O
reaction	O
,	O
the	O
GPI	B-COM
transamidase	I-COM
forms	O
a	O
carbonyl	B-MED
intermediate	O
with	O
a	O
substrate	O
protein	O
.	O

It	O
was	O
known	O
that	O
the	O
GPI	B-COM
transamidase	I-COM
is	O
a	O
complex	O
containing	O
GAA1	B-GGP
and	O
GPI8	B-GGP
.	O

Here	O
,	O
we	O
report	O
two	O
new	O
components	O
of	O
this	O
enzyme	O
:	O
PIG	B-GGP
-	I-GGP
S	I-GGP
and	O
PIG	B-GGP
-	I-GGP
T	I-GGP
.	O

To	O
determine	O
roles	O
for	O
PIG	B-GGP
-	I-GGP
S	I-GGP
and	O
PIG	B-GGP
-	I-GGP
T	I-GGP
,	O
we	O
disrupted	O
these	O
genes	O
in	O
mouse	O
F9	O
cells	O
by	O
homologous	O
recombination	O
.	O

PIG	B-GGP
-	I-GGP
S	I-GGP
and	O
PIG	B-GGP
-	I-GGP
T	I-GGP
knockout	O
cells	O
were	O
defective	O
in	O
transfer	O
of	O
GPI	B-MED
to	O
proteins	O
,	O
particularly	O
in	O
formation	O
of	O
the	O
carbonyl	B-MED
intermediates	O
.	O

We	O
also	O
demonstrate	O
that	O
PIG	B-GGP
-	I-GGP
S	I-GGP
and	O
PIG	B-GGP
-	I-GGP
T	I-GGP
form	O
a	O
protein	O
complex	O
with	O
GAA1	B-GGP
and	O
GPI8	B-GGP
,	O
and	O
that	O
PIG	B-GGP
-	I-GGP
T	I-GGP
maintains	O
the	O
complex	O
by	O
stabilizing	O
the	O
expression	O
of	O
GAA1	B-GGP
and	O
GPI8	B-GGP
.	O

Saccharomyces	O
cerevisiae	O
Gpi16p	B-GGP
(	O
YHR188C	B-GGP
)	O
and	O
Gpi17p	B-GGP
(	O
YDR434W	B-GGP
)	O
are	O
orthologues	O
of	O
PIG	B-GGP
-	I-GGP
T	I-GGP
and	O
PIG	B-GGP
-	I-GGP
S	I-GGP
,	O
respectively	O
.	O

Disruption	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
signaling	O
and	O
chemokine	O
gene	O
activation	O
by	O
retroviral	O
mediated	O
expression	O
of	O
IKK	B-GGP
gamma	I-GGP
/	O
NEMO	B-GGP
mutants	O
.	O

Phosphorylation	O
of	O
I	B-GGP
kappa	I-GGP
Bs	I-GGP
-	O
-	O
the	O
cytoplasmic	B-CC
inhibitors	O
of	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
transcription	O
factors	O
-	O
-	O
is	O
the	O
key	O
event	O
which	O
triggers	O
activation	O
of	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
cascade	O
.	O

Signal	O
-	O
mediated	O
phosphorylation	O
of	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
is	O
mediated	O
by	O
a	O
multiprotein	O
complex	O
,	O
the	O
I	B-COM
kappa	I-COM
B	I-COM
kinase	I-COM
(	O
IKK	B-COM
)	O
complex	O
,	O
which	O
is	O
composed	O
of	O
at	O
least	O
three	O
identified	O
subunits	O
.	O

Two	O
of	O
these	O
polypeptides	O
,	O
IKK	B-GGP
alpha	I-GGP
and	O
IKK	B-GGP
beta	I-GGP
,	O
also	O
known	O
as	O
IKK1	B-GGP
and	O
IKK2	B-GGP
,	O
are	O
the	O
catalytic	O
subunits	O
of	O
the	O
kinase	O
complex	O
and	O
phosphorylate	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
and	O
I	B-GGP
kappa	I-GGP
B	I-GGP
beta	I-GGP
.	O

The	O
third	O
component	O
,	O
NEMO	B-GGP
/	O
IKK	B-GGP
gamma	I-GGP
,	O
does	O
not	O
exhibit	O
kinase	O
activity	O
,	O
but	O
rather	O
constitutes	O
a	O
regulatory	O
subunit	O
.	O

In	O
the	O
present	O
study	O
,	O
C	O
-	O
terminal	O
truncated	O
forms	O
of	O
IKK	B-GGP
gamma	I-GGP
-	O
-	O
Delta	B-GGP
C	I-GGP
-	I-GGP
IKK	I-GGP
gamma	I-GGP
306	I-GGP
and	O
Delta	B-GGP
C	I-GGP
-	I-GGP
IKK	I-GGP
gamma	I-GGP
261	I-GGP
-	O
-	O
were	O
stably	O
expressed	O
in	O
the	O
myeloid	O
cell	O
line	O
U937	O
by	O
retroviral	O
-	O
mediated	O
gene	O
transfer	O
.	O

Overexpression	O
of	O
Delta	B-GGP
C	I-GGP
-	I-GGP
IKK	I-GGP
gamma	I-GGP
resulted	O
in	O
a	O
reduction	O
in	O
IKK	B-COM
kinase	O
activity	O
in	O
vitro	O
,	O
a	O
subsequent	O
decrease	O
in	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
DNA	O
binding	O
activity	O
,	O
and	O
inhibition	O
of	O
chemokine	O
gene	O
induction	O
in	O
response	O
to	O
TNFalpha	B-GGP
stimulation	O
or	O
paramyxovirus	O
infection	O
.	O

This	O
study	O
demonstrates	O
the	O
efficacy	O
of	O
Delta	B-GGP
C	I-GGP
-	I-GGP
IKK	I-GGP
gamma	I-GGP
as	O
a	O
repressor	O
of	O
IKK	B-COM
signaling	O
and	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
activation	O
and	O
suggests	O
a	O
potential	O
gene	O
therapy	O
approach	O
to	O
limit	O
chronic	O
inflammation	O
due	O
to	O
chemokine	O
hyperactivation	O
.	O

Regulation	O
of	O
Snf1	B-COM
kinase	O
.	O

Activation	O
requires	O
phosphorylation	O
of	O
threonine	B-MED
210	I-MED
by	O
an	O
upstream	O
kinase	O
as	O
well	O
as	O
a	O
distinct	O
step	O
mediated	O
by	O
the	O
Snf4	B-GGP
subunit	O
.	O

The	O
yeast	O
Snf1	B-COM
kinase	O
and	O
its	O
metazoan	O
orthologues	O
,	O
the	O
AMP	B-MED
-	O
activated	O
protein	O
kinases	O
,	O
are	O
activated	O
in	O
response	O
to	O
nutrient	O
limitation	O
.	O

Activation	O
requires	O
the	O
phosphorylation	O
of	O
a	O
conserved	O
threonine	B-MED
residue	O
in	O
the	O
activation	O
loop	O
of	O
the	O
catalytic	O
subunit	O
.	O

A	O
phosphopeptide	O
antibody	O
was	O
generated	O
that	O
specifically	O
recognizes	O
Snf1	B-COM
protein	O
that	O
is	O
phosphorylated	O
in	O
its	O
activation	O
loop	O
on	O
threonine	B-MED
210	I-MED
.	O

Using	O
this	O
reagent	O
,	O
we	O
show	O
that	O
phosphorylation	O
of	O
threonine	B-MED
210	I-MED
correlates	O
with	O
Snf1	B-COM
activity	O
,	O
since	O
it	O
is	O
detected	O
in	O
cells	O
subjected	O
to	O
glucose	B-MED
limitation	O
but	O
not	O
in	O
cells	O
grown	O
in	O
abundant	O
glucose	B-MED
.	O

A	O
Snf1	B-COM
mutant	O
completely	O
lacking	O
kinase	O
activity	O
was	O
phosphorylated	O
normally	O
on	O
threonine	B-MED
210	I-MED
in	O
glucose	B-MED
-	O
starved	O
cells	O
,	O
eliminating	O
the	O
possibility	O
that	O
the	O
threonine	B-MED
210	I-MED
modification	O
is	O
due	O
to	O
an	O
autophosphorylation	O
event	O
.	O

Cells	O
lacking	O
the	O
Reg1	B-GGP
protein	O
,	O
a	O
regulatory	O
subunit	O
for	O
the	O
Glc7	B-COM
phosphatase	O
,	O
showed	O
constitutive	O
phosphorylation	O
of	O
Snf1	B-COM
threonine	B-MED
210	I-MED
.	O

Exposure	O
of	O
cells	O
to	O
high	O
concentrations	O
of	O
sodium	B-MED
chloride	I-MED
also	O
induced	O
phosphorylation	O
of	O
Snf1	B-COM
.	O

Interestingly	O
,	O
Mig1	B-GGP
,	O
a	O
downstream	O
target	O
of	O
Snf1	B-COM
kinase	O
,	O
is	O
phosphorylated	O
in	O
glucose	B-MED
-	O
stressed	O
but	O
not	O
sodium	B-MED
-	O
stressed	O
cells	O
.	O

Finally	O
,	O
cells	O
lacking	O
the	O
gamma	O
subunit	O
of	O
the	O
Snf1	B-COM
kinase	O
complex	O
encoded	O
by	O
the	O
SNF4	B-GGP
gene	O
exhibited	O
normal	O
regulation	O
of	O
threonine	B-MED
210	I-MED
phosphorylation	O
in	O
response	O
to	O
glucose	B-MED
limitation	O
but	O
are	O
unable	O
to	O
phosphorylate	O
Mig1	B-GGP
efficiently	O
.	O

Our	O
data	O
indicate	O
that	O
activation	O
of	O
the	O
Snf1	B-COM
kinase	O
complex	O
involves	O
two	O
steps	O
,	O
one	O
that	O
requires	O
a	O
distinct	O
upstream	O
kinase	O
and	O
one	O
that	O
is	O
mediated	O
by	O
the	O
gamma	O
subunit	O
of	O
the	O
kinase	O
itself	O
.	O

Mechanisms	O
controlling	O
differential	O
promoter	O
-	O
occupancy	O
by	O
the	O
yeast	O
forkhead	B-GGP
proteins	O
Fkh1p	B-GGP
and	O
Fkh2p	B-GGP
:	O
implications	O
for	O
regulating	O
the	O
cell	O
cycle	O
and	O
differentiation	O
.	O

The	O
roles	O
of	O
DNA	O
and	O
Mcm1p	B-GGP
interactions	O
in	O
determining	O
the	O
overlapping	O
and	O
distinct	O
functions	O
of	O
the	O
yeast	O
cell	O
cycle	O
regulatory	O
transcription	O
factors	O
Fkh1p	B-GGP
and	O
Fkh2p	B-GGP
were	O
examined	O
.	O

Full	O
-	O
length	O
recombinant	O
Fkh1p	B-GGP
and	O
Fkh2p	B-GGP
were	O
purified	O
and	O
their	O
binding	O
to	O
bona	O
fide	O
promoters	O
examined	O
in	O
vitro	O
.	O

Each	O
protein	O
bound	O
a	O
variety	O
of	O
target	O
promoters	O
with	O
similar	O
specificity	O
in	O
vitro	O
,	O
consistent	O
with	O
the	O
observation	O
that	O
these	O
proteins	O
bind	O
common	O
promoters	O
in	O
vivo	O
.	O

However	O
,	O
in	O
vivo	O
,	O
the	O
Fkh1p	B-GGP
and	O
Fkh2p	B-GGP
occupied	O
different	O
target	O
promoters	O
to	O
different	O
extents	O
,	O
suggesting	O
that	O
each	O
was	O
primarily	O
responsible	O
for	O
controlling	O
a	O
different	O
set	O
of	O
genes	O
.	O

Additional	O
in	O
vitro	O
studies	O
provided	O
a	O
mechanistic	O
explanation	O
for	O
this	O
differential	O
promoter	O
-	O
occupancy	O
.	O

Specifically	O
,	O
the	O
Fkh2p	B-GGP
,	O
but	O
not	O
the	O
Fkh1p	B-GGP
,	O
was	O
capable	O
of	O
binding	O
cooperatively	O
with	O
Mcm1p	B-GGP
.	O

The	O
Mcm1p	B-GGP
-	O
Fkh2p	B-GGP
cooperative	O
binding	O
was	O
enhanced	O
by	O
,	O
but	O
did	O
not	O
require	O
,	O
the	O
presence	O
of	O
a	O
Mcm1p	B-GGP
-	O
binding	O
site	O
within	O
a	O
target	O
promoter	O
.	O

Consistent	O
with	O
these	O
data	O
,	O
Mcm1p	B-GGP
was	O
present	O
at	O
Fkh	B-GGP
-	O
controlled	O
promoters	O
in	O
vivo	O
regardless	O
of	O
whether	O
they	O
contained	O
Mcm1p	B-GGP
-	O
binding	O
sites	O
,	O
suggesting	O
a	O
role	O
for	O
Mcm1p	B-GGP
at	O
promoters	O
not	O
thought	O
previously	O
to	O
be	O
under	O
Mcm1p	B-GGP
control	O
.	O

Analysis	O
of	O
Fkh1p	B-GGP
and	O
Fkh2p	B-GGP
binding	O
to	O
promoter	O
targets	O
in	O
vivo	O
by	O
use	O
of	O
mutant	O
strains	O
indicated	O
that	O
the	O
two	O
proteins	O
compete	O
for	O
promoter	O
-	O
occupancy	O
at	O
a	O
number	O
of	O
target	O
promoters	O
.	O

We	O
postulate	O
that	O
Fkh1p	B-GGP
and	O
a	O
stable	O
Fkh2p	B-COM
/	I-COM
Mcm1p	I-COM
complex	O
compete	O
for	O
binding	O
to	O
target	O
promoters	O
and	O
that	O
the	O
levels	O
and	O
/	O
or	O
binding	O
activity	O
of	O
Fkh1p	B-GGP
,	O
but	O
not	O
Fkh2p	B-GGP
,	O
are	O
most	O
limiting	O
for	O
promoter	O
-	O
occupancy	O
in	O
vivo	O
.	O

Interestingly	O
,	O
the	O
in	O
vitro	O
DNA	O
-	O
binding	O
assays	O
,	O
using	O
a	O
variety	O
of	O
promoter	O
targets	O
,	O
revealed	O
that	O
bona	O
fide	O
Fkh	B-GGP
target	O
promoters	O
contained	O
two	O
or	O
more	O
Fkh	B-GGP
-	O
binding	O
sites	O
that	O
allowed	O
the	O
Fkh1p	B-GGP
and	O
Fkh2p	B-GGP
proteins	O
to	O
form	O
multiple	O
protein	O
-	O
DNA	O
complexes	O
in	O
vitro	O
.	O

Multiple	O
Fkh	B-GGP
-	O
binding	O
sites	O
may	O
be	O
a	O
distinguishing	O
feature	O
of	O
bona	O
fide	O
Fkh	B-GGP
promoters	O
in	O
yeast	O
and	O
other	O
organisms	O
.	O

Defects	O
in	O
transcription	O
coupled	O
repair	O
interfere	O
with	O
expression	O
of	O
p90	B-GGP
(	O
MDM2	B-GGP
)	O
in	O
response	O
to	O
ultraviolet	O
light	O
.	O

Ultraviolet	O
(	O
UV	O
)	O
irradiation	O
transiently	O
stabilizes	O
p53	B-GGP
through	O
a	O
mechanism	O
that	O
may	O
require	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
the	O
ubiquitin	B-GGP
ligase	O
,	O
p90	B-GGP
(	O
MDM2	B-GGP
)	O
.	O

Conversely	O
,	O
the	O
recovery	O
of	O
low	O
levels	O
of	O
p53	B-GGP
following	O
UV	O
exposure	O
may	O
depend	O
on	O
an	O
increase	O
in	O
p90	B-GGP
(	O
MDM2	B-GGP
)	O
.	O

The	O
level	O
of	O
p90	B-GGP
(	O
MDM2	B-GGP
)	O
is	O
increased	O
by	O
UV	O
light	O
following	O
the	O
p53	B-GGP
-	O
dependent	O
induction	O
of	O
an	O
internal	O
mdm2	B-GGP
promoter	O
,	O
P2	O
.	O

If	O
this	O
induction	O
of	O
mdm2	B-GGP
were	O
critical	O
for	O
the	O
recovery	O
of	O
low	O
levels	O
of	O
p53	B-GGP
following	O
UV	O
exposure	O
,	O
defects	O
in	O
mdm2	B-GGP
'	O
s	O
transcription	O
would	O
result	O
in	O
a	O
prolonged	O
increase	O
in	O
p53	B-GGP
.	O

Cells	O
defective	O
in	O
transcription	O
coupled	O
repair	O
(	O
TCR	O
)	O
maintain	O
high	O
levels	O
of	O
p53	B-GGP
for	O
a	O
prolonged	O
period	O
following	O
UV	O
exposure	O
.	O

Such	O
cells	O
also	O
have	O
defects	O
in	O
general	O
transcription	O
after	O
UV	O
irradiation	O
.	O

We	O
investigated	O
whether	O
TCR	O
-	O
deficient	O
cells	O
express	O
diminished	O
levels	O
of	O
mdm2	B-GGP
mRNA	O
and	O
p90	B-GGP
(	O
MDM2	B-GGP
)	O
following	O
UV	O
exposure	O
.	O

We	O
found	O
that	O
transcription	O
of	O
mdm2	B-GGP
was	O
reduced	O
in	O
TCR	O
-	O
deficient	O
cells	O
.	O

The	O
uninducible	O
mdm2	B-GGP
promoter	O
,	O
P1	O
,	O
was	O
more	O
sensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
UV	O
irradiation	O
than	O
the	O
P2	O
promoter	O
.	O

The	O
decrease	O
in	O
transcription	O
from	O
the	O
P1	O
promoter	O
was	O
sufficient	O
to	O
reduce	O
the	O
level	O
of	O
p90	B-GGP
(	O
MDM2	B-GGP
)	O
and	O
correlated	O
with	O
a	O
prolonged	O
increase	O
in	O
p53	B-GGP
.	O

Thus	O
,	O
p53	B-GGP
-	O
independent	O
transcription	O
of	O
mdm2	B-GGP
appears	O
critical	O
to	O
p53	B-GGP
'	I-GGP
s	I-GGP
regulation	O
.	O

Degradation	O
of	O
the	O
kinesin	O
Kip1p	B-GGP
at	O
anaphase	O
onset	O
is	O
mediated	O
by	O
the	O
anaphase	B-COM
-	I-COM
promoting	I-COM
complex	I-COM
and	O
Cdc20p	B-GGP
.	O

Kip1p	B-GGP
of	O
Saccharomyces	O
cerevisiae	O
is	O
a	O
bipolar	O
kinesin	O
in	O
the	O
conserved	O
bimC	B-GGP
kinesin	O
subfamily	O
that	O
mediates	O
mitotic	B-CC
spindle	I-CC
-	O
pole	B-CC
separation	O
.	O

Here	O
,	O
we	O
show	O
that	O
Kip1p	B-GGP
is	O
regulated	O
immediately	O
after	O
anaphase	O
initiation	O
by	O
its	O
rapid	O
degradation	O
.	O

Degradation	O
required	O
the	O
ubiquitin	B-GGP
protein	O
ligase	O
called	O
the	O
anaphase	B-COM
-	I-COM
promoting	I-COM
complex	I-COM
,	O
the	O
anaphase	B-COM
-	I-COM
promoting	I-COM
complex	I-COM
activating	O
protein	O
Cdc20	B-GGP
,	O
and	O
a	O
unique	O
43	O
-	O
aa	O
sequence	O
in	O
Kip1p	B-GGP
.	O

Degradation	O
also	O
required	O
import	O
of	O
Kip1p	B-GGP
into	O
the	O
nucleus	B-CC
,	O
but	O
occurred	O
independently	O
of	O
spindle	B-CC
association	O
.	O

A	O
mutation	O
that	O
stabilized	O
Kip1p	B-GGP
impaired	O
anaphase	O
progression	O
.	O

The	O
timing	O
of	O
degradation	O
suggests	O
that	O
Kip1p	B-GGP
functions	O
primarily	O
during	O
spindle	B-CC
assembly	O
and	O
metaphase	O
,	O
and	O
that	O
Kip1p	B-GGP
degradation	O
facilitates	O
structural	O
changes	O
in	O
the	O
mitotic	B-CC
spindle	I-CC
as	O
anaphase	O
progresses	O
.	O

Cloning	O
and	O
expression	O
of	O
human	O
core	B-GGP
1	I-GGP
beta1	I-GGP
,	I-GGP
3	I-GGP
-	I-GGP
galactosyltransferase	I-GGP
.	O

The	O
common	O
core	B-MED
1	I-MED
O	I-MED
-	I-MED
glycan	I-MED
structure	O
Galbeta1	B-MED
-	I-MED
-	I-MED
>	I-MED
3GalNAc	I-MED
-	I-MED
R	I-MED
is	O
the	O
precursor	O
for	O
many	O
extended	O
mucin	O
-	O
type	O
O	B-MED
-	I-MED
glycan	I-MED
structures	O
in	O
animal	O
cell	B-CC
surface	I-CC
and	O
secreted	O
glycoproteins	O
.	O

Core	B-MED
1	I-MED
is	O
synthesized	O
by	O
the	O
transfer	O
of	O
Gal	B-MED
from	O
UDP	B-MED
-	I-MED
Gal	I-MED
to	O
GalNAcalpha1	B-MED
-	I-MED
R	I-MED
by	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
galactosyltransferase	I-GGP
(	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
Gal	I-GGP
-	I-GGP
T	I-GGP
)	O
.	O

Amino	O
acid	O
sequences	O
from	O
purified	O
rat	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
Gal	I-GGP
-	I-GGP
T	I-GGP
(	O
Ju	O
,	O
T	O
.	O
,	O
Cummings	O
,	O
R	O
.	O
D	O
.	O
,	O
and	O
Canfield	O
,	O
W	O
.	O
M	O
.	O
(	O
2002	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
277	O
,	O
169	O
-	O
177	O
)	O
were	O
used	O
to	O
identify	O
the	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
Gal	I-GGP
-	I-GGP
T	I-GGP
sequences	O
in	O
the	O
human	O
expressed	O
sequence	O
tag	O
data	O
bases	O
.	O

A	O
1794	O
-	O
bp	O
human	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
Gal	I-GGP
-	I-GGP
T	I-GGP
cDNA	O
sequence	O
was	O
determined	O
by	O
sequencing	O
the	O
expressed	O
sequence	O
tag	O
and	O
performing	O
5	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

The	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
Gal	I-GGP
-	I-GGP
T	I-GGP
predicts	O
a	O
363	O
-	O
amino	O
acid	O
type	O
II	O
transmembrane	B-CC
protein	O
.	O

Expression	O
of	O
both	O
the	O
full	O
-	O
length	O
and	O
epitope	O
-	O
tagged	O
soluble	O
forms	O
of	O
the	O
putative	O
enzyme	O
in	O
human	O
293T	O
cells	O
generated	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
Gal	I-GGP
-	I-GGP
T	I-GGP
activity	O
that	O
transferred	O
galactose	B-MED
from	O
UDP	B-MED
-	I-MED
Gal	I-MED
to	O
GalNAcalpha1	B-MED
-	I-MED
O	I-MED
-	I-MED
phenyl	I-MED
,	O
and	O
a	O
synthetic	O
glycopeptide	O
with	O
Thr	B-MED
-	O
linked	O
GalNAc	B-MED
and	O
the	O
product	O
was	O
shown	O
to	O
have	O
the	O
core	B-MED
1	I-MED
structure	O
.	O

Northern	O
analysis	O
demonstrated	O
widespread	O
expression	O
of	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
Gal	I-GGP
-	I-GGP
T	I-GGP
in	O
tissues	O
with	O
a	O
predominance	O
in	O
kidney	O
,	O
heart	O
,	O
placenta	O
,	O
and	O
liver	O
.	O

Highly	O
homologous	O
cDNAs	O
were	O
identified	O
and	O
cloned	O
from	O
rat	O
,	O
mouse	O
,	O
Drosophila	O
melanogaster	O
,	O
and	O
Caenorhabditis	O
elegans	O
,	O
suggesting	O
that	O
the	O
enzyme	O
is	O
widely	O
distributed	O
in	O
metazoans	O
.	O

The	O
core	B-GGP
1	I-GGP
beta3	I-GGP
-	I-GGP
Gal	I-GGP
-	I-GGP
T	I-GGP
sequence	O
has	O
minimal	O
homology	O
with	O
conserved	O
sequences	O
found	O
in	O
previously	O
described	O
beta3	B-GGP
-	I-GGP
galactosyltransferases	I-GGP
,	O
suggesting	O
this	O
enzyme	O
is	O
only	O
distantly	O
related	O
to	O
the	O
known	O
beta3	B-GGP
-	I-GGP
galactosyltransferase	I-GGP
family	O
.	O

Hierarchical	O
phosphorylation	O
of	O
the	O
translation	O
inhibitor	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
.	O

In	O
most	O
instances	O
,	O
translation	O
is	O
regulated	O
at	O
the	O
initiation	O
phase	O
,	O
when	O
a	O
ribosome	B-CC
is	O
recruited	O
to	O
the	O
5	O
'	O
end	O
of	O
an	O
mRNA	O
.	O

The	O
eIF4E	B-GGP
-	I-GGP
binding	I-GGP
proteins	I-GGP
(	O
4E	B-GGP
-	I-GGP
BPs	I-GGP
)	O
interdict	O
translation	O
initiation	O
by	O
binding	O
to	O
the	O
translation	O
factor	O
eIF4E	B-GGP
,	O
and	O
preventing	O
recruitment	O
of	O
the	O
translation	O
machinery	O
to	O
mRNA	O
.	O

The	O
4E	B-GGP
-	I-GGP
BPs	I-GGP
inhibit	O
translation	O
in	O
a	O
reversible	O
manner	O
.	O

Hypophosphorylated	O
4E	B-GGP
-	I-GGP
BPs	I-GGP
interact	O
avidly	O
with	O
eIF4E	B-GGP
,	O
whereas	O
4E	B-GGP
-	I-GGP
BP	I-GGP
hyperphosphorylation	O
,	O
elicited	O
by	O
stimulation	O
of	O
cells	O
with	O
hormones	O
,	O
cytokines	O
,	O
or	O
growth	O
factors	O
,	O
results	O
in	O
an	O
abrogation	O
of	O
eIF4E	B-GGP
-	O
binding	O
activity	O
.	O

We	O
reported	O
previously	O
that	O
phosphorylation	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
on	O
Thr	B-MED
37	I-MED
and	O
Thr	B-MED
46	I-MED
is	O
relatively	O
insensitive	O
to	O
serum	O
deprivation	O
and	O
rapamycin	B-MED
treatment	O
,	O
and	O
that	O
phosphorylation	O
of	O
these	O
residues	O
is	O
required	O
for	O
the	O
subsequent	O
phosphorylation	O
of	O
a	O
set	O
of	O
unidentified	O
serum	O
-	O
responsive	O
sites	O
.	O

Here	O
,	O
using	O
mass	O
spectrometry	O
,	O
we	O
identify	O
the	O
serum	O
-	O
responsive	O
,	O
rapamycin	B-MED
-	O
sensitive	O
sites	O
as	O
Ser	B-MED
65	I-MED
and	O
Thr	B-MED
70	I-MED
.	O

Utilizing	O
a	O
novel	O
combination	O
of	O
two	O
-	O
dimensional	O
isoelectric	O
focusing	O
/	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blotting	O
with	O
phosphospecific	O
antibodies	O
,	O
we	O
also	O
establish	O
the	O
order	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
phosphorylation	O
in	O
vivo	O
;	O
phosphorylation	O
of	O
Thr	B-MED
37	I-MED
/	O
Thr	B-MED
46	I-MED
is	O
followed	O
by	O
Thr	B-MED
70	I-MED
phosphorylation	O
,	O
and	O
Ser	B-MED
65	I-MED
is	O
phosphorylated	O
last	O
.	O

Finally	O
,	O
we	O
show	O
that	O
phosphorylation	O
of	O
Ser	B-MED
65	I-MED
and	O
Thr	B-MED
70	I-MED
alone	O
is	O
insufficient	O
to	O
block	O
binding	O
to	O
eIF4E	B-GGP
,	O
indicating	O
that	O
a	O
combination	O
of	O
phosphorylation	O
events	O
is	O
necessary	O
to	O
dissociate	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
from	O
eIF4E	B-GGP
.	O

Phosphorylation	O
of	O
eukaryotic	B-GGP
initiation	I-GGP
factor	I-GGP
4E	I-GGP
markedly	O
reduces	O
its	O
affinity	O
for	O
capped	O
mRNA	O
.	O

In	O
eukaryotes	O
,	O
a	O
key	O
step	O
in	O
the	O
initiation	O
of	O
translation	O
is	O
the	O
binding	O
of	O
the	O
eukaryotic	B-GGP
initiation	I-GGP
factor	I-GGP
4E	I-GGP
(	O
eIF4E	B-GGP
)	O
to	O
the	O
cap	O
structure	O
of	O
the	O
mRNA	O
.	O

Subsequent	O
recruitment	O
of	O
several	O
components	O
,	O
including	O
the	O
small	B-CC
ribosomal	I-CC
subunit	I-CC
,	O
is	O
thought	O
to	O
allow	O
migration	O
of	O
initiation	O
complexes	O
and	O
recognition	O
of	O
the	O
initiation	O
codon	O
.	O

Mitogens	O
and	O
cytokines	O
stimulate	O
the	O
phosphorylation	O
of	O
eIF4E	B-GGP
at	O
Ser	B-MED
(	I-MED
209	I-MED
)	I-MED
,	O
but	O
the	O
functional	O
consequences	O
of	O
this	O
modification	O
have	O
remained	O
a	O
major	O
unresolved	O
question	O
.	O

Using	O
fluorescence	O
spectroscopy	O
and	O
surface	O
plasmon	O
resonance	O
techniques	O
,	O
we	O
show	O
that	O
phosphorylation	O
of	O
eIF4E	B-GGP
markedly	O
reduces	O
its	O
affinity	O
for	O
capped	O
RNA	O
,	O
primarily	O
due	O
to	O
an	O
increased	O
rate	O
of	O
dissociation	O
.	O

Variant	O
eIF4E	B-GGP
proteins	O
harboring	O
negatively	O
charged	O
acidic	O
residues	O
at	O
position	O
209	O
also	O
showed	O
decreased	O
binding	O
to	O
capped	O
RNA	O
.	O

Furthermore	O
,	O
a	O
basic	O
residue	O
at	O
position	O
159	O
was	O
shown	O
to	O
be	O
essential	O
for	O
cap	O
binding	O
.	O

Although	O
eIF4E	B-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
1	I-GGP
greatly	O
stabilized	O
binding	O
of	O
phosphorylated	O
eIF4E	B-GGP
to	O
capped	O
RNA	O
,	O
in	O
the	O
presence	O
of	O
eIF4E	B-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
1	I-GGP
the	O
phosphorylated	O
form	O
still	O
dissociated	O
faster	O
compared	O
with	O
nonphopshorylated	O
eIF4E	B-GGP
.	O

The	O
implications	O
of	O
our	O
findings	O
for	O
the	O
mechanism	O
of	O
translation	O
initiation	O
are	O
discussed	O
.	O

Bub3	B-GGP
interaction	O
with	O
Mad2	B-GGP
,	O
Mad3	B-GGP
and	O
Cdc20	B-GGP
is	O
mediated	O
by	O
WD40	B-GGP
repeats	O
and	O
does	O
not	O
require	O
intact	O
kinetochores	B-CC
.	O

The	O
kinetochore	B-CC
checkpoint	O
pathway	O
,	O
involving	O
the	O
Mad1	B-GGP
,	O
Mad2	B-GGP
,	O
Mad3	B-GGP
,	O
Bub1	B-GGP
,	O
Bub3	B-GGP
and	O
Mps1	B-GGP
proteins	O
,	O
prevents	O
anaphase	O
entry	O
and	O
mitotic	O
exit	O
by	O
inhibiting	O
the	O
anaphase	B-COM
promoting	I-COM
complex	I-COM
activator	O
Cdc20	B-GGP
in	O
response	O
to	O
monopolar	O
attachment	O
of	O
sister	O
kinetochores	B-CC
to	O
spindle	B-CC
fibres	I-CC
.	O

We	O
show	O
here	O
that	O
Cdc20	B-GGP
,	O
which	O
had	O
previously	O
been	O
shown	O
to	O
interact	O
physically	O
with	O
Mad2	B-GGP
and	O
Mad3	B-GGP
,	O
associates	O
also	O
with	O
Bub3	B-GGP
and	O
association	O
is	O
up	O
-	O
regulated	O
upon	O
checkpoint	O
activation	O
.	O

Moreover	O
,	O
co	O
-	O
fractionation	O
experiments	O
suggest	O
that	O
Mad2	B-GGP
,	O
Mad3	B-GGP
and	O
Bub3	B-GGP
may	O
be	O
concomitantly	O
present	O
in	O
protein	O
complexes	O
with	O
Cdc20	B-GGP
.	O

Formation	O
of	O
the	O
Bub3	B-COM
-	I-COM
Cdc20	I-COM
complex	O
requires	O
all	O
kinetochore	B-CC
checkpoint	O
proteins	O
but	O
,	O
surprisingly	O
,	O
not	O
intact	O
kinetochores	B-CC
.	O

Conversely	O
,	O
point	O
mutations	O
altering	O
the	O
conserved	O
WD40	B-GGP
motifs	O
of	O
Bub3	B-GGP
,	O
which	O
might	O
be	O
involved	O
in	O
the	O
formation	O
of	O
a	O
beta	O
-	O
propeller	O
fold	O
devoted	O
to	O
protein	O
-	O
protein	O
interactions	O
,	O
disrupt	O
its	O
association	O
with	O
Mad2	B-GGP
,	O
Mad3	B-GGP
and	O
Cdc20	B-GGP
,	O
as	O
well	O
as	O
proper	O
checkpoint	O
response	O
.	O

We	O
suggest	O
that	O
Bub3	B-GGP
could	O
serve	O
as	O
a	O
platform	O
for	O
interactions	O
between	O
kinetochore	B-CC
checkpoint	O
proteins	O
,	O
and	O
its	O
association	O
with	O
Mad2	B-GGP
,	O
Mad3	B-GGP
and	O
Cdc20	B-GGP
might	O
be	O
instrumental	O
for	O
checkpoint	O
activation	O
.	O

Phosphatidic	B-MED
acid	I-MED
-	O
mediated	O
mitogenic	O
activation	O
of	O
mTOR	B-GGP
signaling	O
.	O

The	O
mammalian	B-GGP
target	I-GGP
of	I-GGP
rapamycin	I-GGP
(	O
mTOR	B-GGP
)	O
governs	O
cell	O
growth	O
and	O
proliferation	O
by	O
mediating	O
the	O
mitogen	O
-	O
and	O
nutrient	O
-	O
dependent	O
signal	O
transduction	O
that	O
regulates	O
messenger	O
RNA	O
translation	O
.	O

We	O
identified	O
phosphatidic	B-MED
acid	I-MED
(	O
PA	B-MED
)	O
as	O
a	O
critical	O
component	O
of	O
mTOR	B-GGP
signaling	O
.	O

In	O
our	O
study	O
,	O
mitogenic	O
stimulation	O
of	O
mammalian	O
cells	O
led	O
to	O
a	O
phospholipase	B-GGP
D	I-GGP
-	O
dependent	O
accumulation	O
of	O
cellular	O
PA	B-MED
,	O
which	O
was	O
required	O
for	O
activation	O
of	O
mTOR	B-GGP
downstream	O
effectors	O
.	O

PA	B-MED
directly	O
interacted	O
with	O
the	O
domain	O
in	O
mTOR	B-GGP
that	O
is	O
targeted	O
by	O
rapamycin	B-MED
,	O
and	O
this	O
interaction	O
was	O
positively	O
correlated	O
with	O
mTOR	B-GGP
'	O
s	O
ability	O
to	O
activate	O
downstream	O
effectors	O
.	O

The	O
involvement	O
of	O
PA	B-MED
in	O
mTOR	B-GGP
signaling	O
reveals	O
an	O
important	O
function	O
of	O
this	O
lipid	O
in	O
signal	O
transduction	O
and	O
protein	O
synthesis	O
,	O
as	O
well	O
as	O
a	O
direct	O
link	O
between	O
mTOR	B-GGP
and	O
mitogens	O
.	O

Furthermore	O
,	O
these	O
studies	O
suggest	O
a	O
potential	O
mechanism	O
for	O
the	O
in	O
vivo	O
actions	O
of	O
the	O
immunosuppressant	O
rapamycin	B-MED
.	O

Negative	O
regulation	O
of	O
toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
-	O
mediated	O
signaling	O
by	O
Tollip	B-GGP
.	O

Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	O
TLR	B-GGP
)	O
-	O
mediated	O
recognition	O
of	O
pathogens	O
represents	O
one	O
of	O
the	O
most	O
important	O
mechanisms	O
of	O
innate	O
immunity	O
and	O
disease	O
resistance	O
.	O

The	O
adaptor	O
protein	O
Tollip	B-GGP
was	O
identified	O
initially	O
as	O
an	O
intermediate	O
in	O
interleukin	B-GGP
(	I-GGP
IL	I-GGP
)	I-GGP
-	I-GGP
1	I-GGP
signaling	O
.	O

Here	O
we	O
report	O
that	O
Tollip	B-GGP
also	O
associates	O
directly	O
with	O
TLR2	B-GGP
and	O
TLR4	B-GGP
and	O
plays	O
an	O
inhibitory	O
role	O
in	O
TLR	B-GGP
-	O
mediated	O
cell	O
activation	O
.	O

Inhibition	O
by	O
Tollip	B-GGP
is	O
mediated	O
through	O
its	O
ability	O
to	O
potently	O
suppress	O
the	O
activity	O
of	O
IL	B-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
-	I-GGP
associated	I-GGP
kinase	I-GGP
(	O
IRAK	B-GGP
)	O
after	O
TLR	B-GGP
activation	O
.	O

In	O
addition	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
Tollip	B-GGP
is	O
a	O
bona	O
fide	O
substrate	O
for	O
IRAK	B-GGP
and	O
is	O
phosphorylated	O
by	O
IRAK	B-GGP
upon	O
stimulation	O
with	O
lipopolysaccharide	B-MED
or	O
IL	B-GGP
-	I-GGP
1	I-GGP
.	O

Negative	O
regulation	O
of	O
TLR	B-GGP
signaling	O
by	O
Tollip	B-GGP
may	O
therefore	O
serve	O
to	O
limit	O
the	O
production	O
of	O
proinflammatory	O
mediators	O
during	O
inflammation	O
and	O
infection	O
.	O

Chlamydial	O
heat	B-GGP
shock	I-GGP
protein	I-GGP
60	I-GGP
activates	O
macrophages	O
and	O
endothelial	O
cells	O
through	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
4	I-GGP
and	O
MD2	B-GGP
in	O
a	O
MyD88	B-GGP
-	O
dependent	O
pathway	O
.	O

Active	O
inflammation	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
contribute	O
fundamentally	O
to	O
atherogenesis	O
and	O
plaque	O
disruption	O
.	O

Accumulating	O
evidence	O
has	O
implicated	O
specific	O
infectious	O
agents	O
including	O
Chlamydia	O
pneumoniae	O
in	O
the	O
progression	O
of	O
atherogenesis	O
.	O

Chlamydial	O
heat	B-GGP
shock	I-GGP
protein	I-GGP
60	I-GGP
(	O
cHSP60	B-GGP
)	O
has	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
deleterious	O
immune	O
responses	O
in	O
human	O
chlamydial	O
infections	O
and	O
has	O
been	O
found	O
to	O
colocalize	O
with	O
infiltrating	O
macrophages	O
in	O
atheroma	O
lesions	O
.	O

cHSP60	B-GGP
might	O
stimulate	O
,	O
enhance	O
,	O
and	O
maintain	O
innate	O
immune	O
and	O
inflammatory	O
responses	O
and	O
contribute	O
to	O
atherogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
signaling	O
mechanism	O
of	O
cHSP60	B-GGP
.	O

Recombinant	O
cHSP60	B-GGP
rapidly	O
activated	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
human	O
microvascular	O
endothelial	O
cells	O
(	O
EC	O
)	O
and	O
in	O
mouse	O
macrophages	O
,	O
and	O
induced	O
human	O
IL	B-GGP
-	I-GGP
8	I-GGP
promoter	O
activity	O
in	O
EC	O
.	O

The	O
inflammatory	O
effect	O
of	O
cHSP60	B-GGP
was	O
heat	O
labile	O
,	O
thus	O
excluding	O
a	O
role	O
of	O
contaminating	O
LPS	B-MED
,	O
and	O
was	O
blocked	O
by	O
specific	O
anti	O
-	O
chlamydial	O
HSP60	B-GGP
mAb	O
.	O

In	O
human	O
vascular	O
EC	O
which	O
express	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
4	I-GGP
(	O
TLR4	B-GGP
)	O
mRNA	O
and	O
protein	O
,	O
nonsignaling	O
TLR4	B-GGP
constructs	O
that	O
act	O
as	O
dominant	O
negative	O
blocked	O
cHSP60	B-GGP
-	O
mediated	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

Furthermore	O
,	O
an	O
anti	O
-	O
TLR4	B-GGP
Ab	O
abolished	O
cHSP60	B-GGP
-	O
induced	O
cellular	O
activation	O
,	O
whereas	O
a	O
control	O
Ab	O
had	O
no	O
effect	O
.	O

In	O
293	O
cells	O
,	O
cHSP60	B-GGP
-	O
mediated	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
required	O
both	O
TLR4	B-GGP
and	O
MD2	B-GGP
.	O

A	O
dominant	O
-	O
negative	O
MyD88	B-GGP
construct	O
also	O
inhibited	O
cHSP60	B-GGP
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
cHSP60	B-GGP
is	O
a	O
potent	O
inducer	O
of	O
vascular	O
EC	O
and	O
macrophage	O
inflammatory	O
responses	O
,	O
which	O
are	O
very	O
relevant	O
to	O
atherogenesis	O
.	O

The	O
inflammatory	O
effects	O
are	O
mediated	O
through	O
the	O
innate	O
immune	O
receptor	O
complex	O
TLR4	B-COM
-	I-COM
MD2	I-COM
and	O
proceeds	O
via	O
the	O
MyD88	B-GGP
-	O
dependent	O
signaling	O
pathway	O
.	O

These	O
findings	O
may	O
help	O
elucidate	O
the	O
mechanisms	O
by	O
which	O
chronic	O
asymptomatic	O
chlamydial	O
infection	O
contribute	O
to	O
atherogenesis	O
.	O

Carnitine	B-MED
biosynthesis	O
in	O
mammals	O
.	O

Carnitine	B-MED
is	O
indispensable	O
for	O
energy	O
metabolism	O
,	O
since	O
it	O
enables	O
activated	O
fatty	B-MED
acids	I-MED
to	O
enter	O
the	O
mitochondria	B-CC
,	O
where	O
they	O
are	O
broken	O
down	O
via	O
beta	O
-	O
oxidation	O
.	O

Carnitine	B-MED
is	O
probably	O
present	O
in	O
all	O
animal	O
species	O
,	O
and	O
in	O
numerous	O
micro	O
-	O
organisms	O
and	O
plants	O
.	O

In	O
mammals	O
,	O
carnitine	B-MED
homoeostasis	O
is	O
maintained	O
by	O
endogenous	O
synthesis	O
,	O
absorption	O
from	O
dietary	O
sources	O
and	O
efficient	O
tubular	O
reabsorption	O
by	O
the	O
kidney	O
.	O

This	O
review	O
aims	O
to	O
cover	O
the	O
current	O
knowledge	O
of	O
the	O
enzymological	O
,	O
molecular	O
,	O
metabolic	O
and	O
regulatory	O
aspects	O
of	O
mammalian	O
carnitine	B-MED
biosynthesis	O
,	O
with	O
an	O
emphasis	O
on	O
the	O
human	O
and	O
rat	O
.	O

Separase	B-GGP
,	O
polo	B-GGP
kinase	I-GGP
,	O
the	O
kinetochore	B-CC
protein	O
Slk19	B-GGP
,	O
and	O
Spo12	B-GGP
function	O
in	O
a	O
network	O
that	O
controls	O
Cdc14	B-GGP
localization	O
during	O
early	O
anaphase	O
.	O

In	O
budding	O
yeast	O
,	O
the	O
phosphatase	O
Cdc14	B-GGP
,	O
a	O
key	O
regulator	O
of	O
exit	O
from	O
mitosis	O
,	O
is	O
released	O
from	O
its	O
inhibitor	O
Cfi1	B-GGP
/	O
Net1	B-GGP
in	O
the	O
nucleolus	B-CC
during	O
anaphase	O
.	O

A	O
signaling	O
cascade	O
,	O
known	O
as	O
the	O
mitotic	O
exit	O
network	O
(	O
MEN	O
)	O
,	O
controls	O
this	O
release	O
.	O

We	O
have	O
identified	O
a	O
regulatory	O
network	O
,	O
the	O
FEAR	O
(	O
Cdc	B-GGP
fourteen	O
early	O
anaphase	O
release	O
)	O
network	O
that	O
promotes	O
Cdc14	B-GGP
release	O
from	O
the	O
nucleolus	B-CC
during	O
early	O
anaphase	O
.	O

The	O
FEAR	O
network	O
is	O
comprised	O
of	O
the	O
polo	B-GGP
kinase	I-GGP
Cdc5	B-GGP
,	O
the	O
separase	B-GGP
Esp1	B-GGP
,	O
the	O
kinetochore	B-CC
-	O
associated	O
protein	O
Slk19	B-GGP
,	O
and	O
Spo12	B-GGP
.	O

We	O
also	O
show	O
that	O
the	O
FEAR	O
network	O
initiates	O
Cdc14	B-GGP
release	O
from	O
Cfi1	B-GGP
/	O
Net1	B-GGP
during	O
early	O
anaphase	O
,	O
and	O
MEN	O
maintains	O
Cdc14	B-GGP
in	O
the	O
released	O
state	O
during	O
late	O
anaphase	O
.	O

We	O
propose	O
that	O
one	O
function	O
of	O
Cdc14	B-GGP
released	O
by	O
the	O
FEAR	O
network	O
is	O
to	O
stimulate	O
MEN	O
activity	O
.	O

Novel	O
signal	O
transduction	O
pathway	O
utilized	O
by	O
extracellular	B-CC
HSP70	B-GGP
:	O
role	O
of	O
toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	I-GGP
TLR	I-GGP
)	I-GGP
2	I-GGP
and	O
TLR4	B-GGP
.	O

Recent	O
studies	O
have	O
initiated	O
a	O
paradigm	O
shift	O
in	O
the	O
understanding	O
of	O
the	O
function	O
of	O
heat	B-GGP
shock	I-GGP
proteins	I-GGP
(	O
HSP	B-GGP
)	O
.	O

It	O
is	O
now	O
clear	O
that	O
HSP	B-GGP
can	O
and	O
do	O
exit	O
mammalian	O
cells	O
,	O
interact	O
with	O
cells	O
of	O
the	O
immune	O
system	O
,	O
and	O
exert	O
immunoregulatory	O
effects	O
.	O

We	O
recently	O
demonstrated	O
that	O
exogenously	O
added	O
HSP70	B-GGP
possesses	O
potent	O
cytokine	O
activity	O
,	O
with	O
the	O
ability	O
to	O
bind	O
with	O
high	O
affinity	O
to	O
the	O
plasma	B-CC
membrane	I-CC
,	O
elicit	O
a	O
rapid	O
intracellular	B-CC
Ca	B-MED
(	I-MED
2	I-MED
+	I-MED
)	I-MED
flux	O
,	O
activate	O
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
and	O
up	O
-	O
regulate	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
in	O
human	O
monocytes	O
.	O

Here	O
for	O
the	O
first	O
time	O
,	O
we	O
report	O
that	O
HSP70	B-GGP
-	O
induced	O
proinflammatory	O
cytokine	O
production	O
is	O
mediated	O
via	O
the	O
MyD88	B-GGP
/	O
IRAK	B-GGP
/	O
NF	B-COM
-	I-COM
kappaB	I-COM
signal	O
transduction	O
pathway	O
and	O
that	O
HSP70	B-GGP
utilizes	O
both	O
TLR2	B-GGP
(	O
receptor	O
for	O
Gram	O
-	O
positive	O
bacteria	O
)	O
and	O
TLR4	B-GGP
(	O
receptor	O
for	O
Gram	O
-	O
negative	O
bacteria	O
)	O
to	O
transduce	O
its	O
proinflammatory	O
signal	O
in	O
a	O
CD14	B-GGP
-	O
dependent	O
fashion	O
.	O

These	O
studies	O
now	O
pave	O
the	O
way	O
for	O
the	O
development	O
of	O
highly	O
effective	O
pharmacological	O
or	O
molecular	O
tools	O
that	O
will	O
either	O
up	O
-	O
regulate	O
or	O
suppress	O
HSP70	B-GGP
-	O
induced	O
functions	O
in	O
conditions	O
where	O
HSP70	B-GGP
effects	O
are	O
desirable	O
(	O
cancer	O
)	O
or	O
disorders	O
where	O
HSP70	B-GGP
effects	O
are	O
undesirable	O
(	O
arthritis	O
and	O
arteriosclerosis	O
)	O
.	O

Set2	B-GGP
is	O
a	O
nucleosomal	B-CC
histone	B-GGP
H3	I-GGP
-	O
selective	O
methyltransferase	O
that	O
mediates	O
transcriptional	O
repression	O
.	O

Recent	O
studies	O
of	O
histone	B-GGP
methylation	O
have	O
yielded	O
fundamental	O
new	O
insights	O
pertaining	O
to	O
the	O
role	O
of	O
this	O
modification	O
in	O
gene	O
activation	O
as	O
well	O
as	O
in	O
gene	O
silencing	O
.	O

While	O
a	O
number	O
of	O
methylation	O
sites	O
are	O
known	O
to	O
occur	O
on	O
histones	B-GGP
,	O
only	O
limited	O
information	O
exists	O
regarding	O
the	O
relevant	O
enzymes	O
that	O
mediate	O
these	O
methylation	O
events	O
.	O

We	O
thus	O
sought	O
to	O
identify	O
native	O
histone	B-GGP
methyltransferase	I-GGP
(	O
HMT	B-GGP
)	O
activities	O
from	O
Saccharomyces	O
cerevisiae	O
.	O

Here	O
,	O
we	O
describe	O
the	O
biochemical	O
purification	O
and	O
characterization	O
of	O
Set2	B-GGP
,	O
a	O
novel	O
HMT	B-GGP
that	O
is	O
site	O
-	O
specific	O
for	O
lysine	B-MED
36	I-MED
(	O
Lys36	B-MED
)	O
of	O
the	O
H3	B-GGP
tail	O
.	O

Using	O
an	O
antiserum	O
directed	O
against	O
Lys36	B-MED
methylation	O
in	O
H3	B-GGP
,	O
we	O
show	O
that	O
Set2	B-GGP
,	O
via	O
its	O
SET	O
domain	O
,	O
is	O
responsible	O
for	O
methylation	O
at	O
this	O
site	O
in	O
vivo	O
.	O

Tethering	O
of	O
Set2	B-GGP
to	O
a	O
heterologous	O
promoter	O
reveals	O
that	O
Set2	B-GGP
represses	O
transcription	O
,	O
and	O
part	O
of	O
this	O
repression	O
is	O
mediated	O
through	O
the	O
HMT	B-GGP
activity	O
of	O
the	O
SET	O
domain	O
.	O

These	O
results	O
suggest	O
that	O
Set2	B-GGP
and	O
methylation	O
at	O
H3	B-GGP
Lys36	B-MED
play	O
a	O
role	O
in	O
the	O
repression	O
of	O
gene	O
transcription	O
.	O

Up	O
-	O
regulation	O
of	O
prostaglandin	B-MED
E2	I-MED
synthesis	O
by	O
interleukin	B-GGP
-	I-GGP
1beta	I-GGP
in	O
human	O
orbital	O
fibroblasts	O
involves	O
coordinate	O
induction	O
of	O
prostaglandin	B-GGP
-	I-GGP
endoperoxide	I-GGP
H	I-GGP
synthase	I-GGP
-	I-GGP
2	I-GGP
and	O
glutathione	B-MED
-	O
dependent	O
prostaglandin	B-GGP
E2	I-GGP
synthase	I-GGP
expression	O
.	O

Prostaglandin	B-MED
E	I-MED
(	I-MED
2	I-MED
)	I-MED
(	O
PGE	B-MED
(	I-MED
2	I-MED
)	I-MED
)	O
production	O
involves	O
the	O
activity	O
of	O
a	O
multistep	O
biosynthetic	O
pathway	O
.	O

The	O
terminal	O
components	O
of	O
this	O
cascade	O
,	O
two	O
PGE	B-GGP
(	I-GGP
2	I-GGP
)	I-GGP
synthases	I-GGP
(	O
PGES	B-GGP
)	O
,	O
have	O
very	O
recently	O
been	O
identified	O
as	O
glutathione	B-MED
-	O
dependent	O
proteins	O
.	O

cPGES	B-GGP
is	O
cytoplasmic	B-CC
,	O
apparently	O
identical	O
to	O
the	O
hsp90	B-GGP
chaperone	O
,	O
p23	B-GGP
,	O
and	O
associates	O
functionally	O
with	O
prostaglandin	B-GGP
-	I-GGP
endoperoxide	I-GGP
H	I-GGP
synthase	I-GGP
-	I-GGP
1	I-GGP
(	O
PGHS	B-GGP
-	I-GGP
1	I-GGP
)	O
,	O
the	O
constitutive	O
cyclooxygenase	B-GGP
.	O

A	O
second	O
synthase	O
,	O
designated	O
mPGES	B-GGP
,	O
is	O
microsomal	O
and	O
can	O
be	O
regulated	O
.	O

Here	O
we	O
demonstrate	O
that	O
mPGES	B-GGP
and	O
PGHS	B-GGP
-	I-GGP
2	I-GGP
are	O
expressed	O
at	O
very	O
low	O
levels	O
in	O
untreated	O
human	O
orbital	O
fibroblasts	O
.	O

Interleukin	B-GGP
(	I-GGP
IL	I-GGP
)	I-GGP
-	I-GGP
1beta	I-GGP
treatment	O
elicits	O
high	O
levels	O
of	O
PGHS	B-GGP
-	I-GGP
2	I-GGP
and	O
mPGES	B-GGP
expression	O
.	O

The	O
induction	O
of	O
both	O
enzymes	O
occurs	O
at	O
the	O
pretranslational	O
level	O
,	O
is	O
the	O
consequence	O
of	O
enhanced	O
gene	O
promoter	O
activities	O
,	O
and	O
can	O
be	O
blocked	O
by	O
dexamethasone	B-MED
(	O
10	O
nm	O
)	O
.	O

SC58125	B-MED
,	O
a	O
PGHS	B-GGP
-	I-GGP
2	I-GGP
-	O
selective	O
inhibitor	O
,	O
could	O
attenuate	O
the	O
induction	O
of	O
mPGES	B-GGP
,	O
suggesting	O
a	O
dependence	O
of	O
this	O
enzyme	O
on	O
PGHS	B-GGP
-	I-GGP
2	I-GGP
activity	O
.	O

IL	B-GGP
-	I-GGP
1beta	I-GGP
treatment	O
activates	O
p38	B-GGP
and	O
ERK	B-GGP
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinases	I-GGP
.	O

Induction	O
of	O
both	O
mPGES	B-GGP
and	O
PGHS	B-GGP
-	I-GGP
2	I-GGP
was	O
susceptible	O
to	O
either	O
chemical	O
inhibition	O
or	O
molecular	O
interruption	O
of	O
these	O
pathways	O
with	O
dominant	O
negative	O
constructs	O
.	O

These	O
results	O
indicate	O
that	O
the	O
induction	O
of	O
PGHS	B-GGP
-	I-GGP
2	I-GGP
and	O
mPGES	B-GGP
by	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
underlies	O
robust	O
PGE	B-MED
(	I-MED
2	I-MED
)	I-MED
production	O
in	O
orbital	O
fibroblasts	O
.	O

Calcineurin	B-GGP
-	O
dependent	O
regulation	O
of	O
Crz1p	B-GGP
nuclear	B-CC
export	O
requires	O
Msn5p	B-GGP
and	O
a	O
conserved	O
calcineurin	B-GGP
docking	O
site	O
.	O

Calcineurin	B-GGP
,	O
a	O
conserved	O
Ca	B-MED
(	I-MED
2	I-MED
+	I-MED
)	I-MED
/	O
calmodulin	B-GGP
-	O
regulated	O
protein	O
phosphatase	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
Ca	B-MED
(	I-MED
2	I-MED
+	I-MED
)	I-MED
signaling	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
calcineurin	B-GGP
positively	O
regulates	O
transcription	O
in	O
response	O
to	O
stress	O
by	O
dephosphorylating	O
the	O
transcription	O
factor	O
Crz1p	B-GGP
/	O
Tcn1p	B-GGP
.	O

Dephosphorylation	O
promotes	O
Crz1p	B-GGP
nuclear	B-CC
localization	O
in	O
part	O
by	O
increasing	O
the	O
efficiency	O
of	O
its	O
nuclear	B-CC
import	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
calcineurin	B-GGP
-	O
dependent	O
dephosphorylation	O
of	O
Crz1p	B-GGP
also	O
down	O
-	O
regulates	O
its	O
nuclear	B-CC
export	O
.	O

Using	O
a	O
genetic	O
approach	O
,	O
we	O
identify	O
Msn5p	B-GGP
as	O
the	O
exportin	O
for	O
Crz1p	B-GGP
.	O

In	O
addition	O
,	O
we	O
define	O
the	O
Crz1p	B-GGP
nuclear	B-CC
export	O
signal	O
(	O
NES	O
)	O
and	O
show	O
that	O
it	O
interacts	O
with	O
Msn5p	B-GGP
in	O
a	O
phosphorylation	O
-	O
dependent	O
manner	O
.	O

This	O
indicates	O
that	O
calcineurin	B-GGP
regulates	O
Crz1p	B-GGP
nuclear	B-CC
export	O
by	O
dephosphorylating	O
and	O
inactivating	O
its	O
NES	O
.	O

Finally	O
,	O
we	O
define	O
a	O
motif	O
in	O
Crz1p	B-GGP
,	O
PIISIQ	O
,	O
similar	O
to	O
the	O
PxIxIT	O
docking	O
site	O
for	O
calcineurin	B-GGP
on	O
the	O
mammalian	O
transcription	O
factor	O
NFAT	B-GGP
,	O
that	O
mediates	O
the	O
in	O
vivo	O
interaction	O
between	O
calcineurin	B-GGP
and	O
Crz1p	B-GGP
and	O
is	O
required	O
for	O
calcineurin	B-GGP
-	O
dependent	O
regulation	O
of	O
Crz1p	B-GGP
nuclear	B-CC
export	O
and	O
activity	O
.	O

Therefore	O
,	O
in	O
yeast	O
as	O
in	O
mammals	O
,	O
a	O
docking	O
site	O
is	O
required	O
to	O
target	O
calcineurin	B-GGP
to	O
its	O
substrate	O
such	O
that	O
it	O
can	O
dephosphorylate	O
it	O
efficiently	O
.	O

Regulation	O
of	O
interleukin	B-GGP
-	I-GGP
1	I-GGP
-	O
and	O
lipopolysaccharide	B-MED
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
by	O
alternative	O
splicing	O
of	O
MyD88	B-GGP
.	O

MyD88	B-GGP
is	O
an	O
adaptor	O
protein	O
that	O
is	O
involved	O
in	O
interleukin	B-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
(	O
IL	B-GGP
-	I-GGP
1R	I-GGP
)	O
-	O
and	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	O
TLR	B-GGP
)	O
-	O
induced	O
activation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

It	O
is	O
composed	O
of	O
a	O
C	O
-	O
terminal	O
Toll	B-GGP
/	O
IL	B-GGP
-	I-GGP
1R	I-GGP
homology	O
(	O
TIR	O
)	O
domain	O
and	O
an	O
N	O
-	O
terminal	O
death	O
domain	O
(	O
DD	O
)	O
,	O
which	O
mediate	O
the	O
interaction	O
of	O
MyD88	B-GGP
with	O
the	O
IL	B-GGP
-	I-GGP
1R	I-GGP
/	O
TLR	B-GGP
and	O
the	O
IL	B-GGP
-	I-GGP
1R	I-GGP
-	I-GGP
associated	I-GGP
kinase	I-GGP
(	O
IRAK	B-GGP
)	O
,	O
respectively	O
.	O

The	O
interaction	O
of	O
MyD88	B-GGP
with	O
IRAK	B-GGP
triggers	O
IRAK	B-GGP
phosphorylation	O
,	O
which	O
is	O
essential	O
for	O
its	O
activation	O
and	O
downstream	O
signaling	O
ability	O
.	O

Both	O
domains	O
of	O
MyD88	B-GGP
are	O
separated	O
by	O
a	O
small	O
intermediate	O
domain	O
(	O
ID	O
)	O
of	O
unknown	O
function	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
splice	O
variant	O
of	O
MyD88	B-GGP
,	O
termed	O
MyD88	B-GGP
(	I-GGP
S	I-GGP
)	I-GGP
,	O
which	O
encodes	O
for	O
a	O
protein	O
lacking	O
the	O
ID	O
.	O

MyD88	B-GGP
(	I-GGP
S	I-GGP
)	I-GGP
is	O
mainly	O
expressed	O
in	O
the	O
spleen	O
and	O
can	O
be	O
induced	O
in	O
monocytes	O
upon	O
LPS	B-MED
treatment	O
.	O

Although	O
MyD88	B-GGP
(	I-GGP
S	I-GGP
)	I-GGP
still	O
binds	O
the	O
IL	B-GGP
-	I-GGP
1R	I-GGP
and	O
IRAK	B-GGP
,	O
it	O
is	O
defective	O
in	O
its	O
ability	O
to	O
induce	O
IRAK	B-GGP
phosphorylation	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

In	O
contrast	O
,	O
MyD88	B-GGP
(	I-GGP
S	I-GGP
)	I-GGP
behaves	O
as	O
a	O
dominant	O
-	O
negative	O
inhibitor	O
of	O
IL	B-GGP
-	I-GGP
1	I-GGP
-	O
and	O
LPS	B-MED
-	O
,	O
but	O
not	O
TNF	B-GGP
-	O
induced	O
,	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

These	O
results	O
implicate	O
the	O
ID	O
of	O
MyD88	B-GGP
in	O
the	O
phosphorylation	O
of	O
IRAK	B-GGP
.	O

Moreover	O
,	O
the	O
regulated	O
expression	O
and	O
antagonistic	O
activity	O
of	O
MyD88	B-GGP
(	I-GGP
S	I-GGP
)	I-GGP
suggest	O
an	O
important	O
role	O
for	O
alternative	O
splicing	O
of	O
MyD88	B-GGP
in	O
the	O
regulation	O
of	O
the	O
cellular	O
response	O
to	O
IL	B-GGP
-	I-GGP
1	I-GGP
and	O
LPS	B-MED
.	O

MSK1	B-GGP
and	O
MSK2	B-GGP
are	O
required	O
for	O
the	O
mitogen	O
-	O
and	O
stress	O
-	O
induced	O
phosphorylation	O
of	O
CREB	B-GGP
and	O
ATF1	B-GGP
in	O
fibroblasts	O
.	O

Using	O
mouse	O
knockouts	O
for	O
mitogen	B-GGP
-	I-GGP
and	I-GGP
stress	I-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
1	I-GGP
(	O
MSK1	B-GGP
)	O
and	O
MSK2	B-GGP
and	O
a	O
double	O
knockout	O
of	O
both	O
MSK1	B-GGP
and	O
MSK2	B-GGP
,	O
we	O
show	O
that	O
these	O
protein	O
kinases	O
are	O
required	O
for	O
the	O
stress	O
-	O
induced	O
phosphorylation	O
of	O
transcription	O
factors	O
CREB	B-GGP
and	O
ATF1	B-GGP
in	O
primary	O
embryonic	O
fibroblasts	O
.	O

In	O
contrast	O
mitogen	O
-	O
induced	O
phosphorylation	O
of	O
CREB	B-GGP
and	O
ATF1	B-GGP
is	O
greatly	O
reduced	O
but	O
not	O
totally	O
abolished	O
.	O

The	O
mitogen	O
-	O
and	O
stress	O
-	O
induced	O
phosphorylation	O
of	O
CREB	B-GGP
at	O
Ser133	B-MED
has	O
been	O
linked	O
to	O
the	O
transcription	O
of	O
several	O
immediate	O
early	O
genes	O
,	O
including	O
c	B-GGP
-	I-GGP
fos	I-GGP
,	O
junB	B-GGP
,	O
and	O
egr1	B-GGP
.	O

The	O
knockout	O
of	O
both	O
MSK1	B-GGP
and	O
MSK2	B-GGP
resulted	O
in	O
a	O
50	O
%	O
reduction	O
in	O
c	B-GGP
-	I-GGP
fos	I-GGP
and	O
junB	B-GGP
gene	O
transcription	O
in	O
response	O
to	O
anisomycin	B-MED
or	O
UV	O
-	O
C	O
radiation	O
but	O
only	O
a	O
small	O
reduction	O
in	O
response	O
to	O
tetradecanoyl	B-MED
phorbol	I-MED
acetate	I-MED
or	O
epidermal	B-GGP
growth	I-GGP
factor	I-GGP
in	O
fibroblasts	O
.	O

The	O
transcription	O
of	O
egr1	B-GGP
in	O
response	O
to	O
both	O
mitogenic	O
and	O
stress	O
stimuli	O
,	O
as	O
well	O
as	O
stress	O
-	O
induced	O
apoptosis	O
,	O
was	O
unaffected	O
in	O
the	O
MSK1	B-GGP
/	O
MSK2	B-GGP
double	O
knockout	O
.	O

E2F	B-GGP
mediates	O
cell	O
cycle	O
-	O
dependent	O
transcriptional	O
repression	O
in	O
vivo	O
by	O
recruitment	O
of	O
an	O
HDAC1	B-COM
/	I-COM
mSin3B	I-COM
corepressor	O
complex	O
.	O

Despite	O
biochemical	O
and	O
genetic	O
data	O
suggesting	O
that	O
E2F	B-GGP
and	O
pRB	B-GGP
(	O
pocket	O
protein	O
)	O
families	O
regulate	O
transcription	O
via	O
chromatin	B-CC
-	O
modifying	O
factors	O
,	O
the	O
precise	O
mechanisms	O
underlying	O
gene	O
regulation	O
by	O
these	O
protein	O
families	O
have	O
not	O
yet	O
been	O
defined	O
in	O
a	O
physiological	O
setting	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
promoter	O
occupancy	O
in	O
wild	O
-	O
type	O
and	O
pocket	O
protein	O
-	O
deficient	O
primary	O
cells	O
.	O

We	O
show	O
that	O
corepressor	O
complexes	O
consisting	O
of	O
histone	B-GGP
deacetylase	I-GGP
(	O
HDAC1	B-GGP
)	O
and	O
mSin3B	B-GGP
were	O
specifically	O
recruited	O
to	O
endogenous	O
E2F	B-GGP
-	O
regulated	O
promoters	O
in	O
quiescent	O
cells	O
.	O

These	O
complexes	O
dissociated	O
from	O
promoters	O
once	O
cells	O
reached	O
late	O
G1	O
,	O
coincident	O
with	O
gene	O
activation	O
.	O

Interestingly	O
,	O
recruitment	O
of	O
HDAC1	B-COM
complexes	I-COM
to	O
promoters	O
depended	O
absolutely	O
on	O
p107	B-GGP
and	O
p130	B-GGP
,	O
and	O
required	O
an	O
intact	O
E2F	B-GGP
-	O
binding	O
site	O
.	O

In	O
contrast	O
,	O
mSin3B	B-GGP
recruitment	O
to	O
certain	O
promoters	O
did	O
not	O
require	O
p107	B-GGP
or	O
p130	B-GGP
,	O
suggesting	O
that	O
recruitment	O
of	O
this	O
corepressor	O
can	O
occur	O
via	O
E2F	B-GGP
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O

Remarkably	O
,	O
loss	O
of	O
pRB	B-GGP
had	O
no	O
effect	O
on	O
HDAC1	B-GGP
or	O
mSin3B	B-GGP
recruitment	O
.	O

p107	B-GGP
/	O
p130	B-GGP
deficiency	O
triggered	O
a	O
dramatic	O
loss	O
of	O
E2F4	B-GGP
nuclear	B-CC
localization	O
as	O
well	O
as	O
transcriptional	O
derepression	O
,	O
which	O
is	O
suggested	O
by	O
nucleosome	B-CC
mapping	O
studies	O
to	O
be	O
the	O
result	O
of	O
localized	O
hyperacetylation	O
of	O
nucleosomes	B-CC
proximal	O
to	O
E2F	B-GGP
-	O
binding	O
sites	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
show	O
that	O
p130	B-GGP
escorts	O
E2F4	B-GGP
into	O
the	O
nucleus	B-CC
and	O
,	O
together	O
with	O
corepressor	O
complexes	O
that	O
contain	O
mSin3B	B-GGP
and	O
/	O
or	O
HDAC1	B-GGP
,	O
directly	O
represses	O
transcription	O
from	O
target	O
genes	O
as	O
cells	O
withdraw	O
from	O
the	O
cell	O
cycle	O
.	O

Kinetic	O
mechanism	O
of	O
activation	O
of	O
the	O
Cdk2	B-COM
/	I-COM
cyclin	I-COM
A	I-COM
complex	O
.	O

Key	O
role	O
of	O
the	O
C	O
-	O
lobe	O
of	O
the	O
Cdk	B-GGP
.	O

Eukaryotic	O
cell	O
cycle	O
progression	O
is	O
controlled	O
by	O
the	O
ordered	O
action	O
of	O
cyclin	B-GGP
-	I-GGP
dependent	I-GGP
kinases	I-GGP
,	O
activation	O
of	O
which	O
occurs	O
through	O
the	O
binding	O
of	O
the	O
cyclin	B-GGP
to	O
the	O
Cdk	B-GGP
followed	O
by	O
phosphorylation	O
of	O
a	O
conserved	O
threonine	B-MED
in	O
the	O
T	O
-	O
loop	O
of	O
the	O
Cdk	B-GGP
by	O
Cdk	B-GGP
-	I-GGP
activating	I-GGP
kinase	I-GGP
(	O
CAK	B-GGP
)	O
.	O

Despite	O
our	O
understanding	O
of	O
the	O
structural	O
changes	O
,	O
which	O
occur	O
upon	O
Cdk	B-COM
/	I-COM
cyclin	I-COM
formation	O
and	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
dynamics	O
of	O
the	O
molecular	O
events	O
involved	O
.	O

We	O
have	O
characterized	O
the	O
mechanism	O
of	O
Cdk2	B-COM
/	I-COM
cyclin	I-COM
A	I-COM
complex	O
formation	O
and	O
activation	O
at	O
the	O
molecular	O
and	O
dynamic	O
level	O
by	O
rapid	O
kinetics	O
and	O
demonstrate	O
here	O
that	O
it	O
is	O
a	O
two	O
-	O
step	O
process	O
.	O

The	O
first	O
step	O
involves	O
the	O
rapid	O
association	O
between	O
the	O
PSTAIRE	O
helix	O
of	O
Cdk2	B-GGP
and	O
helices	O
3	O
and	O
5	O
of	O
the	O
cyclin	B-GGP
to	O
yield	O
an	O
intermediate	O
complex	O
in	O
which	O
the	O
threonine	B-MED
in	O
the	O
T	O
-	O
loop	O
is	O
not	O
accessible	O
for	O
phosphorylation	O
.	O

Additional	O
contacts	O
between	O
the	O
C	O
-	O
lobe	O
of	O
the	O
Cdk	B-GGP
and	O
the	O
N	O
-	O
terminal	O
helix	O
of	O
the	O
cyclin	B-GGP
then	O
induce	O
the	O
isomerization	O
of	O
the	O
Cdk	B-GGP
into	O
a	O
fully	O
mature	O
form	O
by	O
promoting	O
the	O
exposure	O
of	O
the	O
T	O
-	O
loop	O
for	O
phosphorylation	O
by	O
CAK	B-GGP
and	O
the	O
formation	O
of	O
the	O
substrate	O
binding	O
site	O
.	O

This	O
conformational	O
change	O
is	O
selective	O
for	O
the	O
cyclin	B-GGP
partner	O
.	O

Divergence	O
of	O
apoptosis	O
-	O
inducing	O
and	O
preventing	O
signals	O
in	O
bacteria	O
-	O
faced	O
macrophages	O
through	O
myeloid	B-GGP
differentiation	I-GGP
factor	I-GGP
88	I-GGP
and	O
IL	B-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
-	I-GGP
associated	I-GGP
kinase	I-GGP
members	O
.	O

The	O
induction	O
of	O
apoptosis	O
in	O
host	O
cells	O
is	O
a	O
common	O
strategy	O
by	O
which	O
pathogenic	O
bacteria	O
interfere	O
with	O
the	O
host	O
immune	O
response	O
.	O

The	O
Yersinia	O
enterocolitica	O
outer	B-GGP
protein	I-GGP
P	I-GGP
(	O
YopP	B-GGP
)	O
inhibits	O
activation	O
of	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
in	O
macrophages	O
,	O
which	O
suppresses	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
-	O
dependent	O
antiapoptotic	O
activities	O
.	O

The	O
simultaneous	O
initiation	O
of	O
proapoptotic	O
signaling	O
by	O
yersiniae	O
infection	O
or	O
LPS	B-MED
treatment	O
results	O
in	O
macrophage	O
apoptosis	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
YopP	B-GGP
as	O
a	O
tool	O
to	O
dissect	O
survival	O
-	O
and	O
death	O
-	O
inducing	O
pathways	O
in	O
bacteria	O
-	O
faced	O
macrophages	O
.	O

We	O
cotransfected	O
J774A	O
.	O
1	O
macrophages	O
with	O
expression	O
plasmids	O
for	O
YopP	B-GGP
and	O
dominant	O
-	O
negative	O
mutants	O
of	O
signal	O
transmitters	O
of	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
cascade	O
downstream	O
from	O
the	O
LPS	B-COM
receptor	I-COM
complex	O
.	O

Dominant	O
-	O
negative	O
myeloid	B-GGP
differentiation	I-GGP
factor	I-GGP
88	I-GGP
(	O
MyD88	B-GGP
)	O
or	O
IL	B-GGP
-	I-GGP
1R	I-GGP
-	I-GGP
associated	I-GGP
kinase	I-GGP
(	I-GGP
IRAK	I-GGP
)	I-GGP
2	I-GGP
diminished	O
LPS	B-MED
-	O
induced	O
apoptosis	O
in	O
YopP	B-GGP
-	O
transfected	O
macrophages	O
,	O
suggesting	O
implication	O
of	O
MyD88	B-GGP
and	O
IRAK2	B-GGP
in	O
signaling	O
cell	O
death	O
.	O

In	O
contrast	O
,	O
dominant	O
-	O
negative	O
IRAK1	B-GGP
and	O
TNFR	B-GGP
-	I-GGP
associated	I-GGP
factor	I-GGP
6	I-GGP
(	O
TRAF6	B-GGP
)	O
did	O
not	O
provide	O
protection	O
,	O
but	O
augmented	O
LPS	B-MED
-	O
mediated	O
apoptosis	O
in	O
the	O
absence	O
of	O
YopP	B-GGP
,	O
which	O
indicates	O
roles	O
of	O
IRAK1	B-GGP
and	O
TRAF6	B-GGP
in	O
the	O
antiapoptotic	O
signal	O
relay	O
of	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
cascade	O
.	O

The	O
distinct	O
functions	O
of	O
IRAK	B-GGP
members	O
in	O
macrophage	O
survival	O
were	O
reflected	O
by	O
opposing	O
effects	O
of	O
dominant	O
-	O
negative	O
IRAK1	B-GGP
and	O
IRAK2	B-GGP
on	O
Y	O
.	O
enterocolitica	O
-	O
mediated	O
apoptosis	O
.	O

Yersiniae	O
-	O
and	O
LPS	B-MED
-	O
dependent	O
cell	O
death	O
were	O
substantially	O
attenuated	O
by	O
a	O
specific	O
caspase	B-GGP
-	I-GGP
8	I-GGP
inhibitory	O
peptide	O
or	O
by	O
dominant	O
negative	O
Fas	B-GGP
-	I-GGP
associated	I-GGP
death	I-GGP
domain	I-GGP
protein	I-GGP
(	O
FADD	B-GGP
)	O
.	O

This	O
suggests	O
,	O
that	O
Yersinia	O
-	O
induced	O
apoptosis	O
involves	O
a	O
proapoptotic	O
signal	O
relay	O
through	O
MyD88	B-GGP
and	O
IRAK2	B-GGP
,	O
which	O
potentially	O
targets	O
the	O
Fas	B-GGP
-	I-GGP
associated	I-GGP
death	I-GGP
domain	I-GGP
protein	I-GGP
/	O
caspase	B-GGP
-	I-GGP
8	I-GGP
apoptotic	O
pathway	O
,	O
whereas	O
IRAK1	B-GGP
and	O
TRAF6	B-GGP
counteract	O
the	O
bacteria	O
-	O
induced	O
cytotoxic	O
response	O
by	O
signaling	O
macrophage	O
survival	O
.	O

Glycosylphosphatidylinositol	B-GGP
-	I-GGP
anchored	I-GGP
mucin	I-GGP
-	I-GGP
like	I-GGP
glycoproteins	I-GGP
isolated	O
from	O
Trypanosoma	O
cruzi	O
trypomastigotes	O
induce	O
in	O
vivo	O
leukocyte	O
recruitment	O
dependent	O
on	O
MCP	B-GGP
-	I-GGP
1	I-GGP
production	O
by	O
IFN	B-GGP
-	I-GGP
gamma	I-GGP
-	O
primed	O
-	O
macrophages	O
.	O

Glycosylphosphatidylinositol	B-GGP
-	I-GGP
anchored	I-GGP
mucin	I-GGP
-	I-GGP
like	I-GGP
glycoproteins	I-GGP
from	O
Trypanosoma	O
cruzi	O
trypomastigotes	O
(	O
tGPI	B-GGP
-	I-GGP
mucins	I-GGP
)	O
activate	O
macrophages	O
in	O
vitro	O
to	O
produce	O
proinflammatory	O
cytokines	O
,	O
chemokines	O
,	O
and	O
nitric	B-MED
oxide	I-MED
.	O

These	O
effects	O
of	O
tGPI	B-GGP
-	I-GGP
mucins	I-GGP
may	O
be	O
important	O
in	O
the	O
ensuing	O
immune	O
response	O
to	O
T	O
.	O
cruzi	O
.	O

Here	O
,	O
we	O
have	O
sought	O
evidence	O
for	O
a	O
role	O
of	O
tGPI	B-GGP
-	I-GGP
mucins	I-GGP
in	O
mediating	O
leukocyte	O
recruitment	O
in	O
vivo	O
.	O

tGPI	B-GGP
-	I-GGP
mucins	I-GGP
are	O
highly	O
effective	O
in	O
promoting	O
cell	O
recruitment	O
in	O
the	O
pleural	O
cavity	O
of	O
mice	O
primed	O
with	O
IFN	B-GGP
-	I-GGP
gamma	I-GGP
-	O
inducing	O
agents	O
but	O
not	O
in	O
naive	O
mice	O
.	O

Maximal	O
recruitment	O
was	O
observed	O
at	O
a	O
dose	O
between	O
250	O
and	O
1250	O
ng	O
tGPI	B-GGP
-	I-GGP
mucins	I-GGP
.	O

There	O
was	O
a	O
significant	O
elevation	O
in	O
the	O
levels	O
of	O
MCP	B-GGP
-	I-GGP
1	I-GGP
in	O
the	O
pleural	O
cavity	O
of	O
primed	O
animals	O
injected	O
with	O
tGPI	B-GGP
-	I-GGP
mucins	I-GGP
,	O
and	O
in	O
vivo	O
neutralization	O
of	O
MCP	B-GGP
-	I-GGP
1	I-GGP
abolished	O
leukocyte	O
recruitment	O
.	O

Pretreatment	O
with	O
anti	O
-	O
MIP	B-GGP
-	I-GGP
1alpha	I-GGP
or	O
anti	O
-	O
RANTES	B-GGP
had	O
no	O
effect	O
on	O
the	O
recruitment	O
induced	O
by	O
tGPI	B-GGP
-	I-GGP
mucins	I-GGP
.	O

MCP	B-GGP
-	I-GGP
1	I-GGP
immunoreactivity	O
was	O
detected	O
in	O
pleural	O
macrophages	O
,	O
and	O
macrophages	O
produced	O
MCP	B-GGP
-	I-GGP
1	I-GGP
in	O
vitro	O
,	O
especially	O
after	O
priming	O
with	O
IFN	B-GGP
-	I-GGP
gamma	I-GGP
.	O

Finally	O
,	O
tGPI	B-GGP
-	I-GGP
mucins	I-GGP
induced	O
significant	O
leukocyte	O
recruitment	O
in	O
primed	O
C3H	O
/	O
HeJ	O
but	O
not	O
in	O
TLR2	B-GGP
-	O
deficient	O
mice	O
.	O

Together	O
,	O
our	O
results	O
suggest	O
that	O
T	O
.	O
cruzi	O
-	O
derived	O
GPI	B-GGP
-	I-GGP
mucins	I-GGP
in	O
conjunction	O
with	O
IFN	B-GGP
-	I-GGP
gamma	I-GGP
may	O
drive	O
tissue	O
chemokine	O
production	O
and	O
inflammation	O
and	O
bear	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
of	O
Chagas	O
disease	O
.	O

[	O
Study	O
of	O
the	O
effects	O
of	O
quercetin	B-MED
on	O
PML	B-GGP
gene	O
and	O
protein	O
expression	O
and	O
localization	O
in	O
leukemia	O
cells	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
PML	B-GGP
gene	O
and	O
protein	O
expression	O
and	O
localization	O
in	O
leukemia	O
cell	O
lines	O
.	O

METHODS	O
:	O
Cell	O
morphology	O
was	O
assayed	O
by	O
Wright	O
and	O
fluorescence	O
stain	O
,	O
PML	B-GGP
mRNA	O
expression	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
PML	B-GGP
protein	O
localization	O
by	O
immunofluorescence	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
Differentiation	O
was	O
observed	O
by	O
morphology	O
in	O
NB4	O
and	O
HL	O
-	O
60	O
cells	O
after	O
treatment	O
with	O
all	B-MED
-	I-MED
trans	I-MED
retinoic	I-MED
acid	I-MED
(	O
ATRA	B-MED
)	O
while	O
K562	O
cells	O
did	O
not	O
show	O
.	O

Apoptosis	O
was	O
found	O
in	O
each	O
cell	O
line	O
after	O
treatment	O
with	O
quercetin	B-MED
.	O

(	O
2	O
)	O
After	O
treatment	O
with	O
ATRA	B-MED
,	O
the	O
fusion	O
protein	O
disappeared	O
and	O
PML	B-GGP
protein	O
resumed	O
in	O
NB4	O
cells	O
,	O
while	O
in	O
HL	O
-	O
60	O
and	O
K562	O
cells	O
there	O
was	O
no	O
difference	O
from	O
control	O
cells	O
.	O

After	O
treatment	O
with	O
quercetin	B-MED
,	O
the	O
fusion	O
protein	O
disappeared	O
in	O
NB4	O
cells	O
,	O
then	O
degraded	O
,	O
and	O
so	O
did	O
in	O
HL	O
-	O
60	O
cells	O
and	O
K562	O
cells	O
.	O

(	O
3	O
)	O
The	O
expression	O
of	O
PML	B-GGP
mRNA	O
had	O
no	O
change	O
in	O
all	O
the	O
three	O
cell	O
lines	O
after	O
treatment	O
with	O
ATRA	B-MED
or	O
quercetin	B-MED
.	O

CONCLUSION	O
:	O
PML	B-GGP
plays	O
a	O
role	O
of	O
differentiation	O
and	O
apoptosis	O
induction	O
in	O
leukemia	O
cells	O
at	O
the	O
translational	O
level	O
.	O

PML	B-GGP
in	O
POD	O
plays	O
a	O
role	O
of	O
apoptosis	O
induction	O
and	O
growth	O
control	O
of	O
leukemia	O
cells	O
.	O

A	O
63	O
-	O
base	O
pair	O
DNA	O
segment	O
containing	O
an	O
Sp1	B-GGP
site	O
but	O
not	O
a	O
canonical	O
E2F	B-GGP
site	O
can	O
confer	O
growth	O
-	O
dependent	O
and	O
E2F	B-GGP
-	O
mediated	O
transcriptional	O
stimulation	O
of	O
the	O
human	O
ASK	B-GGP
gene	O
encoding	O
the	O
regulatory	O
subunit	O
for	O
human	O
Cdc7	B-GGP
-	I-GGP
related	I-GGP
kinase	I-GGP
.	O

Cdc7	B-COM
-	I-COM
Dbf4	I-COM
kinase	O
complexes	O
,	O
conserved	O
widely	O
in	O
eukaryotes	O
,	O
play	O
essential	O
roles	O
in	O
initiation	O
and	O
progression	O
of	O
the	O
S	O
phase	O
.	O

Cdc7	B-GGP
kinase	O
activity	O
fluctuates	O
during	O
cell	O
cycle	O
,	O
and	O
this	O
is	O
mainly	O
the	O
result	O
of	O
oscillation	O
of	O
expression	O
of	O
the	O
Dbf4	B-GGP
subunit	O
.	O

Therefore	O
,	O
it	O
is	O
crucial	O
to	O
understand	O
the	O
mechanisms	O
of	O
regulation	O
of	O
Dbf4	B-GGP
expression	O
.	O

We	O
have	O
isolated	O
and	O
characterized	O
the	O
promoter	O
region	O
of	O
the	O
human	O
ASK	B-GGP
gene	O
encoding	O
Dbf4	B-GGP
-	O
related	O
regulatory	O
subunit	O
for	O
human	O
Cdc7	B-GGP
kinase	O
.	O

We	O
have	O
identified	O
a	O
63	O
-	O
base	O
pair	O
ASK	B-GGP
promoter	O
segment	O
,	O
which	O
is	O
sufficient	O
for	O
mediating	O
growth	O
stimulation	O
.	O

This	O
minimal	O
promoter	O
segment	O
(	O
MP	O
)	O
,	O
containing	O
an	O
Sp1	B-GGP
site	O
but	O
no	O
canonical	O
E2F	B-GGP
site	O
,	O
can	O
be	O
activated	O
by	O
ectopic	O
E2F	B-GGP
expression	O
as	O
well	O
.	O

Within	O
the	O
63	O
-	O
base	O
pair	O
region	O
,	O
the	O
Sp1	B-GGP
site	O
as	O
well	O
as	O
other	O
elements	O
are	O
essential	O
for	O
stimulation	O
by	O
growth	O
signals	O
and	O
by	O
E2F	B-GGP
,	O
whereas	O
an	O
AT	O
-	O
rich	O
sequence	O
proximal	O
to	O
the	O
coding	O
region	O
may	O
serve	O
as	O
an	O
element	O
required	O
for	O
suppression	O
in	O
quiescence	O
.	O

Gel	O
shift	O
assays	O
in	O
the	O
presence	O
of	O
an	O
antibody	O
demonstrate	O
the	O
presence	O
of	O
E2F1	B-GGP
in	O
the	O
protein	O
-	O
DNA	O
complexes	O
generated	O
on	O
the	O
MP	O
segment	O
.	O

However	O
,	O
the	O
complex	O
formation	O
on	O
MP	O
was	O
not	O
competed	O
by	O
a	O
DHFR	B-GGP
promoter	O
fragment	O
,	O
known	O
to	O
bind	O
to	O
E2F	B-GGP
,	O
nor	O
by	O
a	O
consensus	O
E2F	B-GGP
binding	O
oligonucleotide	O
.	O

Gel	O
shift	O
assays	O
with	O
point	O
mutant	O
MP	O
fragments	O
indicate	O
that	O
a	O
non	O
-	O
canonical	O
E2F	B-GGP
site	O
in	O
the	O
middle	O
of	O
this	O
segment	O
is	O
critical	O
for	O
generation	O
of	O
the	O
E2F	B-COM
complex	I-COM
.	O

Our	O
results	O
suggest	O
that	O
E2F	B-GGP
regulates	O
the	O
ASK	B-GGP
promoter	O
through	O
an	O
atypical	O
mode	O
of	O
recognition	O
of	O
the	O
target	O
site	O
.	O

The	O
turn	O
motif	O
is	O
a	O
phosphorylation	O
switch	O
that	O
regulates	O
the	O
binding	O
of	O
Hsp70	B-GGP
to	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
.	O

Heat	O
shock	O
proteins	O
play	O
central	O
roles	O
in	O
ensuring	O
the	O
correct	O
folding	O
and	O
maturation	O
of	O
cellular	O
proteins	O
.	O

Here	O
we	O
show	O
that	O
the	O
heat	O
shock	O
protein	O
Hsp70	B-GGP
has	O
a	O
novel	O
role	O
in	O
prolonging	O
the	O
lifetime	O
of	O
activated	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
.	O

We	O
identified	O
Hsp70	B-GGP
in	O
a	O
screen	O
for	O
binding	O
partners	O
for	O
the	O
carboxyl	O
terminus	O
of	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
revealed	O
that	O
Hsp70	B-GGP
specifically	O
binds	O
the	O
unphosphorylated	O
turn	O
motif	O
(	O
Thr	B-MED
(	I-MED
641	I-MED
)	I-MED
in	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
beta	I-GGP
II	I-GGP
)	O
,	O
one	O
of	O
three	O
priming	O
sites	O
phosphorylated	O
during	O
the	O
maturation	O
of	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
family	O
members	O
.	O

The	O
interaction	O
of	O
Hsp70	B-GGP
with	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
can	O
be	O
abolished	O
in	O
vivo	O
by	O
co	O
-	O
expression	O
of	O
fusion	O
proteins	O
encoding	O
the	O
carboxyl	O
terminus	O
of	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
or	O
the	O
carboxyl	O
terminus	O
of	O
Hsp70	B-GGP
.	O

Pulse	O
-	O
chase	O
experiments	O
reveal	O
that	O
Hsp70	B-GGP
does	O
not	O
regulate	O
the	O
maturation	O
of	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
:	O
the	O
rate	O
of	O
processing	O
by	O
phosphorylation	O
is	O
the	O
same	O
in	O
the	O
presence	O
or	O
absence	O
of	O
disrupting	O
constructs	O
.	O

Rather	O
,	O
Hsp70	B-GGP
prolongs	O
the	O
lifetime	O
of	O
mature	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
;	O
disruption	O
of	O
the	O
interaction	O
promotes	O
the	O
accumulation	O
of	O
matured	O
and	O
then	O
dephosphorylated	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
in	O
the	O
detergent	O
-	O
insoluble	O
fraction	O
of	O
cells	O
.	O

Furthermore	O
,	O
studies	O
with	O
K562	O
cells	O
reveal	O
that	O
disruption	O
of	O
the	O
interaction	O
with	O
Hsp70	B-GGP
slows	O
the	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
beta	I-GGP
II	I-GGP
-	O
mediated	O
recovery	O
of	O
cells	O
from	O
PMA	O
-	O
induced	O
growth	O
arrest	O
.	O

Last	O
,	O
we	O
show	O
that	O
other	O
members	O
of	O
the	O
AGC	B-GGP
superfamily	O
(	O
Akt	B-GGP
/	O
protein	B-GGP
kinase	I-GGP
B	I-GGP
and	O
protein	B-GGP
kinase	I-GGP
A	I-GGP
)	O
also	O
bind	O
Hsp70	B-GGP
via	O
their	O
unphosphorylated	O
turn	O
motifs	O
.	O

Our	O
data	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
Hsp70	B-GGP
binds	O
the	O
dephosphorylated	O
carboxyl	O
terminus	O
of	O
mature	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
,	O
thus	O
stabilizing	O
the	O
protein	O
and	O
allowing	O
re	O
-	O
phosphorylation	O
of	O
the	O
enzyme	O
.	O

Disruption	O
of	O
this	O
interaction	O
prevents	O
re	O
-	O
phosphorylation	O
and	O
targets	O
the	O
enzyme	O
for	O
down	O
-	O
regulation	O
.	O

Homeostatic	O
control	O
of	O
uridine	B-MED
and	O
the	O
role	O
of	O
uridine	B-GGP
phosphorylase	I-GGP
:	O
a	O
biological	O
and	O
clinical	O
update	O
.	O

Uridine	B-MED
,	O
a	O
pyrimidine	B-MED
nucleoside	I-MED
essential	O
for	O
the	O
synthesis	O
of	O
RNA	O
and	O
bio	B-CC
-	I-CC
membranes	I-CC
,	O
is	O
a	O
crucial	O
element	O
in	O
the	O
regulation	O
of	O
normal	O
physiological	O
processes	O
as	O
well	O
as	O
pathological	O
states	O
.	O

The	O
biological	O
effects	O
of	O
uridine	B-MED
have	O
been	O
associated	O
with	O
the	O
regulation	O
of	O
the	O
cardio	O
-	O
circulatory	O
system	O
,	O
at	O
the	O
reproduction	O
level	O
,	O
with	O
both	O
peripheral	O
and	O
central	O
nervous	O
system	O
modulation	O
and	O
with	O
the	O
functionality	O
of	O
the	O
respiratory	O
system	O
.	O

Furthermore	O
,	O
uridine	B-MED
plays	O
a	O
role	O
at	O
the	O
clinical	O
level	O
in	O
modulating	O
the	O
cytotoxic	O
effects	O
of	O
fluoropyrimidines	B-MED
in	O
both	O
normal	O
and	O
neoplastic	O
tissues	O
.	O

The	O
concentration	O
of	O
uridine	B-MED
in	O
plasma	O
and	O
tissues	O
is	O
tightly	O
regulated	O
by	O
cellular	O
transport	O
mechanisms	O
and	O
by	O
the	O
activity	O
of	O
uridine	B-GGP
phosphorylase	I-GGP
(	O
UPase	B-GGP
)	O
,	O
responsible	O
for	O
the	O
reversible	O
phosphorolysis	O
of	O
uridine	B-MED
to	O
uracil	B-MED
.	O

We	O
have	O
recently	O
completed	O
several	O
studies	O
designed	O
to	O
define	O
the	O
mechanisms	O
regulating	O
UPase	B-GGP
expression	O
and	O
better	O
characterize	O
the	O
multiple	O
biological	O
effects	O
of	O
uridine	B-MED
.	O

Immunohistochemical	O
analysis	O
and	O
co	O
-	O
purification	O
studies	O
have	O
revealed	O
the	O
association	O
of	O
UPase	B-GGP
with	O
the	O
cytoskeleton	B-CC
and	O
the	O
cellular	B-CC
membrane	I-CC
.	O

The	O
characterization	O
of	O
the	O
promoter	O
region	O
of	O
UPase	B-GGP
has	O
indicated	O
a	O
direct	O
regulation	O
of	O
its	O
expression	O
by	O
the	O
tumor	O
suppressor	O
gene	O
p53	B-GGP
.	O

The	O
evaluation	O
of	O
human	O
surgical	O
specimens	O
has	O
shown	O
elevated	O
UPase	B-GGP
activity	O
in	O
tumor	O
tissue	O
compared	O
to	O
paired	O
normal	O
tissue	O
.	O

Potential	O
role	O
of	O
phosphatidylinositol	B-GGP
3	I-GGP
kinase	I-GGP
,	O
rather	O
than	O
DNA	B-COM
-	I-COM
dependent	I-COM
protein	I-COM
kinase	I-COM
,	O
in	O
CpG	O
DNA	O
-	O
induced	O
immune	O
activation	O
.	O

Unmethylated	O
CpG	O
motifs	O
present	O
in	O
bacterial	O
DNA	O
stimulate	O
a	O
strong	O
innate	O
immune	O
response	O
.	O

There	O
is	O
evidence	O
that	O
DNA	B-COM
-	I-COM
dependent	I-COM
protein	I-COM
kinase	I-COM
(	O
DNA	B-COM
-	I-COM
PK	I-COM
)	O
mediates	O
CpG	O
signaling	O
.	O

Specifically	O
,	O
wortmannin	B-MED
(	O
an	O
inhibitor	O
of	O
phosphatidylinositol	B-GGP
3	I-GGP
kinase	I-GGP
[	I-GGP
PI3	I-GGP
]	I-GGP
-	I-GGP
kinases	I-GGP
including	O
DNA	B-COM
-	I-COM
PK	I-COM
)	O
interferes	O
with	O
CpG	O
-	O
dependent	O
cell	O
activation	O
,	O
and	O
DNA	B-COM
-	I-COM
PK	I-COM
knockout	O
(	O
KO	O
)	O
mice	O
fail	O
to	O
respond	O
to	O
CpG	O
stimulation	O
.	O

Current	O
studies	O
establish	O
that	O
wortmannin	B-MED
actually	O
inhibits	O
the	O
uptake	O
and	O
colocalization	O
of	O
CpG	O
DNA	O
with	O
toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	I-GGP
TLR	I-GGP
)	I-GGP
-	I-GGP
9	I-GGP
in	O
endocytic	O
vesicles	B-CC
,	O
thereby	O
preventing	O
CpG	O
-	O
induced	O
activation	O
of	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
cascade	O
.	O

We	O
find	O
that	O
DNA	B-COM
-	I-COM
PK	I-COM
is	O
not	O
involved	O
in	O
this	O
process	O
,	O
since	O
three	O
strains	O
of	O
DNA	B-COM
-	I-COM
PK	I-COM
KO	O
mice	O
responded	O
normally	O
to	O
CpG	O
DNA	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
CpG	O
signaling	O
is	O
mediated	O
through	O
TLR	B-GGP
-	I-GGP
9	I-GGP
but	O
not	O
DNA	B-COM
-	I-COM
PK	I-COM
,	O
and	O
suggest	O
that	O
wortmannin	B-MED
-	O
sensitive	O
member	O
(	O
s	O
)	O
of	O
the	O
PI3	B-GGP
-	I-GGP
kinase	I-GGP
family	O
play	O
a	O
critical	O
role	O
in	O
shuttling	O
CpG	O
DNA	O
to	O
TLR	B-GGP
-	I-GGP
9	I-GGP
.	O

Transcriptional	O
regulation	O
of	O
the	O
mdm2	B-GGP
oncogene	O
by	O
p53	B-GGP
requires	O
TRRAP	B-COM
acetyltransferase	I-COM
complexes	O
.	O

The	O
p53	B-GGP
tumor	O
suppressor	O
regulates	O
the	O
cellular	O
response	O
to	O
genetic	O
damage	O
through	O
its	O
function	O
as	O
a	O
sequence	O
-	O
specific	O
transcription	O
factor	O
.	O

Among	O
the	O
most	O
well	O
-	O
characterized	O
transcriptional	O
targets	O
of	O
p53	B-GGP
is	O
the	O
mdm2	B-GGP
oncogene	O
.	O

Activation	O
of	O
mdm2	B-GGP
is	O
critical	O
in	O
the	O
p53	B-GGP
pathway	O
because	O
the	O
mdm2	B-GGP
protein	O
marks	O
p53	B-GGP
for	O
proteosome	O
-	O
mediated	O
degradation	O
,	O
thereby	O
providing	O
a	O
negative	O
-	O
feedback	O
loop	O
.	O

Here	O
we	O
show	O
that	O
the	O
ATM	O
-	O
related	O
TRRAP	B-GGP
protein	O
functionally	O
cooperates	O
with	O
p53	B-GGP
to	O
activate	O
mdm2	B-GGP
transcription	O
.	O

TRRAP	B-GGP
is	O
a	O
component	O
of	O
several	O
multiprotein	O
acetyltransferase	O
complexes	O
implicated	O
in	O
both	O
transcriptional	O
regulation	O
and	O
DNA	O
repair	O
.	O

In	O
support	O
of	O
a	O
role	O
for	O
these	O
complexes	O
in	O
mdm2	B-GGP
expression	O
,	O
we	O
show	O
that	O
transactivation	O
of	O
the	O
mdm2	B-GGP
gene	O
is	O
augmented	O
by	O
pharmacological	O
inhibition	O
of	O
cellular	O
deacetylases	O
.	O

In	O
vitro	O
analysis	O
demonstrates	O
that	O
p53	B-GGP
directly	O
binds	O
to	O
a	O
TRRAP	B-GGP
domain	O
previously	O
shown	O
to	O
be	O
an	O
activator	O
docking	O
site	O
.	O

Furthermore	O
,	O
transfection	O
of	O
cells	O
with	O
antisense	O
TRRAP	B-GGP
blocks	O
p53	B-GGP
-	O
dependent	O
transcription	O
of	O
mdm2	B-GGP
.	O

Finally	O
,	O
using	O
chromatin	B-CC
immunoprecipitation	O
,	O
we	O
demonstrate	O
direct	O
p53	B-GGP
-	O
dependent	O
recruitment	O
of	O
TRRAP	B-GGP
to	O
the	O
mdm2	B-GGP
promoter	O
,	O
followed	O
by	O
increased	O
histone	B-GGP
acetylation	O
.	O

These	O
findings	O
suggest	O
a	O
model	O
in	O
which	O
p53	B-GGP
directly	O
recruits	O
a	O
TRRAP	B-COM
/	I-COM
acetyltransferase	I-COM
complex	O
to	O
the	O
mdm2	B-GGP
gene	O
to	O
activate	O
transcription	O
.	O

In	O
addition	O
,	O
this	O
study	O
defines	O
a	O
novel	O
biochemical	O
mechanism	O
utilized	O
by	O
the	O
p53	B-GGP
tumor	O
suppressor	O
to	O
regulate	O
gene	O
expression	O
.	O

The	O
FKBP12	B-GGP
-	I-GGP
rapamycin	I-GGP
-	I-GGP
associated	I-GGP
protein	I-GGP
(	O
FRAP	B-GGP
)	O
is	O
a	O
CLIP	B-GGP
-	I-GGP
170	I-GGP
kinase	O
.	O

CLIP	B-GGP
-	I-GGP
170	I-GGP
/	O
Restin	B-GGP
belongs	O
to	O
a	O
family	O
of	O
conserved	O
microtubule	B-CC
(	O
MT	B-CC
)	O
-	O
associated	O
proteins	O
,	O
which	O
are	O
important	O
for	O
MT	B-CC
organization	O
and	O
functions	O
.	O

CLIP	B-GGP
-	I-GGP
170	I-GGP
is	O
a	O
phosphoprotein	O
and	O
phosphorylation	O
is	O
thought	O
to	O
regulate	O
the	O
binding	O
of	O
CLIP	B-GGP
-	I-GGP
170	I-GGP
to	O
MTs	B-CC
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
kinase	O
(	O
s	O
)	O
involved	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
FKBP12	B-GGP
-	I-GGP
rapamycin	I-GGP
-	I-GGP
associated	I-GGP
protein	I-GGP
(	O
FRAP	B-GGP
,	O
also	O
called	O
mTOR	B-GGP
/	O
RAFT	B-GGP
)	O
interacts	O
with	O
CLIP	B-GGP
-	I-GGP
170	I-GGP
.	O

CLIP	B-GGP
-	I-GGP
170	I-GGP
is	O
phosphorylated	O
in	O
vivo	O
at	O
multiple	O
sites	O
,	O
including	O
rapamycin	B-MED
-	O
sensitive	O
and	O
-	O
insensitive	O
sites	O
,	O
and	O
is	O
phosphorylated	O
by	O
FRAP	B-GGP
in	O
vitro	O
at	O
the	O
rapamycin	B-MED
-	O
sensitive	O
sites	O
.	O

In	O
addition	O
,	O
rapamycin	B-MED
inhibited	O
the	O
ability	O
of	O
CLIP	B-GGP
-	I-GGP
170	I-GGP
to	O
bind	O
to	O
MTs	B-CC
.	O

Our	O
observations	O
suggest	O
that	O
multiple	O
CLIP	B-GGP
-	I-GGP
170	I-GGP
kinases	O
are	O
involved	O
in	O
positive	O
and	O
negative	O
control	O
of	O
CLIP	B-GGP
-	I-GGP
170	I-GGP
,	O
and	O
FRAP	B-GGP
is	O
a	O
CLIP	B-GGP
-	I-GGP
170	I-GGP
kinase	O
positively	O
regulating	O
the	O
MT	B-CC
-	O
binding	O
behavior	O
of	O
CLIP	B-GGP
-	I-GGP
170	I-GGP
.	O

Opposing	O
regulatory	O
roles	O
of	O
E2F	B-GGP
in	O
human	B-GGP
telomerase	I-GGP
reverse	I-GGP
transcriptase	I-GGP
(	O
hTERT	B-GGP
)	O
gene	O
expression	O
in	O
human	O
tumor	O
and	O
normal	O
somatic	O
cells	O
.	O

Telomerase	B-COM
activity	O
is	O
closely	O
correlated	O
with	O
cellular	O
proliferative	O
activity	O
in	O
human	O
tissues	O
.	O

Human	O
cells	O
with	O
high	O
proliferative	O
potential	O
,	O
such	O
as	O
tumor	O
cells	O
or	O
stem	O
cells	O
,	O
exhibit	O
telomerase	B-COM
activity	O
,	O
whereas	O
most	O
normal	O
human	O
somatic	O
cells	O
do	O
not	O
.	O

Telomerase	B-COM
activity	O
is	O
tightly	O
regulated	O
by	O
the	O
expression	O
of	O
its	O
catalytic	O
subunit	O
human	B-GGP
telomerase	I-GGP
reverse	I-GGP
transcriptase	I-GGP
(	O
hTERT	B-GGP
)	O
.	O

Through	O
an	O
expression	O
cloning	O
approach	O
,	O
we	O
identified	O
E2F	B-GGP
-	I-GGP
1	I-GGP
as	O
a	O
repressor	O
of	O
the	O
hTERT	B-GGP
gene	O
in	O
human	O
tumor	O
cells	O
.	O

Ectopic	O
expression	O
of	O
E2F	B-GGP
-	I-GGP
1	I-GGP
repressed	O
hTERT	B-GGP
promoter	O
activity	O
by	O
inhibiting	O
Sp1	B-GGP
activation	O
of	O
the	O
hTERT	B-GGP
promoter	O
.	O

In	O
contrast	O
to	O
the	O
repressor	O
function	O
of	O
E2F	B-GGP
-	I-GGP
1	I-GGP
in	O
human	O
tumor	O
cells	O
,	O
we	O
demonstrated	O
that	O
E2F	B-GGP
-	I-GGP
1	I-GGP
is	O
an	O
activator	O
of	O
the	O
hTERT	B-GGP
gene	O
in	O
normal	O
human	O
somatic	O
cells	O
.	O

Ectopically	O
expressed	O
E2F	B-GGP
-	I-GGP
1	I-GGP
activated	O
the	O
hTERT	B-GGP
promoter	O
through	O
a	O
noncanonical	O
DNA	O
binding	O
site	O
.	O

E2F	B-GGP
-	I-GGP
1	I-GGP
,	O
E2F	B-GGP
-	I-GGP
2	I-GGP
,	O
and	O
E2F	B-GGP
-	I-GGP
3	I-GGP
(	O
but	O
not	O
E2F	B-GGP
-	I-GGP
4	I-GGP
and	O
E2F	B-GGP
-	I-GGP
5	I-GGP
)	O
repressed	O
hTERT	B-GGP
promoter	O
activity	O
in	O
human	O
tumor	O
cells	O
,	O
whereas	O
they	O
activated	O
it	O
in	O
normal	O
somatic	O
cells	O
.	O

These	O
contrasting	O
effects	O
of	O
E2F	B-GGP
transcription	O
factors	O
on	O
the	O
hTERT	B-GGP
promoter	O
could	O
underlie	O
the	O
paradoxical	O
biological	O
activities	O
of	O
E2F	B-GGP
,	O
which	O
can	O
both	O
promote	O
and	O
inhibit	O
cellular	O
proliferation	O
and	O
tumorigenesis	O
.	O

The	O
Doc1	B-GGP
subunit	O
is	O
a	O
processivity	O
factor	O
for	O
the	O
anaphase	B-COM
-	I-COM
promoting	I-COM
complex	I-COM
.	O

Ubiquitin	B-GGP
-	O
mediated	O
proteolysis	O
of	O
securin	B-GGP
and	O
mitotic	O
cyclins	B-GGP
is	O
essential	O
for	O
exit	O
from	O
mitosis	O
.	O

The	O
final	O
step	O
in	O
ubiquitination	O
of	O
these	O
and	O
other	O
proteins	O
is	O
catalysed	O
by	O
the	O
anaphase	B-COM
-	I-COM
promoting	I-COM
complex	I-COM
(	O
APC	B-COM
)	O
,	O
a	O
multi	O
-	O
subunit	O
ubiquitin	B-GGP
-	O
protein	O
ligase	O
(	O
E3	O
)	O
.	O

Little	O
is	O
known	O
about	O
the	O
molecular	O
reaction	O
resulting	O
in	O
APC	B-COM
-	O
dependent	O
substrate	O
ubiquitination	O
or	O
the	O
role	O
of	O
individual	O
APC	B-COM
subunits	O
in	O
the	O
reaction	O
.	O

Using	O
a	O
well	O
-	O
defined	O
in	O
vitro	O
system	O
,	O
we	O
show	O
that	O
highly	O
purified	O
APC	B-COM
from	O
Saccharomyces	O
cerevisiae	O
ubiquitinates	O
a	O
model	O
cyclin	B-GGP
substrate	O
in	O
a	O
processive	O
manner	O
.	O

Analysis	O
of	O
mutant	O
APC	B-COM
lacking	O
the	O
Doc1	B-GGP
/	O
Apc10	B-GGP
subunit	O
(	O
APC	B-COM
(	I-COM
doc1	I-COM
Delta	I-COM
)	I-COM
)	O
indicates	O
that	O
Doc1	B-GGP
is	O
required	O
for	O
processivity	O
.	O

The	O
specific	O
molecular	O
defect	O
in	O
APC	B-COM
(	I-COM
doc1	I-COM
Delta	I-COM
)	I-COM
is	O
identified	O
by	O
a	O
large	O
increase	O
in	O
apparent	O
K	O
(	O
M	O
)	O
for	O
the	O
cyclin	B-GGP
substrate	O
relative	O
to	O
the	O
wild	O
-	O
type	O
enzyme	O
.	O

This	O
suggests	O
that	O
Doc1	B-GGP
stimulates	O
processivity	O
by	O
limiting	O
substrate	O
dissociation	O
.	O

Addition	O
of	O
recombinant	O
Doc1	B-GGP
to	O
APC	B-COM
(	I-COM
doc1	I-COM
Delta	I-COM
)	I-COM
fully	O
restores	O
enzyme	O
function	O
.	O

Doc1	B-GGP
-	O
related	O
domains	O
are	O
found	O
in	O
mechanistically	O
distinct	O
ubiquitin	B-GGP
-	O
ligase	O
enzymes	O
and	O
may	O
generally	O
stimulate	O
ubiquitination	O
by	O
contributing	O
to	O
substrate	O
-	O
enzyme	O
affinity	O
.	O

Regulation	O
of	O
the	O
yeast	O
Rlm1	B-GGP
transcription	O
factor	O
by	O
the	O
Mpk1	B-GGP
cell	B-CC
wall	I-CC
integrity	O
MAP	B-GGP
kinase	I-GGP
.	O

The	O
Mpk1	B-GGP
MAP	B-GGP
kinase	I-GGP
of	O
the	O
Saccharomyces	O
cerevisiae	O
cell	B-CC
wall	I-CC
integrity	O
signalling	O
pathway	O
phosphorylates	O
and	O
activates	O
the	O
Rlm1	B-GGP
transcription	O
factor	O
in	O
response	O
to	O
cell	B-CC
wall	I-CC
stress	O
.	O

Rlm1	B-GGP
is	O
related	O
to	O
mammalian	O
MEF2	B-GGP
isoforms	O
,	O
and	O
shares	O
a	O
similar	O
DNA	O
-	O
binding	O
specificity	O
.	O

Signalling	O
through	O
Rlm1	B-GGP
regulates	O
the	O
expression	O
of	O
at	O
least	O
25	O
genes	O
,	O
most	O
of	O
which	O
have	O
been	O
implicated	O
in	O
cell	B-CC
wall	I-CC
biogenesis	O
.	O

We	O
report	O
here	O
the	O
transcriptional	O
induction	O
by	O
agents	O
of	O
cell	B-CC
wall	I-CC
stress	O
of	O
a	O
set	O
of	O
lacZ	B-GGP
reporter	O
plasmids	O
derived	O
from	O
several	O
Rlm1	B-GGP
-	O
responsive	O
genes	O
.	O

Analysis	O
of	O
substitution	O
mutations	O
at	O
putative	O
Mpk1	B-GGP
phosphorylation	O
sites	O
within	O
Rlm1	B-GGP
revealed	O
that	O
Ser427	B-MED
and	O
Thr439	B-MED
are	O
important	O
for	O
its	O
stress	O
-	O
induced	O
transcriptional	O
activation	O
of	O
these	O
reporter	O
plasmids	O
.	O

Assessment	O
of	O
Rlm1	B-GGP
activation	O
potency	O
when	O
fused	O
to	O
a	O
heterologous	O
DNA	O
-	O
binding	O
domain	O
showed	O
that	O
the	O
identified	O
seryl	B-MED
and	O
threonyl	B-MED
residues	O
are	O
necessary	O
for	O
the	O
Rlm1	B-GGP
transcriptional	O
activation	O
function	O
independently	O
of	O
its	O
DNA	O
binding	O
.	O

We	O
also	O
demonstrate	O
that	O
a	O
MAP	B-GGP
kinase	I-GGP
docking	O
site	O
,	O
shown	O
recently	O
to	O
mediate	O
activation	O
of	O
MEF2A	B-GGP
and	O
MEF2C	B-GGP
,	O
is	O
conserved	O
in	O
Rlm1	B-GGP
and	O
is	O
required	O
for	O
its	O
ability	O
to	O
mediate	O
transcriptional	O
activation	O
in	O
response	O
to	O
agents	O
that	O
induce	O
cell	B-CC
wall	I-CC
stress	O
.	O

Finally	O
,	O
intracellular	B-CC
localization	O
analyses	O
show	O
that	O
Rlm1	B-GGP
resides	O
in	O
the	O
nucleus	B-CC
regardless	O
of	O
its	O
activation	O
and	O
phosphorylation	O
status	O
.	O

Together	O
these	O
observations	O
support	O
the	O
inference	O
that	O
Mpk1	B-GGP
regulates	O
the	O
Rlm1	B-GGP
transcriptional	O
activation	O
function	O
by	O
phosphorylation	O
of	O
Ser427	B-MED
and	O
Thr439	B-MED
.	O

GTPase	B-GGP
-	I-GGP
activating	I-GGP
proteins	I-GGP
for	O
Cdc42	B-GGP
.	O

The	O
Rho	B-GGP
-	O
type	O
GTPase	O
,	O
Cdc42	B-GGP
,	O
has	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
functions	O
in	O
the	O
yeast	O
life	O
cycle	O
,	O
including	O
septin	B-GGP
organization	O
for	O
cytokinesis	O
,	O
pheromone	O
response	O
,	O
and	O
haploid	O
invasive	O
growth	O
.	O

A	O
group	O
of	O
proteins	O
called	O
GTPase	B-GGP
-	I-GGP
activating	I-GGP
proteins	I-GGP
(	O
GAPs	B-GGP
)	O
catalyze	O
the	O
hydrolysis	O
of	O
GTP	B-MED
to	O
GDP	B-MED
,	O
thereby	O
inactivating	O
Cdc42	B-GGP
.	O

At	O
the	O
time	O
this	O
study	O
began	O
,	O
there	O
was	O
one	O
known	O
GAP	B-GGP
,	O
Bem3	B-GGP
,	O
and	O
one	O
putative	O
GAP	B-GGP
,	O
Rga1	B-GGP
,	O
for	O
Cdc42	B-GGP
.	O

We	O
identified	O
another	O
putative	O
GAP	B-GGP
for	O
Cdc42	B-GGP
and	O
named	O
it	O
Rga2	B-GGP
(	O
Rho	B-GGP
GTPase	I-GGP
-	I-GGP
activating	I-GGP
protein	I-GGP
2	I-GGP
)	O
.	O

We	O
confirmed	O
by	O
genetic	O
and	O
biochemical	O
criteria	O
that	O
Rga1	B-GGP
,	O
Rga2	B-GGP
,	O
and	O
Bem3	B-GGP
act	O
as	O
GAPs	B-GGP
for	O
Cdc42	B-GGP
.	O

A	O
detailed	O
characterization	O
of	O
Rga1	B-GGP
,	O
Rga2	B-GGP
,	O
and	O
Bem3	B-GGP
suggested	O
that	O
they	O
regulate	O
different	O
subsets	O
of	O
Cdc42	B-GGP
function	O
.	O

In	O
particular	O
,	O
deletion	O
of	O
the	O
individual	O
GAPs	B-GGP
conferred	O
different	O
phenotypes	O
.	O

For	O
example	O
,	O
deletion	O
of	O
RGA1	B-GGP
,	O
but	O
not	O
RGA2	B-GGP
or	O
BEM3	B-GGP
,	O
caused	O
hyperinvasive	O
growth	O
.	O

Furthermore	O
,	O
overproduction	O
or	O
loss	O
of	O
Rga1	B-GGP
and	O
Rga2	B-GGP
,	O
but	O
not	O
Bem3	B-GGP
,	O
affected	O
the	O
two	O
-	O
hybrid	O
interaction	O
of	O
Cdc42	B-GGP
with	O
Ste20	B-GGP
,	O
a	O
p21	B-GGP
-	I-GGP
activated	I-GGP
kinase	I-GGP
(	I-GGP
PAK	I-GGP
)	I-GGP
kinase	I-GGP
required	O
for	O
haploid	O
invasive	O
growth	O
.	O

These	O
results	O
suggest	O
Rga1	B-GGP
,	O
and	O
possibly	O
Rga2	B-GGP
,	O
facilitate	O
the	O
interaction	O
of	O
Cdc42	B-GGP
with	O
Ste20	B-GGP
to	O
mediate	O
signaling	O
in	O
the	O
haploid	O
invasive	O
growth	O
pathway	O
.	O

Deletion	O
of	O
BEM3	B-GGP
resulted	O
in	O
cells	O
with	O
severe	O
morphological	O
defects	O
not	O
observed	O
in	O
rga1delta	B-GGP
or	O
rga2delta	B-GGP
strains	O
.	O

These	O
data	O
suggest	O
that	O
Bem3	B-GGP
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
Rga1	B-GGP
and	O
Rga2	B-GGP
facilitate	O
the	O
role	O
of	O
Cdc42	B-GGP
in	O
septin	B-GGP
organization	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
GAPs	B-GGP
play	O
a	O
role	O
in	O
modulating	O
specific	O
aspects	O
of	O
Cdc42	B-GGP
function	O
.	O

Alternatively	O
,	O
the	O
different	O
phenotypes	O
could	O
reflect	O
quantitative	O
rather	O
than	O
qualitative	O
differences	O
in	O
GAP	B-GGP
activity	O
in	O
the	O
mutant	O
strains	O
.	O

Linking	O
cyclins	B-GGP
to	O
transcriptional	O
control	O
.	O

Cell	O
cycle	O
activation	O
is	O
coordinated	O
by	O
D	B-GGP
-	I-GGP
type	I-GGP
cyclins	I-GGP
which	O
are	O
rate	O
limiting	O
and	O
essential	O
for	O
the	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

D	B-GGP
-	I-GGP
type	I-GGP
cyclins	I-GGP
bind	O
to	O
and	O
activate	O
the	O
cyclin	B-GGP
-	I-GGP
dependent	I-GGP
kinases	I-GGP
Cdk4	B-GGP
and	O
Cdk6	B-GGP
,	O
which	O
in	O
turn	O
phosphorylate	O
their	O
downstream	O
target	O
,	O
the	O
retinoblastoma	B-GGP
protein	I-GGP
Rb	B-GGP
.	O

Upon	O
Rb	B-GGP
phosphorylation	O
,	O
the	O
E2F	B-GGP
transcription	O
factors	O
activate	O
the	O
expression	O
of	O
S	O
-	O
phase	O
genes	O
and	O
thereby	O
induce	O
cell	O
cycle	O
progression	O
.	O

The	O
raise	O
of	O
cyclin	B-GGP
D	I-GGP
levels	O
in	O
early	O
G1	O
also	O
serves	O
to	O
titrate	O
Kip	B-GGP
/	I-GGP
Cip	I-GGP
proteins	O
away	O
from	O
cyclinE	B-COM
/	I-COM
Cdk2	I-COM
complexes	O
,	O
further	O
accelerating	O
cell	O
cycle	O
progression	O
.	O

Therefore	O
,	O
cyclin	B-GGP
D	I-GGP
plays	O
essential	O
roles	O
in	O
the	O
response	O
to	O
mitogens	O
,	O
transmitting	O
their	O
signal	O
to	O
the	O
Rb	B-GGP
/	O
E2F	B-GGP
pathway	O
.	O

Surprisingly	O
,	O
cyclin	B-GGP
D1	I-GGP
-	O
deficient	O
animals	O
are	O
viable	O
and	O
have	O
developmental	O
abnormalities	O
limited	O
to	O
restricted	O
tissues	O
,	O
such	O
as	O
retina	O
,	O
the	O
nervous	O
system	O
and	O
breast	O
epithelium	O
.	O

This	O
observation	O
,	O
combined	O
with	O
several	O
other	O
studies	O
,	O
have	O
raised	O
the	O
possibility	O
that	O
cyclin	B-GGP
D1	I-GGP
may	O
have	O
new	O
activities	O
that	O
are	O
unrelated	O
to	O
its	O
function	O
as	O
a	O
cdk	B-GGP
regulatory	O
subunit	O
and	O
as	O
regulator	O
of	O
Rb	B-GGP
.	O

Effectively	O
,	O
cyclin	B-GGP
D	I-GGP
has	O
been	O
reported	O
to	O
have	O
transcriptional	O
functions	O
since	O
it	O
interacts	O
with	O
several	O
transcription	O
factors	O
to	O
regulate	O
their	O
activity	O
.	O

Most	O
often	O
,	O
this	O
effect	O
does	O
not	O
rely	O
on	O
the	O
kinase	O
function	O
of	O
Cdk4	B-GGP
,	O
indicating	O
that	O
this	O
function	O
is	O
probably	O
independent	O
of	O
cell	O
cycle	O
progression	O
.	O

Further	O
extending	O
its	O
role	O
in	O
gene	O
regulation	O
,	O
cyclin	B-GGP
D	I-GGP
interacts	O
with	O
histone	B-GGP
acetylases	I-GGP
such	O
as	O
P	B-GGP
/	I-GGP
CAF	I-GGP
or	O
NcoA	B-GGP
/	O
SRC1a	B-GGP
but	O
also	O
with	O
components	O
of	O
the	O
transcriptional	O
machinery	O
such	O
as	O
TAF	B-GGP
(	I-GGP
II	I-GGP
)	I-GGP
250	I-GGP
.	O

Therefore	O
,	O
these	O
studies	O
suggest	O
that	O
the	O
functions	O
of	O
cyclin	B-GGP
D	I-GGP
might	O
need	O
to	O
be	O
reevaluated	O
.	O

They	O
have	O
established	O
a	O
new	O
cdk	B-GGP
-	O
independent	O
role	O
of	O
cyclin	B-GGP
D1	I-GGP
as	O
a	O
transcriptional	O
regulator	O
,	O
indicating	O
that	O
cyclin	B-GGP
D1	I-GGP
can	O
act	O
via	O
two	O
different	O
mechanisms	O
,	O
as	O
a	O
cdk	B-GGP
activator	O
it	O
regulates	O
cell	O
cycle	O
progression	O
and	O
as	O
a	O
transcriptional	O
regulator	O
,	O
it	O
modulates	O
the	O
activity	O
of	O
transcription	O
factors	O
.	O

The	O
transformation	O
suppressor	O
Pdcd4	B-GGP
is	O
a	O
novel	O
eukaryotic	B-GGP
translation	I-GGP
initiation	I-GGP
factor	I-GGP
4A	I-GGP
binding	O
protein	O
that	O
inhibits	O
translation	O
.	O

Pdcd4	B-GGP
is	O
a	O
novel	O
transformation	O
suppressor	O
that	O
inhibits	O
tumor	O
promoter	O
-	O
induced	O
neoplastic	O
transformation	O
and	O
the	O
activation	O
of	O
AP	B-GGP
-	I-GGP
1	I-GGP
-	O
dependent	O
transcription	O
required	O
for	O
transformation	O
.	O

A	O
yeast	O
two	O
-	O
hybrid	O
analysis	O
revealed	O
that	O
Pdcd4	B-GGP
associates	O
with	O
the	O
eukaryotic	O
translation	O
initiation	O
factors	O
eIF4AI	B-GGP
and	O
eIF4AII	B-GGP
.	O

Immunofluorescent	O
confocal	O
microscopy	O
showed	O
that	O
Pdcd4	B-GGP
colocalizes	O
with	O
eIF4A	B-GGP
in	O
the	O
cytoplasm	B-CC
.	O

eIF4A	B-GGP
is	O
an	O
ATP	B-MED
-	O
dependent	O
RNA	O
helicase	O
needed	O
to	O
unwind	O
5	O
'	O
mRNA	O
secondary	O
structure	O
.	O

Recombinant	O
Pdcd4	B-GGP
specifically	O
inhibited	O
the	O
helicase	O
activity	O
of	O
eIF4A	B-GGP
and	O
eIF4F	B-GGP
.	O

In	O
vivo	O
translation	O
assays	O
showed	O
that	O
Pdcd4	B-GGP
inhibited	O
cap	O
-	O
dependent	O
but	O
not	O
internal	O
ribosome	B-CC
entry	O
site	O
(	O
IRES	O
)	O
-	O
dependent	O
translation	O
.	O

In	O
contrast	O
,	O
Pdcd4	B-GGP
(	I-GGP
D418A	I-GGP
)	I-GGP
,	O
a	O
mutant	O
inactivated	O
for	O
binding	O
to	O
eIF4A	B-GGP
,	O
failed	O
to	O
inhibit	O
cap	O
-	O
dependent	O
or	O
IRES	O
-	O
dependent	O
translation	O
or	O
AP	B-GGP
-	I-GGP
1	I-GGP
transactivation	O
.	O

Recombinant	O
Pdcd4	B-GGP
prevented	O
eIF4A	B-GGP
from	O
binding	O
to	O
the	O
C	O
-	O
terminal	O
region	O
of	O
eIF4G	B-GGP
(	O
amino	B-MED
acids	I-MED
1040	I-MED
to	O
1560	B-MED
)	O
but	O
not	O
to	O
the	O
middle	O
region	O
of	O
eIF4G	B-GGP
(	O
amino	B-MED
acids	I-MED
635	I-MED
to	O
1039	B-MED
)	O
.	O

In	O
addition	O
,	O
both	O
Pdcd4	B-GGP
and	O
Pdcd4	B-GGP
(	I-GGP
D418A	I-GGP
)	I-GGP
bound	O
to	O
the	O
middle	O
region	O
of	O
eIF4G	B-GGP
.	O

The	O
mechanism	O
by	O
which	O
Pdcd4	B-GGP
inhibits	O
translation	O
thus	O
appears	O
to	O
involve	O
inhibition	O
of	O
eIF4A	B-GGP
helicase	O
,	O
interference	O
with	O
eIF4A	B-GGP
association	O
-	O
dissociation	O
from	O
eIF4G	B-GGP
,	O
and	O
inhibition	O
of	O
eIF4A	B-GGP
binding	O
to	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
eIF4G	B-GGP
.	O

Pdcd4	B-GGP
binding	O
to	O
eIF4A	B-GGP
is	O
linked	O
to	O
its	O
transformation	O
-	O
suppressing	O
activity	O
,	O
as	O
Pdcd4	B-GGP
-	O
eIF4A	B-GGP
binding	O
and	O
consequent	O
inhibition	O
of	O
translation	O
are	O
required	O
for	O
Pdcd4	B-GGP
transrepression	O
of	O
AP	B-GGP
-	I-GGP
1	I-GGP
.	O

The	O
tuberin	B-COM
-	I-COM
hamartin	I-COM
complex	O
negatively	O
regulates	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
activity	O
.	O

Tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
is	O
characterized	O
by	O
the	O
formation	O
of	O
hamartomas	O
in	O
multiple	O
organs	O
resulting	O
from	O
mutations	O
in	O
the	O
TSC1	B-GGP
or	O
TSC2	B-GGP
gene	O
.	O

Their	O
protein	O
products	O
,	O
hamartin	B-GGP
and	O
tuberin	B-GGP
,	O
respectively	O
,	O
form	O
a	O
functional	O
complex	O
that	O
affects	O
cell	O
growth	O
,	O
differentiation	O
,	O
and	O
proliferation	O
.	O

Several	O
lines	O
of	O
evidence	O
,	O
including	O
renal	O
tumors	O
derived	O
from	O
TSC2	B-GGP
+	O
/	O
-	O
animals	O
,	O
suggest	O
that	O
the	O
loss	O
or	O
inhibition	O
of	O
tuberin	B-GGP
is	O
associated	O
with	O
up	O
-	O
regulation	O
of	O
cyclin	B-GGP
D1	I-GGP
.	O

As	O
cyclin	B-GGP
D1	I-GGP
can	O
be	O
regulated	O
through	O
the	O
canonical	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
pathway	O
,	O
we	O
hypothesize	O
that	O
the	O
cell	O
proliferative	O
effects	O
of	O
hamartin	B-GGP
and	O
tuberin	B-GGP
are	O
partly	O
mediated	O
through	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
.	O

In	O
this	O
study	O
,	O
total	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
protein	O
levels	O
were	O
found	O
to	O
be	O
elevated	O
in	O
the	O
TSC2	B-GGP
-	O
related	O
renal	O
tumors	O
.	O

Ectopic	O
expression	O
of	O
hamartin	B-GGP
and	O
wild	O
-	O
type	O
tuberin	B-GGP
,	O
but	O
not	O
mutant	O
tuberin	B-GGP
,	O
reduced	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
steady	O
-	O
state	O
levels	O
and	O
its	O
half	O
-	O
life	O
.	O

The	O
TSC1	B-COM
-	I-COM
TSC2	I-COM
complex	O
also	O
inhibited	O
Wnt	B-GGP
-	I-GGP
1	I-GGP
stimulated	O
Tcf	B-GGP
/	O
LEF	B-GGP
luciferase	B-GGP
reporter	O
activity	O
.	O

This	O
inhibition	O
was	O
eliminated	O
by	O
constitutively	O
active	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
but	O
not	O
by	O
Disheveled	B-GGP
,	O
suggesting	O
that	O
hamartin	B-GGP
and	O
tuberin	B-GGP
function	O
at	O
the	O
level	O
of	O
the	O
beta	B-COM
-	I-COM
catenin	I-COM
degradation	I-COM
complex	I-COM
.	O

Indeed	O
,	O
hamartin	B-GGP
and	O
tuberin	B-GGP
co	O
-	O
immunoprecipitated	O
with	O
glycogen	B-GGP
synthase	I-GGP
kinase	I-GGP
3	I-GGP
beta	I-GGP
and	O
Axin	B-GGP
,	O
components	O
of	O
this	O
complex	O
in	O
a	O
Wnt	B-GGP
-	I-GGP
1	I-GGP
-	O
dependent	O
manner	O
.	O

Our	O
data	O
suggest	O
that	O
hamartin	B-GGP
and	O
tuberin	B-GGP
negatively	O
regulate	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
stability	O
and	O
activity	O
by	O
participating	O
in	O
the	O
beta	B-COM
-	I-COM
catenin	I-COM
degradation	I-COM
complex	I-COM
.	O

Phosphorylation	O
of	O
Raf	B-GGP
-	I-GGP
1	I-GGP
by	O
p21	B-GGP
-	I-GGP
activated	I-GGP
kinase	I-GGP
1	I-GGP
and	O
Src	B-GGP
regulates	O
Raf	B-GGP
-	I-GGP
1	I-GGP
autoinhibition	O
.	O

Exposure	O
of	O
cells	O
to	O
mitogens	O
or	O
growth	O
factors	O
stimulates	O
Raf	B-GGP
-	I-GGP
1	I-GGP
activity	O
through	O
a	O
complex	O
mechanism	O
that	O
involves	O
binding	O
to	O
active	O
Ras	B-GGP
,	O
phosphorylation	O
on	O
multiple	O
residues	O
,	O
and	O
protein	O
-	O
protein	O
interactions	O
.	O

Recently	O
it	O
was	O
shown	O
that	O
the	O
amino	O
terminus	O
of	O
Raf	B-GGP
-	I-GGP
1	I-GGP
contains	O
an	O
autoregulatory	O
domain	O
that	O
can	O
inhibit	O
its	O
activity	O
in	O
Xenopus	O
oocytes	O
.	O

In	O
the	O
present	O
work	O
we	O
show	O
that	O
expression	O
of	O
the	O
Raf	B-GGP
-	I-GGP
1	I-GGP
autoinhibitory	O
domain	O
blocks	O
extracellular	B-GGP
signal	I-GGP
-	I-GGP
regulated	I-GGP
kinase	I-GGP
2	I-GGP
activation	O
by	O
the	O
Raf	B-GGP
-	I-GGP
1	I-GGP
catalytic	O
domain	O
in	O
mammalian	O
cells	O
.	O

We	O
also	O
show	O
that	O
phosphorylation	O
of	O
Raf	B-GGP
-	I-GGP
1	I-GGP
on	O
serine	B-MED
338	I-MED
by	O
PAK1	B-GGP
and	O
tyrosines	B-MED
340	I-MED
and	O
341	B-MED
by	O
Src	B-GGP
relieves	O
autoinhibition	O
and	O
that	O
this	O
occurs	O
through	O
a	O
specific	O
decrease	O
in	O
the	O
binding	O
of	O
the	O
Raf	B-GGP
-	I-GGP
1	I-GGP
regulatory	O
domain	O
to	O
its	O
catalytic	O
domain	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
phosphorylation	O
of	O
threonine	B-MED
491	I-MED
and	O
serine	B-MED
494	I-MED
,	O
two	O
phosphorylation	O
sites	O
in	O
the	O
catalytic	O
domain	O
that	O
are	O
required	O
for	O
Raf	B-GGP
-	I-GGP
1	I-GGP
activation	O
,	O
is	O
unlikely	O
to	O
regulate	O
autoinhibition	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
autoinhibitory	O
domain	O
of	O
Raf	B-GGP
-	I-GGP
1	I-GGP
is	O
functional	O
in	O
mammalian	O
cells	O
and	O
that	O
its	O
interaction	O
with	O
the	O
Raf	B-GGP
-	I-GGP
1	I-GGP
catalytic	O
domain	O
is	O
regulated	O
by	O
phosphorylation	O
of	O
serine	B-MED
338	I-MED
and	O
tyrosines	B-MED
340	I-MED
and	O
341	B-MED
.	O

Structure	O
-	O
function	O
analysis	O
of	O
the	O
A20	B-GGP
-	I-GGP
binding	I-GGP
inhibitor	I-GGP
of	I-GGP
NF	I-GGP
-	I-GGP
kappa	I-GGP
B	I-GGP
activation	I-GGP
,	O
ABIN	B-GGP
-	I-GGP
1	I-GGP
.	O

Nuclear	B-COM
factor	I-COM
kappa	I-COM
B	I-COM
(	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
)	O
-	O
dependent	O
gene	O
expression	O
plays	O
an	O
important	O
role	O
in	O
numerous	O
cellular	O
processes	O
including	O
stress	O
responses	O
,	O
inflammation	O
and	O
cell	O
proliferation	O
.	O

Therefore	O
,	O
the	O
activity	O
of	O
this	O
transcription	O
factor	O
needs	O
to	O
be	O
tightly	O
regulated	O
.	O

Among	O
others	O
,	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
-	O
dependent	O
zinc	B-MED
finger	O
protein	O
A20	B-GGP
is	O
involved	O
in	O
the	O
negative	O
feedback	O
regulation	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
activation	O
in	O
response	O
to	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
(	O
TNF	B-GGP
)	O
.	O

We	O
previously	O
demonstrated	O
that	O
A20	B-GGP
can	O
interact	O
with	O
A20	B-GGP
-	I-GGP
binding	I-GGP
inhibitors	I-GGP
of	I-GGP
NF	I-GGP
-	I-GGP
kappa	I-GGP
B	I-GGP
activation	I-GGP
(	O
ABINs	B-GGP
)	O
,	O
which	O
have	O
the	O
potential	O
to	O
inhibit	O
TNF	B-GGP
-	O
induced	O
activation	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
upon	O
overexpression	O
.	O

The	O
ABIN	B-GGP
proteins	O
were	O
therefore	O
proposed	O
to	O
mediate	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
inhibiting	O
function	O
of	O
A20	B-GGP
.	O

Here	O
we	O
demonstrate	O
the	O
presence	O
of	O
a	O
short	O
homologous	O
region	O
in	O
ABINs	B-GGP
and	O
I	B-GGP
kappa	I-GGP
B	I-GGP
kinase	I-GGP
gamma	I-GGP
,	O
the	O
regulatory	O
subunit	O
of	O
the	O
I	B-COM
kappa	I-COM
B	I-COM
kinase	I-COM
complex	O
.	O

Site	O
-	O
specific	O
mutagenesis	O
of	O
this	O
region	O
abolished	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
inhibiting	O
function	O
of	O
ABIN	B-GGP
-	I-GGP
1	I-GGP
,	O
without	O
affecting	O
the	O
interaction	O
with	O
A20	B-GGP
.	O

Furthermore	O
,	O
coexpression	O
of	O
these	O
ABIN	B-GGP
-	I-GGP
1	I-GGP
mutants	O
interfered	O
in	O
a	O
dominant	O
negative	O
manner	O
with	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
inhibiting	O
function	O
of	O
ABIN	B-GGP
-	I-GGP
1	I-GGP
,	O
whereas	O
the	O
A20	B-GGP
-	O
mediated	O
inhibition	O
was	O
unaffected	O
.	O

These	O
results	O
suggest	O
that	O
A20	B-GGP
and	O
ABIN	B-GGP
-	I-GGP
1	I-GGP
probably	O
act	O
independently	O
of	O
their	O
mutual	O
interaction	O
.	O

The	O
C	O
terminus	O
of	O
initiation	B-GGP
factor	I-GGP
4E	I-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
1	I-GGP
contains	O
multiple	O
regulatory	O
features	O
that	O
influence	O
its	O
function	O
and	O
phosphorylation	O
.	O

Eukaryotic	B-GGP
initiation	I-GGP
factor	I-GGP
4E	I-GGP
(	O
eIF4E	B-GGP
)	O
binds	O
the	O
mRNA	O
cap	O
structure	O
and	O
forms	O
eIF4F	B-COM
complexes	O
that	O
recruit	O
40S	O
subunits	O
to	O
the	O
mRNA	O
.	O

Formation	O
of	O
eIF4F	B-COM
is	O
blocked	O
by	O
eIF4E	B-GGP
-	O
binding	O
proteins	O
such	O
as	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
,	O
which	O
interacts	O
with	O
eIF4E	B-GGP
via	O
a	O
motif	O
in	O
the	O
center	O
of	O
its	O
118	O
-	O
residue	O
sequence	O
.	O

4E	B-GGP
-	I-GGP
BP1	I-GGP
plays	O
key	O
roles	O
in	O
cell	O
proliferation	O
,	O
growth	O
,	O
and	O
survival	O
.	O

Binding	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
to	O
eIF4E	B-GGP
is	O
regulated	O
by	O
hierarchical	O
multisite	O
phosphorylation	O
.	O

Here	O
we	O
demonstrate	O
that	O
three	O
different	O
features	O
in	O
the	O
C	O
terminus	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
play	O
distinct	O
roles	O
in	O
regulating	O
its	O
phosphorylation	O
and	O
function	O
.	O

Firstly	O
,	O
we	O
identify	O
a	O
new	O
phosphorylation	O
site	O
in	O
its	O
C	O
terminus	O
(	O
S101	B-MED
)	O
.	O

A	O
serine	B-MED
or	O
glutamate	B-MED
at	O
this	O
position	O
is	O
required	O
for	O
efficient	O
phosphorylation	O
at	O
Ser65	B-MED
.	O

A	O
second	O
C	O
-	O
terminal	O
site	O
,	O
S112	B-MED
,	O
directly	O
affects	O
binding	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
to	O
eIF4E	B-GGP
without	O
influencing	O
phosphorylation	O
of	O
other	O
sites	O
.	O

Thirdly	O
,	O
a	O
conserved	O
C	O
-	O
terminal	O
motif	O
influences	O
phosphorylation	O
of	O
multiple	O
residues	O
,	O
including	O
rapamycin	B-MED
-	O
insensitive	O
sites	O
.	O

These	O
relatively	O
long	O
-	O
range	O
effects	O
are	O
surprising	O
given	O
the	O
reportedly	O
unstructured	O
nature	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
and	O
may	O
imply	O
that	O
phosphorylation	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
and	O
/	O
or	O
binding	O
to	O
eIF4E	B-GGP
induces	O
a	O
more	O
-	O
ordered	O
structure	O
.	O

4E	B-GGP
-	I-GGP
BP2	I-GGP
and	O
-	B-GGP
3	I-GGP
lack	O
phosphorylatable	O
residues	O
corresponding	O
to	O
both	O
S101	B-MED
and	O
S112	B-MED
.	O

However	O
,	O
in	O
4E	B-GGP
-	I-GGP
BP3	I-GGP
,	O
replacement	O
of	O
the	O
alanine	B-MED
at	O
the	O
position	O
corresponding	O
to	O
S112	B-MED
by	O
serine	B-MED
or	O
glutamate	B-MED
did	O
not	O
confer	O
the	O
ability	O
to	O
be	O
released	O
from	O
eIF4E	B-GGP
in	O
response	O
to	O
insulin	B-GGP
.	O

Regulation	O
of	O
the	O
cyclin	B-GGP
D3	I-GGP
promoter	O
by	O
E2F1	B-GGP
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
E2F1	B-GGP
is	O
sufficient	O
to	O
drive	O
quiescent	O
cells	O
into	O
S	O
phase	O
and	O
that	O
E2F1	B-GGP
expression	O
can	O
contribute	O
to	O
oncogenic	O
transformation	O
.	O

Key	O
target	O
genes	O
in	O
this	O
process	O
include	O
master	O
regulators	O
of	O
the	O
cell	O
cycle	O
,	O
such	O
as	O
cyclin	B-GGP
E	I-GGP
,	O
which	O
regulates	O
G	O
(	O
1	O
)	O
progression	O
,	O
and	O
cyclin	B-GGP
A	I-GGP
,	O
which	O
is	O
required	O
for	O
the	O
initiation	O
of	O
DNA	O
synthesis	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
present	O
novel	O
evidence	O
that	O
a	O
second	O
G	O
(	O
1	O
)	O
cyclin	B-GGP
,	O
cyclin	B-GGP
D3	I-GGP
,	O
is	O
also	O
potently	O
activated	O
by	O
E2F1	B-GGP
.	O

First	O
,	O
an	O
estrogen	B-GGP
receptor	I-GGP
-	I-GGP
E2F1	I-GGP
fusion	O
protein	O
(	O
ER	B-GGP
-	I-GGP
E2F1	I-GGP
)	O
potently	O
activates	O
the	O
endogenous	O
cyclin	B-GGP
D3	I-GGP
mRNA	O
upon	O
treatment	O
with	O
4	B-MED
-	I-MED
hydroxytamoxifen	I-MED
,	O
which	O
induces	O
nuclear	B-CC
accumulation	O
of	O
the	O
otherwise	O
cytosolic	B-CC
fusion	O
protein	O
.	O

Furthermore	O
,	O
trans	O
-	O
activation	O
of	O
cyclin	B-GGP
D3	I-GGP
by	O
ER	B-GGP
-	I-GGP
E2F1	I-GGP
occurs	O
even	O
in	O
the	O
presence	O
of	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	B-MED
and	O
thus	O
appears	O
direct	O
.	O

Second	O
,	O
all	O
of	O
the	O
growth	O
-	O
stimulatory	O
members	O
of	O
the	O
E2F	B-GGP
family	O
(	O
E2F1	B-GGP
,	O
-	B-GGP
2	I-GGP
,	O
and	O
-	B-GGP
3A	I-GGP
)	O
potently	O
activate	O
a	O
cyclin	B-GGP
D3	I-GGP
promoter	O
reporter	O
,	O
whereas	O
growth	O
-	O
restraining	O
members	O
of	O
the	O
family	O
(	O
E2F4	B-GGP
,	O
-	B-GGP
5	I-GGP
,	O
and	O
-	B-GGP
6	I-GGP
)	O
have	O
little	O
effect	O
.	O

Third	O
,	O
recombinant	O
E2F1	B-GGP
binds	O
with	O
high	O
affinity	O
to	O
the	O
cyclin	B-GGP
D3	I-GGP
promoter	O
in	O
vitro	O
.	O

Fourth	O
,	O
chromatin	B-CC
immunoprecipitation	O
assays	O
demonstrate	O
that	O
endogenous	O
E2F1	B-GGP
is	O
associated	O
with	O
the	O
cyclin	B-GGP
D3	I-GGP
promoter	O
in	O
vivo	O
.	O

Finally	O
,	O
mapping	O
experiments	O
localize	O
the	O
essential	O
E2F	B-GGP
regulatory	O
element	O
of	O
the	O
cyclin	B-GGP
D3	I-GGP
promoter	O
to	O
a	O
noncanonical	O
E2F	B-GGP
site	O
in	O
the	O
promoter	O
between	O
nucleotides	O
-	O
143	O
and	O
-	O
135	O
relative	O
to	O
the	O
initiating	O
methionine	B-MED
codon	O
.	O

We	O
conclude	O
that	O
in	O
addition	O
to	O
cyclins	B-GGP
E	I-GGP
and	O
A	B-GGP
,	O
E2F	B-GGP
family	O
members	O
can	O
also	O
activate	O
one	O
member	O
of	O
the	O
D	B-GGP
-	I-GGP
type	I-GGP
cyclins	I-GGP
,	O
further	O
contributing	O
to	O
the	O
ability	O
of	O
the	O
stimulatory	O
E2F	B-GGP
family	O
members	O
to	O
drive	O
cellular	O
proliferation	O
.	O

Phosphatidylinositol	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
is	O
involved	O
in	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
4	I-GGP
-	O
mediated	O
cytokine	O
expression	O
in	O
mouse	O
macrophages	O
.	O

Recent	O
evidence	O
suggests	O
a	O
role	O
for	O
phosphatidylinositol	B-GGP
(	I-GGP
PI	I-GGP
)	I-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
in	O
various	O
inflammatory	O
responses	O
.	O

In	O
this	O
study	O
,	O
the	O
consequences	O
of	O
LPS	B-MED
-	O
induced	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
activation	O
on	O
cytokine	O
and	O
chemokine	O
expression	O
and	O
the	O
intracellular	B-CC
mechanisms	O
of	O
inflammatory	O
activation	O
were	O
examined	O
in	O
mouse	O
macrophages	O
.	O

LPS	B-MED
stimulation	O
induced	O
a	O
complex	O
formation	O
between	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
and	O
myeloid	B-GGP
differentiation	I-GGP
factor	I-GGP
88	I-GGP
(	O
MyD88	B-GGP
)	O
,	O
which	O
was	O
followed	O
by	O
an	O
induction	O
of	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
,	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
-	I-GGP
alpha	I-GGP
(	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
)	O
and	O
macrophage	B-GGP
inflammatory	I-GGP
protein	I-GGP
(	I-GGP
MIP	I-GGP
)	I-GGP
-	I-GGP
2	I-GGP
.	O

The	O
induction	O
of	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
,	O
but	O
not	O
of	O
MIP	B-GGP
-	I-GGP
2	I-GGP
or	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
,	O
was	O
blocked	O
by	O
the	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
inhibitors	O
LY294002	B-MED
and	O
wortmannin	B-MED
.	O

The	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
(	O
NF	B-COM
-	I-COM
kappaB	I-COM
)	O
inhibitor	O
pyrrolidinedithiocarbamate	B-MED
(	O
PDTC	B-MED
)	O
blocked	O
the	O
induction	O
of	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
and	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
,	O
but	O
had	O
no	O
effect	O
on	O
MIP	B-GGP
-	I-GGP
2	I-GGP
expression	O
.	O

Inhibition	O
of	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
decreased	O
the	O
LPS	B-MED
-	O
induced	O
transcriptional	O
activity	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
but	O
it	O
had	O
no	O
effect	O
on	O
the	O
nuclear	B-CC
DNA	O
binding	O
activity	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

These	O
findings	O
suggest	O
that	O
,	O
while	O
NF	B-COM
-	I-COM
kappaB	I-COM
nuclear	B-CC
localization	O
and	O
DNA	O
binding	O
are	O
necessary	O
,	O
they	O
are	O
not	O
sufficient	O
for	O
transcriptional	O
activation	O
of	O
the	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
gene	O
in	O
the	O
absence	O
of	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
activity	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
activation	O
of	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	I-GGP
TLR	I-GGP
)	I-GGP
-	I-GGP
4	I-GGP
results	O
in	O
PI	B-COM
3	I-COM
-	I-COM
kinase	I-COM
-	I-COM
MyD88	I-COM
complex	O
formation	O
,	O
and	O
that	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
activity	O
selectively	O
leads	O
to	O
cytokine	O
induction	O
downstream	O
of	O
TLR4	B-GGP
.	O

14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3beta	I-GGP
is	O
a	O
p90	B-GGP
ribosomal	I-GGP
S6	I-GGP
kinase	I-GGP
(	I-GGP
RSK	I-GGP
)	I-GGP
isoform	I-GGP
1	I-GGP
-	O
binding	O
protein	O
that	O
negatively	O
regulates	O
RSK	B-GGP
kinase	O
activity	O
.	O

p90	B-GGP
ribosomal	I-GGP
S6	I-GGP
kinase	I-GGP
1	I-GGP
(	O
RSK1	B-GGP
)	O
is	O
a	O
serine	B-MED
/	O
threonine	B-MED
kinase	O
that	O
is	O
activated	O
by	O
extracellular	B-GGP
signal	I-GGP
-	I-GGP
related	I-GGP
kinases	I-GGP
1	I-GGP
/	I-GGP
2	I-GGP
and	O
phosphoinositide	B-GGP
-	I-GGP
dependent	I-GGP
protein	I-GGP
kinase	I-GGP
1	I-GGP
upon	O
mitogen	O
stimulation	O
.	O

Under	O
basal	O
conditions	O
,	O
RSK1	B-GGP
is	O
located	O
in	O
the	O
cytosol	B-CC
and	O
upon	O
stimulation	O
,	O
RSK1	B-GGP
translocates	O
to	O
the	O
plasma	B-CC
membrane	I-CC
where	O
it	O
is	O
fully	O
activated	O
.	O

The	O
ability	O
of	O
RSK1	B-GGP
to	O
bind	O
the	O
adapter	O
protein	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3beta	I-GGP
was	O
investigated	O
because	O
RSK1	B-GGP
contains	O
several	O
putative	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
-	O
binding	O
motifs	O
.	O

We	O
demonstrate	O
that	O
RSK1	B-GGP
specifically	O
and	O
directly	O
binds	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3beta	I-GGP
.	O

This	O
interaction	O
was	O
dependent	O
on	O
phosphorylation	O
of	O
serine	B-MED
154	I-MED
within	O
the	O
motif	O
RLSKEV	O
of	O
RSK1	B-GGP
.	O

Binding	O
of	O
RSK1	B-GGP
to	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3beta	I-GGP
was	O
maximal	O
under	O
basal	O
conditions	O
and	O
decreased	O
significantly	O
upon	O
mitogen	O
stimulation	O
.	O

After	O
5	O
min	O
of	O
serum	O
stimulation	O
,	O
a	O
portion	O
of	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3beta	I-GGP
and	O
RSK1	B-GGP
translocated	O
to	O
the	O
membrane	B-CC
fraction	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
colocalization	O
of	O
RSK1	B-GGP
and	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3beta	I-GGP
at	O
the	O
plasma	B-CC
membrane	I-CC
in	O
vivo	O
.	O

Incubation	O
of	O
recombinant	O
RSK1	B-GGP
with	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3beta	I-GGP
decreased	O
RSK1	B-GGP
kinase	O
activity	O
by	O
approximately	O
50	O
%	O
.	O

Mutation	O
of	O
RSK1	B-GGP
serine	B-MED
154	I-MED
increased	O
both	O
basal	O
and	O
serum	O
-	O
stimulated	O
RSK	B-GGP
activity	O
.	O

In	O
addition	O
,	O
the	O
epidermal	O
growth	O
factor	O
response	O
of	O
RSK1S154A	B-GGP
was	O
enhanced	O
compared	O
with	O
wild	O
type	O
RSK	B-GGP
.	O

The	O
amount	O
of	O
RSK1S154A	B-GGP
was	O
significantly	O
increased	O
in	O
the	O
membrane	B-CC
fraction	O
under	O
basal	O
conditions	O
.	O

Increased	O
phosphorylation	O
of	O
two	O
sites	O
essential	O
for	O
RSK1	B-GGP
kinase	O
activity	O
(	O
Ser	B-MED
(	I-MED
380	I-MED
)	I-MED
and	O
Ser	B-MED
(	I-MED
363	I-MED
)	I-MED
)	O
in	O
RSK1S154A	B-GGP
compared	O
with	O
RSK1	B-GGP
wild	O
type	O
,	O
demonstrated	O
that	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
interferes	O
with	O
RSK1	B-GGP
phosphorylation	O
.	O

These	O
data	O
suggest	O
that	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3beta	I-GGP
binding	O
negatively	O
regulates	O
RSK1	B-GGP
activity	O
to	O
maintain	O
signal	O
specificity	O
and	O
that	O
association	O
/	O
dissociation	O
of	O
the	O
14	B-COM
-	I-COM
3	I-COM
-	I-COM
3beta	I-COM
-	I-COM
RSK1	I-COM
complex	O
is	O
likely	O
to	O
be	O
important	O
for	O
mitogen	O
-	O
mediated	O
RSK1	B-GGP
activation	O
.	O

E2F1	B-GGP
activates	O
the	O
human	O
p53	B-GGP
promoter	O
and	O
overcomes	O
the	O
repressive	O
effect	O
of	O
hepatitis	B-GGP
B	I-GGP
viral	I-GGP
X	I-GGP
protein	I-GGP
(	O
Hbx	B-GGP
)	O
on	O
the	O
p53	B-GGP
promoter	O
.	O

The	O
functional	O
effect	O
of	O
the	O
interaction	O
of	O
E2F1	B-GGP
and	O
hepatitis	B-GGP
B	I-GGP
virus	I-GGP
X	I-GGP
protein	I-GGP
(	O
HBx	B-GGP
)	O
on	O
the	O
promoter	O
of	O
human	O
p53	B-GGP
gene	O
was	O
studied	O
using	O
chloramphenicol	B-GGP
acetyl	I-GGP
transferase	I-GGP
(	O
CAT	B-GGP
)	O
assay	O
.	O

E2F1	B-GGP
activated	O
the	O
p53	B-GGP
promoter	O
through	O
E2F1	B-GGP
binding	O
site	O
.	O

As	O
previously	O
reported	O
,	O
HBx	B-GGP
repressed	O
the	O
p53	B-GGP
promoter	O
through	O
E	O
-	O
box	O
.	O

When	O
E2F1	B-GGP
was	O
cotransfected	O
with	O
HBx	B-GGP
,	O
E2F1	B-GGP
overcame	O
the	O
repressive	O
effect	O
of	O
HBx	B-GGP
on	O
the	O
p53	B-GGP
promoter	O
through	O
the	O
E2F1	B-GGP
site	O
.	O

However	O
,	O
in	O
the	O
thymidine	B-GGP
kinase	I-GGP
(	O
tk	B-GGP
)	O
heterologous	O
promoter	O
system	O
with	O
the	O
E2F1	B-GGP
binding	O
sites	O
,	O
cotransfection	O
of	O
E2F1	B-GGP
and	O
HBx	B-GGP
showed	O
a	O
strong	O
synergistic	O
activation	O
.	O

An	O
in	O
vitro	O
interaction	O
assay	O
showed	O
that	O
E2F1	B-GGP
and	O
HBx	B-GGP
physically	O
bind	O
with	O
each	O
other	O
.	O

Analyses	O
of	O
the	O
interaction	O
domain	O
with	O
the	O
GAL4	B-GGP
fusion	O
protein	O
showed	O
that	O
the	O
pRb	B-GGP
-	O
binding	O
domain	O
of	O
E2F1	B-GGP
was	O
necessary	O
for	O
the	O
functional	O
interaction	O
of	O
these	O
two	O
proteins	O
.	O

Taken	O
together	O
,	O
these	O
results	O
imply	O
the	O
functional	O
inhibitory	O
action	O
of	O
E2F1	B-GGP
on	O
the	O
HBV	O
life	O
cycle	O
and	O
HBV	O
-	O
mediated	O
hepatocellular	O
carcinogenesis	O
(	O
HCC	O
)	O
.	O

Therefore	O
,	O
the	O
normal	O
or	O
enhanced	O
function	O
of	O
E2F1	B-GGP
gene	O
would	O
be	O
important	O
in	O
controlling	O
the	O
HBx	B-GGP
function	O
in	O
HCC	O
.	O

Phosphorylation	O
-	O
dependent	O
regulation	O
of	O
septin	B-GGP
dynamics	O
during	O
the	O
cell	O
cycle	O
.	O

Septins	B-GGP
are	O
GTPases	O
involved	O
in	O
cytokinesis	O
.	O

In	O
yeast	O
,	O
they	O
form	O
a	O
ring	O
at	O
the	O
cleavage	O
site	O
.	O

Using	O
FRAP	O
,	O
we	O
show	O
that	O
septins	B-GGP
are	O
mobile	O
within	O
the	O
ring	O
at	O
bud	B-CC
emergence	O
and	O
telophase	O
and	O
are	O
immobile	O
during	O
S	O
,	O
G2	O
,	O
and	O
M	O
phases	O
.	O

Immobilization	O
of	O
the	O
septins	B-GGP
is	O
dependent	O
on	O
both	O
Cla4	B-GGP
,	O
a	O
PAK	B-GGP
-	I-GGP
like	I-GGP
kinase	I-GGP
,	O
and	O
Gin4	B-GGP
,	O
a	O
septin	B-GGP
-	O
dependent	O
kinase	O
that	O
can	O
phosphorylate	O
the	O
septin	B-GGP
Shs1	B-GGP
/	O
Sep7	B-GGP
.	O

Induction	O
of	O
septin	B-GGP
ring	O
dynamics	O
in	O
telophase	O
is	O
triggered	O
by	O
the	O
translocation	O
of	O
Rts1	B-GGP
,	O
a	O
kinetochore	B-CC
-	O
associated	O
regulatory	O
subunit	O
of	O
PP2A	B-COM
phosphatase	O
,	O
to	O
the	O
bud	B-CC
neck	I-CC
and	O
correlates	O
with	O
Rts1	B-GGP
-	O
dependent	O
dephosphorylation	O
of	O
Shs1	B-GGP
.	O

In	O
rts1	B-GGP
-	O
Delta	O
cells	O
,	O
the	O
actomyosin	B-COM
ring	O
contracts	O
properly	O
but	O
cytokinesis	O
fails	O
.	O

Together	O
our	O
results	O
implicate	O
septins	B-GGP
in	O
a	O
late	O
step	O
of	O
cytokinesis	O
and	O
indicate	O
that	O
proper	O
regulation	O
of	O
septin	B-GGP
dynamics	O
,	O
possibly	O
through	O
the	O
control	O
of	O
their	O
phosphorylation	O
state	O
,	O
is	O
required	O
for	O
the	O
completion	O
of	O
cytokinesis	O
.	O

The	O
role	O
of	O
disulfide	O
bonds	O
in	O
the	O
assembly	O
and	O
function	O
of	O
MD	B-GGP
-	I-GGP
2	I-GGP
.	O

MD	B-GGP
-	I-GGP
2	I-GGP
is	O
a	O
secreted	O
glycoprotein	O
that	O
binds	O
to	O
the	O
extracellular	B-CC
domain	O
of	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
4	I-GGP
(	O
TLR4	B-GGP
)	O
and	O
is	O
required	O
for	O
the	O
activation	O
of	O
TLR4	B-GGP
by	O
lipopolysaccharide	B-MED
(	O
LPS	B-MED
)	O
.	O

The	O
protein	O
contains	O
seven	O
Cys	B-MED
residues	O
and	O
consists	O
of	O
a	O
heterogeneous	O
collection	O
of	O
disulfide	O
-	O
linked	O
oligomers	O
.	O

To	O
investigate	O
the	O
role	O
of	O
sulfhydryls	B-MED
in	O
MD	B-GGP
-	I-GGP
2	I-GGP
structure	O
and	O
function	O
,	O
we	O
created	O
17	O
single	O
and	O
multiple	O
Cys	B-MED
substitution	O
mutants	O
.	O

All	O
of	O
the	O
MD	B-GGP
-	I-GGP
2	I-GGP
mutant	O
proteins	O
,	O
including	O
one	O
totally	O
lacking	O
Cys	B-MED
residues	O
,	O
were	O
secreted	O
and	O
stable	O
.	O

SDSPAGE	O
analyses	O
indicated	O
that	O
most	O
Cys	B-MED
residues	O
could	O
participate	O
in	O
oligomer	O
formation	O
and	O
that	O
no	O
single	O
Cys	B-MED
residue	O
was	O
required	O
for	O
oligomerization	O
.	O

Of	O
the	O
single	O
Cys	B-MED
substitutions	O
,	O
only	O
C95S	O
and	O
C105S	O
failed	O
to	O
confer	O
LPS	B-MED
responsiveness	O
on	O
TLR4	B-GGP
when	O
mutant	O
and	O
TLR4	B-GGP
were	O
cotransfected	O
into	O
cells	O
expressing	O
an	O
NF	B-COM
-	I-COM
kappaB	I-COM
reporter	O
plasmid	O
.	O

Surprisingly	O
,	O
substitution	O
of	O
both	O
C95	B-MED
and	O
C105	B-MED
partially	O
restored	O
activity	O
.	O

Structural	O
analyses	O
revealed	O
that	O
C95	B-MED
and	O
C105	B-MED
formed	O
an	O
intrachain	O
disulfide	O
bond	O
,	O
whereas	O
C95	B-MED
by	O
itself	O
produced	O
an	O
inactive	O
dimer	O
.	O

In	O
contrast	O
to	O
the	O
cotransfection	O
experiments	O
,	O
only	O
WT	O
MD	B-GGP
-	I-GGP
2	I-GGP
conferred	O
responsiveness	O
to	O
LPS	B-MED
when	O
secreted	O
proteins	O
were	O
added	O
directly	O
to	O
TLR4	B-GGP
reporter	O
cells	O
.	O

Our	O
data	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
most	O
,	O
possibly	O
all	O
sulfhydryls	B-MED
lie	O
on	O
the	O
surface	O
of	O
a	O
stable	O
MD	B-GGP
-	I-GGP
2	I-GGP
core	O
structure	O
where	O
they	O
form	O
both	O
intra	O
-	O
and	O
interchain	O
disulfide	O
bridges	O
.	O

These	O
disulfide	O
bonds	O
produce	O
a	O
heterogeneous	O
array	O
of	O
oligomers	O
,	O
including	O
some	O
species	O
that	O
can	O
form	O
an	O
active	O
complex	O
with	O
TLR4	B-GGP
.	O

The	O
activation	O
of	O
c	B-GGP
-	I-GGP
Jun	I-GGP
NH2	I-GGP
-	I-GGP
terminal	I-GGP
kinase	I-GGP
(	O
JNK	B-GGP
)	O
by	O
DNA	O
-	O
damaging	O
agents	O
serves	O
to	O
promote	O
drug	O
resistance	O
via	O
activating	B-GGP
transcription	I-GGP
factor	I-GGP
2	I-GGP
(	O
ATF2	B-GGP
)	O
-	O
dependent	O
enhanced	O
DNA	O
repair	O
.	O

The	O
activating	B-GGP
transcription	I-GGP
factor	I-GGP
2	I-GGP
(	O
ATF2	B-GGP
)	O
is	O
a	O
member	O
of	O
the	O
ATF	B-GGP
/	I-GGP
cAMP	I-GGP
-	I-GGP
response	I-GGP
element	I-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
family	O
of	O
basic	O
-	O
leucine	B-MED
zipper	O
proteins	O
involved	O
in	O
cellular	O
stress	O
response	O
.	O

The	O
transcription	O
potential	O
of	O
ATF2	B-GGP
is	O
enhanced	O
markedly	O
by	O
NH2	O
-	O
terminal	O
phosphorylation	O
by	O
c	B-GGP
-	I-GGP
Jun	I-GGP
NH2	I-GGP
-	I-GGP
terminal	I-GGP
kinase	I-GGP
(	O
JNK	B-GGP
)	O
and	O
mediates	O
stress	O
responses	O
including	O
DNA	O
-	O
damaging	O
events	O
.	O

We	O
have	O
observed	O
that	O
four	O
DNA	O
-	O
damaging	O
agents	O
(	O
cisplatin	B-MED
,	O
actinomycin	B-MED
D	I-MED
,	O
MMS	B-MED
,	O
and	O
etoposide	B-MED
)	O
,	O
but	O
not	O
the	O
cisplatin	B-MED
isomer	O
,	O
transplatin	B-MED
,	O
which	O
does	O
not	O
readily	O
damage	O
DNA	O
,	O
strongly	O
activate	O
JNK	B-GGP
,	O
p38	B-GGP
,	O
and	O
extracellular	B-GGP
signal	I-GGP
-	I-GGP
regulated	I-GGP
kinase	I-GGP
(	O
ERK	B-GGP
)	O
,	O
and	O
strongly	O
increase	O
phosphorylation	O
and	O
ATF2	B-GGP
-	O
dependent	O
transcriptional	O
activity	O
.	O

Selective	O
inhibition	O
studies	O
with	O
PD98059	B-MED
,	O
SB202190	B-MED
,	O
SP600125	B-MED
,	O
and	O
the	O
dominant	O
negative	O
JNK	B-GGP
indicate	O
that	O
activation	O
of	O
JNK	B-GGP
but	O
not	O
p38	B-GGP
kinase	O
or	O
ERK	B-GGP
kinase	O
is	O
required	O
for	O
the	O
phosphorylation	O
and	O
transcriptional	O
activation	O
of	O
ATF2	B-GGP
.	O

Stable	O
expression	O
of	O
ATF2	B-GGP
in	O
human	O
breast	O
carcinoma	O
BT474	O
cells	O
increases	O
transcriptional	O
activity	O
and	O
confers	O
resistance	O
to	O
the	O
four	O
DNA	O
-	O
damaging	O
agents	O
,	O
but	O
not	O
to	O
transplatin	B-MED
.	O

Conversely	O
,	O
stable	O
expression	O
of	O
a	O
dominant	O
negative	O
ATF2	B-GGP
(	O
dnATF2	B-GGP
)	O
quantitatively	O
blocks	O
phosphorylation	O
of	O
endogenous	O
ATF2	B-GGP
leading	O
to	O
a	O
marked	O
decrease	O
in	O
transcriptional	O
activity	O
by	O
endogenous	O
ATF2	B-GGP
and	O
a	O
markedly	O
increased	O
sensitivity	O
to	O
the	O
four	O
agents	O
as	O
judged	O
by	O
decreased	O
cell	O
viability	O
.	O

Similarly	O
,	O
application	O
of	O
SB202190	B-MED
at	O
50	O
micro	O
m	O
or	O
SP600125	B-MED
inhibited	O
JNK	B-GGP
activity	O
,	O
blocked	O
transactivation	O
,	O
and	O
sensitized	O
parental	O
cells	O
to	O
the	O
four	O
DNA	O
-	O
damaging	O
drugs	O
.	O

Moreover	O
,	O
the	O
wild	O
type	O
ATF2	B-GGP
-	O
expressing	O
clones	O
exhibited	O
rapid	O
DNA	O
repair	O
after	O
treatment	O
with	O
the	O
four	O
DNA	O
-	O
damaging	O
agents	O
but	O
not	O
transplatin	B-MED
.	O

Conversely	O
,	O
expression	O
of	O
dnATF2	B-GGP
quantitatively	O
blocks	O
DNA	O
repair	O
.	O

These	O
results	O
indicate	O
that	O
JNK	B-GGP
-	O
dependent	O
phosphorylation	O
of	O
ATF2	B-GGP
plays	O
an	O
important	O
role	O
in	O
the	O
drug	O
resistance	O
phenotype	O
likely	O
by	O
mediating	O
enhanced	O
DNA	O
repair	O
by	O
a	O
p53	B-GGP
-	O
independent	O
mechanism	O
.	O

JNK	B-GGP
may	O
be	O
a	O
rational	O
target	O
for	O
sensitizing	O
tumor	O
cells	O
to	O
DNA	O
-	O
damaging	O
chemotherapy	O
agents	O
.	O

NPAT	B-GGP
expression	O
is	O
regulated	O
by	O
E2F	B-GGP
and	O
is	O
essential	O
for	O
cell	O
cycle	O
progression	O
.	O

NPAT	B-GGP
is	O
an	O
in	O
vivo	O
substrate	O
of	O
cyclin	B-COM
E	I-COM
-	I-COM
Cdk2	I-COM
kinase	O
and	O
is	O
thought	O
to	O
play	O
a	O
critical	O
role	O
in	O
coordinated	O
transcriptional	O
activation	O
of	O
histone	B-GGP
genes	O
during	O
the	O
G	O
(	O
1	O
)	O
/	O
S	O
-	O
phase	O
transition	O
and	O
in	O
S	O
-	O
phase	O
entry	O
in	O
mammalian	O
cells	O
.	O

Here	O
we	O
show	O
that	O
NPAT	B-GGP
transcription	O
is	O
up	O
-	O
regulated	O
at	O
the	O
G	O
(	O
1	O
)	O
/	O
S	O
-	O
phase	O
boundary	O
in	O
growth	O
-	O
stimulated	O
cells	O
and	O
that	O
the	O
NPAT	B-GGP
promoter	O
responds	O
to	O
activation	O
by	O
E2F	B-GGP
proteins	O
.	O

We	O
demonstrate	O
that	O
endogenous	O
E2F	B-GGP
proteins	O
interact	O
with	O
the	O
promoter	O
of	O
the	O
NPAT	B-GGP
gene	O
in	O
vivo	O
and	O
that	O
induced	O
expression	O
of	O
E2F1	B-GGP
stimulates	O
NPAT	B-GGP
mRNA	O
expression	O
,	O
supporting	O
the	O
idea	O
that	O
the	O
expression	O
of	O
NPAT	B-GGP
is	O
regulated	O
by	O
E2F	B-GGP
.	O

Consistently	O
,	O
we	O
find	O
that	O
the	O
E2F	B-GGP
sites	O
in	O
the	O
NPAT	B-GGP
promoter	O
are	O
required	O
for	O
its	O
activation	O
during	O
the	O
G	O
(	O
1	O
)	O
/	O
S	O
-	O
phase	O
transition	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
NPAT	B-GGP
accelerates	O
S	O
-	O
phase	O
entry	O
in	O
cells	O
released	O
from	O
quiescence	O
.	O

The	O
inhibition	O
of	O
NPAT	B-GGP
expression	O
by	O
small	O
interfering	O
RNA	O
duplexes	O
impedes	O
cell	O
cycle	O
progression	O
and	O
histone	B-GGP
gene	O
expression	O
in	O
tissue	O
culture	O
cells	O
.	O

Thus	O
,	O
NPAT	B-GGP
is	O
an	O
important	O
E2F	B-GGP
target	O
that	O
is	O
required	O
for	O
cell	O
cycle	O
progression	O
in	O
mammalian	O
cells	O
.	O

As	O
NPAT	B-GGP
is	O
involved	O
in	O
the	O
regulation	O
of	O
S	O
-	O
phase	O
-	O
specific	O
histone	B-GGP
gene	O
transcription	O
,	O
our	O
findings	O
indicate	O
that	O
NPAT	B-GGP
links	O
E2F	B-GGP
to	O
the	O
activation	O
of	O
S	O
-	O
phase	O
-	O
specific	O
histone	B-GGP
gene	O
transcription	O
.	O

Effects	O
of	O
red	O
orpiment	O
on	O
cell	O
morphology	O
and	O
expression	O
of	O
PML	B-GGP
mRNA	O
and	O
protein	O
in	O
NB4	O
and	O
HL	O
-	O
60	O
cells	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
red	O
orpiment	O
on	O
cell	O
morphology	O
,	O
expression	O
of	O
promyelocytic	B-GGP
leukemia	I-GGP
(	O
PML	B-GGP
)	O
mRNA	O
and	O
its	O
protein	O
localization	O
in	O
NB4	O
and	O
HL	O
-	O
60	O
cell	O
lines	O
.	O

METHODS	O
:	O
Cell	O
morphology	O
was	O
assayed	O
by	O
Wright	O
'	O
s	O
staining	O
and	O
fluorescence	O
staining	O
,	O
while	O
PML	B-GGP
mRNA	O
expression	O
was	O
determined	O
by	O
RT	O
-	O
PCR	O
.	O

PML	B-GGP
protein	O
localization	O
by	O
evaluated	O
by	O
immunofluorescence	O
staining	O
.	O

RESULTS	O
:	O
The	O
typical	O
apoptosis	O
was	O
found	O
in	O
NB4	O
and	O
HL	O
-	O
60	O
cells	O
after	O
treatment	O
with	O
red	O
orpiment	O
.	O

The	O
fusion	O
protein	O
was	O
no	O
longer	O
observed	O
in	O
NB4	O
cells	O
,	O
PML	B-GGP
protein	O
was	O
relocated	O
,	O
and	O
then	O
degraded	O
.	O

In	O
HL	O
-	O
60	O
cells	O
,	O
PML	B-GGP
protein	O
underwent	O
a	O
similar	O
progress	O
.	O

The	O
expression	O
of	O
promyelocytic	B-GGP
leukemia	I-GGP
(	O
PML	B-GGP
)	O
mRNA	O
was	O
not	O
changed	O
in	O
the	O
treated	O
cells	O
.	O

CONCLUSION	O
:	O
Red	O
orpiment	O
inhibits	O
the	O
proliferation	O
of	O
leukemia	O
cells	O
by	O
inducing	O
them	O
to	O
undergo	O
apoptosis	O
.	O

IKKepsilon	B-GGP
and	O
TBK1	B-GGP
are	O
essential	O
components	O
of	O
the	O
IRF3	B-GGP
signaling	O
pathway	O
.	O

The	O
transcription	O
factors	O
interferon	B-GGP
regulatory	I-GGP
factor	I-GGP
3	I-GGP
(	O
IRF3	B-GGP
)	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
are	O
required	O
for	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
innate	O
immune	O
response	O
.	O

Viral	O
infection	O
,	O
or	O
the	O
binding	O
of	O
double	O
-	O
stranded	O
RNA	O
to	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
3	I-GGP
,	O
results	O
in	O
the	O
coordinate	O
activation	O
of	O
IRF3	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

Activation	O
of	O
IRF3	B-GGP
requires	O
signal	O
-	O
dependent	O
phosphorylation	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
signaling	O
pathway	O
or	O
kinases	O
involved	O
.	O

Here	O
we	O
report	O
that	O
the	O
noncanonical	O
IkappaB	B-GGP
kinase	I-GGP
homologs	O
,	O
IkappaB	B-GGP
kinase	I-GGP
-	I-GGP
epsilon	I-GGP
(	O
IKKepsilon	B-GGP
)	O
and	O
TANK	B-GGP
-	I-GGP
binding	I-GGP
kinase	I-GGP
-	I-GGP
1	I-GGP
(	O
TBK1	B-GGP
)	O
,	O
which	O
were	O
previously	O
implicated	O
in	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
,	O
are	O
also	O
essential	O
components	O
of	O
the	O
IRF3	B-GGP
signaling	O
pathway	O
.	O

Thus	O
,	O
IKKepsilon	B-GGP
and	O
TBK1	B-GGP
have	O
a	O
pivotal	O
role	O
in	O
coordinating	O
the	O
activation	O
of	O
IRF3	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
the	O
innate	O
immune	O
response	O
.	O

Peroxisomal	B-CC
membrane	I-CC
monocarboxylate	B-MED
transporters	O
:	O
evidence	O
for	O
a	O
redox	O
shuttle	O
system	O
?	O

One	O
of	O
the	O
many	O
functions	O
of	O
liver	O
peroxisomes	B-CC
is	O
the	O
beta	O
-	O
oxidation	O
of	O
long	B-MED
-	I-MED
chain	I-MED
fatty	I-MED
acids	I-MED
.	O

It	O
is	O
essential	O
for	O
the	O
continuation	O
of	O
peroxisomal	B-CC
beta	O
-	O
oxidation	O
that	O
a	O
redox	O
shuttle	O
system	O
exist	O
across	O
the	O
peroxisomal	B-CC
membrane	I-CC
to	O
reoxidize	O
NADH	B-MED
.	O

We	O
propose	O
that	O
this	O
redox	O
shuttle	O
system	O
consists	O
of	O
a	O
substrate	O
cycle	O
between	O
lactate	B-MED
and	O
pyruvate	B-MED
.	O

Here	O
we	O
present	O
evidence	O
that	O
purified	O
peroxisomal	B-CC
membranes	I-CC
contain	O
both	O
monocarboxylate	B-GGP
transporter	I-GGP
1	I-GGP
(	O
MCT	B-GGP
1	I-GGP
)	O
and	O
MCT	B-GGP
2	I-GGP
and	O
that	O
along	O
with	O
peroxisomal	B-CC
lactate	B-GGP
dehydrogenase	I-GGP
(	O
pLDH	B-GGP
)	O
form	O
a	O
Peroxisomal	B-CC
Lactate	O
Shuttle	O
.	O

Peroxisomal	B-CC
beta	O
-	O
oxidation	O
was	O
greatly	O
stimulated	O
by	O
the	O
addition	O
of	O
pyruvate	B-MED
and	O
this	O
increase	O
was	O
partially	O
inhibited	O
by	O
the	O
addition	O
of	O
the	O
MCT	O
blocker	O
alpha	B-MED
-	I-MED
cyano	I-MED
-	I-MED
4	I-MED
-	I-MED
hydroxycinnamate	I-MED
(	O
CINN	B-MED
)	O
.	O

We	O
also	O
found	O
that	O
peroxisomes	B-CC
generated	O
lactate	B-MED
in	O
the	O
presence	O
of	O
pyruvate	B-MED
.	O

Together	O
these	O
data	O
provide	O
compelling	O
that	O
the	O
Peroxisome	O
Lactate	O
Shuttle	O
helps	O
maintain	O
organelle	O
redox	O
and	O
the	O
proper	O
functioning	O
of	O
peroxisomal	B-CC
beta	O
-	O
oxidation	O
.	O

Osmostress	O
-	O
induced	O
transcription	O
by	O
Hot1	B-GGP
depends	O
on	O
a	O
Hog1	B-GGP
-	O
mediated	O
recruitment	O
of	O
the	O
RNA	B-COM
Pol	I-COM
II	I-COM
.	O

In	O
budding	O
yeast	O
,	O
the	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
(	O
MAPK	B-GGP
)	O
Hog1	B-GGP
coordinates	O
the	O
transcriptional	O
program	O
required	O
for	O
cell	O
survival	O
upon	O
osmostress	O
.	O

The	O
Hot1	B-GGP
transcription	O
factor	O
acts	O
downstream	O
of	O
the	O
MAPK	B-GGP
and	O
regulates	O
a	O
subset	O
of	O
Hog1	B-GGP
-	O
responsive	O
genes	O
.	O

In	O
response	O
to	O
high	O
osmolarity	O
,	O
Hot1	B-GGP
targets	O
Hog1	B-GGP
to	O
specific	O
osmostress	O
-	O
responsive	O
promoters	O
.	O

Here	O
,	O
we	O
show	O
that	O
assembly	O
of	O
the	O
general	O
transcription	O
machinery	O
at	O
Hot1	B-GGP
-	O
dependent	O
promoters	O
depends	O
on	O
the	O
presence	O
of	O
Hot1	B-GGP
and	O
active	O
Hog1	B-GGP
MAPK	I-GGP
.	O

Unexpectedly	O
,	O
recruitment	O
of	O
RNA	B-COM
polymerase	I-COM
(	I-COM
Pol	I-COM
)	I-COM
II	I-COM
complex	O
to	O
target	O
promoters	O
does	O
not	O
depend	O
on	O
the	O
phosphorylation	O
of	O
the	O
Hot1	B-GGP
activator	O
by	O
the	O
MAPK	B-GGP
.	O

Hog1	B-GGP
interacts	O
with	O
the	O
RNA	B-COM
Pol	I-COM
II	I-COM
and	O
with	O
general	O
components	O
of	O
the	O
transcription	O
machinery	O
.	O

More	O
over	O
,	O
when	O
tethered	O
to	O
a	O
promoter	O
as	O
a	O
LexA	B-GGP
fusion	O
protein	O
,	O
Hog1	B-GGP
activates	O
transcription	O
in	O
a	O
stress	O
-	O
regulated	O
manner	O
.	O

Thus	O
,	O
anchoring	O
of	O
active	O
Hog1	B-GGP
to	O
promoters	O
by	O
the	O
Hot1	B-GGP
activator	O
is	O
essential	O
for	O
recruitment	O
and	O
activation	O
of	O
RNA	B-COM
Pol	I-COM
II	I-COM
.	O

The	O
mammalian	O
p38	B-GGP
also	O
interacts	O
with	O
the	O
RNA	B-COM
Pol	I-COM
II	I-COM
,	O
which	O
might	O
suggest	O
a	O
conserved	O
mechanism	O
for	O
regulation	O
of	O
gene	O
expression	O
by	O
SAPKs	B-GGP
among	O
eukaryotic	O
cells	O
.	O

p53	B-GGP
-	O
independent	O
activation	O
of	O
the	O
hdm2	B-GGP
-	O
P2	O
promoter	O
through	O
multiple	O
transcription	O
factor	O
response	O
elements	O
results	O
in	O
elevated	O
hdm2	B-GGP
expression	O
in	O
estrogen	B-GGP
receptor	I-GGP
alpha	I-GGP
-	O
positive	O
breast	O
cancer	O
cells	O
.	O

The	O
negative	O
-	O
regulatory	O
feedback	O
loop	O
between	O
p53	B-GGP
and	O
hdm2	B-GGP
forms	O
part	O
of	O
a	O
finely	O
balanced	O
regulatory	O
network	O
of	O
proteins	O
that	O
controls	O
cell	O
cycle	O
progression	O
and	O
commitment	O
to	O
apoptosis	O
.	O

Expression	O
of	O
hdm2	B-GGP
,	O
and	O
its	O
mouse	O
orthologue	O
mdm2	B-GGP
,	O
is	O
known	O
to	O
be	O
induced	O
by	O
p53	B-GGP
,	O
but	O
recent	O
evidence	O
has	O
demonstrated	O
mdm2	B-GGP
expression	O
can	O
also	O
be	O
regulated	O
via	O
p53	B-GGP
-	O
independent	O
pathways	O
.	O

However	O
the	O
p53	B-GGP
independent	O
mechanisms	O
that	O
control	O
transcription	O
of	O
the	O
human	O
hdm2	B-GGP
gene	O
have	O
not	O
been	O
studied	O
.	O

Differential	O
levels	O
of	O
hdm2	B-GGP
mRNA	O
and	O
protein	O
expression	O
have	O
been	O
reported	O
in	O
several	O
types	O
of	O
human	O
malignancy	O
,	O
including	O
breast	O
cancers	O
in	O
which	O
hdm2	B-GGP
expression	O
correlates	O
with	O
positive	O
estrogen	B-GGP
receptor	I-GGP
alpha	I-GGP
(	O
ERalpha	B-GGP
)	O
status	O
.	O

Experimental	O
models	O
have	O
demonstrated	O
that	O
hdm2	B-GGP
overexpression	O
can	O
promote	O
breast	O
cancer	O
development	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
elevated	O
level	O
of	O
hdm2	B-GGP
protein	O
in	O
ERalpha	B-GGP
(	O
+	O
ve	O
)	O
breast	O
cancer	O
cell	O
lines	O
such	O
as	O
MCF	O
-	O
7	O
and	O
T47D	O
is	O
because	O
of	O
transcription	O
from	O
the	O
p53	B-GGP
-	O
inducible	O
P2	O
promoter	O
of	O
hdm2	B-GGP
.	O

The	O
P2	O
promoter	O
is	O
inactive	O
in	O
ERalpha	B-GGP
(	O
-	O
ve	O
)	O
cell	O
lines	O
such	O
as	O
SKBr3	O
.	O

Hdm2	B-GGP
-	O
P2	O
promoter	O
activity	O
in	O
T47D	O
cells	O
is	O
independent	O
of	O
p53	B-GGP
,	O
as	O
well	O
as	O
of	O
known	O
regulators	O
of	O
the	O
mouse	O
mdm2	B-GGP
-	O
P2	O
promoter	O
,	O
including	O
ERalpha	B-GGP
and	O
ras	B-GGP
-	O
raf	B-GGP
-	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
/	I-GGP
extracellular	I-GGP
signal	I-GGP
-	I-GGP
regulated	I-GGP
kinase	I-GGP
(	O
MEK	B-GGP
)	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
(	O
MAPK	B-GGP
)	O
signaling	O
.	O

We	O
show	O
that	O
hdm2	B-GGP
-	O
P2	O
activity	O
in	O
T47D	O
cells	O
is	O
dependent	O
on	O
the	O
integrity	O
of	O
both	O
an	O
evolutionarily	O
conserved	O
composite	O
binding	O
site	O
for	O
AP1	B-GGP
and	O
ETS	B-GGP
family	O
transcription	O
factors	O
(	O
AP1	B-GGP
-	O
ETS	B-GGP
)	O
and	O
a	O
nonconserved	O
upstream	O
(	O
nnGGGGC	O
)	O
(	O
5	O
)	O
repeat	O
sequence	O
.	O

Lack	O
of	O
hdm2	B-GGP
-	O
P2	O
activity	O
in	O
ERalpha	B-GGP
(	O
-	O
ve	O
)	O
cells	O
is	O
shown	O
to	O
be	O
a	O
consequence	O
of	O
reduced	O
transcriptional	O
activation	O
through	O
the	O
AP1	B-GGP
-	O
ETS	B-GGP
element	O
.	O

Overexpression	O
of	O
ETS2	B-GGP
in	O
SKBr3	O
cells	O
reconstitutes	O
AP1	B-GGP
-	O
ETS	B-GGP
element	O
-	O
dependent	O
hdm2	B-GGP
-	O
P2	O
promoter	O
activity	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
hdm2	B-GGP
protein	O
in	O
the	O
cells	O
.	O

Our	O
findings	O
support	O
the	O
hypothesis	O
that	O
the	O
elevated	O
levels	O
of	O
hdm2	B-GGP
expression	O
reported	O
in	O
cancers	O
such	O
as	O
ERalpha	B-GGP
(	O
+	O
ve	O
)	O
breast	O
tumors	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
these	O
tumors	O
.	O

Molecular	O
mechanisms	O
and	O
regulation	O
of	O
iron	B-MED
transport	O
.	O

Iron	B-MED
homeostasis	O
is	O
primarily	O
maintained	O
through	O
regulation	O
of	O
its	O
transport	O
.	O

This	O
review	O
summarizes	O
recent	O
discoveries	O
in	O
the	O
field	O
of	O
iron	B-MED
transport	O
that	O
have	O
shed	O
light	O
on	O
the	O
molecular	O
mechanisms	O
of	O
dietary	O
iron	B-MED
uptake	O
,	O
pathways	O
for	O
iron	B-MED
efflux	O
to	O
and	O
between	O
peripheral	O
tissues	O
,	O
proteins	O
implicated	O
in	O
organellar	B-CC
transport	O
of	O
iron	B-MED
(	O
particularly	O
the	O
mitochondrion	B-CC
)	O
,	O
and	O
novel	O
regulators	O
that	O
have	O
been	O
proposed	O
to	O
control	O
iron	B-MED
assimilation	O
.	O

The	O
transport	O
of	O
both	O
transferrin	B-GGP
-	O
bound	O
and	O
nontransferrin	B-GGP
-	O
bound	O
iron	B-MED
to	O
peripheral	O
tissues	O
is	O
discussed	O
.	O

Finally	O
,	O
the	O
regulation	O
of	O
iron	B-MED
transport	O
is	O
also	O
considered	O
at	O
the	O
molecular	O
level	O
,	O
with	O
posttranscriptional	O
,	O
transcriptional	O
,	O
and	O
posttranslational	O
control	O
mechanisms	O
being	O
reviewed	O
.	O

The	O
role	O
of	O
glucosidase	B-GGP
II	I-GGP
and	O
endomannosidase	B-GGP
in	O
glucose	B-MED
trimming	O
of	O
asparagine	B-MED
-	O
linked	O
oligosaccharides	B-MED
.	O

This	O
review	O
covers	O
various	O
aspects	O
of	O
glucose	B-MED
trimming	O
reactions	O
occurring	O
on	O
asparagine	B-MED
-	O
linked	O
oligosaccharides	B-MED
.	O

Structural	O
and	O
functional	O
features	O
of	O
two	O
enzymes	O
,	O
glucosidase	B-GGP
II	I-GGP
and	O
endo	B-GGP
-	I-GGP
alpha	I-GGP
-	I-GGP
mannosidase	I-GGP
,	O
prominently	O
involved	O
in	O
this	O
process	O
are	O
summarized	O
and	O
their	O
striking	O
differences	O
in	O
terms	O
of	O
substrate	O
specificities	O
are	O
highlighted	O
.	O

Recent	O
results	O
of	O
analyses	O
by	O
immunoelectron	O
microscopy	O
of	O
their	O
distribution	O
pattern	O
are	O
presented	O
which	O
demonstrate	O
that	O
glucose	B-MED
trimming	O
is	O
not	O
restricted	O
to	O
the	O
endoplasmic	B-CC
reticulum	I-CC
(	O
ER	B-CC
)	O
but	O
additionally	O
is	O
a	O
function	O
accommodated	O
by	O
the	O
Golgi	B-CC
apparatus	I-CC
.	O

The	O
mutually	O
exclusive	O
subcellular	B-CC
distribution	O
of	O
glucosidase	B-GGP
II	I-GGP
and	O
endomannosidase	B-GGP
are	O
discussed	O
in	O
terms	O
of	O
their	O
significance	O
for	O
quality	O
control	O
of	O
protein	O
folding	O
and	O
N	O
-	O
glycosylation	O
.	O

Genomic	O
identification	O
and	O
biochemical	O
characterization	O
of	O
a	O
second	O
spermidine	B-GGP
/	I-GGP
spermine	I-GGP
N1	I-GGP
-	I-GGP
acetyltransferase	I-GGP
.	O

In	O
the	O
polyamine	B-MED
back	O
-	O
conversion	O
pathway	O
,	O
spermine	B-MED
and	O
spermidine	B-MED
are	O
first	O
acetylated	O
by	O
spermidine	B-GGP
/	I-GGP
spermine	I-GGP
N	I-GGP
(	I-GGP
1	I-GGP
)	I-GGP
-	I-GGP
acetyl	I-GGP
-	I-GGP
transferase	I-GGP
(	O
SSAT	B-GGP
-	I-GGP
1	I-GGP
)	O
and	O
then	O
oxidized	O
by	O
polyamine	B-GGP
oxidase	I-GGP
to	O
produce	O
spermidine	B-MED
and	O
putrescine	B-MED
respectively	O
.	O

Herein	O
we	O
apply	O
homology	O
-	O
search	O
methods	O
to	O
identify	O
novel	O
sequences	O
belonging	O
to	O
a	O
second	O
SSAT	B-GGP
,	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
,	O
with	O
a	O
chromosomal	B-CC
location	O
at	O
17p13	O
.	O
1	O
,	O
which	O
is	O
distinct	O
from	O
SSAT	B-GGP
-	I-GGP
1	I-GGP
at	O
Xp22	O
.	O

Human	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
cDNA	O
derived	O
from	O
small	O
-	O
cell	O
lung	O
carcinoma	O
was	O
deduced	O
to	O
encode	O
a	O
170	O
-	O
amino	O
-	O
acid	O
protein	O
having	O
46	O
%	O
sequence	O
identity	O
and	O
64	O
%	O
sequence	O
similarity	O
with	O
SSAT	B-GGP
-	I-GGP
1	I-GGP
.	O

When	O
transiently	O
transfected	O
into	O
HEK	O
-	O
293	O
cells	O
,	O
SSAT	B-GGP
-	I-GGP
1	I-GGP
decreased	O
spermidine	B-MED
and	O
spermine	B-MED
pools	O
by	O
approximately	O
30	O
%	O
,	O
while	O
,	O
at	O
the	O
same	O
time	O
,	O
significantly	O
increasing	O
putrescine	B-MED
,	O
N	B-MED
(	I-MED
1	I-MED
)	I-MED
-	I-MED
acetylspermidine	I-MED
,	O
N	B-MED
(	I-MED
1	I-MED
)	I-MED
-	I-MED
acetylspermine	I-MED
and	O
N	B-MED
(	I-MED
1	I-MED
)	I-MED
,	I-MED
N	I-MED
(	I-MED
12	I-MED
)	I-MED
-	I-MED
diacetylspermine	I-MED
pools	O
.	O

By	O
contrast	O
,	O
transfected	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
had	O
no	O
effect	O
on	O
intracellular	B-CC
polyamine	B-MED
or	O
acetylated	O
polyamine	B-MED
pools	O
.	O

When	O
enzyme	O
activity	O
was	O
assayed	O
on	O
enzyme	O
extracts	O
from	O
transfected	O
cells	O
,	O
both	O
SSAT	B-GGP
-	I-GGP
1	I-GGP
and	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
demonstrated	O
much	O
higher	O
acetylating	O
activity	O
than	O
vector	O
-	O
transfected	O
cells	O
.	O

The	O
data	O
suggest	O
that	O
,	O
in	O
intact	O
cells	O
,	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
may	O
be	O
compartmentalized	O
or	O
it	O
may	O
be	O
inefficient	O
at	O
low	O
intracellular	B-CC
polyamine	B-MED
concentrations	O
.	O

By	O
substituting	O
candidate	O
substrates	O
in	O
the	O
enzyme	O
assay	O
,	O
we	O
determined	O
that	O
SSAT	B-GGP
-	I-GGP
1	I-GGP
shows	O
the	O
substrate	O
preference	O
norspermidine	B-MED
=	O
spermidine	B-MED
>	O
spermine	B-MED
>	O
N	B-MED
(	I-MED
1	I-MED
)	I-MED
-	I-MED
acetylspermine	I-MED
>	O
putrescine	B-MED
,	O
whereas	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
shows	O
the	O
preference	O
norspermidine	B-MED
>	O
spermidine	B-MED
=	O
spermine	B-MED
>	O
N	B-MED
(	I-MED
1	I-MED
)	I-MED
-	I-MED
acetylspermine	I-MED
=	O
putrescine	B-MED
.	O

Analysis	O
of	O
mRNA	O
levels	O
in	O
cell	O
lines	O
and	O
ESTs	O
(	O
expressed	O
sequence	O
tags	O
)	O
from	O
various	O
tissues	O
by	O
digiNorthern	O
(	O
a	O
web	O
-	O
based	O
tool	O
for	O
virtually	O
displaying	O
expression	O
profiles	O
of	O
query	O
genes	O
based	O
on	O
EST	O
sequences	O
)	O
indicated	O
that	O
SSAT	B-GGP
-	I-GGP
1	I-GGP
tends	O
to	O
be	O
more	O
widely	O
and	O
highly	O
expressed	O
than	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
.	O

While	O
SSAT	B-GGP
-	I-GGP
1	I-GGP
mRNA	O
was	O
inducible	O
by	O
polyamine	B-MED
analogues	O
in	O
a	O
variety	O
of	O
cell	O
lines	O
,	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
was	O
not	O
.	O

The	O
existence	O
of	O
an	O
active	O
,	O
but	O
possibly	O
sequestered	O
,	O
SSAT	B-GGP
-	I-GGP
2	I-GGP
enzyme	O
suggests	O
that	O
,	O
under	O
certain	O
conditions	O
,	O
it	O
may	O
be	O
recruited	O
into	O
basal	O
or	O
perturbed	O
polyamine	B-MED
metabolism	O
.	O

The	O
human	O
multidrug	B-GGP
resistance	I-GGP
protein	I-GGP
MRP4	B-GGP
functions	O
as	O
a	O
prostaglandin	B-MED
efflux	O
transporter	O
and	O
is	O
inhibited	O
by	O
nonsteroidal	O
antiinflammatory	O
drugs	O
.	O

Prostaglandins	B-MED
are	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
physiological	O
and	O
pathophysiological	O
processes	O
,	O
but	O
the	O
mechanism	O
of	O
prostaglandin	B-MED
release	O
from	O
cells	O
is	O
not	O
completely	O
understood	O
.	O

Although	O
poorly	O
membrane	B-CC
permeable	O
,	O
prostaglandins	B-MED
are	O
believed	O
to	O
exit	O
cells	O
by	O
passive	O
diffusion	O
.	O

We	O
have	O
investigated	O
the	O
interaction	O
between	O
prostaglandins	B-MED
and	O
members	O
of	O
the	O
ATP	B-GGP
-	I-GGP
binding	I-GGP
cassette	I-GGP
(	I-GGP
ABC	I-GGP
)	I-GGP
transporter	I-GGP
ABCC	I-GGP
[	O
multidrug	B-GGP
resistance	I-GGP
protein	I-GGP
(	O
MRP	B-GGP
)	O
]	O
family	O
of	O
membrane	B-CC
export	O
pumps	O
.	O

In	O
inside	O
-	O
out	O
membrane	B-CC
vesicles	I-CC
derived	O
from	O
insect	O
cells	O
or	O
HEK293	O
cells	O
,	O
MRP4	B-GGP
catalyzed	O
the	O
time	O
-	O
and	O
ATP	B-MED
-	O
dependent	O
uptake	O
of	O
prostaglandin	B-MED
E1	I-MED
(	O
PGE1	B-MED
)	O
and	O
PGE2	B-MED
.	O

In	O
contrast	O
,	O
MRP1	B-GGP
,	O
MRP2	B-GGP
,	O
MRP3	B-GGP
,	O
and	O
MRP5	B-GGP
did	O
not	O
transport	O
PGE1	B-MED
or	O
PGE2	B-MED
.	O

The	O
MRP4	B-GGP
-	O
mediated	O
transport	O
of	O
PGE1	B-MED
and	O
PGE2	B-MED
displayed	O
saturation	O
kinetics	O
,	O
with	O
Km	O
values	O
of	O
2	O
.	O
1	O
and	O
3	O
.	O
4	O
microM	O
,	O
respectively	O
.	O

Further	O
studies	O
showed	O
that	O
PGF1alpha	B-MED
,	O
PGF2alpha	B-MED
,	O
PGA1	B-MED
,	O
and	O
thromboxane	B-MED
B2	I-MED
were	O
high	O
-	O
affinity	O
inhibitors	O
(	O
and	O
therefore	O
presumably	O
substrates	O
)	O
of	O
MRP4	B-GGP
.	O

Furthermore	O
,	O
several	O
nonsteroidal	O
antiinflammatory	O
drugs	O
were	O
potent	O
inhibitors	O
of	O
MRP4	B-GGP
at	O
concentrations	O
that	O
did	O
not	O
inhibit	O
MRP1	B-GGP
.	O

In	O
cells	O
expressing	O
the	O
prostaglandin	B-MED
transporter	O
PGT	B-GGP
,	O
the	O
steady	O
-	O
state	O
accumulation	O
of	O
PGE1	B-MED
and	O
PGE2	B-MED
was	O
reduced	O
proportional	O
to	O
MRP4	B-GGP
expression	O
.	O

Inhibition	O
of	O
MRP4	B-GGP
by	O
an	O
MRP4	B-GGP
-	O
specific	O
RNA	O
interference	O
construct	O
or	O
by	O
indomethacin	B-MED
reversed	O
this	O
accumulation	O
deficit	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
MRP4	B-GGP
can	O
release	O
prostaglandins	B-MED
from	O
cells	O
,	O
and	O
that	O
,	O
in	O
addition	O
to	O
inhibiting	O
prostaglandin	B-MED
synthesis	O
,	O
some	O
nonsteroidal	O
antiinflammatory	O
drugs	O
might	O
also	O
act	O
by	O
inhibiting	O
this	O
release	O
.	O

ICBP90	B-GGP
belongs	O
to	O
a	O
new	O
family	O
of	O
proteins	O
with	O
an	O
expression	O
that	O
is	O
deregulated	O
in	O
cancer	O
cells	O
.	O

ICBP90	B-GGP
(	O
Inverted	B-GGP
CCAAT	I-GGP
box	I-GGP
Binding	I-GGP
Protein	I-GGP
of	I-GGP
90	I-GGP
kDa	I-GGP
)	O
is	O
a	O
recently	O
identified	O
nuclear	B-CC
protein	O
that	O
binds	O
to	O
one	O
of	O
the	O
inverted	O
CCAAT	O
boxes	O
of	O
the	O
topoisomerase	B-GGP
IIalpha	I-GGP
(	O
TopoIIalpha	B-GGP
)	O
gene	O
promoter	O
.	O

Here	O
,	O
we	O
show	O
that	O
ICBP90	B-GGP
shares	O
structural	O
homology	O
with	O
several	O
other	O
proteins	O
,	O
including	O
Np95	B-GGP
,	O
the	O
human	O
and	O
mouse	O
NIRF	B-GGP
,	O
suggesting	O
the	O
emergence	O
of	O
a	O
new	O
family	O
of	O
nuclear	B-CC
proteins	O
.	O

Towards	O
elucidating	O
the	O
functions	O
of	O
this	O
family	O
,	O
we	O
analysed	O
the	O
expression	O
of	O
ICBP90	B-GGP
in	O
various	O
cancer	O
or	O
noncancer	O
cell	O
lines	O
and	O
in	O
normal	O
or	O
breast	O
carcinoma	O
tissues	O
.	O

We	O
found	O
that	O
cancer	O
cell	O
lines	O
express	O
higher	O
levels	O
of	O
ICBP90	B-GGP
and	O
TopoIIalpha	B-GGP
than	O
noncancer	O
cell	O
lines	O
.	O

By	O
using	O
cell	O
-	O
cycle	O
phase	O
-	O
blocking	O
drugs	O
,	O
we	O
show	O
that	O
in	O
primary	O
cultured	O
human	O
lung	O
fibroblasts	O
,	O
ICBP90	B-GGP
expression	O
peaks	O
at	O
late	O
G1	O
and	O
during	O
G2	O
/	O
M	O
phases	O
.	O

In	O
contrast	O
,	O
cancer	O
cell	O
lines	O
such	O
as	O
HeLa	O
,	O
Jurkat	O
and	O
A549	O
show	O
constant	O
ICBP90	B-GGP
expression	O
throughout	O
the	O
entire	O
cell	O
cycle	O
.	O

The	O
effect	O
of	O
overexpression	O
of	O
E2F	B-GGP
-	I-GGP
1	I-GGP
is	O
more	O
efficient	O
on	O
ICBP90	B-GGP
and	O
TopoIIalpha	B-GGP
expression	O
in	O
noncancer	O
cells	O
(	O
IMR90	O
,	O
WI38	O
)	O
than	O
in	O
cancer	O
cells	O
(	O
U2OS	O
,	O
SaOs	O
)	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
ICBP90	B-GGP
expression	O
is	O
altered	O
in	O
cancer	O
cell	O
lines	O
and	O
is	O
upregulated	O
by	O
E2F	B-GGP
-	I-GGP
1	I-GGP
overexpression	O
with	O
an	O
efficiency	O
depending	O
on	O
the	O
cancer	O
status	O
of	O
the	O
cell	O
line	O
.	O

Identification	O
of	O
a	O
novel	O
human	O
uridine	B-GGP
phosphorylase	I-GGP
.	O

Uridine	B-GGP
phosphorylase	I-GGP
catalyzes	O
the	O
reversible	O
phosphorylytic	O
cleavage	O
of	O
uridine	B-MED
and	O
deoxyuridine	B-MED
to	O
uracil	B-MED
and	O
ribose	B-MED
-	O
or	O
deoxyribose	B-MED
-	I-MED
1	I-MED
-	I-MED
phosphate	I-MED
.	O

The	O
enzyme	O
has	O
an	O
important	O
role	O
in	O
the	O
metabolism	O
of	O
pyrimidine	B-MED
analogs	O
used	O
in	O
cancer	O
chemotherapy	O
.	O

The	O
cDNA	O
of	O
a	O
novel	O
317	O
amino	O
acid	O
human	O
uridine	B-GGP
phosphorylase	I-GGP
approximately	O
60	O
%	O
identical	O
to	O
the	O
previously	O
identified	O
human	O
uridine	B-GGP
phosphorylase	I-GGP
was	O
cloned	O
.	O

The	O
novel	O
enzyme	O
,	O
named	O
uridine	B-GGP
phosphorylase	I-GGP
-	I-GGP
2	I-GGP
(	O
UPase	B-GGP
-	I-GGP
2	I-GGP
)	O
,	O
showed	O
broad	O
substrate	O
specificity	O
and	O
accepted	O
uridine	B-MED
,	O
deoxyuridine	B-MED
,	O
and	O
thymidine	B-MED
as	O
well	O
as	O
the	O
two	O
pyrimidine	B-MED
nucleoside	I-MED
analogs	O
5	B-MED
-	I-MED
fluorouridine	I-MED
and	O
5	B-MED
-	I-MED
fluoro	I-MED
-	I-MED
2	I-MED
(	I-MED
'	I-MED
)	I-MED
-	I-MED
deoxyuridine	I-MED
.	O

The	O
human	O
UPase	B-GGP
-	I-GGP
2	I-GGP
gene	O
was	O
mapped	O
to	O
chromosome	B-CC
2q24	O
.	O
1	O
and	O
the	O
2	O
.	O
2	O
-	O
kb	O
mRNA	O
was	O
predominantly	O
expressed	O
in	O
kidney	O
.	O

The	O
mouse	O
UPase	B-GGP
-	I-GGP
2	I-GGP
cDNA	O
was	O
also	O
identified	O
and	O
shown	O
to	O
be	O
predominantly	O
expressed	O
in	O
liver	O
.	O

The	O
identification	O
of	O
a	O
novel	O
uridine	B-GGP
phosphorylase	I-GGP
with	O
broad	O
substrate	O
specificity	O
is	O
important	O
for	O
studies	O
on	O
both	O
nucleoside	O
metabolism	O
as	O
well	O
as	O
for	O
studies	O
on	O
the	O
pharmacological	O
mechanisms	O
of	O
therapeutic	O
pyrimidine	B-MED
nucleoside	I-MED
analogs	O
.	O

Distinct	O
functions	O
of	O
Nijmegen	O
breakage	O
syndrome	O
in	O
ataxia	O
telangiectasia	O
mutated	O
-	O
dependent	O
responses	O
to	O
DNA	O
damage	O
.	O

Phosphorylation	O
of	O
NBS1	B-GGP
,	O
the	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
Nijmegen	O
breakage	O
syndrome	O
(	O
NBS	O
)	O
,	O
by	O
ataxia	B-GGP
telangiectasia	I-GGP
mutated	I-GGP
(	O
ATM	B-GGP
)	O
,	O
the	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
ataxia	O
telangiectasia	O
,	O
is	O
required	O
for	O
activation	O
of	O
the	O
S	O
phase	O
checkpoint	O
in	O
response	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
.	O

However	O
,	O
NBS1	B-GGP
is	O
also	O
thought	O
to	O
play	O
additional	O
roles	O
in	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O

To	O
clarify	O
these	O
additional	O
functions	O
of	O
NBS1	B-GGP
,	O
we	O
generated	O
NBS	O
cell	O
lines	O
stably	O
expressing	O
various	O
NBS1	B-GGP
mutants	O
from	O
retroviral	O
vectors	O
.	O

The	O
ATM	B-GGP
-	O
dependent	O
activation	O
of	O
CHK2	B-GGP
by	O
IR	O
was	O
defective	O
in	O
NBS	O
cells	O
but	O
was	O
restored	O
by	O
ectopic	O
expression	O
of	O
wild	O
-	O
type	O
NBS1	B-GGP
.	O

The	O
defects	O
in	O
ATM	B-GGP
-	O
dependent	O
activation	O
of	O
CHK2	B-GGP
,	O
S	O
phase	O
checkpoint	O
control	O
,	O
IR	O
-	O
induced	O
nuclear	B-CC
focus	I-CC
formation	O
,	O
and	O
radiation	O
sensitivity	O
apparent	O
in	O
NBS	O
cells	O
were	O
not	O
corrected	O
by	O
expression	O
of	O
NBS1	B-GGP
mutants	O
that	O
lack	O
an	O
intact	O
MRE11	B-GGP
binding	O
domain	O
,	O
suggesting	O
that	O
formation	O
of	O
the	O
NBS1	B-COM
-	I-COM
MRE11	I-COM
-	I-COM
RAD50	I-COM
complex	O
is	O
required	O
for	O
the	O
corresponding	O
normal	O
phenotypes	O
.	O

Expression	O
of	O
NBS1	B-GGP
proteins	O
with	O
mutated	O
ATM	B-GGP
-	O
targeted	O
phosphorylation	O
sites	O
(	O
serines	B-MED
278	I-MED
or	O
343	B-MED
)	O
did	O
not	O
restore	O
S	O
phase	O
checkpoint	O
control	O
but	O
did	O
restore	O
the	O
ability	O
of	O
IR	O
to	O
activate	O
CHK2	B-GGP
and	O
to	O
induce	O
nuclear	B-CC
focus	I-CC
formation	O
and	O
normalized	O
the	O
radiation	O
sensitivity	O
of	O
NBS	O
cells	O
.	O

Expression	O
of	O
NBS1	B-GGP
containing	O
mutations	O
in	O
the	O
forkhead	O
-	O
associated	O
or	O
BRCA1	B-GGP
COOH	O
terminus	O
domains	O
did	O
not	O
correct	O
the	O
defects	O
in	O
radiation	O
sensitivity	O
or	O
nuclear	B-CC
focus	I-CC
formation	O
but	O
did	O
restore	O
S	O
phase	O
checkpoint	O
control	O
in	O
NBS	O
cells	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
multiple	O
functional	O
domains	O
of	O
NBS1	B-GGP
are	O
required	O
for	O
ATM	B-GGP
-	O
dependent	O
activation	O
of	O
CHK2	B-GGP
,	O
nuclear	B-CC
focus	I-CC
formation	O
,	O
S	O
phase	O
checkpoint	O
control	O
,	O
and	O
cell	O
survival	O
after	O
exposure	O
to	O
IR	O
.	O

Structural	O
complementarity	O
of	O
Toll	B-GGP
/	I-GGP
interleukin	I-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
domains	O
in	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptors	I-GGP
and	O
the	O
adaptors	O
Mal	B-GGP
and	O
MyD88	B-GGP
.	O

The	O
Toll	B-GGP
/	I-GGP
interleukin	I-GGP
1	I-GGP
receptor	I-GGP
(	O
TIR	B-GGP
)	O
domain	O
is	O
a	O
region	O
found	O
in	O
the	O
cytoplasmic	B-CC
tails	O
of	O
members	O
of	O
the	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
/	I-GGP
interleukin	I-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
superfamily	O
.	O

The	O
domain	O
is	O
essential	O
for	O
signaling	O
and	O
is	O
also	O
found	O
in	O
the	O
adaptor	O
proteins	O
Mal	B-GGP
(	O
MyD88	B-GGP
adaptor	I-GGP
-	I-GGP
like	I-GGP
)	O
and	O
MyD88	B-GGP
,	O
which	O
function	O
to	O
couple	O
activation	O
of	O
the	O
receptor	O
to	O
downstream	O
signaling	O
components	O
.	O

Experimental	O
structures	O
of	O
two	O
Toll	B-GGP
/	I-GGP
interleukin	I-GGP
1	I-GGP
receptor	I-GGP
domains	O
reveal	O
a	O
alpha	O
-	O
beta	O
-	O
fold	O
similar	O
to	O
that	O
of	O
the	O
bacterial	O
chemotaxis	O
protein	O
CheY	B-GGP
,	O
and	O
other	O
evidence	O
suggests	O
that	O
the	O
adaptors	O
can	O
make	O
heterotypic	O
interactions	O
with	O
both	O
the	O
receptors	O
and	O
themselves	O
.	O

Here	O
we	O
show	O
that	O
the	O
purified	O
TIR	B-GGP
domains	O
of	O
Mal	B-GGP
and	O
MyD88	B-GGP
can	O
form	O
stable	O
heterodimers	O
and	O
also	O
that	O
Mal	B-GGP
homodimers	O
and	O
oligomers	O
are	O
dissociated	O
in	O
the	O
presence	O
of	O
ATP	B-MED
.	O

To	O
identify	O
structural	O
features	O
that	O
may	O
contribute	O
to	O
the	O
formation	O
of	O
signaling	O
complexes	O
,	O
we	O
produced	O
models	O
of	O
the	O
TIR	B-GGP
domains	O
from	O
human	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
4	I-GGP
(	O
TLR4	B-GGP
)	O
,	O
Mal	B-GGP
,	O
and	O
MyD88	B-GGP
.	O

We	O
found	O
that	O
although	O
the	O
overall	O
fold	O
is	O
conserved	O
the	O
electrostatic	O
surface	O
potentials	O
are	O
quite	O
distinct	O
.	O

Docking	O
studies	O
of	O
the	O
models	O
suggest	O
that	O
Mal	B-GGP
and	O
MyD88	B-GGP
bind	O
to	O
different	O
regions	O
in	O
TLRs	B-GGP
2	I-GGP
and	O
4	B-GGP
,	O
a	O
finding	O
consistent	O
with	O
a	O
cooperative	O
role	O
of	O
the	O
two	O
adaptors	O
in	O
signaling	O
.	O

Mal	B-GGP
and	O
MyD88	B-GGP
are	O
predicted	O
to	O
interact	O
at	O
a	O
third	O
non	O
-	O
overlapping	O
site	O
,	O
suggesting	O
that	O
the	O
receptor	O
and	O
adaptors	O
may	O
form	O
heterotetrameric	O
complexes	O
.	O

The	O
theoretical	O
model	O
of	O
the	O
interactions	O
is	O
supported	O
by	O
experimental	O
data	O
from	O
glutathione	B-GGP
S	I-GGP
-	I-GGP
transferase	I-GGP
pull	O
-	O
downs	O
and	O
co	O
-	O
immunoprecipitations	O
.	O

Neither	O
theoretical	O
nor	O
experimental	O
data	O
suggest	O
a	O
direct	O
role	O
for	O
the	O
conserved	O
proline	B-MED
in	O
the	O
BB	O
-	O
loop	O
in	O
the	O
association	O
of	O
TLR4	B-GGP
,	O
Mal	B-GGP
,	O
and	O
MyD88	B-GGP
.	O

Finally	O
we	O
show	O
a	O
sequence	O
relationship	O
between	O
the	O
Drosophila	O
protein	O
Tube	B-GGP
and	O
Mal	B-GGP
that	O
may	O
indicate	O
a	O
functional	O
equivalence	O
of	O
these	O
two	O
adaptors	O
in	O
the	O
Drosophila	O
and	O
vertebrate	O
Toll	B-GGP
pathways	O
.	O

Identification	O
of	O
complex	O
formation	O
between	O
two	O
intracellular	B-CC
tyrosine	B-MED
kinase	O
substrates	O
:	O
human	O
c	B-GGP
-	I-GGP
Rel	I-GGP
and	O
the	O
p105	B-GGP
precursor	O
of	O
p50	B-GGP
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
.	O

Immune	O
complexes	O
of	O
the	O
product	O
of	O
the	O
c	B-GGP
-	I-GGP
rel	I-GGP
protooncogene	O
and	O
of	O
p105	B-GGP
,	O
the	O
p50	B-GGP
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
precursor	O
,	O
isolated	O
from	O
human	O
T	O
-	O
lymphoblastoid	O
cell	O
lines	O
are	O
comprised	O
of	O
multiple	O
proteins	O
.	O

Only	O
p105	B-GGP
and	O
human	O
c	B-GGP
-	I-GGP
Rel	I-GGP
(	O
hc	B-GGP
-	I-GGP
Rel	I-GGP
)	O
are	O
common	O
to	O
complexes	O
precipitated	O
with	O
antiserum	O
directed	O
against	O
either	O
p105	B-GGP
or	O
hc	B-GGP
-	I-GGP
Rel	I-GGP
.	O

Both	O
proteins	O
are	O
inducible	O
by	O
phytohemagglutinin	B-GGP
(	O
PHA	B-GGP
)	O
and	O
phorbol	B-MED
12	I-MED
-	I-MED
myristate	I-MED
13	I-MED
-	I-MED
acetate	I-MED
(	O
PMA	B-MED
)	O
and	O
their	O
subcellular	B-CC
distribution	O
is	O
affected	O
by	O
this	O
induction	O
.	O

We	O
demonstrate	O
that	O
the	O
Rel	B-GGP
immune	O
complex	O
contains	O
a	O
protein	O
with	O
a	O
molecular	O
weight	O
in	O
the	O
40	O
kDa	O
range	O
(	O
p40	B-GGP
)	O
which	O
apparently	O
is	O
exclusively	O
cytoplasmic	B-CC
.	O

We	O
were	O
not	O
able	O
to	O
detect	O
p40	B-GGP
in	O
the	O
p105	B-GGP
immune	O
complex	O
,	O
though	O
hc	B-GGP
-	I-GGP
Rel	I-GGP
is	O
present	O
.	O

This	O
indicates	O
that	O
hc	B-GGP
-	I-GGP
Rel	I-GGP
exists	O
in	O
different	O
multi	O
-	O
protein	O
complexes	O
and	O
fits	O
a	O
model	O
of	O
functional	O
regulation	O
mediated	O
by	O
differential	O
protein	O
-	O
protein	O
interaction	O
.	O

We	O
also	O
demonstrate	O
considerable	O
isoform	O
diversity	O
of	O
both	O
hc	B-GGP
-	I-GGP
Rel	I-GGP
and	O
p105	B-GGP
.	O

We	O
show	O
that	O
this	O
heterogeneity	O
is	O
,	O
in	O
part	O
,	O
the	O
result	O
of	O
phosphorylation	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p105	B-GGP
and	O
hc	B-GGP
-	I-GGP
Rel	I-GGP
are	O
tyrosine	B-MED
kinase	O
substrates	O
.	O

This	O
finding	O
indicates	O
a	O
role	O
for	O
both	O
proteins	O
in	O
intracellular	B-CC
signal	O
transduction	O
pathways	O
which	O
are	O
modulated	O
by	O
modification	O
of	O
their	O
phosphorylation	O
status	O
.	O

Expression	O
and	O
localization	O
of	O
the	O
multidrug	B-GGP
resistance	I-GGP
protein	I-GGP
5	I-GGP
(	O
MRP5	B-GGP
/	O
ABCC5	B-GGP
)	O
,	O
a	O
cellular	O
export	O
pump	O
for	O
cyclic	B-MED
nucleotides	I-MED
,	O
in	O
human	O
heart	O
.	O

The	O
multidrug	B-GGP
resistance	I-GGP
protein	I-GGP
5	I-GGP
(	O
MRP5	B-GGP
/	O
ABCC5	B-GGP
)	O
has	O
been	O
recently	O
identified	O
as	O
cellular	O
export	O
pump	O
for	O
cyclic	B-MED
nucleotides	I-MED
with	O
3	B-MED
'	I-MED
,	I-MED
5	I-MED
'	I-MED
-	I-MED
cyclic	I-MED
GMP	I-MED
(	O
cGMP	B-MED
)	O
as	O
a	O
high	O
-	O
affinity	O
substrate	O
.	O

In	O
view	O
of	O
the	O
important	O
role	O
of	O
cGMP	B-MED
for	O
cardiovascular	O
function	O
,	O
expression	O
of	O
this	O
transport	O
protein	O
in	O
human	O
heart	O
is	O
of	O
relevance	O
.	O

We	O
analyzed	O
the	O
expression	O
and	O
localization	O
of	O
MRP5	B-GGP
in	O
human	O
heart	O
[	O
21	O
auricular	O
(	O
AS	O
)	O
and	O
15	O
left	O
ventricular	O
samples	O
(	O
LV	O
)	O
including	O
5	O
samples	O
of	O
dilated	O
and	O
ischemic	O
cardiomyopathy	O
]	O
.	O

Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
normalized	O
to	O
beta	B-GGP
-	I-GGP
actin	I-GGP
revealed	O
expression	O
of	O
the	O
MRP5	B-GGP
gene	O
in	O
all	O
samples	O
(	O
LV	O
,	O
38	O
.	O
5	O
+	O
/	O
-	O
12	O
.	O
9	O
;	O
AS	O
,	O
12	O
.	O
7	O
+	O
/	O
-	O
5	O
.	O
6	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

An	O
MRP5	B-GGP
-	O
specific	O
polyclonal	O
antibody	O
detected	O
a	O
glycoprotein	O
of	O
approximately	O
190	O
kd	O
in	O
crude	O
cell	B-CC
membrane	I-CC
fractions	O
from	O
these	O
samples	O
.	O

Immunohistochemistry	O
with	O
the	O
affinity	O
-	O
purified	O
antibody	O
revealed	O
localization	O
of	O
MRP5	B-GGP
in	O
cardiomyocytes	O
as	O
well	O
as	O
in	O
cardiovascular	O
endothelial	O
and	O
smooth	O
muscle	O
cells	O
.	O

Furthermore	O
,	O
we	O
could	O
detect	O
MRP5	B-GGP
and	O
ATP	B-MED
-	O
dependent	O
transport	O
of	O
[	B-MED
(	I-MED
3	I-MED
)	I-MED
H	I-MED
]	I-MED
cGMP	I-MED
in	O
sarcolemma	O
vesicles	B-CC
of	O
human	O
heart	O
.	O

Quantitative	O
analysis	O
of	O
the	O
immunoblots	O
indicated	O
an	O
interindividual	O
variability	O
with	O
a	O
higher	O
expression	O
of	O
MRP5	B-GGP
in	O
the	O
ischemic	O
(	O
104	O
+	O
/	O
-	O
38	O
%	O
of	O
recombinant	O
MRP5	B-GGP
standard	O
)	O
compared	O
to	O
normal	O
ventricular	O
samples	O
(	O
53	O
+	O
/	O
-	O
36	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
we	O
screened	O
genomic	O
DNA	O
from	O
our	O
samples	O
for	O
20	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
the	O
MRP5	B-GGP
gene	O
.	O

These	O
results	O
indicate	O
that	O
MRP5	B-GGP
is	O
localized	O
in	O
cardiac	O
and	O
cardiovascular	O
myocytes	O
as	O
well	O
as	O
endothelial	O
cells	O
with	O
increased	O
expression	O
in	O
ischemic	O
cardiomyopathy	O
.	O

Therefore	O
,	O
MRP5	B-GGP
-	O
mediated	O
cellular	O
export	O
may	O
represent	O
a	O
novel	O
,	O
disease	O
-	O
dependent	O
pathway	O
for	O
cGMP	B-MED
removal	O
from	O
cardiac	O
cells	O
.	O

LPS	B-MED
-	O
TLR4	B-GGP
signaling	O
to	O
IRF	B-GGP
-	I-GGP
3	I-GGP
/	O
7	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
involves	O
the	O
toll	O
adapters	O
TRAM	B-GGP
and	O
TRIF	B-GGP
.	O

Toll	B-GGP
-	I-GGP
IL	I-GGP
-	I-GGP
1	I-GGP
-	I-GGP
resistance	I-GGP
(	I-GGP
TIR	I-GGP
)	I-GGP
domain	I-GGP
-	I-GGP
containing	I-GGP
adaptor	I-GGP
-	I-GGP
inducing	I-GGP
IFN	I-GGP
-	I-GGP
beta	I-GGP
(	I-GGP
TRIF	I-GGP
)	I-GGP
-	I-GGP
related	I-GGP
adaptor	I-GGP
molecule	I-GGP
(	O
TRAM	B-GGP
)	O
is	O
the	O
fourth	O
TIR	B-GGP
domain	O
-	O
containing	O
adaptor	O
protein	O
to	O
be	O
described	O
that	O
participates	O
in	O
Toll	B-GGP
receptor	I-GGP
signaling	O
.	O

Like	O
TRIF	B-GGP
,	O
TRAM	B-GGP
activates	O
interferon	B-GGP
regulatory	I-GGP
factor	I-GGP
(	I-GGP
IRF	I-GGP
)	I-GGP
-	I-GGP
3	I-GGP
,	O
IRF	B-GGP
-	I-GGP
7	I-GGP
,	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
dependent	O
signaling	O
pathways	O
.	O

Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	I-GGP
TLR	I-GGP
)	I-GGP
3	I-GGP
and	O
4	B-GGP
activate	O
these	O
pathways	O
to	O
induce	O
IFN	B-GGP
-	I-GGP
alpha	I-GGP
/	I-GGP
beta	I-GGP
,	O
regulated	B-GGP
on	I-GGP
activation	I-GGP
,	I-GGP
normal	I-GGP
T	I-GGP
cell	I-GGP
expressed	I-GGP
and	I-GGP
secreted	I-GGP
(	O
RANTES	B-GGP
)	O
,	O
and	O
gamma	B-GGP
interferon	I-GGP
-	I-GGP
inducible	I-GGP
protein	I-GGP
10	I-GGP
(	O
IP	B-GGP
-	I-GGP
10	I-GGP
)	O
expression	O
independently	O
of	O
the	O
adaptor	O
protein	O
myeloid	B-GGP
differentiation	I-GGP
factor	I-GGP
88	I-GGP
(	O
MyD88	B-GGP
)	O
.	O

Dominant	O
negative	O
and	O
siRNA	O
studies	O
performed	O
here	O
demonstrate	O
that	O
TRIF	B-GGP
functions	O
downstream	O
of	O
both	O
the	O
TLR3	B-GGP
(	O
dsRNA	O
)	O
and	O
TLR4	B-GGP
(	O
LPS	B-MED
)	O
signaling	O
pathways	O
,	O
whereas	O
the	O
function	O
of	O
TRAM	B-GGP
is	O
restricted	O
to	O
the	O
TLR4	B-GGP
pathway	O
.	O

TRAM	B-GGP
interacts	O
with	O
TRIF	B-GGP
,	O
MyD88	B-GGP
adaptor	I-GGP
-	I-GGP
like	I-GGP
protein	I-GGP
(	O
Mal	B-GGP
)	O
/	O
TIRAP	B-GGP
,	O
and	O
TLR4	B-GGP
but	O
not	O
with	O
TLR3	B-GGP
.	O

These	O
studies	O
suggest	O
that	O
TRIF	B-GGP
and	O
TRAM	B-GGP
both	O
function	O
in	O
LPS	B-MED
-	O
TLR4	B-GGP
signaling	O
to	O
regulate	O
the	O
MyD88	B-GGP
-	O
independent	O
pathway	O
during	O
the	O
innate	O
immune	O
response	O
to	O
LPS	B-MED
.	O

Pharmacological	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
required	O
for	O
oxidative	O
burst	O
in	O
chicken	O
heterophils	O
stimulated	O
by	O
a	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
2	I-GGP
agonist	O
.	O

Toll	B-GGP
-	I-GGP
like	I-GGP
receptors	I-GGP
(	O
TLRs	B-GGP
)	O
play	O
an	O
important	O
role	O
in	O
the	O
innate	O
immune	O
response	O
of	O
avian	O
heterophils	O
.	O

We	O
previously	O
used	O
the	O
pharmacological	O
inhibitors	O
genistein	B-MED
,	O
verapamil	B-MED
,	O
chelerythrine	B-MED
,	O
and	O
pertussis	B-GGP
toxin	I-GGP
to	O
investigate	O
the	O
upstream	O
signaling	O
events	O
involved	O
in	O
TLR2	B-GGP
-	O
mediated	O
oxidative	O
burst	O
in	O
chicken	O
heterophils	O
.	O

Only	O
chelerythrine	B-MED
,	O
a	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
inhibitor	O
,	O
was	O
found	O
to	O
significantly	O
inhibit	O
oxidative	O
burst	O
stimulated	O
by	O
the	O
TLR2	B-GGP
agonist	O
lipoteichoic	B-MED
acid	I-MED
(	O
LTA	B-MED
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
selective	O
pharmacological	O
inhibitors	O
to	O
investigate	O
the	O
roles	O
of	O
phosphatidylinositol	B-GGP
-	I-GGP
3	I-GGP
'	I-GGP
-	I-GGP
kinase	I-GGP
(	O
PI3	B-GGP
-	I-GGP
K	I-GGP
)	O
,	O
phospholipase	B-GGP
C	I-GGP
(	O
PLC	B-GGP
)	O
,	O
calcium	B-MED
-	O
dependent	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
(	O
PKC	B-GGP
)	O
,	O
extra	B-GGP
-	I-GGP
cellular	I-GGP
signal	I-GGP
regulated	I-GGP
kinase	I-GGP
(	O
ERK	B-GGP
)	O
,	O
and	O
nuclear	B-COM
translocation	I-COM
factor	I-COM
kappa	I-COM
B	I-COM
(	O
NF	B-COM
-	I-COM
kappaB	I-COM
)	O
on	O
TLR2	B-GGP
-	O
mediated	O
oxidative	O
burst	O
.	O

U	B-MED
-	I-MED
73122	I-MED
(	O
a	O
PLC	B-GGP
inhibitor	O
)	O
,	O
wortmannin	B-MED
(	O
a	O
PI3	B-GGP
-	I-GGP
K	I-GGP
inhibitor	O
)	O
,	O
PD	B-MED
98059	I-MED
(	O
an	O
ERK	B-GGP
inhibitor	O
)	O
,	O
Go	B-MED
6976	I-MED
(	O
a	O
PKC	B-GGP
inhibitor	O
)	O
and	O
Bay	B-MED
11	I-MED
-	I-MED
7082	I-MED
(	O
a	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitor	O
)	O
significantly	O
decreased	O
LTA	B-MED
-	O
stimulated	O
oxidative	O
burst	O
in	O
heterophils	O
by	O
77	O
%	O
,	O
30	O
%	O
,	O
36	O
%	O
,	O
78	O
%	O
,	O
and	O
61	O
%	O
,	O
respectively	O
.	O

Activated	O
TLR2	B-GGP
utilizes	O
PI3	B-GGP
-	I-GGP
K	I-GGP
,	O
PLC	B-GGP
,	O
PKC	B-GGP
,	O
ERK	B-GGP
,	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
as	O
signaling	O
factors	O
that	O
mediate	O
the	O
oxidative	O
burst	O
of	O
chicken	O
heterophils	O
.	O

mTOR	B-GGP
signaling	O
to	O
translation	O
.	O

Over	O
the	O
past	O
few	O
years	O
,	O
the	O
target	B-GGP
of	I-GGP
rapamycin	I-GGP
(	O
TOR	B-GGP
)	O
pathway	O
has	O
been	O
implicated	O
in	O
the	O
control	O
of	O
translation	O
,	O
both	O
in	O
yeast	O
and	O
in	O
higher	O
eukaryotes	O
.	O

In	O
this	O
review	O
,	O
we	O
provide	O
an	O
overview	O
of	O
translation	O
in	O
eukaryotes	O
,	O
and	O
discuss	O
the	O
mechanisms	O
and	O
advantages	O
of	O
the	O
regulation	O
of	O
translation	O
.	O

We	O
then	O
describe	O
how	O
the	O
TOR	B-GGP
pathway	O
can	O
modulate	O
translation	O
in	O
yeast	O
and	O
in	O
mammals	O
,	O
through	O
the	O
modulation	O
of	O
the	O
phosphorylation	O
of	O
key	O
translation	O
components	O
,	O
and	O
the	O
regulation	O
of	O
the	O
abundance	O
of	O
ribosomes	B-CC
and	O
translation	O
factors	O
.	O

Protein	O
phosphatases	O
that	O
regulate	O
multifunctional	O
Ca2	B-GGP
+	I-GGP
/	I-GGP
calmodulin	I-GGP
-	I-GGP
dependent	I-GGP
protein	I-GGP
kinases	I-GGP
:	O
from	O
biochemistry	O
to	O
pharmacology	O
.	O

Multifunctional	O
Ca	B-GGP
(	I-GGP
2	I-GGP
+	I-GGP
)	I-GGP
/	I-GGP
calmodulin	I-GGP
-	I-GGP
dependent	I-GGP
protein	I-GGP
kinases	I-GGP
(	O
CaMKs	B-GGP
)	O
play	O
pivotal	O
roles	O
in	O
Ca	B-MED
(	I-MED
2	I-MED
+	I-MED
)	I-MED
signaling	O
pathways	O
,	O
such	O
as	O
the	O
regulation	O
of	O
the	O
neuronal	O
functions	O
of	O
learning	O
,	O
memory	O
,	O
and	O
neuronal	O
cell	O
death	O
.	O

The	O
activities	O
of	O
the	O
kinases	O
are	O
strictly	O
regulated	O
by	O
protein	O
phosphorylation	O
/	O
dephosphorylation	O
.	O

Although	O
the	O
activation	O
mechanisms	O
for	O
multifunctional	O
CaMKs	B-GGP
through	O
phosphorylation	O
,	O
which	O
correspond	O
to	O
"	O
switch	O
on	O
,	O
"	O
have	O
been	O
extensively	O
studied	O
,	O
the	O
negative	O
regulatory	O
mechanisms	O
through	O
dephosphorylation	O
,	O
which	O
correspond	O
to	O
"	O
switch	O
off	O
,	O
"	O
have	O
not	O
.	O

In	O
this	O
review	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
multifunctional	O
CaMKs	B-GGP
by	O
the	O
protein	O
phosphatases	O
responsible	O
.	O

We	O
first	O
summarized	O
the	O
current	O
understanding	O
of	O
negative	O
regulation	O
of	O
CaMKs	B-GGP
by	O
known	O
protein	O
phosphatases	O
and	O
their	O
physiological	O
significance	O
.	O

We	O
then	O
discussed	O
newly	O
developed	O
methods	O
for	O
detection	O
of	O
protein	O
phosphatases	O
involved	O
in	O
the	O
regulation	O
of	O
CaMKs	B-GGP
.	O

We	O
also	O
summarized	O
the	O
biochemical	O
properties	O
of	O
a	O
novel	O
protein	O
phosphatase	O
,	O
which	O
we	O
isolated	O
with	O
the	O
new	O
methods	O
and	O
designated	O
as	O
CaMK	B-GGP
phosphatase	I-GGP
(	O
CaMKP	B-GGP
)	O
,	O
and	O
its	O
homologue	O
.	O

Pharmacological	O
implications	O
for	O
neuronal	O
functions	O
including	O
memory	O
and	O
neuronal	O
cell	O
death	O
are	O
discussed	O
from	O
the	O
viewpoint	O
that	O
regulation	O
of	O
protein	O
kinase	O
activity	O
can	O
be	O
elucidated	O
by	O
focusing	O
on	O
protein	O
phosphatases	O
involved	O
in	O
its	O
"	O
switch	O
off	O
"	O
mechanism	O
.	O

Soluble	O
forms	O
of	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	I-GGP
TLR	I-GGP
)	I-GGP
2	I-GGP
capable	O
of	O
modulating	O
TLR2	B-GGP
signaling	O
are	O
present	O
in	O
human	O
plasma	O
and	O
breast	O
milk	O
.	O

Dysregulation	O
of	O
the	O
initial	O
,	O
innate	O
immune	O
response	O
to	O
bacterial	O
infection	O
may	O
lead	O
to	O
septic	O
shock	O
and	O
death	O
.	O

Toll	B-GGP
-	I-GGP
like	I-GGP
receptors	I-GGP
(	O
TLRs	B-GGP
)	O
play	O
a	O
crucial	O
role	O
in	O
this	O
innate	O
immune	O
response	O
,	O
and	O
yet	O
the	O
regulatory	O
mechanisms	O
controlling	O
microbial	O
-	O
induced	O
TLR	B-GGP
triggering	O
are	O
still	O
to	O
be	O
fully	O
understood	O
.	O

We	O
have	O
therefore	O
sought	O
specific	O
regulatory	O
mechanisms	O
that	O
may	O
modulate	O
TLR	B-GGP
signaling	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
for	O
the	O
possible	O
existence	O
of	O
a	O
functionally	O
active	O
soluble	O
form	O
of	O
TLR2	B-GGP
.	O

We	O
demonstrated	O
the	O
existence	O
of	O
natural	O
soluble	O
forms	O
of	O
TLR2	B-GGP
(	O
sTLR2	B-GGP
)	O
,	O
which	O
we	O
show	O
to	O
be	O
capable	O
of	O
modulating	O
cell	O
activation	O
.	O

We	O
found	O
that	O
blood	O
monocytes	O
released	O
sTLR2	B-GGP
constitutively	O
and	O
that	O
the	O
kinetics	O
of	O
sTLR2	B-GGP
release	O
increased	O
upon	O
cell	O
activation	O
.	O

Analysis	O
of	O
cells	O
expressing	O
the	O
human	O
TLR2	B-GGP
cDNA	O
or	O
its	O
c	B-GGP
-	I-GGP
myc	I-GGP
-	O
tagged	O
version	O
indicated	O
that	O
sTLR2	B-GGP
resulted	O
from	O
the	O
posttranslational	O
modification	O
of	O
the	O
TLR2	B-GGP
protein	O
in	O
an	O
intracellular	B-CC
compartment	I-CC
.	O

Moreover	O
,	O
an	O
intracellular	B-CC
pool	O
of	O
sTLR2	B-GGP
is	O
maintained	O
.	O

sTLR2	B-GGP
was	O
found	O
naturally	O
expressed	O
in	O
breast	O
milk	O
and	O
plasma	O
.	O

Milk	O
sTLR2	B-GGP
levels	O
mirrored	O
those	O
of	O
the	O
TLR	B-GGP
coreceptor	O
soluble	O
CD14	B-GGP
.	O

Depletion	O
of	O
sTLR2	B-GGP
from	O
serum	O
resulted	O
in	O
an	O
increased	O
cellular	O
response	O
to	O
bacterial	O
lipopeptide	B-MED
.	O

Notably	O
,	O
serum	O
sTLR2	B-GGP
was	O
lower	O
in	O
tuberculosis	O
patients	O
.	O

Coimmunoprecipitation	O
experiments	O
and	O
computational	O
molecular	O
docking	O
studies	O
showed	O
an	O
interaction	O
between	O
sTLR2	B-GGP
and	O
soluble	O
CD14	B-GGP
in	O
plasma	O
and	O
milk	O
.	O

These	O
findings	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
and	O
specific	O
innate	O
immune	O
mechanism	O
regulating	O
microbial	O
-	O
induced	O
TLR	B-GGP
triggering	O
,	O
and	O
may	O
lead	O
to	O
new	O
therapeutics	O
for	O
the	O
prevention	O
and	O
/	O
or	O
treatment	O
of	O
severe	O
infectious	O
diseases	O
.	O

Vasoactive	O
effects	O
of	O
methylamine	B-MED
in	O
isolated	O
human	O
blood	O
vessels	O
:	O
role	O
of	O
semicarbazide	B-GGP
-	I-GGP
sensitive	I-GGP
amine	I-GGP
oxidase	I-GGP
,	O
formaldehyde	B-MED
,	O
and	O
hydrogen	B-MED
peroxide	I-MED
.	O

It	O
is	O
hypothesized	O
that	O
methylamine	B-MED
(	O
MA	B-MED
)	O
and	O
semicarbazide	B-GGP
-	I-GGP
sensitive	I-GGP
amine	I-GGP
oxidase	I-GGP
(	O
SSAO	B-GGP
)	O
activity	O
are	O
involved	O
in	O
the	O
cardiovascular	O
complications	O
in	O
human	O
diabetics	O
.	O

To	O
test	O
this	O
,	O
we	O
1	O
)	O
determined	O
the	O
acute	O
vasoactive	O
effects	O
of	O
MA	B-MED
(	O
1	O
-	O
1	O
,	O
000	O
micromol	O
/	O
l	O
)	O
in	O
uncontracted	O
and	O
norepinephrine	B-MED
(	O
NE	B-MED
;	O
1	O
micromol	O
/	O
l	O
)	O
-	O
precontracted	O
human	O
blood	O
vessels	O
used	O
for	O
coronary	O
artery	O
bypass	O
grafts	O
[	O
left	O
internal	O
mammary	O
artery	O
(	O
LIMA	O
)	O
,	O
radial	O
artery	O
(	O
RA	O
)	O
,	O
and	O
right	O
saphenous	O
vein	O
(	O
RSV	O
)	O
]	O
;	O
2	O
)	O
tested	O
whether	O
MA	B-MED
effects	O
in	O
LIMA	O
and	O
RSV	O
were	O
dependent	O
on	O
SSAO	B-GGP
activity	O
using	O
the	O
SSAO	B-GGP
inhibitor	O
semicarbazide	B-MED
(	O
1	O
mmol	O
/	O
l	O
,	O
15	O
min	O
)	O
;	O
3	O
)	O
determined	O
the	O
effects	O
of	O
MA	B-MED
metabolites	O
formaldehyde	B-MED
and	O
hydrogen	B-MED
peroxide	I-MED
in	O
LIMA	O
and	O
RSV	O
;	O
4	O
)	O
tested	O
whether	O
the	O
MA	B-MED
response	O
was	O
nitric	B-MED
oxide	I-MED
,	O
prostaglandin	B-MED
,	O
or	O
hyperpolarization	O
dependent	O
;	O
5	O
)	O
measured	O
the	O
LIMA	O
and	O
RSV	O
cGMP	B-MED
levels	O
after	O
MA	B-MED
exposure	O
;	O
and	O
6	O
)	O
quantified	O
SSAO	B-GGP
activity	O
in	O
LIMA	O
,	O
RA	O
,	O
and	O
RSV	O
.	O

In	O
NE	B-MED
-	O
precontracted	O
vessels	O
,	O
MA	B-MED
stimulated	O
a	O
biphasic	O
response	O
in	O
RA	O
and	O
RSV	O
(	O
rapid	O
contraction	O
followed	O
by	O
prolonged	O
relaxation	O
)	O
and	O
dominant	O
relaxation	O
in	O
LIMA	O
(	O
mean	O
+	O
/	O
-	O
SE	O
,	O
%	O
relaxation	O
:	O
55	O
.	O
4	O
+	O
/	O
-	O
3	O
.	O
9	O
,	O
n	O
=	O
30	O
)	O
.	O

The	O
MA	B-MED
-	O
induced	O
relaxation	O
in	O
LIMA	O
was	O
repeatable	O
,	O
nontoxic	O
,	O
and	O
age	O
independent	O
.	O

Semicarbazide	B-MED
significantly	O
blocked	O
MA	B-MED
-	O
induced	O
relaxation	O
(	O
%	O
inhibition	O
:	O
82	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
8	O
,	O
n	O
=	O
7	O
)	O
and	O
SSAO	B-GGP
activity	O
(	O
%	O
inhibition	O
:	O
98	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
3	O
,	O
n	O
=	O
26	O
)	O
in	O
LIMA	O
.	O

Formaldehyde	B-MED
(	O
%	O
relaxation	O
:	O
37	O
.	O
3	O
+	O
/	O
-	O
18	O
.	O
6	O
,	O
n	O
=	O
3	O
)	O
and	O
H	B-MED
(	I-MED
2	I-MED
)	I-MED
O	I-MED
(	I-MED
2	I-MED
)	I-MED
(	O
%	O
relaxation	O
:	O
55	O
.	O
6	O
+	O
/	O
-	O
9	O
.	O
0	O
,	O
n	O
=	O
9	O
)	O
at	O
1	O
mmol	O
/	O
l	O
relaxed	O
NE	B-MED
-	O
precontracted	O
LIMA	O
comparable	O
with	O
MA	B-MED
.	O

MA	B-MED
-	O
induced	O
relaxation	O
in	O
LIMA	O
was	O
nitric	B-MED
oxide	I-MED
,	O
prostaglandin	B-MED
,	O
and	O
possibly	O
cGMP	B-MED
independent	O
and	O
blocked	O
by	O
hyperpolarization	O
.	O

We	O
conclude	O
that	O
vascular	O
SSAO	B-GGP
activity	O
may	O
convert	O
endogenous	O
amines	B-MED
,	O
like	O
MA	B-MED
,	O
to	O
vasoactive	O
metabolites	O
.	O

Crystal	O
structures	O
of	O
human	O
bifunctional	O
enzyme	O
aminoimidazole	B-GGP
-	I-GGP
4	I-GGP
-	I-GGP
carboxamide	I-GGP
ribonucleotide	I-GGP
transformylase	I-GGP
/	I-GGP
IMP	I-GGP
cyclohydrolase	I-GGP
in	O
complex	O
with	O
potent	O
sulfonyl	B-MED
-	O
containing	O
antifolates	B-MED
.	O

Aminoimidazole	B-GGP
-	I-GGP
4	I-GGP
-	I-GGP
carboxamide	I-GGP
ribonucleotide	I-GGP
(	I-GGP
AICAR	I-GGP
)	I-GGP
transformylase	I-GGP
/	I-GGP
IMP	I-GGP
cyclohydrolase	I-GGP
(	O
ATIC	B-GGP
)	O
is	O
a	O
bifunctional	O
enzyme	O
with	O
folate	B-MED
-	O
dependent	O
AICAR	B-GGP
transformylase	I-GGP
and	O
IMP	B-GGP
cyclohydrolase	I-GGP
activities	O
that	O
catalyzes	O
the	O
last	O
two	O
steps	O
of	O
purine	B-MED
biosynthesis	O
.	O

The	O
AICAR	B-GGP
transformylase	I-GGP
inhibitors	O
BW1540	B-MED
and	O
BW2315	B-MED
are	O
sulfamido	B-MED
-	O
bridged	O
5	B-MED
,	I-MED
8	I-MED
-	I-MED
dideazafolate	I-MED
analogs	O
with	O
remarkably	O
potent	O
K	O
(	O
i	O
)	O
values	O
of	O
8	O
and	O
6	O
nm	O
,	O
respectively	O
,	O
compared	O
with	O
most	O
other	O
antifolates	B-MED
.	O

Crystal	O
structures	O
of	O
ATIC	B-GGP
at	O
2	O
.	O
55	O
and	O
2	O
.	O
60	O
A	O
with	O
each	O
inhibitor	O
,	O
in	O
the	O
presence	O
of	O
substrate	O
AICAR	B-GGP
,	O
revealed	O
that	O
the	O
sulfonyl	B-MED
groups	O
dominate	O
inhibitor	O
binding	O
and	O
orientation	O
through	O
interaction	O
with	O
the	O
proposed	O
oxyanion	B-MED
hole	O
.	O

These	O
agents	O
then	O
appear	O
to	O
mimic	O
the	O
anionic	O
transition	O
state	O
and	O
now	O
implicate	O
Asn	B-MED
(	I-MED
431	I-MED
'	I-MED
)	I-MED
in	O
the	O
reaction	O
mechanism	O
along	O
with	O
previously	O
identified	O
key	O
catalytic	O
residues	O
Lys	B-MED
(	I-MED
266	I-MED
)	I-MED
and	O
His	B-MED
(	I-MED
267	I-MED
)	I-MED
.	O

Potent	O
and	O
selective	O
inhibition	O
of	O
the	O
AICAR	B-GGP
transformylase	I-GGP
active	O
site	O
,	O
compared	O
with	O
other	O
folate	B-MED
-	O
dependent	O
enzymes	O
,	O
should	O
therefore	O
be	O
pursued	O
by	O
further	O
design	O
of	O
sulfonyl	B-MED
-	O
containing	O
antifolates	B-MED
.	O

A	O
novel	O
mTOR	B-GGP
-	O
regulated	O
phosphorylation	O
site	O
in	O
elongation	B-GGP
factor	I-GGP
2	I-GGP
kinase	I-GGP
modulates	O
the	O
activity	O
of	O
the	O
kinase	O
and	O
its	O
binding	O
to	O
calmodulin	B-GGP
.	O

Eukaryotic	B-GGP
elongation	I-GGP
factor	I-GGP
2	I-GGP
(	I-GGP
eEF2	I-GGP
)	I-GGP
kinase	I-GGP
is	O
an	O
unusual	O
calcium	B-MED
-	O
and	O
calmodulin	B-GGP
-	O
dependent	O
protein	O
kinase	O
that	O
is	O
regulated	O
by	O
insulin	B-GGP
through	O
the	O
rapamycin	B-MED
-	O
sensitive	O
mTOR	B-GGP
pathway	O
.	O

Here	O
we	O
show	O
that	O
insulin	B-GGP
decreases	O
the	O
ability	O
of	O
eEF2	B-GGP
kinase	I-GGP
to	O
bind	O
calmodulin	B-GGP
in	O
a	O
rapamycin	B-MED
-	O
sensitive	O
manner	O
.	O

We	O
identify	O
a	O
novel	O
phosphorylation	O
site	O
in	O
eEF2	B-GGP
kinase	I-GGP
(	O
Ser78	B-MED
)	O
that	O
is	O
located	O
immediately	O
next	O
to	O
its	O
calmodulin	B-GGP
-	O
binding	O
motif	O
.	O

Phosphorylation	O
of	O
this	O
site	O
is	O
increased	O
by	O
insulin	B-GGP
in	O
a	O
rapamycin	B-MED
-	O
sensitive	O
fashion	O
.	O

Regulation	O
of	O
the	O
phosphorylation	O
of	O
Ser78	B-MED
also	O
requires	O
amino	O
acids	O
and	O
the	O
protein	O
kinase	O
phosphoinositide	B-GGP
-	I-GGP
dependent	I-GGP
kinase	I-GGP
1	I-GGP
.	O

Mutation	O
of	O
this	O
site	O
to	O
alanine	B-MED
strongly	O
attenuates	O
the	O
effects	O
of	O
insulin	B-GGP
and	O
rapamycin	B-MED
both	O
on	O
the	O
binding	O
of	O
calmodulin	B-GGP
to	O
eEF2	B-GGP
kinase	I-GGP
and	O
on	O
eEF2	B-GGP
kinase	I-GGP
activity	O
.	O

Phosphorylation	O
of	O
Ser78	B-MED
is	O
thus	O
likely	O
to	O
link	O
insulin	B-GGP
and	O
mTOR	B-GGP
signaling	O
to	O
the	O
control	O
of	O
eEF2	B-GGP
phosphorylation	O
and	O
chain	O
elongation	O
.	O

This	O
site	O
is	O
not	O
a	O
target	O
for	O
known	O
kinases	O
in	O
the	O
mTOR	B-GGP
pathway	O
,	O
e	O
.	O
g	O
.	O
,	O
the	O
S6	B-GGP
kinases	I-GGP
,	O
implying	O
that	O
it	O
is	O
phosphorylated	O
by	O
a	O
novel	O
mTOR	B-GGP
-	O
linked	O
protein	O
kinase	O
that	O
serves	O
to	O
couple	O
hormones	O
and	O
amino	O
acids	O
to	O
the	O
control	O
of	O
translation	O
elongation	O
.	O

eEF2	B-GGP
kinase	I-GGP
is	O
thus	O
a	O
target	O
for	O
mTOR	B-GGP
signaling	O
independently	O
of	O
previously	O
known	O
downstream	O
components	O
of	O
the	O
pathway	O
.	O

The	O
replication	O
fork	O
block	O
protein	O
Fob1	B-GGP
functions	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
FEAR	O
network	O
.	O

BACKGROUND	O
:	O
The	O
protein	O
phosphatase	O
Cdc14	B-GGP
is	O
a	O
key	O
regulator	O
of	O
exit	O
from	O
mitosis	O
in	O
budding	O
yeast	O
.	O

Its	O
activation	O
during	O
anaphase	O
is	O
characterized	O
by	O
dissociation	O
from	O
its	O
inhibitor	O
Cfi1	B-GGP
/	O
Net1	B-GGP
in	O
the	O
nucleolus	B-CC
and	O
is	O
controlled	O
by	O
two	O
regulatory	O
networks	O
.	O

The	O
Cdc14	B-GGP
early	O
anaphase	O
release	O
(	O
FEAR	O
)	O
network	O
promotes	O
activation	O
of	O
the	O
phosphatase	O
during	O
early	O
anaphase	O
,	O
whereas	O
the	O
mitotic	O
exit	O
network	O
(	O
MEN	O
)	O
activates	O
Cdc14	B-GGP
during	O
late	O
stages	O
of	O
anaphase	O
.	O

RESULTS	O
:	O
Here	O
we	O
investigate	O
how	O
the	O
FEAR	O
network	O
component	O
Spo12	B-GGP
regulates	O
Cdc14	B-GGP
activation	O
.	O

We	O
identify	O
the	O
replication	O
fork	O
block	O
protein	O
Fob1	B-GGP
as	O
a	O
Spo12	B-GGP
-	O
interacting	O
factor	O
.	O

Inactivation	O
of	O
FOB1	B-GGP
leads	O
to	O
premature	O
release	O
of	O
Cdc14	B-GGP
from	O
the	O
nucleolus	B-CC
in	O
metaphase	O
-	O
arrested	O
cells	O
.	O

Conversely	O
,	O
high	O
levels	O
of	O
FOB1	B-GGP
delay	O
the	O
release	O
of	O
Cdc14	B-GGP
from	O
the	O
nucleolus	B-CC
.	O

Fob1	B-GGP
associates	O
with	O
Cfi1	B-GGP
/	O
Net1	B-GGP
,	O
and	O
consistent	O
with	O
this	O
observation	O
,	O
we	O
find	O
that	O
the	O
bulk	O
of	O
Cdc14	B-GGP
localizes	O
to	O
the	O
Fob1	B-GGP
binding	O
region	O
within	O
the	O
rDNA	O
repeats	O
.	O

Finally	O
,	O
we	O
show	O
that	O
Spo12	B-GGP
phosphorylation	O
is	O
cell	O
cycle	O
regulated	O
and	O
affects	O
its	O
binding	O
to	O
Fob1	B-GGP
.	O

CONCLUSIONS	O
:	O
Fob1	B-GGP
functions	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
FEAR	O
network	O
.	O

We	O
propose	O
that	O
Fob1	B-GGP
helps	O
to	O
prevent	O
the	O
dissociation	O
of	O
Cdc14	B-GGP
from	O
Cfi1	B-GGP
/	O
Net1	B-GGP
prior	O
to	O
anaphase	O
and	O
that	O
Spo12	B-GGP
activation	O
during	O
early	O
anaphase	O
promotes	O
the	O
release	O
of	O
Cdc14	B-GGP
from	O
its	O
inhibitor	O
by	O
antagonizing	O
Fob1	B-GGP
function	O
.	O

The	O
proapoptotic	O
gene	O
SIVA	B-GGP
is	O
a	O
direct	O
transcriptional	O
target	O
for	O
the	O
tumor	O
suppressors	O
p53	B-GGP
and	O
E2F1	B-GGP
.	O

The	O
p53	B-GGP
tumor	O
suppressor	O
gene	O
is	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
neuronal	O
cell	O
death	O
in	O
acute	O
neurological	O
disease	O
and	O
in	O
neurodegeneration	O
.	O

The	O
p53	B-GGP
signaling	O
cascade	O
is	O
complex	O
,	O
and	O
the	O
mechanism	O
by	O
which	O
p53	B-GGP
induces	O
apoptosis	O
is	O
cell	O
type	O
-	O
dependent	O
.	O

Using	O
DNA	O
microarray	O
analysis	O
,	O
we	O
have	O
found	O
a	O
striking	O
induction	O
of	O
the	O
proapoptotic	O
gene	O
,	O
SIVA	B-GGP
.	O

SIVA	B-GGP
is	O
a	O
proapoptotic	O
protein	O
containing	O
a	O
death	O
domain	O
and	O
interacts	O
with	O
members	O
of	O
the	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
receptor	I-GGP
family	O
as	O
well	O
as	O
anti	O
-	O
apoptotic	O
Bcl	B-GGP
-	I-GGP
2	I-GGP
family	O
proteins	O
.	O

SIVA	B-GGP
is	O
induced	O
following	O
direct	O
p53	B-GGP
gene	O
delivery	O
,	O
treatment	O
with	O
a	O
DNA	O
-	O
damaging	O
agent	O
camptothecin	B-MED
,	O
and	O
stroke	O
injury	O
in	O
vivo	O
.	O

SIVA	B-GGP
up	O
-	O
regulation	O
is	O
sufficient	O
to	O
initiate	O
the	O
apoptotic	O
cascade	O
in	O
neurons	O
.	O

Through	O
isolation	O
and	O
analysis	O
of	O
the	O
SIVA	B-GGP
promoter	O
,	O
we	O
have	O
identified	O
response	O
elements	O
for	O
both	O
p53	B-GGP
and	O
E2F1	B-GGP
.	O

Like	O
p53	B-GGP
,	O
E2F1	B-GGP
is	O
another	O
tumor	O
suppressor	O
gene	O
involved	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
including	O
neuronal	O
injury	O
models	O
.	O

We	O
have	O
identified	O
E2F	B-GGP
consensus	O
sites	O
in	O
the	O
promoter	O
region	O
,	O
whereas	O
p53	B-GGP
recognition	O
sequences	O
were	O
found	O
in	O
intron1	O
.	O

Sequence	O
analysis	O
has	O
shown	O
that	O
these	O
consensus	O
sites	O
are	O
also	O
conserved	O
between	O
mouse	O
and	O
human	O
SIVA	B-GGP
genes	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
reveal	O
that	O
both	O
transcription	O
factors	O
are	O
capable	O
of	O
binding	O
to	O
putative	O
consensus	O
sites	O
,	O
and	O
luciferase	B-GGP
reporter	O
assays	O
reveal	O
that	O
E2F1	B-GGP
and	O
p53	B-GGP
can	O
activate	O
transcription	O
from	O
the	O
SIVA	B-GGP
promoter	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
proapoptotic	O
gene	O
,	O
SIVA	B-GGP
,	O
which	O
functions	O
in	O
a	O
broad	O
spectrum	O
of	O
cell	O
types	O
,	O
is	O
a	O
direct	O
transcriptional	O
target	O
for	O
both	O
tumor	O
suppressors	O
,	O
p53	B-GGP
and	O
E2F1	B-GGP
.	O

Inactivating	O
Cdc25	B-GGP
,	O
mitotic	O
style	O
.	O

Mitotic	O
entry	O
and	O
exit	O
require	O
activation	O
and	O
inactivation	O
of	O
the	O
Cdk1	B-COM
-	I-COM
cyclin	I-COM
B	I-COM
kinase	O
complex	O
,	O
respectively	O
.	O

The	O
Cdc25	B-GGP
protein	O
phosphatase	O
family	O
activates	O
Cdk1	B-COM
-	I-COM
cyclin	I-COM
B	I-COM
at	O
the	O
G2	O
/	O
M	O
transition	O
by	O
removing	O
inhibitory	O
phosphate	O
groups	O
.	O

Cdc25	B-GGP
family	O
members	O
,	O
held	O
inactive	O
during	O
interphase	O
,	O
are	O
activated	O
during	O
mitotic	O
progression	O
in	O
an	O
amplification	O
loop	O
involving	O
Cdk1	B-COM
-	I-COM
cyclin	I-COM
B	I-COM
.	O

While	O
Cdc25	B-GGP
activation	O
at	O
the	O
G2	O
/	O
M	O
transition	O
is	O
required	O
for	O
the	O
timely	O
initiation	O
of	O
mitosis	O
,	O
recent	O
evidence	O
suggests	O
that	O
the	O
inactivation	O
of	O
Cdc25	B-GGP
in	O
late	O
mitosis	O
may	O
play	O
a	O
role	O
in	O
supporting	O
Cdk1	B-COM
-	I-COM
cyclin	I-COM
B	I-COM
inactivation	O
.	O

Here	O
,	O
we	O
discuss	O
the	O
mechanisms	O
of	O
Cdc25	B-GGP
regulation	O
and	O
how	O
they	O
pertain	O
to	O
both	O
mitotic	O
entry	O
and	O
exit	O
.	O

Molecular	O
mechanisms	O
of	O
E2F	B-GGP
-	O
dependent	O
activation	O
and	O
pRB	B-GGP
-	O
mediated	O
repression	O
.	O

Alterations	O
in	O
transcription	O
of	O
genes	O
regulated	O
by	O
members	O
of	O
the	O
E2F	B-GGP
family	O
of	O
transcription	O
factors	O
can	O
be	O
viewed	O
as	O
a	O
measure	O
of	O
the	O
ebb	O
and	O
flow	O
in	O
a	O
constantly	O
evolving	O
battle	O
between	O
repressor	O
and	O
activator	O
complexes	O
.	O

Various	O
chromatin	B-CC
regulatory	O
complexes	O
have	O
been	O
linked	O
to	O
Rb	B-GGP
/	O
E2F	B-GGP
proteins	O
,	O
and	O
changes	O
in	O
histone	B-GGP
modifications	O
correlate	O
with	O
states	O
of	O
E2F	B-GGP
-	O
dependent	O
transcription	O
.	O

E2F	B-GGP
has	O
traditionally	O
been	O
viewed	O
in	O
the	O
context	O
of	O
cell	O
-	O
cycle	O
control	O
.	O

However	O
,	O
several	O
recent	O
studies	O
have	O
revealed	O
a	O
new	O
aspect	O
of	O
E2F	B-GGP
function	O
in	O
which	O
pRB	B-GGP
/	O
E2F	B-GGP
-	O
family	O
proteins	O
confer	O
stable	O
repression	O
of	O
transcription	O
.	O

Such	O
repression	O
is	O
evident	O
in	O
both	O
actively	O
proliferating	O
cells	O
and	O
in	O
cells	O
that	O
have	O
withdrawn	O
from	O
the	O
cell	O
cycle	O
.	O

nemo	B-GGP
-	I-GGP
like	I-GGP
kinase	I-GGP
is	O
an	O
essential	O
co	O
-	O
activator	O
of	O
Wnt	B-GGP
signaling	O
during	O
early	O
zebrafish	O
development	O
.	O

Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
regulates	O
many	O
aspects	O
of	O
early	O
vertebrate	O
development	O
,	O
including	O
patterning	O
of	O
the	O
mesoderm	O
and	O
neurectoderm	O
during	O
gastrulation	O
.	O

In	O
zebrafish	O
,	O
Wnt	B-GGP
signaling	O
overcomes	O
basal	O
repression	O
in	O
the	O
prospective	O
caudal	O
neurectoderm	O
by	O
Tcf	B-GGP
homologs	O
that	O
act	O
as	O
inhibitors	O
of	O
Wnt	B-GGP
target	O
genes	O
.	O

The	O
vertebrate	O
homolog	O
of	O
Drosophila	O
nemo	B-GGP
,	O
nemo	B-GGP
-	I-GGP
like	I-GGP
kinase	I-GGP
(	O
Nlk	B-GGP
)	O
,	O
can	O
phosphorylate	O
Tcf	B-GGP
/	I-GGP
Lef	I-GGP
proteins	O
and	O
inhibit	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
beta	B-COM
-	I-COM
catenin	I-COM
/	I-COM
Tcf	I-COM
complexes	O
,	O
thereby	O
blocking	O
activation	O
of	O
Wnt	B-GGP
targets	O
.	O

By	O
contrast	O
,	O
mutations	O
in	O
a	O
C	O
.	O
elegans	O
homolog	O
show	O
that	O
Nlk	B-GGP
is	O
required	O
to	O
activate	O
Wnt	B-GGP
targets	O
that	O
are	O
constitutively	O
repressed	O
by	O
Tcf	B-GGP
.	O

We	O
show	O
that	O
overexpressed	O
zebrafish	O
nlk	B-GGP
,	O
in	O
concert	O
with	O
wnt8	B-GGP
,	O
can	O
downregulate	O
two	O
tcf3	B-GGP
homologs	O
,	O
tcf3a	B-GGP
and	O
tcf3b	B-GGP
,	O
that	O
repress	O
Wnt	B-GGP
targets	O
during	O
neurectodermal	O
patterning	O
.	O

Inhibition	O
of	O
nlk	B-GGP
using	O
morpholino	O
oligos	O
reveals	O
essential	O
roles	O
in	O
regulating	O
ventrolateral	O
mesoderm	O
formation	O
in	O
conjunction	O
with	O
wnt8	B-GGP
,	O
and	O
in	O
patterning	O
of	O
the	O
midbrain	O
,	O
possibly	O
functioning	O
with	O
wnt8b	B-GGP
.	O

In	O
both	O
instances	O
,	O
nlk	B-GGP
appears	O
to	O
function	O
as	O
a	O
positive	O
regulator	O
of	O
Wnt	B-GGP
signaling	O
.	O

Additionally	O
,	O
nlk	B-GGP
strongly	O
enhances	O
convergent	O
/	O
extension	O
phenotypes	O
associated	O
with	O
wnt11	B-GGP
/	O
silberblick	B-GGP
,	O
suggesting	O
a	O
role	O
in	O
modulating	O
cell	O
movements	O
as	O
well	O
as	O
cell	O
fate	O
.	O

Repression	O
of	O
the	O
Arf	B-GGP
tumor	O
suppressor	O
by	O
E2F3	B-GGP
is	O
required	O
for	O
normal	O
cell	O
cycle	O
kinetics	O
.	O

Tumor	O
development	O
is	O
dependent	O
upon	O
the	O
inactivation	O
of	O
two	O
key	O
tumor	O
-	O
suppressor	O
networks	O
,	O
p16	B-GGP
(	O
Ink4a	B-GGP
)	O
-	O
cycD	B-COM
/	I-COM
cdk4	I-COM
-	O
pRB	B-GGP
-	O
E2F	B-GGP
and	O
p19	B-GGP
(	O
Arf	B-GGP
)	O
-	O
mdm2	B-GGP
-	O
p53	B-GGP
,	O
that	O
regulate	O
cellular	O
proliferation	O
and	O
the	O
tumor	O
surveillance	O
response	O
.	O

These	O
networks	O
are	O
known	O
to	O
intersect	O
with	O
one	O
another	O
,	O
but	O
the	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
E2F	B-GGP
directly	O
participates	O
in	O
the	O
transcriptional	O
control	O
of	O
Arf	B-GGP
in	O
both	O
normal	O
and	O
transformed	O
cells	O
.	O

This	O
occurs	O
in	O
a	O
manner	O
that	O
is	O
significantly	O
different	O
from	O
the	O
regulation	O
of	O
classic	O
E2F	B-GGP
-	O
responsive	O
targets	O
.	O

In	O
wild	O
-	O
type	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
,	O
the	O
Arf	B-GGP
promoter	O
is	O
occupied	O
by	O
E2F3	B-GGP
and	O
not	O
other	O
E2F	B-GGP
family	O
members	O
.	O

In	O
quiescent	O
cells	O
,	O
this	O
role	O
is	O
largely	O
fulfilled	O
by	O
E2F3b	B-GGP
,	O
an	O
E2F3	B-GGP
isoform	O
whose	O
function	O
was	O
previously	O
undetermined	O
.	O

E2f3	B-GGP
loss	O
is	O
sufficient	O
to	O
derepress	O
Arf	B-GGP
,	O
triggering	O
activation	O
of	O
p53	B-GGP
and	O
expression	O
of	O
p21	B-GGP
(	O
Cip1	B-GGP
)	O
.	O

Thus	O
,	O
E2F3	B-GGP
is	O
a	O
key	O
repressor	O
of	O
the	O
p19	B-GGP
(	O
Arf	B-GGP
)	O
-	O
p53	B-GGP
pathway	O
in	O
normal	O
cells	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
Arf	B-GGP
mutation	O
suppresses	O
the	O
activation	O
of	O
p53	B-GGP
and	O
p21	B-GGP
(	O
Cip1	B-GGP
)	O
in	O
E2f3	B-GGP
-	O
deficient	O
MEFs	O
.	O

Arf	B-GGP
loss	O
also	O
rescues	O
the	O
known	O
cell	O
cycle	O
re	O
-	O
entry	O
defect	O
of	O
E2f3	B-GGP
(	O
-	O
/	O
-	O
)	O
cells	O
,	O
and	O
this	O
correlates	O
with	O
restoration	O
of	O
appropriate	O
activation	O
of	O
classic	O
E2F	B-GGP
-	O
responsive	O
genes	O
.	O

Our	O
data	O
also	O
demonstrate	O
a	O
direct	O
role	O
for	O
E2F	B-GGP
in	O
the	O
oncogenic	O
activation	O
of	O
Arf	B-GGP
.	O

Specifically	O
,	O
we	O
observe	O
recruitment	O
of	O
the	O
endogenous	O
activating	O
E2Fs	B-GGP
,	O
E2F1	B-GGP
,	O
and	O
E2F3a	B-GGP
,	O
to	O
the	O
Arf	B-GGP
promoter	O
.	O

Thus	O
,	O
distinct	O
E2F	B-COM
complexes	I-COM
directly	O
contribute	O
to	O
the	O
normal	O
repression	O
and	O
oncogenic	O
activation	O
of	O
Arf	B-GGP
.	O

We	O
propose	O
that	O
monitoring	O
of	O
E2F	B-GGP
levels	O
and	O
/	O
or	O
activity	O
is	O
a	O
key	O
component	O
of	O
Arf	B-GGP
'	O
s	O
ability	O
to	O
respond	O
to	O
inappropriate	O
,	O
but	O
not	O
normal	O
cellular	O
proliferation	O
.	O

Aberrant	O
regulation	O
of	O
survivin	B-GGP
by	O
the	O
RB	B-GGP
/	O
E2F	B-GGP
family	O
of	O
proteins	O
.	O

Survivin	B-GGP
is	O
a	O
putative	O
oncogene	O
that	O
is	O
aberrantly	O
expressed	O
in	O
cancer	O
cells	O
.	O

It	O
has	O
been	O
hypothesized	O
to	O
play	O
a	O
central	O
role	O
in	O
cancer	O
progression	O
and	O
resistance	O
to	O
therapy	O
in	O
diverse	O
tumor	O
types	O
.	O

Although	O
some	O
of	O
the	O
transcriptional	O
processes	O
regulating	O
its	O
expression	O
have	O
been	O
established	O
,	O
the	O
diversity	O
of	O
genes	O
that	O
may	O
be	O
controlling	O
the	O
levels	O
of	O
its	O
expression	O
in	O
both	O
normal	O
cells	O
as	O
well	O
as	O
in	O
cancer	O
cells	O
has	O
not	O
been	O
fully	O
explored	O
.	O

The	O
most	O
common	O
genetically	O
mutated	O
pathways	O
in	O
human	O
malignancies	O
are	O
the	O
p53	B-GGP
tumor	O
suppressor	O
pathway	O
and	O
the	O
RB	B-GGP
/	O
E2F	B-GGP
pathway	O
.	O

Both	O
of	O
these	O
pathways	O
,	O
when	O
intact	O
,	O
provide	O
essential	O
checkpoints	O
in	O
the	O
maintenance	O
of	O
normal	O
cell	O
growth	O
and	O
protect	O
the	O
cell	O
from	O
DNA	O
damage	O
.	O

Using	O
non	O
-	O
transformed	O
embryonic	O
fibroblasts	O
,	O
we	O
provide	O
evidence	O
of	O
a	O
molecular	O
link	O
between	O
the	O
regulation	O
of	O
survivin	B-GGP
transcription	O
and	O
the	O
RB	B-GGP
/	O
E2F	B-GGP
family	O
of	O
proteins	O
.	O

We	O
demonstrate	O
that	O
both	O
pRB	B-GGP
and	O
p130	B-GGP
can	O
interact	O
with	O
the	O
survivin	B-GGP
promoter	O
and	O
can	O
repress	O
survivin	B-GGP
transcription	O
.	O

We	O
also	O
show	O
that	O
the	O
E2F	B-GGP
activators	O
(	O
E2F1	B-GGP
,	O
E2F2	B-GGP
,	O
and	O
E2F3	B-GGP
)	O
can	O
bind	O
to	O
the	O
survivin	B-GGP
promoter	O
and	O
induce	O
survivin	B-GGP
transcription	O
.	O

Genetically	O
modified	O
cells	O
that	O
harbor	O
deletions	O
in	O
various	O
members	O
of	O
the	O
RB	B-GGP
/	O
E2F	B-GGP
family	O
confirm	O
our	O
data	O
from	O
the	O
wild	O
-	O
type	O
cells	O
.	O

Our	O
findings	O
implicate	O
several	O
members	O
of	O
the	O
RB	B-GGP
/	O
E2F	B-GGP
pathway	O
in	O
an	O
intricate	O
mechanism	O
of	O
survivin	B-GGP
gene	O
regulation	O
that	O
,	O
when	O
genetically	O
altered	O
during	O
the	O
process	O
of	O
tumorigenesis	O
,	O
may	O
function	O
within	O
cancer	O
cells	O
to	O
aberrantly	O
alter	O
survivin	B-GGP
levels	O
and	O
enhance	O
tumor	O
progression	O
.	O

The	O
ubiquitin	B-GGP
-	O
modifying	O
enzyme	O
A20	B-GGP
is	O
required	O
for	O
termination	O
of	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
responses	O
.	O

A20	B-GGP
is	O
a	O
cytoplasmic	B-CC
protein	O
required	O
for	O
the	O
termination	O
of	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
(	O
TNF	B-GGP
)	O
-	O
induced	O
signals	O
.	O

We	O
show	O
here	O
that	O
mice	O
doubly	O
deficient	O
in	O
either	O
A20	B-GGP
and	O
TNF	B-GGP
or	O
A20	B-GGP
and	O
TNF	B-GGP
receptor	I-GGP
1	I-GGP
developed	O
spontaneous	O
inflammation	O
,	O
indicating	O
that	O
A20	B-GGP
is	O
also	O
critical	O
for	O
the	O
regulation	O
of	O
TNF	B-GGP
-	O
independent	O
signals	O
in	O
vivo	O
.	O

A20	B-GGP
was	O
required	O
for	O
the	O
termination	O
of	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
-	O
induced	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
proinflammatory	O
gene	O
expression	O
in	O
macrophages	O
,	O
and	O
this	O
function	O
protected	O
mice	O
from	O
endotoxic	O
shock	O
.	O

A20	B-GGP
accomplished	O
this	O
biochemically	O
by	O
directly	O
removing	O
ubiquitin	B-GGP
moieties	O
from	O
the	O
signaling	O
molecule	O
TRAF6	B-GGP
.	O

The	O
critical	O
function	O
of	O
this	O
deubiquitinating	O
enzyme	O
in	O
the	O
restriction	O
of	O
TLR	B-GGP
signals	O
emphasizes	O
the	O
importance	O
of	O
the	O
regulation	O
of	O
ubiquitin	B-GGP
conjugation	O
in	O
innate	O
immune	O
cells	O
.	O

The	O
p16INK4a	B-GGP
-	O
RB	B-GGP
pathway	O
:	O
molecular	O
link	O
between	O
cellular	O
senescence	O
and	O
tumor	O
suppression	O
.	O

The	O
p16INK4a	B-GGP
tumor	O
suppressor	O
protein	O
functions	O
as	O
an	O
inhibitor	O
of	O
CDK4	B-GGP
and	O
CDK6	B-GGP
,	O
the	O
D	B-GGP
-	I-GGP
type	I-GGP
cyclin	I-GGP
-	I-GGP
dependent	I-GGP
kinases	I-GGP
that	O
initiate	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	O
tumor	O
suppressor	O
protein	O
,	O
RB	B-GGP
.	O

Thus	O
,	O
p16INK4a	B-GGP
has	O
the	O
capacity	O
to	O
arrest	O
cells	O
in	O
the	O
G1	O
-	O
phase	O
of	O
the	O
cell	O
cycle	O
and	O
its	O
probable	O
physiological	O
role	O
is	O
in	O
the	O
implementation	O
of	O
irreversible	O
growth	O
arrest	O
termed	O
cellular	O
senescence	O
.	O

Cellular	O
senescence	O
is	O
a	O
state	O
of	O
permanent	O
growth	O
arrest	O
that	O
can	O
be	O
induced	O
by	O
a	O
variety	O
of	O
stresses	O
such	O
as	O
DNA	O
-	O
damage	O
and	O
aberrant	O
mitogenic	O
signaling	O
in	O
human	O
primary	O
cells	O
.	O

In	O
contrast	O
to	O
normal	O
cells	O
,	O
the	O
function	O
of	O
the	O
p16INK4a	B-GGP
gene	O
or	O
its	O
downstream	O
mediators	O
is	O
frequently	O
deregulated	O
in	O
many	O
types	O
of	O
human	O
cancers	O
,	O
illustrating	O
the	O
importance	O
of	O
cellular	O
senescence	O
in	O
tumor	O
suppression	O
.	O

Here	O
we	O
discuss	O
the	O
molecular	O
mechanisms	O
that	O
direct	O
cellular	O
senescence	O
and	O
reveal	O
its	O
potential	O
for	O
tumor	O
suppression	O
.	O

11beta	B-GGP
-	I-GGP
hydroxysteroid	I-GGP
dehydrogenase	I-GGP
type	I-GGP
1	I-GGP
:	O
a	O
tissue	O
-	O
specific	O
regulator	O
of	O
glucocorticoid	B-MED
response	O
.	O

11beta	B-GGP
-	I-GGP
hydroxysteroid	I-GGP
dehydrogenase	I-GGP
type	I-GGP
1	I-GGP
(	O
11beta	B-GGP
-	I-GGP
HSD1	I-GGP
)	O
interconverts	O
inactive	O
cortisone	B-MED
and	O
active	O
cortisol	B-MED
.	O

Although	O
bidirectional	O
,	O
in	O
vivo	O
it	O
is	O
believed	O
to	O
function	O
as	O
a	O
reductase	O
generating	O
active	O
glucocorticoid	B-MED
at	O
a	O
prereceptor	O
level	O
,	O
enhancing	O
glucocorticoid	B-GGP
receptor	I-GGP
activation	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
both	O
the	O
genetic	O
and	O
enzymatic	O
characterization	O
of	O
11beta	B-GGP
-	I-GGP
HSD1	I-GGP
,	O
as	O
well	O
as	O
describing	O
its	O
role	O
in	O
physiology	O
and	O
pathology	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
.	O

The	O
molecular	O
basis	O
of	O
cortisone	B-GGP
reductase	I-GGP
deficiency	O
,	O
the	O
putative	O
"	O
11beta	B-GGP
-	I-GGP
HSD1	I-GGP
knockout	O
state	O
"	O
in	O
humans	O
,	O
has	O
been	O
defined	O
and	O
is	O
caused	O
by	O
intronic	O
mutations	O
in	O
HSD11B1	B-GGP
that	O
decrease	O
gene	O
transcription	O
together	O
with	O
mutations	O
in	O
hexose	B-GGP
-	I-GGP
6	I-GGP
-	I-GGP
phosphate	I-GGP
dehydrogenase	I-GGP
,	O
an	O
endoluminal	O
enzyme	O
that	O
provides	O
reduced	O
nicotinamide	B-MED
-	I-MED
adenine	I-MED
dinucleotide	I-MED
phosphate	I-MED
as	O
cofactor	O
to	O
11beta	B-GGP
-	I-GGP
HSD1	I-GGP
to	O
permit	O
reductase	O
activity	O
.	O

We	O
speculate	O
that	O
hexose	B-GGP
-	I-GGP
6	I-GGP
-	I-GGP
phosphate	I-GGP
dehydrogenase	I-GGP
activity	O
and	O
therefore	O
reduced	O
nicotinamide	B-MED
-	I-MED
adenine	I-MED
dinucleotide	I-MED
phosphate	I-MED
supply	O
may	O
be	O
crucial	O
in	O
determining	O
the	O
directionality	O
of	O
11beta	B-GGP
-	I-GGP
HSD1	I-GGP
activity	O
.	O

Therapeutic	O
inhibition	O
of	O
11beta	B-GGP
-	I-GGP
HSD1	I-GGP
reductase	O
activity	O
in	O
patients	O
with	O
obesity	O
and	O
the	O
metabolic	O
syndrome	O
,	O
as	O
well	O
as	O
in	O
glaucoma	O
and	O
osteoporosis	O
,	O
remains	O
an	O
exciting	O
prospect	O
.	O

A	O
role	O
for	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
tau	I-GGP
in	O
E2F1	B-GGP
stabilization	O
and	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
.	O

Genotoxic	O
stress	O
triggers	O
apoptosis	O
through	O
multiple	O
signaling	O
pathways	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
a	O
specific	O
induction	O
of	O
E2F1	B-GGP
accumulation	O
and	O
a	O
role	O
for	O
E2F1	B-GGP
in	O
apoptosis	O
upon	O
DNA	O
damage	O
.	O

Induction	O
of	O
E2F1	B-GGP
is	O
mediated	O
by	O
phosphorylation	O
events	O
that	O
are	O
dependent	O
on	O
DNA	O
damage	O
-	O
responsive	O
protein	O
kinases	O
,	O
such	O
as	O
ATM	B-GGP
.	O

How	O
ATM	B-GGP
phosphorylation	O
leads	O
to	O
E2F1	B-GGP
stabilization	O
is	O
unknown	O
.	O

We	O
now	O
show	O
that	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
tau	I-GGP
,	O
a	O
phosphoserine	B-MED
-	O
binding	O
protein	O
,	O
mediates	O
E2F1	B-GGP
stabilization	O
.	O

14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
tau	I-GGP
interacts	O
with	O
ATM	B-GGP
-	O
phosphorylated	O
E2F1	B-GGP
during	O
DNA	O
damage	O
and	O
inhibits	O
E2F1	B-GGP
ubiquitination	O
.	O

Depletion	O
of	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
tau	I-GGP
or	O
E2F1	B-GGP
,	O
but	O
not	O
E2F2	B-GGP
or	O
E2F3	B-GGP
,	O
blocks	O
adriamycin	O
-	O
induced	O
apoptosis	O
.	O

14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
tau	I-GGP
is	O
also	O
required	O
for	O
expression	O
and	O
induction	O
of	O
E2F1	B-GGP
apoptotic	O
targets	O
,	O
such	O
as	O
p73	B-GGP
,	O
Apaf	B-GGP
-	I-GGP
1	I-GGP
,	O
and	O
caspases	B-GGP
,	O
during	O
DNA	O
damage	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
a	O
novel	O
function	O
for	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
tau	I-GGP
in	O
the	O
regulation	O
of	O
E2F1	B-GGP
protein	O
stability	O
and	O
apoptosis	O
during	O
DNA	O
damage	O
.	O

E2Fs	B-GGP
link	O
the	O
control	O
of	O
G1	O
/	O
S	O
and	O
G2	O
/	O
M	O
transcription	O
.	O

Previous	O
work	O
has	O
provided	O
evidence	O
for	O
E2F	B-GGP
-	O
dependent	O
transcription	O
control	O
of	O
both	O
G1	O
/	O
S	O
-	O
and	O
G2	O
/	O
M	O
-	O
regulated	O
genes	O
.	O

Analysis	O
of	O
the	O
G2	O
-	O
regulated	O
cdc2	B-GGP
and	O
cyclin	B-GGP
B1	I-GGP
genes	O
reveals	O
the	O
presence	O
of	O
both	O
positive	O
-	O
and	O
negative	O
-	O
acting	O
E2F	B-GGP
promoter	O
elements	O
.	O

Additional	O
elements	O
provide	O
both	O
positive	O
(	O
CCAAT	O
and	O
Myb	O
)	O
and	O
negative	O
(	O
CHR	O
)	O
control	O
.	O

Chromatin	B-CC
immunoprecipitation	O
assays	O
identify	O
multiple	O
interactions	O
of	O
E2F	B-GGP
proteins	O
that	O
include	O
those	O
previously	O
shown	O
to	O
activate	O
and	O
repress	O
transcription	O
.	O

We	O
find	O
that	O
E2F1	B-GGP
,	O
E2F2	B-GGP
,	O
and	O
E2F3	B-GGP
bind	O
to	O
the	O
positive	O
-	O
acting	O
E2F	B-GGP
site	O
in	O
the	O
cdc2	B-GGP
promoter	O
,	O
whereas	O
E2F4	B-GGP
binds	O
to	O
the	O
negative	O
-	O
acting	O
site	O
.	O

We	O
also	O
find	O
that	O
binding	O
of	O
an	O
activator	O
E2F	B-GGP
is	O
dependent	O
on	O
an	O
adjacent	O
CCAAT	O
site	O
that	O
is	O
bound	O
by	O
the	O
NF	B-COM
-	I-COM
Y	I-COM
transcription	O
factor	O
and	O
binding	O
of	O
a	O
repressor	O
E2F	B-GGP
is	O
dependent	O
on	O
an	O
adjacent	O
CHR	O
element	O
,	O
suggesting	O
a	O
role	O
for	O
cooperative	O
interactions	O
in	O
determining	O
both	O
activation	O
and	O
repression	O
.	O

Finally	O
,	O
the	O
kinetics	O
of	O
B	B-GGP
-	I-GGP
Myb	I-GGP
interaction	O
with	O
the	O
G2	O
-	O
regulated	O
promoters	O
coincides	O
with	O
the	O
activation	O
of	O
the	O
genes	O
,	O
and	O
RNAi	O
-	O
mediated	O
reduction	O
of	O
B	B-GGP
-	I-GGP
Myb	I-GGP
inhibits	O
expression	O
of	O
cyclin	B-GGP
B1	I-GGP
and	O
cdc2	B-GGP
.	O

The	O
ability	O
of	O
B	B-GGP
-	I-GGP
Myb	I-GGP
to	O
interact	O
with	O
the	O
cdc2	B-GGP
promoter	O
is	O
dependent	O
on	O
an	O
intact	O
E2F	B-GGP
binding	O
site	O
.	O

These	O
results	O
thus	O
point	O
to	O
a	O
role	O
for	O
E2Fs	B-GGP
,	O
together	O
with	O
B	B-GGP
-	I-GGP
Myb	I-GGP
,	O
which	O
is	O
an	O
E2F	B-GGP
-	O
regulated	O
gene	O
expressed	O
at	O
G1	O
/	O
S	O
,	O
in	O
linking	O
the	O
regulation	O
of	O
genes	O
at	O
G1	O
/	O
S	O
and	O
G2	O
/	O
M	O
.	O

A	O
novel	O
repressive	O
E2F6	B-GGP
complex	O
containing	O
the	O
polycomb	B-GGP
group	I-GGP
protein	I-GGP
,	O
EPC1	B-GGP
,	O
that	O
interacts	O
with	O
EZH2	B-GGP
in	O
a	O
proliferation	O
-	O
specific	O
manner	O
.	O

The	O
transcriptional	O
repressor	O
E2F6	B-GGP
has	O
been	O
identified	O
as	O
a	O
component	O
of	O
two	O
distinct	O
polycomb	B-GGP
group	I-GGP
protein	I-GGP
(	O
PcG	B-GGP
)	O
-	O
containing	O
complexes	O
,	O
suggesting	O
a	O
mechanism	O
for	O
the	O
recruitment	O
of	O
repressive	O
complexes	O
to	O
target	O
sequences	O
in	O
DNA	O
.	O

Whereas	O
one	O
complex	O
is	O
involved	O
in	O
the	O
repression	O
of	O
classic	O
E2F	B-GGP
target	O
genes	O
in	O
G0	O
,	O
a	O
role	O
for	O
E2F6	B-GGP
within	O
the	O
cell	O
cycle	O
has	O
yet	O
to	O
be	O
defined	O
.	O

We	O
searched	O
for	O
novel	O
E2F6	B-GGP
-	O
binding	O
proteins	O
using	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
and	O
identified	O
the	O
PcG	B-GGP
protein	O
,	O
EPC1	B-GGP
.	O

We	O
showed	O
that	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
E2F6	B-GGP
,	O
DP1	B-GGP
,	O
and	O
EPC1	B-GGP
form	O
a	O
stable	O
core	O
complex	O
with	O
repressive	O
activity	O
.	O

Furthermore	O
,	O
we	O
identified	O
the	O
proliferation	O
-	O
specific	O
PcG	B-GGP
,	O
EZH2	B-GGP
,	O
as	O
an	O
EPC1	B-GGP
-	O
interacting	O
protein	O
.	O

Using	O
affinity	O
purification	O
,	O
we	O
showed	O
that	O
E2F6	B-GGP
,	O
DP1	B-GGP
,	O
EPC1	B-GGP
,	O
EZH2	B-GGP
,	O
and	O
Sin3B	B-GGP
co	O
-	O
elute	O
,	O
suggesting	O
the	O
identification	O
of	O
a	O
novel	O
E2F6	B-GGP
complex	O
that	O
exists	O
in	O
vivo	O
in	O
both	O
normal	O
and	O
transformed	O
human	O
cell	O
lines	O
.	O

EZH2	B-GGP
is	O
required	O
for	O
cellular	O
proliferation	O
and	O
consistent	O
with	O
this	O
,	O
EZH2	B-GGP
elutes	O
with	O
the	O
E2F6	B-COM
-	I-COM
EPC1	I-COM
complex	O
only	O
in	O
proliferating	O
cells	O
.	O

Thus	O
we	O
have	O
identified	O
a	O
novel	O
E2F6	B-COM
-	I-COM
PcG	I-COM
complex	O
(	O
E2F6	B-COM
-	I-COM
EPC1	I-COM
)	O
that	O
interacts	O
with	O
EZH2	B-GGP
and	O
may	O
regulate	O
genes	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O

Differential	O
regulation	O
of	O
Tec1	B-GGP
by	O
Fus3	B-GGP
and	O
Kss1	B-GGP
confers	O
signaling	O
specificity	O
in	O
yeast	O
development	O
.	O

Transcriptional	O
regulation	O
by	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
(	I-GGP
MAP	I-GGP
)	I-GGP
kinase	I-GGP
signaling	O
cascades	O
is	O
a	O
major	O
control	O
mechanism	O
for	O
eukaryotic	O
development	O
.	O

In	O
budding	O
yeast	O
,	O
Fus3	B-GGP
and	O
Kss1	B-GGP
are	O
two	O
MAP	B-GGP
kinases	I-GGP
that	O
control	O
two	O
distinct	O
developmental	O
programs	O
-	O
mating	O
and	O
invasive	O
growth	O
.	O

We	O
investigated	O
whether	O
signal	O
-	O
specific	O
activation	O
of	O
mating	O
and	O
invasive	O
growth	O
involves	O
regulation	O
of	O
the	O
transcription	O
factor	O
Tec1	B-GGP
by	O
Fus3	B-GGP
and	O
Kss1	B-GGP
.	O

We	O
present	O
evidence	O
that	O
,	O
during	O
mating	O
,	O
Fus3	B-GGP
phosphorylates	O
Tec1	B-GGP
to	O
downregulate	O
this	O
invasive	O
growth	O
-	O
specific	O
transcription	O
factor	O
and	O
its	O
target	O
genes	O
.	O

This	O
function	O
of	O
Fus3	B-GGP
is	O
essential	O
for	O
correct	O
execution	O
of	O
the	O
mating	O
program	O
and	O
is	O
not	O
shared	O
by	O
Kss1	B-GGP
.	O

We	O
find	O
that	O
Kss1	B-GGP
controls	O
the	O
activity	O
of	O
Tec1	B-GGP
mainly	O
during	O
invasive	O
growth	O
by	O
control	O
of	O
TEC1	B-GGP
gene	O
expression	O
.	O

Our	O
study	O
suggests	O
that	O
signaling	O
specificity	O
can	O
arise	O
from	O
differential	O
regulation	O
of	O
a	O
single	O
transcription	O
factor	O
by	O
two	O
MAP	B-GGP
kinases	I-GGP
with	O
shared	O
functions	O
in	O
distinct	O
developmental	O
programs	O
.	O

DNA	O
binding	O
of	O
repressor	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
p50	B-COM
/	I-COM
p50	I-COM
depends	O
on	O
phosphorylation	O
of	O
Ser337	B-MED
by	O
the	O
protein	B-GGP
kinase	I-GGP
A	I-GGP
catalytic	I-GGP
subunit	I-GGP
.	O

The	O
NF	B-COM
-	I-COM
kappaB	I-COM
p50	B-COM
/	I-COM
p50	I-COM
homodimer	O
is	O
mainly	O
associated	O
with	O
transcriptional	O
repression	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
phosphorylation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
p50	B-GGP
Ser	B-MED
(	I-MED
337	I-MED
)	I-MED
is	O
critical	O
for	O
DNA	O
binding	O
.	O

Here	O
,	O
we	O
report	O
that	O
p50	B-GGP
Ser	B-MED
(	I-MED
337	I-MED
)	I-MED
is	O
constitutively	O
phosphorylated	O
by	O
the	O
protein	B-GGP
kinase	I-GGP
A	I-GGP
catalytic	I-GGP
subunit	I-GGP
(	O
PKAc	B-GGP
)	O
in	O
three	O
different	O
cell	O
types	O
,	O
which	O
may	O
account	O
for	O
the	O
constant	O
binding	O
of	O
p50	B-COM
/	I-COM
p50	I-COM
to	O
DNA	O
in	O
unstimulated	O
cells	O
.	O

This	O
was	O
demonstrated	O
first	O
by	O
showing	O
that	O
treatment	O
of	O
cells	O
with	O
PKAc	B-GGP
-	O
specific	O
inhibitors	O
blocked	O
p50	B-COM
/	I-COM
p50	I-COM
DNA	O
binding	O
.	O

Second	O
,	O
phosphorylation	O
of	O
p50	B-GGP
by	O
PKAc	B-GGP
was	O
prevented	O
by	O
substitution	O
of	O
Ser	B-MED
(	I-MED
337	I-MED
)	I-MED
to	O
alanine	B-MED
.	O

Third	O
,	O
both	O
p50	B-GGP
and	O
PKAc	B-GGP
proteins	O
as	O
well	O
as	O
kinase	O
activity	O
that	O
phosphorylates	O
p50	B-GGP
were	O
found	O
to	O
co	O
-	O
fractionate	O
following	O
gel	O
filtration	O
chromatography	O
.	O

Finally	O
,	O
PKAc	B-GGP
and	O
p50	B-GGP
were	O
shown	O
to	O
be	O
able	O
to	O
reciprocally	O
co	O
-	O
immunoprecipitate	O
one	O
another	O
,	O
and	O
their	O
physical	O
association	O
was	O
blocked	O
by	O
a	O
PKA	B-COM
catalytic	O
site	O
inhibitory	O
peptide	O
.	O

This	O
indicates	O
that	O
phosphorylation	O
of	O
p50	B-GGP
Ser	B-MED
(	I-MED
337	I-MED
)	I-MED
involves	O
direct	O
contact	O
with	O
the	O
PKAc	B-GGP
catalytic	O
center	O
.	O

In	O
contrast	O
to	O
the	O
dramatic	O
elevation	O
of	O
nuclear	B-CC
p50	B-COM
/	I-COM
p65	I-COM
heterodimers	O
induced	O
by	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
alpha	I-GGP
,	O
DNA	O
binding	O
of	O
p50	B-COM
/	I-COM
p50	I-COM
homodimers	O
was	O
not	O
greatly	O
altered	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
reveal	O
for	O
the	O
first	O
time	O
that	O
there	O
is	O
a	O
direct	O
interaction	O
between	O
PKAc	B-GGP
and	O
p50	B-GGP
that	O
accounts	O
for	O
constitutive	O
phosphorylation	O
of	O
p50	B-GGP
Ser	B-MED
(	I-MED
337	I-MED
)	I-MED
and	O
the	O
existence	O
of	O
DNA	O
bound	O
p50	B-COM
/	I-COM
p50	I-COM
in	O
the	O
nuclei	B-CC
of	O
most	O
resting	O
cells	O
.	O

This	O
mechanism	O
of	O
DNA	O
binding	O
by	O
p50	B-COM
/	I-COM
p50	I-COM
following	O
phosphorylation	O
of	O
Ser	B-MED
(	I-MED
337	I-MED
)	I-MED
by	O
PKAc	B-GGP
may	O
represent	O
an	O
important	O
means	O
for	O
maintaining	O
stable	O
negative	O
regulation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
gene	O
expression	O
in	O
the	O
absence	O
of	O
extracellular	B-CC
stimulation	O
.	O

Ran	B-GGP
GTPase	O
regulates	O
Mad2	B-GGP
localization	O
to	O
the	O
nuclear	B-CC
pore	I-CC
complex	I-CC
.	O

In	O
yeast	O
and	O
mammalian	O
cells	O
,	O
the	O
spindle	B-CC
assembly	O
checkpoint	O
proteins	O
Mad1p	B-GGP
and	O
Mad2p	B-GGP
localize	O
to	O
the	O
nuclear	B-CC
pore	I-CC
complex	I-CC
(	O
NPC	B-CC
)	O
during	O
interphase	O
.	O

Deletion	O
of	O
MAD1	B-GGP
or	O
MAD2	B-GGP
did	O
not	O
affect	O
steady	O
-	O
state	O
nucleocytoplasmic	B-CC
distribution	O
of	O
a	O
classical	O
nuclear	B-CC
localization	O
signal	O
-	O
containing	O
reporter	O
,	O
a	O
nuclear	B-CC
export	O
signal	O
-	O
containing	O
reporter	O
,	O
or	O
Ran	B-GGP
localization	O
.	O

We	O
utilized	O
cells	O
with	O
conditional	O
mutations	O
in	O
the	O
yeast	O
Ran	B-GGP
GTPase	O
pathway	O
to	O
examine	O
the	O
relationship	O
between	O
Ran	B-GGP
and	O
targeting	O
of	O
checkpoint	O
regulators	O
to	O
the	O
NPC	B-CC
.	O

Mutations	O
that	O
disrupt	O
the	O
concentration	O
of	O
Ran	B-GGP
in	O
the	O
nucleus	B-CC
displaced	O
Mad2p	B-GGP
but	O
not	O
Mad1p	B-GGP
from	O
the	O
NPC	B-CC
.	O

The	O
displacement	O
of	O
Mad2p	B-GGP
in	O
M	O
-	O
phase	O
cells	O
was	O
correlated	O
with	O
activation	O
of	O
the	O
spindle	B-CC
checkpoint	O
.	O

Our	O
observations	O
demonstrate	O
that	O
Mad2p	B-GGP
localization	O
at	O
NPCs	B-CC
is	O
sensitive	O
to	O
nuclear	B-CC
levels	O
of	O
Ran	B-GGP
and	O
suggest	O
that	O
release	O
of	O
Mad2p	B-GGP
from	O
NPCs	B-CC
is	O
closely	O
linked	O
with	O
spindle	B-CC
assembly	O
checkpoint	O
activation	O
in	O
yeast	O
.	O

This	O
is	O
the	O
first	O
evidence	O
indicating	O
that	O
Ran	B-GGP
affects	O
the	O
localization	O
of	O
Mad2p	B-GGP
to	O
the	O
NPC	B-CC
.	O

Cyclin	B-GGP
specificity	O
in	O
the	O
phosphorylation	O
of	O
cyclin	B-GGP
-	I-GGP
dependent	I-GGP
kinase	I-GGP
substrates	O
.	O

Cell	O
-	O
cycle	O
events	O
are	O
controlled	O
by	O
cyclin	B-GGP
-	I-GGP
dependent	I-GGP
kinases	I-GGP
(	O
CDKs	B-GGP
)	O
,	O
whose	O
periodic	O
activation	O
is	O
driven	O
by	O
cyclins	B-GGP
.	O

Different	O
cyclins	B-GGP
promote	O
distinct	O
cell	O
-	O
cycle	O
events	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
these	O
differences	O
remains	O
unclear	O
.	O

Here	O
we	O
compare	O
the	O
specificity	O
of	O
two	O
budding	O
yeast	O
cyclins	B-GGP
,	O
the	O
S	O
-	O
phase	O
cyclin	B-GGP
Clb5	I-GGP
and	O
the	O
M	O
-	O
phase	O
cyclin	B-GGP
Clb2	I-GGP
,	O
in	O
the	O
phosphorylation	O
of	O
150	O
Cdk1	B-GGP
(	O
Cdc28	B-GGP
)	O
substrates	O
.	O

About	O
24	O
%	O
of	O
these	O
proteins	O
were	O
phosphorylated	O
more	O
efficiently	O
by	O
Clb5	B-COM
-	I-COM
Cdk1	I-COM
than	O
Clb2	B-COM
-	I-COM
Cdk1	I-COM
.	O

The	O
Clb5	B-GGP
-	O
specific	O
targets	O
include	O
several	O
proteins	O
(	O
Sld2	B-GGP
,	O
Cdc6	B-GGP
,	O
Orc6	B-GGP
,	O
Mcm3	B-GGP
and	O
Cdh1	B-GGP
)	O
involved	O
in	O
early	O
S	O
-	O
phase	O
events	O
.	O

Clb5	B-GGP
specificity	O
depended	O
on	O
an	O
interaction	O
between	O
a	O
hydrophobic	O
patch	O
in	O
Clb5	B-GGP
and	O
a	O
short	O
sequence	O
in	O
the	O
substrate	O
(	O
the	O
RXL	O
or	O
Cy	O
motif	O
)	O
.	O

Phosphorylation	O
of	O
Clb5	B-GGP
-	O
specific	O
targets	O
during	O
S	O
phase	O
was	O
reduced	O
by	O
replacing	O
Clb5	B-GGP
with	O
Clb2	B-GGP
or	O
by	O
mutating	O
the	O
substrate	O
RXL	O
motif	O
,	O
confirming	O
the	O
importance	O
of	O
Clb5	B-GGP
specificity	O
in	O
vivo	O
.	O

Although	O
we	O
did	O
not	O
identify	O
any	O
highly	O
Clb2	B-GGP
-	O
specific	O
substrates	O
,	O
we	O
found	O
that	O
Clb2	B-COM
-	I-COM
Cdk1	I-COM
possessed	O
higher	O
intrinsic	O
kinase	O
activity	O
than	O
Clb5	B-COM
-	I-COM
Cdk1	I-COM
,	O
enabling	O
efficient	O
phosphorylation	O
of	O
a	O
broad	O
range	O
of	O
mitotic	O
Cdk1	B-GGP
targets	O
.	O

Thus	O
,	O
Clb5	B-GGP
and	O
Clb2	B-GGP
use	O
distinct	O
mechanisms	O
to	O
enhance	O
the	O
phosphorylation	O
of	O
S	O
-	O
phase	O
and	O
M	O
-	O
phase	O
substrates	O
.	O

E2F1	B-GGP
up	O
-	O
regulates	O
the	O
expression	O
of	O
the	O
tumour	O
suppressor	O
axin2	B-GGP
both	O
by	O
activation	O
of	O
transcription	O
and	O
by	O
mRNA	O
stabilisation	O
.	O

Axin2	B-GGP
is	O
a	O
negative	O
regulator	O
of	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signalling	O
with	O
roles	O
in	O
early	O
development	O
and	O
tumour	O
suppression	O
.	O

Axin2	B-GGP
is	O
induced	O
by	O
E2F1	B-GGP
and	O
therefore	O
acts	O
as	O
a	O
point	O
of	O
cross	O
-	O
talk	O
between	O
the	O
pRb	B-GGP
/	O
E2F	B-GGP
and	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
pathways	O
:	O
two	O
of	O
the	O
most	O
frequently	O
deregulated	O
pathways	O
in	O
human	O
cancers	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
E2F1	B-GGP
up	O
-	O
regulates	O
axin2	B-GGP
by	O
two	O
independent	O
mechanisms	O
.	O

The	O
human	O
axin2	B-GGP
gene	O
allows	O
transcription	O
of	O
messages	O
with	O
three	O
different	O
5	O
'	O
untranslated	O
regions	O
and	O
in	O
the	O
first	O
mechanism	O
E2F1	B-GGP
directly	O
activates	O
the	O
transcription	O
of	O
only	O
one	O
of	O
these	O
species	O
by	O
acting	O
at	O
canonical	O
E2F	B-GGP
binding	O
sites	O
.	O

Second	O
,	O
E2F1	B-GGP
induces	O
stabilisation	O
of	O
axin2	B-GGP
mRNAs	O
.	O

We	O
discuss	O
this	O
regulation	O
with	O
respect	O
to	O
other	O
known	O
E2F	B-GGP
targets	O
.	O

Distinct	O
signaling	O
events	O
downstream	O
of	O
mTOR	B-GGP
cooperate	O
to	O
mediate	O
the	O
effects	O
of	O
amino	O
acids	O
and	O
insulin	B-GGP
on	O
initiation	B-GGP
factor	I-GGP
4E	I-GGP
-	O
binding	O
proteins	O
.	O

Signaling	O
through	O
the	O
mammalian	B-GGP
target	I-GGP
of	I-GGP
rapamycin	I-GGP
(	O
mTOR	B-GGP
)	O
controls	O
cell	O
size	O
and	O
growth	O
as	O
well	O
as	O
other	O
functions	O
,	O
and	O
it	O
is	O
a	O
potential	O
therapeutic	O
target	O
for	O
graft	O
rejection	O
,	O
certain	O
cancers	O
,	O
and	O
disorders	O
characterized	O
by	O
inappropriate	O
cell	O
or	O
tissue	O
growth	O
.	O

mTOR	B-GGP
signaling	O
is	O
positively	O
regulated	O
by	O
hormones	O
or	O
growth	O
factors	O
and	O
amino	O
acids	O
.	O

mTOR	B-GGP
signaling	O
regulates	O
the	O
phosphorylation	O
of	O
several	O
proteins	O
,	O
the	O
best	O
characterized	O
being	O
ones	O
that	O
control	O
mRNA	O
translation	O
.	O

Eukaryotic	B-GGP
initiation	I-GGP
factor	I-GGP
4E	I-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
1	I-GGP
(	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
)	O
undergoes	O
phosphorylation	O
at	O
multiple	O
sites	O
.	O

Here	O
we	O
show	O
that	O
amino	O
acids	O
regulate	O
the	O
N	O
-	O
terminal	O
phosphorylation	O
sites	O
in	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
through	O
the	O
RAIP	O
motif	O
in	O
a	O
rapamycin	B-MED
-	O
insensitive	O
manner	O
.	O

Several	O
criteria	O
indicate	O
this	O
reflects	O
a	O
rapamycin	B-MED
-	O
insensitive	O
output	O
from	O
mTOR	B-GGP
.	O

In	O
contrast	O
,	O
the	O
insulin	B-GGP
-	O
stimulated	O
phosphorylation	O
of	O
the	O
C	O
-	O
terminal	O
site	O
Ser64	B-MED
/	O
65	B-MED
is	O
generally	O
sensitive	O
to	O
rapamycin	B-MED
,	O
as	O
is	O
phosphorylation	O
of	O
another	O
well	O
-	O
characterized	O
target	O
for	O
mTOR	B-GGP
signaling	O
,	O
S6K1	B-GGP
.	O

Our	O
data	O
imply	O
that	O
it	O
is	O
unlikely	O
that	O
mTOR	B-GGP
directly	O
phosphorylates	O
Thr69	B-MED
/	O
70	B-MED
in	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
.	O

Although	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
and	O
S6K1	B-GGP
bind	O
the	O
mTOR	B-GGP
partner	O
,	O
raptor	B-GGP
,	O
our	O
data	O
indicate	O
that	O
the	O
outputs	O
from	O
mTOR	B-GGP
to	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
and	O
S6K1	B-GGP
are	O
distinct	O
.	O

In	O
cells	O
,	O
efficient	O
phosphorylation	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
requires	O
it	O
to	O
be	O
able	O
to	O
bind	O
to	O
eIF4E	B-GGP
,	O
whereas	O
phosphorylation	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
by	O
mTOR	B-GGP
in	O
vitro	O
shows	O
no	O
such	O
preference	O
.	O

These	O
data	O
have	O
important	O
implications	O
for	O
understanding	O
signaling	O
downstream	O
of	O
mTOR	B-GGP
and	O
the	O
development	O
of	O
new	O
strategies	O
to	O
impair	O
mTOR	B-GGP
signaling	O
.	O

Pocket	B-GGP
proteins	I-GGP
and	O
cell	O
cycle	O
control	O
.	O

The	O
retinoblastoma	B-GGP
protein	I-GGP
(	O
pRB	B-GGP
)	O
and	O
the	O
pRB	B-GGP
-	O
related	O
p107	B-GGP
and	O
p130	B-GGP
comprise	O
the	O
'	O
pocket	B-GGP
protein	I-GGP
'	O
family	O
of	O
cell	O
cycle	O
regulators	O
.	O

These	O
proteins	O
are	O
best	O
known	O
for	O
their	O
roles	O
in	O
restraining	O
the	O
G1	O
-	O
S	O
transition	O
through	O
the	O
regulation	O
of	O
E2F	B-GGP
-	O
responsive	O
genes	O
.	O

pRB	B-GGP
and	O
the	O
p107	B-GGP
/	O
p130	B-GGP
pair	O
are	O
required	O
for	O
the	O
repression	O
of	O
distinct	O
sets	O
of	O
genes	O
,	O
potentially	O
due	O
to	O
their	O
selective	O
interactions	O
with	O
E2Fs	B-GGP
that	O
are	O
engaged	O
at	O
specific	O
promoter	O
elements	O
.	O

In	O
addition	O
to	O
regulating	O
E2F	B-GGP
-	O
responsive	O
genes	O
in	O
a	O
reversible	O
manner	O
,	O
pocket	B-GGP
proteins	I-GGP
contribute	O
to	O
silencing	O
of	O
such	O
genes	O
in	O
cells	O
that	O
are	O
undergoing	O
senescence	O
or	O
differentiation	O
.	O

Pocket	B-GGP
proteins	I-GGP
also	O
affect	O
the	O
G1	O
-	O
S	O
transition	O
through	O
E2F	B-GGP
-	O
independent	O
mechanisms	O
,	O
such	O
as	O
by	O
inhibiting	O
Cdk2	B-GGP
or	O
by	O
stabilizing	O
p27	B-GGP
(	O
Kip1	B-GGP
)	O
,	O
and	O
they	O
are	O
implicated	O
in	O
the	O
control	O
of	O
G0	O
exit	O
,	O
the	O
spatial	O
organization	O
of	O
replication	O
,	O
and	O
genomic	O
rereplication	O
.	O

New	O
insights	O
into	O
pocket	B-GGP
protein	I-GGP
regulation	O
have	O
also	O
been	O
obtained	O
.	O

Kinases	O
previously	O
thought	O
to	O
be	O
crucial	O
to	O
pocket	B-GGP
protein	I-GGP
phosphorylation	O
have	O
been	O
shown	O
to	O
be	O
redundant	O
,	O
and	O
new	O
modes	O
of	O
phosphorylation	O
and	O
dephosphorylation	O
have	O
been	O
identified	O
.	O

Despite	O
these	O
advances	O
,	O
much	O
remains	O
to	O
be	O
learned	O
about	O
the	O
pocket	B-GGP
proteins	I-GGP
,	O
particularly	O
with	O
regard	O
to	O
their	O
developmental	O
and	O
tumor	O
suppressor	O
functions	O
.	O

Thus	O
continues	O
the	O
story	O
of	O
the	O
pocket	B-GGP
proteins	I-GGP
and	O
the	O
cell	O
cycle	O
.	O

LRP5	B-GGP
mutations	O
in	O
osteoporosis	O
-	O
pseudoglioma	O
syndrome	O
and	O
high	O
-	O
bone	O
-	O
mass	O
disorders	O
.	O

The	O
LDL	B-GGP
receptor	I-GGP
-	I-GGP
related	I-GGP
protein	I-GGP
5	I-GGP
(	O
LRP5	B-GGP
)	O
is	O
a	O
member	O
of	O
the	O
LDL	B-GGP
receptor	I-GGP
family	O
,	O
which	O
also	O
includes	O
the	O
VLDL	B-GGP
receptor	I-GGP
and	O
the	O
apolipoprotein	B-GGP
E	I-GGP
receptor	I-GGP
2	I-GGP
.	O

The	O
LRP5	B-GGP
is	O
a	O
co	O
-	O
receptor	O
of	O
Wnt	B-GGP
located	O
on	O
the	O
osteoblast	O
membrane	B-CC
between	O
two	O
other	O
receptors	O
,	O
Frizzled	B-GGP
and	O
Kremen	B-GGP
.	O

Frizzled	B-GGP
and	O
LRP5	B-GGP
bind	O
to	O
Wnt	B-GGP
,	O
thereby	O
stabilizing	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
and	O
activating	O
bone	O
formation	O
.	O

When	O
the	O
dickkopf	B-GGP
protein	O
(	O
Dkk	B-GGP
)	O
binds	O
to	O
Kremen	B-GGP
and	O
LRP5	B-GGP
,	O
this	O
last	O
undergoes	O
internalization	O
and	O
therefore	O
becomes	O
unable	O
to	O
bind	O
Wnt	B-GGP
;	O
this	O
leads	O
to	O
degradation	O
of	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
and	O
to	O
inhibition	O
of	O
bone	O
formation	O
.	O

In	O
humans	O
,	O
loss	O
of	O
LRP5	B-GGP
function	O
causes	O
osteoporosis	O
-	O
pseudoglioma	O
syndrome	O
,	O
which	O
is	O
characterized	O
by	O
congenital	O
blindness	O
and	O
extremely	O
severe	O
childhood	O
-	O
onset	O
osteoporosis	O
(	O
lumbar	O
spine	O
Z	O
-	O
score	O
often	O
<	O
-	O
4	O
)	O
with	O
fractures	O
.	O

The	O
G171V	O
mutation	O
prevents	O
Dkk	B-GGP
from	O
binding	O
to	O
LRP5	B-GGP
,	O
thereby	O
increasing	O
LRP5	B-GGP
function	O
;	O
the	O
result	O
is	O
high	O
bone	O
mass	O
due	O
to	O
uncoupling	O
of	O
bone	O
formation	O
and	O
resorption	O
.	O

The	O
Z	O
-	O
scores	O
in	O
this	O
condition	O
can	O
exceed	O
+	O
6	O
at	O
the	O
hip	O
and	O
spine	O
.	O

The	O
LRP5	B-GGP
and	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
reflect	O
the	O
level	O
of	O
bone	O
formation	O
and	O
play	O
a	O
central	O
role	O
in	O
bone	O
mass	O
accrual	O
and	O
normal	O
distribution	O
.	O

Furthermore	O
,	O
LRP5	B-GGP
may	O
contribute	O
to	O
mediate	O
mechanical	O
loads	O
within	O
bone	O
tissue	O
.	O

Identification	O
of	O
the	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
pathway	O
is	O
a	O
breakthrough	O
in	O
the	O
elucidation	O
of	O
pathophysiological	O
mechanisms	O
affecting	O
bone	O
tissue	O
and	O
suggests	O
new	O
treatment	O
targets	O
for	O
patients	O
with	O
osteoporosis	O
or	O
specific	O
malignant	O
conditions	O
such	O
as	O
myeloma	O
and	O
sclerotic	O
bone	O
metastases	O
.	O

Selection	O
of	O
novel	O
mediators	O
of	O
E2F1	B-GGP
-	O
induced	O
apoptosis	O
through	O
retroviral	O
expression	O
of	O
an	O
antisense	O
cDNA	O
library	O
.	O

The	O
E2F1	B-GGP
transcription	O
factor	O
is	O
an	O
essential	O
mediator	O
of	O
p53	B-GGP
-	O
dependent	O
and	O
p53	B-GGP
-	O
independent	O
apoptosis	O
as	O
part	O
of	O
an	O
anti	O
-	O
tumour	O
safeguard	O
mechanism	O
.	O

In	O
this	O
study	O
,	O
a	O
functional	O
so	O
-	O
called	O
technical	O
knockout	O
(	O
TKO	O
)	O
approach	O
was	O
applied	O
to	O
Saos	O
-	O
2ERE2F1	O
cells	O
that	O
conditionally	O
activate	O
E2F1	B-GGP
by	O
the	O
addition	O
of	O
4	B-MED
-	I-MED
hydroxytamoxifen	I-MED
to	O
search	O
for	O
p53	B-GGP
-	O
independent	O
pro	O
-	O
apoptotic	O
E2F1	B-GGP
targets	O
.	O

The	O
approach	O
was	O
based	O
on	O
random	O
inactivation	O
of	O
genes	O
after	O
retroviral	O
transfer	O
of	O
an	O
antisense	O
cDNA	O
library	O
enriched	O
of	O
E2F1	B-GGP
-	O
induced	O
genes	O
,	O
followed	O
by	O
the	O
selection	O
of	O
Saos	O
-	O
2ERE2F1	O
cells	O
that	O
survive	O
in	O
the	O
presence	O
of	O
the	O
apoptotic	O
stimulus	O
.	O

We	O
identified	O
13	O
novel	O
E2F1	B-GGP
target	O
genes	O
encoding	O
proteins	O
of	O
known	O
cellular	O
function	O
,	O
including	O
apoptosis	O
and	O
RNA	O
binding	O
.	O

FACS	O
analysis	O
revealed	O
that	O
E2F1	B-GGP
-	O
induced	O
apoptosis	O
was	O
significantly	O
attenuated	O
in	O
cell	O
clones	O
containing	O
the	O
antisense	O
cDNA	O
fragments	O
of	O
these	O
genes	O
,	O
demonstrating	O
their	O
participation	O
in	O
E2F1	B-GGP
death	O
pathways	O
.	O

Moreover	O
,	O
inactivation	O
of	O
the	O
target	O
genes	O
resulted	O
in	O
a	O
clear	O
increase	O
of	O
cell	O
viability	O
(	O
>	O
80	O
%	O
)	O
in	O
response	O
to	O
E2F1	B-GGP
activation	O
compared	O
with	O
controls	O
(	O
approximately	O
30	O
%	O
)	O
.	O

Four	O
genes	O
showed	O
an	O
increase	O
in	O
expression	O
intensity	O
in	O
the	O
presence	O
of	O
cycloheximide	B-MED
,	O
suggesting	O
a	O
direct	O
effect	O
of	O
E2F1	B-GGP
on	O
gene	O
transcription	O
,	O
whereas	O
one	O
gene	O
was	O
identified	O
as	O
an	O
indirect	O
target	O
.	O

Our	O
data	O
provide	O
new	O
insight	O
in	O
the	O
regulation	O
of	O
E2F1	B-GGP
-	O
induced	O
apoptosis	O
.	O

Aberrant	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
in	O
tuberous	O
sclerosis	O
.	O

The	O
pathology	O
associated	O
with	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
shows	O
diverse	O
phenotypes	O
that	O
suggest	O
abnormal	O
signaling	O
of	O
multiple	O
pathways	O
.	O

Besides	O
the	O
negative	O
regulatory	O
role	O
of	O
the	O
TSC1	B-GGP
/	O
TSC2	B-GGP
proteins	O
on	O
mTOR	B-GGP
,	O
we	O
have	O
reported	O
an	O
effect	O
on	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
at	O
the	O
level	O
of	O
the	O
degradation	O
complex	O
in	O
vitro	O
.	O

The	O
TSC1	B-COM
/	I-COM
TSC2	I-COM
complex	O
associates	O
with	O
GSK3	B-GGP
and	O
Axin	B-GGP
and	O
promotes	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
degradation	O
to	O
inhibit	O
Wnt	B-GGP
-	O
stimulated	O
TCF	B-GGP
/	O
LEF	B-GGP
-	O
dependent	O
transcription	O
.	O

Here	O
,	O
we	O
show	O
that	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
and	O
its	O
effectors	O
,	O
cyclin	B-GGP
D1	I-GGP
and	O
connexin	B-GGP
43	I-GGP
,	O
were	O
up	O
-	O
regulated	O
in	O
TSC	O
-	O
related	O
angiomyolipomas	O
and	O
lymphangioleiomyomatosis	O
.	O

This	O
was	O
supported	O
by	O
the	O
failure	O
of	O
three	O
disease	O
-	O
causing	O
TSC2	B-GGP
missense	O
mutants	O
to	O
inhibit	O
Wnt	B-GGP
signaling	O
.	O

Further	O
,	O
the	O
interaction	O
between	O
TSC1	B-COM
/	I-COM
TSC2	I-COM
and	O
components	O
of	O
the	O
beta	B-COM
-	I-COM
catenin	I-COM
degradation	I-COM
complex	I-COM
was	O
dependent	O
on	O
Wnt	B-GGP
stimulation	O
such	O
that	O
binding	O
of	O
tuberin	B-GGP
to	O
GSK3	B-GGP
and	O
Axin	B-GGP
was	O
reduced	O
in	O
the	O
presence	O
of	O
Wnt	B-GGP
whereas	O
the	O
tuberin	B-GGP
-	O
Dishevelled	B-GGP
interaction	O
was	O
increased	O
.	O

GSK3	B-GGP
activity	O
played	O
a	O
role	O
in	O
regulating	O
the	O
assembly	O
/	O
stability	O
of	O
the	O
degradation	O
complex	O
.	O

Inhibition	O
of	O
GSK3	B-GGP
by	O
lithium	B-MED
chloride	I-MED
reduced	O
its	O
association	O
with	O
TSC1	B-GGP
whereas	O
disruption	O
of	O
GSK3	B-GGP
-	O
phosphorylation	O
sites	O
in	O
TSC1	B-GGP
reduced	O
interaction	O
between	O
TSC2	B-GGP
and	O
TSC1	B-GGP
.	O

Collectively	O
,	O
our	O
data	O
provide	O
further	O
evidence	O
that	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
plays	O
a	O
role	O
in	O
TSC	O
pathogenesis	O
in	O
vivo	O
and	O
suggest	O
a	O
novel	O
role	O
of	O
GSK3	B-GGP
in	O
modulating	O
the	O
TSC1	B-COM
/	I-COM
TSC2	I-COM
complex	O
through	O
TSC1	B-GGP
phosphorylation	O
.	O

RhoA	B-GGP
-	O
mediated	O
Phospholipase	B-GGP
D1	I-GGP
signaling	O
is	O
not	O
required	O
for	O
the	O
formation	O
of	O
stress	B-CC
fibers	I-CC
and	O
focal	B-CC
adhesions	I-CC
.	O

The	O
small	O
GTPase	O
RhoA	B-GGP
regulates	O
a	O
wide	O
spectrum	O
of	O
cellular	O
functions	O
including	O
transformation	O
and	O
cytoskeletal	B-CC
reorganization	O
.	O

A	O
large	O
number	O
of	O
proteins	O
have	O
been	O
identified	O
as	O
targets	O
of	O
RhoA	B-GGP
,	O
but	O
their	O
specific	O
roles	O
in	O
these	O
processes	O
are	O
not	O
clear	O
.	O

Phospholipase	B-GGP
D	I-GGP
(	O
PLD	B-GGP
)	O
was	O
shown	O
to	O
be	O
one	O
such	O
target	O
several	O
years	O
ago	O
;	O
more	O
recent	O
work	O
from	O
our	O
laboratory	O
and	O
others	O
has	O
demonstrated	O
that	O
of	O
the	O
two	O
mammalian	O
PLD	B-GGP
isozymes	O
,	O
PLD1	B-GGP
but	O
not	O
PLD2	B-GGP
is	O
activated	O
by	O
RhoA	B-GGP
and	O
this	O
activation	O
proceeds	O
through	O
direct	O
binding	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
series	O
of	O
RhoA	B-GGP
mutants	O
,	O
we	O
have	O
defined	O
a	O
PLD1	B-GGP
-	O
specific	O
interacting	O
site	O
on	O
RhoA	B-GGP
composed	O
of	O
the	O
residues	O
Asn41	B-MED
,	O
Trp58	B-MED
and	O
Asp76	B-MED
,	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
co	O
-	O
immunoprecipitation	O
,	O
and	O
a	O
PLD	B-GGP
in	O
vivo	O
assay	O
.	O

The	O
results	O
further	O
substantiate	O
our	O
previous	O
finding	O
that	O
RhoA	B-GGP
activates	O
PLD1	B-GGP
through	O
direct	O
interaction	O
.	O

These	O
mutants	O
were	O
then	O
used	O
to	O
investigate	O
the	O
role	O
of	O
PLD1	B-GGP
in	O
the	O
cytoskeletal	B-CC
reorganization	O
stimulated	O
by	O
RhoA	B-GGP
signaling	O
.	O

Our	O
results	O
show	O
that	O
PLD1	B-GGP
is	O
not	O
required	O
for	O
the	O
RhoA	B-GGP
-	O
mediated	O
stress	B-CC
fiber	I-CC
and	O
focal	B-CC
adhesion	I-CC
formation	O
.	O

The	O
lack	O
of	O
importance	O
of	O
PLD1	B-GGP
signaling	O
in	O
RhoA	B-GGP
-	O
mediated	O
cytoskeletal	B-CC
reorganization	O
is	O
further	O
supported	O
by	O
the	O
observation	O
that	O
PLD1	B-GGP
depletion	O
using	O
an	O
shRNA	O
approach	O
and	O
tetracycline	B-MED
-	O
induced	O
overexpression	O
of	O
the	O
wild	O
-	O
type	O
and	O
the	O
catalytically	O
inactive	O
mutant	O
of	O
PLD1	B-GGP
in	O
stable	O
cell	O
lines	O
do	O
not	O
alter	O
stress	B-CC
fiber	I-CC
and	O
focal	B-CC
adhesion	I-CC
formation	O
.	O

Activating	O
E2Fs	B-GGP
mediate	O
transcriptional	O
regulation	O
of	O
human	O
E2F6	B-GGP
repressor	O
.	O

E2F6	B-GGP
is	O
believed	O
to	O
repress	O
E2F	B-GGP
-	O
responsive	O
genes	O
and	O
therefore	O
serve	O
a	O
role	O
in	O
cell	O
cycle	O
regulation	O
.	O

Analysis	O
of	O
the	O
human	O
E2F6	B-GGP
promoter	O
region	O
revealed	O
the	O
presence	O
of	O
two	O
putative	O
E2F	B-GGP
binding	O
sites	O
,	O
both	O
of	O
which	O
were	O
found	O
to	O
be	O
functionally	O
critical	O
because	O
deletion	O
or	O
mutations	O
of	O
these	O
sites	O
abolished	O
promoter	O
activity	O
.	O

Ectopic	O
expression	O
of	O
E2F1	B-GGP
protein	O
was	O
found	O
to	O
increase	O
E2F6	B-GGP
mRNA	O
levels	O
and	O
significantly	O
upregulate	O
E2F6	B-GGP
promoter	O
activity	O
.	O

Deletion	O
or	O
mutation	O
of	O
the	O
putative	O
E2F	B-GGP
binding	O
sites	O
nullified	O
the	O
effects	O
of	O
E2F1	B-GGP
on	O
the	O
E2F6	B-GGP
promoter	O
activity	O
.	O

Studies	O
on	O
the	O
temporal	O
induction	O
of	O
E2F	B-GGP
family	O
members	O
demonstrated	O
that	O
the	O
activating	O
E2Fs	B-GGP
,	O
and	O
most	O
notably	O
E2F1	B-GGP
,	O
were	O
upregulated	O
before	O
E2F6	B-GGP
during	O
cell	O
cycle	O
progression	O
at	O
the	O
G1	O
/	O
S	O
phase	O
,	O
and	O
this	O
coincided	O
with	O
the	O
time	O
course	O
of	O
induction	O
experienced	O
by	O
the	O
E2F6	B-GGP
promoter	O
during	O
the	O
course	O
of	O
the	O
cell	O
cycle	O
.	O

EMSAs	O
indicated	O
the	O
specific	O
binding	O
of	O
nuclear	B-CC
complexes	O
to	O
the	O
E2F6	B-GGP
promoter	O
that	O
contained	O
E2F1	B-GGP
-	O
related	O
species	O
whose	O
binding	O
was	O
specifically	O
competed	O
by	O
the	O
consensus	O
E2F	B-GGP
binding	O
site	O
.	O

Chromatin	B-CC
immunoprecipitation	O
assays	O
with	O
anti	O
-	O
E2Fs	B-GGP
demonstrated	O
the	O
association	O
of	O
E2F	B-GGP
family	O
members	O
with	O
the	O
E2F6	B-GGP
promoter	O
in	O
vivo	O
.	O

These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
the	O
E2F6	B-GGP
repressor	O
is	O
influenced	O
at	O
the	O
transcriptional	O
level	O
by	O
E2F	B-GGP
family	O
members	O
and	O
suggest	O
that	O
interplay	O
among	O
these	O
transcriptional	O
regulators	O
,	O
especially	O
E2F1	B-GGP
,	O
may	O
be	O
critical	O
for	O
cell	O
cycle	O
regulation	O
.	O

DNA	O
damage	O
induces	O
cdk2	B-GGP
protein	O
levels	O
and	O
histone	B-GGP
H2B	I-GGP
phosphorylation	O
in	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

DNA	O
damage	O
and	O
activation	O
of	O
the	O
cell	O
cycle	O
have	O
been	O
implicated	O
in	O
numerous	O
neurodegenerative	O
diseases	O
,	O
including	O
Alzheimer	O
disease	O
,	O
Parkinson	O
'	O
s	O
disease	O
,	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
cell	O
cycle	O
proteins	O
in	O
DNA	O
-	O
damage	O
induced	O
neuronal	O
cell	O
death	O
,	O
we	O
examined	O
various	O
cell	O
cycle	O
proteins	O
during	O
camptothecin	B-MED
-	O
induced	O
death	O
of	O
human	O
neuroblastoma	O
cells	O
.	O

We	O
report	O
a	O
rapid	O
induction	O
of	O
p53	B-GGP
and	O
increased	O
expression	O
of	O
p21	B-GGP
,	O
concurrent	O
with	O
reduced	O
levels	O
of	O
many	O
cell	O
cycle	O
proteins	O
that	O
regulate	O
G1	O
to	O
S	O
phase	O
cell	O
cycle	O
progression	O
.	O

However	O
,	O
we	O
found	O
increased	O
levels	O
of	O
cdk2	B-GGP
and	O
cyclin	B-GGP
E	I-GGP
,	O
and	O
formation	O
of	O
a	O
cyclin	B-COM
E	I-COM
-	I-COM
cdk2	I-COM
-	I-COM
p21	I-COM
protein	O
complex	O
.	O

DNA	O
damage	O
failed	O
to	O
induce	O
activation	O
and	O
progression	O
of	O
the	O
cell	O
cycle	O
.	O

Finally	O
,	O
camptothecin	B-MED
-	O
induced	O
neuronal	O
cell	O
death	O
occurred	O
concurrent	O
with	O
phosphorylation	O
of	O
histone	B-GGP
H2B	I-GGP
.	O

Pretreatment	O
of	O
cells	O
with	O
cdk	B-GGP
inhibitor	O
olomoucine	B-MED
impeded	O
cdk2	B-COM
-	I-COM
cyclin	I-COM
E	I-COM
accumulation	O
,	O
but	O
not	O
the	O
induction	O
of	O
p53	B-GGP
.	O

Olomucine	B-MED
concurrently	O
delayed	O
histone	B-GGP
H2B	I-GGP
phosphorylation	O
,	O
caspase	B-GGP
-	I-GGP
3	I-GGP
activation	O
and	O
cell	O
death	O
.	O

These	O
findings	O
suggest	O
that	O
DNA	O
-	O
damage	O
of	O
differentiated	O
neuroblastoma	O
cells	O
induces	O
a	O
rapid	O
p53	B-GGP
-	O
mediated	O
inhibition	O
of	O
cell	O
cycle	O
progression	O
and	O
induction	O
of	O
cdk2	B-COM
-	I-COM
cyclin	I-COM
E	I-COM
,	O
followed	O
by	O
caspase	B-GGP
-	I-GGP
3	I-GGP
activation	O
,	O
phosphorylation	O
of	O
histone	B-GGP
and	O
cell	O
death	O
.	O

E2F	B-COM
-	I-COM
HDAC	I-COM
complexes	O
negatively	O
regulate	O
the	O
tumor	O
suppressor	O
gene	O
ARHI	B-GGP
in	O
breast	O
cancer	O
.	O

ARHI	B-GGP
is	O
a	O
maternally	O
imprinted	O
tumor	O
suppressor	O
gene	O
whose	O
expression	O
is	O
markedly	O
downregulated	O
in	O
breast	O
cancer	O
.	O

Reactivation	O
of	O
ARHI	B-GGP
expression	O
in	O
breast	O
cancer	O
cells	O
is	O
associated	O
with	O
increased	O
histone	B-GGP
H3	I-GGP
acetylation	O
and	O
decreased	O
lysine	B-MED
9	I-MED
methylation	O
of	O
histone	B-GGP
H3	I-GGP
.	O

An	O
ARHI	B-GGP
promoter	O
segment	O
that	O
spanned	O
bases	O
-	O
420	O
to	O
+	O
58	O
(	O
designated	O
the	O
P2	O
region	O
)	O
exhibits	O
significantly	O
higher	O
promoter	O
activity	O
in	O
normal	O
cells	O
than	O
in	O
cancer	O
cells	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
contributing	O
to	O
this	O
differential	O
transcriptional	O
activity	O
,	O
we	O
sought	O
to	O
identify	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
P2	O
region	O
of	O
the	O
ARHI	B-GGP
promoter	O
and	O
regulate	O
its	O
activity	O
.	O

Sequence	O
analysis	O
and	O
oligonucleotide	O
competition	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
identified	O
an	O
A2	O
fragment	O
containing	O
an	O
E2F	B-GGP
-	O
binding	O
site	O
.	O

Using	O
specific	O
antibodies	O
in	O
supershift	O
assays	O
,	O
we	O
have	O
shown	O
that	O
anti	O
-	O
E2F1	B-GGP
and	O
4	B-GGP
antibodies	O
can	O
supershift	O
the	O
A2	O
-	O
protein	O
complexes	O
,	O
whereas	O
anti	O
-	O
E2F2	B-GGP
and	O
6	B-GGP
antibodies	O
cannot	O
,	O
demonstrating	O
that	O
the	O
A2	O
fragment	O
interacts	O
with	O
specific	O
members	O
of	O
the	O
E2F	B-GGP
family	O
proteins	O
.	O

When	O
compared	O
with	O
normal	O
breast	O
epithelial	O
cells	O
,	O
breast	O
cancer	O
cells	O
have	O
significantly	O
elevated	O
expression	O
of	O
E2F1	B-GGP
,	O
4	B-GGP
and	O
increased	O
E2F	B-GGP
DNA	O
-	O
binding	O
activity	O
.	O

Moreover	O
,	O
chromatin	B-CC
immunoprecipitation	O
experiments	O
revealed	O
that	O
both	O
E2F1	B-GGP
and	O
4	B-GGP
bind	O
to	O
the	O
ARHI	B-GGP
promoter	O
in	O
breast	O
cancer	O
cells	O
in	O
vivo	O
.	O

This	O
binding	O
was	O
reduced	O
when	O
the	O
cells	O
were	O
treated	O
with	O
the	O
histone	B-GGP
deacetylase	I-GGP
(	O
HDAC	B-GGP
)	O
inhibitor	O
-	O
-	O
trichostatin	B-MED
A	I-MED
(	O
TSA	B-MED
)	O
.	O

When	O
SKBr3	O
cells	O
were	O
cotransfected	O
with	O
an	O
ARHI	B-GGP
/	O
luciferase	B-GGP
reporter	O
and	O
E2F	B-GGP
-	O
expression	O
vectors	O
,	O
E2F1	B-GGP
and	O
4	B-GGP
reduced	O
ARHI	B-GGP
promoter	O
activity	O
2	O
-	O
3	O
-	O
fold	O
,	O
and	O
this	O
reduction	O
could	O
be	O
reversed	O
by	O
TSA	B-MED
treatment	O
.	O

The	O
negative	O
regulation	O
by	O
E2F	B-COM
-	I-COM
HDAC	I-COM
complexes	O
could	O
also	O
be	O
reduced	O
by	O
small	O
interfering	O
RNA	O
of	O
E2F1	B-GGP
and	O
4	B-GGP
.	O

While	O
the	O
retinoblastoma	B-GGP
protein	I-GGP
,	O
pRB	B-GGP
,	O
alone	O
had	O
no	O
effect	O
on	O
ARHI	B-GGP
promoter	O
activity	O
,	O
repression	O
by	O
E2F1	B-GGP
,	O
but	O
not	O
E2F4	B-GGP
,	O
was	O
enhanced	O
by	O
the	O
coexpression	O
of	O
pRB	B-GGP
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
E2F1	B-GGP
,	O
4	B-GGP
and	O
their	O
complexes	O
with	O
HDAC	B-GGP
play	O
an	O
important	O
role	O
in	O
downregulating	O
the	O
expression	O
of	O
the	O
tumor	O
suppressor	O
gene	O
ARHI	B-GGP
in	O
breast	O
cancer	O
cells	O
.	O

Characterization	O
of	O
E2F8	B-GGP
,	O
a	O
novel	O
E2F	B-GGP
-	O
like	O
cell	O
-	O
cycle	O
regulated	O
repressor	O
of	O
E2F	B-GGP
-	O
activated	O
transcription	O
.	O

The	O
E2F	B-GGP
family	O
of	O
transcription	O
factors	O
are	O
downstream	O
effectors	O
of	O
the	O
retinoblastoma	B-GGP
protein	I-GGP
,	O
pRB	B-GGP
,	O
pathway	O
and	O
are	O
essential	O
for	O
the	O
timely	O
regulation	O
of	O
genes	O
necessary	O
for	O
cell	O
-	O
cycle	O
progression	O
.	O

Here	O
we	O
describe	O
the	O
characterization	O
of	O
human	O
and	O
murine	O
E2F8	B-GGP
,	O
a	O
new	O
member	O
of	O
the	O
E2F	B-GGP
family	O
.	O

Sequence	O
analysis	O
of	O
E2F8	B-GGP
predicts	O
the	O
presence	O
of	O
two	O
distinct	O
E2F	B-GGP
-	O
related	O
DNA	O
binding	O
domains	O
suggesting	O
that	O
E2F8	B-GGP
and	O
,	O
the	O
recently	O
,	O
identified	O
E2F7	B-GGP
form	O
a	O
subgroup	O
within	O
the	O
E2F	B-GGP
family	O
.	O

We	O
show	O
that	O
E2F	B-GGP
transcription	O
factors	O
bind	O
the	O
E2F8	B-GGP
promoter	O
in	O
vivo	O
and	O
that	O
expression	O
of	O
E2F8	B-GGP
is	O
being	O
induced	O
at	O
the	O
G1	O
/	O
S	O
transition	O
.	O

Purified	O
recombinant	O
E2F8	B-GGP
binds	O
specifically	O
to	O
a	O
consensus	O
E2F	B-GGP
-	O
DNA	O
-	O
binding	O
site	O
indicating	O
that	O
E2F8	B-GGP
,	O
like	O
E2F7	B-GGP
,	O
binds	O
DNA	O
without	O
the	O
requirement	O
of	O
co	O
-	O
factors	O
such	O
as	O
DP1	B-GGP
.	O

E2F8	B-GGP
inhibits	O
E2F	B-GGP
-	O
driven	O
promoters	O
suggesting	O
that	O
E2F8	B-GGP
is	O
transcriptional	O
repressor	O
like	O
E2F7	B-GGP
.	O

Ectopic	O
expression	O
of	O
E2F8	B-GGP
in	O
diploid	O
human	O
fibroblasts	O
reduces	O
expression	O
of	O
E2F	B-GGP
-	O
target	O
genes	O
and	O
inhibits	O
cell	O
growth	O
consistent	O
with	O
a	O
role	O
for	O
repressing	O
E2F	B-GGP
transcriptional	O
activity	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
E2F8	B-GGP
has	O
an	O
important	O
role	O
in	O
turning	O
of	O
the	O
expression	O
of	O
E2F	B-GGP
-	O
target	O
genes	O
in	O
the	O
S	O
-	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

A	O
dual	O
role	O
for	O
PP1	B-GGP
in	O
shaping	O
the	O
Msn2	B-GGP
-	O
dependent	O
transcriptional	O
response	O
to	O
glucose	B-MED
starvation	O
.	O

In	O
yeast	O
,	O
glucose	B-MED
depletion	O
elicits	O
a	O
quick	O
response	O
in	O
the	O
transcription	O
of	O
stress	O
-	O
related	O
genes	O
.	O

The	O
main	O
transcriptional	O
activator	O
that	O
orchestrates	O
this	O
response	O
is	O
Msn2	B-GGP
,	O
whose	O
nuclear	B-CC
localization	O
and	O
DNA	O
binding	O
are	O
negatively	O
controlled	O
by	O
the	O
cAMP	B-GGP
-	I-GGP
dependent	I-GGP
protein	I-GGP
kinase	I-GGP
(	O
PKA	B-GGP
)	O
.	O

Msn2	B-GGP
activation	O
by	O
sudden	O
glucose	B-MED
depletion	O
correlates	O
with	O
a	O
fast	O
but	O
transient	O
decrease	O
in	O
phosphorylation	O
of	O
several	O
sites	O
in	O
its	O
nuclear	B-CC
localization	O
signal	O
(	O
NLS	O
)	O
.	O

Here	O
we	O
show	O
that	O
protein	B-GGP
phosphatase	I-GGP
1	I-GGP
(	O
PP1	B-GGP
)	O
is	O
the	O
direct	O
antagonist	O
of	O
PKA	B-GGP
-	O
dependent	O
phosphorylation	O
at	O
the	O
Msn2	B-GGP
nuclear	B-CC
import	O
domain	O
and	O
therefore	O
a	O
potential	O
mediator	O
of	O
glucose	B-MED
starvation	O
signals	O
that	O
target	O
this	O
transcription	O
factor	O
.	O

Apart	O
from	O
PKA	B-GGP
,	O
the	O
protein	O
kinase	O
Snf1	B-GGP
can	O
also	O
directly	O
modify	O
one	O
of	O
the	O
Msn2	B-GGP
phosphorylation	O
sites	O
(	O
S582	B-MED
)	O
and	O
thereby	O
repress	O
Msn2	B-GGP
function	O
.	O

Consequently	O
,	O
in	O
snf1	B-GGP
mutants	O
,	O
rephosphorylation	O
of	O
the	O
NLS	O
happens	O
to	O
be	O
much	O
slower	O
during	O
prolonged	O
starvation	O
.	O

Thus	O
,	O
a	O
second	O
,	O
Reg1	B-GGP
-	O
dependent	O
form	O
of	O
PP1	B-GGP
indirectly	O
influences	O
Msn2	B-GGP
functionality	O
by	O
modulating	O
Snf1	B-GGP
kinase	O
activation	O
and	O
repression	O
.	O

Different	O
activities	O
of	O
PP1	B-GGP
are	O
therefore	O
involved	O
in	O
shaping	O
induction	O
and	O
adaptation	O
of	O
the	O
transcriptional	O
stress	O
response	O
during	O
acute	O
glucose	B-MED
starvation	O
.	O

mTOR	B-GGP
and	O
S6K1	B-GGP
mediate	O
assembly	O
of	O
the	O
translation	B-COM
preinitiation	I-COM
complex	I-COM
through	O
dynamic	O
protein	O
interchange	O
and	O
ordered	O
phosphorylation	O
events	O
.	O

In	O
response	O
to	O
nutrients	O
,	O
energy	O
sufficiency	O
,	O
hormones	O
,	O
and	O
mitogenic	O
agents	O
,	O
S6K1	B-GGP
phosphorylates	O
several	O
targets	O
linked	O
to	O
translation	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
whereby	O
S6K1	B-GGP
is	O
activated	O
,	O
encounters	O
substrate	O
,	O
and	O
contributes	O
to	O
translation	O
initiation	O
are	O
poorly	O
understood	O
.	O

We	O
show	O
that	O
mTOR	B-GGP
and	O
S6K1	B-GGP
maneuver	O
on	O
and	O
off	O
the	O
eukaryotic	B-COM
initiation	I-COM
factor	I-COM
3	I-COM
(	I-COM
eIF3	I-COM
)	I-COM
translation	I-COM
initiation	I-COM
complex	I-COM
in	O
a	O
signal	O
-	O
dependent	O
,	O
choreographed	O
fashion	O
.	O

When	O
inactive	O
,	O
S6K1	B-GGP
associates	O
with	O
the	O
eIF3	B-COM
complex	I-COM
,	O
while	O
the	O
S6K1	B-GGP
activator	O
mTOR	B-GGP
/	O
raptor	B-GGP
does	O
not	O
.	O

Cell	O
stimulation	O
promotes	O
mTOR	B-GGP
/	O
raptor	B-GGP
binding	O
to	O
the	O
eIF3	B-COM
complex	I-COM
and	O
phosphorylation	O
of	O
S6K1	B-GGP
at	O
its	O
hydrophobic	O
motif	O
.	O

Phosphorylation	O
results	O
in	O
S6K1	B-GGP
dissociation	O
,	O
activation	O
,	O
and	O
subsequent	O
phosphorylation	O
of	O
its	O
translational	O
targets	O
,	O
including	O
eIF4B	B-GGP
,	O
which	O
is	O
then	O
recruited	O
into	O
the	O
complex	O
in	O
a	O
phosphorylation	O
-	O
dependent	O
manner	O
.	O

Thus	O
,	O
the	O
eIF3	B-COM
preinitiation	I-COM
complex	I-COM
acts	O
as	O
a	O
scaffold	O
to	O
coordinate	O
a	O
dynamic	O
sequence	O
of	O
events	O
in	O
response	O
to	O
stimuli	O
that	O
promote	O
efficient	O
protein	O
synthesis	O
.	O

Signal	O
transduction	O
in	O
Saccharomyces	O
cerevisiae	O
requires	O
tyrosine	B-MED
and	O
threonine	B-MED
phosphorylation	O
of	O
FUS3	B-GGP
and	O
KSS1	B-GGP
.	O

The	O
FUS3	B-GGP
and	O
KSS1	B-GGP
kinases	O
are	O
components	O
of	O
the	O
pheromone	O
-	O
dependent	O
signal	O
transduction	O
pathway	O
in	O
yeast	O
.	O

We	O
show	O
that	O
FUS3	B-GGP
and	O
KSS1	B-GGP
become	O
rapidly	O
phosphorylated	O
after	O
pheromone	O
treatment	O
.	O

Similar	O
to	O
mammalian	O
MAP	B-GGP
kinases	I-GGP
,	O
this	O
modification	O
occurs	O
at	O
two	O
amino	O
acids	O
of	O
FUS3	B-GGP
,	O
threonine	B-MED
-	I-MED
180	I-MED
and	O
tyrosine	B-MED
-	I-MED
182	I-MED
.	O

A	O
mutation	O
introduced	O
at	O
either	O
position	O
results	O
in	O
complete	O
loss	O
of	O
function	O
in	O
vivo	O
.	O

Amino	O
acid	O
substitutions	O
that	O
destroy	O
catalytic	O
activity	O
of	O
the	O
kinase	O
do	O
not	O
prevent	O
phosphorylation	O
of	O
the	O
mutant	O
products	O
,	O
a	O
result	O
that	O
excludes	O
an	O
autocatalytic	O
activation	O
pathway	O
.	O

The	O
modification	O
of	O
FUS3	B-GGP
is	O
dependent	O
on	O
kinases	O
encoded	O
by	O
the	O
STE11	B-GGP
and	O
STE7	B-GGP
genes	O
.	O

Furthermore	O
,	O
a	O
hyperactive	O
allele	O
of	O
STE11	B-GGP
causes	O
increased	O
phosphorylation	O
of	O
FUS3	B-GGP
in	O
the	O
absence	O
of	O
pheromone	O
stimulation	O
.	O

Thus	O
,	O
either	O
STE7	B-GGP
or	O
STE11	B-GGP
could	O
be	O
the	O
kinase	O
responsible	O
for	O
the	O
phosphorylation	O
of	O
FUS3	B-GGP
.	O

Blockade	O
of	O
NFAT	B-GGP
activation	O
by	O
the	O
second	O
calcineurin	B-COM
binding	O
site	O
.	O

Activation	O
of	O
NFAT	B-GGP
transcription	O
factors	O
requires	O
their	O
dephosphorylation	O
by	O
the	O
phosphatase	O
calcineurin	B-COM
(	O
CN	B-COM
)	O
.	O

NFATs	B-GGP
contain	O
two	O
CN	B-COM
binding	O
motifs	O
:	O
PxIxIT	O
and	O
CnBP	O
-	O
B	O
/	O
CNBR2	O
(	O
which	O
we	O
call	O
LxVP	O
)	O
.	O

Here	O
we	O
carry	O
out	O
a	O
detailed	O
comparative	O
analysis	O
of	O
the	O
CN	B-COM
binding	O
activity	O
displayed	O
by	O
the	O
PxIxIT	O
and	O
LxVP	O
sites	O
from	O
different	O
NFATs	B-GGP
.	O

Dose	O
-	O
response	O
CN	B-COM
binding	O
experiments	O
with	O
GST	B-GGP
fusion	O
proteins	O
of	O
NFATc1	B-GGP
and	O
NFATc2	B-GGP
showed	O
that	O
NFATc1	B-GGP
binds	O
CN	B-COM
in	O
vitro	O
more	O
efficiently	O
than	O
does	O
NFATc2	B-GGP
.	O

This	O
difference	O
in	O
binding	O
appears	O
to	O
be	O
caused	O
by	O
the	O
different	O
CN	B-COM
binding	O
potencies	O
of	O
the	O
corresponding	O
LxVP	O
sites	O
;	O
thus	O
while	O
the	O
LxVPc2	B-GGP
peptide	O
fused	O
to	O
GST	B-GGP
did	O
not	O
bind	O
CN	B-COM
,	O
GST	B-GGP
-	I-GGP
LxVPc1	I-GGP
bound	O
it	O
more	O
efficiently	O
than	O
did	O
GST	B-GGP
-	I-GGP
PxIxITc1	I-GGP
or	O
GST	B-GGP
-	I-GGP
PxIxITc2	I-GGP
.	O

Furthermore	O
,	O
an	O
NFATc2	B-GGP
chimera	O
protein	O
containing	O
the	O
LxVP	O
motif	O
from	O
NFATc1	B-GGP
interacted	O
with	O
CN	B-COM
much	O
more	O
potently	O
than	O
did	O
wild	O
-	O
type	O
NFATc2	B-GGP
.	O

Free	O
peptides	O
spanning	O
the	O
LxVP	O
motifs	O
from	O
NFATc1	B-GGP
,	O
c3	B-GGP
or	O
c4	B-GGP
displaced	O
CN	B-COM
from	O
GST	B-COM
-	I-COM
NFATc1	I-COM
and	O
GST	B-COM
-	I-COM
NFATc2	I-COM
more	O
efficiently	O
than	O
any	O
PxIxIT	B-GGP
peptide	O
.	O

PxIxITc2	B-GGP
and	O
LxVPc1	B-GGP
peptides	O
were	O
each	O
able	O
to	O
cross	O
-	O
compete	O
GST	B-COM
-	I-COM
LxVPc1	I-COM
-	I-COM
CN	I-COM
and	O
GST	B-COM
-	I-COM
PxIxITc2	I-COM
-	I-COM
CN	I-COM
binding	O
.	O

In	O
contrast	O
with	O
PxIxITc2	B-GGP
,	O
the	O
LxVP	B-GGP
peptide	O
not	O
only	O
blocked	O
CN	B-COM
-	O
NFAT	B-GGP
binding	O
but	O
also	O
inhibited	O
CN	B-COM
phosphatase	O
activity	O
in	O
vitro	O
.	O

Furthermore	O
,	O
exogenous	O
LxVPc1	B-GGP
blocked	O
NFATc2	B-GGP
phosphorylation	O
and	O
nuclear	B-CC
translocation	O
in	O
vivo	O
.	O

These	O
results	O
suggest	O
a	O
model	O
in	O
which	O
the	O
different	O
CN	B-COM
binding	O
characteristics	O
of	O
the	O
PxIxIT	O
and	O
LxVP	O
sites	O
enable	O
different	O
NFAT	B-GGP
members	O
to	O
influence	O
each	O
others	O
activities	O
in	O
cells	O
where	O
they	O
are	O
co	O
-	O
expressed	O
.	O

Rec8	B-GGP
phosphorylation	O
and	O
recombination	O
promote	O
the	O
step	O
-	O
wise	O
loss	O
of	O
cohesins	B-COM
in	O
meiosis	O
.	O

During	O
meiosis	O
,	O
cohesins	B-COM
-	O
-	O
protein	O
complexes	O
that	O
hold	O
sister	O
chromatids	B-CC
together	O
-	O
-	O
are	O
lost	O
from	O
chromosomes	B-CC
in	O
a	O
step	O
-	O
wise	O
manner	O
.	O

Loss	O
of	O
cohesins	B-COM
from	O
chromosome	B-CC
arms	I-CC
is	O
necessary	O
for	O
homologous	O
chromosomes	B-CC
to	O
segregate	O
during	O
meiosis	O
I	O
.	O

Retention	O
of	O
cohesins	B-COM
around	O
centromeres	O
until	O
meiosis	O
II	O
is	O
required	O
for	O
the	O
accurate	O
segregation	O
of	O
sister	O
chromatids	B-CC
.	O

Here	O
we	O
show	O
that	O
phosphorylation	O
of	O
the	O
cohesin	B-COM
subunit	O
Rec8	B-GGP
contributes	O
to	O
step	O
-	O
wise	O
cohesin	B-COM
removal	O
.	O

Our	O
data	O
further	O
implicate	O
two	O
other	O
key	O
regulators	O
of	O
meiotic	O
chromosome	B-CC
segregation	O
,	O
the	O
cohesin	B-COM
protector	O
Sgo1	B-GGP
and	O
meiotic	O
recombination	O
in	O
bringing	O
about	O
the	O
step	O
-	O
wise	O
loss	O
of	O
cohesins	B-COM
and	O
thus	O
the	O
establishment	O
of	O
the	O
meiotic	O
chromosome	B-CC
segregation	O
pattern	O
.	O

Understanding	O
the	O
interplay	O
between	O
these	O
processes	O
should	O
provide	O
insight	O
into	O
the	O
events	O
underlying	O
meiotic	O
chromosome	B-CC
mis	O
-	O
segregation	O
,	O
the	O
leading	O
cause	O
of	O
miscarriages	O
and	O
mental	O
retardation	O
in	O
humans	O
.	O

Regulation	O
of	O
the	O
Pur	B-GGP
-	I-GGP
alpha	I-GGP
promoter	O
by	O
E2F	B-GGP
-	I-GGP
1	I-GGP
.	O

Puralpha	B-GGP
is	O
a	O
ubiquitously	O
expressed	O
multifunctional	O
nucleic	O
acid	O
-	O
binding	O
protein	O
that	O
is	O
involved	O
in	O
many	O
cellular	O
processes	O
including	O
transcriptional	O
regulation	O
,	O
the	O
cell	O
cycle	O
,	O
oncogenic	O
transformation	O
,	O
and	O
post	O
-	O
natal	O
brain	O
development	O
.	O

Previously	O
,	O
Puralpha	B-GGP
protein	O
was	O
found	O
to	O
bind	O
to	O
E2F	B-GGP
-	I-GGP
1	I-GGP
,	O
inhibit	O
E2F	B-GGP
-	I-GGP
1	I-GGP
transcriptional	O
activity	O
,	O
and	O
reverse	O
the	O
effects	O
of	O
ectopic	O
E2F	B-GGP
-	I-GGP
1	I-GGP
expression	O
on	O
cell	O
growth	O
.	O

Also	O
Puralpha	B-GGP
binds	O
to	O
a	O
GC	O
/	O
GA	O
-	O
rich	O
sequence	O
within	O
its	O
own	O
promoter	O
and	O
inhibits	O
gene	O
expression	O
,	O
that	O
is	O
,	O
Puralpha	B-GGP
is	O
autoregulated	O
.	O

We	O
now	O
report	O
that	O
the	O
Puralpha	B-GGP
promoter	O
(	O
pPuralpha	B-GGP
)	O
is	O
induced	O
by	O
E2F	B-GGP
-	I-GGP
1	I-GGP
and	O
that	O
this	O
activity	O
maps	O
to	O
a	O
consensus	O
E2F	B-GGP
-	I-GGP
1	I-GGP
binding	O
motif	O
that	O
is	O
juxtaposed	O
to	O
the	O
Puralpha	B-GGP
binding	O
site	O
.	O

Deletion	O
mutants	O
of	O
the	O
E2F	B-GGP
-	I-GGP
1	I-GGP
protein	O
showed	O
that	O
the	O
region	O
between	O
amino	O
acid	O
residues	O
88	O
-	O
241	O
is	O
important	O
for	O
this	O
activity	O
.	O

E2F	B-GGP
-	I-GGP
1	I-GGP
-	O
associated	O
activation	O
of	O
the	O
pPuralpha	B-GGP
was	O
inhibited	O
by	O
co	O
-	O
expression	O
of	O
Puralpha	B-GGP
,	O
pRb	B-GGP
,	O
and	O
an	O
RNA	O
species	O
with	O
specific	O
binding	O
to	O
E2F	B-GGP
-	I-GGP
1	I-GGP
.	O

Chromatin	B-CC
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
using	O
primers	O
that	O
flanked	O
the	O
juxtaposed	O
Puralpha	B-GGP
and	O
E2F	B-GGP
-	I-GGP
1	I-GGP
binding	O
sites	O
verified	O
the	O
presence	O
of	O
Puralpha	B-GGP
and	O
E2F	B-GGP
-	I-GGP
1	I-GGP
on	O
the	O
pPuralpha	B-GGP
in	O
vivo	O
.	O

In	O
a	O
Tet	B-GGP
-	O
inducible	O
cell	O
line	O
,	O
Puralpha	B-GGP
delayed	O
cell	O
cycle	O
progression	O
.	O

Thus	O
,	O
E2F	B-GGP
-	I-GGP
1	I-GGP
and	O
Puralpha	B-GGP
interplay	O
appears	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
Puralpha	B-GGP
expression	O
and	O
the	O
cell	O
cycle	O
.	O

Deletion	O
of	O
a	O
single	O
allele	O
of	O
the	O
Dkk1	B-GGP
gene	O
leads	O
to	O
an	O
increase	O
in	O
bone	O
formation	O
and	O
bone	O
mass	O
.	O

UNLABELLED	O
:	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
has	O
been	O
proven	O
to	O
play	O
a	O
central	O
role	O
in	O
bone	O
biology	O
.	O

Unexpectedly	O
,	O
the	O
Wnt	B-GGP
antagonist	O
Dkk2	B-GGP
is	O
required	O
for	O
terminal	O
osteoblast	O
differentiation	O
and	O
mineralized	O
matrix	B-CC
formation	O
.	O

We	O
show	O
that	O
Dkk1	B-GGP
,	O
unlike	O
Dkk2	B-GGP
,	O
negatively	O
regulates	O
osteoblast	O
differentiation	O
and	O
bone	O
formation	O
.	O

INTRODUCTION	O
:	O
The	O
Wnt	B-GGP
co	O
-	O
receptor	O
LRP5	B-GGP
is	O
a	O
critical	O
regulator	O
of	O
bone	O
mass	O
.	O

Dickkopf	B-GGP
(	O
Dkk	B-GGP
)	O
proteins	O
act	O
as	O
natural	O
Wnt	B-GGP
antagonists	O
by	O
bridging	O
LRP5	B-GGP
/	O
6	B-GGP
and	O
Kremen	B-GGP
,	O
inducing	O
the	O
internalization	O
of	O
the	O
complex	O
.	O

Wnt	B-GGP
antagonists	O
are	O
thus	O
expected	O
to	O
negatively	O
regulation	O
bone	O
formation	O
.	O

However	O
,	O
Dkk2	B-GGP
deficiency	O
results	O
in	O
increased	O
bone	O
,	O
questioning	O
the	O
precise	O
role	O
of	O
Dkks	B-GGP
in	O
bone	O
metabolism	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
investigated	O
specifically	O
the	O
role	O
of	O
Dkk1	B-GGP
in	O
bone	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Using	O
rat	O
primary	O
calvaria	O
cells	O
,	O
we	O
studied	O
the	O
effect	O
of	O
retroviral	O
expression	O
of	O
Dkk1	B-GGP
on	O
osteoblast	O
differentiation	O
.	O

In	O
addition	O
,	O
the	O
effect	O
of	O
Dkk1	B-GGP
osteoblast	O
was	O
studied	O
in	O
MC3T3	O
-	O
E1	O
cells	O
by	O
means	O
of	O
recombinant	O
protein	O
.	O

Finally	O
,	O
to	O
address	O
the	O
role	O
of	O
Dkk1	B-GGP
in	O
vivo	O
,	O
we	O
analyzed	O
the	O
bone	O
phenotype	O
of	O
Dkk1	B-GGP
(	O
+	O
/	O
-	O
)	O
animals	O
.	O

RESULTS	O
:	O
Retroviral	O
expression	O
of	O
Dkk1	B-GGP
in	O
rat	O
primary	O
calvaria	O
cells	O
resulted	O
in	O
a	O
complete	O
inhibition	O
of	O
osteoblast	O
differentiation	O
and	O
formation	O
of	O
mineralized	O
nodules	O
,	O
with	O
a	O
marked	O
decrease	O
in	O
the	O
expression	O
of	O
alkaline	B-GGP
phosphatase	I-GGP
.	O

Dkk1	B-GGP
expression	O
also	O
increased	O
adipocyte	O
differentiation	O
in	O
these	O
cell	O
cultures	O
.	O

Recombinant	O
murine	O
Dkk1	B-GGP
(	O
rmDkk1	B-GGP
)	O
inhibited	O
spontaneous	O
and	O
induced	O
osteoblast	O
differentiation	O
of	O
MC3T3	O
-	O
E1	O
cells	O
.	O

To	O
determine	O
the	O
role	O
of	O
Dkk1	B-GGP
in	O
vivo	O
and	O
overcome	O
the	O
embryonic	O
lethality	O
of	O
homozygous	O
deletion	O
,	O
we	O
studied	O
the	O
bone	O
phenotype	O
in	O
heterozygous	O
Dkk1	B-GGP
-	O
deficient	O
mice	O
.	O

Structural	O
,	O
dynamic	O
,	O
and	O
cellular	O
analysis	O
of	O
bone	O
remodeling	O
in	O
Dkk1	B-GGP
(	O
+	O
/	O
-	O
)	O
mice	O
showed	O
an	O
increase	O
in	O
all	O
bone	O
formation	O
parameters	O
,	O
with	O
no	O
change	O
in	O
bone	O
resorption	O
,	O
leading	O
to	O
a	O
marked	O
increase	O
in	O
bone	O
mass	O
.	O

Importantly	O
,	O
the	O
number	O
of	O
osteoblasts	O
,	O
mineral	O
apposition	O
,	O
and	O
bone	O
formation	O
rate	O
were	O
all	O
increased	O
several	O
fold	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
Dkk1	B-GGP
protein	O
is	O
a	O
potent	O
negative	O
regulator	O
of	O
osteoblasts	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Given	O
that	O
a	O
heterozygous	O
decrease	O
in	O
Dkk1	B-GGP
expression	O
is	O
sufficient	O
to	O
induce	O
a	O
significant	O
increase	O
in	O
bone	O
mass	O
,	O
antagonizing	O
Dkk1	B-GGP
should	O
result	O
in	O
a	O
potent	O
anabolic	O
effect	O
.	O

Peptidoglycan	B-MED
-	O
induced	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
is	O
mediated	O
by	O
cyclooxygenase	B-GGP
-	I-GGP
2	I-GGP
,	O
PGE2	B-GGP
/	O
PGE4	B-GGP
receptors	I-GGP
,	O
protein	B-COM
kinase	I-COM
A	I-COM
,	O
I	B-COM
kappa	I-COM
B	I-COM
kinase	I-COM
,	O
and	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
signaling	O
pathway	O
involved	O
in	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
caused	O
by	O
peptidoglycan	B-MED
(	O
PGN	B-MED
)	O
,	O
a	O
cell	B-CC
wall	I-CC
component	O
of	O
the	O
Gram	O
-	O
positive	O
bacterium	O
,	O
Staphylococcus	O
aureus	O
,	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
.	O

PGN	B-MED
caused	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
increases	O
in	O
IL	B-GGP
-	I-GGP
6	I-GGP
,	O
PGE	B-MED
(	I-MED
2	I-MED
)	I-MED
,	O
and	O
cAMP	B-MED
production	O
.	O

PGN	B-MED
-	O
mediated	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
was	O
inhibited	O
by	O
a	O
nonselective	O
cyclooxygenase	B-GGP
(	O
COX	B-GGP
)	O
inhibitor	O
(	O
indomethacin	B-MED
)	O
,	O
a	O
selective	O
COX	B-GGP
-	I-GGP
2	I-GGP
inhibitor	O
(	O
NS398	B-MED
)	O
,	O
a	O
PGE	B-MED
(	I-MED
2	I-MED
)	I-MED
(	O
EP2	B-MED
)	O
antagonist	O
(	O
AH6809	B-MED
)	O
,	O
a	O
PGE	B-MED
(	I-MED
4	I-MED
)	I-MED
(	O
EP4	B-MED
)	O
antagonist	O
(	O
AH23848	B-MED
)	O
,	O
and	O
a	O
protein	B-COM
kinase	I-COM
A	I-COM
(	O
PKA	B-COM
)	O
inhibitor	O
(	O
KT5720	B-MED
)	O
,	O
but	O
not	O
by	O
a	O
nonselective	O
NO	B-GGP
synthase	I-GGP
inhibitor	O
(	O
N	B-MED
(	I-MED
G	I-MED
)	I-MED
-	I-MED
nitro	I-MED
-	I-MED
l	I-MED
-	I-MED
arginine	I-MED
methyl	I-MED
ester	I-MED
)	O
.	O

Furthermore	O
,	O
PGE	B-MED
(	I-MED
2	I-MED
)	I-MED
,	O
an	O
EP2	B-MED
agonist	O
(	O
butaprost	B-MED
)	O
,	O
an	O
EP2	B-MED
/	O
PGE	B-MED
(	I-MED
3	I-MED
)	I-MED
(	O
EP3	B-MED
)	O
/	O
EP4	B-MED
agonist	O
(	O
misoprostol	B-MED
)	O
,	O
and	O
misoprostol	B-MED
in	O
the	O
presence	O
of	O
AH6809	B-MED
all	O
induced	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
,	O
whereas	O
an	O
EP1	B-MED
/	O
EP3	B-MED
agonist	O
(	O
sulprostone	B-MED
)	O
did	O
not	O
.	O

PGN	B-MED
caused	O
time	O
-	O
dependent	O
activations	O
of	O
IkappaB	B-GGP
kinase	I-GGP
alphabeta	I-GGP
(	O
IKKdbeta	B-GGP
)	O
and	O
p65	B-GGP
phosphorylation	O
at	O
Ser	B-MED
(	I-MED
276	I-MED
)	I-MED
,	O
and	O
these	O
effects	O
were	O
inhibited	O
by	O
NS398	B-MED
and	O
KT5720	B-MED
.	O

Both	O
PGE	B-MED
(	I-MED
2	I-MED
)	I-MED
and	O
8	B-MED
-	I-MED
bromo	I-MED
-	I-MED
cAMP	I-MED
also	O
caused	O
IKKdbeta	B-GGP
kinase	I-GGP
alphabeta	I-GGP
phosphorylation	O
.	O

PGN	B-MED
resulted	O
in	O
two	O
waves	O
of	O
the	O
formation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
specific	O
DNA	O
-	O
protein	O
complexes	O
.	O

The	O
first	O
wave	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
occurred	O
at	O
10	O
-	O
60	O
min	O
of	O
treatment	O
,	O
whereas	O
the	O
later	O
wave	O
occurred	O
at	O
2	O
-	O
12	O
h	O
of	O
treatment	O
.	O

The	O
PGN	B-MED
-	O
induced	O
increase	O
in	O
kappaB	B-COM
luciferase	B-GGP
activity	O
was	O
inhibited	O
by	O
NS398	B-MED
,	O
AH6809	B-MED
,	O
AH23848	B-MED
,	O
KT5720	B-MED
,	O
a	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
inhibitor	O
(	O
Ro31	B-MED
-	I-MED
8220	I-MED
)	O
,	O
and	O
a	O
p38	B-GGP
MAPK	I-GGP
inhibitor	O
(	O
SB203580	B-MED
)	O
.	O

These	O
results	O
suggest	O
that	O
PGN	B-MED
-	O
induced	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
involves	O
COX	B-GGP
-	I-GGP
2	I-GGP
-	O
generated	O
PGE	B-MED
(	I-MED
2	I-MED
)	I-MED
,	O
activation	O
of	O
the	O
EP2	B-GGP
and	O
EP4	B-GGP
receptors	I-GGP
,	O
cAMP	B-MED
formation	O
,	O
and	O
the	O
activation	O
of	O
PKA	B-COM
,	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
,	O
p38	B-GGP
MAPK	I-GGP
,	O
IKKdbeta	B-GGP
,	O
kinase	B-GGP
alphabeta	I-GGP
,	O
p65	B-GGP
phosphorylation	O
,	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

However	O
,	O
PGN	B-MED
-	O
induced	O
NO	B-MED
release	O
is	O
not	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
PGN	B-MED
-	O
induced	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
.	O

Direct	O
phosphorylation	O
and	O
activation	O
of	O
a	O
Nim1	B-GGP
-	O
related	O
kinase	O
Gin4	B-GGP
by	O
Elm1	B-GGP
in	O
budding	O
yeast	O
.	O

In	O
budding	O
yeast	O
,	O
Gin4	B-GGP
,	O
a	O
Nim1	B-GGP
-	O
related	O
kinase	O
,	O
plays	O
an	O
important	O
role	O
in	O
proper	O
organization	O
of	O
the	O
septin	B-GGP
ring	O
at	O
the	O
mother	B-CC
-	I-CC
bud	I-CC
neck	I-CC
,	O
a	O
filamentous	O
structure	O
that	O
is	O
critical	O
for	O
diverse	O
cellular	O
processes	O
including	O
mitotic	O
entry	O
and	O
cytokinesis	O
.	O

How	O
Gin4	B-GGP
kinase	O
activity	O
is	O
regulated	O
is	O
not	O
known	O
.	O

Here	O
we	O
showed	O
that	O
a	O
neck	B-CC
-	O
associated	O
Ser	B-MED
/	O
Thr	B-MED
kinase	O
Elm1	B-GGP
,	O
which	O
is	O
important	O
for	O
septin	B-GGP
assembly	O
,	O
is	O
critical	O
for	O
proper	O
modification	O
of	O
Gin4	B-GGP
and	O
its	O
physiological	O
substrate	O
Shs1	B-GGP
.	O

In	O
vitro	O
studies	O
with	O
purified	O
recombinant	O
proteins	O
demonstrated	O
that	O
Elm1	B-GGP
directly	O
phosphorylates	O
and	O
activates	O
Gin4	B-GGP
,	O
which	O
in	O
turn	O
phosphorylates	O
Shs1	B-GGP
.	O

Consistent	O
with	O
these	O
observations	O
,	O
acute	O
inhibition	O
of	O
Elm1	B-GGP
activity	O
abolished	O
mitotic	O
Gin4	B-GGP
phosphorylation	O
and	O
Gin4	B-GGP
-	O
dependent	O
Shs1	B-GGP
modification	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
a	O
gin4	B-GGP
mutant	O
lacking	O
the	O
Elm1	B-GGP
-	O
dependent	O
phosphorylation	O
sites	O
exhibited	O
an	O
impaired	O
localization	O
to	O
the	O
bud	B-CC
-	I-CC
neck	I-CC
and	O
,	O
as	O
a	O
result	O
,	O
induced	O
a	O
significant	O
growth	O
defect	O
with	O
an	O
elongated	O
bud	B-CC
morphology	O
.	O

Thus	O
,	O
Elm1	B-GGP
regulates	O
the	O
septin	B-GGP
assembly	O
-	O
dependent	O
cellular	O
events	O
by	O
directly	O
phosphorylating	O
and	O
activating	O
the	O
Gin4	B-GGP
-	O
dependent	O
pathway	O
(	O
s	O
)	O
.	O

Mind	O
the	O
GAP	O
:	O
Wnt	B-GGP
steps	O
onto	O
the	O
mTORC1	B-COM
train	O
.	O

The	O
TSC1	B-COM
/	I-COM
2	I-COM
tumor	O
-	O
suppressor	O
complex	O
controls	O
protein	O
synthesis	O
through	O
the	O
regulation	O
of	O
mTOR	B-GGP
.	O

In	O
this	O
issue	O
of	O
Cell	O
,	O
Inoki	O
et	O
al	O
.	O

(	O
2006	O
)	O
report	O
that	O
the	O
kinases	O
GSK3	B-GGP
and	O
AMPK	B-GGP
cooperate	O
in	O
the	O
activation	O
of	O
TSC2	B-GGP
to	O
inhibit	O
mTOR	B-GGP
activity	O
.	O

Surprisingly	O
,	O
the	O
phosphorylation	O
of	O
TSC2	B-GGP
by	O
GSK3	B-GGP
is	O
markedly	O
suppressed	O
by	O
Wnt	B-GGP
signaling	O
.	O

This	O
suggests	O
that	O
components	O
of	O
the	O
mTOR	B-GGP
pathway	O
may	O
be	O
therapeutic	O
targets	O
for	O
diseases	O
linked	O
to	O
hyperactive	O
Wnt	B-GGP
signaling	O
.	O

Polo	B-GGP
kinase	I-GGP
controls	O
cell	O
-	O
cycle	O
-	O
dependent	O
transcription	O
by	O
targeting	O
a	O
coactivator	O
protein	O
.	O

Polo	B-GGP
kinases	I-GGP
have	O
crucial	O
conserved	O
functions	O
in	O
controlling	O
the	O
eukaryotic	O
cell	O
cycle	O
through	O
orchestrating	O
several	O
events	O
during	O
mitosis	O
.	O

An	O
essential	O
element	O
of	O
cell	O
cycle	O
control	O
is	O
exerted	O
by	O
altering	O
the	O
expression	O
of	O
key	O
regulators	O
.	O

Here	O
we	O
show	O
an	O
important	O
function	O
for	O
the	O
polo	B-GGP
kinase	I-GGP
Cdc5p	B-GGP
in	O
controlling	O
cell	O
-	O
cycle	O
-	O
dependent	O
gene	O
expression	O
that	O
is	O
crucial	O
for	O
the	O
execution	O
of	O
mitosis	O
in	O
the	O
model	O
eukaryote	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
particular	O
,	O
we	O
find	O
that	O
Cdc5p	B-GGP
is	O
temporally	O
recruited	O
to	O
promoters	O
of	O
the	O
cell	O
-	O
cycle	O
-	O
regulated	O
CLB2	B-GGP
gene	O
cluster	O
,	O
where	O
it	O
targets	O
the	O
Mcm1p	B-COM
-	I-COM
Fkh2p	I-COM
-	I-COM
Ndd1p	I-COM
transcription	O
factor	O
complex	O
,	O
through	O
direct	O
phosphorylation	O
of	O
the	O
coactivator	O
protein	O
Ndd1p	B-GGP
.	O

This	O
phosphorylation	O
event	O
is	O
required	O
for	O
the	O
normal	O
temporal	O
expression	O
of	O
cell	O
-	O
cycle	O
-	O
regulated	O
genes	O
such	O
as	O
CLB2	B-GGP
and	O
SWI5	B-GGP
in	O
G2	O
/	O
M	O
phases	O
.	O

Furthermore	O
,	O
severe	O
defects	O
in	O
cell	O
division	O
occur	O
in	O
the	O
absence	O
of	O
Cdc5p	B-GGP
-	O
mediated	O
phosphorylation	O
of	O
Ndd1p	B-GGP
.	O

Thus	O
,	O
polo	B-GGP
kinase	I-GGP
is	O
required	O
for	O
the	O
production	O
of	O
key	O
mitotic	O
regulators	O
,	O
in	O
addition	O
to	O
previously	O
defined	O
roles	O
in	O
controlling	O
other	O
mitotic	O
events	O
.	O

Human	O
cyclins	B-GGP
A	I-GGP
and	O
B1	B-GGP
are	O
differentially	O
located	O
in	O
the	O
cell	O
and	O
undergo	O
cell	O
cycle	O
-	O
dependent	O
nuclear	B-CC
transport	O
.	O

We	O
have	O
used	O
immunofluorescence	O
staining	O
to	O
study	O
the	O
subcellular	B-CC
distribution	O
of	O
cyclin	B-GGP
A	I-GGP
and	O
B1	B-GGP
during	O
the	O
somatic	O
cell	O
cycle	O
.	O

In	O
both	O
primary	O
human	O
fibroblasts	O
and	O
in	O
epithelial	O
tumor	O
cells	O
,	O
we	O
find	O
that	O
cyclin	B-GGP
A	I-GGP
is	O
predominantly	O
nuclear	B-CC
from	O
S	O
phase	O
onwards	O
.	O

Cyclin	B-GGP
A	I-GGP
may	O
associated	O
with	O
condensing	O
chromosomes	B-CC
in	O
prophase	O
,	O
but	O
is	O
not	O
associated	O
with	O
condensed	O
chromosomes	B-CC
in	O
metaphase	O
.	O

By	O
contrast	O
,	O
cyclin	B-GGP
B1	I-GGP
accumulates	O
in	O
the	O
cytoplasm	B-CC
of	O
interphase	O
cells	O
and	O
only	O
enters	O
the	O
nucleus	B-CC
at	O
the	O
beginning	O
of	O
mitosis	O
,	O
before	O
nuclear	B-CC
lamina	I-CC
breakdown	O
.	O

In	O
mitotic	O
cells	O
,	O
cyclin	B-GGP
B1	I-GGP
associates	O
with	O
condensed	O
chromosomes	B-CC
in	O
prophase	O
and	O
metaphase	O
,	O
and	O
with	O
the	O
mitotic	B-CC
apparatus	I-CC
.	O

Cyclin	B-GGP
A	I-GGP
is	O
degraded	O
during	O
metaphase	O
and	O
cyclin	B-GGP
B1	I-GGP
is	O
precipitously	O
destroyed	O
at	O
the	O
metaphase	O
-	O
-	O
-	O
-	O
anaphase	O
transition	O
.	O

Cell	O
fractionation	O
and	O
immunoprecipitation	O
studies	O
showed	O
that	O
both	O
cyclin	B-GGP
A	I-GGP
and	O
cyclin	B-GGP
B1	I-GGP
are	O
associated	O
with	O
PSTAIRE	O
-	O
containing	O
proteins	O
.	O

The	O
nuclear	B-CC
,	O
but	O
not	O
the	O
cytoplasmic	B-CC
form	O
,	O
of	O
cyclin	B-GGP
A	I-GGP
is	O
associated	O
with	O
a	O
33	O
-	O
kD	O
PSTAIRE	O
-	O
containing	O
protein	O
.	O

Cyclin	B-GGP
B1	I-GGP
is	O
associated	O
with	O
p34cdc2	B-GGP
in	O
the	O
cytoplasm	B-CC
.	O

Thus	O
we	O
propose	O
that	O
the	O
different	O
localization	O
of	O
cyclin	B-GGP
A	I-GGP
and	O
cyclin	B-GGP
B1	I-GGP
in	O
the	O
cell	O
cycle	O
could	O
be	O
the	O
means	O
by	O
which	O
the	O
two	O
types	O
of	O
mitotic	O
cyclin	B-GGP
confer	O
substrate	O
specificity	O
upon	O
their	O
associated	O
PSTAIRE	O
-	O
containing	O
protein	O
kinase	O
subunit	O
.	O

The	O
checkpoint	O
clamp	O
activates	O
Mec1	B-GGP
kinase	O
during	O
initiation	O
of	O
the	O
DNA	O
damage	O
checkpoint	O
.	O

Yeast	O
Mec1	B-COM
/	I-COM
Ddc2	I-COM
protein	O
kinase	O
,	O
the	O
ortholog	O
of	O
human	O
ATR	B-COM
/	I-COM
ATRIP	I-COM
,	O
plays	O
a	O
central	O
role	O
in	O
the	O
DNA	O
damage	O
checkpoint	O
.	O

The	O
PCNA	O
-	O
like	O
clamp	O
Rad17	B-COM
/	I-COM
Mec3	I-COM
/	I-COM
Ddc1	I-COM
(	O
the	O
9	B-COM
-	I-COM
1	I-COM
-	I-COM
1	I-COM
complex	O
in	O
human	O
)	O
and	O
its	O
loader	O
Rad24	B-COM
-	I-COM
RFC	I-COM
are	O
also	O
essential	O
components	O
of	O
this	O
signal	O
transduction	O
pathway	O
.	O

Here	O
we	O
have	O
studied	O
the	O
role	O
of	O
the	O
clamp	O
in	O
regulating	O
Mec1	B-GGP
,	O
and	O
we	O
delineate	O
how	O
the	O
signal	O
generated	O
by	O
DNA	O
lesions	O
is	O
transduced	O
to	O
the	O
Rad53	B-GGP
effector	O
kinase	O
.	O

The	O
checkpoint	O
clamp	O
greatly	O
activates	O
the	O
kinase	O
activity	O
of	O
Mec1	B-GGP
,	O
but	O
only	O
if	O
the	O
clamp	O
is	O
appropriately	O
loaded	O
upon	O
partial	O
duplex	O
DNA	O
.	O

Activated	O
Mec1	B-GGP
phosphorylates	O
the	O
Ddc1	B-GGP
and	O
Mec3	B-GGP
subunits	O
of	O
the	O
clamp	O
,	O
the	O
Rad24	B-GGP
subunit	O
of	O
the	O
loader	O
,	O
and	O
the	O
Rpa1	B-GGP
and	O
Rpa2	B-GGP
subunits	O
of	O
RPA	B-COM
.	O

Phosphorylation	O
of	O
Rad53	B-GGP
,	O
and	O
of	O
human	O
PHAS	B-GGP
-	I-GGP
1	I-GGP
,	O
a	O
nonspecific	O
target	O
,	O
also	O
requires	O
a	O
properly	O
loaded	O
clamp	O
.	O

Phosphorylation	O
and	O
binding	O
studies	O
with	O
individual	O
clamp	O
subunits	O
indicate	O
that	O
the	O
Ddc1	B-GGP
subunit	O
mediates	O
the	O
functional	O
interactions	O
with	O
Mec1	B-GGP
.	O

Suppression	O
of	O
p53	B-GGP
-	O
activated	O
gene	O
,	O
PAG608	B-GGP
,	O
attenuates	O
methamphetamine	B-MED
-	O
induced	O
neurotoxicity	O
.	O

The	O
p53	B-GGP
-	I-GGP
activated	I-GGP
gene	I-GGP
608	I-GGP
(	O
PAG608	B-GGP
)	O
is	O
a	O
proapoptotic	O
gene	O
activated	O
and	O
regulated	O
by	O
p53	B-GGP
expression	O
in	O
oxidative	O
stress	O
-	O
induced	O
apoptosis	O
of	O
neuronal	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
role	O
of	O
PAG608	B-GGP
in	O
methamphetamine	B-MED
-	O
induced	O
neurotoxicity	O
.	O

Treatment	O
of	O
mouse	O
dopaminergic	O
CATH	O
.	O
a	O
cells	O
with	O
2	O
mM	O
methamphetamine	B-MED
increased	O
PAG608	B-GGP
expression	O
at	O
3h	O
followed	O
by	O
increase	O
in	O
phosphorylated	O
p53	B-GGP
expression	O
.	O

Transient	O
transfection	O
of	O
PAG608	B-GGP
antisense	O
cDNA	O
or	O
RNA	O
interference	O
using	O
PAG608	B-GGP
small	O
interfering	O
RNA	O
significantly	O
attenuated	O
the	O
dose	O
-	O
dependent	O
decrease	O
in	O
cell	O
viability	O
of	O
CATH	O
.	O
a	O
cells	O
by	O
methamphetamine	B-MED
(	O
1	O
-	O
4	O
mM	O
)	O
exposure	O
.	O

In	O
monoaminergic	O
neuronal	O
B65	O
cells	O
,	O
which	O
contain	O
serotonin	B-MED
rather	O
than	O
dopamine	B-MED
,	O
methamphetamine	B-MED
-	O
induced	O
cell	O
death	O
was	O
also	O
significantly	O
but	O
partially	O
protected	O
by	O
transient	O
transfection	O
of	O
PAG608	B-GGP
antisense	O
cDNA	O
.	O

Furthermore	O
,	O
cell	O
death	O
of	O
PC12	O
cells	O
produced	O
by	O
methamphetamine	B-MED
(	O
1	O
-	O
5	O
mM	O
)	O
was	O
almost	O
completely	O
prevented	O
by	O
stable	O
expression	O
of	O
PAG608	B-GGP
antisense	O
cDNA	O
,	O
compared	O
with	O
significant	O
reduction	O
of	O
cell	O
viability	O
in	O
control	O
PC12	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
suppression	O
of	O
PAG608	B-GGP
using	O
transient	O
and	O
stable	O
transfection	O
with	O
PAG608	B-GGP
antisense	O
cDNA	O
or	O
small	O
interfering	O
RNA	O
attenuates	O
methamphetamine	B-MED
-	O
induced	O
death	O
of	O
various	O
monoaminergic	O
neuronal	O
cells	O
,	O
suggesting	O
that	O
methamphetamine	B-MED
neurotoxicity	O
in	O
monoaminergic	O
cells	O
is	O
related	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
induction	O
of	O
PAG608	B-GGP
expression	O
.	O

p27	B-GGP
phosphorylation	O
by	O
Src	B-GGP
regulates	O
inhibition	O
of	O
cyclin	B-COM
E	I-COM
-	I-COM
Cdk2	I-COM
.	O

The	O
kinase	O
inhibitor	O
p27Kip1	B-GGP
regulates	O
the	O
G1	O
cell	O
cycle	O
phase	O
.	O

Here	O
,	O
we	O
present	O
data	O
indicating	O
that	O
the	O
oncogenic	O
kinase	O
Src	B-GGP
regulates	O
p27	B-GGP
stability	O
through	O
phosphorylation	O
of	O
p27	B-GGP
at	O
tyrosine	B-MED
74	I-MED
and	O
tyrosine	B-MED
88	I-MED
.	O

Src	B-GGP
inhibitors	O
increase	O
cellular	O
p27	B-GGP
stability	O
,	O
and	O
Src	B-GGP
overexpression	O
accelerates	O
p27	B-GGP
proteolysis	O
.	O

Src	B-GGP
-	O
phosphorylated	O
p27	B-GGP
is	O
shown	O
to	O
inhibit	O
cyclin	B-COM
E	I-COM
-	I-COM
Cdk2	I-COM
poorly	O
in	O
vitro	O
,	O
and	O
Src	B-GGP
transfection	O
reduces	O
p27	B-COM
-	I-COM
cyclin	I-COM
E	I-COM
-	I-COM
Cdk2	I-COM
complexes	O
.	O

Our	O
data	O
indicate	O
that	O
phosphorylation	O
by	O
Src	B-GGP
impairs	O
the	O
Cdk2	B-GGP
inhibitory	O
action	O
of	O
p27	B-GGP
and	O
reduces	O
its	O
steady	O
-	O
state	O
binding	O
to	O
cyclin	B-COM
E	I-COM
-	I-COM
Cdk2	I-COM
to	O
facilitate	O
cyclin	B-COM
E	I-COM
-	I-COM
Cdk2	I-COM
-	O
dependent	O
p27	B-GGP
proteolysis	O
.	O

Furthermore	O
,	O
we	O
find	O
that	O
Src	B-GGP
-	O
activated	O
breast	O
cancer	O
lines	O
show	O
reduced	O
p27	B-GGP
and	O
observe	O
a	O
correlation	O
between	O
Src	B-GGP
activation	O
and	O
reduced	O
nuclear	B-CC
p27	B-GGP
in	O
482	O
primary	O
human	O
breast	O
cancers	O
.	O

Importantly	O
,	O
we	O
report	O
that	O
in	O
tamoxifen	B-MED
-	O
resistant	O
breast	O
cancer	O
cell	O
lines	O
,	O
Src	B-GGP
inhibition	O
can	O
increase	O
p27	B-GGP
levels	O
and	O
restore	O
tamoxifen	B-MED
sensitivity	O
.	O

These	O
data	O
provide	O
a	O
new	O
rationale	O
for	O
Src	B-GGP
inhibitors	O
in	O
cancer	O
therapy	O
.	O

Insulin	B-GGP
signalling	O
to	O
mTOR	B-GGP
mediated	O
by	O
the	O
Akt	B-GGP
/	O
PKB	B-GGP
substrate	O
PRAS40	B-GGP
.	O

Insulin	B-GGP
stimulates	O
protein	O
synthesis	O
and	O
cell	O
growth	O
by	O
activation	O
of	O
the	O
protein	O
kinases	O
Akt	B-GGP
(	O
also	O
known	O
as	O
protein	B-GGP
kinase	I-GGP
B	I-GGP
,	O
PKB	B-GGP
)	O
and	O
mammalian	B-GGP
target	I-GGP
of	I-GGP
rapamycin	I-GGP
(	O
mTOR	B-GGP
)	O
.	O

It	O
was	O
reported	O
that	O
Akt	B-GGP
activates	O
mTOR	B-GGP
by	O
phosphorylation	O
and	O
inhibition	O
of	O
tuberous	B-GGP
sclerosis	I-GGP
complex	I-GGP
2	I-GGP
(	O
TSC2	B-GGP
)	O
.	O

However	O
,	O
in	O
recent	O
studies	O
the	O
physiological	O
requirement	O
of	O
Akt	B-GGP
phosphorylation	O
of	O
TSC2	B-GGP
for	O
mTOR	B-GGP
activation	O
has	O
been	O
questioned	O
.	O

Here	O
,	O
we	O
identify	O
PRAS40	B-GGP
(	O
proline	B-GGP
-	I-GGP
rich	I-GGP
Akt	I-GGP
/	I-GGP
PKB	I-GGP
substrate	I-GGP
40	I-GGP
kDa	I-GGP
)	O
as	O
a	O
novel	O
mTOR	B-GGP
binding	O
partner	O
that	O
mediates	O
Akt	B-GGP
signals	O
to	O
mTOR	B-GGP
.	O

PRAS40	B-GGP
binds	O
the	O
mTOR	B-GGP
kinase	O
domain	O
and	O
its	O
interaction	O
with	O
mTOR	B-GGP
is	O
induced	O
under	O
conditions	O
that	O
inhibit	O
mTOR	B-GGP
signalling	O
,	O
such	O
as	O
nutrient	O
or	O
serum	O
deprivation	O
or	O
mitochondrial	B-CC
metabolic	O
inhibition	O
.	O

Binding	O
of	O
PRAS40	B-GGP
inhibits	O
mTOR	B-GGP
activity	O
and	O
suppresses	O
constitutive	O
activation	O
of	O
mTOR	B-GGP
in	O
cells	O
lacking	O
TSC2	B-GGP
.	O

PRAS40	B-GGP
silencing	O
inactivates	O
insulin	B-GGP
-	I-GGP
receptor	I-GGP
substrate	I-GGP
-	I-GGP
1	I-GGP
(	O
IRS	B-GGP
-	I-GGP
1	I-GGP
)	O
and	O
Akt	B-GGP
,	O
and	O
uncouples	O
the	O
response	O
of	O
mTOR	B-GGP
to	O
Akt	B-GGP
signals	O
.	O

Furthermore	O
,	O
PRAS40	B-GGP
phosphorylation	O
by	O
Akt	B-GGP
and	O
association	O
with	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
,	O
a	O
cytosolic	B-CC
anchor	O
protein	O
,	O
are	O
crucial	O
for	O
insulin	B-GGP
to	O
stimulate	O
mTOR	B-GGP
.	O

These	O
findings	O
identify	O
PRAS40	B-GGP
as	O
an	O
important	O
regulator	O
of	O
insulin	B-GGP
sensitivity	O
of	O
the	O
Akt	B-GGP
-	O
mTOR	B-GGP
pathway	O
and	O
a	O
potential	O
target	O
for	O
the	O
treatment	O
of	O
cancers	O
,	O
insulin	B-GGP
resistance	O
and	O
hamartoma	O
syndromes	O
.	O

Parallel	O
pathways	O
of	O
gene	O
regulation	O
:	O
homologous	O
regulators	O
SWI5	B-GGP
and	O
ACE2	B-GGP
differentially	O
control	O
transcription	O
of	O
HO	B-GGP
and	O
chitinase	B-GGP
.	O

Two	O
independent	O
pathways	O
of	O
transcriptional	O
regulation	O
that	O
show	O
functional	O
homology	O
have	O
been	O
identified	O
in	O
yeast	O
.	O

It	O
has	O
been	O
demonstrated	O
previously	O
that	O
SWI5	B-GGP
encodes	O
a	O
zinc	B-MED
finger	O
DNA	O
-	O
binding	O
protein	O
whose	O
transcription	O
and	O
cellular	O
localization	O
both	O
are	O
cell	O
cycle	O
regulated	O
.	O

We	O
show	O
that	O
ACE2	B-GGP
,	O
whose	O
zinc	B-MED
finger	O
region	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
SWI5	B-GGP
,	O
shows	O
patterns	O
of	O
cell	O
cycle	O
-	O
regulated	O
transcription	O
and	O
nuclear	B-CC
localization	O
similar	O
to	O
those	O
seen	O
previously	O
for	O
SWI5	B-GGP
.	O

Despite	O
their	O
similarities	O
,	O
SWI5	B-GGP
and	O
ACE2	B-GGP
function	O
in	O
separate	O
pathways	O
of	O
transcriptional	O
regulation	O
.	O

SWI5	B-GGP
is	O
a	O
transcriptional	O
activator	O
of	O
the	O
HO	B-GGP
endonuclease	O
gene	O
,	O
whereas	O
ACE2	B-GGP
is	O
not	O
.	O

In	O
contrast	O
,	O
ACE2	B-GGP
is	O
a	O
transcriptional	O
activator	O
of	O
the	O
CTS1	B-GGP
gene	O
(	O
which	O
encodes	O
chitinase	B-GGP
)	O
,	O
whereas	O
SWI5	B-GGP
is	O
not	O
.	O

An	O
additional	O
parallel	O
between	O
the	O
SWI5	B-GGP
/	O
HO	B-GGP
pathway	O
and	O
the	O
ACE2	B-GGP
/	O
CTS1	B-GGP
pathway	O
is	O
that	O
HO	B-GGP
and	O
CTS1	B-GGP
both	O
are	O
cell	O
cycle	O
regulated	O
in	O
the	O
same	O
way	O
,	O
and	O
HO	B-GGP
and	O
CTS1	B-GGP
both	O
require	O
the	O
SWI4	B-GGP
and	O
SWI6	B-GGP
transcriptional	O
activators	O
.	O

Overproduction	O
of	O
either	O
SWI5	B-GGP
or	O
ACE2	B-GGP
permits	O
transcriptional	O
activation	O
of	O
the	O
target	O
gene	O
from	O
the	O
other	O
pathway	O
,	O
suggesting	O
that	O
the	O
DNA	O
-	O
binding	O
proteins	O
are	O
capable	O
of	O
binding	O
in	O
vivo	O
to	O
promoters	O
that	O
they	O
do	O
not	O
usually	O
activate	O
.	O

Chimeric	O
SWI5	B-GGP
/	I-GGP
ACE2	I-GGP
protein	O
fusion	O
experiments	O
suggest	O
that	O
promoter	O
specificity	O
resides	O
in	O
a	O
domain	O
distinct	O
from	O
the	O
zinc	B-MED
finger	O
domain	O
.	O

Phosphoinositide	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
is	O
required	O
for	O
high	O
glucose	B-MED
-	O
induced	O
hypertrophy	O
and	O
p21WAF1	B-GGP
expression	O
in	O
LLC	O
-	O
PK1	O
cells	O
.	O

Transforming	B-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
beta	I-GGP
(	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
)	O
,	O
Smads	B-GGP
,	O
and	O
the	O
cyclin	B-GGP
-	I-GGP
dependent	I-GGP
kinase	I-GGP
(	O
cdk	B-GGP
)	O
inhibitor	O
p21	B-GGP
(	O
WAF1	B-GGP
)	O
are	O
important	O
in	O
the	O
pathogenesis	O
of	O
diabetic	O
tubular	O
hypertrophy	O
.	O

Phosphoinositide	B-GGP
3	I-GGP
kinase	I-GGP
(	O
PI3K	B-GGP
)	O
/	O
Akt	B-GGP
kinase	I-GGP
activity	O
is	O
increased	O
in	O
diabetic	O
glomerular	O
hypertrophy	O
.	O

Thus	O
,	O
we	O
studied	O
the	O
role	O
of	O
PI3K	B-GGP
in	O
high	O
glucose	B-MED
(	O
30	O
mM	O
)	O
-	O
induced	O
p21	B-GGP
(	O
WAF1	B-GGP
)	O
,	O
Smad2	B-GGP
/	I-GGP
3	I-GGP
,	O
and	O
cell	O
cycle	O
-	O
dependent	O
hypertrophy	O
in	O
LLC	O
-	O
PK1	O
cells	O
.	O

We	O
found	O
that	O
high	O
glucose	B-MED
time	O
-	O
dependently	O
(	O
1	O
-	O
48	O
h	O
)	O
increased	O
PI3K	B-GGP
/	O
Akt	B-GGP
kinase	I-GGP
activity	O
.	O

LY294002	B-MED
(	O
a	O
PI3K	B-GGP
inhibitor	O
)	O
attenuated	O
high	O
glucose	B-MED
-	O
induced	O
cell	O
cycle	O
-	O
dependent	O
(	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
phase	O
)	O
hypertrophy	O
at	O
72	O
h	O
while	O
attenuating	O
high	O
glucose	B-MED
-	O
induced	O
p21	B-GGP
(	O
WAF1	B-GGP
)	O
gene	O
transcription	O
and	O
protein	O
expression	O
at	O
36	O
-	O
48	O
h	O
.	O

LY294002	B-MED
also	O
attenuated	O
high	O
glucose	B-MED
-	O
induced	O
binding	O
of	O
p21	B-GGP
(	O
WAF1	B-GGP
)	O
to	O
the	O
cyclin	B-COM
E	I-COM
/	I-COM
cdk2	I-COM
complex	O
,	O
whereas	O
attenuating	O
high	O
glucose	B-MED
-	O
induced	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
bioactivity	O
,	O
Smad2	B-GGP
/	I-GGP
3	I-GGP
phosphorylation	O
,	O
and	O
Smad2	B-GGP
/	I-GGP
3	I-GGP
DNA	O
-	O
binding	O
activity	O
at	O
36	O
-	O
48	O
h	O
.	O

We	O
concluded	O
that	O
PI3K	B-GGP
is	O
required	O
for	O
high	O
glucose	B-MED
-	O
induced	O
cell	O
cycle	O
-	O
dependent	O
hypertrophy	O
,	O
p21	B-GGP
(	O
WAF1	B-GGP
)	O
transcription	O
and	O
expression	O
,	O
p21	B-GGP
(	O
WAF1	B-GGP
)	O
binding	O
to	O
the	O
cyclin	B-COM
E	I-COM
/	I-COM
cdk2	I-COM
complex	O
,	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
bioactivity	O
,	O
and	O
Smad2	B-GGP
/	I-GGP
3	I-GGP
activity	O
in	O
LLC	O
-	O
PK1	O
cells	O
.	O

Nutrient	O
-	O
responsive	O
mTOR	B-GGP
signalling	O
grows	O
on	O
Sterile	O
ground	O
.	O

The	O
control	O
of	O
cell	O
growth	O
,	O
that	O
is	O
cell	O
size	O
,	O
is	O
largely	O
controlled	O
by	O
mTOR	B-GGP
(	O
the	O
mammalian	B-GGP
target	I-GGP
of	I-GGP
rapamycin	I-GGP
)	O
,	O
a	O
large	O
serine	B-GGP
/	I-GGP
threonine	I-GGP
protein	I-GGP
kinase	I-GGP
that	O
regulates	O
ribosome	B-CC
biogenesis	O
and	O
protein	O
translation	O
.	O

mTOR	B-GGP
activity	O
is	O
regulated	O
both	O
by	O
the	O
availability	O
of	O
growth	O
factors	O
,	O
such	O
as	O
insulin	B-GGP
/	O
IGF	B-GGP
-	I-GGP
1	I-GGP
(	O
insulin	B-GGP
-	I-GGP
like	I-GGP
growth	I-GGP
factor	I-GGP
1	I-GGP
)	O
,	O
and	O
by	O
nutrients	O
,	O
notably	O
the	O
supply	O
of	O
certain	O
key	O
amino	O
acids	O
.	O

The	O
last	O
few	O
years	O
have	O
seen	O
a	O
remarkable	O
increase	O
in	O
our	O
understanding	O
of	O
the	O
canonical	O
,	O
growth	B-GGP
factor	I-GGP
-	O
regulated	O
pathway	O
for	O
mTOR	B-GGP
activation	O
,	O
which	O
is	O
mediated	O
by	O
the	O
class	B-GGP
I	I-GGP
PI3Ks	I-GGP
(	O
phosphoinositide	B-GGP
3	I-GGP
-	I-GGP
kinases	I-GGP
)	O
,	O
PKB	B-GGP
(	O
protein	B-GGP
kinase	I-GGP
B	I-GGP
)	O
,	O
TSC1	B-COM
/	O
2	O
(	O
the	O
tuberous	B-COM
sclerosis	I-COM
complex	I-COM
)	O
and	O
the	O
small	O
GTPase	B-GGP
,	O
Rheb	B-GGP
.	O

However	O
,	O
the	O
nutrient	O
-	O
responsive	O
input	O
into	O
mTOR	B-GGP
is	O
important	O
in	O
its	O
own	O
right	O
and	O
is	O
also	O
required	O
for	O
maximal	O
activation	O
of	O
mTOR	B-GGP
signalling	O
by	O
growth	O
factors	O
.	O

Despite	O
this	O
,	O
the	O
details	O
of	O
the	O
nutrient	O
-	O
responsive	O
signalling	O
pathway	O
(	O
s	O
)	O
controlling	O
mTOR	B-GGP
have	O
remained	O
elusive	O
,	O
although	O
recent	O
studies	O
have	O
suggested	O
a	O
role	O
for	O
the	O
class	B-GGP
III	I-GGP
PI3K	I-GGP
hVps34	B-GGP
.	O

In	O
this	O
issue	O
of	O
the	O
Biochemical	O
Journal	O
,	O
Findlay	O
et	O
al	O
.	O
demonstrate	O
that	O
the	O
protein	O
kinase	O
MAP4K3	B-GGP
[	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
kinase	I-GGP
kinase	I-GGP
kinase	I-GGP
-	I-GGP
3	I-GGP
,	O
a	O
Ste20	B-GGP
family	O
protein	O
kinase	O
also	O
known	O
as	O
GLK	B-GGP
(	O
germinal	B-GGP
centre	I-GGP
-	I-GGP
like	I-GGP
kinase	I-GGP
)	O
]	O
is	O
a	O
new	O
component	O
of	O
the	O
nutrient	O
-	O
responsive	O
pathway	O
.	O

MAP4K3	B-GGP
activity	O
is	O
stimulated	O
by	O
administration	O
of	O
amino	O
acids	O
,	O
but	O
not	O
growth	O
factors	O
,	O
and	O
this	O
is	O
insensitive	O
to	O
rapamycin	B-MED
,	O
most	O
likely	O
placing	O
MAP4K3	B-GGP
upstream	O
of	O
mTOR	B-GGP
.	O

Indeed	O
,	O
MAP4K3	B-GGP
is	O
required	O
for	O
phosphorylation	O
of	O
known	O
mTOR	B-GGP
targets	O
such	O
as	O
S6K1	B-GGP
(	O
S6	B-GGP
kinase	I-GGP
1	I-GGP
)	O
,	O
and	O
overexpression	O
of	O
MAP4K3	B-GGP
promotes	O
the	O
rapamycin	B-MED
-	O
sensitive	O
phosphorylation	O
of	O
these	O
same	O
targets	O
.	O

Finally	O
,	O
knockdown	O
of	O
MAP4K3	B-GGP
levels	O
causes	O
a	O
decrease	O
in	O
cell	O
size	O
.	O

The	O
results	O
suggest	O
that	O
MAP4K3	B-GGP
is	O
a	O
new	O
component	O
in	O
the	O
nutrient	O
-	O
responsive	O
pathway	O
for	O
mTOR	B-GGP
activation	O
and	O
reveal	O
a	O
completely	O
new	O
function	O
for	O
MAP4K3	B-GGP
in	O
promoting	O
cell	O
growth	O
.	O

Given	O
that	O
mTOR	B-GGP
activity	O
is	O
frequently	O
deregulated	O
in	O
cancer	O
,	O
there	O
is	O
much	O
interest	O
in	O
new	O
strategies	O
for	O
inhibition	O
of	O
this	O
pathway	O
.	O

In	O
this	O
context	O
,	O
MAP4K3	B-GGP
looks	O
like	O
an	O
attractive	O
drug	O
target	O
since	O
inhibitors	O
of	O
this	O
enzyme	O
should	O
switch	O
off	O
mTOR	B-GGP
,	O
thereby	O
inhibiting	O
cell	O
growth	O
and	O
proliferation	O
,	O
and	O
promoting	O
apoptosis	O
.	O

Signalling	O
to	O
translation	O
:	O
how	O
signal	O
transduction	O
pathways	O
control	O
the	O
protein	O
synthetic	O
machinery	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
of	O
both	O
the	O
regulation	O
of	O
components	O
of	O
the	O
translational	O
machinery	O
and	O
the	O
upstream	O
signalling	O
pathways	O
that	O
modulate	O
them	O
have	O
provided	O
important	O
new	O
insights	O
into	O
the	O
mechanisms	O
by	O
which	O
hormones	O
,	O
growth	O
factors	O
,	O
nutrients	O
and	O
cellular	O
energy	O
status	O
control	O
protein	O
synthesis	O
in	O
mammalian	O
cells	O
.	O

The	O
importance	O
of	O
proper	O
control	O
of	O
mRNA	O
translation	O
is	O
strikingly	O
illustrated	O
by	O
the	O
fact	O
that	O
defects	O
in	O
this	O
process	O
or	O
its	O
control	O
are	O
implicated	O
in	O
a	O
number	O
of	O
disease	O
states	O
,	O
such	O
as	O
cancer	O
,	O
tissue	O
hypertrophy	O
and	O
neurodegeneration	O
.	O

Signalling	O
pathways	O
such	O
as	O
those	O
involving	O
mTOR	B-GGP
(	O
mammalian	B-GGP
target	I-GGP
of	I-GGP
rapamycin	I-GGP
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
modulate	O
the	O
phosphorylation	O
of	O
translation	O
factors	O
,	O
the	O
activities	O
of	O
the	O
protein	O
kinases	O
that	O
act	O
upon	O
them	O
and	O
the	O
association	O
of	O
RNA	O
-	O
binding	O
proteins	O
with	O
specific	O
mRNAs	O
.	O

These	O
effects	O
contribute	O
both	O
to	O
the	O
overall	O
control	O
of	O
protein	O
synthesis	O
(	O
which	O
is	O
linked	O
to	O
cell	O
growth	O
)	O
and	O
to	O
the	O
modulation	O
of	O
the	O
translation	O
or	O
stability	O
of	O
specific	O
mRNAs	O
.	O

However	O
,	O
important	O
questions	O
remain	O
about	O
both	O
the	O
contributions	O
of	O
individual	O
regulatory	O
events	O
to	O
the	O
control	O
of	O
general	O
protein	O
synthesis	O
and	O
the	O
mechanisms	O
by	O
which	O
the	O
translation	O
of	O
specific	O
mRNAs	O
is	O
controlled	O
.	O

Mitotic	O
phosphorylation	O
of	O
the	O
anaphase	B-COM
-	I-COM
promoting	I-COM
complex	I-COM
inhibitory	O
subunit	O
Mnd2	B-GGP
is	O
necessary	O
for	O
efficient	O
progression	O
through	O
meiosis	O
i	O
.	O

The	O
yeast	O
anaphase	B-COM
-	I-COM
promoting	I-COM
complex	I-COM
(	O
APC	B-COM
)	O
subunit	O
Mnd2	B-GGP
is	O
necessary	O
for	O
maintaining	O
sister	B-CC
chromatid	I-CC
cohesion	O
in	O
prophase	O
I	O
of	O
meiosis	O
by	O
inhibiting	O
premature	O
ubiquitination	O
and	O
subsequent	O
degradation	O
of	O
substrates	O
by	O
the	O
APC	B-COM
(	I-COM
Ama1	I-COM
)	I-COM
ubiquitin	B-GGP
ligase	O
.	O

In	O
a	O
proteomics	O
screen	O
for	O
post	O
-	O
translational	O
modifications	O
on	O
the	O
APC	B-COM
,	O
we	O
discovered	O
that	O
Mnd2	B-GGP
is	O
phosphorylated	O
during	O
mitosis	O
in	O
a	O
cell	O
cycle	O
-	O
dependent	O
manner	O
.	O

We	O
identified	O
and	O
characterized	O
the	O
sites	O
of	O
mitotic	O
Mnd2	B-GGP
phosphorylation	O
during	O
the	O
cell	O
cycle	O
.	O

Collective	O
mutation	O
of	O
Mnd2	B-GGP
phosphorylation	O
sites	O
to	O
alanine	B-MED
had	O
no	O
effect	O
on	O
vegetative	O
growth	O
but	O
a	O
striking	O
effect	O
(	O
>	O
85	O
%	O
reduction	O
)	O
on	O
the	O
percentage	O
of	O
tetrad	O
-	O
forming	O
cells	O
compared	O
with	O
the	O
wild	O
type	O
strain	O
.	O

Similar	O
to	O
the	O
MND2	B-GGP
deletion	O
strain	O
,	O
cells	O
harboring	O
the	O
alanine	B-MED
mutant	O
that	O
did	O
not	O
form	O
spores	O
arrested	O
after	O
premeiotic	O
S	O
phase	O
with	O
a	O
single	O
undivided	O
nucleus	B-CC
and	O
low	O
levels	O
of	O
the	O
APC	B-COM
(	I-COM
Ama1	I-COM
)	I-COM
meiotic	O
substrate	O
,	O
Clb5	B-GGP
,	O
relative	O
to	O
wild	O
type	O
cells	O
.	O

In	O
contrast	O
,	O
collective	O
mutation	O
of	O
Mnd2	B-GGP
phosphorylation	O
sites	O
to	O
aspartic	B-MED
acid	I-MED
resulted	O
in	O
partial	O
suppression	O
of	O
the	O
sporulation	O
defect	O
.	O

No	O
differences	O
were	O
observed	O
in	O
the	O
binding	O
between	O
each	O
Mnd2	B-GGP
isoform	O
and	O
the	O
APC	B-COM
in	O
vitro	O
.	O

However	O
,	O
in	O
vivo	O
,	O
we	O
observed	O
a	O
gradient	O
in	O
the	O
abundance	O
of	O
APC	B-COM
-	O
associated	O
Mnd2	B-GGP
in	O
each	O
strain	O
that	O
was	O
proportional	O
to	O
the	O
observed	O
differences	O
in	O
sporulation	O
and	O
Clb5	B-GGP
levels	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
mitotic	O
phosphorylation	O
of	O
Mnd2	B-GGP
is	O
necessary	O
for	O
APC	B-COM
-	O
mediated	O
progression	O
beyond	O
the	O
first	O
meiotic	O
nuclear	B-CC
division	O
.	O

Identification	O
of	O
Protor	B-GGP
as	O
a	O
novel	O
Rictor	B-GGP
-	O
binding	O
component	O
of	O
mTOR	B-COM
complex	I-COM
-	I-COM
2	I-COM
.	O

The	O
mTOR	B-GGP
(	O
mammalian	B-GGP
target	I-GGP
of	I-GGP
rapamycin	I-GGP
)	O
protein	O
kinase	O
is	O
an	O
important	O
regulator	O
of	O
cell	O
growth	O
.	O

Two	O
complexes	O
of	O
mTOR	B-GGP
have	O
been	O
identified	O
:	O
complex	B-COM
1	I-COM
,	O
consisting	O
of	O
mTOR	B-GGP
-	O
Raptor	B-GGP
(	O
regulatory	B-GGP
associated	I-GGP
protein	I-GGP
of	I-GGP
mTOR	I-GGP
)	O
-	O
mLST8	B-GGP
(	O
termed	O
mTORC1	B-COM
)	O
,	O
and	O
complex	B-COM
2	I-COM
,	O
comprising	O
mTOR	B-GGP
-	O
Rictor	B-GGP
(	O
rapamycininsensitive	B-GGP
companion	I-GGP
of	I-GGP
mTOR	I-GGP
)	O
-	O
mLST8	B-GGP
-	O
Sin1	B-GGP
(	O
termed	O
mTORC2	B-COM
)	O
.	O

mTORC1	B-COM
phosphorylates	O
the	O
p70	B-GGP
ribosomal	I-GGP
S6K	I-GGP
(	B-GGP
S6	I-GGP
kinase	I-GGP
)	O
at	O
its	O
hydrophobic	O
motif	O
(	O
Thr389	B-MED
)	O
,	O
whereas	O
mTORC2	B-COM
phosphorylates	O
PKB	B-GGP
(	O
protein	B-GGP
kinase	I-GGP
B	I-GGP
)	O
at	O
its	O
hydrophobic	O
motif	O
(	B-MED
Ser473	I-MED
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
that	O
widely	O
expressed	O
isoforms	O
of	O
unstudied	O
proteins	O
termed	O
Protor	B-GGP
-	I-GGP
1	I-GGP
(	O
protein	B-GGP
observed	I-GGP
with	I-GGP
Rictor	I-GGP
-	I-GGP
1	I-GGP
)	O
and	O
Protor	B-GGP
-	I-GGP
2	I-GGP
interact	O
with	O
Rictor	B-GGP
and	O
are	O
components	O
of	O
mTORC2	B-COM
.	O

We	O
demonstrate	O
that	O
immunoprecipitation	O
of	O
Protor	B-GGP
-	I-GGP
1	I-GGP
or	O
Protor	B-GGP
-	I-GGP
2	I-GGP
results	O
in	O
the	O
co	O
-	O
immunoprecipitation	O
of	O
other	O
mTORC2	B-COM
subunits	O
,	O
but	O
not	O
Raptor	B-GGP
,	O
a	O
specific	O
component	O
of	O
mTORC1	B-COM
.	O

We	O
show	O
that	O
detergents	O
such	O
as	O
Triton	B-MED
X	I-MED
-	I-MED
100	I-MED
or	O
n	B-MED
-	I-MED
octylglucoside	I-MED
dissociate	O
mTOR	B-GGP
and	O
mLST8	B-GGP
from	O
a	O
complex	O
of	O
Protor	B-GGP
-	I-GGP
1	I-GGP
,	O
Sin1	B-GGP
and	O
Rictor	B-GGP
.	O

We	O
also	O
provide	O
evidence	O
that	O
Rictor	B-GGP
regulates	O
the	O
expression	O
of	O
Protor	B-GGP
-	I-GGP
1	I-GGP
,	O
and	O
that	O
Protor	B-GGP
-	I-GGP
1	I-GGP
is	O
not	O
required	O
for	O
the	O
assembly	O
of	O
other	O
mTORC2	B-COM
subunits	O
into	O
a	O
complex	O
.	O

Protor	B-GGP
-	I-GGP
1	I-GGP
is	O
a	O
novel	O
Rictor	B-GGP
-	O
binding	O
subunit	O
of	O
mTORC2	B-COM
,	O
but	O
further	O
work	O
is	O
required	O
to	O
establish	O
its	O
role	O
.	O

PAC1	B-GGP
is	O
a	O
direct	O
transcription	O
target	O
of	O
E2F	B-GGP
-	I-GGP
1	I-GGP
in	O
apoptotic	O
signaling	O
.	O

E2F	B-GGP
-	I-GGP
1	I-GGP
controls	O
multiple	O
cellular	O
activities	O
through	O
transcriptional	O
regulation	O
of	O
its	O
target	O
genes	O
.	O

As	O
a	O
mediator	O
of	O
cell	O
death	O
,	O
E2F	B-GGP
-	I-GGP
1	I-GGP
can	O
eliminate	O
latent	O
neoplastic	O
cells	O
through	O
apoptosis	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
E2F	B-GGP
-	I-GGP
1	I-GGP
mediates	O
cancer	O
cell	O
killing	O
is	O
largely	O
unknown	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
that	O
phosphatase	B-GGP
of	I-GGP
activated	I-GGP
cells	I-GGP
1	I-GGP
(	O
PAC1	B-GGP
)	O
phosphatase	O
is	O
a	O
direct	O
transcription	O
target	O
of	O
E2F	B-GGP
-	I-GGP
1	I-GGP
in	O
signaling	O
apoptosis	O
.	O

We	O
show	O
that	O
ectopic	O
E2F	B-GGP
-	I-GGP
1	I-GGP
increases	O
expression	O
of	O
PAC1	B-GGP
at	O
both	O
transcriptional	O
and	O
translational	O
levels	O
in	O
breast	O
cancer	O
cells	O
.	O

E2F	B-GGP
-	I-GGP
1	I-GGP
physically	O
interacts	O
with	O
the	O
promoter	O
of	O
PAC1	B-GGP
,	O
binds	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
promoter	O
and	O
transactivates	O
the	O
PAC1	B-GGP
promoter	O
.	O

E2F	B-GGP
-	I-GGP
1	I-GGP
suppresses	O
extracellular	B-GGP
signal	I-GGP
-	I-GGP
regulated	I-GGP
kinase	I-GGP
(	O
ERK	B-GGP
)	O
phosphorylation	O
through	O
PAC1	B-GGP
and	O
causes	O
cancer	O
cell	O
death	O
by	O
apoptosis	O
following	O
treatment	O
with	O
a	O
chemotherapeutic	O
agent	O
N	B-MED
-	I-MED
4	I-MED
-	I-MED
hydroxyphenylretinamide	I-MED
(	O
4	B-MED
-	I-MED
HPR	I-MED
)	O
.	O

Furthermore	O
,	O
ectopic	O
PAC1	B-GGP
inhibits	O
ERK	B-GGP
phosphorylation	O
and	O
mediates	O
cell	O
killing	O
.	O

Moreover	O
,	O
endogenous	O
E2F	B-GGP
-	I-GGP
1	I-GGP
upregulates	O
PAC1	B-GGP
and	O
suppresses	O
ERK	B-GGP
activity	O
,	O
leading	O
to	O
cell	O
death	O
in	O
response	O
to	O
4	B-MED
-	I-MED
HPR	I-MED
.	O

These	O
results	O
reveal	O
a	O
crucial	O
role	O
of	O
PAC1	B-GGP
in	O
E2F	B-GGP
-	I-GGP
1	I-GGP
-	O
directed	O
apoptosis	O
.	O

Our	O
study	O
demonstrates	O
that	O
E2F	B-GGP
-	I-GGP
1	I-GGP
mediates	O
apoptosis	O
through	O
transcriptional	O
regulation	O
of	O
PAC1	B-GGP
and	O
subsequent	O
suppression	O
of	O
the	O
ERK	B-GGP
signaling	O
.	O

Our	O
findings	O
establish	O
a	O
functional	O
link	O
between	O
E2F	B-GGP
-	I-GGP
1	I-GGP
and	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinases	I-GGP
.	O

The	O
E2F	B-GGP
-	I-GGP
1	I-GGP
-	O
PAC1	B-GGP
cascade	O
in	O
cancer	O
cell	O
killing	O
may	O
provide	O
a	O
molecular	O
basis	O
for	O
cancer	O
therapeutic	O
intervention	O
.	O

Ipl1p	B-GGP
-	O
dependent	O
phosphorylation	O
of	O
Mad3p	B-GGP
is	O
required	O
for	O
the	O
spindle	B-CC
checkpoint	O
response	O
to	O
lack	O
of	O
tension	O
at	O
kinetochores	B-CC
.	O

The	O
spindle	B-CC
checkpoint	O
delays	O
anaphase	O
onset	O
until	O
all	O
chromosomes	B-CC
are	O
correctly	O
attached	O
to	O
microtubules	B-CC
.	O

Ipl1	B-GGP
protein	O
kinase	O
(	O
Aurora	B-GGP
B	I-GGP
)	O
is	O
required	O
to	O
correct	O
inappropriate	O
kinetochore	B-CC
-	O
microtubule	B-CC
attachments	O
and	O
for	O
the	O
response	O
to	O
lack	O
of	O
tension	O
between	O
sister	O
kinetochores	B-CC
.	O

Here	O
we	O
identify	O
residues	O
in	O
the	O
checkpoint	O
protein	O
Mad3p	B-GGP
that	O
are	O
phosphorylated	O
by	O
Ipl1p	B-GGP
.	O

When	O
phosphorylation	O
of	O
Mad3p	B-GGP
at	O
two	O
sites	O
is	O
prevented	O
,	O
the	O
cell	O
'	O
s	O
response	O
to	O
reduced	O
kinetochore	B-CC
tension	O
is	O
dramatically	O
curtailed	O
.	O

Our	O
data	O
provide	O
strong	O
evidence	O
for	O
a	O
distinct	O
checkpoint	O
pathway	O
responding	O
to	O
lack	O
of	O
sister	O
kinetochore	B-CC
tension	O
,	O
in	O
which	O
Ipl1p	B-GGP
-	O
dependent	O
phosphorylation	O
of	O
Mad3p	B-GGP
is	O
a	O
key	O
step	O
.	O

Nerve	B-GGP
growth	I-GGP
factor	I-GGP
potentiates	O
p53	B-GGP
DNA	O
binding	O
but	O
inhibits	O
nitric	B-MED
oxide	I-MED
-	O
induced	O
apoptosis	O
in	O
neuronal	O
PC12	O
cells	O
.	O

NGF	B-GGP
is	O
recognized	O
for	O
its	O
role	O
in	O
neuronal	O
differentiation	O
and	O
maintenance	O
.	O

Differentiation	O
of	O
PC12	O
cells	O
by	O
NGF	B-GGP
involves	O
p53	B-GGP
,	O
a	O
transcription	O
factor	O
that	O
controls	O
growth	O
arrest	O
and	O
apoptosis	O
.	O

We	O
investigated	O
NGF	B-GGP
influence	O
over	O
p53	B-GGP
activity	O
during	O
NO	B-MED
-	O
induced	O
apoptosis	O
by	O
sodium	B-MED
nitroprusside	I-MED
in	O
differentiated	O
and	O
mitotic	O
PC12	O
cells	O
.	O

NGF	B-GGP
-	O
differentiation	O
produced	O
increased	O
p53	B-GGP
levels	O
,	O
nuclear	B-CC
localization	O
and	O
sequence	O
-	O
specific	O
DNA	O
binding	O
.	O

Apoptosis	O
in	O
mitotic	O
cells	O
also	O
produced	O
these	O
events	O
but	O
the	O
accompanying	O
activation	O
of	O
caspases	B-GGP
1	I-GGP
-	O
10	B-GGP
and	O
mitochondrial	B-CC
depolarization	O
were	O
inhibited	O
during	O
NGF	B-GGP
differentiation	O
and	O
could	O
be	O
reversed	O
in	O
p53	B-GGP
-	O
silenced	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
PUMA	B-GGP
and	O
survivin	B-GGP
expression	O
were	O
not	O
inhibited	O
by	O
NGF	B-GGP
,	O
although	O
NO	B-MED
-	O
induced	O
mitochondrial	B-CC
depolarization	O
was	O
dependent	O
upon	O
de	O
novo	O
gene	O
transcription	O
and	O
only	O
occurred	O
in	O
mitotic	O
cells	O
.	O

We	O
conclude	O
that	O
NGF	B-GGP
mediates	O
prosurvival	O
signaling	O
by	O
increasing	O
factors	O
such	O
as	O
Bcl	B-GGP
-	I-GGP
2	I-GGP
and	O
p21	B-GGP
(	O
Waf1	B-GGP
/	O
Cip1	B-GGP
)	O
without	O
altering	O
p53	B-GGP
transcriptional	O
activity	O
to	O
inhibit	O
mitochondrial	B-CC
depolarization	O
,	O
caspase	B-GGP
activation	O
and	O
apoptosis	O
.	O

PRAS40	B-GGP
is	O
a	O
target	O
for	O
mammalian	B-COM
target	I-COM
of	I-COM
rapamycin	I-COM
complex	I-COM
1	I-COM
and	O
is	O
required	O
for	O
signaling	O
downstream	O
of	O
this	O
complex	O
.	O

Signaling	O
through	O
the	O
mammalian	B-COM
target	I-COM
of	I-COM
rapamycin	I-COM
complex	I-COM
1	I-COM
(	O
mTORC1	B-COM
)	O
is	O
positively	O
regulated	O
by	O
amino	O
acids	O
and	O
insulin	B-GGP
.	O

PRAS40	B-GGP
associates	O
with	O
mTORC1	B-COM
(	O
which	O
contains	O
raptor	B-GGP
)	O
but	O
not	O
mTORC2	B-COM
.	O

PRAS40	B-GGP
interacts	O
with	O
raptor	B-GGP
,	O
and	O
this	O
requires	O
an	O
intact	O
TOR	B-GGP
-	O
signaling	O
(	O
TOS	O
)	O
motif	O
in	O
PRAS40	B-GGP
.	O

Like	O
TOS	O
motif	O
-	O
containing	O
proteins	O
such	O
as	O
eIF4E	B-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
1	I-GGP
(	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
)	O
,	O
PRAS40	B-GGP
is	O
a	O
substrate	O
for	O
phosphorylation	O
by	O
mTORC1	B-COM
.	O

Consistent	O
with	O
this	O
,	O
starvation	O
of	O
cells	O
of	O
amino	O
acids	O
or	O
treatment	O
with	O
rapamycin	B-MED
alters	O
the	O
phosphorylation	O
of	O
PRAS40	B-GGP
.	O

PRAS40	B-GGP
binds	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
proteins	O
,	O
and	O
this	O
requires	O
both	O
amino	O
acids	O
and	O
insulin	B-GGP
.	O

Binding	O
of	O
PRAS40	B-GGP
to	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
proteins	O
is	O
inhibited	O
by	O
TSC1	B-GGP
/	O
2	B-GGP
(	O
negative	O
regulators	O
of	O
mTORC1	B-COM
)	O
and	O
stimulated	O
by	O
Rheb	B-GGP
in	O
a	O
rapamycin	B-MED
-	O
sensitive	O
manner	O
.	O

This	O
confirms	O
that	O
PRAS40	B-GGP
is	O
a	O
target	O
for	O
regulation	O
by	O
mTORC1	B-COM
.	O

Small	O
interfering	O
RNA	O
-	O
mediated	O
knockdown	O
of	O
PRAS40	B-GGP
impairs	O
both	O
the	O
amino	O
acid	O
-	O
and	O
insulin	B-GGP
-	O
stimulated	O
phosphorylation	O
of	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
and	O
the	O
phosphorylation	O
of	O
S6	B-GGP
.	O

However	O
,	O
this	O
has	O
no	O
effect	O
on	O
the	O
phosphorylation	O
of	O
Akt	B-GGP
or	O
TSC2	B-GGP
(	O
an	O
Akt	B-GGP
substrate	O
)	O
.	O

These	O
data	O
place	O
PRAS40	B-GGP
downstream	O
of	O
mTORC1	B-COM
but	O
upstream	O
of	O
its	O
effectors	O
,	O
such	O
as	O
S6K1	B-GGP
and	O
4E	B-GGP
-	I-GGP
BP1	I-GGP
.	O

A	O
Bir1p	B-COM
Sli15p	I-COM
kinetochore	B-CC
passenger	O
complex	O
regulates	O
septin	B-GGP
organization	O
during	O
anaphase	O
.	O

Kinetochore	O
-	O
passenger	O
complexes	O
in	O
metazoans	O
have	O
been	O
proposed	O
to	O
coordinate	O
the	O
segregation	O
of	O
chromosomes	B-CC
in	O
anaphase	O
with	O
the	O
induction	O
of	O
cytokinesis	O
.	O

Passenger	O
protein	O
homologues	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
play	O
a	O
critical	O
role	O
early	O
in	O
mitosis	O
,	O
ensuring	O
proper	O
biorientation	O
of	O
kinetochore	B-CC
-	O
microtubule	B-CC
attachments	O
.	O

Our	O
recent	O
work	O
has	O
implicated	O
the	O
passenger	O
protein	O
Bir1p	B-GGP
(	O
Survivin	B-GGP
)	O
and	O
the	O
inner	O
kinetochore	B-CC
complex	O
centromere	B-GGP
binding	I-GGP
factor	I-GGP
3	I-GGP
(	O
CBF3	B-GGP
)	O
in	O
the	O
regulation	O
of	O
septin	B-GGP
dynamics	O
during	O
anaphase	O
.	O

Here	O
,	O
we	O
present	O
data	O
that	O
is	O
consistent	O
with	O
there	O
being	O
multiple	O
passenger	O
protein	O
complexes	O
.	O

Our	O
data	O
show	O
that	O
Bir1p	B-GGP
links	O
together	O
a	O
large	O
passenger	O
complex	O
containing	O
Ndc10p	B-GGP
,	O
Sli15p	B-GGP
(	O
INCENP	B-GGP
)	O
,	O
and	O
Ipl1p	B-GGP
(	O
Aurora	B-GGP
B	I-GGP
)	O
and	O
that	O
the	O
interaction	O
between	O
Bir1p	B-GGP
and	O
Sli15p	B-GGP
is	O
specifically	O
involved	O
in	O
regulating	O
septin	B-GGP
dynamics	O
during	O
anaphase	O
.	O

Neither	O
conditional	O
alleles	O
nor	O
mutants	O
of	O
BIR1	B-GGP
that	O
disrupt	O
the	O
interaction	O
between	O
Bir1p	B-GGP
and	O
Sli15p	B-GGP
resulted	O
in	O
mono	O
-	O
attached	O
kinetochores	B-CC
,	O
suggesting	O
that	O
the	O
Bir1p	B-COM
-	I-COM
Sli15p	I-COM
complex	O
functions	O
in	O
anaphase	O
and	O
independently	O
from	O
Sli15p	B-COM
-	I-COM
Ipl1p	I-COM
complexes	O
.	O

We	O
present	O
a	O
model	O
for	O
how	O
discrete	O
passenger	O
complexes	O
coordinate	O
distinct	O
aspects	O
of	O
mitosis	O
.	O

Acetylation	O
of	O
lysine	B-MED
56	I-MED
of	O
histone	B-GGP
H3	I-GGP
catalyzed	O
by	O
RTT109	B-GGP
and	O
regulated	O
by	O
ASF1	B-GGP
is	O
required	O
for	O
replisome	O
integrity	O
.	O

In	O
budding	O
yeast	O
,	O
acetylation	O
of	O
histone	B-GGP
H3	I-GGP
lysine	B-MED
56	I-MED
(	O
H3	B-GGP
-	O
K56	B-MED
)	O
is	O
catalyzed	O
by	O
the	O
Rtt109	B-COM
-	I-COM
Vps75	I-COM
histone	B-GGP
acetyltransferase	I-GGP
(	O
HAT	B-GGP
)	O
complex	O
,	O
with	O
Rtt109	B-GGP
being	O
the	O
catalytic	O
subunit	O
,	O
and	O
histone	B-GGP
chaperone	O
Asf1	B-GGP
is	O
required	O
for	O
this	O
modification	O
.	O

Cells	O
lacking	O
Rtt109	B-GGP
are	O
susceptible	O
to	O
perturbations	O
in	O
DNA	O
replication	O
.	O

However	O
,	O
how	O
Asf1	B-GGP
regulates	O
acetylation	O
of	O
H3	B-GGP
-	O
K56	B-MED
and	O
how	O
loss	O
of	O
H3	B-GGP
-	O
K56	B-MED
acetylation	O
affects	O
DNA	O
replication	O
are	O
unclear	O
.	O

We	O
show	O
that	O
at	O
low	O
concentrations	O
the	O
Rtt109	B-COM
-	I-COM
Vps75	I-COM
HAT	B-GGP
complex	O
acetylates	O
H3	B-GGP
-	O
K56	B-MED
in	O
vitro	O
when	O
H3	B-GGP
/	O
H4	B-GGP
is	O
complexed	O
with	O
Asf1	B-GGP
,	O
but	O
not	O
H3	B-COM
/	I-COM
H4	I-COM
tetramers	O
,	O
recapitulating	O
the	O
in	O
vivo	O
requirement	O
of	O
Asf1	B-GGP
for	O
H3	B-GGP
-	O
K56	B-MED
acetylation	O
using	O
recombinant	O
proteins	O
.	O

Moreover	O
,	O
the	O
Rtt109	B-COM
-	I-COM
Vps75	I-COM
complex	O
interacts	O
with	O
Asf1	B-COM
-	I-COM
H3	I-COM
/	O
H4	B-COM
but	O
not	O
Asf1	B-GGP
.	O

In	O
vivo	O
,	O
the	O
Rtt109	B-COM
-	I-COM
Asf1	I-COM
interaction	O
is	O
also	O
dependent	O
on	O
the	O
ability	O
of	O
Asf1	B-GGP
to	O
bind	O
H3	B-GGP
/	I-GGP
H4	I-GGP
.	O

Furthermore	O
,	O
the	O
Rtt109	B-GGP
homolog	O
in	O
Schizosaccharomyces	O
pombe	O
(	O
SpRtt109	B-GGP
)	O
also	O
displayed	O
an	O
Asf1	B-GGP
-	O
dependent	O
H3	B-GGP
-	O
K56	B-MED
HAT	B-GGP
activity	O
in	O
vitro	O
.	O

These	O
results	O
indicate	O
that	O
Asf1	B-GGP
regulates	O
H3	B-GGP
-	O
K56	B-MED
acetylation	O
by	O
presenting	O
histones	B-GGP
H3	I-GGP
and	O
H4	B-GGP
to	O
Rtt109	B-COM
-	I-COM
Vps575	I-COM
for	O
acetylation	O
,	O
and	O
this	O
mechanism	O
is	O
likely	O
to	O
be	O
conserved	O
.	O

Finally	O
,	O
we	O
have	O
shown	O
that	O
cells	O
lacking	O
Rtt109	B-GGP
or	O
expressing	O
H3	B-GGP
-	O
K56	B-MED
mutants	O
exhibited	O
significant	O
reduction	O
in	O
the	O
association	O
of	O
three	O
proteins	O
with	O
stalled	O
DNA	O
replication	O
forks	O
and	O
hyper	O
-	O
recombination	O
of	O
replication	O
forks	O
stalled	O
at	O
replication	O
fork	O
barriers	O
of	O
the	O
ribosomal	B-CC
DNA	O
locus	O
compared	O
with	O
wild	O
-	O
type	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
studies	O
provide	O
novel	O
insight	O
into	O
the	O
role	O
of	O
Asf1	B-GGP
in	O
the	O
regulation	O
of	O
H3	B-GGP
-	O
K56	B-MED
acetylation	O
and	O
the	O
function	O
of	O
this	O
modification	O
in	O
DNA	O
replication	O
.	O

IKK	B-GGP
beta	I-GGP
suppression	O
of	O
TSC1	B-GGP
links	O
inflammation	O
and	O
tumor	O
angiogenesis	O
via	O
the	O
mTOR	B-GGP
pathway	O
.	O

TNFalpha	B-GGP
has	O
recently	O
emerged	O
as	O
a	O
regulator	O
linking	O
inflammation	O
to	O
cancer	O
pathogenesis	O
,	O
but	O
the	O
detailed	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
this	O
link	O
remain	O
to	O
be	O
elucidated	O
.	O

The	O
tuberous	B-COM
sclerosis	I-COM
1	I-COM
(	I-COM
TSC1	I-COM
)	I-COM
/	I-COM
TSC2	I-COM
tumor	O
suppressor	O
complex	O
serves	O
as	O
a	O
repressor	O
of	O
the	O
mTOR	B-GGP
pathway	O
,	O
and	O
disruption	O
of	O
TSC1	B-COM
/	I-COM
TSC2	I-COM
complex	O
function	O
may	O
contribute	O
to	O
tumorigenesis	O
.	O

Here	O
we	O
show	O
that	O
IKKbeta	B-GGP
,	O
a	O
major	O
downstream	O
kinase	O
in	O
the	O
TNFalpha	B-GGP
signaling	O
pathway	O
,	O
physically	O
interacts	O
with	O
and	O
phosphorylates	O
TSC1	B-GGP
at	O
Ser487	B-MED
and	O
Ser511	B-MED
,	O
resulting	O
in	O
suppression	O
of	O
TSC1	B-GGP
.	O

The	O
IKKbeta	B-GGP
-	O
mediated	O
TSC1	B-GGP
suppression	O
activates	O
the	O
mTOR	B-GGP
pathway	O
,	O
enhances	O
angiogenesis	O
,	O
and	O
results	O
in	O
tumor	O
development	O
.	O

We	O
further	O
find	O
that	O
expression	O
of	O
activated	O
IKKbeta	B-GGP
is	O
associated	O
with	O
TSC1	B-GGP
Ser511	B-MED
phosphorylation	O
and	O
VEGF	B-GGP
production	O
in	O
multiple	O
tumor	O
types	O
and	O
correlates	O
with	O
poor	O
clinical	O
outcome	O
of	O
breast	O
cancer	O
patients	O
.	O

Our	O
findings	O
identify	O
a	O
pathway	O
that	O
is	O
critical	O
for	O
inflammation	O
-	O
mediated	O
tumor	O
angiogenesis	O
and	O
may	O
provide	O
a	O
target	O
for	O
clinical	O
intervention	O
in	O
human	O
cancer	O
.	O

Forkhead	B-GGP
proteins	O
control	O
the	O
outcome	O
of	O
transcription	O
factor	O
binding	O
by	O
antiactivation	O
.	O

Transcription	O
factors	O
with	O
identical	O
DNA	O
-	O
binding	O
specificity	O
often	O
activate	O
different	O
genes	O
in	O
vivo	O
.	O

Yeast	O
Ace2	B-GGP
and	O
Swi5	B-GGP
are	O
such	O
activators	O
,	O
with	O
targets	O
we	O
classify	O
as	O
Swi5	B-GGP
-	O
only	O
,	O
Ace2	B-GGP
-	O
only	O
,	O
or	O
both	O
.	O

We	O
define	O
two	O
unique	O
regulatory	O
modes	O
.	O

Ace2	B-GGP
and	O
Swi5	B-GGP
both	O
bind	O
in	O
vitro	O
to	O
Swi5	B-GGP
-	O
only	O
genes	O
such	O
as	O
HO	B-GGP
,	O
but	O
only	O
Swi5	B-GGP
binds	O
and	O
activates	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
Ace2	B-GGP
and	O
Swi5	B-GGP
both	O
bind	O
in	O
vivo	O
to	O
Ace2	B-GGP
-	O
only	O
genes	O
,	O
such	O
as	O
CTS1	B-GGP
,	O
but	O
promoter	O
-	O
bound	O
Swi5	B-GGP
fails	O
to	O
activate	O
.	O

We	O
show	O
that	O
activation	O
by	O
Swi5	B-GGP
is	O
prevented	O
by	O
the	O
binding	O
of	O
the	O
Forkhead	B-GGP
factors	O
Fkh1	B-GGP
and	O
Fkh2	B-GGP
,	O
which	O
recruit	O
the	O
Rpd3	B-COM
(	O
Large	O
)	O
histone	B-GGP
deacetylase	I-GGP
complex	O
to	O
the	O
CTS1	B-GGP
promoter	O
.	O

Global	O
analysis	O
shows	O
that	O
all	O
Ace2	B-GGP
-	O
only	O
genes	O
are	O
bound	O
by	O
both	O
Ace2	B-GGP
and	O
Swi5	B-GGP
,	O
and	O
also	O
by	O
Fkh1	B-GGP
/	O
2	B-GGP
.	O

Genes	O
normally	O
activated	O
by	O
either	O
Ace2	B-GGP
or	O
Swi5	B-GGP
can	O
be	O
converted	O
to	O
Ace2	B-GGP
-	O
only	O
genes	O
by	O
the	O
insertion	O
of	O
Fkh	B-GGP
-	O
binding	O
sites	O
.	O

Thus	O
Fkh	B-GGP
proteins	O
,	O
which	O
function	O
initially	O
to	O
activate	O
SWI5	B-GGP
and	O
ACE2	B-GGP
,	O
subsequently	O
function	O
as	O
Swi5	B-GGP
-	O
specific	O
antiactivators	O
.	O

mTOR	B-GGP
controls	O
mitochondrial	B-CC
oxidative	O
function	O
through	O
a	O
YY1	B-COM
-	I-COM
PGC	I-COM
-	I-COM
1alpha	I-COM
transcriptional	O
complex	O
.	O

Transcriptional	O
complexes	O
that	O
contain	O
peroxisome	B-GGP
-	I-GGP
proliferator	I-GGP
-	I-GGP
activated	I-GGP
receptor	I-GGP
coactivator	I-GGP
(	I-GGP
PGC	I-GGP
)	I-GGP
-	I-GGP
1alpha	I-GGP
control	O
mitochondrial	B-CC
oxidative	O
function	O
to	O
maintain	O
energy	O
homeostasis	O
in	O
response	O
to	O
nutrient	O
and	O
hormonal	O
signals	O
.	O

An	O
important	O
component	O
in	O
the	O
energy	O
and	O
nutrient	O
pathways	O
is	O
mammalian	B-GGP
target	I-GGP
of	I-GGP
rapamycin	I-GGP
(	O
mTOR	B-GGP
)	O
,	O
a	O
kinase	O
that	O
regulates	O
cell	O
growth	O
,	O
size	O
and	O
survival	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
and	O
how	O
mTOR	B-GGP
controls	O
mitochondrial	B-CC
oxidative	O
activities	O
.	O

Here	O
we	O
show	O
that	O
mTOR	B-GGP
is	O
necessary	O
for	O
the	O
maintenance	O
of	O
mitochondrial	B-CC
oxidative	O
function	O
.	O

In	O
skeletal	O
muscle	O
tissues	O
and	O
cells	O
,	O
the	O
mTOR	B-GGP
inhibitor	O
rapamycin	B-MED
decreased	O
the	O
gene	O
expression	O
of	O
the	O
mitochondrial	B-CC
transcriptional	O
regulators	O
PGC	B-GGP
-	I-GGP
1alpha	I-GGP
,	O
oestrogen	B-GGP
-	I-GGP
related	I-GGP
receptor	I-GGP
alpha	I-GGP
and	O
nuclear	B-CC
respiratory	O
factors	O
,	O
resulting	O
in	O
a	O
decrease	O
in	O
mitochondrial	B-CC
gene	O
expression	O
and	O
oxygen	B-MED
consumption	O
.	O

Using	O
computational	O
genomics	O
,	O
we	O
identified	O
the	O
transcription	O
factor	O
yin	B-GGP
-	I-GGP
yang	I-GGP
1	I-GGP
(	O
YY1	B-GGP
)	O
as	O
a	O
common	O
target	O
of	O
mTOR	B-GGP
and	O
PGC	B-GGP
-	I-GGP
1alpha	I-GGP
.	O

Knockdown	O
of	O
YY1	B-GGP
caused	O
a	O
significant	O
decrease	O
in	O
mitochondrial	B-CC
gene	O
expression	O
and	O
in	O
respiration	O
,	O
and	O
YY1	B-GGP
was	O
required	O
for	O
rapamycin	B-MED
-	O
dependent	O
repression	O
of	O
those	O
genes	O
.	O

Moreover	O
,	O
mTOR	B-GGP
and	O
raptor	B-GGP
interacted	O
with	O
YY1	B-GGP
,	O
and	O
inhibition	O
of	O
mTOR	B-GGP
resulted	O
in	O
a	O
failure	O
of	O
YY1	B-GGP
to	O
interact	O
with	O
and	O
be	O
coactivated	O
by	O
PGC	B-GGP
-	I-GGP
1alpha	I-GGP
.	O

We	O
have	O
therefore	O
identified	O
a	O
mechanism	O
by	O
which	O
a	O
nutrient	O
sensor	O
(	O
mTOR	B-GGP
)	O
balances	O
energy	O
metabolism	O
by	O
means	O
of	O
the	O
transcriptional	O
control	O
of	O
mitochondrial	B-CC
oxidative	O
function	O
.	O

These	O
results	O
have	O
important	O
implications	O
for	O
our	O
understanding	O
of	O
how	O
these	O
pathways	O
might	O
be	O
altered	O
in	O
metabolic	O
diseases	O
and	O
cancer	O
.	O

The	O
functions	O
and	O
possible	O
significance	O
of	O
Kremen	B-GGP
as	O
the	O
gatekeeper	O
of	O
Wnt	B-GGP
signalling	O
in	O
development	O
and	O
pathology	O
.	O

Kremen	B-GGP
(	O
Krm	B-GGP
)	O
was	O
originally	O
discovered	O
as	O
a	O
novel	O
transmembrane	O
protein	O
containing	O
the	O
kringle	O
domain	O
.	O

Both	O
Krm1	B-GGP
(	O
the	O
first	O
identified	O
Krm	B-GGP
)	O
and	O
its	O
relative	O
Krm2	B-GGP
were	O
later	O
identified	O
to	O
be	O
the	O
high	O
-	O
affinity	O
receptors	O
for	O
Dickkopf	B-GGP
(	O
Dkk	B-GGP
)	O
,	O
the	O
inhibitor	O
of	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signalling	O
.	O

The	O
formation	O
of	O
a	O
ternary	O
complex	O
composed	O
of	O
Krm	B-GGP
,	O
Dkk	B-GGP
,	O
and	O
Lrp5	B-GGP
/	I-GGP
6	I-GGP
(	O
the	O
coreceptor	O
of	O
Wnt	B-GGP
)	O
inhibits	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signalling	O
.	O

In	O
Xenopus	O
gastrula	O
embryos	O
,	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signalling	O
regulates	O
anterior	O
-	O
posterior	O
patterning	O
,	O
with	O
low	O
-	O
signalling	O
in	O
anterior	O
regions	O
.	O

Inhibition	O
of	O
Krm1	B-GGP
/	O
2	B-GGP
induces	O
embryonic	O
head	O
defects	O
.	O

Together	O
with	O
anterior	O
localization	O
of	O
Krms	B-GGP
and	O
Dkks	B-GGP
,	O
the	O
inhibition	O
of	O
Wnt	B-GGP
signalling	O
by	O
Dkk	B-GGP
-	O
Krm	B-GGP
action	O
seems	O
to	O
allow	O
anterior	O
embryonic	O
development	O
.	O

During	O
mammalian	O
development	O
,	O
krm1	B-GGP
mRNA	O
expression	O
is	O
low	O
in	O
the	O
early	O
stages	O
,	O
but	O
gradually	O
and	O
continuously	O
increases	O
with	O
developmental	O
progression	O
and	O
differentiation	O
.	O

In	O
contrast	O
with	O
the	O
wide	O
,	O
strong	O
expression	O
of	O
krm1	B-GGP
mRNA	O
in	O
mature	O
tissues	O
,	O
expression	O
of	O
krm1	B-GGP
is	O
diminished	O
in	O
a	O
variety	O
of	O
human	O
tumor	O
cells	O
.	O

Since	O
stem	O
cells	O
and	O
undifferentiated	O
cells	O
rely	O
on	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signalling	O
for	O
maintenance	O
in	O
a	O
low	O
differentiation	O
state	O
,	O
the	O
physiological	O
shutdown	O
of	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signalling	O
by	O
Dkk	B-GGP
-	O
Krm	B-GGP
is	O
likely	O
to	O
set	O
cells	O
on	O
a	O
divergent	O
path	O
toward	O
differentiation	O
.	O

In	O
tumour	O
cells	O
,	O
a	O
deficit	O
of	O
Krm	B-GGP
may	O
increase	O
the	O
susceptibility	O
to	O
tumourigenic	O
transformation	O
.	O

Both	O
positive	O
and	O
negative	O
regulation	O
of	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signalling	O
definitively	O
contributes	O
to	O
diverse	O
developmental	O
and	O
physiological	O
processes	O
,	O
including	O
cell	O
-	O
fate	O
determination	O
,	O
tissue	O
patterning	O
and	O
stem	O
cell	O
regulation	O
.	O

Krm	B-GGP
is	O
quite	O
significant	O
in	O
these	O
processes	O
as	O
the	O
gatekeeper	O
of	O
the	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signalling	O
pathway	O
.	O

Differential	O
effects	O
of	O
chemotherapeutic	O
drugs	O
versus	O
the	O
MDM	B-GGP
-	I-GGP
2	I-GGP
antagonist	O
nutlin	B-MED
-	I-MED
3	I-MED
on	O
cell	O
cycle	O
progression	O
and	O
induction	O
of	O
apoptosis	O
in	O
SKW6	O
.	O
4	O
lymphoblastoid	O
B	O
-	O
cells	O
.	O

We	O
have	O
compared	O
the	O
cytotoxic	O
/	O
cytostatic	O
responses	O
of	O
the	O
SKW6	O
.	O
4	O
lymphoblastoid	O
B	O
-	O
cells	O
to	O
the	O
alkylating	O
agent	O
chlorambucil	B-MED
,	O
the	O
purine	B-MED
analog	O
fludarabine	B-MED
,	O
the	O
non	O
-	O
genotoxic	O
activator	O
of	O
the	O
p53	B-GGP
pathway	O
,	O
Nutlin	B-MED
-	I-MED
3	I-MED
,	O
used	O
alone	O
or	O
in	O
association	O
with	O
the	O
death	O
-	O
inducing	O
ligand	O
recombinant	O
TRAIL	B-GGP
.	O

Exposure	O
to	O
chlorambucil	B-MED
,	O
fludarabine	B-MED
,	O
and	O
Nutlin	B-MED
-	I-MED
3	I-MED
induced	O
p53	B-GGP
accumulation	O
and	O
variably	O
affected	O
cell	O
cycle	O
progression	O
in	O
SKW6	O
.	O
4	O
lymphoblastoid	O
cells	O
.	O

In	O
particular	O
,	O
chlorambucil	B-MED
induced	O
cell	O
cycle	O
accumulation	O
at	O
the	O
G2	O
/	O
M	O
checkpoint	O
;	O
Nutlin	B-MED
-	I-MED
3	I-MED
induced	O
early	O
cell	O
cycle	O
arrest	O
at	O
the	O
G1	O
/	O
S	O
checkpoint	O
,	O
while	O
fludarabine	B-MED
showed	O
an	O
intermediate	O
behavior	O
.	O

On	O
the	O
other	O
hand	O
,	O
recombinant	O
TRAIL	B-GGP
alone	O
did	O
not	O
affect	O
cell	O
cycle	O
progression	O
but	O
induced	O
a	O
rapid	O
increase	O
of	O
apoptosis	O
.	O

Analysis	O
of	O
the	O
gene	O
expression	O
profile	O
of	O
the	O
p53	B-GGP
-	O
transcriptional	O
targets	O
showed	O
distinct	O
features	O
between	O
chlorambucil	B-MED
,	O
Nutlin	B-MED
-	I-MED
3	I-MED
and	O
fludarabine	B-MED
,	O
which	O
likely	O
account	O
for	O
their	O
differential	O
effect	O
on	O
cell	O
cycle	O
in	O
SKW6	O
.	O
4	O
cells	O
.	O

In	O
particular	O
,	O
chlorambucil	B-MED
upregulated	O
the	O
steady	O
-	O
state	O
mRNA	O
expression	O
of	O
SFN	B-GGP
/	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3sigma	I-GGP
,	O
a	O
gene	O
involved	O
in	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
.	O

Of	O
note	O
,	O
all	O
agonists	O
upregulated	O
TRAIL	B-GGP
-	I-GGP
R2	I-GGP
expression	O
in	O
SKW6	O
.	O
4	O
cells	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

Consistently	O
,	O
pretreatment	O
with	O
chlorambucil	B-MED
,	O
fludarabine	B-MED
and	O
Nutlin	B-MED
-	I-MED
3	I-MED
enhanced	O
SKW6	O
.	O
4	O
sensitivity	O
to	O
TRAIL	B-GGP
-	O
mediated	O
apoptosis	O
.	O

Hypoxia	O
regulates	O
TSC1	B-GGP
/	O
2	B-GGP
-	O
mTOR	B-GGP
signaling	O
and	O
tumor	O
suppression	O
through	O
REDD1	B-GGP
-	O
mediated	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
shuttling	O
.	O

Hypoxia	O
induces	O
rapid	O
and	O
dramatic	O
changes	O
in	O
cellular	O
metabolism	O
,	O
in	O
part	O
through	O
inhibition	O
of	O
target	B-COM
of	I-COM
rapamycin	I-COM
(	I-COM
TOR	I-COM
)	I-COM
kinase	I-COM
complex	I-COM
1	I-COM
(	O
TORC1	B-COM
)	O
activity	O
.	O

Genetic	O
studies	O
have	O
shown	O
the	O
tuberous	O
sclerosis	O
tumor	O
suppressors	O
TSC1	B-GGP
/	O
2	B-GGP
and	O
the	O
REDD1	B-GGP
protein	O
to	O
be	O
essential	O
for	O
hypoxia	O
regulation	O
of	O
TORC1	B-GGP
activity	O
in	O
Drosophila	O
and	O
in	O
mammalian	O
cells	O
.	O

The	O
molecular	O
mechanism	O
and	O
physiologic	O
significance	O
of	O
this	O
effect	O
of	O
hypoxia	O
remain	O
unknown	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
hypoxia	O
and	O
REDD1	B-GGP
suppress	O
mammalian	B-COM
TORC1	I-COM
(	O
mTORC1	B-COM
)	O
activity	O
by	O
releasing	O
TSC2	B-GGP
from	O
its	O
growth	O
factor	O
-	O
induced	O
association	O
with	O
inhibitory	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
proteins	O
.	O

Endogenous	O
REDD1	B-GGP
is	O
required	O
for	O
both	O
dissociation	O
of	O
endogenous	O
TSC2	B-COM
/	I-COM
14	I-COM
-	I-COM
3	I-COM
-	I-COM
3	I-COM
and	O
inhibition	O
of	O
mTORC1	B-COM
in	O
response	O
to	O
hypoxia	O
.	O

REDD1	B-GGP
mutants	O
that	O
fail	O
to	O
bind	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
are	O
defective	O
in	O
eliciting	O
TSC2	B-COM
/	I-COM
14	I-COM
-	I-COM
3	I-COM
-	I-COM
3	I-COM
dissociation	O
and	O
mTORC1	B-COM
inhibition	O
,	O
while	O
TSC2	B-GGP
mutants	O
that	O
do	O
not	O
bind	O
14	B-GGP
-	I-GGP
3	I-GGP
-	I-GGP
3	I-GGP
are	O
inactive	O
in	O
hypoxia	O
signaling	O
to	O
mTORC1	B-COM
.	O

In	O
vitro	O
,	O
loss	O
of	O
REDD1	B-GGP
signaling	O
promotes	O
proliferation	O
and	O
anchorage	O
-	O
independent	O
growth	O
under	O
hypoxia	O
through	O
mTORC1	B-COM
dysregulation	O
.	O

In	O
vivo	O
,	O
REDD1	B-GGP
loss	O
elicits	O
tumorigenesis	O
in	O
a	O
mouse	O
model	O
,	O
and	O
down	O
-	O
regulation	O
of	O
REDD1	B-GGP
is	O
observed	O
in	O
a	O
subset	O
of	O
human	O
cancers	O
.	O

Together	O
,	O
these	O
findings	O
define	O
a	O
molecular	O
mechanism	O
of	O
signal	O
integration	O
by	O
TSC1	B-GGP
/	O
2	B-GGP
that	O
provides	O
insight	O
into	O
the	O
ability	O
of	O
REDD1	B-GGP
to	O
function	O
in	O
a	O
hypoxia	O
-	O
dependent	O
tumor	O
suppressor	O
pathway	O
.	O

Specific	O
induction	O
of	O
PAG608	B-GGP
in	O
cranial	O
and	O
spinal	O
motor	O
neurons	O
of	O
L	B-MED
-	I-MED
DOPA	I-MED
-	O
treated	O
parkinsonian	O
rats	O
.	O

We	O
identified	O
p53	B-GGP
-	I-GGP
activated	I-GGP
gene	I-GGP
608	I-GGP
(	O
PAG608	B-GGP
)	O
as	O
a	O
specifically	O
induced	O
gene	O
in	O
striatal	O
tissue	O
of	O
L	B-MED
-	I-MED
DOPA	I-MED
(	O
100mg	O
/	O
kg	O
)	O
-	O
injected	O
hemi	O
-	O
parkinsonian	O
rats	O
using	O
differential	O
display	O
assay	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
examined	O
morphological	O
distribution	O
of	O
PAG608	B-GGP
in	O
the	O
central	O
nervous	O
system	O
of	O
L	B-MED
-	I-MED
DOPA	I-MED
-	O
treated	O
hemi	O
-	O
parkinsonian	O
rats	O
.	O

PAG608	B-GGP
expression	O
was	O
markedly	O
induced	O
in	O
fibers	O
and	O
neuronal	O
cells	O
of	O
the	O
lateral	O
globus	O
pallidus	O
and	O
reticular	O
thalamic	O
nucleus	O
adjacent	O
to	O
internal	O
capsule	O
,	O
specifically	O
in	O
the	O
parkinsonian	O
side	O
of	O
L	B-MED
-	I-MED
DOPA	I-MED
-	O
treated	O
models	O
.	O

The	O
protein	O
was	O
also	O
constitutively	O
expressed	O
in	O
motor	O
neurons	O
specifically	O
in	O
either	O
side	O
of	O
the	O
pontine	O
nucleus	O
and	O
motor	O
nuclei	O
of	O
trigeminal	O
and	O
facial	O
nerves	O
.	O

Furthermore	O
,	O
L	B-MED
-	I-MED
DOPA	I-MED
-	O
induced	O
PAG608	B-GGP
expression	O
on	O
motor	O
neurons	O
in	O
the	O
contralateral	O
side	O
of	O
the	O
ventral	O
horn	O
of	O
the	O
spinal	O
cord	O
and	O
the	O
lateral	O
corticospinal	O
tract	O
without	O
cell	O
loss	O
.	O

The	O
specific	O
induction	O
of	O
PAG608	B-GGP
6	O
-	O
48h	O
after	O
L	B-MED
-	I-MED
DOPA	I-MED
injection	O
in	O
the	O
extrapyramidal	O
tracts	O
,	O
pyramidal	O
tracts	O
and	O
corresponding	O
lower	O
motor	O
neurons	O
of	O
the	O
spinal	O
cords	O
suggests	O
its	O
involvement	O
in	O
molecular	O
events	O
in	O
stimulated	O
motor	O
neurons	O
.	O

Taken	O
together	O
with	O
the	O
constitutive	O
expression	O
of	O
PAG608	B-GGP
in	O
the	O
motor	O
nuclei	O
of	O
cranial	O
nerves	O
,	O
PAG608	B-GGP
may	O
be	O
a	O
useful	O
marker	O
of	O
stressed	O
or	O
activated	O
lower	O
motor	O
neurons	O
.	O

Small	O
molecular	O
weight	O
variants	O
of	O
p53	B-GGP
are	O
expressed	O
in	O
human	O
melanoma	O
cells	O
and	O
are	O
induced	O
by	O
the	O
DNA	O
-	O
damaging	O
agent	O
cisplatin	B-MED
.	O

PURPOSE	O
:	O
Metastatic	O
melanoma	O
is	O
largely	O
unresponsive	O
to	O
DNA	O
-	O
damaging	O
chemotherapy	O
agents	O
,	O
although	O
WTp53	B-GGP
is	O
frequently	O
detected	O
.	O

Several	O
isoforms	O
of	O
p53	B-GGP
have	O
been	O
discovered	O
,	O
some	O
of	O
which	O
inhibit	O
p53	B-GGP
function	O
.	O

We	O
therefore	O
examined	O
whether	O
p53	B-GGP
isoforms	O
were	O
present	O
in	O
melanoma	O
and	O
whether	O
they	O
may	O
contribute	O
to	O
aberrant	O
p53	B-GGP
function	O
in	O
melanoma	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
studied	O
the	O
expression	O
and	O
subcellular	B-CC
localization	O
of	O
p53	B-GGP
and	O
its	O
isoforms	O
in	O
a	O
panel	O
of	O
human	O
melanoma	O
cell	O
lines	O
using	O
Western	O
blot	O
,	O
two	O
-	O
dimensional	O
electrophoresis	O
,	O
and	O
reverse	O
transcription	O
-	O
PCR	O
.	O

We	O
also	O
characterized	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
p53	B-GGP
,	O
p53	B-GGP
isoforms	O
,	O
and	O
p53	B-GGP
target	O
genes	O
following	O
treatment	O
with	O
the	O
DNA	O
-	O
damaging	O
agent	O
cisplatin	B-MED
.	O

RESULTS	O
:	O
We	O
report	O
that	O
p53beta	B-GGP
and	O
Delta40p53	B-GGP
were	O
expressed	O
in	O
the	O
majority	O
of	O
melanoma	O
cell	O
lines	O
at	O
the	O
mRNA	O
level	O
,	O
but	O
were	O
absent	O
or	O
expressed	O
at	O
low	O
levels	O
in	O
fibroblasts	O
and	O
melanocytes	O
,	O
suggesting	O
that	O
their	O
expression	O
may	O
play	O
a	O
role	O
in	O
melanoma	O
development	O
.	O

Analysis	O
by	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
revealed	O
that	O
p53beta	B-GGP
was	O
expressed	O
at	O
the	O
protein	O
level	O
in	O
melanoma	O
cells	O
.	O

Both	O
p53	B-GGP
and	O
the	O
small	O
molecular	O
weight	O
forms	O
of	O
p53	B-GGP
were	O
aberrantly	O
expressed	O
between	O
the	O
nuclear	B-CC
and	O
cytosolic	B-CC
fractions	I-CC
of	O
melanoma	O
cell	O
lines	O
,	O
compared	O
with	O
normal	O
fibroblasts	O
.	O

Treatment	O
with	O
cisplatin	B-MED
had	O
differential	O
effects	O
on	O
WTp53	B-GGP
and	O
the	O
small	O
molecular	O
weight	O
form	O
of	O
p53	B-GGP
that	O
were	O
cell	O
line	O
dependent	O
.	O

Delta40p53	B-GGP
was	O
shown	O
to	O
inhibit	O
,	O
whereas	O
p53beta	B-GGP
was	O
shown	O
to	O
enhance	O
,	O
p53	B-GGP
-	O
dependent	O
transcription	O
of	O
p21	B-GGP
and	O
PUMA	B-GGP
.	O

CONCLUSIONS	O
:	O
p53beta	B-GGP
and	O
Delta40p53	B-GGP
are	O
expressed	O
in	O
melanoma	O
and	O
this	O
may	O
have	O
important	O
implications	O
for	O
understanding	O
resistance	O
of	O
melanoma	O
to	O
DNA	O
-	O
damaging	O
chemotherapy	O
.	O

PTEN	B-GGP
represses	O
RNA	B-GGP
polymerase	I-GGP
III	I-GGP
-	O
dependent	O
transcription	O
by	O
targeting	O
the	O
TFIIIB	B-COM
complex	O
.	O

PTEN	B-GGP
,	O
a	O
tumor	O
suppressor	O
whose	O
function	O
is	O
frequently	O
lost	O
in	O
human	O
cancers	O
,	O
possesses	O
a	O
lipid	O
phosphatase	O
activity	O
that	O
represses	O
phosphatidylinositol	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
(	O
PI3K	B-GGP
)	O
signaling	O
,	O
controlling	O
cell	O
growth	O
,	O
proliferation	O
,	O
and	O
survival	O
.	O

The	O
potential	O
for	O
PTEN	B-GGP
to	O
regulate	O
the	O
synthesis	O
of	O
RNA	B-GGP
polymerase	I-GGP
(	I-GGP
Pol	I-GGP
)	I-GGP
III	I-GGP
transcription	O
products	O
,	O
including	O
tRNAs	O
and	O
5S	O
rRNAs	O
,	O
was	O
evaluated	O
.	O

The	O
expression	O
of	O
PTEN	B-GGP
in	O
PTEN	B-GGP
-	O
deficient	O
cells	O
repressed	O
RNA	B-GGP
Pol	I-GGP
III	I-GGP
transcription	O
,	O
whereas	O
decreased	O
PTEN	B-GGP
expression	O
enhanced	O
transcription	O
.	O

Transcription	O
repression	O
by	O
PTEN	B-GGP
was	O
uncoupled	O
from	O
PTEN	B-GGP
-	O
mediated	O
effects	O
on	O
the	O
cell	O
cycle	O
and	O
was	O
independent	O
of	O
p53	B-GGP
.	O

PTEN	B-GGP
acts	O
through	O
its	O
lipid	O
phosphatase	O
activity	O
,	O
inhibiting	O
the	O
PI3K	B-GGP
/	O
Akt	B-GGP
/	O
mTOR	B-GGP
/	O
S6K	B-GGP
pathway	O
to	O
decrease	O
transcription	O
.	O

PTEN	B-GGP
,	O
through	O
the	O
inactivation	O
of	O
mTOR	B-GGP
,	O
targets	O
the	O
TFIIIB	B-COM
complex	O
,	O
disrupting	O
the	O
association	O
between	O
TATA	B-GGP
-	I-GGP
binding	I-GGP
protein	I-GGP
and	O
Brf1	B-GGP
.	O

Kinetic	O
analysis	O
revealed	O
that	O
PTEN	B-GGP
initially	O
induces	O
a	O
decrease	O
in	O
the	O
serine	B-MED
phosphorylation	O
of	O
Brf1	B-GGP
,	O
leading	O
to	O
a	O
selective	O
reduction	O
in	O
the	O
occupancy	O
of	O
all	O
TFIIIB	B-GGP
subunits	O
on	O
tRNA	O
(	O
Leu	O
)	O
genes	O
,	O
whereas	O
prolonged	O
PTEN	B-GGP
expression	O
results	O
in	O
the	O
enhanced	O
serine	B-MED
phosphorylation	O
of	O
Bdp1	B-GGP
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
a	O
new	O
class	O
of	O
genes	O
regulated	O
by	O
PTEN	B-GGP
through	O
its	O
ability	O
to	O
repress	O
the	O
activation	O
of	O
PI3K	B-GGP
/	O
Akt	B-GGP
/	O
mTOR	B-GGP
/	O
S6K	B-GGP
signaling	O
.	O

Inhibitory	O
effect	O
of	O
citral	B-MED
on	O
NO	B-MED
production	O
by	O
suppression	O
of	O
iNOS	B-GGP
expression	O
and	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
activation	O
in	O
RAW264	O
.	O
7	O
cells	O
.	O

Citral	B-MED
is	O
a	O
major	O
compound	O
of	O
lemongrass	O
(	O
Cymbopogon	O
citratus	O
L	O
.	O
)	O
that	O
has	O
many	O
pharmacological	O
activities	O
such	O
as	O
anti	O
-	O
fungal	O
and	O
anti	O
-	O
bacterial	O
effects	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
citral	B-MED
and	O
defined	O
its	O
mechanism	O
of	O
action	O
in	O
lipopolysaccharide	B-MED
(	O
LPS	B-MED
)	O
-	O
stimulated	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

Citral	B-MED
(	O
3	O
-	O
12	O
microg	O
/	O
mL	O
)	O
significantly	O
inhibited	O
LPS	B-MED
-	O
induced	O
nitric	B-MED
oxide	I-MED
(	O
NO	B-MED
)	O
production	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
IC50	O
:	O
6	O
.	O
5	O
microg	O
/	O
mL	O
)	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
citral	B-MED
effectively	O
inhibited	O
the	O
transcriptional	O
activity	O
and	O
expression	O
of	O
iNOS	B-GGP
,	O
and	O
potently	O
suppressed	O
the	O
DNA	O
binding	O
activity	O
and	O
nuclear	B-CC
translocation	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
as	O
well	O
as	O
I	B-GGP
kappa	I-GGP
B	I-GGP
phosphorylation	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

These	O
results	O
suggest	O
that	O
citral	B-MED
is	O
anti	O
-	O
inflammatory	O
,	O
and	O
its	O
effects	O
may	O
be	O
due	O
to	O
the	O
inhibition	O
of	O
NO	B-MED
production	O
through	O
the	O
suppression	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
activation	O
.	O

Positive	O
feedback	O
sharpens	O
the	O
anaphase	O
switch	O
.	O

At	O
the	O
onset	O
of	O
anaphase	O
,	O
sister	B-CC
-	I-CC
chromatid	I-CC
cohesion	O
is	O
dissolved	O
abruptly	O
and	O
irreversibly	O
,	O
ensuring	O
that	O
all	O
chromosome	B-CC
pairs	O
disjoin	O
almost	O
simultaneously	O
.	O

The	O
regulatory	O
mechanisms	O
that	O
generate	O
this	O
switch	O
-	O
like	O
behaviour	O
are	O
unclear	O
.	O

Anaphase	O
is	O
initiated	O
when	O
a	O
ubiquitin	B-GGP
ligase	O
,	O
the	O
anaphase	B-COM
-	I-COM
promoting	I-COM
complex	I-COM
(	O
APC	B-COM
)	O
,	O
triggers	O
the	O
destruction	O
of	O
securin	B-GGP
,	O
thereby	O
allowing	O
separase	B-GGP
,	O
a	O
protease	O
,	O
to	O
disrupt	O
sister	B-CC
-	I-CC
chromatid	I-CC
cohesion	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
cyclin	B-GGP
-	I-GGP
dependent	I-GGP
kinase	I-GGP
1	I-GGP
(	O
Cdk1	B-GGP
)	O
-	O
dependent	O
phosphorylation	O
of	O
securin	B-GGP
near	O
its	O
destruction	O
-	O
box	O
motif	O
inhibits	O
securin	B-GGP
ubiquitination	O
by	O
the	O
APC	B-COM
.	O

The	O
phosphatase	O
Cdc14	B-GGP
reverses	O
securin	B-GGP
phosphorylation	O
,	O
thereby	O
increasing	O
the	O
rate	O
of	O
securin	B-GGP
ubiquitination	O
.	O

Because	O
separase	B-GGP
is	O
known	O
to	O
activate	O
Cdc14	B-GGP
(	O
refs	O
5	O
and	O
6	O
)	O
,	O
our	O
results	O
support	O
the	O
existence	O
of	O
a	O
positive	O
feedback	O
loop	O
that	O
increases	O
the	O
abruptness	O
of	O
anaphase	O
.	O

Consistent	O
with	O
this	O
model	O
,	O
we	O
show	O
that	O
mutations	O
that	O
disrupt	O
securin	B-GGP
phosphoregulation	O
decrease	O
the	O
synchrony	O
of	O
chromosome	B-CC
segregation	O
.	O

Our	O
results	O
also	O
suggest	O
that	O
coupling	O
securin	B-GGP
degradation	O
with	O
changes	O
in	O
Cdk1	B-GGP
and	O
Cdc14	B-GGP
activities	O
helps	O
coordinate	O
the	O
initiation	O
of	O
sister	B-CC
-	I-CC
chromatid	I-CC
separation	O
with	O
changes	O
in	O
spindle	B-CC
dynamics	O
.	O

Promyelocytic	B-GGP
leukemia	I-GGP
(	O
PML	B-GGP
)	O
gene	O
expression	O
is	O
a	O
prognostic	O
factor	O
in	O
ampullary	O
cancer	O
patients	O
.	O

BACKGROUND	O
:	O
Promyelocytic	B-GGP
leukemia	I-GGP
(	O
PML	B-GGP
)	O
tumor	O
suppressor	O
gene	O
plays	O
a	O
key	O
role	O
in	O
acute	O
PML	O
pathogenesis	O
but	O
its	O
involvement	O
in	O
pathogenesis	O
and	O
prognosis	O
of	O
solid	O
cancers	O
has	O
not	O
been	O
defined	O
yet	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
In	O
all	O
,	O
62	O
ampullary	O
adenocarcinoma	O
patients	O
who	O
underwent	O
curative	O
surgery	O
between	O
1996	O
and	O
2005	O
were	O
included	O
.	O

Expression	O
analysis	O
of	O
PML	B-GGP
was	O
carried	O
out	O
by	O
immunohistochemical	O
staining	O
and	O
correlated	O
with	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

RESULTS	O
:	O
In	O
24	O
tumor	O
specimens	O
(	O
38	O
.	O
7	O
%	O
)	O
,	O
PML	B-GGP
was	O
classified	O
as	O
absent	O
,	O
in	O
16	O
(	O
25	O
.	O
8	O
%	O
)	O
as	O
focally	O
expressed	O
and	O
in	O
22	O
(	O
35	O
.	O
5	O
%	O
)	O
as	O
diffusely	O
expressed	O
.	O

By	O
univariate	O
analysis	O
,	O
DFS	O
was	O
significantly	O
influenced	O
by	O
pathological	O
T	O
stage	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
,	O
lymph	O
nodal	O
involvement	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
PML	B-GGP
expression	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

DFS	O
in	O
patients	O
without	O
PML	B-GGP
expression	O
was	O
28	O
.	O
0	O
months	O
versus	O
45	O
.	O
1	O
and	O
75	O
.	O
5	O
for	O
patients	O
with	O
focal	O
and	O
diffuse	O
expression	O
,	O
respectively	O
.	O

OS	O
in	O
the	O
group	O
of	O
patients	O
without	O
PML	B-GGP
expression	O
,	O
with	O
focal	O
expression	O
,	O
and	O
with	O
diffuse	O
expression	O
was	O
40	O
,	O
48	O
,	O
and	O
77	O
months	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

By	O
a	O
multivariate	O
analysis	O
,	O
PML	B-GGP
expression	O
was	O
the	O
strongest	O
prognostic	O
factor	O
for	O
DFS	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
the	O
only	O
statically	O
significant	O
prognostic	O
factor	O
for	O
OS	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
preliminary	O
data	O
suggest	O
PML	B-GGP
as	O
a	O
novel	O
prognostic	O
tool	O
for	O
ampullary	O
cancer	O
patients	O
.	O

Phosphorylation	O
of	O
p27Kip1	B-GGP
regulates	O
assembly	O
and	O
activation	O
of	O
cyclin	B-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
.	O

p27	B-GGP
mediates	O
Cdk2	B-GGP
inhibition	O
and	O
is	O
also	O
found	O
in	O
cyclin	B-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
complexes	O
.	O

The	O
present	O
data	O
support	O
a	O
role	O
for	O
p27	B-GGP
in	O
the	O
assembly	O
of	O
D	B-COM
-	I-COM
type	I-COM
cyclin	I-COM
-	I-COM
Cdk	I-COM
complexes	O
and	O
indicate	O
that	O
both	O
cyclin	B-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
-	I-COM
p27	I-COM
assembly	O
and	O
kinase	O
activation	O
are	O
regulated	O
by	O
p27	B-GGP
phosphorylation	O
.	O

Prior	O
work	O
showed	O
that	O
p27	B-GGP
can	O
be	O
phosphorylated	O
by	O
protein	B-GGP
kinase	I-GGP
B	I-GGP
/	O
Akt	B-GGP
(	O
PKB	B-GGP
/	O
Akt	B-GGP
)	O
at	O
T157	B-MED
and	O
T198	B-MED
.	O

Here	O
we	O
show	O
that	O
PKB	B-GGP
activation	O
and	O
the	O
appearance	O
of	O
p27pT157	B-GGP
and	O
p27pT198	B-GGP
precede	O
p27	B-COM
-	I-COM
cyclin	I-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
assembly	O
in	O
early	O
G	O
(	O
1	O
)	O
.	O

PI3K	B-GGP
/	O
PKB	B-GGP
inhibition	O
rapidly	O
reduced	O
p27pT157	B-GGP
and	O
p27pT198	B-GGP
and	O
dissociated	O
cellular	O
p27	B-COM
-	I-COM
cyclin	I-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
.	O

Mutant	O
p27	B-GGP
allele	O
products	O
lacking	O
phosphorylation	O
at	O
T157	B-MED
and	O
T198	B-MED
bound	O
poorly	O
to	O
cellular	O
cyclin	B-GGP
D1	I-GGP
and	O
Cdk4	B-GGP
.	O

Cellular	O
p27pT157	B-GGP
and	O
p27pT198	B-GGP
coprecipitated	O
with	O
Cdk4	B-GGP
but	O
were	O
not	O
detected	O
in	O
Cdk2	B-GGP
complexes	O
.	O

The	O
addition	O
of	O
p27	B-GGP
to	O
recombinant	O
cyclin	B-GGP
D1	I-GGP
and	O
Cdk4	B-GGP
led	O
to	O
cyclin	B-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
-	I-COM
p27	I-COM
complex	O
formation	O
in	O
vitro	O
.	O

p27	B-GGP
phosphorylation	O
by	O
PKB	B-GGP
increased	O
p27	B-COM
-	I-COM
cyclin	I-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
assembly	O
in	O
vitro	O
but	O
yielded	O
inactive	O
Cdk4	B-GGP
.	O

In	O
contrast	O
,	O
Src	B-GGP
pretreatment	O
of	O
p27	B-GGP
did	O
not	O
affect	O
p27	B-COM
-	I-COM
cyclin	I-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
complex	O
formation	O
.	O

However	O
,	O
Src	B-GGP
treatment	O
led	O
to	O
tyrosine	B-MED
phosphorylation	O
of	O
p27	B-GGP
and	O
catalytic	O
activation	O
of	O
assembled	O
cyclin	B-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
-	I-COM
p27	I-COM
complexes	O
.	O

Thus	O
,	O
while	O
PKB	B-GGP
-	O
dependent	O
p27	B-GGP
phosphorylation	O
appears	O
to	O
increase	O
cyclin	B-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
-	I-COM
p27	I-COM
assembly	O
or	O
stabilize	O
these	O
complexes	O
in	O
vitro	O
,	O
cyclin	B-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
-	I-COM
p27	I-COM
activation	O
requires	O
the	O
tyrosine	B-MED
phosphorylation	O
of	O
p27	B-GGP
.	O

Constitutive	O
activation	O
of	O
PKB	B-GGP
and	O
Abl	B-GGP
or	O
Src	B-GGP
family	O
kinases	O
in	O
cancers	O
would	O
drive	O
p27	B-GGP
phosphorylation	O
,	O
increase	O
cyclin	B-COM
D1	I-COM
-	I-COM
Cdk4	I-COM
assembly	O
and	O
activation	O
,	O
and	O
reduce	O
the	O
cyclin	B-COM
E	I-COM
-	I-COM
Cdk2	I-COM
inhibitory	O
function	O
of	O
p27	B-GGP
.	O

Combined	O
therapy	O
with	O
both	O
Src	B-GGP
and	O
PI3K	B-GGP
/	O
PKB	B-GGP
inhibitors	O
may	O
reverse	O
this	O
process	O
.	O

Stably	O
overexpressed	O
human	O
Frizzled	B-GGP
-	I-GGP
2	I-GGP
signals	O
through	O
the	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
pathway	O
and	O
does	O
not	O
activate	O
Ca2	B-MED
+	I-MED
-	O
mobilization	O
in	O
Human	O
Embryonic	O
Kidney	O
293	O
cells	O
.	O

Signal	O
transduction	O
via	O
the	O
Frizzled	B-GGP
family	O
of	O
seven	O
-	O
transmembrane	O
receptors	O
controls	O
important	O
developmental	O
processes	O
.	O

Aberrant	O
signaling	O
caused	O
by	O
altered	O
Frizzled	B-GGP
receptor	O
activity	O
or	O
by	O
mutations	O
in	O
downstream	O
signaling	O
components	O
has	O
been	O
implicated	O
in	O
several	O
adult	O
pathologies	O
.	O

A	O
diverse	O
array	O
of	O
intracellular	B-CC
signaling	O
pathways	O
has	O
been	O
suggested	O
to	O
transduce	O
the	O
signals	O
exerted	O
in	O
cells	O
when	O
secreted	O
ligands	O
of	O
the	O
Wnt	B-GGP
family	O
bind	O
to	O
Frizzled	B-GGP
receptors	O
.	O

Studies	O
with	O
a	O
chimeric	O
receptor	O
composed	O
of	O
Frizzled	B-GGP
-	I-GGP
2	I-GGP
and	O
the	O
beta2	B-GGP
-	I-GGP
adrenergic	I-GGP
receptor	I-GGP
have	O
suggested	O
that	O
the	O
binding	O
of	O
Wnt	B-GGP
-	I-GGP
5a	I-GGP
to	O
Frizzled	B-GGP
-	I-GGP
2	I-GGP
results	O
in	O
the	O
activation	O
of	O
G	B-GGP
proteins	I-GGP
of	O
the	O
Galpha	B-GGP
(	I-GGP
i	I-GGP
)	I-GGP
family	O
,	O
the	O
mobilization	O
of	O
calcium	B-MED
from	O
intracellular	B-CC
stores	I-CC
and	O
the	O
induction	O
of	O
gene	O
transcription	O
through	O
nuclear	B-GGP
factor	I-GGP
of	I-GGP
activated	I-GGP
T	I-GGP
cells	I-GGP
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
by	O
using	O
beta	B-GGP
-	I-GGP
lactamase	I-GGP
reporter	O
gene	O
technology	O
that	O
full	O
-	O
length	O
,	O
wild	O
-	O
type	O
human	O
Frizzled	B-GGP
-	I-GGP
2	I-GGP
does	O
not	O
couple	O
to	O
calcium	B-MED
-	O
mediated	O
signaling	O
in	O
HEK293	O
cells	O
following	O
stimulation	O
with	O
purified	O
recombinant	O
mouse	O
Wnt	B-GGP
-	I-GGP
5a	I-GGP
.	O

In	O
contrast	O
,	O
when	O
stimulated	O
with	O
recombinant	O
mouse	O
Wnt	B-GGP
-	I-GGP
3a	I-GGP
,	O
Frizzled	B-GGP
-	I-GGP
2	I-GGP
activates	O
the	O
canonical	O
Wnt	B-GGP
/	O
Frizzled	B-GGP
signaling	O
pathway	O
,	O
involving	O
the	O
transcriptional	O
modulator	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
.	O

Our	O
report	O
underlines	O
the	O
importance	O
of	O
using	O
cell	O
lines	O
stably	O
overexpressing	O
wild	O
-	O
type	O
Frizzled	B-GGP
receptors	O
and	O
the	O
use	O
of	O
purified	O
ligands	O
when	O
studying	O
receptor	O
pharmacology	O
.	O

This	O
approach	O
has	O
allowed	O
us	O
to	O
measure	O
the	O
half	O
-	O
maximal	O
concentration	O
for	O
activation	O
of	O
human	O
Frizzled	B-GGP
-	I-GGP
2	I-GGP
(	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
4	O
nM	O
;	O
avg	O
.	O
+	O
/	O
-	O
SD	O
)	O
and	O
human	O
Frizzled	B-GGP
-	I-GGP
1	I-GGP
(	O
1	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
5	O
nM	O
)	O
following	O
stimulation	O
by	O
Wnt	B-GGP
-	I-GGP
3a	I-GGP
.	O

Our	O
results	O
suggest	O
that	O
there	O
is	O
receptor	O
redundancy	O
with	O
regard	O
to	O
Wnt	B-GGP
-	I-GGP
3a	I-GGP
reception	O
.	O

In	O
addition	O
,	O
we	O
introduce	O
beta	B-GGP
-	I-GGP
lactamase	I-GGP
reporter	O
gene	O
technology	O
as	O
an	O
alternative	O
to	O
luciferase	B-GGP
-	O
based	O
reporters	O
to	O
measure	O
Frizzled	B-GGP
receptor	O
modulation	O
for	O
the	O
discovery	O
of	O
Frizzled	B-GGP
receptor	O
-	O
interacting	O
drugs	O
.	O

Porin	B-GGP
-	O
incorporated	O
liposome	O
induces	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptors	I-GGP
2	I-GGP
-	O
and	O
6	B-GGP
-	O
dependent	O
maturation	O
and	O
type	O
1	O
response	O
of	O
dendritic	O
cell	O
.	O

Porin	B-GGP
of	O
Shigella	O
dysenteriae	O
was	O
incorporated	O
in	O
liposome	O
(	O
PIL	B-GGP
)	O
and	O
presented	O
to	O
mouse	O
splenic	O
dendritic	O
cells	O
(	O
DC	O
)	O
.	O

PIL	B-GGP
up	O
-	O
regulated	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
(	I-GGP
TLR	I-GGP
)	I-GGP
2	I-GGP
and	O
TLR6	B-GGP
on	O
DC	O
,	O
showing	O
that	O
co	O
-	O
expression	O
of	O
the	O
two	O
TLRs	B-GGP
is	O
involved	O
in	O
recognition	O
of	O
porin	B-GGP
.	O

Detection	O
of	O
myeloid	B-COM
differentiating	I-COM
factor	I-COM
88	I-COM
(	I-COM
MyD88	I-COM
)	I-COM
-	I-COM
TLR2	I-COM
complex	O
confirmed	O
interaction	O
between	O
the	O
two	O
for	O
triggering	O
the	O
downstream	O
signaling	O
,	O
which	O
ultimately	O
led	O
to	O
TLR2	B-GGP
-	O
dependent	O
nuclear	B-CC
translocation	O
of	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappa	I-COM
B	I-COM
.	O

PIL	B-GGP
-	O
induced	O
expression	O
of	O
MHC	B-COM
class	I-COM
II	I-COM
(	O
I	O
-	O
Ab	O
)	O
,	O
CD40	B-GGP
and	O
CD80	B-GGP
showed	O
maturation	O
of	O
DC	O
,	O
whereas	O
up	O
-	O
regulation	O
of	O
intercellular	B-GGP
adhesion	I-GGP
molecule	I-GGP
-	I-GGP
1	I-GGP
and	O
CCR7	B-GGP
implicated	O
the	O
capacity	O
of	O
splenic	O
DC	O
to	O
migrate	O
.	O

Induction	O
of	O
messenger	O
ribonucleic	O
acid	O
for	O
the	O
chemokines	O
,	O
macrophage	B-GGP
-	I-GGP
inflammatory	I-GGP
protein	I-GGP
(	I-GGP
MIP	I-GGP
)	I-GGP
-	I-GGP
1alpha	I-GGP
,	O
MIP	B-GGP
-	I-GGP
1beta	I-GGP
and	O
regulated	B-GGP
upon	I-GGP
activation	I-GGP
,	I-GGP
normal	I-GGP
T	I-GGP
cell	I-GGP
expressed	I-GGP
and	I-GGP
secreted	I-GGP
indicated	O
a	O
strong	O
bias	O
of	O
PIL	B-GGP
for	O
type	O
1	O
polarization	O
that	O
was	O
supported	O
by	O
the	O
intracellular	B-CC
expression	O
and	O
release	O
of	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
(	I-GGP
TNF	I-GGP
)	I-GGP
-	I-GGP
alpha	I-GGP
and	O
IL	B-GGP
-	I-GGP
12	I-GGP
.	O

Along	O
with	O
CD40	B-GGP
and	O
CD80	B-GGP
expression	O
,	O
release	O
of	O
the	O
cytokines	O
of	O
CD11c	B-GGP
+	O
JAWS	O
II	O
cells	O
was	O
inhibited	O
by	O
TLR2	B-GGP
or	O
simultaneous	O
TLR2	B-GGP
and	O
6	B-GGP
knockdown	O
showing	O
that	O
recognition	O
of	O
PIL	B-GGP
by	O
the	O
two	O
TLRs	B-GGP
is	O
essential	O
for	O
DC	O
activation	O
and	O
type	O
1	O
polarization	O
.	O

The	O
signaling	O
pathway	O
initiated	O
upon	O
recognition	O
of	O
PIL	B-GGP
by	O
the	O
TLRs	B-GGP
was	O
MyD88	B-GGP
dependent	O
as	O
confirmed	O
by	O
inhibition	O
of	O
IL	B-GGP
-	I-GGP
6	I-GGP
,	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
and	O
IL	B-GGP
-	I-GGP
12	I-GGP
release	O
of	O
MyD88	B-GGP
-	O
knockdown	O
JAWS	O
II	O
cells	O
.	O

The	O
maturation	O
and	O
polarization	O
of	O
DC	O
induced	O
T	O
(	O
h	O
)	O
1	O
phenotype	O
,	O
as	O
evident	O
from	O
proliferation	O
,	O
activation	O
and	O
IFN	B-GGP
-	I-GGP
gamma	I-GGP
release	O
of	O
allogeneic	O
CD4	B-GGP
+	O
T	O
cells	O
in	O
response	O
to	O
PIL	B-GGP
-	O
stimulated	O
DC	O
,	O
thereby	O
suggesting	O
that	O
the	O
adjuvant	O
activity	O
of	O
PIL	B-GGP
can	O
successfully	O
bridge	O
the	O
innate	O
and	O
adaptive	O
immunity	O
.	O

TCDD	B-MED
induces	O
cell	O
migration	O
via	O
NFATc1	B-GGP
/	O
ATX	B-GGP
-	O
signaling	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

Breast	O
cancer	O
is	O
characterized	O
,	O
among	O
others	O
,	O
by	O
the	O
concurrence	O
of	O
lipophilic	O
xenobiotica	O
such	O
as	O
2	B-MED
,	I-MED
3	I-MED
,	I-MED
7	I-MED
,	I-MED
8	I-MED
-	I-MED
tetrachlorodibenzo	I-MED
-	I-MED
para	I-MED
-	I-MED
dioxin	I-MED
(	O
TCDD	B-MED
)	O
with	O
hypoxic	O
tissue	O
conditions	O
.	O

This	O
condition	O
activates	O
the	O
transcription	O
factors	O
hypoxia	B-GGP
inducible	I-GGP
factor	I-GGP
-	I-GGP
1alpha	I-GGP
(	O
HIF	B-GGP
-	I-GGP
1alpha	I-GGP
)	O
and	O
aryl	B-GGP
hydrocarbon	I-GGP
receptor	I-GGP
(	O
AhR	B-GGP
)	O
that	O
are	O
known	O
to	O
promote	O
tumor	O
progression	O
.	O

An	O
interrelation	O
between	O
these	O
transcription	O
factors	O
and	O
nuclear	B-GGP
factor	I-GGP
of	I-GGP
activated	I-GGP
T	I-GGP
-	I-GGP
cells	I-GGP
(	O
NFAT	B-GGP
)	O
was	O
implied	O
by	O
gene	O
array	O
analysis	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
interplay	O
of	O
the	O
three	O
transcription	O
factors	O
was	O
studied	O
and	O
correlated	O
with	O
the	O
migration	O
of	O
MCF	O
-	O
7	O
cells	O
in	O
response	O
to	O
TCDD	B-MED
and	O
/	O
or	O
hypoxia	O
.	O

An	O
AhR	B-GGP
-	O
activation	O
by	O
10nM	O
TCDD	B-MED
and	O
HIF	B-GGP
-	I-GGP
1alpha	I-GGP
activation	O
by	O
5	O
%	O
oxygen	B-MED
induced	O
activation	O
of	O
NFATc1	B-GGP
.	O

The	O
effects	O
were	O
inhibited	O
by	O
cyclosporine	B-MED
A	I-MED
(	O
CsA	B-MED
)	O
,	O
suggesting	O
that	O
the	O
activation	O
of	O
NFAT	B-GGP
by	O
AhR	B-GGP
or	O
HIF	B-GGP
-	I-GGP
1alpha	I-GGP
signaling	O
is	O
calcineurin	B-COM
-	O
dependent	O
.	O

The	O
expression	O
/	O
activity	O
of	O
the	O
NFAT	B-GGP
target	O
gene	O
autotaxin	B-GGP
(	O
ATX	B-GGP
)	O
was	O
increased	O
.	O

ATX	B-GGP
is	O
known	O
to	O
stimulate	O
migration	O
of	O
tumor	O
cells	O
.	O

The	O
hydrolysis	O
product	O
of	O
ATX	B-GGP
,	O
lysophosphatidic	B-MED
acid	I-MED
(	O
LPA	B-MED
)	O
,	O
increased	O
the	O
migration	O
of	O
MCF	O
-	O
7	O
cells	O
under	O
normoxia	O
but	O
not	O
under	O
hypoxia	O
.	O

This	O
effect	O
correlated	O
with	O
increased	O
migration	O
observed	O
after	O
TCDD	B-MED
treatment	O
.	O

Hypoxia	O
did	O
not	O
promote	O
migration	O
of	O
MCF	O
-	O
7	O
cells	O
,	O
suggesting	O
that	O
ATX	B-GGP
down	O
-	O
stream	O
signaling	O
was	O
inhibited	O
by	O
hypoxia	O
.	O

In	O
conclusion	O
,	O
the	O
TCDD	B-MED
-	O
mediated	O
activation	O
of	O
NFATc1	B-GGP
is	O
suggested	O
to	O
promote	O
cell	O
migration	O
via	O
ATX	B-GGP
/	O
LPA	B-MED
-	O
signaling	O
.	O

The	O
adaptor	O
protein	O
MyD88	B-GGP
is	O
essential	O
for	O
E	O
coli	O
-	O
induced	O
preterm	O
delivery	O
in	O
mice	O
.	O

OBJECTIVE	O
:	O
We	O
used	O
a	O
mouse	O
model	O
of	O
infection	O
-	O
induced	O
preterm	O
delivery	O
to	O
examine	O
the	O
roles	O
of	O
2	O
adaptor	O
proteins	O
with	O
central	O
functions	O
in	O
Toll	B-GGP
-	I-GGP
like	I-GGP
receptor	I-GGP
signaling	O
:	O
MyD88	B-GGP
(	O
myeloid	B-GGP
differentiation	I-GGP
primary	I-GGP
-	I-GGP
response	I-GGP
gene	I-GGP
88	I-GGP
)	O
and	O
TRIF	B-GGP
(	O
Toll	B-GGP
/	I-GGP
IL	I-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
(	I-GGP
TIR	I-GGP
)	I-GGP
-	I-GGP
domain	I-GGP
-	I-GGP
containing	I-GGP
adaptor	I-GGP
protein	I-GGP
-	I-GGP
inducing	I-GGP
IFN	I-GGP
-	I-GGP
beta	I-GGP
)	O
.	O

STUDY	O
DESIGN	O
:	O
Mice	O
deficient	O
(	O
KO	O
)	O
for	O
MyD88	B-GGP
,	O
TRIF	B-GGP
,	O
both	O
(	O
DKO	O
)	O
or	O
neither	O
(	O
WT	O
)	O
were	O
inoculated	O
into	O
the	O
uterus	O
with	O
killed	O
Escherichia	O
coli	O
.	O

Delivery	O
outcomes	O
,	O
fetal	O
status	O
,	O
serum	O
progesterone	B-MED
,	O
and	O
nuclear	B-CC
translocation	O
of	O
the	O
transcription	B-GGP
factor	I-GGP
nuclear	I-GGP
factor	I-GGP
kappa	I-GGP
B	I-GGP
(	O
NFkappaB	B-GGP
)	O
were	O
determined	O
.	O

RESULTS	O
:	O
Preterm	O
birth	O
(	O
delivery	O
in	O
less	O
than	O
48	O
hours	O
)	O
occurred	O
in	O
WT	O
and	O
TRIF	B-GGP
-	O
KO	O
animals	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
reaching	O
100	O
%	O
with	O
5	O
-	O
10	O
x	O
10	O
(	O
9	O
)	O
bacteria	O
,	O
while	O
MyD88	B-GGP
-	O
KO	O
and	O
DKO	O
animals	O
were	O
completely	O
protected	O
from	O
delivery	O
.	O

Intrauterine	O
fetal	O
survival	O
,	O
maintenance	O
of	O
circulating	O
progesterone	B-MED
levels	O
,	O
and	O
nuclear	B-CC
translocation	O
of	O
NFkappaB	B-GGP
were	O
also	O
dependent	O
upon	O
MyD88	B-GGP
but	O
not	O
TRIF	B-GGP
.	O

In	O
contrast	O
,	O
induction	O
of	O
uterine	B-GGP
interleukin	I-GGP
(	I-GGP
IL	I-GGP
)	I-GGP
-	I-GGP
1beta	I-GGP
and	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
alpha	I-GGP
(	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
)	O
depends	O
upon	O
actions	O
of	O
both	O
MyD88	B-GGP
and	O
TRIF	B-GGP
.	O

CONCLUSION	O
:	O
E	O
coli	O
-	O
induced	O
preterm	O
delivery	O
in	O
the	O
mouse	O
is	O
completely	O
dependent	O
upon	O
MyD88	B-GGP
but	O
not	O
TRIF	B-GGP
.	O

Small	O
molecule	O
-	O
mediated	O
disruption	O
of	O
Wnt	B-GGP
-	O
dependent	O
signaling	O
in	O
tissue	O
regeneration	O
and	O
cancer	O
.	O

The	O
pervasive	O
influence	O
of	O
secreted	O
Wnt	B-GGP
signaling	O
proteins	O
in	O
tissue	O
homeostasis	O
and	O
tumorigenesis	O
has	O
galvanized	O
efforts	O
to	O
identify	O
small	O
molecules	O
that	O
target	O
Wnt	B-GGP
-	O
mediated	O
cellular	O
responses	O
.	O

By	O
screening	O
a	O
diverse	O
synthetic	O
chemical	O
library	O
,	O
we	O
have	O
discovered	O
two	O
new	O
classes	O
of	O
small	O
molecules	O
that	O
disrupt	O
Wnt	B-GGP
pathway	O
responses	O
;	O
whereas	O
one	O
class	O
inhibits	O
the	O
activity	O
of	O
Porcupine	B-GGP
,	O
a	O
membrane	B-CC
-	O
bound	O
acyltransferase	O
that	O
is	O
essential	O
to	O
the	O
production	O
of	O
Wnt	B-GGP
proteins	O
,	O
the	O
other	O
abrogates	O
destruction	O
of	O
Axin	B-GGP
proteins	O
,	O
which	O
are	O
suppressors	O
of	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
pathway	O
activity	O
.	O

With	O
these	O
small	O
molecules	O
,	O
we	O
establish	O
a	O
chemical	O
genetic	O
approach	O
for	O
studying	O
Wnt	B-GGP
pathway	O
responses	O
and	O
stem	O
cell	O
function	O
in	O
adult	O
tissue	O
.	O

We	O
achieve	O
transient	O
,	O
reversible	O
suppression	O
of	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
pathway	O
response	O
in	O
vivo	O
,	O
and	O
we	O
establish	O
a	O
mechanism	O
-	O
based	O
approach	O
to	O
target	O
cancerous	O
cell	O
growth	O
.	O

The	O
signal	O
transduction	O
mechanisms	O
shown	O
here	O
to	O
be	O
chemically	O
tractable	O
additionally	O
contribute	O
to	O
Wnt	B-GGP
-	O
independent	O
signal	O
transduction	O
pathways	O
and	O
thus	O
could	O
be	O
broadly	O
exploited	O
for	O
chemical	O
genetics	O
and	O
therapeutic	O
goals	O
.	O

Kaiso	B-GGP
is	O
a	O
bimodal	O
modulator	O
for	O
Wnt	B-GGP
/	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
.	O

The	O
Wnt	B-GGP
family	O
of	O
secreted	O
ligands	O
plays	O
critical	O
roles	O
during	O
embryonic	O
development	O
and	O
tumorigenesis	O
.	O

Here	O
we	O
show	O
that	O
Kaiso	B-GGP
,	O
a	O
dual	O
specific	O
DNA	O
-	O
binding	O
protein	O
,	O
functions	O
as	O
a	O
bimodal	O
regulator	O
of	O
canonical	O
Wnt	B-GGP
signaling	O
.	O

Loss	O
-	O
of	O
-	O
function	O
analysis	O
of	O
Kaiso	B-GGP
abrogated	O
Wnt	B-GGP
-	O
mediated	O
reporter	O
activity	O
and	O
axis	O
duplication	O
,	O
whereas	O
gain	O
-	O
of	O
-	O
function	O
analysis	O
of	O
Kaiso	B-GGP
dose	O
-	O
dependently	O
resulted	O
in	O
synergistic	O
and	O
suppressive	O
effects	O
.	O

Our	O
analyses	O
further	O
suggest	O
Kaiso	B-GGP
can	O
regulate	O
TCF	B-GGP
/	I-GGP
LEF1	I-GGP
-	O
activity	O
for	O
these	O
effects	O
via	O
modulating	O
HDAC1	B-GGP
and	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
-	O
complex	O
formation	O
.	O

Our	O
studies	O
together	O
provide	O
insights	O
into	O
why	O
Kaiso	B-GGP
null	O
mice	O
display	O
resistance	O
to	O
intestinal	O
tumors	O
when	O
crossed	O
onto	O
an	O
Apc	B-GGP
(	O
Min	O
/	O
+	O
)	O
background	O
.	O

Licochalcone	B-MED
A	I-MED
significantly	O
suppresses	O
LPS	B-MED
signaling	O
pathway	O
through	O
the	O
inhibition	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
p65	B-GGP
phosphorylation	O
at	O
serine	B-MED
276	I-MED
.	O

Licorice	O
root	O
,	O
Glycyrrhiza	O
inflata	O
,	O
has	O
been	O
used	O
as	O
a	O
traditional	O
medicine	O
for	O
the	O
treatment	O
of	O
bronchial	O
asthma	O
and	O
inflammation	O
;	O
however	O
,	O
the	O
mechanism	O
of	O
its	O
anti	O
-	O
inflammatory	O
activity	O
has	O
not	O
been	O
clarified	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
Licochalcone	B-MED
A	I-MED
,	O
a	O
major	O
component	O
of	O
G	O
.	O
inflata	O
,	O
on	O
the	O
LPS	B-MED
signaling	O
pathway	O
.	O

We	O
found	O
that	O
Licochalcone	B-MED
A	I-MED
remarkably	O
inhibited	O
LPS	B-MED
-	O
induced	O
NO	B-MED
production	O
,	O
and	O
TNFalpha	B-GGP
expression	O
and	O
MCP	B-GGP
-	I-GGP
1	I-GGP
expression	O
in	O
both	O
RAW264	O
.	O
7	O
cells	O
and	O
primary	O
macrophages	O
.	O

Furthermore	O
,	O
when	O
injected	O
with	O
Licochalcone	B-MED
A	I-MED
prior	O
to	O
injection	O
of	O
LPS	B-MED
,	O
the	O
serum	O
level	O
of	O
TNFalpha	B-GGP
and	O
MCP	B-GGP
-	I-GGP
1	I-GGP
in	O
C57BL	O
/	O
6	O
mice	O
was	O
clearly	O
decreased	O
,	O
indicating	O
that	O
Licochalcone	B-MED
A	I-MED
has	O
a	O
potent	O
anti	O
-	O
inflammatory	O
effect	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Strikingly	O
,	O
Licochalcone	B-MED
A	I-MED
significantly	O
inhibited	O
LPS	B-MED
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
transcriptional	O
activation	O
;	O
however	O
,	O
it	O
had	O
no	O
effect	O
on	O
not	O
only	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-GGP
but	O
also	O
nuclear	B-CC
translocation	O
and	O
DNA	O
binding	O
activity	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
p65	B-GGP
.	O

Interestingly	O
,	O
Licochalcone	B-MED
A	I-MED
markedly	O
inhibited	O
the	O
phosphorylation	O
of	O
p65	B-GGP
at	O
serine	B-MED
276	I-MED
.	O

As	O
a	O
result	O
,	O
it	O
reduced	O
NF	B-COM
-	I-COM
kappaB	I-COM
transactivation	O
by	O
preventing	O
the	O
interaction	O
of	O
p65	B-GGP
with	O
p300	B-GGP
.	O

Taken	O
together	O
,	O
Licochalcone	B-MED
A	I-MED
might	O
contribute	O
to	O
the	O
potent	O
anti	O
-	O
inflammatory	O
effect	O
of	O
G	O
.	O
inflata	O
through	O
the	O
unique	O
mechanism	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibition	O
.	O

SDF	B-GGP
-	I-GGP
1alpha	I-GGP
up	O
-	O
regulates	O
interleukin	B-GGP
-	I-GGP
6	I-GGP
through	O
CXCR4	B-GGP
,	O
PI3K	B-GGP
/	O
Akt	B-GGP
,	O
ERK	B-GGP
,	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
dependent	O
pathway	O
in	O
microglia	O
.	O

Stromal	B-GGP
cell	I-GGP
-	I-GGP
derived	I-GGP
factor	I-GGP
-	I-GGP
1	I-GGP
(	O
SDF	B-GGP
-	I-GGP
1	I-GGP
)	O
,	O
also	O
known	O
as	O
CXCL12	B-GGP
,	O
and	O
its	O
receptor	B-GGP
CXC	I-GGP
chemokine	I-GGP
receptor	I-GGP
4	I-GGP
(	O
CXCR4	B-GGP
)	O
express	O
in	O
various	O
kinds	O
of	O
cells	O
in	O
central	O
nervous	O
system	O
.	O

The	O
SDF	B-GGP
-	I-GGP
1	I-GGP
/	O
CXCR4	B-GGP
signaling	O
pathway	O
is	O
regulated	O
by	O
diverse	O
biological	O
effects	O
.	O

SDF	B-GGP
-	I-GGP
1	I-GGP
is	O
up	O
-	O
regulated	O
in	O
the	O
ischemic	O
penumbra	O
following	O
stroke	O
and	O
has	O
been	O
known	O
to	O
be	O
associated	O
with	O
the	O
homing	O
of	O
bone	O
marrow	O
cells	O
to	O
injury	O
.	O

However	O
,	O
the	O
effect	O
of	O
SDF	B-GGP
-	I-GGP
1alpha	I-GGP
/	O
CXCR4	B-GGP
on	O
cytokine	O
production	O
in	O
microglia	O
is	O
mostly	O
unknown	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
SDF	B-GGP
-	I-GGP
1alpha	I-GGP
enhanced	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
in	O
both	O
primary	O
cultured	O
microglia	O
and	O
BV	O
-	O
2	O
microglia	O
.	O

We	O
further	O
investigated	O
the	O
signaling	O
pathway	O
involved	O
in	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
stimulated	O
by	O
SDF	B-GGP
-	I-GGP
1alpha	I-GGP
in	O
microglia	O
.	O

SDF	B-GGP
-	I-GGP
1alpha	I-GGP
increased	O
IL	B-GGP
-	I-GGP
6	I-GGP
production	O
in	O
both	O
protein	O
and	O
mRNA	O
levels	O
.	O

These	O
effects	O
were	O
attenuated	O
by	O
ERK	B-GGP
,	O
phosphatidylinositol	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
(	O
PI3K	B-GGP
)	O
,	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitors	O
,	O
and	O
IkappaB	B-GGP
protease	O
inhibitor	O
.	O

Stimulation	O
of	O
microglia	O
with	O
SDF	B-GGP
-	I-GGP
1alpha	I-GGP
also	O
increased	O
Akt	B-GGP
and	O
ERK1	B-GGP
/	I-GGP
2	I-GGP
phosphorylation	O
.	O

In	O
addition	O
,	O
SDF	B-GGP
-	I-GGP
1alpha	I-GGP
treatment	O
also	O
increased	O
IkappaB	B-GGP
kinase	I-GGP
alpha	I-GGP
/	O
beta	B-GGP
(	O
IKK	B-GGP
alpha	I-GGP
/	O
beta	B-GGP
)	O
phosphorylation	O
,	O
IkappaBalpha	B-GGP
phosphorylation	O
,	O
IkappaBalpha	B-GGP
degradation	O
,	O
p65	B-GGP
phosphorylation	O
at	O
Ser	B-MED
(	I-MED
276	I-MED
)	I-MED
,	O
translocation	O
of	O
p65	B-GGP
and	O
p50	B-GGP
from	O
cytosol	B-CC
to	O
nucleus	B-CC
and	O
kappaB	B-COM
-	O
luciferase	O
activity	O
.	O

Moreover	O
,	O
SDF	B-GGP
-	I-GGP
1alpha	I-GGP
-	O
mediated	O
increase	O
of	O
kappaB	B-COM
-	O
luciferase	O
activity	O
was	O
inhibited	O
by	O
pre	O
-	O
transfection	O
of	O
DN	O
-	O
p85	B-GGP
,	O
DN	O
-	O
Akt	B-GGP
or	O
DN	O
-	O
ERK2	B-GGP
.	O

Increase	O
of	O
IKK	B-GGP
alpha	I-GGP
/	O
beta	B-GGP
phosphorylation	O
and	O
binding	O
of	O
p65	B-GGP
and	O
p50	B-GGP
to	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
element	O
were	O
both	O
antagonized	O
by	O
PI3K	B-GGP
and	O
ERK	B-GGP
inhibitors	O
.	O

Our	O
results	O
demonstrate	O
a	O
mechanism	O
linking	O
SDF	B-GGP
-	I-GGP
1alpha	I-GGP
and	O
IL	B-GGP
-	I-GGP
6	I-GGP
,	O
and	O
provide	O
additional	O
support	O
for	O
the	O
notion	O
that	O
SDF	B-GGP
-	I-GGP
1alpha	I-GGP
plays	O
a	O
regulatory	O
role	O
in	O
microglia	O
activation	O
.	O

NPM	B-GGP
-	I-GGP
ALK	I-GGP
inhibits	O
the	O
p53	B-GGP
tumor	O
suppressor	O
pathway	O
in	O
an	O
MDM2	B-GGP
and	O
JNK	B-GGP
-	O
dependent	O
manner	O
.	O

Anaplastic	O
large	O
cell	O
lymphoma	O
(	O
ALCL	O
)	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
the	O
t	O
(	O
2	O
;	O
5	O
)	O
(	O
p23	O
;	O
q35	O
)	O
generating	O
the	O
nucleophosmin	B-GGP
-	I-GGP
anaplastic	I-GGP
lymphoma	I-GGP
kinase	I-GGP
(	O
NPM	B-GGP
-	I-GGP
ALK	I-GGP
)	O
fusion	O
protein	O
,	O
a	O
hyperactive	O
kinase	O
with	O
transforming	O
properties	O
.	O

Among	O
these	O
properties	O
is	O
the	O
ability	O
to	O
regulate	O
activity	O
of	O
the	O
p53	B-GGP
tumor	O
suppressor	O
protein	O
.	O

In	O
many	O
human	O
cancers	O
,	O
p53	B-GGP
is	O
inactivated	O
by	O
mutation	O
or	O
other	O
means	O
,	O
in	O
some	O
cases	O
as	O
a	O
result	O
of	O
up	O
-	O
regulation	O
of	O
the	O
negative	O
regulator	O
MDM2	B-GGP
.	O

However	O
,	O
the	O
majority	O
of	O
ALK	B-GGP
-	O
expressing	O
ALCL	O
carry	O
wild	O
-	O
type	O
p53	B-GGP
and	O
do	O
not	O
over	O
express	O
MDM2	B-GGP
.	O

We	O
demonstrate	O
a	O
novel	O
p53	B-GGP
-	O
dependent	O
pathogenetic	O
mechanism	O
in	O
ALK	B-GGP
-	O
expressing	O
lymphoma	O
.	O

We	O
confirm	O
previously	O
published	O
reports	O
of	O
NPM	B-GGP
-	I-GGP
ALK	I-GGP
-	O
induced	O
activation	O
of	O
the	O
phosphoinositide	B-GGP
(	I-GGP
PI	I-GGP
)	I-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
and	O
Jun	B-GGP
N	I-GGP
-	I-GGP
terminal	I-GGP
kinase	I-GGP
(	O
JNK	B-GGP
)	O
stress	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
(	I-GGP
SAP	I-GGP
)	I-GGP
kinase	I-GGP
proteins	O
,	O
but	O
in	O
this	O
study	O
demonstrate	O
a	O
role	O
for	O
these	O
in	O
the	O
regulation	O
of	O
p53	B-GGP
activity	O
in	O
an	O
intricate	O
signaling	O
system	O
.	O

Specifically	O
,	O
constitutive	O
ALK	B-GGP
signaling	O
leads	O
to	O
the	O
functional	O
inactivation	O
and	O
/	O
or	O
degradation	O
of	O
p53	B-GGP
in	O
JNK	B-GGP
and	O
MDM2	B-GGP
dependent	O
manners	O
.	O

We	O
also	O
show	O
nuclear	B-CC
exclusion	O
of	O
p53	B-GGP
in	O
a	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
reactivation	O
of	O
p53	B-GGP
in	O
ALK	B-GGP
-	O
expressing	O
cells	O
as	O
a	O
result	O
of	O
pharmacologic	O
inhibition	O
of	O
JNK	B-GGP
,	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
,	O
and	O
/	O
or	O
MDM2	B-GGP
activities	O
results	O
in	O
the	O
induction	O
of	O
apoptosis	O
suggesting	O
a	O
novel	O
therapeutic	O
modality	O
.	O

[	O
CCR4	B-GGP
,	O
HTLV	O
-	O
1	O
infection	O
,	O
and	O
ATL	O
oncogenesis	O
]	O
.	O

Adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
is	O
a	O
malignancy	O
of	O
mature	O
CD4	B-GGP
+	O
T	O
cells	O
that	O
is	O
etiologically	O
associated	O
with	O
the	O
infection	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
,	O
an	O
exogenous	O
human	O
retrovirus	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
leukemic	O
cells	O
of	O
most	O
ATL	O
patients	O
express	O
CCR4	B-GGP
,	O
a	O
chemokine	O
receptor	O
known	O
to	O
be	O
selectively	O
expressed	O
by	O
T	O
cell	O
subsets	O
such	O
as	O
Th2	O
cells	O
,	O
skin	O
-	O
homing	O
memory	O
/	O
effector	O
T	O
cells	O
,	O
and	O
regulatory	O
T	O
cells	O
.	O

Therefore	O
,	O
the	O
expression	O
of	O
CCR4	B-GGP
suggests	O
that	O
ATL	O
cells	O
are	O
mostly	O
derived	O
from	O
one	O
of	O
these	O
T	O
cell	O
subsets	O
.	O

We	O
have	O
also	O
shown	O
that	O
Tax	B-GGP
,	O
the	O
HTLV	O
-	O
1	O
-	O
encoded	O
potent	O
transcriptional	O
activator	O
,	O
strongly	O
induces	O
the	O
expression	O
of	O
CCL22	B-GGP
,	O
a	O
CCR4	B-GGP
ligand	O
,	O
which	O
promotes	O
the	O
cell	O
-	O
dependent	O
transmission	O
of	O
HTLV	O
-	O
1	O
from	O
HTLV	O
-	O
1	O
-	O
infected	O
T	O
cells	O
to	O
CCR4	B-GGP
+	O
target	O
T	O
cells	O
by	O
inducing	O
close	O
cell	O
-	O
to	O
-	O
cell	O
interactions	O
.	O

We	O
have	O
also	O
shown	O
that	O
ATL	O
cells	O
aberrantly	O
express	O
the	O
AP	B-GGP
-	I-GGP
1	I-GGP
family	O
member	O
Fra	B-GGP
-	I-GGP
2	I-GGP
which	O
,	O
by	O
forming	O
the	O
heterodimer	O
with	O
JunD	B-GGP
,	O
potently	O
induces	O
the	O
expression	O
of	O
not	O
only	O
CCR4	B-GGP
but	O
also	O
the	O
genes	O
such	O
as	O
c	B-GGP
-	I-GGP
Myb	I-GGP
,	O
MDM2	B-GGP
and	O
Bcl	B-GGP
-	I-GGP
6	I-GGP
,	O
the	O
well	O
-	O
known	O
proto	O
-	O
oncogenes	O
.	O

Thus	O
,	O
Fra	B-GGP
-	I-GGP
2	I-GGP
is	O
a	O
novel	O
oncogene	O
of	O
ATL	O
,	O
and	O
CCR4	B-GGP
may	O
be	O
regarded	O
as	O
a	O
useful	O
tumor	O
marker	O
of	O
ATL	O
.	O

Notch1	B-GGP
signaling	O
sensitizes	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
-	I-GGP
related	I-GGP
apoptosis	I-GGP
-	I-GGP
inducing	I-GGP
ligand	I-GGP
-	O
induced	O
apoptosis	O
in	O
human	O
hepatocellular	O
carcinoma	O
cells	O
by	O
inhibiting	O
Akt	B-GGP
/	O
Hdm2	B-GGP
-	O
mediated	O
p53	B-GGP
degradation	O
and	O
up	O
-	O
regulating	O
p53	B-GGP
-	O
dependent	O
DR5	B-GGP
expression	O
.	O

Notch	B-GGP
signaling	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
overexpression	O
of	O
Notch1	B-GGP
could	O
inhibit	O
human	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
cell	O
growth	O
by	O
arresting	O
the	O
cell	O
cycle	O
and	O
inducing	O
apoptosis	O
.	O

HCC	O
cells	O
are	O
resistant	O
to	O
apoptotic	O
induction	O
by	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
-	I-GGP
related	I-GGP
apoptosis	I-GGP
-	I-GGP
inducing	I-GGP
ligand	I-GGP
(	O
TRAIL	B-GGP
)	O
,	O
so	O
new	O
therapeutic	O
approaches	O
have	O
been	O
explored	O
to	O
sensitize	O
HCC	O
cells	O
to	O
TRAIL	B-GGP
-	O
induced	O
apoptosis	O
.	O

We	O
are	O
wondering	O
whether	O
and	O
how	O
Notch1	B-GGP
signaling	O
can	O
enhance	O
the	O
sensitivity	O
of	O
HCC	O
cells	O
to	O
TRAIL	B-GGP
-	O
induced	O
apoptosis	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
overexpression	O
of	O
ICN	B-GGP
,	O
the	O
constitutive	O
activated	O
form	O
of	O
Notch1	B-GGP
,	O
up	O
-	O
regulated	O
p53	B-GGP
protein	O
expression	O
in	O
HCC	O
cells	O
by	O
inhibiting	O
proteasome	O
degradation	O
.	O

p53	B-GGP
up	O
-	O
regulation	O
was	O
further	O
observed	O
in	O
human	O
primary	O
hepatocellular	O
carcinoma	O
cells	O
after	O
activation	O
of	O
Notch	B-GGP
signaling	O
.	O

Inhibition	O
of	O
the	O
Akt	B-GGP
/	O
Hdm2	B-GGP
pathway	O
by	O
Notch1	B-GGP
signaling	O
was	O
responsible	O
for	O
the	O
suppression	O
of	O
p53	B-GGP
proteasomal	B-CC
degradation	O
,	O
thus	O
contributing	O
to	O
the	O
Notch1	B-GGP
signaling	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
p53	B-GGP
expression	O
.	O

Accordingly	O
,	O
Notch1	B-GGP
signaling	O
could	O
make	O
HCC	O
cells	O
more	O
sensitive	O
to	O
TRAIL	B-GGP
-	O
induced	O
apoptosis	O
,	O
whereas	O
Notch1	B-GGP
signaling	O
lost	O
the	O
synergistic	O
promotion	O
of	O
TRAIL	B-GGP
-	O
induced	O
apoptosis	O
in	O
p53	B-GGP
-	O
silenced	O
HepG2	O
HCC	O
cells	O
and	O
p53	B-GGP
-	O
defective	O
Hep3B	O
HCC	O
cells	O
.	O

The	O
data	O
suggest	O
that	O
enhancement	O
of	O
TRAIL	B-GGP
-	O
induced	O
apoptosis	O
by	O
Notch1	B-GGP
signaling	O
is	O
dependent	O
upon	O
p53	B-GGP
up	O
-	O
regulation	O
.	O

Furthermore	O
,	O
Notch1	B-GGP
signaling	O
could	O
enhance	O
DR5	B-GGP
expression	O
in	O
a	O
p53	B-GGP
-	O
dependent	O
manner	O
.	O

Taken	O
together	O
,	O
Notch1	B-GGP
signaling	O
sensitizes	O
TRAIL	B-GGP
-	O
induced	O
apoptosis	O
in	O
HCC	O
cells	O
by	O
inhibiting	O
Akt	B-GGP
/	O
Hdm2	B-GGP
-	O
mediated	O
p53	B-GGP
degradation	O
and	O
up	O
-	O
regulating	O
p53	B-GGP
-	O
dependent	O
DR5	B-GGP
expression	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
activation	O
of	O
Notch1	B-GGP
signaling	O
may	O
be	O
a	O
promising	O
approach	O
to	O
improve	O
the	O
therapeutic	O
efficacy	O
of	O
TRAIL	B-GGP
-	O
resistant	O
HCC	O
.	O

Pyrrolidine	B-MED
dithiocarbamate	I-MED
,	O
a	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitor	O
,	O
upregulates	O
MMP	B-GGP
-	I-GGP
1	I-GGP
and	O
MMP	B-GGP
-	I-GGP
13	I-GGP
in	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
-	O
stimulated	O
rheumatoid	O
arthritis	O
fibroblast	O
-	O
like	O
synoviocytes	O
.	O

Activated	O
NF	B-COM
-	I-COM
kappaB	I-COM
plays	O
an	O
important	O
role	O
in	O
the	O
expression	O
of	O
matrix	B-GGP
metalloproteinase	I-GGP
(	I-GGP
MMP	I-GGP
)	I-GGP
-	I-GGP
1	I-GGP
and	O
MMP	B-GGP
-	I-GGP
13	I-GGP
in	O
rheumatoid	O
arthritis	O
and	O
osteoarthritis	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitor	O
pyrrolidine	B-MED
dithiocarbamate	I-MED
(	O
PDTC	B-MED
)	O
on	O
the	O
expression	O
of	O
MMPs	B-GGP
in	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
-	O
stimulated	O
fibroblast	O
-	O
like	O
synoviocytes	O
(	O
FLSs	O
)	O
of	O
rheumatoid	O
arthritis	O
patients	O
.	O

FLSs	O
were	O
treated	O
with	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
(	O
10	O
ng	O
/	O
ml	O
)	O
for	O
24	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
PDTC	B-MED
.	O

The	O
level	O
of	O
MMP	B-GGP
-	I-GGP
1	I-GGP
and	O
MMP	B-GGP
-	I-GGP
13	I-GGP
increased	O
in	O
response	O
to	O
PDTC	B-MED
in	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manners	O
in	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
-	O
stimulated	O
FLSs	O
;	O
the	O
expressions	O
of	O
IL	B-GGP
-	I-GGP
6	I-GGP
and	O
vascular	B-GGP
endothelial	I-GGP
growth	I-GGP
factor	I-GGP
(	O
VEGF	B-GGP
)	O
decreased	O
in	O
a	O
PDTC	B-MED
concentration	O
-	O
dependent	O
manner	O
.	O

However	O
,	O
PDTC	B-MED
-	O
mediated	O
repression	O
of	O
IL	B-GGP
-	I-GGP
6	I-GGP
and	O
VEGF	B-GGP
expression	O
was	O
not	O
observed	O
in	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
-	O
stimulated	O
rheumatoid	O
arthritis	O
FLSs	O
.	O

In	O
contrast	O
,	O
other	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitors	O
,	O
such	O
as	O
fenofibrate	B-MED
,	O
N	B-MED
-	I-MED
acetylcysteine	I-MED
and	O
MG132	B-MED
,	O
decreased	O
MMP	B-GGP
expression	O
in	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
-	O
stimulated	O
FLSs	O
.	O

The	O
stimulatory	O
effect	O
of	O
PDTC	B-MED
on	O
MMP	B-GGP
expression	O
was	O
not	O
mimicked	O
by	O
specific	O
inhibitors	O
of	O
the	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
(	O
MAPK	B-GGP
)	O
signaling	O
pathway	O
.	O

Treatments	O
with	O
100	O
muM	O
PDTC	B-MED
did	O
not	O
inhibit	O
the	O
phosphorylation	O
of	O
p	O
-	O
ERK1	B-GGP
/	I-GGP
2	I-GGP
,	O
p	O
-	O
P38	B-GGP
,	O
and	O
p	O
-	O
JNK	B-GGP
,	O
or	O
the	O
transnuclear	B-CC
migration	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
through	O
degradation	O
of	O
IkappaB	B-GGP
-	I-GGP
alpha	I-GGP
in	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
-	O
stimulated	O
FLSs	O
.	O

These	O
results	O
suggest	O
that	O
the	O
increase	O
of	O
MMP	B-GGP
expression	O
may	O
occur	O
in	O
a	O
stimuli	O
-	O
specific	O
manner	O
or	O
by	O
an	O
NF	B-COM
-	I-COM
kappaB	I-COM
independent	O
mechanism	O
.	O

Therefore	O
,	O
therapeutic	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitors	O
should	O
be	O
thoroughly	O
studied	O
before	O
their	O
clinical	O
use	O
in	O
treating	O
rheumatoid	O
arthritis	O
,	O
as	O
undesirable	O
genes	O
may	O
be	O
upregulated	O
through	O
unknown	O
mechanisms	O
,	O
possibly	O
resulting	O
in	O
worse	O
symptoms	O
.	O

PUMA	B-GGP
suppresses	O
intestinal	O
tumorigenesis	O
in	O
mice	O
.	O

Defective	O
apoptosis	O
contributes	O
to	O
tumorigenesis	O
,	O
although	O
the	O
critical	O
molecular	O
targets	O
remain	O
to	O
be	O
fully	O
characterized	O
.	O

PUMA	B-GGP
,	O
a	O
BH3	O
-	O
only	O
protein	O
essential	O
for	O
p53	B-GGP
-	O
dependent	O
apoptosis	O
,	O
has	O
been	O
shown	O
to	O
suppress	O
lymphomagenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
PUMA	B-GGP
in	O
intestinal	O
tumorigenesis	O
using	O
two	O
animal	O
models	O
.	O

In	O
the	O
azoxymethane	B-MED
(	O
AOM	B-MED
)	O
/	O
dextran	B-MED
sulfate	B-MED
sodium	I-MED
salt	I-MED
model	O
,	O
PUMA	B-GGP
deficiency	O
increased	O
the	O
multiplicity	O
and	O
size	O
of	O
colon	O
tumors	O
but	O
reduced	O
the	O
frequency	O
of	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
hotspot	O
mutations	O
.	O

The	O
absence	O
of	O
PUMA	B-GGP
led	O
to	O
a	O
significantly	O
elevated	O
incidence	O
of	O
precursor	O
lesions	O
induced	O
by	O
AOM	B-MED
.	O

AOM	B-MED
was	O
found	O
to	O
induce	O
p53	B-GGP
-	O
dependent	O
PUMA	B-GGP
expression	O
and	O
PUMA	B-GGP
-	O
dependent	O
apoptosis	O
in	O
the	O
colonic	O
crypts	O
and	O
stem	O
cell	O
compartment	O
.	O

Furthermore	O
,	O
PUMA	B-GGP
deficiency	O
significantly	O
enhanced	O
the	O
formation	O
of	O
spontaneous	O
macroadenomas	O
and	O
microadenomas	O
in	O
the	O
distal	O
small	O
intestine	O
and	O
colon	O
of	O
APC	B-GGP
(	O
Min	O
/	O
+	O
)	O
mice	O
.	O

These	O
results	O
show	O
an	O
essential	O
role	O
of	O
PUMA	B-GGP
-	O
mediated	O
apoptosis	O
in	O
suppressing	O
intestinal	O
tumorigenesis	O
in	O
mice	O
.	O

TP53	B-GGP
R72P	O
and	O
MDM2	B-GGP
SNP309	O
polymorphisms	O
in	O
modification	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
susceptibility	O
.	O

Genomic	O
and	O
immunologic	O
surveillance	O
mechanisms	O
are	O
crucial	O
in	O
protection	O
from	O
cancer	O
.	O

The	O
tumor	O
suppressor	O
protein	O
p53	B-GGP
,	O
encoded	O
by	O
TP53	B-GGP
,	O
is	O
a	O
major	O
regulator	O
of	O
genome	O
surveillance	O
.	O

Among	O
the	O
natural	O
sequence	O
variants	O
of	O
TP53	B-GGP
,	O
rs1042522	O
(	O
R72P	O
)	O
modifies	O
the	O
risk	O
for	O
solid	O
tumors	O
.	O

To	O
investigate	O
its	O
relevance	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
susceptibility	O
,	O
we	O
genotyped	O
114	O
cases	O
and	O
414	O
newborn	O
controls	O
from	O
Wales	O
(	O
UK	O
)	O
for	O
polymorphisms	O
in	O
TP53	B-GGP
(	O
R72P	O
)	O
,	O
its	O
negative	O
regulator	O
MDM2	B-GGP
(	O
single	O
-	O
nucleotide	O
polymorphism	O
SNP309	O
,	O
rs2279744	O
)	O
,	O
and	O
selected	O
HLA	B-COM
complex	O
genes	O
whose	O
products	O
interact	O
with	O
TP53	B-GGP
.	O

TP53	B-GGP
R72P	O
showed	O
a	O
risk	O
association	O
with	O
gene	O
dosage	O
effect	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
resulting	O
in	O
a	O
strong	O
association	O
of	O
homozygous	O
genotype	O
(	O
OR	O
=	O
2	O
.	O
9	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
5	O
-	O
5	O
.	O
6	O
)	O
and	O
no	O
sex	O
effect	O
.	O

SNP309	O
did	O
not	O
show	O
any	O
association	O
with	O
primary	O
susceptibility	O
to	O
childhood	O
ALL	O
,	O
even	O
after	O
stratification	O
by	O
sex	O
.	O

However	O
,	O
females	O
with	O
SNP309	O
minor	O
allele	O
had	O
earlier	O
onset	O
of	O
childhood	O
ALL	O
(	O
median	O
age	O
at	O
diagnosis	O
was	O
36	O
months	O
in	O
females	O
,	O
but	O
60	O
months	O
in	O
males	O
;	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
HLA	B-COM
complex	O
genes	O
did	O
not	O
show	O
any	O
statistically	O
significant	O
interaction	O
with	O
R72P	O
.	O

We	O
have	O
therefore	O
identified	O
TP53	B-GGP
R72P	O
as	O
a	O
possible	O
risk	O
modifier	O
for	O
childhood	O
ALL	O
and	O
the	O
association	O
of	O
MDM2	B-GGP
with	O
age	O
at	O
onset	O
with	O
sex	O
effect	O
suggests	O
prenatal	O
hormonal	O
programming	O
of	O
childhood	O
ALL	O
susceptibility	O
.	O

A	O
feed	O
-	O
forward	O
circuit	O
controlling	O
inducible	O
NF	B-COM
-	I-COM
kappaB	I-COM
target	O
gene	O
activation	O
by	O
promoter	O
histone	B-GGP
demethylation	O
.	O

Activation	O
of	O
transcription	O
from	O
a	O
silenced	O
state	O
is	O
crucial	O
to	O
achieve	O
specific	O
gene	O
expression	O
in	O
many	O
biological	O
contexts	O
.	O

Methylation	O
of	O
lysine	B-MED
9	I-MED
on	O
histone	B-GGP
H3	I-GGP
(	O
H3K9	B-GGP
)	O
is	O
widely	O
associated	O
with	O
transcriptional	O
silencing	O
,	O
and	O
its	O
disappearance	O
is	O
linked	O
to	O
the	O
activation	O
of	O
several	O
inflammatory	O
genes	O
by	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

Here	O
we	O
describe	O
that	O
this	O
event	O
is	O
controlled	O
by	O
a	O
feed	O
-	O
forward	O
circuit	O
catalyzed	O
by	O
the	O
activity	O
of	O
the	O
histone	B-GGP
demethylase	O
Aof1	B-GGP
(	O
also	O
known	O
as	O
Lsd2	B-GGP
/	O
Kdm1b	B-GGP
)	O
.	O

We	O
find	O
that	O
Aof1	B-GGP
is	O
required	O
for	O
removal	O
of	O
dimethyl	O
H3K9	B-GGP
at	O
specific	O
promoters	O
,	O
and	O
thereby	O
it	O
controls	O
stimulus	O
-	O
induced	O
recruitment	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
gene	O
expression	O
.	O

However	O
,	O
Aof1	B-GGP
is	O
itself	O
recruited	O
by	O
interaction	O
with	O
the	O
c	B-GGP
-	I-GGP
Rel	I-GGP
subunit	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
which	O
is	O
found	O
at	O
low	O
levels	O
associated	O
with	O
promoters	O
in	O
unstimulated	O
cells	O
.	O

Thus	O
,	O
at	O
these	O
tightly	O
regulated	O
genes	O
,	O
NF	B-COM
-	I-COM
kappaB	I-COM
functions	O
both	O
as	O
a	O
transcriptional	O
activator	O
and	O
as	O
an	O
upstream	O
targeting	O
signal	O
that	O
marks	O
promoters	O
to	O
be	O
derepressed	O
by	O
histone	B-GGP
demethylation	O
.	O

NEMO	B-GGP
stabilizes	O
c	B-GGP
-	I-GGP
Myc	I-GGP
through	O
direct	O
interaction	O
in	O
the	O
nucleus	B-CC
.	O

The	O
transcription	O
factor	O
c	B-GGP
-	I-GGP
Myc	I-GGP
is	O
a	O
cellular	O
oncoprotein	O
generally	O
upregulated	O
in	O
most	O
of	O
human	O
cancers	O
.	O

NF	B-GGP
-	I-GGP
kappaB	I-GGP
essential	I-GGP
modulator	I-GGP
(	O
NEMO	B-GGP
)	O
caused	O
phosphorylation	O
and	O
stabilization	O
of	O
c	B-GGP
-	I-GGP
Myc	I-GGP
protein	O
in	O
the	O
nucleus	B-CC
through	O
direct	O
interaction	O
.	O

The	O
interaction	O
caused	O
reduced	O
ubiquitination	O
of	O
c	B-GGP
-	I-GGP
Myc	I-GGP
by	O
inhibiting	O
ubiquitinating	O
activity	O
of	O
Fbw7	B-GGP
without	O
blocking	O
the	O
interaction	O
between	O
c	B-GGP
-	I-GGP
Myc	I-GGP
and	O
Fbw7	B-GGP
.	O

As	O
a	O
consequence	O
,	O
NEMO	B-GGP
enhanced	O
the	O
expression	O
of	O
several	O
selected	O
c	B-GGP
-	I-GGP
Myc	I-GGP
targets	O
.	O

Compared	O
to	O
the	O
classical	O
role	O
as	O
an	O
essential	O
subunit	O
for	O
the	O
activity	O
of	O
IKK	B-COM
complex	O
,	O
stabilization	O
of	O
c	B-GGP
-	I-GGP
Myc	I-GGP
by	O
direct	O
interaction	O
is	O
a	O
unique	O
function	O
of	O
NEMO	B-GGP
,	O
representing	O
a	O
new	O
mechanism	O
to	O
regulate	O
c	B-GGP
-	I-GGP
Myc	I-GGP
activity	O
.	O

Interaction	O
between	O
nuclear	B-CC
insulin	B-GGP
receptor	I-GGP
substrate	I-GGP
-	I-GGP
2	I-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
IGF	B-GGP
-	I-GGP
1	I-GGP
induces	O
response	O
in	O
breast	O
cancer	O
cells	O
.	O

Despite	O
significant	O
homology	O
between	O
IRS	B-GGP
-	I-GGP
1	I-GGP
and	O
IRS	B-GGP
-	I-GGP
2	I-GGP
,	O
recent	O
studies	O
have	O
revealed	O
distinct	O
functions	O
for	O
these	O
adaptor	O
proteins	O
in	O
regulating	O
breast	O
cancer	O
progression	O
.	O

Thus	O
far	O
,	O
most	O
of	O
the	O
studies	O
on	O
breast	O
cancer	O
have	O
focused	O
upon	O
IRS	B-GGP
-	I-GGP
1	I-GGP
,	O
the	O
biological	O
pattern	O
of	O
IRS	B-GGP
-	I-GGP
2	I-GGP
is	O
limited	O
.	O

We	O
demonstrated	O
that	O
depletion	O
of	O
endogenous	O
IRS	B-GGP
-	I-GGP
2	I-GGP
by	O
antisense	O
strategies	O
impaired	O
cell	O
proliferation	O
after	O
serum	O
withdrawal	O
,	O
blunted	O
PI3K	B-GGP
/	O
Akt	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
in	O
IGF	B-GGP
-	I-GGP
1	I-GGP
induced	O
response	O
in	O
MCF	O
-	O
7	O
and	O
BT	O
-	O
20	O
breast	O
cancer	O
cells	O
.	O

In	O
addition	O
,	O
IGF	B-GGP
-	I-GGP
1	I-GGP
promote	O
nuclear	B-CC
translocation	O
of	O
IRS	B-GGP
-	I-GGP
2	I-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
MCF	O
-	O
7	O
and	O
BT	O
-	O
20	O
cells	O
.	O

Nuclear	B-CC
IRS	B-GGP
-	I-GGP
2	I-GGP
interaction	O
with	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
p65	B-GGP
and	O
PI3K	B-GGP
binding	O
tyrosine	B-MED
residues	O
of	O
IRS	B-GGP
-	I-GGP
2	I-GGP
are	O
crucial	O
for	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
activities	O
.	O

Moreover	O
,	O
nuclear	B-CC
IRS	B-GGP
-	I-GGP
2	I-GGP
is	O
recruited	O
to	O
the	O
cyclin	B-GGP
D1	I-GGP
promoter	O
both	O
in	O
MCF	O
-	O
7	O
and	O
BT	O
-	O
20	O
cells	O
.	O

The	O
selective	O
inhibition	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
65	B-GGP
abolished	O
the	O
occupancy	O
of	O
IRS	B-GGP
-	I-GGP
2	I-GGP
to	O
the	O
cyclin	B-GGP
D1	I-GGP
promoters	O
.	O

Our	O
studies	O
suggest	O
that	O
IRS	B-GGP
-	I-GGP
2	I-GGP
plays	O
a	O
significant	O
role	O
by	O
activating	O
,	O
at	O
least	O
in	O
part	O
,	O
NF	B-COM
-	I-COM
kappaB	I-COM
via	O
PI3K	B-GGP
/	O
Akt	B-GGP
pathway	O
in	O
IGF	B-GGP
-	I-GGP
1	I-GGP
-	O
induced	O
responses	O
in	O
breast	O
cancer	O
cells	O
and	O
the	O
crosstalk	O
between	O
nuclear	B-CC
IRS	B-GGP
-	I-GGP
2	I-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
might	O
be	O
responsible	O
for	O
transcriptional	O
progression	O
of	O
the	O
breast	O
cancer	O
cells	O
.	O

Regulation	O
of	O
Angiotensin	B-GGP
II	I-GGP
receptor	I-GGP
signaling	O
by	O
cysteine	B-MED
modification	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

Angiotensin	B-GGP
II	I-GGP
(	O
Ang	B-GGP
II	I-GGP
)	O
is	O
a	O
major	O
vasoactive	O
peptide	O
of	O
the	O
renin	B-GGP
-	O
angiotensin	B-GGP
system	O
.	O

Ang	B-GGP
II	I-GGP
is	O
originally	O
found	O
as	O
one	O
of	O
potent	O
vasoconstrictors	O
,	O
but	O
is	O
now	O
attracted	O
attention	O
as	O
an	O
essential	O
mediator	O
of	O
many	O
cardiovascular	O
problems	O
,	O
including	O
endothelial	O
dysfunction	O
,	O
arrhythmia	O
and	O
structural	O
remodeling	O
of	O
cardiovascular	O
systems	O
.	O

Most	O
of	O
the	O
known	O
pathophysiological	O
effects	O
of	O
Ang	B-GGP
II	I-GGP
are	O
mediated	O
through	O
Ang	B-GGP
type1	I-GGP
receptors	I-GGP
(	O
AT	B-GGP
(	I-GGP
1	I-GGP
)	I-GGP
Rs	I-GGP
)	O
,	O
and	O
the	O
up	O
-	O
regulation	O
of	O
AT	B-GGP
(	I-GGP
1	I-GGP
)	I-GGP
Rs	I-GGP
is	O
one	O
of	O
important	O
causes	O
by	O
which	O
Ang	B-GGP
II	I-GGP
can	O
contribute	O
to	O
cardiovascular	O
diseases	O
.	O

A	O
growing	O
body	O
of	O
evidence	O
has	O
suggested	O
that	O
reactive	B-MED
oxygen	I-MED
species	I-MED
(	O
ROS	B-MED
)	O
and	O
reactive	B-MED
nitrogen	I-MED
species	I-MED
(	O
RNS	B-MED
)	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
AT	B-GGP
(	I-GGP
1	I-GGP
)	I-GGP
R	I-GGP
signaling	O
.	O

In	O
cardiac	O
fibroblasts	O
,	O
stimulation	O
with	O
cytokines	O
or	O
bacterial	O
toxins	O
induces	O
AT	B-GGP
(	I-GGP
1	I-GGP
)	I-GGP
R	I-GGP
up	O
-	O
regulation	O
through	O
NADPH	B-GGP
oxidase	I-GGP
-	O
dependent	O
ROS	B-MED
production	O
.	O

In	O
contrast	O
,	O
nitric	B-MED
oxide	I-MED
(	O
NO	B-MED
)	O
decreases	O
AT	B-GGP
(	I-GGP
1	I-GGP
)	I-GGP
R	I-GGP
density	O
through	O
cysteine	B-MED
modification	O
(	O
S	O
-	O
nitrosylation	O
)	O
of	O
a	O
transcriptional	O
factor	O
,	O
nuclear	B-COM
factor	I-COM
kappaB	I-COM
(	O
NF	B-COM
-	I-COM
kappaB	I-COM
)	O
.	O

The	O
difference	O
between	O
the	O
effects	O
of	O
ROS	B-MED
and	O
NO	B-MED
on	O
AT	B-GGP
(	I-GGP
1	I-GGP
)	I-GGP
R	I-GGP
expression	O
may	O
be	O
caused	O
by	O
the	O
difference	O
between	O
intracellular	B-CC
location	O
of	O
ROS	B-MED
signaling	O
and	O
that	O
of	O
NO	B-MED
signaling	O
,	O
as	O
the	O
agonist	O
-	O
induced	O
S	O
-	O
nitrosylation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
requires	O
a	O
local	O
interaction	O
between	O
NO	B-GGP
synthase	I-GGP
(	O
NOS	B-GGP
)	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
the	O
perinuclear	O
region	O
.	O

Thus	O
,	O
the	O
spatial	O
and	O
temporal	O
regulation	O
of	O
cysteine	B-MED
modification	O
by	O
ROS	B-MED
or	O
RNS	B-MED
may	O
underlie	O
the	O
resultant	O
changes	O
of	O
AT	B-GGP
(	I-GGP
1	I-GGP
)	I-GGP
R	I-GGP
signaling	O
induced	O
by	O
agonist	O
stimulation	O
.	O

Negative	O
feedback	O
regulation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
action	O
by	O
CITED2	B-GGP
in	O
the	O
nucleus	B-CC
.	O

NF	B-COM
-	I-COM
kappaB	I-COM
is	O
a	O
family	O
of	O
important	O
transcription	O
factors	O
that	O
modulate	O
immunity	O
,	O
development	O
,	O
inflammation	O
,	O
and	O
cancer	O
.	O

The	O
biological	O
activity	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
is	O
subjected	O
to	O
various	O
spatial	O
and	O
temporal	O
regulations	O
.	O

Bioinformatics	O
analysis	O
predicts	O
that	O
CITED2	B-GGP
is	O
topologically	O
close	O
to	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
the	O
protein	O
interaction	O
networks	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
or	O
knockdown	O
of	O
CITED2	B-GGP
attenuates	O
or	O
potentiates	O
,	O
respectively	O
,	O
the	O
expression	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
responsive	O
genes	O
.	O

Mechanistically	O
,	O
CITED2	B-GGP
constitutively	O
localizes	O
inside	O
the	O
nucleus	B-CC
and	O
interacts	O
specifically	O
with	O
the	O
coactivator	O
p300	B-GGP
.	O

This	O
prevents	O
p65	B-GGP
from	O
binding	O
to	O
p300	B-GGP
,	O
impairs	O
p65	B-GGP
acetylation	O
,	O
and	O
attenuates	O
p65	B-GGP
binding	O
to	O
its	O
cognate	O
promoters	O
.	O

Furthermore	O
,	O
LPS	B-MED
induces	O
CITED2	B-GGP
expression	O
via	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
macrophages	O
.	O

CITED2	B-GGP
sensitizes	O
cells	O
to	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
-	O
induced	O
apoptosis	O
.	O

Collectively	O
,	O
this	O
study	O
identifies	O
CITED2	B-GGP
as	O
a	O
novel	O
regulator	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
the	O
nucleus	B-CC
,	O
which	O
reveals	O
a	O
negative	O
feedback	O
mechanism	O
for	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
.	O

The	O
activator	B-COM
protein	I-COM
1	I-COM
binding	O
motifs	O
within	O
the	O
human	O
cytomegalovirus	O
major	O
immediate	O
-	O
early	O
enhancer	O
are	O
functionally	O
redundant	O
and	O
act	O
in	O
a	O
cooperative	O
manner	O
with	O
the	O
NF	B-COM
-	I-COM
{	I-COM
kappa	I-COM
}	I-COM
B	I-COM
sites	O
during	O
acute	O
infection	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
infection	O
causes	O
a	O
rapid	O
induction	O
of	O
c	B-GGP
-	I-GGP
Fos	I-GGP
and	O
c	B-GGP
-	I-GGP
Jun	I-GGP
,	O
the	O
major	O
subunits	O
of	O
activator	B-COM
protein	I-COM
1	I-COM
(	O
AP	B-COM
-	I-COM
1	I-COM
)	O
,	O
which	O
in	O
turn	O
have	O
been	O
postulated	O
to	O
activate	O
the	O
viral	O
immediate	O
-	O
early	O
(	O
IE	O
)	O
genes	O
.	O

Accordingly	O
,	O
the	O
major	B-GGP
IE	I-GGP
promoter	I-GGP
(	O
MIEP	B-GGP
)	O
enhancer	O
,	O
a	O
critical	O
control	O
region	O
for	O
initiating	O
lytic	O
HCMV	O
infection	O
and	O
reactivation	O
from	O
the	O
latent	O
state	O
,	O
contains	O
one	O
well	O
-	O
characterized	O
AP	B-COM
-	I-COM
1	I-COM
site	O
and	O
a	O
second	O
candidate	O
interaction	O
site	O
.	O

In	O
this	O
study	O
we	O
explored	O
the	O
role	O
of	O
these	O
AP	B-COM
-	I-COM
1	I-COM
elements	O
in	O
the	O
context	O
of	O
the	O
infection	O
.	O

We	O
first	O
show	O
that	O
the	O
distal	O
candidate	O
AP	B-COM
-	I-COM
1	I-COM
motif	O
binds	O
c	B-COM
-	I-COM
Fos	I-COM
/	I-COM
c	I-COM
-	I-COM
Jun	I-COM
heterodimers	O
(	O
AP	B-COM
-	I-COM
1	I-COM
complex	O
)	O
and	O
confers	O
c	B-COM
-	I-COM
Fos	I-COM
/	I-COM
c	I-COM
-	I-COM
Jun	I-COM
-	O
mediated	O
activity	O
to	O
a	O
core	O
promoter	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
indicate	O
that	O
both	O
AP	B-COM
-	I-COM
1	I-COM
response	O
elements	O
are	O
critical	O
for	O
12	B-MED
-	I-MED
O	I-MED
-	I-MED
tetradecanoylphorbol	I-MED
-	I-MED
13	I-MED
-	I-MED
acetate	I-MED
(	O
TPA	B-MED
)	O
-	O
enhanced	O
MIEP	B-GGP
activity	O
in	O
transient	O
-	O
transfection	O
assays	O
.	O

In	O
marked	O
contrast	O
to	O
the	O
results	O
obtained	O
with	O
the	O
isolated	O
promoter	O
,	O
disruption	O
of	O
the	O
AP	B-COM
-	I-COM
1	I-COM
recognition	O
sites	O
of	O
the	O
MIEP	B-GGP
in	O
the	O
context	O
of	O
the	O
infectious	O
HCMV	O
genome	O
has	O
no	O
significant	O
influence	O
on	O
the	O
expression	O
of	O
the	O
MIE	O
protein	O
IE1	B-GGP
or	O
viral	O
replication	O
in	O
different	O
cell	O
types	O
.	O

Moreover	O
,	O
a	O
chimeric	O
murine	O
CMV	O
driven	O
by	O
the	O
HCMV	O
MIEP	B-GGP
(	O
hMCMV	B-GGP
-	I-GGP
ES	I-GGP
)	O
with	O
the	O
two	O
AP	B-COM
-	I-COM
1	I-COM
binding	O
sites	O
mutated	O
is	O
not	O
compromised	O
in	O
virulence	O
,	O
is	O
able	O
to	O
grow	O
and	O
disseminate	O
to	O
different	O
organs	O
of	O
the	O
newborn	O
mice	O
as	O
efficiently	O
as	O
the	O
parental	O
virus	O
,	O
and	O
is	O
competent	O
in	O
reactivation	O
.	O

We	O
show	O
,	O
however	O
,	O
that	O
combined	O
inactivation	O
of	O
the	O
enhancer	O
AP	B-COM
-	I-COM
1	I-COM
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
recognition	O
sites	O
leads	O
to	O
an	O
attenuation	O
of	O
the	O
hMCMV	B-GGP
-	I-GGP
ES	I-GGP
in	O
the	O
neonatal	O
murine	O
infection	O
model	O
,	O
not	O
observed	O
when	O
each	O
single	O
element	O
is	O
abolished	O
.	O

Altogether	O
,	O
these	O
results	O
underline	O
the	O
functional	O
redundancy	O
of	O
the	O
MIEP	B-GGP
elements	O
,	O
highlighting	O
the	O
plasticity	O
of	O
this	O
region	O
,	O
which	O
probably	O
evolved	O
to	O
ensure	O
maximal	O
transcriptional	O
performance	O
across	O
many	O
diverse	O
environments	O
.	O

IL	B-COM
-	I-COM
17R	I-COM
activation	O
of	O
human	O
periodontal	O
ligament	O
fibroblasts	O
induces	O
IL	B-COM
-	I-COM
23	I-COM
p19	B-GGP
production	O
:	O
Differential	O
involvement	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
versus	O
JNK	B-GGP
/	O
AP	B-COM
-	I-COM
1	I-COM
pathways	O
.	O

Interleukin	B-COM
(	I-COM
IL	I-COM
)	I-COM
-	I-COM
23	I-COM
is	O
an	O
essential	O
cytokine	O
involved	O
in	O
the	O
expansion	O
of	O
a	O
novel	O
CD4	B-GGP
(	O
+	O
)	O
T	O
helper	O
subset	O
known	O
as	O
Th17	O
,	O
which	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
periodontitis	O
recently	O
.	O

This	O
study	O
hypothesised	O
that	O
Th17	O
signature	O
cytokine	O
IL	B-COM
-	I-COM
17	I-COM
may	O
target	O
specialised	O
human	O
periodontal	O
ligament	O
fibroblasts	O
(	O
hPDLFs	O
)	O
for	O
production	O
of	O
IL	B-COM
-	I-COM
23	I-COM
p19	B-GGP
,	O
a	O
key	O
subunit	O
of	O
IL	B-COM
-	I-COM
23	I-COM
.	O

Primary	O
hPDLFs	O
had	O
steady	O
expression	O
of	O
IL	B-COM
-	I-COM
17	I-COM
receptor	I-COM
(	O
IL	B-COM
-	I-COM
17R	I-COM
)	O
mRNA	O
and	O
surface	O
-	O
bound	O
protein	O
.	O

IL	B-COM
-	I-COM
17	I-COM
was	O
capable	O
of	O
stimulating	O
the	O
expression	O
of	O
IL	B-COM
-	I-COM
23	I-COM
p19	B-GGP
mRNA	O
and	O
protein	O
in	O
cultured	O
hPDLFs	O
,	O
which	O
was	O
attenuated	O
by	O
IL	B-COM
-	I-COM
17	I-COM
or	O
IL	B-COM
-	I-COM
17R	I-COM
neutralising	O
antibodies	O
.	O

In	O
accordance	O
with	O
the	O
enhanced	O
expression	O
of	O
IL	B-COM
-	I-COM
23	I-COM
p19	B-GGP
,	O
IL	B-COM
-	I-COM
17	I-COM
stimulation	O
resulted	O
in	O
rapid	O
activation	O
of	O
Akt	B-GGP
,	O
p38	B-GGP
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
(	O
MAPK	B-GGP
)	O
,	O
extracellular	B-GGP
signal	I-GGP
-	I-GGP
regulated	I-GGP
kinase	I-GGP
(	I-GGP
ERK	I-GGP
)	I-GGP
1	I-GGP
/	I-GGP
2	I-GGP
,	O
c	B-GGP
-	I-GGP
Jun	I-GGP
-	I-GGP
N	I-GGP
-	I-GGP
terminal	I-GGP
kinase	I-GGP
(	O
JNK	B-GGP
)	O
,	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
(	O
NF	B-COM
-	I-COM
kappaB	I-COM
)	O
,	O
and	O
activator	B-COM
protein	I-COM
-	I-COM
1	I-COM
(	O
AP	B-COM
-	I-COM
1	I-COM
)	O
in	O
hPDLFs	O
.	O

Inhibitors	O
of	O
Akt	B-GGP
,	O
p38	B-GGP
MAPK	I-GGP
,	O
ERK	B-GGP
1	I-GGP
/	I-GGP
2	I-GGP
,	O
or	O
NF	B-COM
-	I-COM
kappaB	I-COM
significantly	O
suppressed	O
,	O
whereas	O
blocking	O
JNK	B-GGP
and	O
AP	B-COM
-	I-COM
1	I-COM
substantially	O
augmented	O
IL	B-COM
-	I-COM
23	I-COM
p19	B-GGP
production	O
from	O
IL	B-COM
-	I-COM
17	I-COM
-	O
stimulated	O
hPDLFs	O
.	O

Moreover	O
,	O
IL	B-COM
-	I-COM
17	I-COM
-	O
initiated	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
was	O
blocked	O
by	O
Akt	B-GGP
,	O
p38	B-GGP
MAPK	I-GGP
,	O
or	O
ERK	B-GGP
1	I-GGP
/	I-GGP
2	I-GGP
inhibition	O
,	O
while	O
AP	B-COM
-	I-COM
1	I-COM
activity	O
was	O
specifically	O
abrogated	O
by	O
JNK	B-GGP
inhibition	O
.	O

Thus	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
hPDLFs	O
are	O
a	O
target	O
of	O
Th17	O
,	O
and	O
that	O
IL	B-COM
-	I-COM
17	I-COM
appears	O
to	O
up	O
-	O
regulate	O
the	O
expression	O
of	O
IL	B-COM
-	I-COM
23	I-COM
p19	B-GGP
via	O
a	O
homeostatic	O
mechanism	O
involving	O
Akt	B-GGP
-	O
,	O
p38	B-GGP
MAPK	I-GGP
-	O
,	O
and	O
ERK	B-GGP
1	I-GGP
/	I-GGP
2	I-GGP
-	O
dependent	O
NF	B-COM
-	I-COM
kappaB	I-COM
signalling	O
versus	O
the	O
JNK	B-GGP
/	O
AP	B-COM
-	I-COM
1	I-COM
pathway	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
disruption	O
of	O
the	O
interaction	O
between	O
IL	B-COM
-	I-COM
17	I-COM
and	O
IL	B-COM
-	I-COM
23	I-COM
may	O
be	O
a	O
potential	O
therapeutic	O
approach	O
in	O
the	O
treatment	O
of	O
periodontitis	O
.	O

Inhibition	O
of	O
proinflammatory	O
RANTES	B-GGP
expression	O
by	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
is	O
mediated	O
by	O
glycogen	B-GGP
synthase	I-GGP
kinase	I-GGP
-	I-GGP
3beta	I-GGP
-	O
dependent	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
signaling	O
.	O

TGF	B-GGP
-	I-GGP
beta1	I-GGP
is	O
a	O
pleiotropic	O
cytokine	O
with	O
potent	O
anti	O
-	O
inflammation	O
property	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
suppression	O
of	O
inflammation	O
remain	O
largely	O
unexplored	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
inhibited	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
-	O
or	O
IL	B-GGP
-	I-GGP
1	I-GGP
-	O
induced	O
RANTES	B-GGP
expression	O
in	O
human	O
kidney	O
tubular	O
epithelial	O
cells	O
(	O
HKC	O
-	O
8	O
)	O
.	O

To	O
delineate	O
the	O
mechanism	O
by	O
which	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
inhibits	O
RANTES	B-GGP
expression	O
,	O
we	O
examined	O
the	O
potential	O
signal	O
pathway	O
activated	O
by	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
in	O
suppressing	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
.	O

TGF	B-GGP
-	I-GGP
beta1	I-GGP
affected	O
neither	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
-	O
induced	O
IkappaBalpha	B-GGP
phosphorylation	O
and	O
subsequent	O
degradation	O
,	O
nor	O
p65	B-GGP
NF	B-COM
-	I-COM
kappaB	I-COM
phosphorylation	O
and	O
its	O
nuclear	B-CC
translocation	O
.	O

However	O
,	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
could	O
inhibit	O
p65	B-GGP
and	O
p50	B-GGP
binding	O
to	O
the	O
kappaB	B-COM
site	O
in	O
human	O
RANTES	B-GGP
promoter	O
as	O
revealed	O
by	O
chromatin	B-CC
immunoprecipitation	O
assay	O
and	O
protein	O
-	O
DNA	O
binding	O
assay	O
.	O

We	O
found	O
that	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
induced	O
glycogen	B-GGP
synthase	I-GGP
kinase	I-GGP
-	I-GGP
3beta	I-GGP
(	O
GSK	B-GGP
-	I-GGP
3beta	I-GGP
)	O
phosphorylation	O
on	O
Ser	B-MED
-	I-MED
9	I-MED
in	O
HKC	O
-	O
8	O
cells	O
,	O
leading	O
to	O
its	O
inactivation	O
.	O

Knockdown	O
of	O
GSK	B-GGP
-	I-GGP
3beta	I-GGP
mimicked	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
and	O
inhibited	O
RANTES	B-GGP
induction	O
,	O
whereas	O
overexpression	O
of	O
GSK	B-GGP
-	I-GGP
3beta	I-GGP
abolished	O
the	O
inhibitory	O
effect	O
of	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
and	O
completely	O
restored	O
RANTES	B-GGP
expression	O
.	O

Furthermore	O
,	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
induced	O
the	O
dephosphorylation	O
and	O
activation	O
of	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
,	O
a	O
major	O
downstream	O
target	O
of	O
GSK	B-GGP
-	I-GGP
3beta	I-GGP
.	O

Ectopic	O
expression	O
of	O
constitutively	O
active	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
mimicked	O
the	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
effect	O
and	O
completely	O
suppressed	O
RANTES	B-GGP
expression	O
induced	O
by	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
.	O

Interestingly	O
,	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
induced	O
a	O
physical	O
interaction	O
between	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
and	O
p65	B-GGP
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
which	O
prevented	O
p65	B-GGP
binding	O
to	O
the	O
kappaB	B-COM
site	O
,	O
sequestered	O
its	O
trans	O
-	O
activating	O
activity	O
,	O
and	O
repressed	O
p65	B-GGP
-	O
mediated	O
gene	O
transcription	O
.	O

We	O
conclude	O
that	O
TGF	B-GGP
-	I-GGP
beta1	I-GGP
inhibition	O
of	O
proinflammatory	O
RANTES	B-GGP
expression	O
is	O
mediated	O
by	O
beta	B-GGP
-	I-GGP
catenin	I-GGP
-	O
triggered	O
blockade	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
.	O

Nuclear	O
factor	O
p65	B-GGP
interacts	O
with	O
Keap1	B-GGP
to	O
repress	O
the	O
Nrf2	B-GGP
-	O
ARE	B-GGP
pathway	O
.	O

Keap1	B-GGP
is	O
an	O
inhibitor	O
of	O
Nrf2	B-GGP
involved	O
in	O
Nrf2	B-GGP
-	O
dependent	O
antioxidant	O
response	O
.	O

However	O
,	O
the	O
mechanisms	O
on	O
how	O
Keap1	B-GGP
regulates	O
Nrf2	B-GGP
-	O
ARE	B-GGP
signaling	O
pathway	O
remains	O
to	O
be	O
determined	O
.	O

Here	O
,	O
by	O
using	O
a	O
yeast	O
two	O
-	O
hybrid	O
technology	O
,	O
p65	B-GGP
subunit	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
transcription	O
factor	O
was	O
identified	O
as	O
a	O
partner	O
of	O
Keap1	B-GGP
.	O

We	O
show	O
that	O
Keap1	B-GGP
physically	O
associated	O
with	O
p65	B-GGP
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Overexpression	O
of	O
p65	B-GGP
inhibited	O
Nrf2	B-GGP
-	O
dependent	O
transcription	O
induced	O
by	O
diethylmaleate	B-MED
(	O
DEM	B-MED
)	O
or	O
tert	B-MED
-	I-MED
butyl	I-MED
hydroxyquinone	I-MED
(	O
tBHQ	B-MED
)	O
.	O

Knock	O
down	O
of	O
Keap1	B-GGP
by	O
RNA	O
interference	O
partially	O
blocked	O
the	O
repression	O
of	O
Nrf2	B-GGP
-	O
mediated	O
activation	O
by	O
p65	B-GGP
.	O

It	O
was	O
demonstrated	O
that	O
p65	B-GGP
decreased	O
Nrf2	B-GGP
binding	O
to	O
its	O
cognate	O
DNA	O
sequences	O
and	O
enhanced	O
Nrf2	B-GGP
ubiquitination	O
.	O

The	O
N	O
-	O
terminal	O
region	O
of	O
p65	B-GGP
is	O
necessary	O
for	O
both	O
the	O
interaction	O
with	O
Keap1	B-GGP
and	O
its	O
transcriptional	O
suppression	O
activity	O
.	O

Moreover	O
,	O
nuclear	B-CC
translocation	O
of	O
Keap1	B-GGP
was	O
augmented	O
by	O
p65	B-GGP
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
inhibits	O
Nrf2	B-GGP
-	O
ARE	B-GGP
pathway	O
through	O
the	O
interaction	O
of	O
p65	B-GGP
and	O
Keap1	B-GGP
.	O

Overexpression	O
of	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
in	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
:	O
a	O
potential	O
indicator	O
for	O
poor	O
prognosis	O
.	O

The	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
have	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
the	O
development	O
and	O
progression	O
of	O
human	O
cancers	O
.	O

However	O
,	O
the	O
functional	O
significance	O
of	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
in	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
and	O
the	O
correlation	O
between	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
remain	O
unclear	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
have	O
shown	O
that	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
were	O
significantly	O
overexpressed	O
in	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
tissues	O
and	O
precancerous	O
lesions	O
,	O
compared	O
with	O
adjacent	O
normal	O
tissues	O
(	O
both	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
overexpression	O
of	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
was	O
significantly	O
associated	O
with	O
histologic	O
differentiation	O
(	O
rs	O
=	O
0	O
.	O
321	O
,	O
P	O
=	O
.	O
002	O
)	O
,	O
T	O
stage	O
(	O
rs	O
=	O
0	O
.	O
276	O
,	O
P	O
=	O
.	O
009	O
)	O
,	O
lymph	O
node	O
metastasis	O
(	O
rs	O
=	O
0	O
.	O
266	O
,	O
P	O
=	O
.	O
012	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
rs	O
=	O
0	O
.	O
272	O
,	O
P	O
=	O
.	O
010	O
)	O
;	O
overexpression	O
of	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
was	O
significantly	O
associated	O
with	O
T	O
stage	O
(	O
rs	O
=	O
0	O
.	O
404	O
,	O
P	O
<	O
.	O
001	O
)	O
,	O
lymph	O
node	O
metastasis	O
(	O
rs	O
=	O
0	O
.	O
293	O
,	O
P	O
=	O
.	O
005	O
)	O
,	O
and	O
clinical	O
stage	O
(	O
rs	O
=	O
0	O
.	O
425	O
,	O
P	O
<	O
.	O
001	O
)	O
.	O

Overexpressions	O
of	O
both	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
were	O
associated	O
with	O
worse	O
overall	O
survival	O
(	O
P	O
=	O
.	O
041	O
and	O
P	O
<	O
.	O
001	O
,	O
respectively	O
)	O
.	O

Multivariate	O
Cox	O
regression	O
analysis	O
showed	O
that	O
T	O
stage	O
,	O
lymph	O
node	O
metastasis	O
,	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
were	O
independent	O
prognostic	O
factors	O
for	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
(	O
P	O
=	O
.	O
038	O
,	O
P	O
=	O
.	O
014	O
,	O
and	O
P	O
=	O
.	O
005	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
a	O
significant	O
correlation	O
was	O
observed	O
between	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
(	O
rs	O
=	O
0	O
.	O
683	O
,	O
P	O
<	O
.	O
001	O
)	O
,	O
indicating	O
the	O
potential	O
direct	O
or	O
indirect	O
interaction	O
between	O
them	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
overexpressions	O
of	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
and	O
the	O
possible	O
interaction	O
between	O
them	O
may	O
play	O
important	O
roles	O
in	O
the	O
development	O
and	O
progression	O
of	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
,	O
and	O
Forkhead	B-GGP
Box	I-GGP
M1	I-GGP
transcription	O
factor	O
and	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
may	O
serve	O
as	O
useful	O
prognostic	O
markers	O
for	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
.	O

C	B-GGP
/	I-GGP
EBPalpha	I-GGP
and	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
oncoproteins	O
regulate	O
nfkb1	B-GGP
and	O
displace	O
histone	B-GGP
deacetylases	I-GGP
from	O
NF	B-COM
-	I-COM
kappaB	I-COM
p50	B-COM
homodimers	I-COM
to	O
induce	O
NF	B-COM
-	I-COM
kappaB	I-COM
target	O
genes	O
.	O

Mutated	O
CEBPA	B-GGP
defines	O
a	O
subgroup	O
of	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

We	O
have	O
previously	O
shown	O
that	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
or	O
its	O
AML	O
mutants	O
synergize	O
with	O
NF	B-COM
-	I-COM
kappaB	I-COM
p50	B-GGP
to	O
activate	O
antiapoptotic	O
genes	O
,	O
including	O
BCL2	B-GGP
and	O
FLIP	B-GGP
.	O

Furthermore	O
,	O
p50	B-GGP
binds	O
and	O
activates	O
the	O
CEBPA	B-GGP
gene	O
in	O
myeloid	O
cells	O
.	O

We	O
now	O
report	O
that	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
or	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
leucine	B-MED
zipper	O
AML	O
mutants	O
bind	O
in	O
vivo	O
to	O
the	O
nfkb1	B-GGP
(	O
p50	B-GGP
)	O
promoter	O
and	O
induce	O
its	O
expression	O
even	O
in	O
the	O
presence	O
of	O
cycloheximide	B-MED
.	O

Induction	O
of	O
p50	B-GGP
by	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
depends	O
on	O
2	O
conserved	O
kappaB	B-COM
sites	O
in	O
the	O
nfkb1	B-GGP
promoter	O
.	O

C	B-GGP
/	I-GGP
EBPalpha	I-GGP
did	O
not	O
induce	O
p65	B-GGP
expression	O
.	O

Thus	O
,	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
and	O
p50	B-GGP
reciprocally	O
regulate	O
each	O
other	O
'	O
s	O
expression	O
,	O
establishing	O
a	O
positive	O
feedback	O
relationship	O
.	O

Although	O
p50	B-COM
homodimers	I-COM
inhibit	O
transcription	O
,	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
and	O
p50	B-GGP
synergistically	O
activate	O
antiapoptotic	O
genes	O
.	O

ChIP	O
analysis	O
showed	O
that	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
diminishes	O
the	O
occupation	O
of	O
histone	B-GGP
deacetylase	I-GGP
1	I-GGP
(	O
HDAC1	B-GGP
)	O
or	O
HDAC3	B-GGP
on	O
the	O
endogenous	O
FLIP	B-GGP
promoter	O
but	O
not	O
in	O
mice	O
lacking	O
p50	B-GGP
.	O

Coimmunoprecipitation	O
confirmed	O
that	O
C	B-GGP
/	I-GGP
EBPalpha	I-GGP
,	O
its	O
AML	O
variants	O
,	O
or	O
C	B-GGP
/	I-GGP
EBPbeta	I-GGP
disrupt	O
interaction	O
between	O
p50	B-GGP
and	O
HDACs	B-GGP
dependent	O
on	O
the	O
C	B-GGP
/	I-GGP
EBP	I-GGP
basic	O
region	O
.	O

These	O
findings	O
suggest	O
that	O
C	B-GGP
/	I-GGP
EBPs	I-GGP
displace	O
HDACs	B-GGP
from	O
p50	B-COM
homodimers	I-COM
bound	O
to	O
antiapoptotic	O
genes	O
,	O
contributing	O
to	O
NF	B-COM
-	I-COM
kappaB	I-COM
dysregulation	O
in	O
leukemia	O
,	O
and	O
that	O
the	O
C	B-COM
/	I-COM
EBPalpha	I-COM
:	I-COM
p50	I-COM
complex	O
is	O
a	O
potential	O
therapeutic	O
target	O
.	O

Optineurin	B-GGP
is	O
required	O
for	O
CYLD	B-GGP
-	O
dependent	O
inhibition	O
of	O
TNFalpha	B-GGP
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

The	O
nuclear	B-COM
factor	I-COM
kappa	I-COM
B	I-COM
(	O
NF	B-COM
-	I-COM
kappaB	I-COM
)	O
regulates	O
genes	O
that	O
function	O
in	O
diverse	O
cellular	O
processes	O
like	O
inflammation	O
,	O
immunity	O
and	O
cell	O
survival	O
.	O

The	O
activation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
is	O
tightly	O
controlled	O
and	O
the	O
deubiquitinase	O
CYLD	B-GGP
has	O
emerged	O
as	O
a	O
key	O
negative	O
regulator	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
signalling	O
.	O

Optineurin	B-GGP
,	O
mutated	O
in	O
certain	O
glaucomas	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
is	O
also	O
a	O
negative	O
regulator	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

It	O
competes	O
with	O
NEMO	B-GGP
(	O
NF	B-GGP
-	I-GGP
kappaB	I-GGP
essential	I-GGP
modulator	I-GGP
)	O
for	O
binding	O
to	O
ubiquitinated	O
RIP	B-GGP
(	O
receptor	B-GGP
interacting	I-GGP
protein	I-GGP
)	O
to	O
prevent	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

Recently	O
we	O
identified	O
CYLD	B-GGP
as	O
optineurin	B-GGP
-	O
interacting	O
protein	O
.	O

Here	O
we	O
have	O
analysed	O
the	O
functional	O
significance	O
of	O
interaction	O
of	O
optineurin	B-GGP
with	O
CYLD	B-GGP
.	O

Our	O
results	O
show	O
that	O
a	O
glaucoma	O
-	O
associated	O
mutant	O
of	O
optineurin	B-GGP
,	O
H486R	B-GGP
,	O
is	O
altered	O
in	O
its	O
interaction	O
with	O
CYLD	B-GGP
.	O

Unlike	O
wild	O
-	O
type	O
optineurin	B-GGP
,	O
the	O
H486R	B-GGP
mutant	O
did	O
not	O
inhibit	O
tumour	B-GGP
necrosis	I-GGP
factor	I-GGP
alpha	I-GGP
(	O
TNFalpha	B-GGP
)	O
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

CYLD	B-GGP
mediated	O
inhibition	O
of	O
TNFalpha	B-GGP
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
was	O
abrogated	O
by	O
expression	O
of	O
the	O
H486R	B-GGP
mutant	O
.	O

Upon	O
knockdown	O
of	O
optineurin	B-GGP
,	O
CYLD	B-GGP
was	O
unable	O
to	O
inhibit	O
TNFalpha	B-GGP
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
and	O
showed	O
drastically	O
reduced	O
interaction	O
with	O
ubiquitinated	O
RIP	B-GGP
.	O

The	O
level	O
of	O
ubiquitinated	O
RIP	B-GGP
was	O
increased	O
in	O
optineurin	B-GGP
knockdown	O
cells	O
.	O

Deubiquitination	O
of	O
RIP	B-GGP
by	O
over	O
-	O
expressed	O
CYLD	B-GGP
was	O
abrogated	O
in	O
optineurin	B-GGP
knockdown	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
optineurin	B-GGP
regulates	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
by	O
mediating	O
interaction	O
of	O
CYLD	B-GGP
with	O
ubiquitinated	O
RIP	B-GGP
thus	O
facilitating	O
deubiquitination	O
of	O
RIP	B-GGP
.	O

Identification	O
of	O
CD44	B-GGP
as	O
a	O
downstream	O
target	O
of	O
noncanonical	O
NF	B-COM
-	I-COM
kappaB	I-COM
pathway	O
activated	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
-	O
encoded	O
Tax	B-GGP
protein	O
.	O

Our	O
previous	O
study	O
showed	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B-GGP
induces	O
osteopontin	B-GGP
(	O
OPN	B-GGP
)	O
expression	O
by	O
transactivating	O
its	O
promoter	O
.	O

As	O
an	O
extension	O
,	O
we	O
investigated	O
here	O
the	O
possible	O
influence	O
of	O
Tax	B-GGP
on	O
CD44	B-GGP
,	O
an	O
important	O
receptor	O
for	O
OPN	B-GGP
.	O

Co	O
-	O
expression	O
of	O
Tax	B-GGP
,	O
but	O
not	O
its	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
defective	O
mutant	O
,	O
significantly	O
increased	O
the	O
reporter	O
gene	O
expression	O
directed	O
by	O
CD44	B-GGP
promoter	O
.	O

Tax	B-GGP
-	O
mediated	O
CD44	B-GGP
activation	O
was	O
largely	O
diminished	O
by	O
disrupting	O
an	O
element	O
similar	O
to	O
the	O
noncanonical	O
kappabeta	O
site	O
found	O
in	O
other	O
IKKalpha	B-GGP
target	O
genes	O
,	O
and	O
further	O
,	O
co	O
-	O
transfection	O
of	O
RelB	B-GGP
siRNA	O
abolished	O
CD44	B-GGP
induction	O
by	O
Tax	B-GGP
,	O
suggesting	O
an	O
involvement	O
of	O
noncanonical	O
NF	B-COM
-	I-COM
kappaB	I-COM
pathway	O
in	O
Tax	B-GGP
-	O
mediated	O
transactivation	O
.	O

Consistently	O
,	O
chromatin	B-CC
immunoprecipitation	O
revealed	O
a	O
specific	O
interaction	O
of	O
CD44	B-GGP
promoter	O
with	O
RelB	B-GGP
-	O
containing	O
complex	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
D44	B-GGP
gene	O
is	O
one	O
of	O
the	O
downstream	O
target	O
genes	O
of	O
aberrantly	O
activated	O
noncanonical	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
by	O
Tax	B-GGP
,	O
providing	O
an	O
additional	O
line	O
of	O
evidence	O
explaining	O
how	O
Tax	B-GGP
-	O
induced	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
is	O
integrated	O
into	O
a	O
fate	O
-	O
determining	O
cellular	O
program	O
.	O

Purification	O
of	O
SUMO	B-GGP
-	I-GGP
1	I-GGP
modified	O
IkappaBalpha	B-GGP
and	O
complex	O
formation	O
with	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

Covalent	O
modification	O
of	O
proteins	O
with	O
SUMO	B-GGP
(	O
Small	B-GGP
Ubiquitin	I-GGP
-	I-GGP
like	I-GGP
MOdifier	I-GGP
)	O
affects	O
many	O
cellular	O
processes	O
,	O
including	O
transcriptional	O
regulation	O
,	O
DNA	O
repair	O
and	O
signal	O
transduction	O
.	O

Although	O
hundreds	O
of	O
SUMO	B-GGP
targets	O
have	O
been	O
identified	O
,	O
many	O
biological	O
outcomes	O
of	O
protein	O
sumoylation	O
remain	O
poorly	O
understood	O
.	O

In	O
particular	O
,	O
biochemical	O
and	O
structural	O
analysis	O
can	O
only	O
be	O
easily	O
conducted	O
if	O
highly	O
pure	O
sumoylated	O
substrates	O
are	O
available	O
.	O

Purification	O
of	O
sumoylated	O
substrates	O
in	O
vitro	O
or	O
in	O
bacteria	O
have	O
been	O
previously	O
reported	O
but	O
separating	O
the	O
sumoylated	O
protein	O
from	O
the	O
undesired	O
unmodified	O
fraction	O
is	O
often	O
technically	O
challenging	O
,	O
inefficient	O
and	O
time	O
consuming	O
.	O

Here	O
we	O
develop	O
a	O
new	O
vector	O
system	O
for	O
in	O
vivo	O
sumoylation	O
in	O
Escherichia	O
coli	O
which	O
improves	O
purification	O
of	O
sumoylated	O
proteins	O
.	O

We	O
describe	O
the	O
purification	O
of	O
IkappaBalpha	B-GGP
,	O
its	O
sumoylation	O
,	O
the	O
subsequent	O
separation	O
and	O
purification	O
of	O
the	O
modified	O
and	O
the	O
unmodified	O
forms	O
and	O
the	O
purification	O
of	O
the	O
complex	O
IkappaBalpha	B-COM
-	I-COM
SUMO	I-COM
-	I-COM
1	I-COM
/	I-COM
NF	I-COM
-	I-COM
kappaB	I-COM
.	O

After	O
a	O
first	O
GST	B-GGP
affinity	O
chromatography	O
and	O
GST	B-GGP
-	O
tag	O
removal	O
,	O
a	O
unique	O
metal	O
-	O
ion	O
affinity	O
chromatography	O
using	O
a	O
6xHis	B-GGP
-	I-GGP
SUMO	I-GGP
-	I-GGP
1	I-GGP
tag	O
results	O
in	O
mgs	O
of	O
highly	O
pure	O
SUMO	B-GGP
-	I-GGP
1	I-GGP
modified	O
IkappaBalpha	B-GGP
.	O

Our	O
pure	O
SUMO	B-GGP
-	I-GGP
1	I-GGP
modified	O
IkappaB	B-COM
/	I-COM
NF	I-COM
-	I-COM
kappaB	I-COM
complex	O
could	O
be	O
a	O
useful	O
tool	O
to	O
identify	O
new	O
interaction	O
partner	O
specific	O
of	O
the	O
SUMO	B-GGP
-	I-GGP
1	I-GGP
modified	O
IkappaBalpha	B-GGP
form	O
.	O

This	O
approach	O
may	O
be	O
extended	O
to	O
other	O
SUMO	B-GGP
substrates	O
not	O
isolable	O
by	O
classical	O
chromatography	O
techniques	O
.	O

The	O
dual	O
function	O
cytokine	O
IL	B-GGP
-	I-GGP
33	I-GGP
interacts	O
with	O
the	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
to	O
dampen	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
stimulated	O
gene	O
transcription	O
.	O

Full	O
-	O
length	O
IL	B-GGP
-	I-GGP
33	I-GGP
is	O
a	O
member	O
of	O
the	O
IL	B-GGP
-	I-GGP
1	I-GGP
family	O
of	O
cytokines	O
,	O
which	O
can	O
act	O
in	O
an	O
autocrine	O
or	O
paracrine	O
manner	O
by	O
binding	O
to	O
the	O
IL	B-GGP
-	I-GGP
33R	I-GGP
on	O
several	O
different	O
target	O
cell	O
types	O
.	O

In	O
addition	O
,	O
IL	B-GGP
-	I-GGP
33	I-GGP
can	O
act	O
in	O
an	O
intracrine	O
fashion	O
by	O
translocating	O
to	O
the	O
nucleus	B-CC
,	O
where	O
it	O
binds	O
to	O
the	O
chromatin	B-CC
and	O
modulates	O
gene	O
expression	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
that	O
full	O
-	O
length	O
IL	B-GGP
-	I-GGP
33	I-GGP
,	O
but	O
not	O
mature	O
IL	B-GGP
-	I-GGP
33	I-GGP
,	O
interacts	O
with	O
the	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

This	O
interaction	O
occurs	O
between	O
the	O
N	O
-	O
terminal	O
part	O
of	O
IL	B-GGP
-	I-GGP
33	I-GGP
from	O
aa	B-MED
66	I-MED
-	O
109	B-MED
and	O
the	O
N	O
-	O
terminal	O
Rel	B-GGP
homology	O
domain	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
p65	B-GGP
.	O

Coimmunoprecipitation	O
experiments	O
in	O
cells	O
overexpressing	O
IL	B-GGP
-	I-GGP
33	I-GGP
or	O
endogenously	O
expressing	O
IL	B-GGP
-	I-GGP
33	I-GGP
revealed	O
rhIL	B-GGP
-	I-GGP
1beta	I-GGP
-	O
stimulated	O
association	O
between	O
IL	B-GGP
-	I-GGP
33	I-GGP
and	O
p65	B-GGP
,	O
whereas	O
binding	O
to	O
the	O
p50	B-GGP
subunit	O
was	O
constitutive	O
.	O

The	O
biological	O
consequence	O
of	O
IL	B-COM
-	I-COM
33	I-COM
/	I-COM
NF	I-COM
-	I-COM
kappaB	I-COM
complex	O
formation	O
was	O
reduction	O
in	O
NF	B-COM
-	I-COM
kappaB	I-COM
p65	B-GGP
binding	O
to	O
its	O
cognate	O
DNA	O
and	O
impairment	O
of	O
p65	B-GGP
-	O
triggered	O
transactivation	O
.	O

Overexpression	O
of	O
IL	B-GGP
-	I-GGP
33	I-GGP
resulted	O
in	O
a	O
reduction	O
and	O
delay	O
in	O
the	O
rhIL	B-GGP
-	I-GGP
1beta	I-GGP
-	O
stimulated	O
expression	O
of	O
endogenous	O
NF	B-COM
-	I-COM
kappaB	I-COM
target	O
genes	O
such	O
as	O
IkappaBalpha	B-GGP
,	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
,	O
and	O
C	B-GGP
-	I-GGP
REL	I-GGP
.	O

We	O
suggest	O
that	O
nuclear	B-CC
IL	B-GGP
-	I-GGP
33	I-GGP
sequesters	O
nuclear	B-CC
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
reduces	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
triggered	O
gene	O
expression	O
to	O
dampen	O
proinflammatory	O
signaling	O
.	O

Mapping	O
of	O
NRF	B-GGP
binding	O
motifs	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
p65	B-GGP
subunit	O
.	O

NF	B-GGP
-	I-GGP
kappaB	I-GGP
repressing	I-GGP
factor	I-GGP
(	O
NRF	B-GGP
)	O
is	O
a	O
nuclear	B-CC
transcription	O
factor	O
that	O
binds	O
to	O
a	O
specific	O
DNA	O
sequence	O
in	O
NF	B-COM
-	I-COM
kappaB	I-COM
target	O
promoters	O
.	O

Previous	O
reports	O
suggested	O
that	O
NRF	B-GGP
interferes	O
with	O
the	O
transcriptional	O
activity	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
binding	O
sites	O
through	O
a	O
direct	O
interaction	O
with	O
NF	B-COM
-	I-COM
kappaB	I-COM
subunits	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
map	O
specific	O
NRF	B-GGP
binding	O
domains	O
in	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
proteins	O
,	O
p65	B-GGP
and	O
p50	B-GGP
.	O

Our	O
data	O
demonstrate	O
that	O
NRF	B-GGP
is	O
able	O
to	O
interact	O
with	O
the	O
p65	B-GGP
subunit	O
and	O
inhibit	O
its	O
transcription	O
enhancing	O
activity	O
in	O
reporter	O
gene	O
experiments	O
.	O

Using	O
tandem	O
affinity	O
purifications	O
(	O
TAP	O
)	O
,	O
we	O
show	O
that	O
NRF	B-GGP
protein	O
significantly	O
binds	O
to	O
the	O
endogenous	O
p65	B-GGP
,	O
subunit	O
but	O
not	O
to	O
the	O
p50	B-GGP
subunit	O
.	O

The	O
selective	O
binding	O
activity	O
of	O
the	O
NRF	B-GGP
protein	O
is	O
consistently	O
mediated	O
by	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
NRF	B-GGP
(	O
Amino	B-MED
acids	I-MED
1	I-MED
-	O
380	B-MED
)	O
.	O

Moreover	O
,	O
the	O
Rel	B-GGP
homology	O
domain	O
(	O
RHD	O
)	O
of	O
p65	B-GGP
is	O
sufficient	O
for	O
binding	O
to	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
NRF	B-GGP
.	O

Using	O
detailed	O
peptide	O
mapping	O
studies	O
,	O
we	O
finally	O
identify	O
three	O
peptide	O
motifs	O
in	O
p65	B-GGP
RHD	O
showing	O
distinctive	O
binding	O
specificities	O
for	O
the	O
NRF	B-GGP
protein	O
.	O

According	O
to	O
the	O
predicted	O
structure	O
of	O
p65	B-GGP
,	O
all	O
three	O
peptide	O
motifs	O
align	O
within	O
an	O
exposed	O
region	O
of	O
p65	B-GGP
and	O
might	O
hint	O
at	O
promising	O
targets	O
for	O
inhibitors	O
.	O

A	O
novel	O
kinase	O
inhibitor	O
of	O
FADD	B-GGP
phosphorylation	O
chemosensitizes	O
through	O
the	O
inhibition	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
.	O

Fas	B-GGP
-	I-GGP
associated	I-GGP
protein	I-GGP
with	I-GGP
death	I-GGP
domain	I-GGP
(	O
FADD	B-GGP
)	O
is	O
a	O
cytosolic	B-CC
adapter	O
protein	O
essential	O
for	O
mediating	O
death	O
receptor	O
-	O
induced	O
apoptosis	O
.	O

It	O
has	O
also	O
been	O
implicated	O
in	O
a	O
number	O
of	O
nonapoptotic	O
activities	O
including	O
embryogenesis	O
,	O
cell	O
-	O
cycle	O
progression	O
,	O
cell	O
proliferation	O
,	O
and	O
tumorigenesis	O
.	O

Our	O
recent	O
studies	O
have	O
shown	O
that	O
high	O
levels	O
of	O
phosphorylated	O
FADD	B-GGP
(	O
p	O
-	O
FADD	B-GGP
)	O
in	O
tumor	O
cells	O
correlate	O
with	O
increased	O
activation	O
of	O
the	O
antiapoptotic	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
is	O
a	O
biomarker	O
for	O
aggressive	O
disease	O
and	O
poor	O
clinical	O
outcome	O
.	O

These	O
findings	O
suggest	O
that	O
inhibition	O
of	O
FADD	B-GGP
phosphorylation	O
is	O
a	O
viable	O
target	O
for	O
cancer	O
therapy	O
.	O

A	O
high	O
-	O
throughput	O
screen	O
using	O
a	O
cell	O
-	O
based	O
assay	O
for	O
monitoring	O
FADD	B-GGP
-	O
kinase	O
activity	O
identified	O
NSC	B-MED
47147	I-MED
as	O
a	O
small	O
molecule	O
inhibitor	O
of	O
FADD	B-GGP
phosphorylation	O
.	O

The	O
compound	O
was	O
evaluated	O
in	O
live	O
cells	O
and	O
mouse	O
tumors	O
for	O
its	O
efficacy	O
as	O
an	O
inhibitor	O
of	O
FADD	B-GGP
-	O
kinase	O
activity	O
through	O
the	O
inhibition	O
of	O
casein	B-GGP
kinase	I-GGP
1alpha	I-GGP
.	O

NSC	B-MED
47147	I-MED
was	O
shown	O
to	O
decrease	O
levels	O
of	O
p	O
-	O
FADD	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
activity	O
such	O
that	O
combination	O
therapy	O
leads	O
to	O
greater	O
induction	O
of	O
apoptosis	O
and	O
enhanced	O
tumor	O
control	O
than	O
either	O
agent	O
alone	O
.	O

The	O
studies	O
described	O
here	O
show	O
the	O
utility	O
of	O
bioluminescent	O
cell	O
-	O
based	O
assays	O
for	O
the	O
identification	O
of	O
active	O
compounds	O
and	O
the	O
validation	O
of	O
drug	O
-	O
target	O
interaction	O
in	O
a	O
living	O
subject	O
.	O

In	O
addition	O
,	O
the	O
presented	O
results	O
provide	O
proof	O
-	O
of	O
-	O
principle	O
studies	O
as	O
to	O
the	O
validity	O
of	O
targeting	O
FADD	B-GGP
-	O
kinase	O
activity	O
as	O
a	O
novel	O
cancer	O
therapy	O
strategy	O
.	O

Uncoupling	O
of	O
Pyrin	B-GGP
-	I-GGP
only	I-GGP
protein	I-GGP
2	I-GGP
(	O
POP2	B-GGP
)	O
-	O
mediated	O
dual	O
regulation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
the	O
inflammasome	O
.	O

Activation	O
of	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
inflammasome	O
-	O
directed	O
caspase	B-GGP
-	I-GGP
1	I-GGP
cleavage	O
of	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
are	O
key	O
processes	O
in	O
the	O
inflammatory	O
response	O
to	O
pathogen	O
or	O
host	O
-	O
derived	O
signals	O
.	O

Pyrin	B-GGP
-	I-GGP
only	I-GGP
proteins	I-GGP
(	O
POPs	B-GGP
)	O
are	O
restricted	O
to	O
Old	O
World	O
monkeys	O
,	O
apes	O
,	O
and	O
humans	O
and	O
have	O
previously	O
been	O
shown	O
to	O
impair	O
inflammasome	O
assembly	O
and	O
/	O
or	O
NF	B-COM
-	I-COM
kappaB	I-COM
p65	B-GGP
transcriptional	O
activity	O
in	O
transfected	O
epithelial	O
cells	O
.	O

However	O
,	O
the	O
biological	O
role	O
of	O
POP2	B-GGP
and	O
the	O
molecular	O
basis	O
for	O
its	O
observed	O
functions	O
are	O
not	O
well	O
understood	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
POP2	B-GGP
regulates	O
TNFalpha	B-GGP
and	O
IL	B-GGP
-	I-GGP
1beta	I-GGP
responses	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
and	O
in	O
stable	O
transfectants	O
of	O
mouse	O
J774A	O
.	O
1	O
macrophages	O
.	O

Deletion	O
analysis	O
of	O
POP2	B-GGP
revealed	O
that	O
the	O
first	O
alpha	O
-	O
helix	O
(	O
residues	O
1	O
-	O
19	O
)	O
is	O
necessary	O
and	O
sufficient	O
for	O
both	O
inflammasome	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitory	O
functions	O
.	O

Further	O
,	O
key	O
acidic	O
residues	O
Glu	B-MED
(	I-MED
6	I-MED
)	I-MED
,	O
Asp	B-MED
(	I-MED
8	I-MED
)	I-MED
,	O
and	O
Glu	B-MED
(	I-MED
16	I-MED
)	I-MED
,	O
believed	O
critical	O
for	O
Pyrin	B-GGP
/	O
Pyrin	B-GGP
domain	O
interaction	O
,	O
are	O
important	O
for	O
inflammasome	O
inhibition	O
.	O

Moreover	O
,	O
these	O
mutations	O
did	O
not	O
reduce	O
the	O
effect	O
of	O
POP2	B-GGP
upon	O
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
indicating	O
that	O
the	O
inflammasome	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitory	O
properties	O
of	O
POP2	B-GGP
can	O
be	O
uncoupled	O
mechanistically	O
.	O

Collectively	O
,	O
these	O
data	O
demonstrate	O
that	O
POP2	B-GGP
acts	O
as	O
a	O
regulator	O
of	O
inflammatory	O
signals	O
and	O
exerts	O
its	O
two	O
known	O
functions	O
through	O
distinct	O
modalities	O
employed	O
by	O
its	O
first	O
alpha	O
-	O
helix	O
.	O

The	O
kinase	O
GLK	B-GGP
controls	O
autoimmunity	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
by	O
activating	O
the	O
kinase	O
PKC	B-GGP
-	I-GGP
theta	I-GGP
in	O
T	O
cells	O
.	O

Protein	B-GGP
kinase	I-GGP
C	I-GGP
-	I-GGP
theta	I-GGP
(	O
PKC	B-GGP
-	I-GGP
theta	I-GGP
)	O
is	O
required	O
for	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
induced	O
by	O
signaling	O
via	O
the	O
T	B-COM
cell	I-COM
antigen	I-COM
receptor	I-COM
(	O
TCR	B-COM
)	O
;	O
however	O
,	O
the	O
direct	O
activator	O
of	O
PKC	B-GGP
-	I-GGP
theta	I-GGP
is	O
unknown	O
.	O

We	O
report	O
that	O
the	O
kinase	O
GLK	B-GGP
(	O
MAP4K3	B-GGP
)	O
directly	O
activated	O
PKC	B-GGP
-	I-GGP
theta	I-GGP
during	O
TCR	B-COM
signaling	O
.	O

TCR	B-COM
signaling	O
activated	O
GLK	B-GGP
by	O
inducing	O
its	O
direct	O
interaction	O
with	O
the	O
upstream	O
adaptor	O
SLP	B-GGP
-	I-GGP
76	I-GGP
.	O

GLK	B-GGP
-	O
deficient	O
mice	O
had	O
impaired	O
immune	O
responses	O
and	O
were	O
resistant	O
to	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Consistent	O
with	O
that	O
,	O
people	O
with	O
systemic	O
lupus	O
erythematosus	O
had	O
considerable	O
enhanced	O
GLK	B-GGP
expression	O
and	O
activation	O
of	O
PKC	B-GGP
-	I-GGP
theta	I-GGP
and	O
the	O
kinase	O
IKK	B-COM
in	O
T	O
cells	O
,	O
and	O
the	O
frequency	O
of	O
GLK	B-GGP
-	O
overexpressing	O
T	O
cells	O
was	O
directly	O
correlated	O
with	O
disease	O
severity	O
.	O

Thus	O
,	O
GLK	B-GGP
is	O
a	O
direct	O
activator	O
of	O
PKC	B-GGP
-	I-GGP
theta	I-GGP
,	O
and	O
activation	O
of	O
GLK	B-GGP
-	O
PKC	B-GGP
-	I-GGP
theta	I-GGP
-	O
IKK	B-COM
could	O
be	O
used	O
as	O
new	O
diagnostic	O
biomarkers	O
and	O
therapeutic	O
targets	O
for	O
systemic	O
lupus	O
erythematosus	O
.	O

PPARgamma	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
regulate	O
the	O
gene	O
promoter	O
activity	O
of	O
their	O
shared	O
repressor	O
,	O
TNIP1	B-GGP
.	O

Human	O
TNFAIP3	B-GGP
interacting	I-GGP
protein	I-GGP
1	I-GGP
(	O
TNIP1	B-GGP
)	O
has	O
diverse	O
functions	O
including	O
support	O
of	O
HIV	O
replication	O
through	O
its	O
interaction	O
with	O
viral	O
Nef	B-GGP
and	O
matrix	B-CC
proteins	O
,	O
reduction	O
of	O
TNFalpha	B-GGP
-	O
induced	O
signaling	O
through	O
its	O
interaction	O
with	O
NF	B-COM
-	I-COM
kappaB	I-COM
pathway	O
proteins	O
,	O
and	O
corepression	O
of	O
agonist	O
-	O
bound	O
retinoic	B-GGP
acid	I-GGP
receptors	I-GGP
and	O
peroxisome	B-GGP
proliferator	I-GGP
-	I-GGP
activated	I-GGP
receptors	I-GGP
(	O
PPAR	B-GGP
)	O
.	O

The	O
wide	O
tissue	O
distribution	O
of	O
TNIP1	B-GGP
provides	O
the	O
opportunity	O
to	O
influence	O
numerous	O
cellular	O
responses	O
in	O
these	O
roles	O
and	O
defining	O
control	O
of	O
TNIP1	B-GGP
expression	O
would	O
be	O
central	O
to	O
improved	O
understanding	O
of	O
its	O
impact	O
on	O
cell	O
function	O
.	O

We	O
cloned	O
6kb	O
of	O
the	O
human	O
TNIP1	B-GGP
promoter	O
and	O
performed	O
predictive	O
and	O
functional	O
analyses	O
to	O
identify	O
regulatory	O
elements	O
.	O

The	O
promoter	O
region	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
is	O
GC	O
-	O
rich	O
without	O
a	O
recognizable	O
TATA	O
box	O
.	O

In	O
contrast	O
to	O
this	O
proximal	O
~	O
500bp	O
region	O
,	O
6kb	O
of	O
the	O
promoter	O
increased	O
reporter	O
construct	O
constitutive	O
activity	O
over	O
five	O
-	O
fold	O
.	O

Throughout	O
the	O
6kb	O
length	O
,	O
in	O
silico	O
analysis	O
identified	O
several	O
potential	O
binding	O
sites	O
for	O
both	O
constitutive	O
and	O
inducible	O
transcription	O
factors	O
;	O
among	O
the	O
latter	O
were	O
candidate	O
NF	B-COM
-	I-COM
kappaB	I-COM
binding	O
sequences	O
and	O
peroxisome	O
proliferator	O
response	O
elements	O
(	O
PPREs	O
)	O
.	O

We	O
tested	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
PPAR	B-GGP
regulation	O
of	O
the	O
endogenous	O
TNIP1	B-GGP
gene	O
and	O
cloned	O
promoter	O
by	O
expression	O
studies	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
chromatin	B-CC
immunoprecipitations	O
.	O

We	O
validated	O
NF	B-COM
-	I-COM
kappaB	I-COM
sites	O
in	O
the	O
TNIP1	B-GGP
promoter	O
proximal	O
and	O
distal	O
regions	O
as	O
well	O
as	O
one	O
PPRE	O
in	O
the	O
distal	O
region	O
.	O

The	O
ultimate	O
control	O
of	O
the	O
TNIP1	B-GGP
promoter	O
is	O
likely	O
to	O
be	O
a	O
combination	O
of	O
constitutive	O
transcription	O
factors	O
and	O
those	O
subject	O
to	O
activation	O
such	O
as	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
PPAR	B-GGP
.	O

AML1	B-GGP
/	O
RUNX1	B-GGP
functions	O
as	O
a	O
cytoplasmic	B-CC
attenuator	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
in	O
the	O
repression	O
of	O
myeloid	O
tumors	O
.	O

Functional	O
deregulation	O
of	O
transcription	O
factors	O
has	O
been	O
found	O
in	O
many	O
types	O
of	O
tumors	O
.	O

Transcription	O
factor	O
AML1	B-GGP
/	O
RUNX1	B-GGP
is	O
one	O
of	O
the	O
most	O
frequent	O
targets	O
of	O
chromosomal	B-CC
abnormalities	O
in	O
human	O
leukemia	O
and	O
altered	O
function	O
of	O
AML1	B-GGP
is	O
closely	O
associated	O
with	O
malignant	O
transformation	O
of	O
hematopoietic	O
cells	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
and	O
therapeutic	O
targets	O
of	O
AML1	B-GGP
-	O
related	O
leukemia	O
are	O
still	O
elusive	O
.	O

Here	O
,	O
we	O
explored	O
immediate	O
target	O
pathways	O
of	O
AML1	B-GGP
by	O
in	O
vitro	O
synchronous	O
inactivation	O
in	O
hematopoietic	O
cells	O
.	O

We	O
found	O
that	O
AML1	B-GGP
inhibits	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
through	O
interaction	O
with	O
IkappaB	B-COM
kinase	I-COM
complex	O
in	O
the	O
cytoplasm	B-CC
.	O

Remarkably	O
,	O
AML1	B-GGP
mutants	O
found	O
in	O
myeloid	O
tumors	O
lack	O
the	O
ability	O
to	O
inhibit	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
,	O
and	O
human	O
cases	O
with	O
AML1	B-GGP
-	O
related	O
leukemia	O
exhibits	O
distinctly	O
activated	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
in	O
leukemic	O
cells	O
with	O
mutated	O
AML1	B-GGP
efficiently	O
blocks	O
their	O
growth	O
and	O
development	O
of	O
leukemia	O
.	O

These	O
findings	O
reveal	O
a	O
novel	O
role	O
for	O
AML1	B-GGP
as	O
a	O
cytoplasmic	B-CC
attenuator	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
and	O
indicate	O
that	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
is	O
one	O
of	O
the	O
promising	O
therapeutic	O
targets	O
of	O
hematologic	O
malignancies	O
with	O
AML1	B-GGP
abnormality	O
.	O

Formation	O
of	O
ternary	O
complex	O
of	O
human	O
biliverdin	B-GGP
reductase	I-GGP
-	O
protein	B-GGP
kinase	I-GGP
Cdelta	I-GGP
-	O
ERK2	B-GGP
protein	O
is	O
essential	O
for	O
ERK2	B-GGP
-	O
mediated	O
activation	O
of	O
Elk1	B-GGP
protein	O
,	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
,	O
and	O
inducible	O
nitric	B-GGP
-	I-GGP
oxidase	I-GGP
synthase	I-GGP
(	O
iNOS	B-GGP
)	O
.	O

Growth	O
factors	O
,	O
insulin	B-GGP
,	O
oxidative	O
stress	O
,	O
and	O
cytokines	O
activate	O
ERK1	B-GGP
/	I-GGP
2	I-GGP
by	O
PKCdelta	B-GGP
and	O
MEK1	B-GGP
/	I-GGP
2	I-GGP
.	O

Human	O
biliverdin	B-GGP
reductase	I-GGP
(	O
hBVR	B-GGP
)	O
,	O
a	O
Ser	B-MED
/	O
Thr	B-MED
/	O
Tyr	B-MED
kinase	O
and	O
intracellular	B-CC
scaffold	O
/	O
bridge	O
/	O
anchor	O
,	O
is	O
a	O
nuclear	B-CC
transporter	O
of	O
MEK1	B-GGP
/	I-GGP
2	I-GGP
-	O
stimulated	O
ERK1	B-GGP
/	I-GGP
2	I-GGP
(	O
Lerner	O
-	O
Marmarosh	O
,	O
N	O
.	O
,	O
Miralem	O
,	O
T	O
.	O
,	O
Gibbs	O
,	O
P	O
.	O
E	O
.	O
,	O
and	O
Maines	O
,	O
M	O
.	O
D	O
.	O
(	O
2008	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
105	O
,	O
6870	O
-	O
6875	O
)	O
.	O

hBVR	B-GGP
,	O
PKCdelta	B-GGP
,	O
and	O
MEK1	B-GGP
/	I-GGP
2	I-GGP
overlap	O
in	O
their	O
tissue	O
expression	O
profile	O
and	O
type	O
of	O
activators	O
.	O

Presently	O
,	O
we	O
report	O
on	O
formation	O
of	O
an	O
hBVR	B-COM
-	I-COM
PKCdelta	I-COM
-	I-COM
ERK2	I-COM
ternary	O
complex	O
that	O
is	O
essential	O
for	O
ERK2	B-GGP
signal	O
transduction	O
and	O
activation	O
of	O
genes	O
linked	O
to	O
cell	O
proliferation	O
and	O
cancer	O
.	O

MEK1	B-GGP
/	I-GGP
2	I-GGP
and	O
the	O
protein	O
phosphatase	O
PP2A	B-GGP
were	O
also	O
present	O
in	O
the	O
complex	O
.	O

When	O
cells	O
were	O
stimulated	O
with	O
insulin	B-GGP
-	I-GGP
like	I-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
1	I-GGP
(	O
IGF	B-GGP
-	I-GGP
1	I-GGP
)	O
,	O
an	O
increased	O
interaction	O
between	O
hBVR	B-GGP
and	O
PKCdelta	B-GGP
was	O
detected	O
by	O
FRET	O
-	O
fluorescence	O
lifetime	O
imaging	O
microscopy	O
.	O

hBVR	B-GGP
and	O
ERK2	B-GGP
were	O
phosphorylated	O
by	O
PKCdelta	B-GGP
;	O
however	O
,	O
the	O
PKC	B-GGP
was	O
not	O
a	O
substrate	O
for	O
either	O
ERK2	B-GGP
or	O
hBVR	B-GGP
.	O

IGF	B-GGP
-	I-GGP
1	I-GGP
and	O
phorbol	B-MED
ester	I-MED
increased	O
hBVR	B-GGP
/	O
PKCdelta	B-GGP
binding	O
;	O
hBVR	B-GGP
was	O
required	O
for	O
the	O
activation	O
of	O
PKCdelta	B-GGP
and	O
its	O
interaction	O
with	O
ERK2	B-GGP
.	O

The	O
C	O
-	O
terminal	O
phenylalanine	O
residues	O
of	O
PKCdelta	B-GGP
(	O
Phe	B-MED
(	I-MED
660	I-MED
)	I-MED
,	O
Phe	B-MED
(	I-MED
663	I-MED
)	I-MED
,	O
and	O
Phe	B-MED
(	I-MED
665	I-MED
)	I-MED
)	O
were	O
necessary	O
for	O
binding	O
to	O
ERK2	B-GGP
but	O
not	O
for	O
hBVR	B-GGP
binding	O
.	O

Formation	O
of	O
the	O
hBVR	B-COM
-	I-COM
PKCdelta	I-COM
-	I-COM
ERK2	I-COM
complex	O
required	O
the	O
hBVR	B-GGP
docking	O
site	O
for	O
ERK	B-GGP
,	O
FXFP	O
(	O
DEF	O
,	O
C	O
-	O
box	O
)	O
and	O
D	O
(	O
delta	O
)	O
-	O
box	O
(	O
ILXXLXL	O
)	O
motifs	O
.	O

The	O
hBVR	B-GGP
-	O
based	O
peptide	O
KKRILHCLGLA	O
inhibited	O
PKC	B-GGP
activation	O
and	O
PKCdelta	B-GGP
/	O
ERK2	B-GGP
interaction	O
.	O

Phorbol	B-MED
ester	I-MED
-	O
and	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
-	O
dependent	O
activation	O
of	O
the	O
ERK	B-GGP
-	O
regulated	O
transcription	O
factors	O
Elk1	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
and	O
expression	O
of	O
the	O
iNOS	B-GGP
gene	O
were	O
suppressed	O
by	O
hBVR	B-GGP
siRNA	O
;	O
those	O
activities	O
were	O
rescued	O
by	O
hBVR	B-GGP
.	O

The	O
findings	O
reveal	O
the	O
direct	O
input	O
of	O
hBVR	B-GGP
in	O
PKCdelta	B-GGP
/	O
ERK	B-GGP
signaling	O
and	O
identify	O
hBVR	B-GGP
-	O
based	O
peptide	O
regulators	O
of	O
ERK	B-GGP
-	O
mediated	O
gene	O
activation	O
.	O

The	O
p65	B-GGP
subunit	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibits	O
COL1A1	B-GGP
gene	O
transcription	O
in	O
human	O
dermal	O
and	O
scleroderma	O
fibroblasts	O
through	O
its	O
recruitment	O
on	O
promoter	O
by	O
protein	O
interaction	O
with	O
transcriptional	O
activators	O
(	O
c	B-GGP
-	I-GGP
Krox	I-GGP
,	O
Sp1	B-GGP
,	O
and	O
Sp3	B-GGP
)	O
.	O

Transcriptional	O
mechanisms	O
regulating	O
type	B-GGP
I	I-GGP
collagen	I-GGP
genes	O
expression	O
in	O
physiopathological	O
situations	O
are	O
not	O
completely	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
nuclear	B-COM
factor	I-COM
-	I-COM
kappaB	I-COM
(	O
NF	B-COM
-	I-COM
kappaB	I-COM
)	O
transcription	O
factor	O
on	O
type	B-GGP
I	I-GGP
collagen	I-GGP
expression	O
in	O
adult	O
normal	O
human	O
(	O
ANF	O
)	O
and	O
scleroderma	O
(	O
SF	O
)	O
fibroblasts	O
.	O

We	O
demonstrated	O
that	O
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
a	O
master	O
transcription	O
factor	O
playing	O
a	O
major	O
role	O
in	O
immune	O
response	O
/	O
apoptosis	O
,	O
down	O
-	O
regulates	O
COL1A1	B-GGP
expression	O
by	O
a	O
transcriptional	O
control	O
involving	O
the	O
-	O
112	O
/	O
-	O
61	O
bp	O
sequence	O
.	O

This	O
51	O
-	O
bp	O
region	O
mediates	O
the	O
action	O
of	O
two	O
zinc	B-MED
fingers	O
,	O
Sp1	B-GGP
(	O
specific	B-GGP
protein	I-GGP
-	I-GGP
1	I-GGP
)	O
and	O
Sp3	B-GGP
,	O
acting	O
as	O
trans	O
-	O
activators	O
of	O
type	B-GGP
I	I-GGP
collagen	I-GGP
expression	O
in	O
ANF	O
and	O
SF	O
.	O

Knockdown	O
of	O
each	O
one	O
of	O
these	O
trans	O
factors	O
by	O
siRNA	O
confirmed	O
the	O
trans	O
-	O
activating	O
effect	O
of	O
Sp1	B-GGP
/	O
Sp3	B-GGP
and	O
the	O
p65	B-GGP
subunit	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
trans	O
-	O
inhibiting	O
effect	O
on	O
COL1A1	B-GGP
expression	O
.	O

Despite	O
no	O
existing	O
kappaB	B-COM
consensus	O
sequence	O
in	O
the	O
COL1A1	B-GGP
promoter	O
,	O
we	O
found	O
that	O
Sp1	B-GGP
/	O
Sp3	B-GGP
/	O
c	B-GGP
-	I-GGP
Krox	I-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
bind	O
and	O
/	O
or	O
are	O
recruited	O
on	O
the	O
proximal	O
promoter	O
in	O
chromatin	B-CC
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
.	O

Attempts	O
to	O
elucidate	O
whether	O
interactions	O
between	O
Sp1	B-GGP
/	O
Sp3	B-GGP
/	O
c	B-GGP
-	I-GGP
Krox	I-GGP
and	O
p65	B-GGP
are	O
necessary	O
to	O
mediate	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitory	O
effect	O
on	O
COL1A1	B-GGP
in	O
ANF	O
and	O
SF	O
were	O
carried	O
out	O
;	O
in	O
this	O
regard	O
,	O
immunoprecipitation	O
assays	O
revealed	O
that	O
they	O
interact	O
,	O
and	O
this	O
was	O
validated	O
by	O
re	O
-	O
ChIP	O
.	O

Finally	O
,	O
the	O
knockdown	O
of	O
Sp1	B-GGP
/	O
Sp3	B-GGP
/	O
c	B-GGP
-	I-GGP
Krox	I-GGP
prevents	O
the	O
p65	B-GGP
inhibitory	O
effect	O
on	O
COL1A1	B-GGP
transcription	O
in	O
ANF	O
,	O
whereas	O
only	O
the	O
siRNAs	O
targeting	O
Sp3	B-GGP
and	O
c	B-GGP
-	I-GGP
Krox	I-GGP
provoked	O
the	O
same	O
effect	O
in	O
SF	O
,	O
suggesting	O
that	O
particular	O
interactions	O
are	O
characteristic	O
of	O
the	O
scleroderma	O
phenotype	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
highlight	O
a	O
new	O
mechanism	O
for	O
COL1A1	B-GGP
transcriptional	O
regulation	O
by	O
NF	B-COM
-	I-COM
kappaB	I-COM
,	O
and	O
these	O
data	O
could	O
allow	O
the	O
development	O
of	O
new	O
antifibrotic	O
strategies	O
.	O

The	O
enteropathogenic	O
E	O
.	O
coli	O
(	O
EPEC	O
)	O
Tir	B-GGP
effector	O
inhibits	O
NF	B-COM
-	I-COM
kappaB	I-COM
activity	O
by	O
targeting	O
TNFalpha	B-GGP
receptor	I-GGP
-	I-GGP
associated	I-GGP
factors	I-GGP
.	O

Enteropathogenic	O
Escherichia	O
coli	O
(	O
EPEC	O
)	O
disease	O
depends	O
on	O
the	O
transfer	O
of	O
effector	O
proteins	O
into	O
epithelia	O
lining	O
the	O
human	O
small	O
intestine	O
.	O

EPEC	O
E2348	O
/	O
69	O
has	O
at	O
least	O
20	O
effector	O
genes	O
of	O
which	O
six	O
are	O
located	O
with	O
the	O
effector	O
-	O
delivery	O
system	O
genes	O
on	O
the	O
Locus	O
of	O
Enterocyte	O
Effacement	O
(	O
LEE	O
)	O
Pathogenicity	O
Island	O
.	O

Our	O
previous	O
work	O
implied	O
that	O
non	O
-	O
LEE	O
-	O
encoded	O
(	O
Nle	O
)	O
effectors	O
possess	O
functions	O
that	O
inhibit	O
epithelial	O
anti	O
-	O
microbial	O
and	O
inflammation	O
-	O
inducing	O
responses	O
by	O
blocking	O
NF	B-COM
-	I-COM
kappaB	I-COM
transcription	O
factor	O
activity	O
.	O

Indeed	O
,	O
screens	O
by	O
us	O
and	O
others	O
have	O
identified	O
novel	O
inhibitory	O
mechanisms	O
for	O
NleC	B-GGP
and	O
NleH	B-GGP
,	O
with	O
key	O
co	O
-	O
operative	O
functions	O
for	O
NleB1	B-GGP
and	O
NleE1	B-GGP
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
LEE	O
-	O
encoded	O
Translocated	B-GGP
-	I-GGP
intimin	I-GGP
receptor	I-GGP
(	O
Tir	B-GGP
)	O
effector	O
has	O
a	O
potent	O
and	O
specific	O
ability	O
to	O
inhibit	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
.	O

Indeed	O
,	O
biochemical	O
,	O
imaging	O
and	O
immunoprecipitation	O
studies	O
reveal	O
a	O
novel	O
inhibitory	O
mechanism	O
whereby	O
Tir	B-GGP
interaction	O
with	O
cytoplasm	O
-	O
located	O
TNFalpha	B-GGP
receptor	I-GGP
-	I-GGP
associated	I-GGP
factor	I-GGP
(	O
TRAF	B-GGP
)	O
adaptor	O
proteins	O
induces	O
their	O
proteasomal	B-CC
-	O
independent	O
degradation	O
.	O

Infection	O
studies	O
support	O
this	O
Tir	B-GGP
-	O
TRAF	B-GGP
relationship	O
but	O
reveal	O
that	O
Tir	B-GGP
,	O
like	O
NleC	B-GGP
and	O
NleH	B-GGP
,	O
has	O
a	O
non	O
-	O
essential	O
contribution	O
in	O
EPEC	O
'	O
s	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitory	O
capacity	O
linked	O
to	O
Tir	B-GGP
'	O
s	O
activity	O
being	O
suppressed	O
by	O
undefined	O
EPEC	O
factors	O
.	O

Infections	O
in	O
a	O
disease	O
-	O
relevant	O
intestinal	O
model	O
confirm	O
key	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitory	O
roles	O
for	O
the	O
NleB1	B-GGP
/	O
NleE1	B-GGP
effectors	O
,	O
with	O
other	O
studies	O
providing	O
insights	O
on	O
host	O
targets	O
.	O

The	O
work	O
not	O
only	O
reveals	O
a	O
second	O
Intimin	O
-	O
independent	O
property	O
for	O
Tir	B-GGP
and	O
a	O
novel	O
EPEC	O
effector	O
-	O
mediated	O
NF	B-COM
-	I-COM
kappaB	I-COM
inhibitory	O
mechanism	O
but	O
also	O
lends	O
itself	O
to	O
speculations	O
on	O
the	O
evolution	O
of	O
EPEC	O
'	O
s	O
capacity	O
to	O
inhibit	O
NF	B-COM
-	I-COM
kappaB	I-COM
function	O
.	O

The	O
transcription	O
factor	O
Erg	B-GGP
controls	O
endothelial	O
cell	O
quiescence	O
by	O
repressing	O
activity	O
of	O
nuclear	B-COM
factor	I-COM
(	I-COM
NF	I-COM
)	I-COM
-	I-COM
kappaB	I-COM
p65	B-GGP
.	O

The	O
interaction	O
of	O
transcription	O
factors	O
with	O
specific	O
DNA	O
sequences	O
is	O
critical	O
for	O
activation	O
of	O
gene	O
expression	O
programs	O
.	O

In	O
endothelial	O
cells	O
(	O
EC	O
)	O
,	O
the	O
transcription	O
factor	O
NF	B-COM
-	I-COM
kappaB	I-COM
is	O
important	O
in	O
the	O
switch	O
from	O
quiescence	O
to	O
activation	O
,	O
and	O
is	O
tightly	O
controlled	O
to	O
avoid	O
excessive	O
inflammation	O
and	O
organ	O
damage	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
mechanism	O
that	O
controls	O
the	O
activation	O
of	O
NF	B-COM
-	I-COM
kappaB	I-COM
in	O
EC	O
.	O

The	O
transcription	O
factor	O
Erg	B-GGP
,	O
the	O
most	O
highly	O
expressed	O
ETS	B-GGP
member	O
in	O
resting	O
EC	O
,	O
controls	O
quiescence	O
by	O
repressing	O
proinflammatory	O
gene	O
expression	O
.	O

Focusing	O
on	O
intercellular	B-GGP
adhesion	I-GGP
molecule	I-GGP
1	I-GGP
(	I-GGP
ICAM	I-GGP
)	I-GGP
-	I-GGP
1	I-GGP
as	O
a	O
model	O
,	O
we	O
identify	O
two	O
ETS	B-GGP
binding	O
sites	O
(	O
EBS	O
-	O
118	O
and	O
-	O
181	O
)	O
within	O
the	O
ICAM	B-GGP
-	I-GGP
1	I-GGP
promoter	O
required	O
for	O
Erg	B-GGP
-	O
mediated	O
repression	O
.	O

We	O
show	O
that	O
Erg	B-GGP
binds	O
to	O
both	O
EBS	O
-	O
118	O
and	O
EBS	O
-	O
181	O
,	O
the	O
latter	O
located	O
within	O
the	O
NF	B-COM
-	I-COM
kappaB	I-COM
binding	O
site	O
.	O

Interestingly	O
,	O
inhibition	O
of	O
Erg	B-GGP
expression	O
in	O
quiescent	O
EC	O
results	O
in	O
increased	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
dependent	O
ICAM	B-GGP
-	I-GGP
1	I-GGP
expression	O
,	O
indicating	O
that	O
Erg	B-GGP
represses	O
basal	O
NF	B-COM
-	I-COM
kappaB	I-COM
activity	O
.	O

Erg	B-GGP
prevents	O
NF	B-COM
-	I-COM
kappaB	I-COM
p65	B-GGP
from	O
binding	O
to	O
the	O
ICAM	B-GGP
-	I-GGP
1	I-GGP
promoter	O
,	O
suggesting	O
a	O
direct	O
mechanism	O
of	O
interference	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
of	O
transcriptome	O
profiles	O
of	O
Erg	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
-	O
dependent	O
genes	O
,	O
together	O
with	O
chromatin	B-CC
immunoprecipitation	O
(	O
ChIP	O
)	O
studies	O
,	O
reveals	O
that	O
this	O
mechanism	O
is	O
common	O
to	O
other	O
proinflammatory	O
genes	O
,	O
including	O
cIAP	B-GGP
-	I-GGP
2	I-GGP
and	O
IL	B-GGP
-	I-GGP
8	I-GGP
.	O

These	O
results	O
identify	O
a	O
role	O
for	O
Erg	B-GGP
as	O
a	O
gatekeeper	O
controlling	O
vascular	O
inflammation	O
,	O
thus	O
providing	O
an	O
important	O
barrier	O
to	O
protect	O
against	O
inappropriate	O
endothelial	O
activation	O
.	O

Consequences	O
of	O
fuzziness	O
in	O
the	O
NFkappaB	B-COM
/	O
IkappaBalpha	B-GGP
interaction	O
.	O

This	O
chapter	O
provides	O
a	O
short	O
review	O
of	O
various	O
biophysical	O
experiments	O
that	O
have	O
been	O
applied	O
to	O
the	O
inhibitor	O
of	O
kappa	B-COM
B	I-COM
,	O
IkappaBalpha	B-GGP
and	O
its	O
binding	O
partner	O
,	O
nuclear	B-COM
factor	I-COM
kappa	I-COM
B	I-COM
,	O
or	O
NFkappaB	B-COM
.	O

The	O
picture	O
that	O
emerges	O
from	O
amide	B-MED
hydrogen	B-MED
/	O
deuterium	B-MED
exchange	O
,	O
NMR	O
and	O
binding	O
kinetics	O
experiments	O
is	O
one	O
in	O
which	O
parts	O
of	O
both	O
proteins	O
are	O
"	O
fuzzy	O
"	O
in	O
the	O
free	O
-	O
state	O
and	O
some	O
parts	O
remain	O
"	O
fuzzy	O
"	O
in	O
the	O
NFkappaB	B-COM
-	I-COM
IkappaBalpha	I-COM
complex	O
.	O

The	O
NFkappaB	B-COM
family	O
of	O
transcription	O
factors	O
responds	O
to	O
inflammatory	O
cytokines	O
with	O
rapid	O
transcriptional	O
activation	O
,	O
in	O
which	O
NFkappaB	B-COM
enters	O
the	O
nucleus	B-CC
and	O
binds	O
DNA	O
.	O

Just	O
as	O
rapidly	O
as	O
transcription	O
is	O
activated	O
,	O
it	O
is	O
subsequently	O
repressed	O
by	O
newly	O
synthesized	O
IkappaBalpha	B-GGP
?	O
that	O
also	O
enters	O
the	O
nucleus	B-CC
and	O
removes	O
NFkappaB	B-COM
from	O
the	O
DNA	O
.	O

Because	O
IkappaBalpha	B-GGP
?	O
is	O
an	O
ankyrin	B-GGP
repeat	O
protein	O
,	O
it	O
'	O
s	O
"	O
fuzziness	O
"	O
can	O
be	O
controlled	O
by	O
mutagenesis	O
to	O
stabilized	O
the	O
folded	O
state	O
.	O

Experimental	O
comparison	O
with	O
such	O
stabilized	O
mutants	O
helps	O
provide	O
evidence	O
that	O
much	O
of	O
the	O
system	O
control	O
depends	O
on	O
the	O
"	O
fuzziness	O
"	O
of	O
IkappaBalpha	B-GGP
.	O

Suppression	O
of	O
the	O
interferon	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
responses	O
by	O
severe	O
fever	O
with	O
thrombocytopenia	O
syndrome	O
virus	O
.	O

Severe	O
fever	O
with	O
thrombocytopenia	O
syndrome	O
(	O
SFTS	O
)	O
is	O
an	O
emerging	O
infectious	O
disease	O
characterized	O
by	O
high	O
fever	O
,	O
thrombocytopenia	O
,	O
multiorgan	O
dysfunction	O
,	O
and	O
a	O
high	O
fatality	O
rate	O
between	O
12	O
and	O
30	O
%	O
.	O

It	O
is	O
caused	O
by	O
SFTS	O
virus	O
(	O
SFTSV	O
)	O
,	O
a	O
novel	O
Phlebovirus	O
in	O
family	O
Bunyaviridae	O
.	O

Although	O
the	O
viral	O
pathogenesis	O
remains	O
largely	O
unknown	O
,	O
hemopoietic	O
cells	O
appear	O
to	O
be	O
targeted	O
by	O
the	O
virus	O
.	O

In	O
this	O
study	O
we	O
report	O
that	O
human	O
monocytes	O
were	O
susceptible	O
to	O
SFTSV	O
,	O
which	O
replicated	O
efficiently	O
,	O
as	O
shown	O
by	O
an	O
immunofluorescence	O
assay	O
and	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
.	O

We	O
examined	O
host	O
responses	O
in	O
the	O
infected	O
cells	O
and	O
found	O
that	O
antiviral	O
interferon	B-GGP
(	O
IFN	B-GGP
)	O
and	O
IFN	B-GGP
-	O
inducible	O
proteins	O
were	O
induced	O
upon	O
infection	O
.	O

However	O
,	O
our	O
data	O
also	O
indicated	O
that	O
downregulation	O
of	O
key	O
molecules	O
such	O
as	O
mitochondrial	B-GGP
antiviral	I-GGP
signaling	I-GGP
protein	I-GGP
(	O
MAVS	B-GGP
)	O
or	O
weakened	O
activation	O
of	O
interferon	B-GGP
regulatory	I-GGP
factor	I-GGP
(	O
IRF	B-GGP
)	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
responses	O
may	O
contribute	O
to	O
a	O
restricted	O
innate	O
immunity	O
against	O
the	O
infection	O
.	O

NSs	B-GGP
,	O
the	O
nonstructural	O
protein	O
encoded	O
by	O
the	O
S	O
segment	O
,	O
suppressed	O
the	O
beta	B-GGP
interferon	I-GGP
(	O
IFN	B-GGP
-	I-GGP
beta	I-GGP
)	O
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
promoter	O
activities	O
,	O
although	O
NF	B-COM
-	I-COM
kappaB	I-COM
activation	O
appears	O
to	O
facilitate	O
SFTSV	O
replication	O
in	O
human	O
monocytes	O
.	O

NSs	B-GGP
was	O
found	O
to	O
be	O
associated	O
with	O
TBK1	B-GGP
and	O
may	O
inhibit	O
the	O
activation	O
of	O
downstream	O
IRF	B-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
through	O
this	O
interaction	O
.	O

Interestingly	O
,	O
we	O
demonstrated	O
that	O
the	O
nucleoprotein	O
(	O
N	O
)	O
,	O
also	O
encoded	O
by	O
the	O
S	O
segment	O
,	O
exhibited	O
a	O
suppressive	O
effect	O
on	O
the	O
activation	O
of	O
IFN	B-GGP
-	I-GGP
beta	I-GGP
and	O
NF	B-COM
-	I-COM
kappaB	I-COM
signaling	O
as	O
well	O
.	O

Infected	O
monocytes	O
,	O
mainly	O
intact	O
and	O
free	O
of	O
apoptosis	O
,	O
may	O
likely	O
be	O
implicated	O
in	O
persistent	O
viral	O
infection	O
,	O
spreading	O
the	O
virus	O
to	O
the	O
circulation	O
and	O
causing	O
primary	O
viremia	O
.	O

Our	O
findings	O
provide	O
the	O
first	O
evidence	O
in	O
dissecting	O
the	O
host	O
responses	O
in	O
monocytes	O
and	O
understanding	O
viral	O
pathogenesis	O
in	O
humans	O
infected	O
with	O
a	O
novel	O
deadly	O
Bunyavirus	O
.	O

Association	O
of	O
initiation	O
factor	O
eIF	B-GGP
-	I-GGP
4E	I-GGP
in	O
a	O
cap	O
binding	O
protein	O
complex	O
(	O
eIF	B-COM
-	I-COM
4F	I-COM
)	O
is	O
critical	O
for	O
and	O
enhances	O
phosphorylation	O
by	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
.	O

Phosphorylation	O
by	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
of	O
the	O
mRNA	O
cap	O
binding	O
protein	O
purified	O
as	O
part	O
of	O
a	O
cap	O
binding	O
protein	O
complex	O
(	O
eIF	B-COM
-	I-COM
4F	I-COM
)	O
or	O
as	O
a	O
single	O
protein	O
(	O
eIF	B-GGP
-	I-GGP
4E	I-GGP
)	O
,	O
has	O
been	O
examined	O
.	O

Significant	O
phosphorylation	O
(	O
up	O
to	O
1	O
mol	O
of	O
phosphate	B-MED
/	O
mol	O
of	O
p25	B-GGP
subunit	O
)	O
occurs	O
only	O
when	O
the	O
protein	O
is	O
part	O
of	O
the	O
eIF	B-COM
-	I-COM
4F	I-COM
complex	O
.	O

With	O
purified	O
eIF	B-GGP
-	I-GGP
4E	I-GGP
,	O
using	O
the	O
same	O
conditions	O
,	O
up	O
to	O
0	O
.	O
1	O
mol	O
of	O
phosphate	B-MED
can	O
be	O
incorporated	O
.	O

Tryptic	O
phosphopeptide	O
maps	O
show	O
that	O
the	O
site	O
phosphorylated	O
in	O
the	O
Mr	O
25	O
,	O
000	O
subunit	O
of	O
eIF	B-COM
-	I-COM
4F	I-COM
(	O
eIF	B-GGP
-	I-GGP
4F	I-GGP
p25	I-GGP
)	O
is	O
the	O
same	O
as	O
that	O
modified	O
in	O
purified	O
eIF	B-GGP
-	I-GGP
4E	I-GGP
.	O

Kinetic	O
measurements	O
obtained	O
from	O
initial	O
rates	O
indicate	O
that	O
the	O
Km	O
values	O
for	O
eIF	B-COM
-	I-COM
4F	I-COM
and	O
eIF	B-GGP
-	I-GGP
4E	I-GGP
are	O
similar	O
,	O
although	O
the	O
Vmax	O
is	O
5	O
-	O
6	O
times	O
higher	O
for	O
the	O
complex	O
.	O

Dephosphorylation	O
of	O
eIF	B-GGP
-	I-GGP
4F	I-GGP
p25	I-GGP
,	O
previously	O
phosphorylated	O
with	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
,	O
occurs	O
in	O
reticulocyte	O
lysate	O
with	O
a	O
half	O
-	O
life	O
of	O
15	O
-	O
20	O
min	O
,	O
whereas	O
little	O
dephosphorylation	O
is	O
observed	O
after	O
15	O
min	O
with	O
the	O
purified	O
phosphorylated	O
eIF	B-GGP
-	I-GGP
4E	I-GGP
.	O

Phosphorylation	O
of	O
eIF	B-COM
-	I-COM
4F	I-COM
on	O
the	O
p220	B-GGP
and	O
p25	B-GGP
subunits	O
does	O
not	O
affect	O
the	O
stability	O
of	O
the	O
complex	O
as	O
indicated	O
by	O
gel	O
filtration	O
on	O
Sephacryl	B-MED
S	I-MED
-	I-MED
300	I-MED
.	O

However	O
,	O
addition	O
of	O
non	O
-	O
phosphorylated	O
eIF	B-GGP
-	I-GGP
4E	I-GGP
to	O
the	O
phosphorylated	O
complex	O
results	O
in	O
the	O
dissociation	O
of	O
the	O
complex	O
.	O

These	O
results	O
suggest	O
that	O
interaction	O
of	O
p25	B-GGP
with	O
other	O
subunits	O
in	O
the	O
complex	O
greatly	O
affects	O
phosphorylation	O
/	O
dephosphorylation	O
of	O
p25	B-GGP
.	O

Since	O
the	O
rate	O
of	O
phosphorylation	O
/	O
dephosphorylation	O
is	O
significantly	O
greater	O
in	O
the	O
complex	O
,	O
regulation	O
of	O
the	O
cap	O
binding	O
protein	O
by	O
phosphorylation	O
appears	O
to	O
occur	O
primarily	O
on	O
eIF	B-COM
-	I-COM
4F	I-COM
.	O

Molecular	O
cloning	O
,	O
primary	O
structure	O
,	O
and	O
expression	O
of	O
the	O
human	O
platelet	O
/	O
erythroleukemia	O
cell	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
.	O

The	O
major	O
pathway	O
of	O
arachidonic	B-MED
acid	I-MED
metabolism	O
in	O
human	O
platelets	O
proceeds	O
via	O
a	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
enzyme	O
;	O
however	O
,	O
the	O
biological	O
role	O
of	O
the	O
product	O
of	O
this	O
reaction	O
,	O
12	B-MED
-	I-MED
hydro	I-MED
(	I-MED
pero	I-MED
)	I-MED
xyeicosatetraenoic	I-MED
acid	I-MED
[	O
12	B-MED
-	I-MED
H	I-MED
(	I-MED
P	I-MED
)	I-MED
ETE	I-MED
]	O
,	O
is	O
unknown	O
.	O

Using	O
a	O
combination	O
of	O
the	O
polymerase	O
chain	O
reaction	O
and	O
conventional	O
screening	O
procedures	O
,	O
we	O
have	O
isolated	O
cDNA	O
clones	O
encoding	O
the	O
human	O
platelet	O
/	O
human	O
erythroleukemia	O
(	O
HEL	O
)	O
cell	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
.	O

From	O
the	O
deduced	O
primary	O
structure	O
,	O
human	O
platelet	O
/	O
HEL	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
would	O
encode	O
a	O
Mr	O
75	O
,	O
000	O
protein	O
consisting	O
of	O
663	O
amino	O
acids	O
.	O

The	O
cDNA	O
encoding	O
the	O
full	O
-	O
length	O
protein	O
(	O
pCDNA	B-GGP
-	I-GGP
121x	I-GGP
)	O
under	O
the	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
was	O
expressed	O
in	O
simian	O
COS	O
-	O
M6	O
cells	O
.	O

Intact	O
cells	O
and	O
lysed	O
-	O
cell	O
supernatants	O
were	O
able	O
to	O
synthesize	O
12	B-MED
-	I-MED
H	I-MED
(	I-MED
P	I-MED
)	I-MED
ETE	I-MED
from	O
arachidonic	B-MED
acid	I-MED
,	O
whereas	O
no	O
12	B-MED
-	I-MED
H	I-MED
(	I-MED
P	I-MED
)	I-MED
ETE	I-MED
synthesis	O
was	O
detected	O
in	O
mock	O
-	O
transfected	O
cells	O
.	O

A	O
single	O
2	O
.	O
4	O
-	O
kilobase	O
mRNA	O
was	O
detected	O
in	O
erythroleukemia	O
cells	O
but	O
not	O
in	O
several	O
other	O
tissues	O
and	O
cell	O
lines	O
evaluated	O
by	O
Northern	O
blot	O
analysis	O
.	O

Comparison	O
of	O
the	O
human	O
platelet	O
/	O
HEL	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
sequence	O
with	O
that	O
of	O
porcine	O
leukocyte	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
and	O
human	O
reticulocyte	O
15	B-GGP
-	I-GGP
lipoxygenase	I-GGP
revealed	O
65	O
%	O
amino	O
acid	O
identity	O
to	O
both	O
enzymes	O
.	O

By	O
contrast	O
,	O
the	O
leukocyte	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
is	O
86	O
%	O
identical	O
to	O
human	O
reticulocyte	O
15	B-GGP
-	I-GGP
lipoxygenase	I-GGP
.	O

Sequence	O
data	O
and	O
previously	O
demonstrated	O
immunochemical	O
and	O
biochemical	O
evidence	O
support	O
the	O
existence	O
of	O
distinct	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
isoforms	O
.	O

The	O
availability	O
of	O
cDNA	O
probes	O
for	O
human	O
platelet	O
/	O
HEL	O
cell	O
12	B-GGP
-	I-GGP
lipoxygenase	I-GGP
should	O
facilitate	O
elucidation	O
of	O
the	O
biological	O
role	O
of	O
this	O
pathway	O
.	O

Kinetic	O
properties	O
of	O
the	O
plasma	B-CC
membrane	I-CC
Na	B-GGP
+	I-GGP
-	I-GGP
H	I-GGP
+	I-GGP
exchanger	I-GGP
.	O

The	O
plasma	B-CC
membrane	I-CC
Na	B-GGP
+	I-GGP
-	I-GGP
H	I-GGP
+	I-GGP
exchanger	I-GGP
is	O
a	O
ubiquitous	O
transport	O
system	O
that	O
participates	O
in	O
diverse	O
cell	O
functions	O
involving	O
the	O
cellular	O
uptake	O
of	O
Na	B-MED
+	I-MED
or	O
extrusion	O
of	O
H	B-MED
+	I-MED
.	O

It	O
has	O
a	O
tightly	O
coupled	O
1	O
:	O
1	O
stoichiometry	O
,	O
has	O
affinity	O
for	O
Li	B-MED
+	I-MED
and	O
NH	B-MED
+	I-MED
4	I-MED
in	O
addition	O
to	O
Na	B-MED
+	I-MED
and	O
H	B-MED
+	I-MED
,	O
and	O
can	O
function	O
in	O
multiple	O
amiloride	B-MED
-	O
sensitive	O
exchange	O
modes	O
involving	O
these	O
cations	B-MED
.	O

These	O
general	O
transport	O
properties	O
may	O
be	O
explained	O
by	O
kinetic	O
models	O
involving	O
either	O
cation	B-MED
-	O
hydroxyl	B-MED
cotransport	O
or	O
actual	O
cation	B-MED
-	O
proton	B-MED
exchange	O
.	O

The	O
most	O
important	O
kinetic	O
property	O
of	O
the	O
Na	B-GGP
+	I-GGP
-	I-GGP
H	I-GGP
+	I-GGP
exchanger	I-GGP
is	O
its	O
greater	O
than	O
first	O
-	O
order	O
dependence	O
on	O
[	B-MED
H	I-MED
+	I-MED
]	I-MED
i	I-MED
.	O

This	O
property	O
enables	O
the	O
Na	B-GGP
+	I-GGP
-	I-GGP
H	I-GGP
+	I-GGP
exchanger	I-GGP
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
intracellular	B-CC
pH	O
.	O

Molecular	O
cloning	O
of	O
the	O
beta	O
-	O
subunit	O
of	O
human	O
prolyl	B-COM
4	I-COM
-	I-COM
hydroxylase	I-COM
.	O

This	O
subunit	O
and	O
protein	B-GGP
disulphide	I-GGP
isomerase	I-GGP
are	O
products	O
of	O
the	O
same	O
gene	O
.	O

Prolyl	B-COM
4	I-COM
-	I-COM
hydroxylase	I-COM
(	O
EC	B-GGP
1	I-GGP
.	I-GGP
14	I-GGP
.	I-GGP
11	I-GGP
.	I-GGP
2	I-GGP
)	O
,	O
an	O
alpha	O
2	O
beta	O
2	O
tetramer	O
,	O
catalyses	O
the	O
formation	O
of	O
4	B-MED
-	I-MED
hydroxyproline	I-MED
in	O
collagens	B-MED
by	O
the	O
hydroxylation	O
of	O
proline	B-MED
residues	O
in	O
peptide	O
linkages	O
.	O

We	O
report	O
here	O
the	O
isolation	O
of	O
cDNA	O
clones	O
coding	O
for	O
the	O
beta	O
-	O
subunit	O
of	O
prolyl	B-COM
4	I-COM
-	I-COM
hydroxylase	I-COM
from	O
a	O
human	O
hepatoma	O
lambda	O
gt11	O
library	O
and	O
a	O
corresponding	O
human	O
placenta	O
library	O
.	O

Five	O
overlapping	O
clones	O
covering	O
all	O
the	O
coding	O
sequences	O
and	O
almost	O
all	O
the	O
non	O
-	O
coding	O
sequences	O
were	O
characterized	O
.	O

The	O
size	O
of	O
the	O
mRNA	O
hybridizing	O
with	O
these	O
clones	O
in	O
Northern	O
blotting	O
is	O
approximately	O
2	O
.	O
5	O
kb	O
.	O

The	O
clones	O
encode	O
a	O
polypeptide	O
of	O
508	O
amino	O
acid	O
residues	O
,	O
including	O
a	O
signal	O
peptide	O
of	O
17	O
amino	O
acids	O
.	O

These	O
human	O
sequences	O
were	O
found	O
to	O
be	O
very	O
similar	O
to	O
those	O
recently	O
reported	O
for	O
rat	O
protein	B-GGP
disulphide	I-GGP
isomerase	I-GGP
(	O
EC	B-GGP
5	I-GGP
.	I-GGP
3	I-GGP
.	I-GGP
4	I-GGP
.	I-GGP
1	I-GGP
)	O
.	O

The	O
degree	O
of	O
homology	O
between	O
these	O
two	O
proteins	O
was	O
84	O
%	O
at	O
the	O
level	O
of	O
nucleotide	O
sequences	O
or	O
94	O
%	O
at	O
the	O
level	O
of	O
amino	O
acid	O
sequences	O
.	O

Southern	O
blot	O
analyses	O
of	O
human	O
genomic	O
DNA	O
with	O
a	O
cDNA	O
probe	O
for	O
the	O
beta	O
-	O
subunit	O
indicated	O
the	O
presence	O
of	O
only	O
one	O
gene	O
containing	O
these	O
sequences	O
.	O

The	O
product	O
of	O
a	O
single	O
gene	O
thus	O
appears	O
to	O
possess	O
two	O
different	O
enzymatic	O
functions	O
depending	O
on	O
whether	O
it	O
is	O
present	O
in	O
cells	O
in	O
monomer	O
form	O
or	O
in	O
the	O
prolyl	B-COM
4	I-COM
-	I-COM
hydroxylase	I-COM
tetramer	O
.	O

Quantitation	O
of	O
the	O
efflux	O
of	O
acylcarnitines	B-MED
from	O
rat	O
heart	O
,	O
brain	O
,	O
and	O
liver	O
mitochondria	B-CC
.	O

The	O
efflux	O
of	O
individual	O
short	O
-	O
chain	O
and	O
medium	O
-	O
chain	O
acylcarnitines	B-MED
from	O
rat	O
liver	O
,	O
heart	O
,	O
and	O
brain	O
mitochondria	B-CC
metabolizing	O
several	O
substrates	O
has	O
been	O
measured	O
.	O

The	O
acylcarnitine	B-MED
efflux	O
profiles	O
depend	O
on	O
the	O
substrate	O
,	O
the	O
source	O
of	O
mitochondria	B-CC
,	O
and	O
the	O
incubation	O
conditions	O
.	O

The	O
largest	O
amount	O
of	O
any	O
acylcarnitine	B-MED
effluxing	O
per	O
mg	O
of	O
protein	O
was	O
acetylcarnitine	B-MED
produced	O
by	O
heart	O
mitochondria	B-CC
from	O
pyruvate	B-MED
.	O

This	O
efflux	O
of	O
acetylcarnitine	B-MED
from	O
heart	O
mitochondria	B-CC
is	O
almost	O
5	O
times	O
greater	O
with	O
1	O
mM	O
than	O
0	O
.	O
2	O
mM	O
carnitine	B-MED
.	O

Apparently	O
the	O
acetyl	B-MED
-	I-MED
CoA	I-MED
generated	O
from	O
pyruvate	B-MED
by	O
pyruvate	B-GGP
dehydrogenase	I-GGP
is	O
very	O
accessible	O
to	O
carnitine	B-GGP
acetyltransferase	I-GGP
.	O

Very	O
little	O
acetylcarnitine	B-MED
effluxes	O
from	O
heart	O
mitochondria	B-CC
when	O
octanoate	B-MED
is	O
the	O
substrate	O
except	O
in	O
the	O
presence	O
of	O
malonate	B-MED
.	O

Acetylcarnitine	B-MED
production	O
from	O
some	O
substrates	O
peaks	O
and	O
then	O
declines	O
,	O
indicating	O
uptake	O
and	O
utilization	O
.	O

The	O
unequivocal	O
demonstration	O
that	O
considerable	O
amounts	O
of	O
propionylcarnitine	B-MED
or	O
isobutyrylcarnitine	B-MED
efflux	O
from	O
heart	O
mitochondria	B-CC
metabolizing	O
alpha	B-MED
-	I-MED
ketoisovalerate	I-MED
and	O
alpha	B-MED
-	I-MED
keto	I-MED
-	I-MED
beta	I-MED
-	I-MED
methylvalerate	I-MED
provides	O
evidence	O
for	O
a	O
role	O
(	O
via	O
removal	O
of	O
non	O
-	O
metabolizable	O
propionyl	B-MED
-	I-MED
CoA	I-MED
or	O
slowly	O
metabolizable	O
acyl	B-MED
-	I-MED
CoAs	I-MED
)	O
for	O
carnitine	B-MED
in	O
tissues	O
which	O
have	O
limited	O
capacity	O
to	O
metabolize	O
propionyl	B-MED
-	I-MED
CoA	I-MED
.	O

These	O
results	O
also	O
show	O
propionyl	B-MED
-	I-MED
CoA	I-MED
must	O
be	O
formed	O
during	O
the	O
metabolism	O
of	O
alpha	B-MED
-	I-MED
ketoisovalerate	I-MED
and	O
that	O
extra	B-CC
-	I-CC
mitochondrial	I-CC
free	O
carnitine	B-MED
rapidly	O
interacts	O
with	O
matrix	B-CC
short	O
-	O
chain	O
aliphatic	O
acyl	B-MED
-	I-MED
CoA	I-MED
generated	O
from	O
alpha	B-MED
-	I-MED
keto	I-MED
acids	I-MED
of	O
branched	O
-	O
chain	O
amino	O
acids	O
and	O
pyruvate	B-MED
in	O
the	O
presence	O
and	O
absence	O
of	O
malate	B-MED
.	O

A	O
sulfatase	O
specific	O
for	O
glucuronic	B-MED
acid	I-MED
2	I-MED
-	I-MED
sulfate	I-MED
residues	O
in	O
glycosaminoglycans	B-MED
.	O

Although	O
2	O
-	O
O	O
-	O
sulfated	O
L	B-MED
-	I-MED
iduronic	I-MED
acid	I-MED
(	O
IdoA	B-MED
)	O
residues	O
have	O
been	O
known	O
to	O
occur	O
in	O
heparin	B-MED
,	O
2	O
-	O
O	O
-	O
sulfated	O
D	B-MED
-	I-MED
glucuronic	I-MED
acid	I-MED
(	O
GlcA	B-MED
)	O
residues	O
have	O
been	O
reported	O
only	O
recently	O
(	O
Bienkowski	O
,	O
M	O
.	O
J	O
.	O
,	O
and	O
Conrad	O
,	O
H	O
.	O
E	O
.	O
(	O
1985	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
250	O
,	O
356	O
-	O
365	O
)	O
.	O

Disaccharides	O
prepared	O
by	O
cleavage	O
of	O
heparin	B-MED
and	O
N	O
-	O
deacetylated	O
chondroitin	B-MED
6	I-MED
-	I-MED
sulfate	I-MED
with	O
nitrous	B-MED
acid	I-MED
were	O
used	O
to	O
demonstrate	O
a	O
new	O
sulfatase	O
that	O
catalyzed	O
the	O
removal	O
of	O
the	O
2	B-MED
-	I-MED
O	I-MED
-	I-MED
sulfate	I-MED
substituents	O
from	O
GlcA	B-MED
but	O
not	O
IdoA	B-MED
residues	O
.	O

The	O
deamination	O
products	O
were	O
labeled	O
by	O
NaB3H4	B-MED
reduction	O
to	O
give	O
disaccharides	O
from	O
heparin	B-MED
and	O
chondroitin	B-MED
sulfate	I-MED
which	O
had	O
reducing	O
terminal	O
2	B-MED
,	I-MED
5	I-MED
-	I-MED
anhydro	I-MED
-	I-MED
D	I-MED
-	I-MED
mannitol	I-MED
(	O
[	B-MED
3H	I-MED
]	I-MED
AManR	I-MED
)	O
and	O
2	B-MED
,	I-MED
5	I-MED
-	I-MED
anhydro	I-MED
-	I-MED
D	I-MED
-	I-MED
talitol	I-MED
(	O
[	B-MED
3H	I-MED
]	I-MED
ATalR	I-MED
)	O
residues	O
,	O
respectively	O
.	O

IdoA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
from	O
heparin	B-MED
and	O
GlcA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
ATalR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
from	O
chondroitin	B-MED
sulfate	I-MED
were	O
purified	O
for	O
use	O
as	O
substrates	O
.	O

GlcA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
was	O
prepared	O
by	O
epimerization	O
of	O
IdoA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
with	O
hydrazine	B-MED
at	O
100	O
degrees	O
C	O
.	O

Lysosomal	B-CC
enzyme	O
preparations	O
from	O
chick	O
embryo	O
chondrocytes	O
and	O
from	O
two	O
normal	O
human	O
fibroblast	O
cell	O
lines	O
catalyzed	O
the	O
removal	O
of	O
the	O
2	B-MED
-	I-MED
O	I-MED
-	I-MED
SO4	I-MED
substituent	O
from	O
the	O
uronic	B-MED
acid	I-MED
residues	O
of	O
IdoA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
,	O
GlcA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
,	O
and	O
GlcA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
ATalR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
.	O

In	O
contrast	O
,	O
a	O
lysosomal	B-CC
enzyme	O
preparation	O
from	O
a	O
human	O
fibroblast	O
cell	O
line	O
deficient	O
in	O
idurono	B-GGP
-	I-GGP
2	I-GGP
-	I-GGP
sulfatase	I-GGP
(	O
Hunter	O
'	O
s	O
-	O
syndrome	O
)	O
,	O
which	O
had	O
no	O
activity	O
on	O
the	O
IdoA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
,	O
converted	O
GlcA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
to	O
a	O
mixture	O
of	O
GlcA	B-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
and	O
[	B-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
.	O

This	O
enzyme	O
also	O
converted	O
GlcA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
ATalR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
to	O
a	O
mixture	O
of	O
GlcA	B-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
ATalR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
and	O
[	B-MED
3H	I-MED
]	I-MED
ATalR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
.	O

Digestion	O
of	O
both	O
GlcA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
AManR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
and	O
GlcA	B-MED
(	I-MED
2	I-MED
-	I-MED
SO4	I-MED
)	I-MED
-	I-MED
[	I-MED
3H	I-MED
]	I-MED
ATalR	I-MED
(	I-MED
6	I-MED
-	I-MED
SO4	I-MED
)	I-MED
was	O
inhibited	O
by	O
35SO2	B-MED
-	I-MED
4	I-MED
and	O
was	O
arrested	O
at	O
the	O
monosulfated	B-MED
disaccharide	I-MED
stage	O
by	O
1	B-MED
,	I-MED
4	I-MED
-	I-MED
saccharolactone	I-MED
.	O

The	O
glucurono	B-GGP
-	I-GGP
2	I-GGP
-	I-GGP
sulfatase	I-GGP
exhibited	O
a	O
pH	O
optimum	O
of	O
4	O
.	O

The	O
results	O
indicate	O
that	O
there	O
exists	O
a	O
separate	O
sulfatase	O
for	O
the	O
removal	O
of	O
sulfate	B-MED
substituents	O
from	O
C	B-MED
-	I-MED
2	I-MED
of	O
GlcA	B-MED
residues	O
in	O
glycosaminoglycans	B-MED
.	O

Negative	O
regulation	O
of	O
the	O
wee1	B-GGP
protein	O
kinase	O
by	O
direct	O
action	O
of	O
the	O
nim1	B-GGP
/	O
cdr1	B-GGP
mitotic	O
inducer	O
.	O

The	O
wee1	B-GGP
protein	O
kinase	O
suppresses	O
the	O
entry	O
into	O
mitosis	O
by	O
mediating	O
the	O
inhibitory	O
tyrosine	B-MED
phosphorylation	O
of	O
p34cdc2	B-GGP
.	O

Genetic	O
studies	O
have	O
suggested	O
that	O
the	O
nim1	B-GGP
protein	O
kinase	O
(	O
also	O
known	O
as	O
cdr1	B-GGP
)	O
acts	O
as	O
a	O
positive	O
regulator	O
of	O
mitosis	O
by	O
down	O
-	O
regulating	O
the	O
wee1	B-GGP
pathway	O
in	O
yeast	O
cells	O
.	O

We	O
have	O
overexpressed	O
the	O
nim1	B-GGP
protein	O
in	O
both	O
bacteria	O
and	O
insect	O
cells	O
.	O

The	O
recombinant	O
nim1	B-GGP
protein	O
autophosphorylates	O
on	O
both	O
tyrosine	B-MED
and	O
serine	B-MED
residues	O
and	O
can	O
phosphorylate	O
the	O
isolated	O
wee1	B-GGP
protein	O
directly	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

The	O
nim1	B-GGP
-	O
catalyzed	O
phosphorylation	O
of	O
the	O
wee1	B-GGP
protein	O
occurs	O
in	O
its	O
C	O
-	O
terminal	O
region	O
and	O
leads	O
to	O
a	O
substantial	O
drop	O
in	O
its	O
activity	O
as	O
a	O
cdc2	B-GGP
-	O
specific	O
tyrosine	B-MED
kinase	O
.	O

This	O
nim1	B-GGP
-	O
dependent	O
inhibition	O
of	O
the	O
wee1	B-GGP
protein	O
kinase	O
can	O
be	O
reversed	O
readily	O
in	O
vitro	O
by	O
treatment	O
with	O
a	O
protein	O
phosphatase	O
.	O

These	O
experiments	O
provide	O
direct	O
biochemical	O
evidence	O
that	O
the	O
wee1	B-GGP
protein	O
is	O
subject	O
to	O
negative	O
regulation	O
by	O
phosphorylation	O
and	O
indicate	O
that	O
the	O
nim1	B-GGP
protein	O
acts	O
as	O
an	O
inhibitory	O
,	O
wee1	B-GGP
-	O
specific	O
kinase	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
second	O
subunit	O
of	O
the	O
interleukin	B-COM
1	I-COM
receptor	I-COM
complex	O
.	O

A	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
was	O
isolated	O
that	O
blocked	O
the	O
binding	O
and	O
bioactivity	O
of	O
both	O
human	O
and	O
murine	O
interleukin	B-GGP
1	I-GGP
beta	I-GGP
(	O
IL	B-GGP
-	I-GGP
1	I-GGP
beta	I-GGP
)	O
on	O
murine	O
IL	B-COM
-	I-COM
1	I-COM
receptor	I-COM
-	O
bearing	O
cells	O
.	O

This	O
mAb	O
recognized	O
a	O
protein	O
that	O
was	O
distinct	O
from	O
the	O
Type	B-GGP
I	I-GGP
and	O
Type	B-GGP
II	I-GGP
IL	I-GGP
-	I-GGP
1	I-GGP
receptors	I-GGP
,	O
suggesting	O
that	O
an	O
additional	O
protein	O
exists	O
that	O
is	O
involved	O
in	O
IL	B-GGP
-	I-GGP
1	I-GGP
biological	O
responses	O
.	O

By	O
expression	O
cloning	O
in	O
COS	O
-	O
7	O
cells	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
from	O
mouse	O
3T3	O
-	O
LI	O
cells	O
encoding	O
this	O
putative	O
auxiliary	O
molecule	O
,	O
which	O
we	O
term	O
the	O
IL	B-GGP
-	I-GGP
1	I-GGP
receptor	I-GGP
accessory	I-GGP
protein	I-GGP
(	O
IL	B-GGP
-	I-GGP
1R	I-GGP
AcP	I-GGP
)	O
.	O

Sequence	O
analysis	O
of	O
the	O
cDNA	O
predicts	O
an	O
open	O
reading	O
frame	O
that	O
encodes	O
a	O
570	O
-	O
amino	O
acid	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
66	O
kDa	O
.	O

The	O
IL	B-GGP
-	I-GGP
1R	I-GGP
AcP	I-GGP
is	O
a	O
member	O
of	O
the	O
Ig	B-GGP
superfamily	O
by	O
analysis	O
of	O
its	O
putative	O
extracellular	B-CC
domain	O
and	O
also	O
bears	O
limited	O
homology	O
throughout	O
the	O
protein	O
to	O
both	O
Type	B-GGP
I	I-GGP
and	O
Type	B-GGP
II	I-GGP
IL	I-GGP
-	I-GGP
1	I-GGP
receptors	I-GGP
.	O

Northern	O
analysis	O
reveals	O
that	O
murine	O
IL	B-GGP
-	I-GGP
1R	I-GGP
AcP	I-GGP
mRNA	O
is	O
expressed	O
in	O
many	O
tissues	O
and	O
appears	O
to	O
be	O
regulated	O
by	O
IL	B-GGP
-	I-GGP
1	I-GGP
.	O

In	O
mammalian	O
cells	O
expressing	O
natural	O
or	O
recombinant	O
Type	B-GGP
I	I-GGP
IL	I-GGP
-	I-GGP
1R	I-GGP
and	O
IL	B-GGP
-	I-GGP
1R	I-GGP
AcP	I-GGP
,	O
the	O
accessory	O
protein	O
forms	O
a	O
complex	O
with	O
the	O
Type	B-GGP
I	I-GGP
IL	I-GGP
-	I-GGP
1R	I-GGP
and	O
either	O
IL	B-GGP
-	I-GGP
1	I-GGP
alpha	I-GGP
or	O
IL	B-GGP
-	I-GGP
1	I-GGP
beta	I-GGP
but	O
not	O
IL	B-GGP
-	I-GGP
1ra	I-GGP
.	O

The	O
recombinant	O
accessory	O
protein	O
also	O
increases	O
the	O
binding	O
affinity	O
of	O
the	O
recombinant	O
Type	B-GGP
I	I-GGP
IL	I-GGP
-	I-GGP
1R	I-GGP
for	O
IL	B-GGP
-	I-GGP
1	I-GGP
beta	I-GGP
when	O
the	O
two	O
receptor	O
proteins	O
are	O
coexpressed	O
.	O

Therefore	O
,	O
the	O
functional	O
IL	B-COM
-	I-COM
1	I-COM
receptor	I-COM
appears	O
to	O
be	O
a	O
complex	O
composed	O
of	O
at	O
least	O
two	O
subunits	O
.	O

Activation	O
of	O
phosphoinositide	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
activity	O
by	O
Cdc42Hs	B-GGP
binding	O
to	O
p85	B-GGP
.	O

The	O
Ras	B-GGP
-	O
like	O
GTPase	O
Cdc42	B-GGP
is	O
essential	O
for	O
cell	O
polarity	O
and	O
bud	O
site	O
assembly	O
in	O
Saccharomyces	O
cerevisiae	O
by	O
regulating	O
cell	O
cycle	O
-	O
dependent	O
reorganization	O
of	O
cortical	O
cytoskeletal	B-CC
elements	I-CC
.	O

However	O
,	O
its	O
role	O
in	O
mammalian	O
cells	O
is	O
unknown	O
.	O

To	O
identify	O
potential	O
effectors	O
of	O
Cdc42Hs	B-GGP
,	O
we	O
incubated	O
lysates	O
from	O
NIH	O
3T3	O
fibroblasts	O
or	O
PC12	O
cells	O
with	O
immobilized	O
glutathione	B-GGP
S	I-GGP
-	I-GGP
transferase	I-GGP
(	I-GGP
GST	I-GGP
)	I-GGP
-	I-GGP
Cdc42Hs	I-GGP
fusion	O
proteins	O
bound	O
to	O
different	O
guanine	B-MED
nucleotides	O
and	O
observed	O
a	O
specific	O
association	O
between	O
the	O
85	O
-	O
kDa	O
subunit	O
(	O
p85	B-GGP
)	O
of	O
phosphatidylinositol	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
(	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
)	O
and	O
GTP	B-MED
gamma	I-MED
S	I-MED
(	O
guanosine	B-MED
5	I-MED
'	I-MED
-	I-MED
3	I-MED
-	I-MED
O	I-MED
-	I-MED
(	I-MED
thio	I-MED
)	I-MED
triphosphate	I-MED
)	O
-	O
bound	O
GST	B-GGP
-	I-GGP
Cdc42Hs	I-GGP
.	O

Recombinant	O
p85	B-GGP
formed	O
a	O
complex	O
with	O
GTP	B-MED
gamma	I-MED
S	I-MED
-	O
bound	O
GST	B-GGP
-	I-GGP
Cdc42Hs	I-GGP
and	O
with	O
a	O
GTPase	O
-	O
defective	O
GTP	B-MED
-	O
bound	O
GST	B-COM
-	I-COM
Cdc42Hs	I-COM
-	I-COM
Q61L	I-COM
mutant	O
,	O
but	O
not	O
with	O
a	O
GTP	B-MED
gamma	I-MED
S	I-MED
-	O
bound	O
,	O
effector	O
domain	O
GST	B-GGP
-	I-GGP
Cdc42HsT35A	I-GGP
mutant	O
.	O

Both	O
the	O
Rho	B-GGP
-	I-GGP
GAP	I-GGP
homology	O
domain	O
of	O
p85	B-GGP
and	O
the	O
Cdc42Hs	B-GGP
-	I-GGP
GAP	I-GGP
competitively	O
inhibited	O
the	O
binding	O
of	O
recombinant	O
p85	B-GGP
to	O
Cdc42Hs	B-GGP
.	O

In	O
addition	O
,	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
activity	O
immunoprecipitated	O
from	O
cell	O
lysates	O
with	O
anti	O
-	O
p85	B-GGP
antibody	O
was	O
stimulated	O
2	O
-	O
4	O
-	O
fold	O
by	O
GST	B-COM
-	I-COM
Cdc42	I-COM
-	I-COM
GTP	I-COM
gamma	I-COM
S	I-COM
.	O

Similar	O
interactions	O
were	O
observed	O
between	O
p85	B-GGP
and	O
GST	B-COM
-	I-COM
Rac1	I-COM
-	I-COM
GTP	I-COM
gamma	I-COM
S	I-COM
but	O
not	O
between	O
p85	B-GGP
and	O
GST	B-COM
-	I-COM
RhoA	I-COM
-	I-COM
GTP	I-COM
gamma	I-COM
S	I-COM
.	O

These	O
findings	O
suggest	O
that	O
PI	B-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
,	O
through	O
the	O
Rho	B-GGP
-	I-GGP
GAP	I-GGP
homology	O
domain	O
of	O
p85	B-GGP
,	O
can	O
couple	O
to	O
the	O
effector	O
domain	O
of	O
Cdc42Hs	B-GGP
and	O
that	O
p85	B-GGP
may	O
be	O
a	O
target	O
for	O
the	O
GTP	B-MED
-	O
bound	O
forms	O
of	O
Cdc42Hs	B-GGP
and	O
Rac1	B-GGP
.	O

Human	O
liver	O
arylacetamide	B-GGP
deacetylase	I-GGP
.	O

Molecular	O
cloning	O
of	O
a	O
novel	O
esterase	B-GGP
involved	O
in	O
the	O
metabolic	O
activation	O
of	O
arylamine	B-MED
carcinogens	O
with	O
high	O
sequence	O
similarity	O
to	O
hormone	B-GGP
-	I-GGP
sensitive	I-GGP
lipase	I-GGP
.	O

Microsomal	O
arylacetamide	B-GGP
deacetylase	I-GGP
(	O
DAC	B-GGP
)	O
competes	O
against	O
the	O
activity	O
of	O
cytosolic	B-CC
arylamine	B-GGP
N	I-GGP
-	I-GGP
acetyltransferase	I-GGP
,	O
which	O
catalyzes	O
one	O
of	O
the	O
initial	O
biotransformation	O
pathways	O
for	O
arylamine	B-MED
and	O
heterocyclic	B-MED
amine	I-MED
carcinogens	O
in	O
many	O
species	O
and	O
tissues	O
.	O

Activity	O
determination	O
and	O
immunoblot	O
analysis	O
of	O
DAC	B-GGP
in	O
human	O
target	O
tissues	O
for	O
arylamine	B-MED
carcinogens	O
revealed	O
that	O
in	O
extrahepatic	O
tissues	O
,	O
additional	O
enzymes	O
are	O
responsible	O
for	O
any	O
deacetylation	O
activity	O
,	O
whereas	O
a	O
single	O
enzyme	O
predominantly	O
catalyzes	O
this	O
hydrolytic	O
reaction	O
in	O
liver	O
.	O

We	O
isolated	O
and	O
characterized	O
a	O
full	O
-	O
length	O
cDNA	O
from	O
a	O
human	O
liver	O
lambda	O
gt11	O
library	O
.	O

This	O
clone	O
encodes	O
an	O
open	O
reading	O
frame	O
of	O
400	O
amino	O
acids	O
with	O
a	O
deduced	O
molecular	O
mass	O
of	O
45	O
.	O
7	O
kDa	O
and	O
contains	O
two	O
putative	O
glycosylation	O
sites	O
.	O

The	O
3	O
'	O
-	O
untranslated	O
region	O
contains	O
two	O
putative	O
polyadenylation	O
signals	O
.	O

The	O
cDNA	O
was	O
confirmed	O
to	O
be	O
that	O
for	O
DAC	B-GGP
in	O
tryptic	O
peptides	O
from	O
the	O
purified	O
human	O
liver	O
protein	O
.	O

Highest	O
sequence	O
similarity	O
of	O
DAC	B-GGP
was	O
found	O
in	O
a	O
series	O
of	O
prokaryotic	O
esterases	O
encompassing	O
the	O
putative	O
active	O
site	O
.	O

Two	O
extended	O
regions	O
of	O
significant	O
sequence	O
homology	O
with	O
hormone	B-GGP
-	I-GGP
sensitive	I-GGP
lipase	I-GGP
and	O
with	O
lipase	B-GGP
2	I-GGP
from	O
Moraxella	O
TA144	O
were	O
identified	O
,	O
whereas	O
similarity	O
to	O
carboxyl	B-GGP
esterases	I-GGP
was	O
restricted	O
to	O
the	O
region	O
encompassing	O
the	O
putative	O
active	O
site	O
,	O
indicating	O
that	O
DAC	B-GGP
should	O
be	O
classified	O
as	O
esterase	B-GGP
.	O

This	O
cDNA	O
provides	O
an	O
important	O
tool	O
to	O
study	O
deacetylation	O
and	O
its	O
effects	O
on	O
the	O
metabolic	O
activation	O
of	O
arylamine	B-MED
and	O
heterocyclic	B-MED
amine	I-MED
carcinogens	O
.	O

p15INK4B	B-GGP
is	O
a	O
potential	O
effector	O
of	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
-	O
induced	O
cell	O
cycle	O
arrest	O
.	O

Transforming	B-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
beta	I-GGP
(	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
)	O
inhibits	O
cell	O
proliferation	O
by	O
inducing	O
a	O
G1	O
-	O
phase	O
cell	O
cycle	O
arrest	O
.	O

Normal	O
progression	O
through	O
G1	O
is	O
promoted	O
by	O
the	O
activity	O
of	O
the	O
cyclin	B-GGP
-	I-GGP
dependent	I-GGP
protein	I-GGP
kinases	I-GGP
CDK4	B-GGP
and	O
CDK6	B-GGP
(	O
ref	O
.	O
2	O
)	O
,	O
which	O
are	O
inhibited	O
by	O
the	O
protein	O
p16INK4	B-GGP
.	O

We	O
have	O
isolated	O
a	O
new	O
member	O
of	O
the	O
p16INK4	B-GGP
family	O
,	O
p15INK4B	B-GGP
.	O

p15	B-GGP
expression	O
is	O
induced	O
approximately	O
30	O
-	O
fold	O
in	O
human	O
keratinocytes	O
by	O
treatment	O
with	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
,	O
suggesting	O
that	O
p15	B-GGP
may	O
act	O
as	O
an	O
effector	O
of	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
-	O
mediated	O
cell	O
cycle	O
arrest	O
.	O

The	O
gene	O
encoding	O
p15	B-GGP
is	O
located	O
on	O
chromosome	B-CC
9	I-CC
adjacent	O
to	O
the	O
p16	B-GGP
gene	O
at	O
a	O
frequent	O
site	O
of	O
chromosomal	B-CC
abnormality	O
in	O
human	O
tumours	O
(	O
9p21	O
)	O
.	O

The	O
t	B-COM
-	I-COM
complex	I-COM
polypeptide	I-COM
1	I-COM
complex	I-COM
is	O
a	O
chaperonin	O
for	O
tubulin	B-GGP
and	O
actin	B-GGP
in	O
vivo	O
.	O

A	O
role	O
in	O
folding	O
newly	O
translated	O
cytoskeletal	B-CC
proteins	O
in	O
the	O
cytosol	B-CC
of	O
eukaryotes	O
has	O
been	O
proposed	O
for	O
t	B-GGP
-	I-GGP
complex	I-GGP
polypeptide	I-GGP
1	I-GGP
(	O
TCP1	B-GGP
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
tubulin	B-GGP
and	O
actin	B-GGP
biogenesis	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
.	O

When	O
extracts	O
of	O
pulse	O
-	O
labeled	O
cells	O
were	O
analyzed	O
by	O
anion	B-MED
-	O
exchange	O
and	O
size	O
-	O
exclusion	O
chromatography	O
,	O
newly	O
synthesized	O
alpha	B-GGP
-	I-GGP
tubulin	I-GGP
,	O
beta	B-GGP
-	I-GGP
tubulin	I-GGP
,	O
and	O
actin	B-GGP
were	O
observed	O
to	O
enter	O
a	O
large	O
molecular	O
mass	O
complex	O
(	O
approximately	O
900	O
kDa	O
)	O
.	O

These	O
proteins	O
were	O
released	O
from	O
this	O
complex	O
capable	O
,	O
in	O
the	O
case	O
of	O
tubulin	B-GGP
,	O
of	O
forming	O
heterodimers	O
.	O

The	O
large	O
molecular	O
mass	O
complexes	O
coeluted	O
with	O
TCP1	B-GGP
and	O
could	O
be	O
immunoprecipitated	O
by	O
using	O
an	O
anti	B-GGP
-	I-GGP
TCP1	I-GGP
antibody	I-GGP
.	O

These	O
findings	O
demonstrate	O
that	O
there	O
is	O
a	O
cytosolic	B-CC
pathway	O
for	O
folding	O
tubulin	B-GGP
and	O
actin	B-GGP
in	O
vivo	O
that	O
involves	O
the	O
TCP1	B-COM
complex	I-COM
.	O

Transactivation	O
of	O
gene	O
expression	O
by	O
Myc	B-GGP
is	O
inhibited	O
by	O
mutation	O
at	O
the	O
phosphorylation	O
sites	O
Thr	B-MED
-	I-MED
58	I-MED
and	O
Ser	B-MED
-	I-MED
62	I-MED
.	O

The	O
product	O
of	O
the	O
human	O
c	B-GGP
-	I-GGP
myc	I-GGP
protooncogene	O
(	O
Myc	B-GGP
)	O
is	O
a	O
sequence	O
-	O
specific	O
DNA	O
binding	O
protein	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
placement	O
of	O
the	O
specific	O
Myc	B-GGP
DNA	O
binding	O
site	O
CACGTG	O
upstream	O
of	O
a	O
luciferase	B-GGP
reporter	O
gene	O
conferred	O
Myc	B-GGP
-	O
stimulated	O
expression	O
that	O
was	O
inhibited	O
by	O
the	O
overexpression	O
of	O
the	O
basic	O
-	O
helix	O
-	O
loop	O
-	O
helix	O
/	O
leucine	B-MED
zipper	O
protein	O
Max	B-GGP
.	O

It	O
was	O
observed	O
that	O
Myc	B-GGP
was	O
phosphorylated	O
in	O
vivo	O
within	O
the	O
NH2	O
-	O
terminal	O
domain	O
at	O
Thr	B-MED
-	I-MED
58	I-MED
and	O
Ser	B-MED
-	I-MED
62	I-MED
.	O

Replacement	O
of	O
these	O
phosphorylation	O
sites	O
with	O
Ala	B-MED
residues	O
caused	O
a	O
marked	O
decrease	O
in	O
Myc	B-GGP
-	O
stimulated	O
reporter	O
gene	O
expression	O
.	O

In	O
contrast	O
,	O
the	O
replacement	O
of	O
Thr	B-MED
-	I-MED
58	I-MED
or	O
Ser	B-MED
-	I-MED
62	I-MED
with	O
an	O
acidic	O
residue	O
(	O
Glu	B-MED
)	O
caused	O
only	O
a	O
small	O
inhibition	O
of	O
transactivation	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
NH2	O
-	O
terminal	O
phosphorylation	O
sites	O
Thr	B-MED
-	I-MED
58	I-MED
and	O
Ser	B-MED
-	I-MED
62	I-MED
are	O
required	O
for	O
high	O
levels	O
of	O
transactivation	O
of	O
gene	O
expression	O
by	O
Myc	B-GGP
.	O

The	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
precursor	O
p105	B-GGP
and	O
the	O
proto	O
-	O
oncogene	O
product	O
Bcl	B-GGP
-	I-GGP
3	I-GGP
are	O
I	B-GGP
kappa	I-GGP
B	I-GGP
molecules	O
and	O
control	O
nuclear	B-CC
translocation	O
of	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
.	O

We	O
have	O
examined	O
the	O
interaction	O
of	O
the	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
precursor	O
p105	B-GGP
with	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
subunits	O
.	O

Similar	O
to	O
an	O
I	B-GGP
kappa	I-GGP
B	I-GGP
molecule	O
,	O
p105	B-GGP
associates	O
in	O
the	O
cytoplasm	B-CC
with	O
p50	B-GGP
or	O
p65	B-GGP
.	O

Through	O
this	O
assembly	O
,	O
p105	B-GGP
efficiently	O
blocks	O
nuclear	B-CC
transfer	O
of	O
either	O
subunit	O
.	O

Moreover	O
,	O
the	O
p105	B-GGP
protein	O
inhibits	O
DNA	O
binding	O
of	O
dimeric	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
subunits	O
in	O
a	O
similar	O
,	O
but	O
not	O
identical	O
,	O
manner	O
to	O
its	O
isolated	O
C	O
-	O
terminal	O
domain	O
,	O
which	O
contains	O
an	O
ankyrin	B-GGP
-	O
like	O
repeat	O
domain	O
(	O
ARD	O
)	O
.	O

The	O
proto	O
-	O
oncogene	O
product	O
Bcl	B-GGP
-	I-GGP
3	I-GGP
also	O
controls	O
nuclear	B-CC
translocation	O
of	O
p50	B-GGP
,	O
but	O
not	O
of	O
p65	B-GGP
.	O

Hence	O
,	O
p50	B-GGP
can	O
be	O
retained	O
in	O
the	O
cytoplasm	B-CC
via	O
at	O
least	O
three	O
distinct	O
interactions	O
:	O
through	O
direct	O
interactions	O
either	O
with	O
its	O
own	O
precursor	O
,	O
with	O
Bcl	B-GGP
-	I-GGP
3	I-GGP
or	O
indirectly	O
through	O
I	B-GGP
kappa	I-GGP
B	I-GGP
alpha	I-GGP
or	O
-	B-GGP
beta	I-GGP
when	O
attached	O
to	O
p65	B-GGP
.	O

We	O
discuss	O
a	O
function	O
of	O
p105	B-GGP
as	O
a	O
cytoplasmic	B-CC
assembly	O
unit	O
for	O
homo	O
-	O
and	O
heteromeric	O
NF	B-COM
-	I-COM
kappa	I-COM
B	I-COM
complexes	O
and	O
of	O
Bcl	B-GGP
-	I-GGP
3	I-GGP
as	O
an	O
I	B-GGP
kappa	I-GGP
B	I-GGP
with	O
novel	O
subunit	O
specificity	O
.	O

Multiple	O
SWI6	B-GGP
-	O
dependent	O
cis	O
-	O
acting	O
elements	O
control	O
SWI4	B-GGP
transcription	O
through	O
the	O
cell	O
cycle	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
SWI4	B-GGP
gene	O
encodes	O
an	O
essential	O
transcription	O
factor	O
which	O
controls	O
gene	O
expression	O
at	O
the	O
G1	O
/	O
S	O
transition	O
of	O
the	O
cell	O
cycle	O
.	O

SWI4	B-GGP
transcription	O
itself	O
is	O
cell	O
cycle	O
regulated	O
,	O
and	O
this	O
periodicity	O
is	O
crucial	O
for	O
the	O
normal	O
cell	O
cycle	O
regulation	O
of	O
HO	B-GGP
and	O
at	O
least	O
two	O
of	O
the	O
G1	B-GGP
cyclins	I-GGP
.	O

Since	O
the	O
regulation	O
of	O
SWI4	B-GGP
is	O
required	O
for	O
normal	O
cell	O
cycle	O
progression	O
,	O
we	O
have	O
characterized	O
cis	O
-	O
and	O
trans	O
-	O
acting	O
regulators	O
of	O
SWI4	B-GGP
transcription	O
.	O

Deletion	O
analysis	O
of	O
the	O
SWI4	B-GGP
promoter	O
has	O
defined	O
a	O
140	O
-	O
bp	O
region	O
which	O
is	O
absolutely	O
required	O
for	O
transcription	O
and	O
can	O
function	O
as	O
a	O
cell	O
cycle	O
-	O
regulated	O
upstream	O
activating	O
sequence	O
(	O
UAS	O
)	O
.	O

The	O
SWI4	B-GGP
UAS	O
contains	O
three	O
potential	O
MluI	B-GGP
cell	O
cycle	O
boxes	O
(	O
MCBs	O
)	O
,	O
which	O
are	O
known	O
cell	O
cycle	O
-	O
regulated	O
promoter	O
elements	O
.	O

Deletion	O
of	O
all	O
three	O
MCBs	O
in	O
the	O
SWI4	B-GGP
UAS	O
decreases	O
the	O
level	O
of	O
SWI4	B-GGP
mRNA	O
10	O
-	O
fold	O
in	O
asynchronous	O
cultures	O
but	O
does	O
not	O
abolish	O
periodicity	O
.	O

These	O
data	O
suggest	O
that	O
MCBs	O
are	O
involved	O
in	O
SWI4	B-GGP
UAS	O
activity	O
,	O
but	O
at	O
least	O
one	O
other	O
periodically	O
regulated	O
element	O
must	O
be	O
present	O
.	O

Since	O
SWI6	B-GGP
is	O
known	O
to	O
bind	O
to	O
MCBs	O
and	O
regulate	O
their	O
activity	O
,	O
the	O
role	O
of	O
SWI6	B-GGP
in	O
SWI4	B-GGP
expression	O
was	O
analyzed	O
.	O

Although	O
the	O
MCBs	O
cannot	O
account	O
for	O
the	O
full	O
cell	O
cycle	O
regulation	O
of	O
SWI4	B-GGP
,	O
mutations	O
in	O
SWI6	B-GGP
eliminate	O
the	O
normal	O
periodicity	O
of	O
SWI4	B-GGP
transcription	O
.	O

This	O
suggests	O
that	O
the	O
novel	O
cell	O
cycle	O
-	O
regulated	O
element	O
within	O
the	O
SWI4	B-GGP
promoter	O
is	O
also	O
SWI6	B-GGP
dependent	O
.	O

The	O
constitutive	O
transcription	O
of	O
SWI4	B-GGP
in	O
SWI6	B-GGP
mutant	O
cells	O
occurs	O
at	O
an	O
intermediate	O
level	O
,	O
which	O
indicates	O
that	O
SWI6	B-GGP
is	O
required	O
for	O
the	O
full	O
activation	O
and	O
repression	O
of	O
SWI4	B-GGP
transcription	O
through	O
the	O
cell	O
cycle	O
.	O

It	O
also	O
suggests	O
that	O
there	O
is	O
another	O
pathway	O
which	O
can	O
activate	O
SWI4	B-GGP
transcription	O
in	O
the	O
absence	O
of	O
SWI6	B-GGP
.	O

The	O
second	O
activator	O
may	O
also	O
target	O
MCB	O
elements	O
,	O
since	O
SWI4	B-GGP
transcription	O
drops	O
dramatically	O
when	O
they	O
are	O
deleted	O
.	O

Human	O
ADP	B-GGP
-	I-GGP
ribosylation	I-GGP
factor	I-GGP
-	O
activated	O
phosphatidylcholine	B-GGP
-	I-GGP
specific	I-GGP
phospholipase	I-GGP
D	I-GGP
defines	O
a	O
new	O
and	O
highly	O
conserved	O
gene	O
family	O
.	O

Activation	O
of	O
phosphatidylcholine	B-GGP
-	I-GGP
specific	I-GGP
phospholipase	I-GGP
D	I-GGP
(	O
PLD	B-GGP
)	O
has	O
been	O
implicated	O
as	O
a	O
critical	O
step	O
in	O
numerous	O
cellular	O
pathways	O
,	O
including	O
signal	O
transduction	O
,	O
membrane	B-CC
trafficking	O
,	O
and	O
the	O
regulation	O
of	O
mitosis	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
the	O
first	O
human	O
PLD	B-GGP
cDNA	O
,	O
which	O
defines	O
a	O
new	O
and	O
highly	O
conserved	O
gene	O
family	O
.	O

Characterization	O
of	O
recombinant	O
human	O
PLD1	B-GGP
reveals	O
that	O
it	O
is	O
membrane	B-CC
-	O
associated	O
,	O
selective	O
for	O
phosphatidylcholine	B-MED
,	O
stimulated	O
by	O
phosphatidylinositol	B-MED
4	I-MED
,	I-MED
5	I-MED
-	I-MED
bisphosphate	I-MED
,	O
activated	O
by	O
the	O
monomeric	O
G	B-GGP
-	I-GGP
protein	I-GGP
ADP	B-GGP
-	I-GGP
ribosylation	I-GGP
factor	I-GGP
-	I-GGP
1	I-GGP
,	O
and	O
inhibited	O
by	O
oleate	B-MED
.	O

PLD1	B-GGP
likely	O
encodes	O
the	O
gene	O
product	O
responsible	O
for	O
the	O
most	O
widely	O
studied	O
endogenous	O
PLD	B-GGP
activity	O
.	O

Protein	B-GGP
kinase	I-GGP
C	I-GGP
is	O
regulated	O
in	O
vivo	O
by	O
three	O
functionally	O
distinct	O
phosphorylations	O
.	O

BACKGROUND	O
:	O
Protein	B-GGP
kinase	I-GGP
Cs	I-GGP
are	O
a	O
family	O
of	O
enzymes	O
that	O
transduce	O
the	O
plethora	O
of	O
signals	O
promoting	O
lipid	B-MED
hydrolysis	O
.	O

Here	O
,	O
we	O
show	O
that	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
must	O
first	O
be	O
processed	O
by	O
three	O
distinct	O
phosphorylations	O
before	O
it	O
is	O
competent	O
to	O
respond	O
to	O
second	O
messengers	O
.	O

RESULTS	O
:	O
We	O
have	O
identified	O
the	O
positions	O
and	O
functions	O
of	O
the	O
in	O
vivo	O
phosphorylation	O
sites	O
of	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
by	O
mass	O
spectrometry	O
and	O
peptide	O
sequencing	O
of	O
native	O
and	O
phosphatase	O
-	O
treated	O
kinase	O
from	O
the	O
detergent	O
-	O
soluble	O
fraction	O
of	O
cells	O
.	O

Specifically	O
,	O
the	O
threonine	B-MED
at	I-MED
position	I-MED
500	I-MED
(	O
T500	B-MED
)	O
on	O
the	O
activation	O
loop	O
,	O
and	O
T641	B-MED
and	O
S660	B-MED
on	O
the	O
carboxyl	O
terminus	O
of	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
beta	I-GGP
II	I-GGP
are	O
phosphorylated	O
in	O
vivo	O
.	O

T500	B-MED
and	O
S660	B-MED
are	O
selectively	O
dephosphorylated	O
in	O
vitro	O
by	O
protein	B-GGP
phosphatase	I-GGP
2A	I-GGP
to	O
yield	O
an	O
enzyme	O
that	O
is	O
still	O
capable	O
of	O
lipid	B-MED
-	O
dependent	O
activation	O
,	O
whereas	O
all	O
three	O
residues	O
are	O
dephosphorylated	O
by	O
protein	B-GGP
phosphatase	I-GGP
1	I-GGP
to	O
yield	O
an	O
inactive	O
enzyme	O
.	O

Biochemical	O
analysis	O
reveals	O
that	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
autophosphorylates	O
on	O
S660	B-MED
,	O
that	O
autophosphorylation	O
on	O
S660	B-MED
follows	O
T641	B-MED
autophosphorylation	O
,	O
that	O
autophosphorylation	O
on	O
S660	B-MED
is	O
accompanied	O
by	O
the	O
release	O
of	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
into	O
the	O
cytosol	B-CC
,	O
and	O
that	O
T500	B-MED
is	O
not	O
an	O
autophosphorylation	O
site	O
.	O

CONCLUSIONS	O
:	O
Structural	O
and	O
biochemical	O
analyses	O
of	O
native	O
and	O
phosphatase	O
-	O
treated	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
indicate	O
that	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
is	O
processed	O
by	O
three	O
phosphorylations	O
.	O

Firstly	O
,	O
trans	O
-	O
phosphorylation	O
on	O
the	O
activation	O
loop	O
(	O
T500	B-MED
)	O
renders	O
it	O
catalytically	O
competent	O
to	O
autophosphorylate	O
.	O

Secondly	O
,	O
a	O
subsequent	O
autophosphorylation	O
on	O
the	O
carboxyl	O
terminus	O
(	O
T641	B-MED
)	O
maintains	O
catalytic	O
competence	O
.	O

Thirdly	O
,	O
a	O
second	O
autophosphorylation	O
on	O
the	O
carboxyl	O
terminus	O
(	O
S660	B-MED
)	O
regulates	O
the	O
enzyme	O
'	O
s	O
subcellular	B-CC
localization	O
.	O

The	O
conservation	O
of	O
each	O
of	O
these	O
residues	O
(	O
or	O
an	O
acidic	O
residue	O
)	O
in	O
conventional	O
,	O
novel	O
and	O
atypical	O
protein	B-GGP
kinase	I-GGP
Cs	I-GGP
underscores	O
the	O
essential	O
role	O
for	O
each	O
in	O
regulating	O
the	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
family	O
.	O

Molecular	O
mechanisms	O
of	O
renal	O
apical	O
Na	B-MED
/	O
phosphate	B-MED
cotransport	O
.	O

In	O
the	O
proximal	O
tubule	O
,	O
sodium	B-MED
-	O
dependent	O
transport	O
of	O
phosphate	B-MED
(	O
Pi	B-MED
)	O
through	O
the	O
brush	O
-	O
border	O
membrane	O
represents	O
the	O
initial	O
step	O
in	O
Pi	B-MED
reabsorption	O
.	O

cDNAs	O
encoding	O
several	O
renal	O
proximal	O
tubule	O
apical	O
Na	B-MED
/	O
Pi	B-MED
cotransport	O
systems	O
have	O
been	O
identified	O
.	O

These	O
Na	B-GGP
/	I-GGP
Pi	I-GGP
cotransporters	I-GGP
are	O
subdivided	O
into	O
type	O
I	O
(	O
NaPi	B-GGP
-	I-GGP
1	I-GGP
)	O
and	O
a	O
type	O
II	O
(	O
NaPi	B-GGP
-	I-GGP
2	I-GGP
)	O
.	O

Electrophysiological	O
studies	O
reveal	O
that	O
Pi	B-MED
transport	O
by	O
Na	B-GGP
/	I-GGP
Pi	I-GGP
cotransporters	I-GGP
is	O
electrogenic	O
.	O

Regulation	O
of	O
proximal	O
Pi	B-MED
reabsorption	O
by	O
dietary	O
Pi	B-MED
intake	O
and	O
parathyroid	B-GGP
hormone	I-GGP
is	O
primarily	O
due	O
to	O
an	O
alteration	O
of	O
apical	O
type	B-GGP
II	I-GGP
Na	I-GGP
/	I-GGP
Pi	I-GGP
cotransport	I-GGP
;	O
a	O
rapid	O
change	O
of	O
brush	O
-	O
border	O
Na	B-MED
/	O
Pi	B-MED
cotransport	O
most	O
likely	O
occurs	O
via	O
an	O
endo	O
/	O
exocytic	O
mechanism	O
.	O

No	O
evidence	O
for	O
physiological	O
control	O
of	O
type	B-GGP
I	I-GGP
cotransporters	I-GGP
has	O
been	O
obtained	O
.	O

Altered	O
Pi	B-MED
reabsorption	O
as	O
observed	O
in	O
X	O
-	O
linked	O
hypophosphatemia	O
is	O
largely	O
via	O
the	O
type	B-GGP
II	I-GGP
Na	I-GGP
/	I-GGP
Pi	I-GGP
cotransporter	I-GGP
.	O

Regional	O
expression	O
of	O
sodium	B-COM
pump	I-COM
subunits	O
isoforms	O
and	O
Na	B-GGP
+	I-GGP
-	I-GGP
Ca	I-GGP
+	I-GGP
+	I-GGP
exchanger	I-GGP
in	O
the	O
human	O
heart	O
.	O

Cardiac	O
glycosides	B-MED
exert	O
a	O
positive	O
inotropic	O
effect	O
by	O
inhibiting	O
sodium	B-COM
pump	I-COM
(	O
Na	B-COM
,	I-COM
K	I-COM
-	I-COM
ATPase	I-COM
)	O
activity	O
,	O
decreasing	O
the	O
driving	O
force	O
for	O
Na	B-MED
+	I-MED
-	O
Ca	B-MED
+	I-MED
+	I-MED
exchange	O
,	O
and	O
increasing	O
cellular	O
content	O
and	O
release	O
of	O
Ca	B-MED
+	I-MED
+	I-MED
during	O
depolarization	O
.	O

Since	O
the	O
inotropic	O
response	O
will	O
be	O
a	O
function	O
of	O
the	O
level	O
of	O
expression	O
of	O
sodium	B-COM
pumps	I-COM
,	O
which	O
are	O
alpha	O
(	O
beta	O
)	O
heterodimers	O
,	O
and	O
of	O
Na	B-GGP
+	I-GGP
-	I-GGP
Ca	I-GGP
+	I-GGP
+	I-GGP
exchangers	I-GGP
,	O
this	O
study	O
aimed	O
to	O
determine	O
the	O
regional	O
pattern	O
of	O
expression	O
of	O
these	O
transporters	O
in	O
the	O
heart	O
.	O

Immunoblot	O
assays	O
of	O
homogenate	O
from	O
atria	O
,	O
ventricles	O
,	O
and	O
septa	O
of	O
14	O
nonfailing	O
human	O
hearts	O
established	O
expression	O
of	O
Na	B-GGP
,	I-GGP
K	I-GGP
-	I-GGP
ATPase	I-GGP
alpha1	I-GGP
,	O
alpha2	B-GGP
,	O
alpha3	B-GGP
,	O
beta1	B-GGP
,	O
and	O
Na	B-GGP
+	I-GGP
-	I-GGP
Ca	I-GGP
+	I-GGP
+	I-GGP
exchangers	I-GGP
in	O
all	O
regions	O
.	O

Na	B-GGP
,	I-GGP
K	I-GGP
-	I-GGP
ATPase	I-GGP
beta2	I-GGP
expression	O
is	O
negligible	O
,	O
indicating	O
that	O
the	O
human	O
cardiac	O
glycoside	B-MED
receptors	O
are	O
alpha1beta1	B-COM
,	O
alpha2beta1	B-COM
,	O
and	O
alpha3beta1	B-COM
.	O

alpha3	B-GGP
,	O
beta1	B-GGP
,	O
sodium	B-COM
pump	I-COM
activity	O
,	O
and	O
Na	B-GGP
+	I-GGP
-	I-GGP
Ca	I-GGP
+	I-GGP
+	I-GGP
exchanger	I-GGP
levels	O
were	O
30	O
-	O
50	O
%	O
lower	O
in	O
atria	O
compared	O
to	O
ventricles	O
and	O
/	O
or	O
septum	O
;	O
differences	O
between	O
ventricles	O
and	O
septum	O
were	O
insignificant	O
.	O

Functionally	O
,	O
the	O
EC50	O
of	O
the	O
sodium	B-MED
channel	O
activator	O
BDF	B-MED
9148	I-MED
to	O
increase	O
force	O
of	O
contraction	O
was	O
lower	O
in	O
atria	O
than	O
ventricle	O
muscle	O
strips	O
(	O
0	O
.	O
36	O
vs	O
.	O
1	O
.	O
54	O
microM	O
)	O
.	O

These	O
results	O
define	O
the	O
distribution	O
of	O
the	O
cardiac	O
glycoside	B-COM
receptor	I-COM
isoforms	O
in	O
the	O
human	O
heart	O
and	O
they	O
demonstrate	O
that	O
atria	O
have	O
fewer	O
sodium	B-COM
pumps	I-COM
,	O
fewer	O
Na	B-GGP
+	I-GGP
-	I-GGP
Ca	I-GGP
+	I-GGP
+	I-GGP
exchangers	I-GGP
,	O
and	O
enhanced	O
sensitivity	O
to	O
inotropic	O
stimulation	O
compared	O
to	O
ventricles	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
adenosine	B-GGP
kinase	I-GGP
gene	O
from	O
rat	O
and	O
human	O
tissues	O
.	O

Adenosine	B-GGP
kinase	I-GGP
is	O
ubiquitous	O
in	O
eukaryotes	O
and	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
regulation	O
of	O
the	O
intracellular	B-CC
levels	O
of	O
adenosine	B-MED
,	O
an	O
important	O
physiological	O
effector	O
of	O
many	O
cells	O
and	O
tissues	O
.	O

In	O
this	O
paper	O
we	O
report	O
the	O
cloning	O
of	O
cDNAs	O
encoding	O
adenosine	B-GGP
kinase	I-GGP
from	O
both	O
rat	O
and	O
human	O
tissues	O
.	O

Two	O
distinct	O
forms	O
of	O
adenosine	B-GGP
kinase	I-GGP
mRNA	O
were	O
identified	O
in	O
human	O
tissues	O
.	O

Sequence	O
variation	O
between	O
the	O
two	O
forms	O
is	O
restricted	O
to	O
the	O
extreme	O
5	O
'	O
-	O
end	O
of	O
the	O
adenosine	B-GGP
kinase	I-GGP
mRNA	O
,	O
including	O
a	O
portion	O
of	O
the	O
coding	O
region	O
,	O
and	O
is	O
consistent	O
with	O
differential	O
splicing	O
of	O
a	O
single	O
transcriptional	O
product	O
.	O

We	O
have	O
expressed	O
both	O
forms	O
in	O
E	O
.	O
coli	O
and	O
produced	O
soluble	O
active	O
enzyme	O
which	O
catalyzes	O
the	O
phosphorylation	O
of	O
adenosine	B-MED
with	O
high	O
specific	O
activity	O
in	O
vitro	O
and	O
is	O
susceptible	O
to	O
known	O
adenosine	B-GGP
kinase	I-GGP
inhibitors	O
.	O

Human	O
Myt1	B-GGP
is	O
a	O
cell	O
cycle	O
-	O
regulated	O
kinase	O
that	O
inhibits	O
Cdc2	B-GGP
but	O
not	O
Cdk2	B-GGP
activity	O
.	O

Activation	O
of	O
the	O
Cdc2	B-COM
.	I-COM
cyclin	I-COM
B	I-COM
kinase	O
is	O
a	O
pivotal	O
step	O
of	O
mitotic	O
initiation	O
.	O

This	O
step	O
is	O
mediated	O
principally	O
by	O
the	O
dephosphorylation	O
of	O
residues	O
threonine	B-MED
14	I-MED
(	O
Thr14	B-MED
)	O
and	O
tyrosine	B-MED
15	I-MED
(	O
Tyr15	B-MED
)	O
on	O
the	O
Cdc2	B-GGP
catalytic	O
subunit	O
.	O

In	O
several	O
organisms	O
homologs	O
of	O
the	O
Wee1	B-GGP
kinase	O
have	O
been	O
shown	O
to	O
be	O
the	O
major	O
activity	O
responsible	O
for	O
phosphorylating	O
the	O
Tyr15	B-MED
inhibitory	O
site	O
.	O

A	O
membrane	B-CC
-	O
bound	O
kinase	O
capable	O
of	O
phosphorylating	O
residue	O
Thr14	B-MED
,	O
the	O
Myt1	B-GGP
kinase	O
,	O
has	O
been	O
identified	O
in	O
the	O
frog	O
Xenopus	O
laevis	O
and	O
more	O
recently	O
in	O
human	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
substrate	O
specificity	O
and	O
cell	O
cycle	O
regulation	O
of	O
the	O
human	O
Myt1	B-GGP
kinase	O
.	O

We	O
find	O
that	O
human	O
Myt1	B-GGP
phosphorylates	O
and	O
inactivates	O
Cdc2	B-GGP
-	O
containing	O
cyclin	B-COM
complexes	I-COM
but	O
not	O
complexes	O
containing	O
Cdk2	B-GGP
or	O
Cdk4	B-GGP
.	O

Analysis	O
of	O
endogenous	O
Myt1	B-GGP
demonstrates	O
that	O
it	O
remains	O
membrane	B-CC
-	O
bound	O
throughout	O
the	O
cell	O
cycle	O
,	O
but	O
its	O
kinase	O
activity	O
decreased	O
during	O
M	O
phase	O
arrest	O
,	O
when	O
Myt1	B-GGP
became	O
hyperphosphorylated	O
.	O

Further	O
,	O
Cdc2	B-COM
.	I-COM
cyclin	I-COM
B1	I-COM
was	O
capable	O
of	O
phosphorylating	O
Myt1	B-GGP
in	O
vitro	O
,	O
but	O
this	O
phosphorylation	O
did	O
not	O
affect	O
Myt1	B-GGP
kinase	O
activity	O
.	O

These	O
findings	O
suggest	O
that	O
human	O
Myt1	B-GGP
is	O
negatively	O
regulated	O
by	O
an	O
M	O
phase	O
-	O
activated	O
kinase	O
and	O
that	O
Myt1	B-GGP
inhibits	O
mitosis	O
due	O
to	O
its	O
specificity	O
for	O
Cdc2	B-COM
.	I-COM
cyclin	I-COM
complexes	O
.	O

Cloning	O
of	O
a	O
human	B-GGP
phosphoinositide	I-GGP
3	I-GGP
-	I-GGP
kinase	I-GGP
with	O
a	O
C2	O
domain	O
that	O
displays	O
reduced	O
sensitivity	O
to	O
the	O
inhibitor	O
wortmannin	B-MED
.	O

The	O
generation	O
of	O
phosphatidylinositide	B-MED
3	I-MED
-	I-MED
phosphates	I-MED
has	O
been	O
observed	O
in	O
a	O
variety	O
of	O
cellular	O
responses	O
.	O

The	O
enzymes	O
that	O
mediate	O
synthesis	O
are	O
the	O
phosphoinositide	B-GGP
3	I-GGP
-	I-GGP
kinases	I-GGP
(	O
PI3	B-GGP
-	I-GGP
Ks	I-GGP
)	O
that	O
form	O
a	O
family	O
of	O
structurally	O
diverse	O
enzymes	O
with	O
distinct	O
substrate	O
specificities	O
.	O

In	O
this	O
paper	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
a	O
novel	O
human	O
PI3	B-GGP
-	I-GGP
K	I-GGP
,	O
namely	O
PI3	B-GGP
-	I-GGP
K	I-GGP
-	I-GGP
C2	I-GGP
alpha	I-GGP
,	O
which	O
contains	O
a	O
C	O
-	O
terminal	O
C2	O
domain	O
.	O

This	O
enzyme	O
can	O
be	O
assigned	O
to	O
the	O
class	B-GGP
II	I-GGP
PI3	I-GGP
-	I-GGP
Ks	I-GGP
,	O
which	O
was	O
defined	O
by	O
characterization	O
of	O
the	O
Drosophila	O
68D	B-GGP
enzyme	O
and	O
includes	O
the	O
recently	O
described	O
murine	O
enzymes	O
m	B-GGP
-	I-GGP
cpk	I-GGP
and	O
p170	B-GGP
.	O

Despite	O
the	O
overall	O
similarity	O
in	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
murine	O
and	O
human	O
enzymes	O
,	O
which	O
suggests	O
that	O
they	O
are	O
encoded	O
by	O
closely	O
related	O
genes	O
,	O
these	O
molecules	O
show	O
marked	O
sequence	O
heterogeneity	O
at	O
their	O
N	O
-	O
termini	O
.	O

Biochemical	O
analysis	O
of	O
recombinant	O
PI3	B-GGP
-	I-GGP
K	I-GGP
-	I-GGP
C2	I-GGP
alpha	I-GGP
demonstrates	O
a	O
restricted	O
lipid	B-MED
substrate	O
specificity	O
.	O

As	O
reported	O
for	O
other	O
members	O
of	O
this	O
class	O
,	O
the	O
enzyme	O
only	O
phosphorylates	O
PtdIns	B-MED
and	O
PtdIns4P	B-MED
when	O
the	O
lipids	B-MED
are	O
presented	O
alone	O
.	O

However	O
,	O
when	O
lipids	B-MED
were	O
presented	O
together	O
with	O
phosphatidylserine	B-MED
acting	O
as	O
a	O
carrier	O
,	O
phosphorylation	O
of	O
PtdIns	B-MED
(	I-MED
4	I-MED
,	I-MED
5	I-MED
)	I-MED
P2	I-MED
was	O
also	O
observed	O
.	O

The	O
catalytic	O
activity	O
of	O
PI3	B-GGP
-	I-GGP
K	I-GGP
-	I-GGP
C2	I-GGP
alpha	I-GGP
is	O
refractory	O
to	O
concentrations	O
of	O
wortmannin	B-MED
and	O
LY294002	B-MED
which	O
inhibit	O
the	O
PI3	B-GGP
-	I-GGP
K	I-GGP
activity	O
of	O
other	O
family	O
members	O
.	O

The	O
comparative	O
insensitivity	O
of	O
PI3	B-GGP
-	I-GGP
K	I-GGP
-	I-GGP
C2	I-GGP
alpha	I-GGP
to	O
these	O
inhibitors	O
suggests	O
that	O
their	O
use	O
should	O
be	O
reevaluated	O
in	O
the	O
study	O
of	O
PI3	B-GGP
-	I-GGP
Ks	I-GGP
.	O

Crystal	O
structure	O
of	O
a	O
calcium	B-MED
-	O
phospholipid	B-MED
binding	O
domain	O
from	O
cytosolic	B-CC
phospholipase	B-GGP
A2	I-GGP
.	O

Cytosolic	B-GGP
phospholipase	I-GGP
A2	I-GGP
(	O
cPLA2	B-GGP
)	O
is	O
a	O
calcium	B-MED
-	O
sensitive	O
85	O
-	O
kDa	O
enzyme	O
that	O
hydrolyzes	O
arachidonic	B-MED
acid	I-MED
-	O
containing	O
membrane	B-CC
phospholipids	B-MED
to	O
initiate	O
the	O
biosynthesis	O
of	O
eicosanoids	B-MED
and	O
platelet	B-MED
-	I-MED
activating	I-MED
factor	I-MED
,	O
potent	O
inflammatory	O
mediators	O
.	O

The	O
calcium	B-MED
-	O
dependent	O
activation	O
of	O
the	O
enzyme	O
is	O
mediated	O
by	O
an	O
N	O
-	O
terminal	O
C2	O
domain	O
,	O
which	O
is	O
responsible	O
for	O
calcium	B-MED
-	O
dependent	O
translocation	O
of	O
the	O
enzyme	O
to	O
membranes	B-CC
and	O
that	O
enables	O
the	O
intact	O
enzyme	O
to	O
hydrolyze	O
membrane	B-CC
-	O
resident	O
substrates	O
.	O

The	O
2	O
.	O
4	O
-	O
A	O
x	O
-	O
ray	O
crystal	O
structure	O
of	O
this	O
C2	O
domain	O
was	O
solved	O
by	O
multiple	O
isomorphous	O
replacement	O
and	O
reveals	O
a	O
beta	O
-	O
sandwich	O
with	O
the	O
same	O
topology	O
as	O
the	O
C2	O
domain	O
from	O
phosphoinositide	B-MED
-	O
specific	O
phospholipase	B-GGP
C	I-GGP
delta	I-GGP
1	I-GGP
.	O

Two	O
clusters	O
of	O
exposed	O
hydrophobic	O
residues	O
surround	O
two	O
adjacent	O
calcium	B-MED
binding	O
sites	O
.	O

This	O
region	O
,	O
along	O
with	O
an	O
adjoining	O
strip	O
of	O
basic	O
residues	O
,	O
appear	O
to	O
constitute	O
the	O
membrane	B-CC
binding	O
motif	O
.	O

The	O
structure	O
provides	O
a	O
striking	O
insight	O
into	O
the	O
relative	O
importance	O
of	O
hydrophobic	O
and	O
electrostatic	O
components	O
of	O
membrane	B-CC
binding	O
for	O
cPLA2	B-GGP
.	O

Although	O
hydrophobic	O
interactions	O
predominate	O
for	O
cPLA2	B-GGP
,	O
for	O
other	O
C2	O
domains	O
such	O
as	O
in	O
"	O
conventional	O
"	O
protein	B-GGP
kinase	I-GGP
C	I-GGP
and	O
synaptotagmins	B-GGP
,	O
electrostatic	O
forces	O
prevail	O
.	O

Mammalian	O
thioredoxin	B-GGP
is	O
a	O
direct	O
inhibitor	O
of	O
apoptosis	B-GGP
signal	I-GGP
-	I-GGP
regulating	I-GGP
kinase	I-GGP
(	I-GGP
ASK	I-GGP
)	I-GGP
1	I-GGP
.	O

Apoptosis	B-GGP
signal	I-GGP
-	I-GGP
regulating	I-GGP
kinase	I-GGP
(	I-GGP
ASK	I-GGP
)	I-GGP
1	I-GGP
was	O
recently	O
identified	O
as	O
a	O
mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
(	I-GGP
MAP	I-GGP
)	I-GGP
kinase	I-GGP
kinase	I-GGP
kinase	I-GGP
which	O
activates	O
the	O
c	B-GGP
-	I-GGP
Jun	I-GGP
N	I-GGP
-	I-GGP
terminal	I-GGP
kinase	I-GGP
(	O
JNK	B-GGP
)	O
and	O
p38	B-GGP
MAP	I-GGP
kinase	I-GGP
pathways	O
and	O
is	O
required	O
for	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
(	I-GGP
TNF	I-GGP
)	I-GGP
-	I-GGP
alpha	I-GGP
-	O
induced	O
apoptosis	O
;	O
however	O
,	O
the	O
mechanism	O
regulating	O
ASK1	B-GGP
activity	O
is	O
unknown	O
.	O

Through	O
genetic	O
screening	O
for	O
ASK1	B-GGP
-	O
binding	O
proteins	O
,	O
thioredoxin	B-GGP
(	O
Trx	B-GGP
)	O
,	O
a	O
reduction	O
/	O
oxidation	O
(	O
redox	O
)	O
-	O
regulatory	O
protein	O
thought	O
to	O
have	O
anti	O
-	O
apoptotic	O
effects	O
,	O
was	O
identified	O
as	O
an	O
interacting	O
partner	O
of	O
ASK1	B-GGP
.	O

Trx	B-GGP
associated	O
with	O
the	O
N	O
-	O
terminal	O
portion	O
of	O
ASK1	B-GGP
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Expression	O
of	O
Trx	B-GGP
inhibited	O
ASK1	B-GGP
kinase	O
activity	O
and	O
the	O
subsequent	O
ASK1	B-GGP
-	O
dependent	O
apoptosis	O
.	O

Treatment	O
of	O
cells	O
with	O
N	B-MED
-	I-MED
acetyl	I-MED
-	I-MED
L	I-MED
-	I-MED
cysteine	I-MED
also	O
inhibited	O
serum	O
withdrawal	O
-	O
,	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
-	O
and	O
hydrogen	B-MED
peroxide	I-MED
-	O
induced	O
activation	O
of	O
ASK1	B-GGP
as	O
well	O
as	O
apoptosis	O
.	O

The	O
interaction	O
between	O
Trx	B-GGP
and	O
ASK1	B-GGP
was	O
found	O
to	O
be	O
highly	O
dependent	O
on	O
the	O
redox	O
status	O
of	O
Trx	B-GGP
.	O

Moreover	O
,	O
inhibition	O
of	O
Trx	B-GGP
resulted	O
in	O
activation	O
of	O
endogenous	O
ASK1	B-GGP
activity	O
,	O
suggesting	O
that	O
Trx	B-GGP
is	O
a	O
physiological	O
inhibitor	O
of	O
ASK1	B-GGP
.	O

The	O
evidence	O
that	O
Trx	B-GGP
is	O
a	O
negative	O
regulator	O
of	O
ASK1	B-GGP
suggests	O
possible	O
mechanisms	O
for	O
redox	O
regulation	O
of	O
the	O
apoptosis	O
signal	O
transduction	O
pathway	O
as	O
well	O
as	O
the	O
effects	O
of	O
antioxidants	O
against	O
cytokine	O
-	O
and	O
stress	O
-	O
induced	O
apoptosis	O
.	O

The	O
CD39	B-GGP
-	O
like	O
gene	O
family	O
:	O
identification	O
of	O
three	O
new	O
human	O
members	O
(	O
CD39L2	B-GGP
,	O
CD39L3	B-GGP
,	O
and	O
CD39L4	B-GGP
)	O
,	O
their	O
murine	O
homologues	O
,	O
and	O
a	O
member	O
of	O
the	O
gene	O
family	O
from	O
Drosophila	O
melanogaster	O
.	O

The	O
human	O
lymphoid	O
cell	O
activation	O
antigen	O
CD39	B-GGP
is	O
a	O
known	O
E	B-GGP
-	I-GGP
type	I-GGP
apyrase	I-GGP
that	O
hydrolyzes	O
extracellular	B-CC
ATP	B-MED
and	O
ADP	B-MED
,	O
a	O
function	O
important	O
in	O
homotypic	O
adhesion	O
,	O
platelet	O
aggregation	O
,	O
and	O
removal	O
by	O
activated	O
lymphocytes	O
of	O
the	O
lytic	O
effect	O
of	O
ATP	B-MED
.	O

The	O
recently	O
identified	O
putative	O
rat	O
homologue	O
of	O
CD39L1	B-GGP
has	O
been	O
shown	O
to	O
have	O
E	B-GGP
-	I-GGP
type	I-GGP
ecto	I-GGP
-	I-GGP
ATPase	I-GGP
activity	O
,	O
by	O
hydrolyzing	O
extracellular	B-CC
ATP	B-MED
.	O

We	O
have	O
characterized	O
three	O
novel	O
CD39	B-GGP
-	O
like	O
transcripts	O
,	O
CD39L2	B-GGP
,	O
CD39L3	B-GGP
,	O
and	O
CD39L4	B-GGP
,	O
which	O
share	O
extensive	O
amino	O
acid	O
homology	O
with	O
other	O
nucleotide	B-GGP
triphosphatases	I-GGP
in	O
vertebrates	O
,	O
invertebrates	O
,	O
and	O
plants	O
,	O
suggesting	O
that	O
these	O
genes	O
also	O
encode	O
proteins	O
with	O
ecto	B-GGP
-	I-GGP
nucleotidase	I-GGP
activity	O
.	O

Isolation	O
and	O
sequencing	O
of	O
full	O
-	O
length	O
cDNA	O
clones	O
for	O
each	O
gene	O
identified	O
putative	O
proteins	O
of	O
485	O
,	O
529	O
,	O
and	O
429	O
amino	O
acids	O
.	O

The	O
expression	O
pattern	O
of	O
all	O
five	O
human	O
members	O
of	O
the	O
gene	O
family	O
was	O
analyzed	O
.	O

CD39L2	B-GGP
,	O
CD39L3	B-GGP
,	O
and	O
CD39L4	B-GGP
were	O
mapped	O
on	O
the	O
human	O
genome	O
,	O
and	O
the	O
murine	O
homologues	O
identified	O
with	O
the	O
putative	O
map	O
locations	O
were	O
assigned	O
on	O
the	O
basis	O
of	O
regions	O
of	O
conserved	O
gene	O
order	O
between	O
human	O
and	O
mouse	O
chromosomes	B-CC
.	O

The	O
map	O
location	O
of	O
mcd39l4	O
places	O
the	O
gene	O
within	O
a	O
region	O
associated	O
with	O
audiogenic	O
seizure	O
susceptibility	O
in	O
mouse	O
.	O

This	O
disorder	O
is	O
characterized	O
by	O
convulsions	O
induced	O
by	O
loud	O
high	O
-	O
frequency	O
sound	O
and	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
increased	O
nucleotide	B-GGP
triphosphatase	I-GGP
activity	O
.	O

Activation	O
of	O
the	O
ATM	B-GGP
kinase	O
by	O
ionizing	O
radiation	O
and	O
phosphorylation	O
of	O
p53	B-GGP
.	O

The	O
p53	B-GGP
tumor	O
suppressor	O
protein	O
is	O
activated	O
and	O
phosphorylated	O
on	O
serine	B-MED
-	I-MED
15	I-MED
in	O
response	O
to	O
various	O
DNA	O
damaging	O
agents	O
.	O

The	O
gene	O
product	O
mutated	B-GGP
in	I-GGP
ataxia	I-GGP
telangiectasia	I-GGP
,	O
ATM	B-GGP
,	O
acts	O
upstream	O
of	O
p53	B-GGP
in	O
a	O
signal	O
transduction	O
pathway	O
initiated	O
by	O
ionizing	O
radiation	O
.	O

Immunoprecipitated	O
ATM	B-GGP
had	O
intrinsic	O
protein	O
kinase	O
activity	O
and	O
phosphorylated	O
p53	B-GGP
on	O
serine	B-MED
-	I-MED
15	I-MED
in	O
a	O
manganese	B-MED
-	O
dependent	O
manner	O
.	O

Ionizing	O
radiation	O
,	O
but	O
not	O
ultraviolet	O
radiation	O
,	O
rapidly	O
enhanced	O
this	O
p53	B-GGP
-	O
directed	O
kinase	O
activity	O
of	O
endogenous	O
ATM	B-GGP
.	O

These	O
observations	O
,	O
along	O
with	O
the	O
fact	O
that	O
phosphorylation	O
of	O
p53	B-GGP
on	O
serine	B-MED
-	I-MED
15	I-MED
in	O
response	O
to	O
ionizing	O
radiation	O
is	O
reduced	O
in	O
ataxia	O
telangiectasia	O
cells	O
,	O
suggest	O
that	O
ATM	B-GGP
is	O
a	O
protein	O
kinase	O
that	O
phosphorylates	O
p53	B-GGP
in	O
vivo	O
.	O

Human	O
CUL	B-GGP
-	I-GGP
1	I-GGP
associates	O
with	O
the	O
SKP1	B-COM
/	I-COM
SKP2	I-COM
complex	O
and	O
regulates	O
p21	B-GGP
(	O
CIP1	B-GGP
/	O
WAF1	B-GGP
)	O
and	O
cyclin	B-GGP
D	I-GGP
proteins	O
.	O

Deregulation	O
of	O
cell	O
proliferation	O
is	O
a	O
hallmark	O
of	O
cancer	O
.	O

In	O
many	O
transformed	O
cells	O
,	O
the	O
cyclin	B-COM
A	I-COM
/	I-COM
CDK2	I-COM
complex	O
that	O
contains	O
S	B-GGP
-	I-GGP
phase	I-GGP
kinase	I-GGP
associated	I-GGP
proteins	I-GGP
1	I-GGP
and	O
2	B-GGP
(	O
SKP1	B-GGP
and	O
SKP2	B-GGP
)	O
is	O
highly	O
induced	O
.	O

To	O
determine	O
the	O
roles	O
of	O
this	O
complex	O
in	O
the	O
cell	O
cycle	O
regulation	O
and	O
transformation	O
,	O
we	O
have	O
examined	O
the	O
composition	O
of	O
this	O
complex	O
.	O

We	O
report	O
here	O
that	O
this	O
complex	O
contained	O
an	O
additional	O
protein	O
,	O
human	O
CUL	B-GGP
-	I-GGP
1	I-GGP
,	O
a	O
member	O
of	O
the	O
cullin	B-GGP
/	O
CDC53	B-GGP
family	O
.	O

The	O
identification	O
of	O
CUL	B-GGP
-	I-GGP
1	I-GGP
as	O
a	O
member	O
of	O
the	O
complex	O
raises	O
the	O
possibility	O
that	O
the	O
p19	B-COM
(	I-COM
SKP1	I-COM
)	I-COM
/	I-COM
p45	I-COM
(	I-COM
SKP2	I-COM
)	I-COM
/	I-COM
CUL	I-COM
-	I-COM
1	I-COM
complex	O
may	O
function	O
as	O
the	O
yeast	O
SKP1	B-COM
-	I-COM
CDC53	I-COM
-	I-COM
F	I-COM
-	I-COM
box	I-COM
(	O
SCF	B-COM
)	O
protein	O
complex	O
that	O
acts	O
as	O
a	O
ubiquitin	B-GGP
E3	O
ligase	O
to	O
regulate	O
the	O
G1	O
/	O
S	O
transition	O
.	O

In	O
mammalian	O
cells	O
,	O
cyclin	B-GGP
D	I-GGP
,	O
p21	B-GGP
(	O
CIP1	B-GGP
/	O
WAF1	B-GGP
)	O
,	O
and	O
p27	B-GGP
(	O
KIP1	B-GGP
)	O
are	O
short	O
-	O
lived	O
proteins	O
that	O
are	O
controlled	O
by	O
ubiquitin	B-GGP
-	O
dependent	O
proteolysis	O
.	O

To	O
determine	O
the	O
potential	O
in	O
vivo	O
targets	O
of	O
the	O
p19	B-COM
(	I-COM
SKP1	I-COM
)	I-COM
/	I-COM
p45	I-COM
(	I-COM
SKP2	I-COM
)	I-COM
/	I-COM
CUL	I-COM
-	I-COM
1	I-COM
complex	O
,	O
we	O
have	O
used	O
the	O
specific	O
antisense	O
oligodeoxynucleotides	O
against	O
either	O
SKP1	B-GGP
,	O
SKP2	B-GGP
,	O
or	O
CUL	B-GGP
-	I-GGP
1	I-GGP
RNA	O
to	O
inhibit	O
their	O
expression	O
.	O

Treatment	O
of	O
cells	O
with	O
these	O
oligonucleotides	O
caused	O
the	O
selective	O
accumulation	O
of	O
p21	B-GGP
and	O
cyclin	B-GGP
D	I-GGP
proteins	O
.	O

The	O
protein	O
level	O
of	O
p27	B-GGP
was	O
not	O
affected	O
.	O

These	O
data	O
suggest	O
that	O
the	O
human	O
p19	B-COM
(	I-COM
SKP1	I-COM
)	I-COM
/	I-COM
p45	I-COM
(	I-COM
SKP2	I-COM
)	I-COM
/	I-COM
CUL	I-COM
-	I-COM
1	I-COM
complex	O
is	O
likely	O
to	O
function	O
as	O
an	O
E3	O
ligase	O
to	O
selectively	O
target	O
cyclin	B-GGP
D	I-GGP
and	O
p21	B-GGP
for	O
the	O
ubiquitin	B-GGP
-	O
dependent	O
protein	O
degradation	O
.	O

Aberrant	O
expression	O
of	O
human	O
p19	B-COM
(	I-COM
SKP1	I-COM
)	I-COM
/	I-COM
p45	I-COM
(	I-COM
SKP2	I-COM
)	I-COM
/	I-COM
CUL	I-COM
-	I-COM
1	I-COM
complex	O
thus	O
may	O
contribute	O
to	O
tumorigenesis	O
by	O
regulating	O
the	O
protein	O
levels	O
of	O
G1	O
cell	O
cycle	O
regulators	O
.	O

Nuclear	B-CC
export	O
of	O
the	O
stress	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
p38	B-GGP
mediated	O
by	O
its	O
substrate	O
MAPKAP	B-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
.	O

BACKGROUND	O
:	O
Mitogen	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
(	I-GGP
MAP	I-GGP
)	I-GGP
kinases	I-GGP
(	O
or	O
extracellular	B-GGP
signal	I-GGP
regulated	I-GGP
kinases	I-GGP
;	O
Erks	B-GGP
)	O
and	O
stress	B-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
(	I-GGP
SAP	I-GGP
)	I-GGP
kinases	I-GGP
mediate	O
cellular	O
responses	O
to	O
a	O
wide	O
variety	O
of	O
signals	O
.	O

In	O
the	O
Erk	B-GGP
MAP	B-GGP
kinase	I-GGP
pathway	O
,	O
activation	O
of	O
MAP	B-GGP
kinases	I-GGP
takes	O
place	O
in	O
the	O
cytoplasm	B-CC
and	O
the	O
activated	O
enzyme	O
moves	O
to	O
the	O
nucleus	B-CC
.	O

This	O
translocation	O
to	O
the	O
nucleus	B-CC
is	O
essential	O
to	O
MAP	B-GGP
kinase	I-GGP
signalling	O
because	O
it	O
enables	O
the	O
kinase	O
to	O
phosphorylate	O
transcription	O
factors	O
.	O

Whether	O
components	O
of	O
the	O
pathway	O
mediated	O
by	O
the	O
SAP	B-GGP
kinase	I-GGP
p38	I-GGP
change	O
their	O
cellular	O
location	O
on	O
activation	O
is	O
not	O
clear	O
;	O
we	O
have	O
therefore	O
studied	O
the	O
cellular	O
localisation	O
of	O
components	O
of	O
this	O
pathway	O
before	O
and	O
after	O
stimulation	O
.	O

RESULTS	O
:	O
The	O
p38	B-GGP
SAP	I-GGP
kinase	I-GGP
substrate	O
MAP	B-GGP
-	I-GGP
kinase	I-GGP
-	I-GGP
activated	I-GGP
protein	I-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
(	O
MAPKAP	B-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
)	O
contains	O
a	O
putative	O
nuclear	B-CC
localisation	O
signal	O
which	O
we	O
show	O
is	O
functional	O
and	O
required	O
for	O
activation	O
by	O
a	O
variety	O
of	O
stimuli	O
.	O

Following	O
phosphorylation	O
of	O
MAPKAP	B-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
,	O
nuclear	B-CC
p38	B-GGP
was	O
exported	O
to	O
the	O
cytoplasm	B-CC
in	O
a	O
complex	O
with	O
MAPKAP	B-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
.	O

Export	O
of	O
MAPKAP	B-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
required	O
phosphorylation	O
by	O
p38	B-GGP
but	O
did	O
not	O
appear	O
to	O
require	O
the	O
kinase	O
activity	O
of	O
MAPKAP	B-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
.	O

The	O
p38	B-GGP
activators	O
MKK3	B-GGP
and	O
MKK6	B-GGP
were	O
present	O
in	O
both	O
the	O
nucleus	B-CC
and	O
the	O
cytoplasm	B-CC
,	O
consistent	O
with	O
a	O
role	O
in	O
activating	O
p38	B-GGP
in	O
the	O
nucleus	B-CC
.	O

CONCLUSIONS	O
:	O
In	O
the	O
p38	B-GGP
SAP	I-GGP
kinase	I-GGP
pathway	O
,	O
MAPKAP	B-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
serves	O
both	O
as	O
an	O
effector	O
of	O
p38	B-GGP
by	O
phosphorylating	O
substrates	O
and	O
as	O
a	O
determinant	O
of	O
cellular	O
localisation	O
of	O
p38	B-GGP
.	O

Nuclear	B-CC
export	O
of	O
p38	B-GGP
and	O
MAPKAP	B-GGP
kinase	I-GGP
-	I-GGP
2	I-GGP
may	O
permit	O
them	O
to	O
phosphorylate	O
substrates	O
in	O
the	O
cytoplasm	B-CC
.	O

